<html>
    <head>
        <meta charset="utf-8">
        
            <script src="lib/bindings/utils.js"></script>
            <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/dist/vis-network.min.css" integrity="sha512-WgxfT5LWjfszlPHXRmBWHkV2eceiWTOBvrKCNbdgDYTHrT2AeLCGbF4sZlZw3UMN3WtL0tGUoIAKsu8mllg/XA==" crossorigin="anonymous" referrerpolicy="no-referrer" />
            <script src="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/vis-network.min.js" integrity="sha512-LnvoEWDFrqGHlHmDD2101OrLcbsfkrzoSpvtSQtxK3RMnRV0eOkhhBN2dXHKRrUU8p2DGRTk35n4O8nWSVe1mQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
            
        
<center>
<h1></h1>
</center>

<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
        <link
          href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/css/bootstrap.min.css"
          rel="stylesheet"
          integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
          crossorigin="anonymous"
        />
        <script
          src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/js/bootstrap.bundle.min.js"
          integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
          crossorigin="anonymous"
        ></script>


        <center>
          <h1></h1>
        </center>
        <style type="text/css">

             #mynetwork {
                 width: 100%;
                 height: 600px;
                 background-color: #ffffff;
                 border: 1px solid lightgray;
                 position: relative;
                 float: left;
             }

             
             #loadingBar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width: 100%;
                 height: 600px;
                 background-color:rgba(200,200,200,0.8);
                 -webkit-transition: all 0.5s ease;
                 -moz-transition: all 0.5s ease;
                 -ms-transition: all 0.5s ease;
                 -o-transition: all 0.5s ease;
                 transition: all 0.5s ease;
                 opacity:1;
             }

             #bar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width:20px;
                 height:20px;
                 margin:auto auto auto auto;
                 border-radius:11px;
                 border:2px solid rgba(30,30,30,0.05);
                 background: rgb(0, 173, 246); /* Old browsers */
                 box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
             }

             #border {
                 position:absolute;
                 top:10px;
                 left:10px;
                 width:500px;
                 height:23px;
                 margin:auto auto auto auto;
                 box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
                 border-radius:10px;
             }

             #text {
                 position:absolute;
                 top:8px;
                 left:530px;
                 width:30px;
                 height:50px;
                 margin:auto auto auto auto;
                 font-size:22px;
                 color: #000000;
             }

             div.outerBorder {
                 position:relative;
                 top:400px;
                 width:600px;
                 height:44px;
                 margin:auto auto auto auto;
                 border:8px solid rgba(0,0,0,0.1);
                 background: rgb(252,252,252); /* Old browsers */
                 background: -moz-linear-gradient(top,  rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
                 background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
                 background: -webkit-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
                 background: -o-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
                 background: -ms-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
                 background: linear-gradient(to bottom,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
                 filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
                 border-radius:72px;
                 box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
             }
             

             

             
        </style>
    </head>


    <body>
        <div class="card" style="width: 100%">
            
            
            <div id="mynetwork" class="card-body"></div>
        </div>

        
            <div id="loadingBar">
              <div class="outerBorder">
                <div id="text">0%</div>
                <div id="border">
                  <div id="bar"></div>
                </div>
              </div>
            </div>
        
        

        <script type="text/javascript">

              // initialize global variables.
              var edges;
              var nodes;
              var allNodes;
              var allEdges;
              var nodeColors;
              var originalNodes;
              var network;
              var container;
              var options, data;
              var filter = {
                  item : '',
                  property : '',
                  value : []
              };

              

              

              // This method is responsible for drawing the graph, returns the drawn network
              function drawGraph() {
                  var container = document.getElementById('mynetwork');

                  

                  // parsing and collecting nodes and edges from the python
                  nodes = new vis.DataSet([{"color": "#97c2fc", "id": "", "label": "", "shape": "dot"}, {"color": "#97c2fc", "id": "##p1 competitive", "label": "##p1 competitive", "shape": "dot"}, {"color": "#97c2fc", "id": "##ctic protein -", "label": "##ctic protein -", "shape": "dot"}, {"color": "#97c2fc", "id": "##s that modulate breast tumor angiogenesis by", "label": "##s that modulate breast tumor angiogenesis by", "shape": "dot"}, {"color": "#97c2fc", "id": "2 m", "label": "2 m", "shape": "dot"}, {"color": "#97c2fc", "id": ". 1096 / fj. 202500461r. the", "label": ". 1096 / fj. 202500461r. the", "shape": "dot"}, {"color": "#97c2fc", "id": "essential", "label": "essential", "shape": "dot"}, {"color": "#97c2fc", "id": "proteins mon", "label": "proteins mon", "shape": "dot"}, {"color": "#97c2fc", "id": "##ocyte", "label": "##ocyte", "shape": "dot"}, {"color": "#97c2fc", "id": "trans", "label": "trans", "shape": "dot"}, {"color": "#97c2fc", "id": "binding", "label": "binding", "shape": "dot"}, {"color": "#97c2fc", "id": "w", "label": "w", "shape": "dot"}, {"color": "#97c2fc", "id": "##os", "label": "##os", "shape": "dot"}, {"color": "#97c2fc", "id": "##u", "label": "##u", "shape": "dot"}, {"color": "#97c2fc", "id": "factor", "label": "factor", "shape": "dot"}, {"color": "#97c2fc", "id": "gene expression have yet to be clarified. here, we discovered", "label": "gene expression have yet to be clarified. here, we discovered", "shape": "dot"}, {"color": "#97c2fc", "id": "##cripts, including vascular endothelial growth factor a", "label": "##cripts, including vascular endothelial growth factor a", "shape": "dot"}, {"color": "#97c2fc", "id": "for", "label": "for", "shape": "dot"}, {"color": "#97c2fc", "id": "college", "label": "college", "shape": "dot"}, {"color": "#97c2fc", "id": "##iu r", "label": "##iu r", "shape": "dot"}, {"color": "#97c2fc", "id": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "label": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "shape": "dot"}, {"color": "#97c2fc", "id": "##gf2bp1 ) function as a pair of", "label": "##gf2bp1 ) function as a pair of", "shape": "dot"}, {"color": "#97c2fc", "id": "##i a", "label": "##i a", "shape": "dot"}, {"color": "#97c2fc", "id": "##i h", "label": "##i h", "shape": "dot"}, {"color": "#97c2fc", "id": "##iu x", "label": "##iu x", "shape": "dot"}, {"color": "#97c2fc", "id": "-", "label": "-", "shape": "dot"}, {"color": "#97c2fc", "id": "related", "label": "related", "shape": "dot"}, {"color": "#97c2fc", "id": "##ine kinase 2", "label": "##ine kinase 2", "shape": "dot"}, {"color": "#97c2fc", "id": "induced protein", "label": "induced protein", "shape": "dot"}, {"color": "#97c2fc", "id": "l", "label": "l", "shape": "dot"}, {"color": "#97c2fc", "id": "2", "label": "2", "shape": "dot"}, {"color": "#97c2fc", "id": "is", "label": "is", "shape": "dot"}, {"color": "#97c2fc", "id": "competitively", "label": "competitively", "shape": "dot"}, {"color": "#97c2fc", "id": "ch", "label": "ch", "shape": "dot"}, {"color": "#97c2fc", "id": ", beijing, china. tumor angiogenesis", "label": ", beijing, china. tumor angiogenesis", "shape": "dot"}, {"color": "#97c2fc", "id": "1. faseb j. 2025 may 31 ; 39", "label": "1. faseb j. 2025 may 31 ; 39", "shape": "dot"}, {"color": "#97c2fc", "id": "proteins mcpip2 and igf2b", "label": "proteins mcpip2 and igf2b", "shape": "dot"}, {"color": "#97c2fc", "id": "x", "label": "x", "shape": "dot"}, {"color": "#97c2fc", "id": "r", "label": "r", "shape": "dot"}, {"color": "#97c2fc", "id": "10", "label": "10", "shape": "dot"}, {"color": "#97c2fc", "id": "##rna", "label": "##rna", "shape": "dot"}, {"color": "#97c2fc", "id": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "label": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "shape": "dot"}, {"color": "#97c2fc", "id": "binding protein 1", "label": "binding protein 1", "shape": "dot"}, {"color": "#97c2fc", "id": "i", "label": "i", "shape": "dot"}, {"color": "#97c2fc", "id": "##emota", "label": "##emota", "shape": "dot"}, {"color": "#97c2fc", "id": "regulating mrna stability of proangiogenic gene", "label": "regulating mrna stability of proangiogenic gene", "shape": "dot"}, {"color": "#97c2fc", "id": "##na -", "label": "##na -", "shape": "dot"}, {"color": "#97c2fc", "id": "antagonist", "label": "antagonist", "shape": "dot"}, {"color": "#97c2fc", "id": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "label": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "shape": "dot"}, {"color": "#97c2fc", "id": "##osomal proteins might be required for mcpip2 - mediated des", "label": "##osomal proteins might be required for mcpip2 - mediated des", "shape": "dot"}, {"color": "#97c2fc", "id": "- x - c motif chem", "label": "- x - c motif chem", "shape": "dot"}, {"color": "#97c2fc", "id": "il", "label": "il", "shape": "dot"}, {"color": "#97c2fc", "id": "can", "label": "can", "shape": "dot"}, {"color": "#97c2fc", "id": "c", "label": "c", "shape": "dot"}, {"color": "#97c2fc", "id": "human", "label": "human", "shape": "dot"}, {"color": "#97c2fc", "id": "with the stem - loop structures in the 3", "label": "with the stem - loop structures in the 3", "shape": "dot"}, {"color": "#97c2fc", "id": "was re", "label": "was re", "shape": "dot"}, {"color": "#97c2fc", "id": "##2 expression", "label": "##2 expression", "shape": "dot"}, {"color": "#97c2fc", "id": "interleuki", "label": "interleuki", "shape": "dot"}, {"color": "#97c2fc", "id": "##d 1", "label": "##d 1", "shape": "dot"}, {"color": "#97c2fc", "id": ",", "label": ",", "shape": "dot"}, {"color": "#97c2fc", "id": "##is", "label": "##is", "shape": "dot"}, {"color": "#97c2fc", "id": "of breast cancer patients, respectively. notably, there was", "label": "of breast cancer patients, respectively. notably, there was", "shape": "dot"}, {"color": "#97c2fc", "id": "##p2 physically", "label": "##p2 physically", "shape": "dot"}, {"color": "#97c2fc", "id": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "label": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "shape": "dot"}, {"color": "#97c2fc", "id": "- untranslated region of proang", "label": "- untranslated region of proang", "shape": "dot"}, {"color": "#97c2fc", "id": "bb2 ),", "label": "bb2 ),", "shape": "dot"}, {"color": "#97c2fc", "id": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "label": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "shape": "dot"}, {"color": "#97c2fc", "id": "##genic transcripts through its rnase domain to des", "label": "##genic transcripts through its rnase domain to des", "shape": "dot"}, {"color": "#97c2fc", "id": "stabilize the proang", "label": "stabilize the proang", "shape": "dot"}, {"color": "#97c2fc", "id": "in", "label": "in", "shape": "dot"}, {"color": "#97c2fc", "id": "\u0027", "label": "\u0027", "shape": "dot"}, {"color": "#97c2fc", "id": "poor", "label": "poor", "shape": "dot"}, {"color": "#97c2fc", "id": "##ta", "label": "##ta", "shape": "dot"}, {"color": "#97c2fc", "id": "##io", "label": "##io", "shape": "dot"}, {"color": "#97c2fc", "id": "##n - 8", "label": "##n - 8", "shape": "dot"}, {"color": "#97c2fc", "id": "##oki", "label": "##oki", "shape": "dot"}, {"color": "#97c2fc", "id": "##1 ), and ephrin a1", "label": "##1 ), and ephrin a1", "shape": "dot"}, {"color": "#97c2fc", "id": "interacted", "label": "interacted", "shape": "dot"}, {"color": "#97c2fc", "id": "a reversed", "label": "a reversed", "shape": "dot"}, {"color": "#97c2fc", "id": "associated with", "label": "associated with", "shape": "dot"}, {"color": "#97c2fc", "id": "tumors", "label": "tumors", "shape": "dot"}, {"color": "#97c2fc", "id": "##pressed", "label": "##pressed", "shape": "dot"}, {"color": "#97c2fc", "id": "##cpip", "label": "##cpip", "shape": "dot"}, {"color": "#97c2fc", "id": "##bilize their mrnas.", "label": "##bilize their mrnas.", "shape": "dot"}, {"color": "#97c2fc", "id": "##igan", "label": "##igan", "shape": "dot"}, {"color": "#97c2fc", "id": "breast", "label": "breast", "shape": "dot"}, {"color": "#97c2fc", "id": "##8 ),", "label": "##8 ),", "shape": "dot"}, {"color": "#97c2fc", "id": "##ne l", "label": "##ne l", "shape": "dot"}, {"color": "#97c2fc", "id": "##l", "label": "##l", "shape": "dot"}, {"color": "#97c2fc", "id": "##cpi", "label": "##cpi", "shape": "dot"}, {"color": "#97c2fc", "id": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "label": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "shape": "dot"}, {"color": "#97c2fc", "id": "rib", "label": "rib", "shape": "dot"}, {"color": "#97c2fc", "id": "survival", "label": "survival", "shape": "dot"}, {"color": "#97c2fc", "id": "##t", "label": "##t", "shape": "dot"}, {"color": "#97c2fc", "id": "of life", "label": "of life", "shape": "dot"}, {"color": "#97c2fc", "id": "##k", "label": "##k", "shape": "dot"}, {"color": "#97c2fc", "id": ") institute for brain sciences research,", "label": ") institute for brain sciences research,", "shape": "dot"}, {"color": "#97c2fc", "id": ":", "label": ":", "shape": "dot"}, {"color": "#97c2fc", "id": "index", "label": "index", "shape": "dot"}, {"color": "#97c2fc", "id": "##osu", "label": "##osu", "shape": "dot"}, {"color": "#97c2fc", "id": "of alzheimer \u0027 s disease -", "label": "of alzheimer \u0027 s disease -", "shape": "dot"}, {"color": "#97c2fc", "id": ". 1096 / fj. 202", "label": ". 1096 / fj. 202", "shape": "dot"}, {"color": "#97c2fc", "id": "may contribute to the", "label": "may contribute to the", "shape": "dot"}, {"color": "#97c2fc", "id": "sciences", "label": "sciences", "shape": "dot"}, {"color": "#97c2fc", "id": "university", "label": "university", "shape": "dot"}, {"color": "#97c2fc", "id": "##lle", "label": "##lle", "shape": "dot"}, {"color": "#97c2fc", "id": "40", "label": "40", "shape": "dot"}, {"color": "#97c2fc", "id": "genes", "label": "genes", "shape": "dot"}, {"color": "#97c2fc", "id": "##i", "label": "##i", "shape": "dot"}, {"color": "#97c2fc", "id": "##f", "label": "##f", "shape": "dot"}, {"color": "#97c2fc", "id": "we", "label": "we", "shape": "dot"}, {"color": "#97c2fc", "id": "##nan university, jinming avenue, kaifeng 475004, china.", "label": "##nan university, jinming avenue, kaifeng 475004, china.", "shape": "dot"}, {"color": "#97c2fc", "id": "##rican centre for cell biology of infectious pathogens", "label": "##rican centre for cell biology of infectious pathogens", "shape": "dot"}, {"color": "#97c2fc", "id": "3 )", "label": "3 )", "shape": "dot"}, {"color": "#97c2fc", "id": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "label": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "shape": "dot"}, {"color": "#97c2fc", "id": "##hie j", "label": "##hie j", "shape": "dot"}, {"color": "#97c2fc", "id": "k", "label": "k", "shape": "dot"}, {"color": "#97c2fc", "id": "doi", "label": "doi", "shape": "dot"}, {"color": "#97c2fc", "id": "b", "label": "b", "shape": "dot"}, {"color": "#97c2fc", "id": "102", "label": "102", "shape": "dot"}, {"color": "#97c2fc", "id": "j", "label": "j", "shape": "dot"}, {"color": "#97c2fc", "id": "##354028 [", "label": "##354028 [", "shape": "dot"}, {"color": "#97c2fc", "id": ".", "label": ".", "shape": "dot"}, {"color": "#97c2fc", "id": "- relationship - a computational study. anyomi", "label": "- relationship - a computational study. anyomi", "shape": "dot"}, {"color": "#97c2fc", "id": "school", "label": "school", "shape": "dot"}, {"color": "#97c2fc", "id": "), agegnehu sb", "label": "), agegnehu sb", "shape": "dot"}, {"color": "#97c2fc", "id": "##ra 00", "label": "##ra 00", "shape": "dot"}, {"color": "#97c2fc", "id": "3 ), lamptey el", "label": "3 ), lamptey el", "shape": "dot"}, {"color": "#97c2fc", "id": "1", "label": "1", "shape": "dot"}, {"color": "#97c2fc", "id": "ka", "label": "ka", "shape": "dot"}, {"color": "#97c2fc", "id": "4", "label": "4", "shape": "dot"}, {"color": "#97c2fc", "id": "of ghana, a", "label": "of ghana, a", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer. \u00a9 2025 the author", "label": "cancer. \u00a9 2025 the author", "shape": "dot"}, {"color": "#97c2fc", "id": "##461r pmid :", "label": "##461r pmid :", "shape": "dot"}, {"color": "#97c2fc", "id": "antiangiogenic therapy of", "label": "antiangiogenic therapy of", "shape": "dot"}, {"color": "#97c2fc", "id": "##1 / acsomega. 4c11571. eco", "label": "##1 / acsomega. 4c11571. eco", "shape": "dot"}, {"color": "#97c2fc", "id": ")", "label": ")", "shape": "dot"}, {"color": "#97c2fc", "id": "he", "label": "he", "shape": "dot"}, {"color": "#97c2fc", "id": "##ction 2025 may 6. decreased", "label": "##ction 2025 may 6. decreased", "shape": "dot"}, {"color": "#97c2fc", "id": "expression", "label": "expression", "shape": "dot"}, {"color": "#97c2fc", "id": "##500", "label": "##500", "shape": "dot"}, {"color": "#97c2fc", "id": "in cancer", "label": "in cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "##mpo s", "label": "##mpo s", "shape": "dot"}, {"color": "#97c2fc", "id": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "label": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "shape": "dot"}, {"color": "#97c2fc", "id": "##cc", "label": "##cc", "shape": "dot"}, {"color": "#97c2fc", "id": "inverse", "label": "inverse", "shape": "dot"}, {"color": "#97c2fc", "id": "new insights into", "label": "new insights into", "shape": "dot"}, {"color": "#97c2fc", "id": "box l", "label": "box l", "shape": "dot"}, {"color": "#97c2fc", "id": "associated with aging. interestingly, an", "label": "associated with aging. interestingly, an", "shape": "dot"}, {"color": "#97c2fc", "id": "of biochemistry cell and molecular biology, p. o.", "label": "of biochemistry cell and molecular biology, p. o.", "shape": "dot"}, {"color": "#97c2fc", "id": "of medical sciences, c.", "label": "of medical sciences, c.", "shape": "dot"}, {"color": "#97c2fc", "id": "these two conditions which", "label": "these two conditions which", "shape": "dot"}, {"color": "#97c2fc", "id": "box", "label": "box", "shape": "dot"}, {"color": "#97c2fc", "id": "been largely prevalent among the older population. with the increasing", "label": "been largely prevalent among the older population. with the increasing", "shape": "dot"}, {"color": "#97c2fc", "id": "care", "label": "care", "shape": "dot"}, {"color": "#97c2fc", "id": "##ra", "label": "##ra", "shape": "dot"}, {"color": "#97c2fc", "id": "00", "label": "00", "shape": "dot"}, {"color": "#97c2fc", "id": "233, ghana.", "label": "233, ghana.", "shape": "dot"}, {"color": "#97c2fc", "id": "limited data on the molecular mechanisms that govern this", "label": "limited data on the molecular mechanisms that govern this", "shape": "dot"}, {"color": "#97c2fc", "id": "##g 77, a", "label": "##g 77, a", "shape": "dot"}, {"color": "#97c2fc", "id": "5", "label": "5", "shape": "dot"}, {"color": "#97c2fc", "id": ") west african genetic medicine centre", "label": ") west african genetic medicine centre", "shape": "dot"}, {"color": "#97c2fc", "id": ". tedam university of technology and applied sciences, p. o.", "label": ". tedam university of technology and applied sciences, p. o.", "shape": "dot"}, {"color": "#97c2fc", "id": "of health", "label": "of health", "shape": "dot"}, {"color": "#97c2fc", "id": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "label": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "shape": "dot"}, {"color": "#97c2fc", "id": "##g 77, university of ghana, a", "label": "##g 77, university of ghana, a", "shape": "dot"}, {"color": "#97c2fc", "id": "been observed", "label": "been observed", "shape": "dot"}, {"color": "#97c2fc", "id": ", university of ghana, p. o.", "label": ", university of ghana, p. o.", "shape": "dot"}, {"color": "#97c2fc", "id": "##233, ghana. alzheimer \u0027 s disease", "label": "##233, ghana. alzheimer \u0027 s disease", "shape": "dot"}, {"color": "#97c2fc", "id": "between", "label": "between", "shape": "dot"}, {"color": "#97c2fc", "id": "of anaesthesia and intensive", "label": "of anaesthesia and intensive", "shape": "dot"}, {"color": "#97c2fc", "id": "##233, ghana.", "label": "##233, ghana.", "shape": "dot"}, {"color": "#97c2fc", "id": "incidence", "label": "incidence", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer and ad", "label": "cancer and ad", "shape": "dot"}, {"color": "#97c2fc", "id": "were formerly", "label": "were formerly", "shape": "dot"}, {"color": "#97c2fc", "id": "24, am133 coffee street, navrongo", "label": "24, am133 coffee street, navrongo", "shape": "dot"}, {"color": "#97c2fc", "id": "has", "label": "has", "shape": "dot"}, {"color": "#97c2fc", "id": "department", "label": "department", "shape": "dot"}, {"color": "#97c2fc", "id": "inverse relationship between", "label": "inverse relationship between", "shape": "dot"}, {"color": "#97c2fc", "id": "of cancer over the years, scientists have explored the relationship", "label": "of cancer over the years, scientists have explored the relationship", "shape": "dot"}, {"color": "#97c2fc", "id": "##regulated", "label": "##regulated", "shape": "dot"}, {"color": "#97c2fc", "id": "ad but significantly down", "label": "ad but significantly down", "shape": "dot"}, {"color": "#97c2fc", "id": "##ly", "label": "##ly", "shape": "dot"}, {"color": "#97c2fc", "id": "##2", "label": "##2", "shape": "dot"}, {"color": "#97c2fc", "id": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "label": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "shape": "dot"}, {"color": "#97c2fc", "id": "##re", "label": "##re", "shape": "dot"}, {"color": "#97c2fc", "id": "differential", "label": "differential", "shape": "dot"}, {"color": "#97c2fc", "id": "##gulated in prostate can", "label": "##gulated in prostate can", "shape": "dot"}, {"color": "#97c2fc", "id": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "label": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "shape": "dot"}, {"color": "#97c2fc", "id": "##gulated in", "label": "##gulated in", "shape": "dot"}, {"color": "#97c2fc", "id": "##gu", "label": "##gu", "shape": "dot"}, {"color": "#97c2fc", "id": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "label": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "shape": "dot"}, {"color": "#97c2fc", "id": "##gs ) between ad and nondemented controls were identified using the geo", "label": "##gs ) between ad and nondemented controls were identified using the geo", "shape": "dot"}, {"color": "#97c2fc", "id": "expressed genes", "label": "expressed genes", "shape": "dot"}, {"color": "#97c2fc", "id": "in breast cancer, 11 significantly down", "label": "in breast cancer, 11 significantly down", "shape": "dot"}, {"color": "#97c2fc", "id": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "label": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "shape": "dot"}, {"color": "#97c2fc", "id": "de", "label": "de", "shape": "dot"}, {"color": "#97c2fc", "id": "risk", "label": "risk", "shape": "dot"}, {"color": "#97c2fc", "id": "of cancer development while", "label": "of cancer development while", "shape": "dot"}, {"color": "#97c2fc", "id": "reduced", "label": "reduced", "shape": "dot"}, {"color": "#97c2fc", "id": "##1 / acsomega. 4", "label": "##1 / acsomega. 4", "shape": "dot"}, {"color": "#97c2fc", "id": ". 52225 / narra. v5i1. 1364. ep", "label": ". 52225 / narra. v5i1. 1364. ep", "shape": "dot"}, {"color": "#97c2fc", "id": "##ve", "label": "##ve", "shape": "dot"}, {"color": "#97c2fc", "id": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "label": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "shape": "dot"}, {"color": "#97c2fc", "id": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "label": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "shape": "dot"}, {"color": "#97c2fc", "id": "10. 102", "label": "10. 102", "shape": "dot"}, {"color": "#97c2fc", "id": "##er and 5 genes down", "label": "##er and 5 genes down", "shape": "dot"}, {"color": "#97c2fc", "id": "upre", "label": "upre", "shape": "dot"}, {"color": "#97c2fc", "id": "were downregulated", "label": "were downregulated", "shape": "dot"}, {"color": "#97c2fc", "id": "pm", "label": "pm", "shape": "dot"}, {"color": "#97c2fc", "id": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "label": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "shape": "dot"}, {"color": "#97c2fc", "id": "##ida", "label": "##ida", "shape": "dot"}, {"color": "#97c2fc", "id": "##gulated", "label": "##gulated", "shape": "dot"}, {"color": "#97c2fc", "id": "play an important role in", "label": "play an important role in", "shape": "dot"}, {"color": "#97c2fc", "id": "##12059893", "label": "##12059893", "shape": "dot"}, {"color": "#97c2fc", "id": "ad. this study serves as a foundational effort to del", "label": "ad. this study serves as a foundational effort to del", "shape": "dot"}, {"color": "#97c2fc", "id": "##c", "label": "##c", "shape": "dot"}, {"color": "#97c2fc", "id": "in all three cancers and may", "label": "in all three cancers and may", "shape": "dot"}, {"color": "#97c2fc", "id": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "label": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "shape": "dot"}, {"color": "#97c2fc", "id": "##11571 pmcid : pm", "label": "##11571 pmcid : pm", "shape": "dot"}, {"color": "#97c2fc", "id": "##id :", "label": "##id :", "shape": "dot"}, {"color": "#97c2fc", "id": "##ibi", "label": "##ibi", "shape": "dot"}, {"color": "#97c2fc", "id": "ri", "label": "ri", "shape": "dot"}, {"color": "#97c2fc", "id": "##sana", "label": "##sana", "shape": "dot"}, {"color": "#97c2fc", "id": "doctoral program in biomedical", "label": "doctoral program in biomedical", "shape": "dot"}, {"color": "#97c2fc", "id": "of biochemistry and molecular biology,", "label": "of biochemistry and molecular biology,", "shape": "dot"}, {"color": "#97c2fc", "id": "of medicine, univers", "label": "of medicine, univers", "shape": "dot"}, {"color": "#97c2fc", "id": "##g", "label": "##g", "shape": "dot"}, {"color": "#97c2fc", "id": "##rta", "label": "##rta", "shape": "dot"}, {"color": "#97c2fc", "id": ") bioinformatics core facilities - im", "label": ") bioinformatics core facilities - im", "shape": "dot"}, {"color": "#97c2fc", "id": "##esia", "label": "##esia", "shape": "dot"}, {"color": "#97c2fc", "id": "##itas in", "label": "##itas in", "shape": "dot"}, {"color": "#97c2fc", "id": "##nandi si", "label": "##nandi si", "shape": "dot"}, {"color": "#97c2fc", "id": "##eri", "label": "##eri", "shape": "dot"}, {"color": "#97c2fc", "id": "master program in biomedical", "label": "master program in biomedical", "shape": "dot"}, {"color": "#97c2fc", "id": "),", "label": "),", "shape": "dot"}, {"color": "#97c2fc", "id": "##esi", "label": "##esi", "shape": "dot"}, {"color": "#97c2fc", "id": "of medical chemistry,", "label": "of medical chemistry,", "shape": "dot"}, {"color": "#97c2fc", "id": "##a.", "label": "##a.", "shape": "dot"}, {"color": "#97c2fc", "id": "faculty", "label": "faculty", "shape": "dot"}, {"color": "#97c2fc", "id": "wa", "label": "wa", "shape": "dot"}, {"color": "#97c2fc", "id": "##don", "label": "##don", "shape": "dot"}, {"color": "#97c2fc", "id": "##a,", "label": "##a,", "shape": "dot"}, {"color": "#97c2fc", "id": "6", "label": "6", "shape": "dot"}, {"color": "#97c2fc", "id": "##aka", "label": "##aka", "shape": "dot"}, {"color": "#97c2fc", "id": "indonesi", "label": "indonesi", "shape": "dot"}, {"color": "#97c2fc", "id": "##itas indonesia", "label": "##itas indonesia", "shape": "dot"}, {"color": "#97c2fc", "id": "of surgery,", "label": "of surgery,", "shape": "dot"}, {"color": "#97c2fc", "id": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "label": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "shape": "dot"}, {"color": "#97c2fc", "id": "7 ) molecular biology and proteomics core fa", "label": "7 ) molecular biology and proteomics core fa", "shape": "dot"}, {"color": "#97c2fc", "id": "2 - positive", "label": "2 - positive", "shape": "dot"}, {"color": "#97c2fc", "id": "changes in the promoter region", "label": "changes in the promoter region", "shape": "dot"}, {"color": "#97c2fc", "id": "9 ) department of internal medicine,", "label": "9 ) department of internal medicine,", "shape": "dot"}, {"color": "#97c2fc", "id": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "label": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "shape": "dot"}, {"color": "#97c2fc", "id": "receptor", "label": "receptor", "shape": "dot"}, {"color": "#97c2fc", "id": "is an", "label": "is an", "shape": "dot"}, {"color": "#97c2fc", "id": "##type", "label": "##type", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal b, human epidermal growth factor", "label": "##nal b, human epidermal growth factor", "shape": "dot"}, {"color": "#97c2fc", "id": "be categorized based on their gene expression profiles using immunohistochemistry into l", "label": "be categorized based on their gene expression profiles using immunohistochemistry into l", "shape": "dot"}, {"color": "#97c2fc", "id": "- negative breast cancer", "label": "- negative breast cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "and", "label": "and", "shape": "dot"}, {"color": "#97c2fc", "id": "##a, jaka", "label": "##a, jaka", "shape": "dot"}, {"color": "#97c2fc", "id": "lead", "label": "lead", "shape": "dot"}, {"color": "#97c2fc", "id": "triple", "label": "triple", "shape": "dot"}, {"color": "#97c2fc", "id": "of medicine, universitas indon", "label": "of medicine, universitas indon", "shape": "dot"}, {"color": "#97c2fc", "id": "cilities - imeri,", "label": "cilities - imeri,", "shape": "dot"}, {"color": "#97c2fc", "id": "##a. breast cancer sub", "label": "##a. breast cancer sub", "shape": "dot"}, {"color": "#97c2fc", "id": "##umi", "label": "##umi", "shape": "dot"}, {"color": "#97c2fc", "id": "##ivers", "label": "##ivers", "shape": "dot"}, {"color": "#97c2fc", "id": "to misclassification. dna methylation", "label": "to misclassification. dna methylation", "shape": "dot"}, {"color": "#97c2fc", "id": "##s", "label": "##s", "shape": "dot"}, {"color": "#97c2fc", "id": "un", "label": "un", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal a, l", "label": "##nal a, l", "shape": "dot"}, {"color": "#97c2fc", "id": "epigenetic modification,", "label": "epigenetic modification,", "shape": "dot"}, {"color": "#97c2fc", "id": "of medicine,", "label": "of medicine,", "shape": "dot"}, {"color": "#97c2fc", "id": "classification of breast cancer : l", "label": "classification of breast cancer : l", "shape": "dot"}, {"color": "#97c2fc", "id": ", h", "label": ", h", "shape": "dot"}, {"color": "#97c2fc", "id": "##methylation", "label": "##methylation", "shape": "dot"}, {"color": "#97c2fc", "id": "tion", "label": "tion", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal b subtypes, with accuracies of 75 % and 76 %,", "label": "##nal b subtypes, with accuracies of 75 % and 76 %,", "shape": "dot"}, {"color": "#97c2fc", "id": "the pt", "label": "the pt", "shape": "dot"}, {"color": "#97c2fc", "id": ". \u00a9 202", "label": ". \u00a9 202", "shape": "dot"}, {"color": "#97c2fc", "id": "##225 / narra. v5i1. 1364 pmcid", "label": "##225 / narra. v5i1. 1364 pmcid", "shape": "dot"}, {"color": "#97c2fc", "id": "##rn2 gene", "label": "##rn2 gene", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal", "label": "##nal", "shape": "dot"}, {"color": "#97c2fc", "id": "##261 ), and tnbc", "label": "##261 ), and tnbc", "shape": "dot"}, {"color": "#97c2fc", "id": "##p", "label": "##p", "shape": "dot"}, {"color": "#97c2fc", "id": "the author", "label": "the author", "shape": "dot"}, {"color": "#97c2fc", "id": "bio", "label": "bio", "shape": "dot"}, {"color": "#97c2fc", "id": "respectively", "label": "respectively", "shape": "dot"}, {"color": "#97c2fc", "id": "##marker for each sub", "label": "##marker for each sub", "shape": "dot"}, {"color": "#97c2fc", "id": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "label": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "shape": "dot"}, {"color": "#97c2fc", "id": "##yper", "label": "##yper", "shape": "dot"}, {"color": "#97c2fc", "id": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "label": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "shape": "dot"}, {"color": "#97c2fc", "id": "improve", "label": "improve", "shape": "dot"}, {"color": "#97c2fc", "id": "##10", "label": "##10", "shape": "dot"}, {"color": "#97c2fc", "id": "##5", "label": "##5", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal a", "label": "##nal a", "shape": "dot"}, {"color": "#97c2fc", "id": "52", "label": "52", "shape": "dot"}, {"color": "#97c2fc", "id": "), hashim", "label": "), hashim", "shape": "dot"}, {"color": "#97c2fc", "id": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "label": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "shape": "dot"}, {"color": "#97c2fc", "id": ") drug development research cluster, indon", "label": ") drug development research cluster, indon", "shape": "dot"}, {"color": "#97c2fc", "id": "##an medical", "label": "##an medical", "shape": "dot"}, {"color": "#97c2fc", "id": "indon", "label": "indon", "shape": "dot"}, {"color": "#97c2fc", "id": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "label": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "shape": "dot"}, {"color": "#97c2fc", "id": "##hibit", "label": "##hibit", "shape": "dot"}, {"color": "#97c2fc", "id": "na", "label": "na", "shape": "dot"}, {"color": "#97c2fc", "id": "education", "label": "education", "shape": "dot"}, {"color": "#97c2fc", "id": "n", "label": "n", "shape": "dot"}, {"color": "#97c2fc", "id": "3", "label": "3", "shape": "dot"}, {"color": "#97c2fc", "id": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "label": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "shape": "dot"}, {"color": "#97c2fc", "id": "##ajrin", "label": "##ajrin", "shape": "dot"}, {"color": "#97c2fc", "id": "), azizah", "label": "), azizah", "shape": "dot"}, {"color": "#97c2fc", "id": "te", "label": "te", "shape": "dot"}, {"color": "#97c2fc", "id": "##djo a", "label": "##djo a", "shape": "dot"}, {"color": "#97c2fc", "id": "##itas", "label": "##itas", "shape": "dot"}, {"color": "#97c2fc", "id": "##b", "label": "##b", "shape": "dot"}, {"color": "#97c2fc", "id": "am", "label": "am", "shape": "dot"}, {"color": "#97c2fc", "id": "nn", "label": "nn", "shape": "dot"}, {"color": "#97c2fc", "id": "of pharmacy, univers", "label": "of pharmacy, univers", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of pharmacognosy, phytochemistry, and natural products,", "label": ") department of pharmacognosy, phytochemistry, and natural products,", "shape": "dot"}, {"color": "#97c2fc", "id": ", indon", "label": ", indon", "shape": "dot"}, {"color": "#97c2fc", "id": "and research instit", "label": "and research instit", "shape": "dot"}, {"color": "#97c2fc", "id": "), ramadanti", "label": "), ramadanti", "shape": "dot"}, {"color": "#97c2fc", "id": "quantitative pcr", "label": "quantitative pcr", "shape": "dot"}, {"color": "#97c2fc", "id": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "label": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "shape": "dot"}, {"color": "#97c2fc", "id": "time", "label": "time", "shape": "dot"}, {"color": "#97c2fc", "id": "##sia", "label": "##sia", "shape": "dot"}, {"color": "#97c2fc", "id": "regulating the cell", "label": "regulating the cell", "shape": "dot"}, {"color": "#97c2fc", "id": "ute,", "label": "ute,", "shape": "dot"}, {"color": "#97c2fc", "id": "##poptosis", "label": "##poptosis", "shape": "dot"}, {"color": "#97c2fc", "id": "##cence, making it", "label": "##cence, making it", "shape": "dot"}, {"color": "#97c2fc", "id": "proliferation", "label": "proliferation", "shape": "dot"}, {"color": "#97c2fc", "id": "and se", "label": "and se", "shape": "dot"}, {"color": "#97c2fc", "id": "a", "label": "a", "shape": "dot"}, {"color": "#97c2fc", "id": "malaya, kuala lumpur, malay", "label": "malaya, kuala lumpur, malay", "shape": "dot"}, {"color": "#97c2fc", "id": "target", "label": "target", "shape": "dot"}, {"color": "#97c2fc", "id": "##nes", "label": "##nes", "shape": "dot"}, {"color": "#97c2fc", "id": "##50 value", "label": "##50 value", "shape": "dot"}, {"color": "#97c2fc", "id": "role in", "label": "role in", "shape": "dot"}, {"color": "#97c2fc", "id": "real", "label": "real", "shape": "dot"}, {"color": "#97c2fc", "id": ". the p53 signaling pathway", "label": ". the p53 signaling pathway", "shape": "dot"}, {"color": "#97c2fc", "id": ", a", "label": ", a", "shape": "dot"}, {"color": "#97c2fc", "id": "key", "label": "key", "shape": "dot"}, {"color": "#97c2fc", "id": ", and", "label": ", and", "shape": "dot"}, {"color": "#97c2fc", "id": "plays", "label": "plays", "shape": "dot"}, {"color": "#97c2fc", "id": "a critical", "label": "a critical", "shape": "dot"}, {"color": "#97c2fc", "id": "cycle", "label": "cycle", "shape": "dot"}, {"color": "#97c2fc", "id": "of downstream genes linked to cell", "label": "of downstream genes linked to cell", "shape": "dot"}, {"color": "#97c2fc", "id": "##a, jakarta,", "label": "##a, jakarta,", "shape": "dot"}, {"color": "#97c2fc", "id": "##iti", "label": "##iti", "shape": "dot"}, {"color": "#97c2fc", "id": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "label": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "shape": "dot"}, {"color": "#97c2fc", "id": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "label": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of pharmaceutical chemistry,", "label": ") department of pharmaceutical chemistry,", "shape": "dot"}, {"color": "#97c2fc", "id": "##t - qpcr ) was used to evaluate the mrna", "label": "##t - qpcr ) was used to evaluate the mrna", "shape": "dot"}, {"color": "#97c2fc", "id": "on the", "label": "on the", "shape": "dot"}, {"color": "#97c2fc", "id": "##ia", "label": "##ia", "shape": "dot"}, {"color": "#97c2fc", "id": "senes", "label": "senes", "shape": "dot"}, {"color": "#97c2fc", "id": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "label": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "shape": "dot"}, {"color": "#97c2fc", "id": "##ene", "label": "##ene", "shape": "dot"}, {"color": "#97c2fc", "id": "which was", "label": "which was", "shape": "dot"}, {"color": "#97c2fc", "id": ": cyce or ccne1", "label": ": cyce or ccne1", "shape": "dot"}, {"color": "#97c2fc", "id": "occur via pathways associated with cell senescence and cell", "label": "occur via pathways associated with cell senescence and cell", "shape": "dot"}, {"color": "#97c2fc", "id": "##8 ), and e2f1", "label": "##8 ), and e2f1", "shape": "dot"}, {"color": "#97c2fc", "id": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "label": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "shape": "dot"}, {"color": "#97c2fc", "id": "##1 ), rbl1", "label": "##1 ), rbl1", "shape": "dot"}, {"color": "#97c2fc", "id": "might", "label": "might", "shape": "dot"}, {"color": "#97c2fc", "id": "arrest. molecular docking results of metabolite compounds from z. n", "label": "arrest. molecular docking results of metabolite compounds from z. n", "shape": "dot"}, {"color": "#97c2fc", "id": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "label": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "shape": "dot"}, {"color": "#97c2fc", "id": "the native", "label": "the native", "shape": "dot"}, {"color": "#97c2fc", "id": "ligan", "label": "ligan", "shape": "dot"}, {"color": "#97c2fc", "id": "im", "label": "im", "shape": "dot"}, {"color": "#97c2fc", "id": "p = 0. 01", "label": "p = 0. 01", "shape": "dot"}, {"color": "#97c2fc", "id": "##rank", "label": "##rank", "shape": "dot"}, {"color": "#97c2fc", "id": "##j", "label": "##j", "shape": "dot"}, {"color": "#97c2fc", "id": "by", "label": "by", "shape": "dot"}, {"color": "#97c2fc", "id": "rerank score", "label": "rerank score", "shape": "dot"}, {"color": "#97c2fc", "id": "##um", "label": "##um", "shape": "dot"}, {"color": "#97c2fc", "id": "##d", "label": "##d", "shape": "dot"}, {"color": "#97c2fc", "id": "of ad", "label": "of ad", "shape": "dot"}, {"color": "#97c2fc", "id": "re", "label": "re", "shape": "dot"}, {"color": "#97c2fc", "id": "##idodiph", "label": "##idodiph", "shape": "dot"}, {"color": "#97c2fc", "id": "p = 0", "label": "p = 0", "shape": "dot"}, {"color": "#97c2fc", "id": "##5 ), which was observed through rt - qp", "label": "##5 ), which was observed through rt - qp", "shape": "dot"}, {"color": "#97c2fc", "id": "- 112. 70 k", "label": "- 112. 70 k", "shape": "dot"}, {"color": "#97c2fc", "id": "score", "label": "score", "shape": "dot"}, {"color": "#97c2fc", "id": "##ine", "label": "##ine", "shape": "dot"}, {"color": "#97c2fc", "id": "##enyl", "label": "##enyl", "shape": "dot"}, {"color": "#97c2fc", "id": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "label": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "shape": "dot"}, {"color": "#97c2fc", "id": "##osphate", "label": "##osphate", "shape": "dot"}, {"color": "#97c2fc", "id": "- 110. 68 k", "label": "- 110. 68 k", "shape": "dot"}, {"color": "#97c2fc", "id": "0", "label": "0", "shape": "dot"}, {"color": "#97c2fc", "id": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "label": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "shape": "dot"}, {"color": "#97c2fc", "id": "/ mol ), and nummular", "label": "/ mol ), and nummular", "shape": "dot"}, {"color": "#97c2fc", "id": "squal", "label": "squal", "shape": "dot"}, {"color": "#97c2fc", "id": "the decrease in p21", "label": "the decrease in p21", "shape": "dot"}, {"color": "#97c2fc", "id": "##mularia stem suggested that", "label": "##mularia stem suggested that", "shape": "dot"}, {"color": "#97c2fc", "id": "##life", "label": "##life", "shape": "dot"}, {"color": "#97c2fc", "id": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "label": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "shape": "dot"}, {"color": "#97c2fc", "id": "##ion of p21", "label": "##ion of p21", "shape": "dot"}, {"color": "#97c2fc", "id": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "label": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "shape": "dot"}, {"color": "#97c2fc", "id": "##in - mediated anti -", "label": "##in - mediated anti -", "shape": "dot"}, {"color": "#97c2fc", "id": ") biochemistry division, chemistry department,", "label": ") biochemistry division, chemistry department,", "shape": "dot"}, {"color": "#97c2fc", "id": "1 ), abdelkrim g", "label": "1 ), abdelkrim g", "shape": "dot"}, {"color": "#97c2fc", "id": "kn1a ) mrna expression. in conclusion, the anti - pro", "label": "kn1a ) mrna expression. in conclusion, the anti - pro", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer effects. foda my", "label": "cancer effects. foda my", "shape": "dot"}, {"color": "#97c2fc", "id": "##press", "label": "##press", "shape": "dot"}, {"color": "#97c2fc", "id": "of science, mansoura university, mansoura, egypt.", "label": "of science, mansoura university, mansoura, egypt.", "shape": "dot"}, {"color": "#97c2fc", "id": "##tat", "label": "##tat", "shape": "dot"}, {"color": "#97c2fc", "id": "jun", "label": "jun", "shape": "dot"}, {"color": "#97c2fc", "id": "2 ), salem ml", "label": "2 ), salem ml", "shape": "dot"}, {"color": "#97c2fc", "id": "in atorvas", "label": "in atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "label": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "shape": "dot"}, {"color": "#97c2fc", "id": "prescribed chole", "label": "prescribed chole", "shape": "dot"}, {"color": "#97c2fc", "id": "has recently", "label": "has recently", "shape": "dot"}, {"color": "#97c2fc", "id": "and its biological functions", "label": "and its biological functions", "shape": "dot"}, {"color": "#97c2fc", "id": "of saida, saida, algeria.", "label": "of saida, saida, algeria.", "shape": "dot"}, {"color": "#97c2fc", "id": "shown", "label": "shown", "shape": "dot"}, {"color": "#97c2fc", "id": "however", "label": "however", "shape": "dot"}, {"color": "#97c2fc", "id": "##xicity against breast cancer lines, with the", "label": "##xicity against breast cancer lines, with the", "shape": "dot"}, {"color": "#97c2fc", "id": "shown potential anti", "label": "shown potential anti", "shape": "dot"}, {"color": "#97c2fc", "id": "##in exhibited notable predicted cyt", "label": "##in exhibited notable predicted cyt", "shape": "dot"}, {"color": "#97c2fc", "id": "##in", "label": "##in", "shape": "dot"}, {"color": "#97c2fc", "id": "unclear. we aim to identify the dysre", "label": "unclear. we aim to identify the dysre", "shape": "dot"}, {"color": "#97c2fc", "id": "particular breast cancer,", "label": "particular breast cancer,", "shape": "dot"}, {"color": "#97c2fc", "id": "still", "label": "still", "shape": "dot"}, {"color": "#97c2fc", "id": "associated with atorvas", "label": "associated with atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "in breast", "label": "in breast", "shape": "dot"}, {"color": "#97c2fc", "id": "lowering", "label": "lowering", "shape": "dot"}, {"color": "#97c2fc", "id": "to be responsive to", "label": "to be responsive to", "shape": "dot"}, {"color": "#97c2fc", "id": "interaction", "label": "interaction", "shape": "dot"}, {"color": "#97c2fc", "id": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "label": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": ") network and", "label": ") network and", "shape": "dot"}, {"color": "#97c2fc", "id": "in the protein - protein", "label": "in the protein - protein", "shape": "dot"}, {"color": "#97c2fc", "id": "drug,", "label": "drug,", "shape": "dot"}, {"color": "#97c2fc", "id": "hub gene", "label": "hub gene", "shape": "dot"}, {"color": "#97c2fc", "id": ", its influence on gene", "label": ", its influence on gene", "shape": "dot"}, {"color": "#97c2fc", "id": "##lated", "label": "##lated", "shape": "dot"}, {"color": "#97c2fc", "id": "was", "label": "was", "shape": "dot"}, {"color": "#97c2fc", "id": "##in,", "label": "##in,", "shape": "dot"}, {"color": "#97c2fc", "id": "ppi", "label": "ppi", "shape": "dot"}, {"color": "#97c2fc", "id": "##oto", "label": "##oto", "shape": "dot"}, {"color": "#97c2fc", "id": "related pathways", "label": "related pathways", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer,", "label": "cancer,", "shape": "dot"}, {"color": "#97c2fc", "id": "expressed", "label": "expressed", "shape": "dot"}, {"color": "#97c2fc", "id": "##cer effects.", "label": "##cer effects.", "shape": "dot"}, {"color": "#97c2fc", "id": "widely", "label": "widely", "shape": "dot"}, {"color": "#97c2fc", "id": "atorvas", "label": "atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "##in treatment and the main players in their biological network. a total of 103 differentially", "label": "##in treatment and the main players in their biological network. a total of 103 differentially", "shape": "dot"}, {"color": "#97c2fc", "id": "##ster", "label": "##ster", "shape": "dot"}, {"color": "#97c2fc", "id": "##ol", "label": "##ol", "shape": "dot"}, {"color": "#97c2fc", "id": "##can", "label": "##can", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer. atorvas", "label": "cancer. atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "was identified as the", "label": "was identified as the", "shape": "dot"}, {"color": "#97c2fc", "id": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "label": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "shape": "dot"}, {"color": "#97c2fc", "id": "expression was linked with better survival outcomes. atorvas", "label": "expression was linked with better survival outcomes. atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "##mol biomed. 2025 may 9.", "label": "##mol biomed. 2025 may 9.", "shape": "dot"}, {"color": "#97c2fc", "id": ". 108", "label": ". 108", "shape": "dot"}, {"color": "#97c2fc", "id": "jun might", "label": "jun might", "shape": "dot"}, {"color": "#97c2fc", "id": "##0", "label": "##0", "shape": "dot"}, {"color": "#97c2fc", "id": "expression.", "label": "expression.", "shape": "dot"}, {"color": "#97c2fc", "id": "in breast cancer, possibly by fine tuning of", "label": "in breast cancer, possibly by fine tuning of", "shape": "dot"}, {"color": "#97c2fc", "id": "##na ss", "label": "##na ss", "shape": "dot"}, {"color": "#97c2fc", "id": "##v", "label": "##v", "shape": "dot"}, {"color": "#97c2fc", "id": "##un", "label": "##un", "shape": "dot"}, {"color": "#97c2fc", "id": "##gno", "label": "##gno", "shape": "dot"}, {"color": "#97c2fc", "id": "activity positively correlated with", "label": "activity positively correlated with", "shape": "dot"}, {"color": "#97c2fc", "id": "##stic biomarker in breast cancer.", "label": "##stic biomarker in breast cancer.", "shape": "dot"}, {"color": "#97c2fc", "id": ". 17305 /", "label": ". 17305 /", "shape": "dot"}, {"color": "#97c2fc", "id": "luki", "label": "luki", "shape": "dot"}, {"color": "#97c2fc", "id": "##v vi", "label": "##v vi", "shape": "dot"}, {"color": "#97c2fc", "id": "logino", "label": "logino", "shape": "dot"}, {"color": "#97c2fc", "id": "may directly interact with", "label": "may directly interact with", "shape": "dot"}, {"color": "#97c2fc", "id": "serve as a valuable pro", "label": "serve as a valuable pro", "shape": "dot"}, {"color": "#97c2fc", "id": "##tatin", "label": "##tatin", "shape": "dot"}, {"color": "#97c2fc", "id": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "label": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "shape": "dot"}, {"color": "#97c2fc", "id": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "label": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "shape": "dot"}, {"color": "#97c2fc", "id": "expression. as such,", "label": "expression. as such,", "shape": "dot"}, {"color": "#97c2fc", "id": "significantly", "label": "significantly", "shape": "dot"}, {"color": "#97c2fc", "id": "##nina", "label": "##nina", "shape": "dot"}, {"color": "#97c2fc", "id": "pro", "label": "pro", "shape": "dot"}, {"color": "#97c2fc", "id": "down", "label": "down", "shape": "dot"}, {"color": "#97c2fc", "id": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "label": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "shape": "dot"}, {"color": "#97c2fc", "id": "array and bioinformatic analysis, we identified seven differentially", "label": "array and bioinformatic analysis, we identified seven differentially", "shape": "dot"}, {"color": "#97c2fc", "id": "##r confirmed their down", "label": "##r confirmed their down", "shape": "dot"}, {"color": "#97c2fc", "id": "four", "label": "four", "shape": "dot"}, {"color": "#97c2fc", "id": "prioriti", "label": "prioriti", "shape": "dot"}, {"color": "#97c2fc", "id": "pc", "label": "pc", "shape": "dot"}, {"color": "#97c2fc", "id": "of health of russia, moscow, russ", "label": "of health of russia, moscow, russ", "shape": "dot"}, {"color": "#97c2fc", "id": "diagnosed", "label": "diagnosed", "shape": "dot"}, {"color": "#97c2fc", "id": "##ncy in women. despite advances in", "label": "##ncy in women. despite advances in", "shape": "dot"}, {"color": "#97c2fc", "id": "incomplete", "label": "incomplete", "shape": "dot"}, {"color": "#97c2fc", "id": "ministry", "label": "ministry", "shape": "dot"}, {"color": "#97c2fc", "id": "##zed through integrative evaluation. qp", "label": "##zed through integrative evaluation. qp", "shape": "dot"}, {"color": "#97c2fc", "id": "diagnostic", "label": "diagnostic", "shape": "dot"}, {"color": "#97c2fc", "id": "mical physics, russian academy of science, moscow, russia.", "label": "mical physics, russian academy of science, moscow, russia.", "shape": "dot"}, {"color": "#97c2fc", "id": "##s and", "label": "##s and", "shape": "dot"}, {"color": "#97c2fc", "id": "##s.", "label": "##s.", "shape": "dot"}, {"color": "#97c2fc", "id": ". breast cancer is the most commonly", "label": ". breast cancer is the most commonly", "shape": "dot"}, {"color": "#97c2fc", "id": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "label": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "shape": "dot"}, {"color": "#97c2fc", "id": "treatment", "label": "treatment", "shape": "dot"}, {"color": "#97c2fc", "id": "##ly understood. this study aimed to identify novel l", "label": "##ly understood. this study aimed to identify novel l", "shape": "dot"}, {"color": "#97c2fc", "id": "- mi", "label": "- mi", "shape": "dot"}, {"color": "#97c2fc", "id": "##gna", "label": "##gna", "shape": "dot"}, {"color": "#97c2fc", "id": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "label": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "shape": "dot"}, {"color": "#97c2fc", "id": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "label": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "shape": "dot"}, {"color": "#97c2fc", "id": "##ncrna", "label": "##ncrna", "shape": "dot"}, {"color": "#97c2fc", "id": "##r", "label": "##r", "shape": "dot"}, {"color": "#97c2fc", "id": "mrna", "label": "mrna", "shape": "dot"}, {"color": "#97c2fc", "id": "mali", "label": "mali", "shape": "dot"}, {"color": "#97c2fc", "id": ", the key molecular mechanisms underlying its development remain", "label": ", the key molecular mechanisms underlying its development remain", "shape": "dot"}, {"color": "#97c2fc", "id": "=", "label": "=", "shape": "dot"}, {"color": "#97c2fc", "id": "##s,", "label": "##s,", "shape": "dot"}, {"color": "#97c2fc", "id": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "label": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "shape": "dot"}, {"color": "#97c2fc", "id": "which is involved in", "label": "which is involved in", "shape": "dot"}, {"color": "#97c2fc", "id": "- 0. 46,", "label": "- 0. 46,", "shape": "dot"}, {"color": "#97c2fc", "id": ". 04 ). collectively, these findings reveal novel co -", "label": ". 04 ). collectively, these findings reveal novel co -", "shape": "dot"}, {"color": "#97c2fc", "id": "mi", "label": "mi", "shape": "dot"}, {"color": "#97c2fc", "id": "- 5p", "label": "- 5p", "shape": "dot"}, {"color": "#97c2fc", "id": "##r - 17", "label": "##r - 17", "shape": "dot"}, {"color": "#97c2fc", "id": "##1", "label": "##1", "shape": "dot"}, {"color": "#97c2fc", "id": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "label": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "shape": "dot"}, {"color": "#97c2fc", "id": ") : e010548.", "label": ") : e010548.", "shape": "dot"}, {"color": "#97c2fc", "id": "5p", "label": "5p", "shape": "dot"}, {"color": "#97c2fc", "id": "hand", "label": "hand", "shape": "dot"}, {"color": "#97c2fc", "id": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "label": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "shape": "dot"}, {"color": "#97c2fc", "id": "03 ) and", "label": "03 ) and", "shape": "dot"}, {"color": "#97c2fc", "id": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "label": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "shape": "dot"}, {"color": "#97c2fc", "id": "##r - 106a -", "label": "##r - 106a -", "shape": "dot"}, {"color": "#97c2fc", "id": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "label": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "shape": "dot"}, {"color": "#97c2fc", "id": "target gene", "label": "target gene", "shape": "dot"}, {"color": "#97c2fc", "id": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "label": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "shape": "dot"}, {"color": "#97c2fc", "id": "- 0. 41,", "label": "- 0. 41,", "shape": "dot"}, {"color": "#97c2fc", "id": "of these lnc", "label": "of these lnc", "shape": "dot"}, {"color": "#97c2fc", "id": "p = 0.", "label": "p = 0.", "shape": "dot"}, {"color": "#97c2fc", "id": "113", "label": "113", "shape": "dot"}, {"color": "#97c2fc", "id": "common", "label": "common", "shape": "dot"}, {"color": "#97c2fc", "id": "regulated", "label": "regulated", "shape": "dot"}, {"color": "#97c2fc", "id": "mts9 - as2 - hand2 - as", "label": "mts9 - as2 - hand2 - as", "shape": "dot"}, {"color": "#97c2fc", "id": "2 ) department of pathology, memorial sloan kettering cancer center,", "label": "2 ) department of pathology, memorial sloan kettering cancer center,", "shape": "dot"}, {"color": "#97c2fc", "id": "), beltran - v", "label": "), beltran - v", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of pathology, co", "label": ") department of pathology, co", "shape": "dot"}, {"color": "#97c2fc", "id": "##ulin", "label": "##ulin", "shape": "dot"}, {"color": "#97c2fc", "id": "##pare therapeutics, boston, massachusetts, usa.", "label": "##pare therapeutics, boston, massachusetts, usa.", "shape": "dot"}, {"color": "#97c2fc", "id": "f", "label": "f", "shape": "dot"}, {"color": "#97c2fc", "id": "new yo", "label": "new yo", "shape": "dot"}, {"color": "#97c2fc", "id": "sloan", "label": "sloan", "shape": "dot"}, {"color": "#97c2fc", "id": "la", "label": "la", "shape": "dot"}, {"color": "#97c2fc", "id": "center", "label": "center", "shape": "dot"}, {"color": "#97c2fc", "id": "us", "label": "us", "shape": "dot"}, {"color": "#97c2fc", "id": "##lum", "label": "##lum", "shape": "dot"}, {"color": "#97c2fc", "id": "##o m", "label": "##o m", "shape": "dot"}, {"color": "#97c2fc", "id": "9", "label": "9", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "label": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "shape": "dot"}, {"color": "#97c2fc", "id": "kette", "label": "kette", "shape": "dot"}, {"color": "#97c2fc", "id": "yo", "label": "yo", "shape": "dot"}, {"color": "#97c2fc", "id": "##ettering cancer", "label": "##ettering cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "##rk, usa.", "label": "##rk, usa.", "shape": "dot"}, {"color": "#97c2fc", "id": "of radiation oncology, memorial sloan ket", "label": "of radiation oncology, memorial sloan ket", "shape": "dot"}, {"color": "#97c2fc", "id": "new york", "label": "new york", "shape": "dot"}, {"color": "#97c2fc", "id": "##bia university,", "label": "##bia university,", "shape": "dot"}, {"color": "#97c2fc", "id": "), shin e", "label": "), shin e", "shape": "dot"}, {"color": "#97c2fc", "id": "##ring cancer", "label": "##ring cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "##rk, new", "label": "##rk, new", "shape": "dot"}, {"color": "#97c2fc", "id": "##urent, quebec, canada.", "label": "##urent, quebec, canada.", "shape": "dot"}, {"color": "#97c2fc", "id": "##isied", "label": "##isied", "shape": "dot"}, {"color": "#97c2fc", "id": "##pare therapeutics, saint -", "label": "##pare therapeutics, saint -", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of radiation oncology, memorial sloan", "label": ") department of radiation oncology, memorial sloan", "shape": "dot"}, {"color": "#97c2fc", "id": "ancers. sinha s", "label": "ancers. sinha s", "shape": "dot"}, {"color": "#97c2fc", "id": "##is - filho j", "label": "##is - filho j", "shape": "dot"}, {"color": "#97c2fc", "id": "##rk,", "label": "##rk,", "shape": "dot"}, {"color": "#97c2fc", "id": "), gardner r", "label": "), gardner r", "shape": "dot"}, {"color": "#97c2fc", "id": ": we generated isogenic atm - null models using", "label": ": we generated isogenic atm - null models using", "shape": "dot"}, {"color": "#97c2fc", "id": "##rates were assessed by flow c", "label": "##rates were assessed by flow c", "shape": "dot"}, {"color": "#97c2fc", "id": ". org.", "label": ". org.", "shape": "dot"}, {"color": "#97c2fc", "id": "regulator", "label": "regulator", "shape": "dot"}, {"color": "#97c2fc", "id": "methods", "label": "methods", "shape": "dot"}, {"color": "#97c2fc", "id": ". org khana7 @ msk", "label": ". org khana7 @ msk", "shape": "dot"}, {"color": "#97c2fc", "id": "##yt", "label": "##yt", "shape": "dot"}, {"color": "#97c2fc", "id": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "label": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "shape": "dot"}, {"color": "#97c2fc", "id": "##ase functions,", "label": "##ase functions,", "shape": "dot"}, {"color": "#97c2fc", "id": "colorec", "label": "colorec", "shape": "dot"}, {"color": "#97c2fc", "id": "are known", "label": "are known", "shape": "dot"}, {"color": "#97c2fc", "id": "polymer", "label": "polymer", "shape": "dot"}, {"color": "#97c2fc", "id": "##r in murine triple -", "label": "##r in murine triple -", "shape": "dot"}, {"color": "#97c2fc", "id": "##chemistry in both murine tumors and human samples from breast and lung cancers", "label": "##chemistry in both murine tumors and human samples from breast and lung cancers", "shape": "dot"}, {"color": "#97c2fc", "id": "##tal", "label": "##tal", "shape": "dot"}, {"color": "#97c2fc", "id": "##lt", "label": "##lt", "shape": "dot"}, {"color": "#97c2fc", "id": "to enhance tumor immunogenicity. ataxia telangiectasia", "label": "to enhance tumor immunogenicity. ataxia telangiectasia", "shape": "dot"}, {"color": "#97c2fc", "id": "tering cancer center, new york, new york, usa riazn @ msk", "label": "tering cancer center, new york, new york, usa riazn @ msk", "shape": "dot"}, {"color": "#97c2fc", "id": "mutated", "label": "mutated", "shape": "dot"}, {"color": "#97c2fc", "id": "negative", "label": "negative", "shape": "dot"}, {"color": "#97c2fc", "id": "crisp", "label": "crisp", "shape": "dot"}, {"color": "#97c2fc", "id": "##ometry and immunohis", "label": "##ometry and immunohis", "shape": "dot"}, {"color": "#97c2fc", "id": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "label": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "shape": "dot"}, {"color": "#97c2fc", "id": "##to", "label": "##to", "shape": "dot"}, {"color": "#97c2fc", "id": "), and the top", "label": "), and the top", "shape": "dot"}, {"color": "#97c2fc", "id": "), a parp", "label": "), a parp", "shape": "dot"}, {"color": "#97c2fc", "id": "##point blockade", "label": "##point blockade", "shape": "dot"}, {"color": "#97c2fc", "id": "etop", "label": "etop", "shape": "dot"}, {"color": "#97c2fc", "id": "##ide - on", "label": "##ide - on", "shape": "dot"}, {"color": "#97c2fc", "id": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "label": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "shape": "dot"}, {"color": "#97c2fc", "id": "##ide, a top", "label": "##ide, a top", "shape": "dot"}, {"color": "#97c2fc", "id": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "label": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "shape": "dot"}, {"color": "#97c2fc", "id": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "label": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "shape": "dot"}, {"color": "#97c2fc", "id": "##ase ii", "label": "##ase ii", "shape": "dot"}, {"color": "#97c2fc", "id": "##g under these conditions. yet, pd - 1 - targeted immune check", "label": "##g under these conditions. yet, pd - 1 - targeted immune check", "shape": "dot"}, {"color": "#97c2fc", "id": "interfer", "label": "interfer", "shape": "dot"}, {"color": "#97c2fc", "id": "fails", "label": "fails", "shape": "dot"}, {"color": "#97c2fc", "id": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "label": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "shape": "dot"}, {"color": "#97c2fc", "id": "type", "label": "type", "shape": "dot"}, {"color": "#97c2fc", "id": "if", "label": "if", "shape": "dot"}, {"color": "#97c2fc", "id": "##fi", "label": "##fi", "shape": "dot"}, {"color": "#97c2fc", "id": ", emerging as the strongest activator of", "label": ", emerging as the strongest activator of", "shape": "dot"}, {"color": "#97c2fc", "id": "##oisomer", "label": "##oisomer", "shape": "dot"}, {"color": "#97c2fc", "id": "##n ) signaling, with etop", "label": "##n ) signaling, with etop", "shape": "dot"}, {"color": "#97c2fc", "id": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "label": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "shape": "dot"}, {"color": "#97c2fc", "id": "to encourage immune effector cell in", "label": "to encourage immune effector cell in", "shape": "dot"}, {"color": "#97c2fc", "id": "does", "label": "does", "shape": "dot"}, {"color": "#97c2fc", "id": "##ltration into tumors, and", "label": "##ltration into tumors, and", "shape": "dot"}, {"color": "#97c2fc", "id": "##on - stimulated gene", "label": "##on - stimulated gene", "shape": "dot"}, {"color": "#97c2fc", "id": "check", "label": "check", "shape": "dot"}, {"color": "#97c2fc", "id": "##on", "label": "##on", "shape": "dot"}, {"color": "#97c2fc", "id": "inhibitor", "label": "inhibitor", "shape": "dot"}, {"color": "#97c2fc", "id": "conclusions", "label": "conclusions", "shape": "dot"}, {"color": "#97c2fc", "id": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "label": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "shape": "dot"}, {"color": "#97c2fc", "id": "10. 113", "label": "10. 113", "shape": "dot"}, {"color": "#97c2fc", "id": "interests", "label": "interests", "shape": "dot"}, {"color": "#97c2fc", "id": ". no commercial re -", "label": ". no commercial re -", "shape": "dot"}, {"color": "#97c2fc", "id": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "label": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "shape": "dot"}, {"color": "#97c2fc", "id": "##ed for medline ] conflict of interest statement : competing", "label": "##ed for medline ] conflict of interest statement : competing", "shape": "dot"}, {"color": "#97c2fc", "id": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "label": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "shape": "dot"}, {"color": "#97c2fc", "id": ". see rights and permissions. published by bmj group.", "label": ". see rights and permissions. published by bmj group.", "shape": "dot"}, {"color": "#97c2fc", "id": ": nr receives research support from bm", "label": ": nr receives research support from bm", "shape": "dot"}, {"color": "#97c2fc", "id": "use", "label": "use", "shape": "dot"}, {"color": "#97c2fc", "id": ": atm deficiency, while com", "label": ": atm deficiency, while com", "shape": "dot"}, {"color": "#97c2fc", "id": "##ide in atm - null syngeneic tumor models, nor", "label": "##ide in atm - null syngeneic tumor models, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "label": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "shape": "dot"}, {"color": "#97c2fc", "id": "point blockade does not bolster the therapeutic activity of etop", "label": "point blockade does not bolster the therapeutic activity of etop", "shape": "dot"}, {"color": "#97c2fc", "id": "), huarte m", "label": "), huarte m", "shape": "dot"}, {"color": "#97c2fc", "id": "12", "label": "12", "shape": "dot"}, {"color": "#97c2fc", "id": "##407.", "label": "##407.", "shape": "dot"}, {"color": "#97c2fc", "id": "), par", "label": "), par", "shape": "dot"}, {"color": "#97c2fc", "id": "ins", "label": "ins", "shape": "dot"}, {"color": "#97c2fc", "id": "##or", "label": "##or", "shape": "dot"}, {"color": "#97c2fc", "id": "##e", "label": "##e", "shape": "dot"}, {"color": "#97c2fc", "id": "s, pfizer, repare therapuetics, and in", "label": "s, pfizer, repare therapuetics, and in", "shape": "dot"}, {"color": "#97c2fc", "id": "with lytix biopharma, promontory and onxeo,", "label": "with lytix biopharma, promontory and onxeo,", "shape": "dot"}, {"color": "#97c2fc", "id": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "label": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "shape": "dot"}, {"color": "#97c2fc", "id": "), aragon s", "label": "), aragon s", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "label": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "shape": "dot"}, {"color": "#97c2fc", "id": "##ory", "label": "##ory", "shape": "dot"}, {"color": "#97c2fc", "id": "), gimenez j", "label": "), gimenez j", "shape": "dot"}, {"color": "#97c2fc", "id": "- lopez i", "label": "- lopez i", "shape": "dot"}, {"color": "#97c2fc", "id": "##rine", "label": "##rine", "shape": "dot"}, {"color": "#97c2fc", "id": "er + / her2 -", "label": "er + / her2 -", "shape": "dot"}, {"color": "#97c2fc", "id": "), prat a", "label": "), prat a", "shape": "dot"}, {"color": "#97c2fc", "id": "research", "label": "research", "shape": "dot"}, {"color": "#97c2fc", "id": "##e. lg is /", "label": "##e. lg is /", "shape": "dot"}, {"color": "#97c2fc", "id": "), buch e", "label": "), buch e", "shape": "dot"}, {"color": "#97c2fc", "id": "##roga v", "label": "##roga v", "shape": "dot"}, {"color": "#97c2fc", "id": "been holding research", "label": "been holding research", "shape": "dot"}, {"color": "#97c2fc", "id": "11", "label": "11", "shape": "dot"}, {"color": "#97c2fc", "id": "101", "label": "101", "shape": "dot"}, {"color": "#97c2fc", "id": "##riaga k", "label": "##riaga k", "shape": "dot"}, {"color": "#97c2fc", "id": "), etxabe i", "label": "), etxabe i", "shape": "dot"}, {"color": "#97c2fc", "id": "##6 / j. tranon. 2025.", "label": "##6 / j. tranon. 2025.", "shape": "dot"}, {"color": "#97c2fc", "id": "1 ) biogipuzkoa", "label": "1 ) biogipuzkoa", "shape": "dot"}, {"color": "#97c2fc", "id": "13", "label": "13", "shape": "dot"}, {"color": "#97c2fc", "id": "therapy", "label": "therapy", "shape": "dot"}, {"color": "#97c2fc", "id": "##ui", "label": "##ui", "shape": "dot"}, {"color": "#97c2fc", "id": "##ez", "label": "##ez", "shape": "dot"}, {"color": "#97c2fc", "id": "##vita", "label": "##vita", "shape": "dot"}, {"color": "#97c2fc", "id": "contracts", "label": "contracts", "shape": "dot"}, {"color": "#97c2fc", "id": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "label": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "shape": "dot"}, {"color": "#97c2fc", "id": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "label": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "shape": "dot"}, {"color": "#97c2fc", "id": "). author information :", "label": "). author information :", "shape": "dot"}, {"color": "#97c2fc", "id": "), urruticoechea a", "label": "), urruticoechea a", "shape": "dot"}, {"color": "#97c2fc", "id": "##rio de v", "label": "##rio de v", "shape": "dot"}, {"color": "#97c2fc", "id": "t", "label": "t", "shape": "dot"}, {"color": "#97c2fc", "id": "##kolog", "label": "##kolog", "shape": "dot"}, {"color": "#97c2fc", "id": ", san", "label": ", san", "shape": "dot"}, {"color": "#97c2fc", "id": "##it", "label": "##it", "shape": "dot"}, {"color": "#97c2fc", "id": ") health", "label": ") health", "shape": "dot"}, {"color": "#97c2fc", "id": ") gynecology and general surgery departments - breast unit, on", "label": ") gynecology and general surgery departments - breast unit, on", "shape": "dot"}, {"color": "#97c2fc", "id": "##iba", "label": "##iba", "shape": "dot"}, {"color": "#97c2fc", "id": "##ialdea", "label": "##ialdea", "shape": "dot"}, {"color": "#97c2fc", "id": "##gipuzkoa", "label": "##gipuzkoa", "shape": "dot"}, {"color": "#97c2fc", "id": "##ko", "label": "##ko", "shape": "dot"}, {"color": "#97c2fc", "id": "##obe", "label": "##obe", "shape": "dot"}, {"color": "#97c2fc", "id": "se", "label": "se", "shape": "dot"}, {"color": "#97c2fc", "id": "##gi", "label": "##gi", "shape": "dot"}, {"color": "#97c2fc", "id": "##tian,", "label": "##tian,", "shape": "dot"}, {"color": "#97c2fc", "id": ") hospital clinico univers", "label": ") hospital clinico univers", "shape": "dot"}, {"color": "#97c2fc", "id": "##r 12, madrid,", "label": "##r 12, madrid,", "shape": "dot"}, {"color": "#97c2fc", "id": "spain", "label": "spain", "shape": "dot"}, {"color": "#97c2fc", "id": "##ale", "label": "##ale", "shape": "dot"}, {"color": "#97c2fc", "id": "##a", "label": "##a", "shape": "dot"}, {"color": "#97c2fc", "id": "##ute", "label": "##ute", "shape": "dot"}, {"color": "#97c2fc", "id": "##ikoa,", "label": "##ikoa,", "shape": "dot"}, {"color": "#97c2fc", "id": "##koa cancer unit / osi donost", "label": "##koa cancer unit / osi donost", "shape": "dot"}, {"color": "#97c2fc", "id": "##donost", "label": "##donost", "shape": "dot"}, {"color": "#97c2fc", "id": ") hospital oct", "label": ") hospital oct", "shape": "dot"}, {"color": "#97c2fc", "id": "research institute", "label": "research institute", "shape": "dot"}, {"color": "#97c2fc", "id": "institute", "label": "institute", "shape": "dot"}, {"color": "#97c2fc", "id": "sa", "label": "sa", "shape": "dot"}, {"color": "#97c2fc", "id": "sebas", "label": "sebas", "shape": "dot"}, {"color": "#97c2fc", "id": "; gynecology and general surgery departments - breast unit, onkologikoa,", "label": "; gynecology and general surgery departments - breast unit, onkologikoa,", "shape": "dot"}, {"color": "#97c2fc", "id": "##ita", "label": "##ita", "shape": "dot"}, {"color": "#97c2fc", "id": ", v", "label": ", v", "shape": "dot"}, {"color": "#97c2fc", "id": "##ps, barcelon", "label": "##ps, barcelon", "shape": "dot"}, {"color": "#97c2fc", "id": ") hospital clinic, barcelona - id", "label": ") hospital clinic, barcelona - id", "shape": "dot"}, {"color": "#97c2fc", "id": "##n", "label": "##n", "shape": "dot"}, {"color": "#97c2fc", "id": "##pu", "label": "##pu", "shape": "dot"}, {"color": "#97c2fc", "id": "sebastian", "label": "sebastian", "shape": "dot"}, {"color": "#97c2fc", "id": "; gip", "label": "; gip", "shape": "dot"}, {"color": "#97c2fc", "id": "- on", "label": "- on", "shape": "dot"}, {"color": "#97c2fc", "id": "7 ) valencia oncology", "label": "7 ) valencia oncology", "shape": "dot"}, {"color": "#97c2fc", "id": "##ncia,", "label": "##ncia,", "shape": "dot"}, {"color": "#97c2fc", "id": "##uz", "label": "##uz", "shape": "dot"}, {"color": "#97c2fc", "id": "; gynecology department - breast unit, osi donost", "label": "; gynecology department - breast unit, osi donost", "shape": "dot"}, {"color": "#97c2fc", "id": "- onkologikoa, san", "label": "- onkologikoa, san", "shape": "dot"}, {"color": "#97c2fc", "id": "##z", "label": "##z", "shape": "dot"}, {"color": "#97c2fc", "id": "##bastian, spa", "label": "##bastian, spa", "shape": "dot"}, {"color": "#97c2fc", "id": "after net", "label": "after net", "shape": "dot"}, {"color": "#97c2fc", "id": "a significant", "label": "a significant", "shape": "dot"}, {"color": "#97c2fc", "id": "offers the opportunity of", "label": "offers the opportunity of", "shape": "dot"}, {"color": "#97c2fc", "id": "##ip", "label": "##ip", "shape": "dot"}, {"color": "#97c2fc", "id": "background", "label": "background", "shape": "dot"}, {"color": "#97c2fc", "id": "##re population of", "label": "##re population of", "shape": "dot"}, {"color": "#97c2fc", "id": "negative breast", "label": "negative breast", "shape": "dot"}, {"color": "#97c2fc", "id": "barrier", "label": "barrier", "shape": "dot"}, {"color": "#97c2fc", "id": "clinical", "label": "clinical", "shape": "dot"}, {"color": "#97c2fc", "id": "##2 -", "label": "##2 -", "shape": "dot"}, {"color": "#97c2fc", "id": "##ly relevant molecular reporters of response to net in a multi", "label": "##ly relevant molecular reporters of response to net in a multi", "shape": "dot"}, {"color": "#97c2fc", "id": "##zkoa", "label": "##zkoa", "shape": "dot"}, {"color": "#97c2fc", "id": "to increase its indications. methods : in this study we searched for", "label": "to increase its indications. methods : in this study we searched for", "shape": "dot"}, {"color": "#97c2fc", "id": "##donostia ) health", "label": "##donostia ) health", "shape": "dot"}, {"color": "#97c2fc", "id": "cancer", "label": "cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "##uzkoa. eus.", "label": "##uzkoa. eus.", "shape": "dot"}, {"color": "#97c2fc", "id": ". electronic address : aurruticoechea @ onkologikoa. org.", "label": ". electronic address : aurruticoechea @ onkologikoa. org.", "shape": "dot"}, {"color": "#97c2fc", "id": ": neoadjuvant endocrine therapy", "label": ": neoadjuvant endocrine therapy", "shape": "dot"}, {"color": "#97c2fc", "id": "personal", "label": "personal", "shape": "dot"}, {"color": "#97c2fc", "id": "##ised therapy.", "label": "##ised therapy.", "shape": "dot"}, {"color": "#97c2fc", "id": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "label": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "shape": "dot"}, {"color": "#97c2fc", "id": "##cent", "label": "##cent", "shape": "dot"}, {"color": "#97c2fc", "id": "oestrogen receptor - positive /", "label": "oestrogen receptor - positive /", "shape": "dot"}, {"color": "#97c2fc", "id": "evaluation of treatment sensitivity by monitoring", "label": "evaluation of treatment sensitivity by monitoring", "shape": "dot"}, {"color": "#97c2fc", "id": "her", "label": "her", "shape": "dot"}, {"color": "#97c2fc", "id": "##ible biomarkers to assess response and long - term pro", "label": "##ible biomarkers to assess response and long - term pro", "shape": "dot"}, {"color": "#97c2fc", "id": "##n sebastian,", "label": "##n sebastian,", "shape": "dot"}, {"color": "#97c2fc", "id": "##umour response", "label": "##umour response", "shape": "dot"}, {"color": "#97c2fc", "id": "a,", "label": "a,", "shape": "dot"}, {"color": "#97c2fc", "id": "##uc", "label": "##uc", "shape": "dot"}, {"color": "#97c2fc", "id": ", the lack of reprod", "label": ", the lack of reprod", "shape": "dot"}, {"color": "#97c2fc", "id": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "label": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "shape": "dot"}, {"color": "#97c2fc", "id": "##c ) allows", "label": "##c ) allows", "shape": "dot"}, {"color": "#97c2fc", "id": "##gnosis", "label": "##gnosis", "shape": "dot"}, {"color": "#97c2fc", "id": "- g", "label": "- g", "shape": "dot"}, {"color": "#97c2fc", "id": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "label": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "shape": "dot"}, {"color": "#97c2fc", "id": "in ki", "label": "in ki", "shape": "dot"}, {"color": "#97c2fc", "id": "##cu", "label": "##cu", "shape": "dot"}, {"color": "#97c2fc", "id": "positive", "label": "positive", "shape": "dot"}, {"color": "#97c2fc", "id": "##logical and pathological tumour responses, a significant larger decrease", "label": "##logical and pathological tumour responses, a significant larger decrease", "shape": "dot"}, {"color": "#97c2fc", "id": "##rrence", "label": "##rrence", "shape": "dot"}, {"color": "#97c2fc", "id": "percentage", "label": "percentage", "shape": "dot"}, {"color": "#97c2fc", "id": "##67 at surgery, lower preoperative endocrine prognostic", "label": "##67 at surgery, lower preoperative endocrine prognostic", "shape": "dot"}, {"color": "#97c2fc", "id": "was associated with decreased response to net. conclusions : our findings highlight the", "label": "was associated with decreased response to net. conclusions : our findings highlight the", "shape": "dot"}, {"color": "#97c2fc", "id": "from l", "label": "from l", "shape": "dot"}, {"color": "#97c2fc", "id": "presented", "label": "presented", "shape": "dot"}, {"color": "#97c2fc", "id": "results", "label": "results", "shape": "dot"}, {"color": "#97c2fc", "id": "pam50 - derived risk of", "label": "pam50 - derived risk of", "shape": "dot"}, {"color": "#97c2fc", "id": "er + /", "label": "er + /", "shape": "dot"}, {"color": "#97c2fc", "id": "##nal a to normal - like", "label": "##nal a to normal - like", "shape": "dot"}, {"color": "#97c2fc", "id": ": our pam50 analyses show that tumours changing from l", "label": ": our pam50 analyses show that tumours changing from l", "shape": "dot"}, {"color": "#97c2fc", "id": "cells", "label": "cells", "shape": "dot"}, {"color": "#97c2fc", "id": "change", "label": "change", "shape": "dot"}, {"color": "#97c2fc", "id": "after", "label": "after", "shape": "dot"}, {"color": "#97c2fc", "id": "##or ) following net. in addition, the", "label": "##or ) following net. in addition, the", "shape": "dot"}, {"color": "#97c2fc", "id": "of intrinsic sub", "label": "of intrinsic sub", "shape": "dot"}, {"color": "#97c2fc", "id": "p53", "label": "p53", "shape": "dot"}, {"color": "#97c2fc", "id": "##is.", "label": "##is.", "shape": "dot"}, {"color": "#97c2fc", "id": "biomark", "label": "biomark", "shape": "dot"}, {"color": "#97c2fc", "id": "subtype after", "label": "subtype after", "shape": "dot"}, {"color": "#97c2fc", "id": "net", "label": "net", "shape": "dot"}, {"color": "#97c2fc", "id": "of", "label": "of", "shape": "dot"}, {"color": "#97c2fc", "id": "##c patients", "label": "##c patients", "shape": "dot"}, {"color": "#97c2fc", "id": "net as a putative", "label": "net as a putative", "shape": "dot"}, {"color": "#97c2fc", "id": "##umour cellularity size", "label": "##umour cellularity size", "shape": "dot"}, {"color": "#97c2fc", "id": "radio", "label": "radio", "shape": "dot"}, {"color": "#97c2fc", "id": ") and lower", "label": ") and lower", "shape": "dot"}, {"color": "#97c2fc", "id": "better", "label": "better", "shape": "dot"}, {"color": "#97c2fc", "id": "of prosigna for adjuvant treatment decisions", "label": "of prosigna for adjuvant treatment decisions", "shape": "dot"}, {"color": "#97c2fc", "id": "am50 - derived ror score and p53 evaluation could also", "label": "am50 - derived ror score and p53 evaluation could also", "shape": "dot"}, {"color": "#97c2fc", "id": "##6 /", "label": "##6 /", "shape": "dot"}, {"color": "#97c2fc", "id": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "label": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "shape": "dot"}, {"color": "#97c2fc", "id": "be validated in independent cohorts,", "label": "be validated in independent cohorts,", "shape": "dot"}, {"color": "#97c2fc", "id": "cost - effectiveness", "label": "cost - effectiveness", "shape": "dot"}, {"color": "#97c2fc", "id": "##ers of response to net and pro", "label": "##ers of response to net and pro", "shape": "dot"}, {"color": "#97c2fc", "id": "10. 101", "label": "10. 101", "shape": "dot"}, {"color": "#97c2fc", "id": "help", "label": "help", "shape": "dot"}, {"color": "#97c2fc", "id": "breast cancer. 2025 apr 15 : s1526 - 8209", "label": "breast cancer. 2025 apr 15 : s1526 - 8209", "shape": "dot"}, {"color": "#97c2fc", "id": "##sis, which", "label": "##sis, which", "shape": "dot"}, {"color": "#97c2fc", "id": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "label": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "shape": "dot"}, {"color": "#97c2fc", "id": "##lin", "label": "##lin", "shape": "dot"}, {"color": "#97c2fc", "id": "should", "label": "should", "shape": "dot"}, {"color": "#97c2fc", "id": "202", "label": "202", "shape": "dot"}, {"color": "#97c2fc", "id": "to identify those patients. thus, this study uncovers potential bio", "label": "to identify those patients. thus, this study uncovers potential bio", "shape": "dot"}, {"color": "#97c2fc", "id": "helping to the", "label": "helping to the", "shape": "dot"}, {"color": "#97c2fc", "id": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "label": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "shape": "dot"}, {"color": "#97c2fc", "id": "implementation of net", "label": "implementation of net", "shape": "dot"}, {"color": "#97c2fc", "id": "##mark", "label": "##mark", "shape": "dot"}, {"color": "#97c2fc", "id": "##ranon.", "label": "##ranon.", "shape": "dot"}, {"color": "#97c2fc", "id": ". clbc. 202", "label": ". clbc. 202", "shape": "dot"}, {"color": "#97c2fc", "id": ". 04. 011. online ahead of print.", "label": ". 04. 011. online ahead of print.", "shape": "dot"}, {"color": "#97c2fc", "id": "##5.", "label": "##5.", "shape": "dot"}, {"color": "#97c2fc", "id": "##rgen, norway.", "label": "##rgen, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "##rgen, nor", "label": "##rgen, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "economics", "label": "economics", "shape": "dot"}, {"color": "#97c2fc", "id": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "label": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "##roms\u00f8, norway ;", "label": "##roms\u00f8, norway ;", "shape": "dot"}, {"color": "#97c2fc", "id": "of oncology, hospital of southern norway, kristiansand, norway.", "label": "of oncology, hospital of southern norway, kristiansand, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "clinical trials", "label": "clinical trials", "shape": "dot"}, {"color": "#97c2fc", "id": "of health management and health", "label": "of health management and health", "shape": "dot"}, {"color": "#97c2fc", "id": ";", "label": ";", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of p", "label": ") department of p", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of oncology, university of north norway,", "label": ") department of oncology, university of north norway,", "shape": "dot"}, {"color": "#97c2fc", "id": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "label": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "shape": "dot"}, {"color": "#97c2fc", "id": "), heie a", "label": "), heie a", "shape": "dot"}, {"color": "#97c2fc", "id": "unit, oslo university hospital, oslo, nor", "label": "unit, oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "be", "label": "be", "shape": "dot"}, {"color": "#97c2fc", "id": "; department of pathology haukeland university hospital,", "label": "; department of pathology haukeland university hospital,", "shape": "dot"}, {"color": "#97c2fc", "id": "ug", "label": "ug", "shape": "dot"}, {"color": "#97c2fc", "id": "##way", "label": "##way", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of", "label": ") department of", "shape": "dot"}, {"color": "#97c2fc", "id": "; menzies health institute queensland and griffith university, southport, austra", "label": "; menzies health institute queensland and griffith university, southport, austra", "shape": "dot"}, {"color": "#97c2fc", "id": "for cancer", "label": "for cancer", "shape": "dot"}, {"color": "#97c2fc", "id": "##lia", "label": "##lia", "shape": "dot"}, {"color": "#97c2fc", "id": "##vanger,", "label": "##vanger,", "shape": "dot"}, {"color": "#97c2fc", "id": "of breast surgery, haukeland university hospital, bergen, norway.", "label": "of breast surgery, haukeland university hospital, bergen, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "##vanger university, s", "label": "##vanger university, s", "shape": "dot"}, {"color": "#97c2fc", "id": "8", "label": "8", "shape": "dot"}, {"color": "#97c2fc", "id": "of cancer genetics,", "label": "of cancer genetics,", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of pathology, st olavs hospital, trondheim, norway.", "label": ") department of pathology, st olavs hospital, trondheim, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "12 ) department", "label": "12 ) department", "shape": "dot"}, {"color": "#97c2fc", "id": ", oslo university hospital, oslo, nor", "label": ", oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "of chemistry, bioscience and environmental engineering, s", "label": "of chemistry, bioscience and environmental engineering, s", "shape": "dot"}, {"color": "#97c2fc", "id": "##vanger university hospital, s", "label": "##vanger university hospital, s", "shape": "dot"}, {"color": "#97c2fc", "id": "ha", "label": "ha", "shape": "dot"}, {"color": "#97c2fc", "id": "norway", "label": "norway", "shape": "dot"}, {"color": "#97c2fc", "id": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "label": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "label": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "of pathology, s", "label": "of pathology, s", "shape": "dot"}, {"color": "#97c2fc", "id": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "label": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "label": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": ", drammen, norway.", "label": ", drammen, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "of clinical medicine,", "label": "of clinical medicine,", "shape": "dot"}, {"color": "#97c2fc", "id": "##dheim, norway.", "label": "##dheim, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "25", "label": "25", "shape": "dot"}, {"color": "#97c2fc", "id": "trust", "label": "trust", "shape": "dot"}, {"color": "#97c2fc", "id": "for cancer research, oslo university hospital, oslo, nor", "label": "for cancer research, oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "label": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": ", hamar, norway.", "label": ", hamar, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": ", kalnes, norway.", "label": ", kalnes, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": ", skien, norway.", "label": ", skien, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "of oslo, oslo, nor", "label": "of oslo, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "label": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "shape": "dot"}, {"color": "#97c2fc", "id": ") department of oncolog", "label": ") department of oncolog", "shape": "dot"}, {"color": "#97c2fc", "id": "##ron", "label": "##ron", "shape": "dot"}, {"color": "#97c2fc", "id": "the", "label": "the", "shape": "dot"}, {"color": "#97c2fc", "id": "profiling tests such as the prosigna - assay are", "label": "profiling tests such as the prosigna - assay are", "shape": "dot"}, {"color": "#97c2fc", "id": "hormone receptor positive", "label": "hormone receptor positive", "shape": "dot"}, {"color": "#97c2fc", "id": "societal perspective", "label": "societal perspective", "shape": "dot"}, {"color": "#97c2fc", "id": "benefits", "label": "benefits", "shape": "dot"}, {"color": "#97c2fc", "id": "surgery", "label": "surgery", "shape": "dot"}, {"color": "#97c2fc", "id": "cost -", "label": "cost -", "shape": "dot"}, {"color": "#97c2fc", "id": ". using individual data collected the first 12 months", "label": ". using individual data collected the first 12 months", "shape": "dot"}, {"color": "#97c2fc", "id": "effectiveness of prosigna against immunohistochemical", "label": "effectiveness of prosigna against immunohistochemical", "shape": "dot"}, {"color": "#97c2fc", "id": "decision", "label": "decision", "shape": "dot"}, {"color": "#97c2fc", "id": "to aid adjuvant treatment", "label": "to aid adjuvant treatment", "shape": "dot"}, {"color": "#97c2fc", "id": "##al", "label": "##al", "shape": "dot"}, {"color": "#97c2fc", "id": "emit - 1 trial", "label": "emit - 1 trial", "shape": "dot"}, {"color": "#97c2fc", "id": "post", "label": "post", "shape": "dot"}, {"color": "#97c2fc", "id": ". materials", "label": ". materials", "shape": "dot"}, {"color": "#97c2fc", "id": "model was", "label": "model was", "shape": "dot"}, {"color": "#97c2fc", "id": "of cancer medicine, oslo university hospital, oslo, norway ;", "label": "of cancer medicine, oslo university hospital, oslo, norway ;", "shape": "dot"}, {"color": "#97c2fc", "id": "used", "label": "used", "shape": "dot"}, {"color": "#97c2fc", "id": ": the", "label": ": the", "shape": "dot"}, {"color": "#97c2fc", "id": "ki - 67", "label": "ki - 67", "shape": "dot"}, {"color": "#97c2fc", "id": ", was evaluated from the norwegian healthcare -", "label": ", was evaluated from the norwegian healthcare -", "shape": "dot"}, {"color": "#97c2fc", "id": "of clinical medicine, university of oslo, oslo, norway. background : gene", "label": "of clinical medicine, university of oslo, oslo, norway. background : gene", "shape": "dot"}, {"color": "#97c2fc", "id": "prosigna was tested", "label": "prosigna was tested", "shape": "dot"}, {"color": "#97c2fc", "id": "prospective", "label": "prospective", "shape": "dot"}, {"color": "#97c2fc", "id": "were measured", "label": "were measured", "shape": "dot"}, {"color": "#97c2fc", "id": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "label": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "shape": "dot"}, {"color": "#97c2fc", "id": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "label": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "observation", "label": "observation", "shape": "dot"}, {"color": "#97c2fc", "id": "division", "label": "division", "shape": "dot"}, {"color": "#97c2fc", "id": "decisions in", "label": "decisions in", "shape": "dot"}, {"color": "#97c2fc", "id": "built", "label": "built", "shape": "dot"}, {"color": "#97c2fc", "id": "impact of", "label": "impact of", "shape": "dot"}, {"color": "#97c2fc", "id": "from a healthcare perspective, but from the societal perspective", "label": "from a healthcare perspective, but from the societal perspective", "shape": "dot"}, {"color": "#97c2fc", "id": "benefit", "label": "benefit", "shape": "dot"}, {"color": "#97c2fc", "id": "##26, 000 ;", "label": "##26, 000 ;", "shape": "dot"}, {"color": "#97c2fc", "id": "effective", "label": "effective", "shape": "dot"}, {"color": "#97c2fc", "id": "it was cost - saving", "label": "it was cost - saving", "shape": "dot"}, {"color": "#97c2fc", "id": "threshold", "label": "threshold", "shape": "dot"}, {"color": "#97c2fc", "id": "- 435, 677 )", "label": "- 435, 677 )", "shape": "dot"}, {"color": "#97c2fc", "id": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "label": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "shape": "dot"}, {"color": "#97c2fc", "id": "##aly", "label": "##aly", "shape": "dot"}, {"color": "#97c2fc", "id": "in the", "label": "in the", "shape": "dot"}, {"color": "#97c2fc", "id": "cost", "label": "cost", "shape": "dot"}, {"color": "#97c2fc", "id": "\u20ac", "label": "\u20ac", "shape": "dot"}, {"color": "#97c2fc", "id": "perspective. incorporating also productivity costs, prosigna", "label": "perspective. incorporating also productivity costs, prosigna", "shape": "dot"}, {"color": "#97c2fc", "id": "- 620170,", "label": "- 620170,", "shape": "dot"}, {"color": "#97c2fc", "id": "##r )", "label": "##r )", "shape": "dot"}, {"color": "#97c2fc", "id": "restricting prosigna - testing to patients assessed as clear / uncertain", "label": "restricting prosigna - testing to patients assessed as clear / uncertain", "shape": "dot"}, {"color": "#97c2fc", "id": "candidates, the strategy", "label": "candidates, the strategy", "shape": "dot"}, {"color": "#97c2fc", "id": "cost - effective", "label": "cost - effective", "shape": "dot"}, {"color": "#97c2fc", "id": "incre", "label": "incre", "shape": "dot"}, {"color": "#97c2fc", "id": "prosigna - test strategy, the test", "label": "prosigna - test strategy, the test", "shape": "dot"}, {"color": "#97c2fc", "id": "##mental", "label": "##mental", "shape": "dot"}, {"color": "#97c2fc", "id": "the cost -", "label": "the cost -", "shape": "dot"}, {"color": "#97c2fc", "id": "was cost - effective", "label": "was cost - effective", "shape": "dot"}, {"color": "#97c2fc", "id": "above", "label": "above", "shape": "dot"}, {"color": "#97c2fc", "id": "was obtained from statistics norway.", "label": "was obtained from statistics norway.", "shape": "dot"}, {"color": "#97c2fc", "id": "per quality - adjusted life -", "label": "per quality - adjusted life -", "shape": "dot"}, {"color": "#97c2fc", "id": "was cost - saving", "label": "was cost - saving", "shape": "dot"}, {"color": "#97c2fc", "id": ": of 2, 178 hr + / her2 - pn0 ebc patients", "label": ": of 2, 178 hr + / her2 - pn0 ebc patients", "shape": "dot"}, {"color": "#97c2fc", "id": "chemotherapy", "label": "chemotherapy", "shape": "dot"}, {"color": "#97c2fc", "id": "in both the healthcare", "label": "in both the healthcare", "shape": "dot"}, {"color": "#97c2fc", "id": "years", "label": "years", "shape": "dot"}, {"color": "#97c2fc", "id": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "label": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "shape": "dot"}, {"color": "#97c2fc", "id": "- per q", "label": "- per q", "shape": "dot"}, {"color": "#97c2fc", "id": "##255, 622 ) in a healthcare", "label": "##255, 622 ) in a healthcare", "shape": "dot"}, {"color": "#97c2fc", "id": ". conclusions", "label": ". conclusions", "shape": "dot"}, {"color": "#97c2fc", "id": ". selecting patient", "label": ". selecting patient", "shape": "dot"}, {"color": "#97c2fc", "id": "ice", "label": "ice", "shape": "dot"}, {"color": "#97c2fc", "id": "##8884 and", "label": "##8884 and", "shape": "dot"}, {"color": "#97c2fc", "id": "gained", "label": "gained", "shape": "dot"}, {"color": "#97c2fc", "id": "the emit", "label": "the emit", "shape": "dot"}, {"color": "#97c2fc", "id": "records. including all pn0 patients", "label": "records. including all pn0 patients", "shape": "dot"}, {"color": "#97c2fc", "id": "sector", "label": "sector", "shape": "dot"}, {"color": "#97c2fc", "id": "not", "label": "not", "shape": "dot"}, {"color": "#97c2fc", "id": "is cost - effective", "label": "is cost - effective", "shape": "dot"}, {"color": "#97c2fc", "id": "of agriculture and natural", "label": "of agriculture and natural", "shape": "dot"}, {"color": "#97c2fc", "id": ". ac.", "label": ". ac.", "shape": "dot"}, {"color": "#97c2fc", "id": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "label": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "shape": "dot"}, {"color": "#97c2fc", "id": "resources", "label": "resources", "shape": "dot"}, {"color": "#97c2fc", "id": "biotechnol. 2025 may 8 : s0168 - 1656", "label": "biotechnol. 2025 may 8 : s0168 - 1656", "shape": "dot"}, {"color": "#97c2fc", "id": "##za. he", "label": "##za. he", "shape": "dot"}, {"color": "#97c2fc", "id": "are", "label": "are", "shape": "dot"}, {"color": "#97c2fc", "id": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "label": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "shape": "dot"}, {"color": "#97c2fc", "id": "##ri - japelaghi r", "label": "##ri - japelaghi r", "shape": "dot"}, {"color": "#97c2fc", "id": "##r.", "label": "##r.", "shape": "dot"}, {"color": "#97c2fc", "id": "who", "label": "who", "shape": "dot"}, {"color": "#97c2fc", "id": "inter", "label": "inter", "shape": "dot"}, {"color": "#97c2fc", "id": "##vin", "label": "##vin", "shape": "dot"}, {"color": "#97c2fc", "id": "of tabriz,", "label": "of tabriz,", "shape": "dot"}, {"color": "#97c2fc", "id": "@ org.", "label": "@ org.", "shape": "dot"}, {"color": "#97c2fc", "id": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "label": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "shape": "dot"}, {"color": "#97c2fc", "id": ". clbc. 2025. 04. 011 pmid :", "label": ". clbc. 2025. 04. 011 pmid :", "shape": "dot"}, {"color": "#97c2fc", "id": "##idari", "label": "##idari", "shape": "dot"}, {"color": "#97c2fc", "id": "s", "label": "s", "shape": "dot"}, {"color": "#97c2fc", "id": "##biotec. 2025. 04. 022. online ahead of print.", "label": "##biotec. 2025. 04. 022. online ahead of print.", "shape": "dot"}, {"color": "#97c2fc", "id": "ta", "label": "ta", "shape": "dot"}, {"color": "#97c2fc", "id": "##ran. electronic address :", "label": "##ran. electronic address :", "shape": "dot"}, {"color": "#97c2fc", "id": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "label": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "shape": "dot"}, {"color": "#97c2fc", "id": ", imam khomeini international university, qaz", "label": ", imam khomeini international university, qaz", "shape": "dot"}, {"color": "#97c2fc", "id": "perspectives", "label": "perspectives", "shape": "dot"}, {"color": "#97c2fc", "id": "##briz,", "label": "##briz,", "shape": "dot"}, {"color": "#97c2fc", "id": "of agriculture,", "label": "of agriculture,", "shape": "dot"}, {"color": "#97c2fc", "id": "##fer", "label": "##fer", "shape": "dot"}, {"color": "#97c2fc", "id": "##ki", "label": "##ki", "shape": "dot"}, {"color": "#97c2fc", "id": "from both", "label": "from both", "shape": "dot"}, {"color": "#97c2fc", "id": "##ran.", "label": "##ran.", "shape": "dot"}, {"color": "#97c2fc", "id": "of agriculture and natural resources, imam khomeini international university, qazvin,", "label": "of agriculture and natural resources, imam khomeini international university, qazvin,", "shape": "dot"}, {"color": "#97c2fc", "id": "##ifer", "label": "##ifer", "shape": "dot"}, {"color": "#97c2fc", "id": "that their activation leads to the antiprol", "label": "that their activation leads to the antiprol", "shape": "dot"}, {"color": "#97c2fc", "id": "##ne - c", "label": "##ne - c", "shape": "dot"}, {"color": "#97c2fc", "id": ", tnf signaling", "label": ", tnf signaling", "shape": "dot"}, {"color": "#97c2fc", "id": ", which", "label": ", which", "shape": "dot"}, {"color": "#97c2fc", "id": "down - regulated", "label": "down - regulated", "shape": "dot"}, {"color": "#97c2fc", "id": "including c", "label": "including c", "shape": "dot"}, {"color": "#97c2fc", "id": "##ytoki", "label": "##ytoki", "shape": "dot"}, {"color": "#97c2fc", "id": "detected", "label": "detected", "shape": "dot"}, {"color": "#97c2fc", "id": "##viral role of the hifn - \u03b3 preparations was evaluated by", "label": "##viral role of the hifn - \u03b3 preparations was evaluated by", "shape": "dot"}, {"color": "#97c2fc", "id": "vs", "label": "vs", "shape": "dot"}, {"color": "#97c2fc", "id": "##cer assays. the", "label": "##cer assays. the", "shape": "dot"}, {"color": "#97c2fc", "id": "or", "label": "or", "shape": "dot"}, {"color": "#97c2fc", "id": "##hibition of vesicular stomatitis virus", "label": "##hibition of vesicular stomatitis virus", "shape": "dot"}, {"color": "#97c2fc", "id": "##ne receptor", "label": "##ne receptor", "shape": "dot"}, {"color": "#97c2fc", "id": "##ap", "label": "##ap", "shape": "dot"}, {"color": "#97c2fc", "id": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "label": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "shape": "dot"}, {"color": "#97c2fc", "id": "##n - \u03b3. moreover, several", "label": "##n - \u03b3. moreover, several", "shape": "dot"}, {"color": "#97c2fc", "id": "via", "label": "via", "shape": "dot"}, {"color": "#97c2fc", "id": "anti", "label": "anti", "shape": "dot"}, {"color": "#97c2fc", "id": "##n - \u03b3", "label": "##n - \u03b3", "shape": "dot"}, {"color": "#97c2fc", "id": "##ran. by performing a biological network analysis, we identified some hub", "label": "##ran. by performing a biological network analysis, we identified some hub", "shape": "dot"}, {"color": "#97c2fc", "id": "f biotechnology engineering,", "label": "f biotechnology engineering,", "shape": "dot"}, {"color": "#97c2fc", "id": "were up -", "label": "were up -", "shape": "dot"}, {"color": "#97c2fc", "id": ", nod - like receptor signaling", "label": ", nod - like receptor signaling", "shape": "dot"}, {"color": "#97c2fc", "id": "##ation, pro", "label": "##ation, pro", "shape": "dot"}, {"color": "#97c2fc", "id": "pathways", "label": "pathways", "shape": "dot"}, {"color": "#97c2fc", "id": "##bility was observed at different concentrations of recombinant", "label": "##bility was observed at different concentrations of recombinant", "shape": "dot"}, {"color": "#97c2fc", "id": ", and nf - \u03bab signaling pathway were", "label": ", and nf - \u03bab signaling pathway were", "shape": "dot"}, {"color": "#97c2fc", "id": "pathway", "label": "pathway", "shape": "dot"}, {"color": "#97c2fc", "id": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "label": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "shape": "dot"}, {"color": "#97c2fc", "id": "- regulate", "label": "- regulate", "shape": "dot"}, {"color": "#97c2fc", "id": "##fn - \u03b3 toward mcf - 7 cells via a", "label": "##fn - \u03b3 toward mcf - 7 cells via a", "shape": "dot"}, {"color": "#97c2fc", "id": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "label": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "shape": "dot"}, {"color": "#97c2fc", "id": "##tic", "label": "##tic", "shape": "dot"}, {"color": "#97c2fc", "id": "##6", "label": "##6", "shape": "dot"}, {"color": "#97c2fc", "id": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "label": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "shape": "dot"}, {"color": "#97c2fc", "id": "##xic effect of", "label": "##xic effect of", "shape": "dot"}, {"color": "#97c2fc", "id": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "label": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "shape": "dot"}, {"color": "#97c2fc", "id": "##fn - \u03b3 preparations on the growth", "label": "##fn - \u03b3 preparations on the growth", "shape": "dot"}, {"color": "#97c2fc", "id": "##xic efficacy of the", "label": "##xic efficacy of the", "shape": "dot"}, {"color": "#97c2fc", "id": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "label": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "shape": "dot"}, {"color": "#97c2fc", "id": ", and stat1 using rt - pcr. furthermore, the", "label": ", and stat1 using rt - pcr. furthermore, the", "shape": "dot"}, {"color": "#97c2fc", "id": "up -", "label": "up -", "shape": "dot"}, {"color": "#97c2fc", "id": "proteins. the maximum amount of the cell", "label": "proteins. the maximum amount of the cell", "shape": "dot"}, {"color": "#97c2fc", "id": "##fn - \u03b3 preparations were significantly able", "label": "##fn - \u03b3 preparations were significantly able", "shape": "dot"}, {"color": "#97c2fc", "id": "development of tumor cells, a", "label": "development of tumor cells, a", "shape": "dot"}, {"color": "#97c2fc", "id": "##348089 conflict o", "label": "##348089 conflict o", "shape": "dot"}, {"color": "#97c2fc", "id": "regulate", "label": "regulate", "shape": "dot"}, {"color": "#97c2fc", "id": "of pro", "label": "of pro", "shape": "dot"}, {"color": "#97c2fc", "id": "##cl -", "label": "##cl -", "shape": "dot"}, {"color": "#97c2fc", "id": "##biotec. 2025.", "label": "##biotec. 2025.", "shape": "dot"}, {"color": "#97c2fc", "id": "04", "label": "04", "shape": "dot"}, {"color": "#97c2fc", "id": "##apopto", "label": "##apopto", "shape": "dot"}, {"color": "#97c2fc", "id": "to", "label": "to", "shape": "dot"}, {"color": "#97c2fc", "id": "##cer and antiviral functions of", "label": "##cer and antiviral functions of", "shape": "dot"}, {"color": "#97c2fc", "id": "2 as an antiapoptotic gene, showing the cyt", "label": "2 as an antiapoptotic gene, showing the cyt", "shape": "dot"}, {"color": "#97c2fc", "id": "and p", "label": "and p", "shape": "dot"}, {"color": "#97c2fc", "id": "##c cell line", "label": "##c cell line", "shape": "dot"}, {"color": "#97c2fc", "id": "hi", "label": "hi", "shape": "dot"}, {"color": "#97c2fc", "id": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "label": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "shape": "dot"}, {"color": "#97c2fc", "id": "##53", "label": "##53", "shape": "dot"}, {"color": "#97c2fc", "id": ". 022 pmid :", "label": ". 022 pmid :", "shape": "dot"}, {"color": "#97c2fc", "id": "bax", "label": "bax", "shape": "dot"}, {"color": "#97c2fc", "id": "f interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper", "label": "f interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper", "shape": "dot"}]);
                  edges = new vis.DataSet([{"from": "", "to": "##p1 competitive", "value": 1}, {"from": "", "to": "##ctic protein -", "value": 1}, {"from": "", "to": "##s that modulate breast tumor angiogenesis by", "value": 1}, {"from": "", "to": "2 m", "value": 1}, {"from": "", "to": ". 1096 / fj. 202500461r. the", "value": 1}, {"from": "", "to": "essential", "value": 1}, {"from": "", "to": "proteins mon", "value": 1}, {"from": "", "to": "##ocyte", "value": 1}, {"from": "", "to": "trans", "value": 1}, {"from": "", "to": "binding", "value": 1}, {"from": "", "to": "w", "value": 1}, {"from": "", "to": "##os", "value": 2}, {"from": "", "to": "##u", "value": 1}, {"from": "", "to": "factor", "value": 1}, {"from": "", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "", "to": "for", "value": 1}, {"from": "", "to": "college", "value": 1}, {"from": "", "to": "##iu r", "value": 1}, {"from": "", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "", "to": "##i a", "value": 1}, {"from": "", "to": "##i h", "value": 1}, {"from": "", "to": "##iu x", "value": 1}, {"from": "", "to": "-", "value": 6}, {"from": "", "to": "related", "value": 2}, {"from": "", "to": "##ine kinase 2", "value": 1}, {"from": "", "to": "induced protein", "value": 1}, {"from": "", "to": "l", "value": 2}, {"from": "", "to": "2", "value": 1}, {"from": "", "to": "is", "value": 2}, {"from": "", "to": "competitively", "value": 1}, {"from": "", "to": "ch", "value": 1}, {"from": "", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "", "to": "x", "value": 1}, {"from": "", "to": "r", "value": 2}, {"from": "", "to": "10", "value": 8}, {"from": "", "to": "##rna", "value": 3}, {"from": "", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "", "to": "binding protein 1", "value": 1}, {"from": "", "to": "i", "value": 3}, {"from": "", "to": "##emota", "value": 1}, {"from": "", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "", "to": "##na -", "value": 1}, {"from": "", "to": "antagonist", "value": 1}, {"from": "", "to": "##t", "value": 2}, {"from": "", "to": "of life", "value": 1}, {"from": "", "to": "##k", "value": 1}, {"from": "", "to": ") institute for brain sciences research,", "value": 1}, {"from": "", "to": ":", "value": 5}, {"from": "", "to": "index", "value": 2}, {"from": "", "to": "##osu", "value": 1}, {"from": "", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "", "to": ". 1096 / fj. 202", "value": 1}, {"from": "", "to": "may contribute to the", "value": 1}, {"from": "", "to": "sciences", "value": 3}, {"from": "", "to": "university", "value": 1}, {"from": "", "to": "##lle", "value": 1}, {"from": "", "to": "40", "value": 1}, {"from": "", "to": ",", "value": 7}, {"from": "", "to": "genes", "value": 2}, {"from": "", "to": "##i", "value": 2}, {"from": "", "to": "##f", "value": 1}, {"from": "", "to": "we", "value": 1}, {"from": "", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "", "to": "3 )", "value": 1}, {"from": "", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "", "to": "##hie j", "value": 1}, {"from": "", "to": "k", "value": 2}, {"from": "", "to": "doi", "value": 5}, {"from": "", "to": "b", "value": 5}, {"from": "", "to": "102", "value": 2}, {"from": "", "to": "j", "value": 5}, {"from": "", "to": "##354028 [", "value": 1}, {"from": "", "to": ".", "value": 10}, {"from": "", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "", "to": "school", "value": 1}, {"from": "", "to": "), agegnehu sb", "value": 1}, {"from": "", "to": "##ra 00", "value": 1}, {"from": "", "to": "3 ), lamptey el", "value": 1}, {"from": "", "to": "1", "value": 4}, {"from": "", "to": "ka", "value": 1}, {"from": "", "to": "4", "value": 5}, {"from": "", "to": "of ghana, a", "value": 1}, {"from": "", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "", "to": "##461r pmid :", "value": 1}, {"from": "", "to": "antiangiogenic therapy of", "value": 1}, {"from": "", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "", "to": ")", "value": 5}, {"from": "", "to": "he", "value": 1}, {"from": "", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "", "to": "expression", "value": 3}, {"from": "", "to": "breast", "value": 4}, {"from": "", "to": "##500", "value": 1}, {"from": "", "to": "in cancer", "value": 1}, {"from": "", "to": "##mpo s", "value": 1}, {"from": "", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "", "to": "##cc", "value": 2}, {"from": "", "to": "inverse", "value": 1}, {"from": "", "to": "new insights into", "value": 1}, {"from": "", "to": "##regulated", "value": 1}, {"from": "", "to": "ad but significantly down", "value": 1}, {"from": "", "to": "##ly", "value": 1}, {"from": "", "to": "##2", "value": 1}, {"from": "", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "", "to": "##re", "value": 2}, {"from": "", "to": "differential", "value": 1}, {"from": "", "to": "##gulated in prostate can", "value": 1}, {"from": "", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "", "to": "##gulated in", "value": 1}, {"from": "", "to": "##gu", "value": 2}, {"from": "", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "", "to": "expressed genes", "value": 1}, {"from": "", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "", "to": "de", "value": 1}, {"from": "", "to": "##ibi", "value": 1}, {"from": "", "to": "ri", "value": 1}, {"from": "", "to": "##sana", "value": 1}, {"from": "", "to": "doctoral program in biomedical", "value": 1}, {"from": "", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "", "to": "of medicine, univers", "value": 2}, {"from": "", "to": "##g", "value": 1}, {"from": "", "to": "##rta", "value": 3}, {"from": "", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "", "to": "##esia", "value": 1}, {"from": "", "to": "##itas in", "value": 1}, {"from": "", "to": "##nandi si", "value": 1}, {"from": "", "to": "##eri", "value": 1}, {"from": "", "to": "master program in biomedical", "value": 2}, {"from": "", "to": "),", "value": 1}, {"from": "", "to": "5", "value": 5}, {"from": "", "to": "##esi", "value": 3}, {"from": "", "to": "of medical chemistry,", "value": 1}, {"from": "", "to": "##a.", "value": 4}, {"from": "", "to": "faculty", "value": 5}, {"from": "", "to": "wa", "value": 1}, {"from": "", "to": "##don", "value": 3}, {"from": "", "to": "##a,", "value": 2}, {"from": "", "to": "6", "value": 2}, {"from": "", "to": "##aka", "value": 3}, {"from": "", "to": "department", "value": 3}, {"from": "", "to": "indonesi", "value": 2}, {"from": "", "to": "##itas indonesia", "value": 2}, {"from": "", "to": "of surgery,", "value": 1}, {"from": "", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "", "to": "2 - positive", "value": 1}, {"from": "", "to": "changes in the promoter region", "value": 1}, {"from": "", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "", "to": "can", "value": 1}, {"from": "", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "", "to": "receptor", "value": 1}, {"from": "", "to": "is an", "value": 1}, {"from": "", "to": "##type", "value": 3}, {"from": "", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "", "to": "in", "value": 8}, {"from": "", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "", "to": "- negative breast cancer", "value": 1}, {"from": "", "to": "and", "value": 3}, {"from": "", "to": "##a, jaka", "value": 2}, {"from": "", "to": "lead", "value": 1}, {"from": "", "to": "triple", "value": 1}, {"from": "", "to": "of medicine, universitas indon", "value": 2}, {"from": "", "to": "cilities - imeri,", "value": 1}, {"from": "", "to": "##a. breast cancer sub", "value": 1}, {"from": "", "to": "##umi", "value": 3}, {"from": "", "to": "##ivers", "value": 1}, {"from": "", "to": "to misclassification. dna methylation", "value": 1}, {"from": "", "to": "##s", "value": 1}, {"from": "", "to": "un", "value": 1}, {"from": "", "to": "##nal a, l", "value": 1}, {"from": "", "to": "epigenetic modification,", "value": 1}, {"from": "", "to": "of medicine,", "value": 1}, {"from": "", "to": "classification of breast cancer : l", "value": 1}, {"from": "", "to": ", h", "value": 1}, {"from": "", "to": "##methylation", "value": 1}, {"from": "", "to": "tion", "value": 1}, {"from": "", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "", "to": "the pt", "value": 1}, {"from": "", "to": ". \u00a9 202", "value": 1}, {"from": "", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "", "to": "##rn2 gene", "value": 1}, {"from": "", "to": "##nal", "value": 1}, {"from": "", "to": "##261 ), and tnbc", "value": 1}, {"from": "", "to": "##p", "value": 1}, {"from": "", "to": "the author", "value": 1}, {"from": "", "to": "bio", "value": 2}, {"from": "", "to": "respectively", "value": 2}, {"from": "", "to": "##marker for each sub", "value": 1}, {"from": "", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "", "to": "##yper", "value": 1}, {"from": "", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "", "to": "improve", "value": 1}, {"from": "", "to": "##10", "value": 1}, {"from": "", "to": "##5", "value": 1}, {"from": "", "to": "##nal a", "value": 1}, {"from": "", "to": "52", "value": 3}, {"from": "", "to": "), hashim", "value": 1}, {"from": "", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "", "to": ") drug development research cluster, indon", "value": 1}, {"from": "", "to": "##an medical", "value": 1}, {"from": "", "to": "indon", "value": 1}, {"from": "", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "", "to": "##hibit", "value": 1}, {"from": "", "to": "na", "value": 1}, {"from": "", "to": "education", "value": 1}, {"from": "", "to": "n", "value": 1}, {"from": "", "to": "3", "value": 1}, {"from": "", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "", "to": "##ajrin", "value": 1}, {"from": "", "to": "), azizah", "value": 1}, {"from": "", "to": "te", "value": 1}, {"from": "", "to": "##djo a", "value": 1}, {"from": "", "to": "##itas", "value": 1}, {"from": "", "to": "##b", "value": 2}, {"from": "", "to": "am", "value": 1}, {"from": "", "to": "nn", "value": 1}, {"from": "", "to": "of pharmacy, univers", "value": 1}, {"from": "", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "", "to": ", indon", "value": 1}, {"from": "", "to": "and research instit", "value": 1}, {"from": "", "to": "), ramadanti", "value": 1}, {"from": "", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "", "to": "##ene", "value": 1}, {"from": "", "to": "which was", "value": 1}, {"from": "", "to": ": cyce or ccne1", "value": 1}, {"from": "", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "", "to": "c", "value": 1}, {"from": "", "to": "##8 ), and e2f1", "value": 1}, {"from": "", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "", "to": "##1 ), rbl1", "value": 1}, {"from": "", "to": "might", "value": 1}, {"from": "", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "", "to": "the native", "value": 1}, {"from": "", "to": "ligan", "value": 1}, {"from": "", "to": "00", "value": 1}, {"from": "", "to": "im", "value": 1}, {"from": "", "to": "p = 0. 01", "value": 1}, {"from": "", "to": "##rank", "value": 1}, {"from": "", "to": "##j", "value": 1}, {"from": "", "to": "by", "value": 2}, {"from": "", "to": "rerank score", "value": 1}, {"from": "", "to": "##um", "value": 1}, {"from": "", "to": "##d", "value": 1}, {"from": "", "to": "of ad", "value": 1}, {"from": "", "to": "re", "value": 3}, {"from": "", "to": "##idodiph", "value": 1}, {"from": "", "to": "p = 0", "value": 2}, {"from": "", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "", "to": "- 112. 70 k", "value": 1}, {"from": "", "to": "score", "value": 2}, {"from": "", "to": "##ine", "value": 1}, {"from": "", "to": "##enyl", "value": 1}, {"from": "", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "", "to": "cycle", "value": 1}, {"from": "", "to": "##osphate", "value": 1}, {"from": "", "to": "- 110. 68 k", "value": 1}, {"from": "", "to": "0", "value": 1}, {"from": "", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "", "to": "##c", "value": 2}, {"from": "", "to": "/ mol ), and nummular", "value": 1}, {"from": "", "to": "squal", "value": 1}, {"from": "", "to": "the decrease in p21", "value": 1}, {"from": "", "to": "##mularia stem suggested that", "value": 1}, {"from": "", "to": "##life", "value": 1}, {"from": "", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "", "to": "##ion of p21", "value": 1}, {"from": "", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "", "to": "##in - mediated anti -", "value": 1}, {"from": "", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "", "to": "1 ), abdelkrim g", "value": 1}, {"from": "", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "", "to": "cancer effects. foda my", "value": 1}, {"from": "", "to": "##press", "value": 1}, {"from": "", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "", "to": "##tat", "value": 2}, {"from": "", "to": "jun", "value": 2}, {"from": "", "to": "2 ), salem ml", "value": 1}, {"from": "", "to": "in atorvas", "value": 1}, {"from": "", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "", "to": "prescribed chole", "value": 1}, {"from": "", "to": "has recently", "value": 1}, {"from": "", "to": "and its biological functions", "value": 1}, {"from": "", "to": "of saida, saida, algeria.", "value": 1}, {"from": "", "to": "shown", "value": 1}, {"from": "", "to": "however", "value": 1}, {"from": "", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "", "to": "shown potential anti", "value": 1}, {"from": "", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "", "to": "a", "value": 2}, {"from": "", "to": "##in", "value": 2}, {"from": "", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "", "to": "particular breast cancer,", "value": 1}, {"from": "", "to": "still", "value": 1}, {"from": "", "to": "associated with atorvas", "value": 1}, {"from": "", "to": "in breast", "value": 1}, {"from": "", "to": "lowering", "value": 1}, {"from": "", "to": "to be responsive to", "value": 1}, {"from": "", "to": "interaction", "value": 1}, {"from": "", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "", "to": ") network and", "value": 1}, {"from": "", "to": "in the protein - protein", "value": 1}, {"from": "", "to": "drug,", "value": 1}, {"from": "", "to": "hub gene", "value": 1}, {"from": "", "to": ", its influence on gene", "value": 1}, {"from": "", "to": "##lated", "value": 1}, {"from": "", "to": "was", "value": 2}, {"from": "", "to": "##in,", "value": 1}, {"from": "", "to": "ppi", "value": 1}, {"from": "", "to": "##oto", "value": 1}, {"from": "", "to": "related pathways", "value": 1}, {"from": "", "to": "cancer,", "value": 1}, {"from": "", "to": "expressed", "value": 2}, {"from": "", "to": "##cer effects.", "value": 1}, {"from": "", "to": "widely", "value": 1}, {"from": "", "to": "atorvas", "value": 1}, {"from": "", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "", "to": "##ster", "value": 1}, {"from": "", "to": "##ol", "value": 1}, {"from": "", "to": "##can", "value": 1}, {"from": "", "to": "cancer. atorvas", "value": 1}, {"from": "", "to": "was identified as the", "value": 1}, {"from": "", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "", "to": "##r confirmed their down", "value": 1}, {"from": "", "to": "four", "value": 1}, {"from": "", "to": "prioriti", "value": 1}, {"from": "", "to": "pc", "value": 1}, {"from": "", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "", "to": "diagnosed", "value": 1}, {"from": "", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "", "to": "incomplete", "value": 1}, {"from": "", "to": "ministry", "value": 1}, {"from": "", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "", "to": "diagnostic", "value": 1}, {"from": "", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "", "to": "##s and", "value": 1}, {"from": "", "to": "##s.", "value": 1}, {"from": "", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "", "to": "treatment", "value": 1}, {"from": "", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "", "to": "- mi", "value": 1}, {"from": "", "to": "##gna", "value": 1}, {"from": "", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "", "to": "##ncrna", "value": 1}, {"from": "", "to": "##r", "value": 2}, {"from": "", "to": "##ia", "value": 2}, {"from": "", "to": "mrna", "value": 1}, {"from": "", "to": "mali", "value": 1}, {"from": "", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "", "to": "=", "value": 1}, {"from": "", "to": "##s,", "value": 1}, {"from": "", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "", "to": "which is involved in", "value": 1}, {"from": "", "to": "- 0. 46,", "value": 1}, {"from": "", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "", "to": "mi", "value": 1}, {"from": "", "to": "- 5p", "value": 1}, {"from": "", "to": "##r - 17", "value": 1}, {"from": "", "to": "##1", "value": 1}, {"from": "", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "", "to": ") : e010548.", "value": 1}, {"from": "", "to": "5p", "value": 1}, {"from": "", "to": "hand", "value": 1}, {"from": "", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "", "to": "03 ) and", "value": 1}, {"from": "", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "", "to": "##r - 106a -", "value": 1}, {"from": "", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "", "to": "target gene", "value": 1}, {"from": "", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "", "to": "- 0. 41,", "value": 1}, {"from": "", "to": "of these lnc", "value": 1}, {"from": "", "to": "p = 0.", "value": 1}, {"from": "", "to": "113", "value": 1}, {"from": "", "to": "common", "value": 1}, {"from": "", "to": "regulated", "value": 1}, {"from": "", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "", "to": "), beltran - v", "value": 1}, {"from": "", "to": ") department of pathology, co", "value": 1}, {"from": "", "to": "##ulin", "value": 1}, {"from": "", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "", "to": "f", "value": 1}, {"from": "", "to": "new yo", "value": 1}, {"from": "", "to": "sloan", "value": 1}, {"from": "", "to": "la", "value": 1}, {"from": "", "to": "center", "value": 1}, {"from": "", "to": "us", "value": 1}, {"from": "", "to": "##lum", "value": 1}, {"from": "", "to": "##o m", "value": 1}, {"from": "", "to": "9", "value": 2}, {"from": "", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "", "to": "kette", "value": 1}, {"from": "", "to": "yo", "value": 1}, {"from": "", "to": "##ettering cancer", "value": 1}, {"from": "", "to": "##rk, usa.", "value": 1}, {"from": "", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "", "to": "new york", "value": 1}, {"from": "", "to": "##bia university,", "value": 1}, {"from": "", "to": "), shin e", "value": 1}, {"from": "", "to": "##ring cancer", "value": 1}, {"from": "", "to": "##rk, new", "value": 1}, {"from": "", "to": "##urent, quebec, canada.", "value": 1}, {"from": "", "to": "##isied", "value": 1}, {"from": "", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "", "to": "ancers. sinha s", "value": 1}, {"from": "", "to": "##is - filho j", "value": 1}, {"from": "", "to": "##rk,", "value": 1}, {"from": "", "to": "), gardner r", "value": 1}, {"from": "", "to": ": we generated isogenic atm - null models using", "value": 1}, {"from": "", "to": "##rates were assessed by flow c", "value": 1}, {"from": "", "to": ". org.", "value": 1}, {"from": "", "to": "regulator", "value": 1}, {"from": "", "to": "methods", "value": 1}, {"from": "", "to": ". org khana7 @ msk", "value": 1}, {"from": "", "to": "##yt", "value": 1}, {"from": "", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "", "to": "##ase functions,", "value": 1}, {"from": "", "to": "colorec", "value": 1}, {"from": "", "to": "are known", "value": 1}, {"from": "", "to": "polymer", "value": 1}, {"from": "", "to": "##r in murine triple -", "value": 1}, {"from": "", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "", "to": "##tal", "value": 1}, {"from": "", "to": "##lt", "value": 1}, {"from": "", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "", "to": "mutated", "value": 1}, {"from": "", "to": "negative", "value": 1}, {"from": "", "to": "crisp", "value": 1}, {"from": "", "to": "##ometry and immunohis", "value": 1}, {"from": "", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "", "to": "##to", "value": 1}, {"from": "", "to": "), and the top", "value": 1}, {"from": "", "to": "##0", "value": 1}, {"from": "", "to": "), a parp", "value": 1}, {"from": "", "to": "##point blockade", "value": 1}, {"from": "", "to": "etop", "value": 1}, {"from": "", "to": "##ide - on", "value": 1}, {"from": "", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "", "to": "##ide, a top", "value": 1}, {"from": "", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "", "to": "##ase ii", "value": 1}, {"from": "", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "", "to": "interfer", "value": 1}, {"from": "", "to": "fails", "value": 1}, {"from": "", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "", "to": "type", "value": 1}, {"from": "", "to": "if", "value": 1}, {"from": "", "to": "##fi", "value": 1}, {"from": "", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "", "to": "##oisomer", "value": 1}, {"from": "", "to": "##n ) signaling, with etop", "value": 1}, {"from": "", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "", "to": "to encourage immune effector cell in", "value": 1}, {"from": "", "to": "does", "value": 1}, {"from": "", "to": "##ltration into tumors, and", "value": 1}, {"from": "", "to": "##on - stimulated gene", "value": 1}, {"from": "", "to": "check", "value": 1}, {"from": "", "to": "##on", "value": 1}, {"from": "", "to": "inhibitor", "value": 1}, {"from": "", "to": "), huarte m", "value": 1}, {"from": "", "to": "12", "value": 1}, {"from": "", "to": "##407.", "value": 1}, {"from": "", "to": "), par", "value": 1}, {"from": "", "to": "ins", "value": 1}, {"from": "", "to": "##or", "value": 1}, {"from": "", "to": "##e", "value": 1}, {"from": "", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "", "to": "), aragon s", "value": 1}, {"from": "", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "", "to": "##ory", "value": 1}, {"from": "", "to": "), gimenez j", "value": 1}, {"from": "", "to": "- lopez i", "value": 1}, {"from": "", "to": "##rine", "value": 1}, {"from": "", "to": "er + / her2 -", "value": 1}, {"from": "", "to": "), prat a", "value": 1}, {"from": "", "to": "research", "value": 1}, {"from": "", "to": "##e. lg is /", "value": 1}, {"from": "", "to": "), buch e", "value": 1}, {"from": "", "to": "##roga v", "value": 1}, {"from": "", "to": "been holding research", "value": 1}, {"from": "", "to": "11", "value": 2}, {"from": "", "to": "101", "value": 1}, {"from": "", "to": "##riaga k", "value": 1}, {"from": "", "to": "), etxabe i", "value": 1}, {"from": "", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "", "to": "13", "value": 1}, {"from": "", "to": "therapy", "value": 1}, {"from": "", "to": "##ui", "value": 1}, {"from": "", "to": "##ez", "value": 1}, {"from": "", "to": "##vita", "value": 1}, {"from": "", "to": "contracts", "value": 1}, {"from": "", "to": "has", "value": 1}, {"from": "", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "", "to": "). author information :", "value": 1}, {"from": "", "to": "), urruticoechea a", "value": 1}, {"from": "", "to": "##rio de v", "value": 1}, {"from": "", "to": "t", "value": 3}, {"from": "", "to": "##kolog", "value": 1}, {"from": "", "to": ", san", "value": 1}, {"from": "", "to": "##it", "value": 1}, {"from": "", "to": ") health", "value": 1}, {"from": "", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "", "to": "##iba", "value": 1}, {"from": "", "to": "##ialdea", "value": 1}, {"from": "", "to": "##gipuzkoa", "value": 1}, {"from": "", "to": "##ko", "value": 1}, {"from": "", "to": "##obe", "value": 1}, {"from": "", "to": "se", "value": 1}, {"from": "", "to": "##gi", "value": 1}, {"from": "", "to": "##tian,", "value": 1}, {"from": "", "to": ") hospital clinico univers", "value": 1}, {"from": "", "to": "##r 12, madrid,", "value": 1}, {"from": "", "to": "spain", "value": 1}, {"from": "", "to": "##ale", "value": 1}, {"from": "", "to": "##a", "value": 1}, {"from": "", "to": "##ute", "value": 1}, {"from": "", "to": "##ikoa,", "value": 1}, {"from": "", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "", "to": "##donost", "value": 1}, {"from": "", "to": ") hospital oct", "value": 1}, {"from": "", "to": "research institute", "value": 1}, {"from": "", "to": "institute", "value": 2}, {"from": "", "to": "sa", "value": 1}, {"from": "", "to": "sebas", "value": 1}, {"from": "", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "", "to": "##ita", "value": 1}, {"from": "", "to": ", v", "value": 1}, {"from": "", "to": "##ps, barcelon", "value": 1}, {"from": "", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "", "to": "##n", "value": 1}, {"from": "", "to": "##pu", "value": 1}, {"from": "", "to": "sebastian", "value": 1}, {"from": "", "to": "; gip", "value": 1}, {"from": "", "to": "- on", "value": 1}, {"from": "", "to": "7 ) valencia oncology", "value": 1}, {"from": "", "to": "##ncia,", "value": 1}, {"from": "", "to": "##uz", "value": 1}, {"from": "", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "", "to": "- onkologikoa, san", "value": 1}, {"from": "", "to": "##z", "value": 1}, {"from": "", "to": "##bastian, spa", "value": 1}, {"from": "", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "", "to": "in ki", "value": 1}, {"from": "", "to": "##cu", "value": 1}, {"from": "", "to": "positive", "value": 1}, {"from": "", "to": "##2 -", "value": 1}, {"from": "", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "", "to": "##rrence", "value": 1}, {"from": "", "to": "percentage", "value": 1}, {"from": "", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "", "to": "##nes", "value": 1}, {"from": "", "to": "from l", "value": 1}, {"from": "", "to": "presented", "value": 1}, {"from": "", "to": "results", "value": 2}, {"from": "", "to": "pam50 - derived risk of", "value": 1}, {"from": "", "to": "her", "value": 1}, {"from": "", "to": "er + /", "value": 1}, {"from": "", "to": "##nal a to normal - like", "value": 1}, {"from": "", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "", "to": "cells", "value": 1}, {"from": "", "to": "change", "value": 1}, {"from": "", "to": "after", "value": 1}, {"from": "", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "", "to": "of intrinsic sub", "value": 1}, {"from": "", "to": "p53", "value": 1}, {"from": "", "to": "##is.", "value": 1}, {"from": "", "to": "biomark", "value": 1}, {"from": "", "to": "subtype after", "value": 1}, {"from": "", "to": "net", "value": 1}, {"from": "", "to": "of", "value": 1}, {"from": "", "to": "##c patients", "value": 1}, {"from": "", "to": "net as a putative", "value": 1}, {"from": "", "to": "##umour cellularity size", "value": 1}, {"from": "", "to": "radio", "value": 1}, {"from": "", "to": ") and lower", "value": 1}, {"from": "", "to": "better", "value": 1}, {"from": "", "to": "##rgen, norway.", "value": 1}, {"from": "", "to": "##rgen, nor", "value": 1}, {"from": "", "to": "economics", "value": 1}, {"from": "", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "", "to": "clinical trials", "value": 1}, {"from": "", "to": "of health management and health", "value": 1}, {"from": "", "to": "of health", "value": 1}, {"from": "", "to": ";", "value": 1}, {"from": "", "to": ") department of p", "value": 1}, {"from": "", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "", "to": "), heie a", "value": 1}, {"from": "", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "", "to": "be", "value": 1}, {"from": "", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "", "to": "ug", "value": 1}, {"from": "", "to": "##way", "value": 1}, {"from": "", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "", "to": "benefit", "value": 1}, {"from": "", "to": "##26, 000 ;", "value": 1}, {"from": "", "to": "effective", "value": 1}, {"from": "", "to": "it was cost - saving", "value": 1}, {"from": "", "to": "threshold", "value": 1}, {"from": "", "to": "- 435, 677 )", "value": 1}, {"from": "", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "", "to": "##aly", "value": 1}, {"from": "", "to": "in the", "value": 1}, {"from": "", "to": "cost", "value": 1}, {"from": "", "to": "\u20ac", "value": 1}, {"from": "", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "", "to": "- 620170,", "value": 1}, {"from": "", "to": "##r )", "value": 1}, {"from": "", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "", "to": "societal perspective", "value": 1}, {"from": "", "to": "candidates, the strategy", "value": 1}, {"from": "", "to": "cost - effective", "value": 1}, {"from": "", "to": "incre", "value": 1}, {"from": "", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "", "to": "##mental", "value": 1}, {"from": "", "to": "the cost -", "value": 1}, {"from": "", "to": "was cost - effective", "value": 1}, {"from": "", "to": "above", "value": 1}, {"from": "", "to": "was obtained from statistics norway.", "value": 1}, {"from": "", "to": "per quality - adjusted life -", "value": 1}, {"from": "", "to": "was cost - saving", "value": 1}, {"from": "", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "", "to": "chemotherapy", "value": 1}, {"from": "", "to": "in both the healthcare", "value": 1}, {"from": "", "to": "years", "value": 1}, {"from": "", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "", "to": "- per q", "value": 1}, {"from": "", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "", "to": ". conclusions", "value": 1}, {"from": "", "to": ". selecting patient", "value": 1}, {"from": "", "to": "ice", "value": 1}, {"from": "", "to": "##8884 and", "value": 1}, {"from": "", "to": "gained", "value": 1}, {"from": "", "to": "the emit", "value": 1}, {"from": "", "to": "records. including all pn0 patients", "value": 1}, {"from": "", "to": "sector", "value": 1}, {"from": "", "to": "not", "value": 1}, {"from": "##p1 competitive", "to": "##ctic protein -", "value": 1}, {"from": "##p1 competitive", "to": "##s that modulate breast tumor angiogenesis by", "value": 1}, {"from": "##p1 competitive", "to": "2 m", "value": 1}, {"from": "##p1 competitive", "to": ". 1096 / fj. 202500461r. the", "value": 1}, {"from": "##p1 competitive", "to": "essential", "value": 1}, {"from": "##p1 competitive", "to": "proteins mon", "value": 1}, {"from": "##p1 competitive", "to": "##ocyte", "value": 1}, {"from": "##p1 competitive", "to": "trans", "value": 1}, {"from": "##p1 competitive", "to": "binding", "value": 1}, {"from": "##p1 competitive", "to": "w", "value": 1}, {"from": "##p1 competitive", "to": "##os", "value": 1}, {"from": "##p1 competitive", "to": "##u", "value": 1}, {"from": "##p1 competitive", "to": "factor", "value": 1}, {"from": "##p1 competitive", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##p1 competitive", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##p1 competitive", "to": "for", "value": 1}, {"from": "##p1 competitive", "to": "college", "value": 1}, {"from": "##p1 competitive", "to": "##iu r", "value": 1}, {"from": "##p1 competitive", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##p1 competitive", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##p1 competitive", "to": "##i a", "value": 1}, {"from": "##p1 competitive", "to": "##i h", "value": 1}, {"from": "##p1 competitive", "to": "##iu x", "value": 1}, {"from": "##p1 competitive", "to": "-", "value": 1}, {"from": "##p1 competitive", "to": "related", "value": 1}, {"from": "##p1 competitive", "to": "##ine kinase 2", "value": 1}, {"from": "##p1 competitive", "to": "induced protein", "value": 1}, {"from": "##p1 competitive", "to": "l", "value": 1}, {"from": "##p1 competitive", "to": "2", "value": 1}, {"from": "##p1 competitive", "to": "is", "value": 1}, {"from": "##p1 competitive", "to": "competitively", "value": 1}, {"from": "##p1 competitive", "to": "ch", "value": 1}, {"from": "##p1 competitive", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##p1 competitive", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##p1 competitive", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##p1 competitive", "to": "x", "value": 1}, {"from": "##p1 competitive", "to": "r", "value": 1}, {"from": "##p1 competitive", "to": "10", "value": 1}, {"from": "##p1 competitive", "to": "##rna", "value": 1}, {"from": "##p1 competitive", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##p1 competitive", "to": "binding protein 1", "value": 1}, {"from": "##p1 competitive", "to": "i", "value": 1}, {"from": "##p1 competitive", "to": "##emota", "value": 1}, {"from": "##p1 competitive", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##p1 competitive", "to": "##na -", "value": 1}, {"from": "##p1 competitive", "to": "antagonist", "value": 1}, {"from": "##ctic protein -", "to": "##s that modulate breast tumor angiogenesis by", "value": 1}, {"from": "##ctic protein -", "to": "2 m", "value": 1}, {"from": "##ctic protein -", "to": ". 1096 / fj. 202500461r. the", "value": 1}, {"from": "##ctic protein -", "to": "essential", "value": 1}, {"from": "##ctic protein -", "to": "proteins mon", "value": 1}, {"from": "##ctic protein -", "to": "##ocyte", "value": 1}, {"from": "##ctic protein -", "to": "trans", "value": 1}, {"from": "##ctic protein -", "to": "binding", "value": 1}, {"from": "##ctic protein -", "to": "w", "value": 1}, {"from": "##ctic protein -", "to": "##os", "value": 1}, {"from": "##ctic protein -", "to": "##u", "value": 1}, {"from": "##ctic protein -", "to": "factor", "value": 1}, {"from": "##ctic protein -", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##ctic protein -", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##ctic protein -", "to": "for", "value": 1}, {"from": "##ctic protein -", "to": "college", "value": 1}, {"from": "##ctic protein -", "to": "##iu r", "value": 1}, {"from": "##ctic protein -", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##ctic protein -", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##ctic protein -", "to": "##i a", "value": 1}, {"from": "##ctic protein -", "to": "##i h", "value": 1}, {"from": "##ctic protein -", "to": "##iu x", "value": 1}, {"from": "##ctic protein -", "to": "-", "value": 1}, {"from": "##ctic protein -", "to": "related", "value": 1}, {"from": "##ctic protein -", "to": "##ine kinase 2", "value": 1}, {"from": "##ctic protein -", "to": "induced protein", "value": 1}, {"from": "##ctic protein -", "to": "l", "value": 1}, {"from": "##ctic protein -", "to": "2", "value": 1}, {"from": "##ctic protein -", "to": "is", "value": 1}, {"from": "##ctic protein -", "to": "competitively", "value": 1}, {"from": "##ctic protein -", "to": "ch", "value": 1}, {"from": "##ctic protein -", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##ctic protein -", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##ctic protein -", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##ctic protein -", "to": "x", "value": 1}, {"from": "##ctic protein -", "to": "r", "value": 1}, {"from": "##ctic protein -", "to": "10", "value": 1}, {"from": "##ctic protein -", "to": "##rna", "value": 1}, {"from": "##ctic protein -", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##ctic protein -", "to": "binding protein 1", "value": 1}, {"from": "##ctic protein -", "to": "i", "value": 1}, {"from": "##ctic protein -", "to": "##emota", "value": 1}, {"from": "##ctic protein -", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##ctic protein -", "to": "##na -", "value": 1}, {"from": "##ctic protein -", "to": "antagonist", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "2 m", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": ". 1096 / fj. 202500461r. the", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "essential", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "proteins mon", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##ocyte", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "trans", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "binding", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "w", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##os", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##u", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "factor", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "for", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "college", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##iu r", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##i a", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##i h", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##iu x", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "-", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "related", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##ine kinase 2", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "induced protein", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "l", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "2", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "is", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "competitively", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "ch", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "x", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "r", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "10", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##rna", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "binding protein 1", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "i", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##emota", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "##na -", "value": 1}, {"from": "##s that modulate breast tumor angiogenesis by", "to": "antagonist", "value": 1}, {"from": "2 m", "to": ". 1096 / fj. 202500461r. the", "value": 1}, {"from": "2 m", "to": "essential", "value": 1}, {"from": "2 m", "to": "proteins mon", "value": 1}, {"from": "2 m", "to": "##ocyte", "value": 1}, {"from": "2 m", "to": "trans", "value": 1}, {"from": "2 m", "to": "binding", "value": 1}, {"from": "2 m", "to": "w", "value": 1}, {"from": "2 m", "to": "##os", "value": 1}, {"from": "2 m", "to": "##u", "value": 1}, {"from": "2 m", "to": "factor", "value": 1}, {"from": "2 m", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "2 m", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "2 m", "to": "for", "value": 1}, {"from": "2 m", "to": "college", "value": 1}, {"from": "2 m", "to": "##iu r", "value": 1}, {"from": "2 m", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "2 m", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "2 m", "to": "##i a", "value": 1}, {"from": "2 m", "to": "##i h", "value": 1}, {"from": "2 m", "to": "##iu x", "value": 1}, {"from": "2 m", "to": "-", "value": 1}, {"from": "2 m", "to": "related", "value": 1}, {"from": "2 m", "to": "##ine kinase 2", "value": 1}, {"from": "2 m", "to": "induced protein", "value": 1}, {"from": "2 m", "to": "l", "value": 1}, {"from": "2 m", "to": "2", "value": 1}, {"from": "2 m", "to": "is", "value": 1}, {"from": "2 m", "to": "competitively", "value": 1}, {"from": "2 m", "to": "ch", "value": 1}, {"from": "2 m", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "2 m", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "2 m", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "2 m", "to": "x", "value": 1}, {"from": "2 m", "to": "r", "value": 1}, {"from": "2 m", "to": "10", "value": 1}, {"from": "2 m", "to": "##rna", "value": 1}, {"from": "2 m", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "2 m", "to": "binding protein 1", "value": 1}, {"from": "2 m", "to": "i", "value": 1}, {"from": "2 m", "to": "##emota", "value": 1}, {"from": "2 m", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "2 m", "to": "##na -", "value": 1}, {"from": "2 m", "to": "antagonist", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "essential", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "proteins mon", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##ocyte", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "trans", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "binding", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "w", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##os", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##u", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "factor", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "for", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "college", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##iu r", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##i a", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##i h", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##iu x", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "-", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "related", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##ine kinase 2", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "induced protein", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "l", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "2", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "is", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "competitively", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "ch", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "x", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "r", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "10", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##rna", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "binding protein 1", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "i", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##emota", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "##na -", "value": 1}, {"from": ". 1096 / fj. 202500461r. the", "to": "antagonist", "value": 1}, {"from": "essential", "to": "proteins mon", "value": 1}, {"from": "essential", "to": "##ocyte", "value": 1}, {"from": "essential", "to": "trans", "value": 1}, {"from": "essential", "to": "binding", "value": 1}, {"from": "essential", "to": "w", "value": 1}, {"from": "essential", "to": "##os", "value": 1}, {"from": "essential", "to": "##u", "value": 1}, {"from": "essential", "to": "factor", "value": 1}, {"from": "essential", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "essential", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "essential", "to": "for", "value": 1}, {"from": "essential", "to": "college", "value": 1}, {"from": "essential", "to": "##iu r", "value": 1}, {"from": "essential", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "essential", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "essential", "to": "##i a", "value": 1}, {"from": "essential", "to": "##i h", "value": 1}, {"from": "essential", "to": "##iu x", "value": 1}, {"from": "essential", "to": "-", "value": 1}, {"from": "essential", "to": "related", "value": 1}, {"from": "essential", "to": "##ine kinase 2", "value": 1}, {"from": "essential", "to": "induced protein", "value": 1}, {"from": "essential", "to": "l", "value": 1}, {"from": "essential", "to": "2", "value": 1}, {"from": "essential", "to": "is", "value": 1}, {"from": "essential", "to": "competitively", "value": 1}, {"from": "essential", "to": "ch", "value": 1}, {"from": "essential", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "essential", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "essential", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "essential", "to": "x", "value": 1}, {"from": "essential", "to": "r", "value": 1}, {"from": "essential", "to": "10", "value": 1}, {"from": "essential", "to": "##rna", "value": 1}, {"from": "essential", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "essential", "to": "binding protein 1", "value": 1}, {"from": "essential", "to": "i", "value": 1}, {"from": "essential", "to": "##emota", "value": 1}, {"from": "essential", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "essential", "to": "##na -", "value": 1}, {"from": "essential", "to": "antagonist", "value": 1}, {"from": "proteins mon", "to": "##ocyte", "value": 1}, {"from": "proteins mon", "to": "trans", "value": 1}, {"from": "proteins mon", "to": "binding", "value": 1}, {"from": "proteins mon", "to": "w", "value": 1}, {"from": "proteins mon", "to": "##os", "value": 1}, {"from": "proteins mon", "to": "##u", "value": 1}, {"from": "proteins mon", "to": "factor", "value": 1}, {"from": "proteins mon", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "proteins mon", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "proteins mon", "to": "for", "value": 1}, {"from": "proteins mon", "to": "college", "value": 1}, {"from": "proteins mon", "to": "##iu r", "value": 1}, {"from": "proteins mon", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "proteins mon", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "proteins mon", "to": "##i a", "value": 1}, {"from": "proteins mon", "to": "##i h", "value": 1}, {"from": "proteins mon", "to": "##iu x", "value": 1}, {"from": "proteins mon", "to": "-", "value": 1}, {"from": "proteins mon", "to": "related", "value": 1}, {"from": "proteins mon", "to": "##ine kinase 2", "value": 1}, {"from": "proteins mon", "to": "induced protein", "value": 1}, {"from": "proteins mon", "to": "l", "value": 1}, {"from": "proteins mon", "to": "2", "value": 1}, {"from": "proteins mon", "to": "is", "value": 1}, {"from": "proteins mon", "to": "competitively", "value": 1}, {"from": "proteins mon", "to": "ch", "value": 1}, {"from": "proteins mon", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "proteins mon", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "proteins mon", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "proteins mon", "to": "x", "value": 1}, {"from": "proteins mon", "to": "r", "value": 1}, {"from": "proteins mon", "to": "10", "value": 1}, {"from": "proteins mon", "to": "##rna", "value": 1}, {"from": "proteins mon", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "proteins mon", "to": "binding protein 1", "value": 1}, {"from": "proteins mon", "to": "i", "value": 1}, {"from": "proteins mon", "to": "##emota", "value": 1}, {"from": "proteins mon", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "proteins mon", "to": "##na -", "value": 1}, {"from": "proteins mon", "to": "antagonist", "value": 1}, {"from": "##ocyte", "to": "trans", "value": 1}, {"from": "##ocyte", "to": "binding", "value": 1}, {"from": "##ocyte", "to": "w", "value": 1}, {"from": "##ocyte", "to": "##os", "value": 1}, {"from": "##ocyte", "to": "##u", "value": 1}, {"from": "##ocyte", "to": "factor", "value": 1}, {"from": "##ocyte", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##ocyte", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##ocyte", "to": "for", "value": 1}, {"from": "##ocyte", "to": "college", "value": 1}, {"from": "##ocyte", "to": "##iu r", "value": 1}, {"from": "##ocyte", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##ocyte", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##ocyte", "to": "##i a", "value": 1}, {"from": "##ocyte", "to": "##i h", "value": 1}, {"from": "##ocyte", "to": "##iu x", "value": 1}, {"from": "##ocyte", "to": "-", "value": 1}, {"from": "##ocyte", "to": "related", "value": 1}, {"from": "##ocyte", "to": "##ine kinase 2", "value": 1}, {"from": "##ocyte", "to": "induced protein", "value": 1}, {"from": "##ocyte", "to": "l", "value": 1}, {"from": "##ocyte", "to": "2", "value": 1}, {"from": "##ocyte", "to": "is", "value": 1}, {"from": "##ocyte", "to": "competitively", "value": 1}, {"from": "##ocyte", "to": "ch", "value": 1}, {"from": "##ocyte", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##ocyte", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##ocyte", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##ocyte", "to": "x", "value": 1}, {"from": "##ocyte", "to": "r", "value": 1}, {"from": "##ocyte", "to": "10", "value": 1}, {"from": "##ocyte", "to": "##rna", "value": 1}, {"from": "##ocyte", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##ocyte", "to": "binding protein 1", "value": 1}, {"from": "##ocyte", "to": "i", "value": 1}, {"from": "##ocyte", "to": "##emota", "value": 1}, {"from": "##ocyte", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##ocyte", "to": "##na -", "value": 1}, {"from": "##ocyte", "to": "antagonist", "value": 1}, {"from": "trans", "to": "binding", "value": 1}, {"from": "trans", "to": "w", "value": 1}, {"from": "trans", "to": "##os", "value": 1}, {"from": "trans", "to": "##u", "value": 1}, {"from": "trans", "to": "factor", "value": 1}, {"from": "trans", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "trans", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "trans", "to": "for", "value": 1}, {"from": "trans", "to": "college", "value": 1}, {"from": "trans", "to": "##iu r", "value": 1}, {"from": "trans", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "trans", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "trans", "to": "##i a", "value": 1}, {"from": "trans", "to": "##i h", "value": 1}, {"from": "trans", "to": "##iu x", "value": 1}, {"from": "trans", "to": "-", "value": 1}, {"from": "trans", "to": "related", "value": 1}, {"from": "trans", "to": "##ine kinase 2", "value": 1}, {"from": "trans", "to": "induced protein", "value": 1}, {"from": "trans", "to": "l", "value": 1}, {"from": "trans", "to": "2", "value": 1}, {"from": "trans", "to": "is", "value": 1}, {"from": "trans", "to": "competitively", "value": 1}, {"from": "trans", "to": "ch", "value": 1}, {"from": "trans", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "trans", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "trans", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "trans", "to": "x", "value": 1}, {"from": "trans", "to": "r", "value": 1}, {"from": "trans", "to": "10", "value": 1}, {"from": "trans", "to": "##rna", "value": 1}, {"from": "trans", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "trans", "to": "binding protein 1", "value": 1}, {"from": "trans", "to": "i", "value": 1}, {"from": "trans", "to": "##emota", "value": 1}, {"from": "trans", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "trans", "to": "##na -", "value": 1}, {"from": "trans", "to": "antagonist", "value": 1}, {"from": "binding", "to": "w", "value": 1}, {"from": "binding", "to": "##os", "value": 1}, {"from": "binding", "to": "##u", "value": 1}, {"from": "binding", "to": "factor", "value": 1}, {"from": "binding", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "binding", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "binding", "to": "for", "value": 1}, {"from": "binding", "to": "college", "value": 1}, {"from": "binding", "to": "##iu r", "value": 1}, {"from": "binding", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "binding", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "binding", "to": "##i a", "value": 1}, {"from": "binding", "to": "##i h", "value": 1}, {"from": "binding", "to": "##iu x", "value": 1}, {"from": "binding", "to": "-", "value": 1}, {"from": "binding", "to": "related", "value": 1}, {"from": "binding", "to": "##ine kinase 2", "value": 1}, {"from": "binding", "to": "induced protein", "value": 1}, {"from": "binding", "to": "l", "value": 1}, {"from": "binding", "to": "2", "value": 1}, {"from": "binding", "to": "is", "value": 1}, {"from": "binding", "to": "competitively", "value": 1}, {"from": "binding", "to": "ch", "value": 1}, {"from": "binding", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "binding", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "binding", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "binding", "to": "x", "value": 1}, {"from": "binding", "to": "r", "value": 1}, {"from": "binding", "to": "10", "value": 1}, {"from": "binding", "to": "##rna", "value": 1}, {"from": "binding", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "binding", "to": "binding protein 1", "value": 1}, {"from": "binding", "to": "i", "value": 1}, {"from": "binding", "to": "##emota", "value": 1}, {"from": "binding", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "binding", "to": "##na -", "value": 1}, {"from": "binding", "to": "antagonist", "value": 1}, {"from": "w", "to": "##os", "value": 1}, {"from": "w", "to": "##u", "value": 1}, {"from": "w", "to": "factor", "value": 1}, {"from": "w", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "w", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "w", "to": "for", "value": 1}, {"from": "w", "to": "college", "value": 1}, {"from": "w", "to": "##iu r", "value": 1}, {"from": "w", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "w", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "w", "to": "##i a", "value": 1}, {"from": "w", "to": "##i h", "value": 1}, {"from": "w", "to": "##iu x", "value": 1}, {"from": "w", "to": "-", "value": 1}, {"from": "w", "to": "related", "value": 1}, {"from": "w", "to": "##ine kinase 2", "value": 1}, {"from": "w", "to": "induced protein", "value": 1}, {"from": "w", "to": "l", "value": 1}, {"from": "w", "to": "2", "value": 1}, {"from": "w", "to": "is", "value": 1}, {"from": "w", "to": "competitively", "value": 1}, {"from": "w", "to": "ch", "value": 1}, {"from": "w", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "w", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "w", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "w", "to": "x", "value": 1}, {"from": "w", "to": "r", "value": 1}, {"from": "w", "to": "10", "value": 1}, {"from": "w", "to": "##rna", "value": 1}, {"from": "w", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "w", "to": "binding protein 1", "value": 1}, {"from": "w", "to": "i", "value": 1}, {"from": "w", "to": "##emota", "value": 1}, {"from": "w", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "w", "to": "##na -", "value": 1}, {"from": "w", "to": "antagonist", "value": 1}, {"from": "##os", "to": "##u", "value": 1}, {"from": "##os", "to": "factor", "value": 1}, {"from": "##os", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##os", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##os", "to": "for", "value": 1}, {"from": "##os", "to": "college", "value": 1}, {"from": "##os", "to": "##iu r", "value": 1}, {"from": "##os", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##os", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##os", "to": "##i a", "value": 1}, {"from": "##os", "to": "##i h", "value": 1}, {"from": "##os", "to": "##iu x", "value": 1}, {"from": "##os", "to": "-", "value": 2}, {"from": "##os", "to": "related", "value": 1}, {"from": "##os", "to": "##ine kinase 2", "value": 1}, {"from": "##os", "to": "induced protein", "value": 1}, {"from": "##os", "to": "l", "value": 1}, {"from": "##os", "to": "2", "value": 1}, {"from": "##os", "to": "is", "value": 2}, {"from": "##os", "to": "competitively", "value": 1}, {"from": "##os", "to": "ch", "value": 1}, {"from": "##os", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##os", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##os", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##os", "to": "x", "value": 1}, {"from": "##os", "to": "r", "value": 1}, {"from": "##os", "to": "10", "value": 1}, {"from": "##os", "to": "##rna", "value": 1}, {"from": "##os", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##os", "to": "binding protein 1", "value": 1}, {"from": "##os", "to": "i", "value": 2}, {"from": "##os", "to": "##emota", "value": 1}, {"from": "##os", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##os", "to": "##na -", "value": 1}, {"from": "##os", "to": "antagonist", "value": 1}, {"from": "##os", "to": "), and the top", "value": 1}, {"from": "##os", "to": "##0", "value": 1}, {"from": "##os", "to": "), a parp", "value": 1}, {"from": "##os", "to": "##point blockade", "value": 1}, {"from": "##os", "to": "etop", "value": 1}, {"from": "##os", "to": "##ide - on", "value": 1}, {"from": "##os", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "##os", "to": "##ide, a top", "value": 1}, {"from": "##os", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##os", "to": "in", "value": 1}, {"from": "##os", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##os", "to": "##ase ii", "value": 1}, {"from": "##os", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##os", "to": "interfer", "value": 1}, {"from": "##os", "to": "fails", "value": 1}, {"from": "##os", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##os", "to": "type", "value": 1}, {"from": "##os", "to": "if", "value": 1}, {"from": "##os", "to": "##fi", "value": 1}, {"from": "##os", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##os", "to": "##oisomer", "value": 1}, {"from": "##os", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##os", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##os", "to": "##b", "value": 1}, {"from": "##os", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##os", "to": "does", "value": 2}, {"from": "##os", "to": "##ltration into tumors, and", "value": 1}, {"from": "##os", "to": "##on - stimulated gene", "value": 1}, {"from": "##os", "to": "check", "value": 1}, {"from": "##os", "to": "##on", "value": 1}, {"from": "##os", "to": "inhibitor", "value": 1}, {"from": "##os", "to": "conclusions", "value": 1}, {"from": "##os", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "##os", "to": ":", "value": 1}, {"from": "##os", "to": "index", "value": 1}, {"from": "##os", "to": "10. 113", "value": 1}, {"from": "##os", "to": "interests", "value": 1}, {"from": "##os", "to": ". no commercial re -", "value": 1}, {"from": "##os", "to": "##p", "value": 1}, {"from": "##os", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "##os", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "##os", "to": "doi", "value": 1}, {"from": "##os", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "##os", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "##os", "to": ": nr receives research support from bm", "value": 1}, {"from": "##os", "to": "use", "value": 1}, {"from": "##os", "to": ": atm deficiency, while com", "value": 1}, {"from": "##os", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "##os", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##os", "to": "##c", "value": 1}, {"from": "##os", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##u", "to": "factor", "value": 1}, {"from": "##u", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "##u", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "##u", "to": "for", "value": 1}, {"from": "##u", "to": "college", "value": 1}, {"from": "##u", "to": "##iu r", "value": 1}, {"from": "##u", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##u", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##u", "to": "##i a", "value": 1}, {"from": "##u", "to": "##i h", "value": 1}, {"from": "##u", "to": "##iu x", "value": 1}, {"from": "##u", "to": "-", "value": 1}, {"from": "##u", "to": "related", "value": 1}, {"from": "##u", "to": "##ine kinase 2", "value": 1}, {"from": "##u", "to": "induced protein", "value": 1}, {"from": "##u", "to": "l", "value": 1}, {"from": "##u", "to": "2", "value": 1}, {"from": "##u", "to": "is", "value": 1}, {"from": "##u", "to": "competitively", "value": 1}, {"from": "##u", "to": "ch", "value": 1}, {"from": "##u", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##u", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##u", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##u", "to": "x", "value": 1}, {"from": "##u", "to": "r", "value": 1}, {"from": "##u", "to": "10", "value": 2}, {"from": "##u", "to": "##rna", "value": 1}, {"from": "##u", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##u", "to": "binding protein 1", "value": 1}, {"from": "##u", "to": "i", "value": 2}, {"from": "##u", "to": "##emota", "value": 1}, {"from": "##u", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##u", "to": "##na -", "value": 1}, {"from": "##u", "to": "antagonist", "value": 1}, {"from": "##u", "to": "is cost - effective", "value": 1}, {"from": "##u", "to": "of agriculture and natural", "value": 1}, {"from": "##u", "to": ". ac.", "value": 1}, {"from": "##u", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "##u", "to": "resources", "value": 1}, {"from": "##u", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "##u", "to": "##za. he", "value": 1}, {"from": "##u", "to": ":", "value": 1}, {"from": "##u", "to": "##6 /", "value": 1}, {"from": "##u", "to": "are", "value": 1}, {"from": "##u", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##u", "to": "##ri - japelaghi r", "value": 1}, {"from": "##u", "to": "university", "value": 1}, {"from": "##u", "to": "40", "value": 1}, {"from": "##u", "to": "##r.", "value": 1}, {"from": "##u", "to": "who", "value": 1}, {"from": "##u", "to": "inter", "value": 1}, {"from": "##u", "to": "##vin", "value": 1}, {"from": "##u", "to": ",", "value": 1}, {"from": "##u", "to": "of tabriz,", "value": 1}, {"from": "##u", "to": "@ org.", "value": 1}, {"from": "##u", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##u", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##u", "to": "##idari", "value": 1}, {"from": "##u", "to": "doi", "value": 1}, {"from": "##u", "to": "s", "value": 1}, {"from": "##u", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##u", "to": "ta", "value": 1}, {"from": "##u", "to": "j", "value": 1}, {"from": "##u", "to": "##ran. electronic address :", "value": 1}, {"from": "##u", "to": ".", "value": 1}, {"from": "##u", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##u", "to": "re", "value": 1}, {"from": "##u", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##u", "to": "101", "value": 1}, {"from": "##u", "to": "##ida", "value": 1}, {"from": "##u", "to": "perspectives", "value": 1}, {"from": "##u", "to": "##briz,", "value": 1}, {"from": "##u", "to": "faculty", "value": 1}, {"from": "##u", "to": "of agriculture,", "value": 1}, {"from": "##u", "to": "##fer", "value": 1}, {"from": "##u", "to": "##on", "value": 1}, {"from": "##u", "to": "##ki", "value": 1}, {"from": "##u", "to": "from both", "value": 1}, {"from": "##u", "to": "##ran.", "value": 1}, {"from": "factor", "to": "gene expression have yet to be clarified. here, we discovered", "value": 1}, {"from": "factor", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "factor", "to": "for", "value": 1}, {"from": "factor", "to": "college", "value": 1}, {"from": "factor", "to": "##iu r", "value": 1}, {"from": "factor", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "factor", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "factor", "to": "##i a", "value": 1}, {"from": "factor", "to": "##i h", "value": 1}, {"from": "factor", "to": "##iu x", "value": 1}, {"from": "factor", "to": "-", "value": 1}, {"from": "factor", "to": "related", "value": 1}, {"from": "factor", "to": "##ine kinase 2", "value": 1}, {"from": "factor", "to": "induced protein", "value": 1}, {"from": "factor", "to": "l", "value": 1}, {"from": "factor", "to": "2", "value": 1}, {"from": "factor", "to": "is", "value": 1}, {"from": "factor", "to": "competitively", "value": 1}, {"from": "factor", "to": "ch", "value": 1}, {"from": "factor", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "factor", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "factor", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "factor", "to": "x", "value": 1}, {"from": "factor", "to": "r", "value": 1}, {"from": "factor", "to": "10", "value": 1}, {"from": "factor", "to": "##rna", "value": 1}, {"from": "factor", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "factor", "to": "binding protein 1", "value": 1}, {"from": "factor", "to": "i", "value": 1}, {"from": "factor", "to": "##emota", "value": 1}, {"from": "factor", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "factor", "to": "##na -", "value": 1}, {"from": "factor", "to": "antagonist", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##cripts, including vascular endothelial growth factor a", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "for", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "college", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##iu r", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##i a", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##i h", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##iu x", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "-", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "related", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##ine kinase 2", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "induced protein", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "l", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "2", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "is", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "competitively", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "ch", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "x", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "r", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "10", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##rna", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "binding protein 1", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "i", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##emota", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "##na -", "value": 1}, {"from": "gene expression have yet to be clarified. here, we discovered", "to": "antagonist", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "for", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "college", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##iu r", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##i a", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##i h", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##iu x", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "-", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "related", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##ine kinase 2", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "induced protein", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "l", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "2", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "is", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "competitively", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "ch", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "x", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "r", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "10", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##rna", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "binding protein 1", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "i", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##emota", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "##na -", "value": 1}, {"from": "##cripts, including vascular endothelial growth factor a", "to": "antagonist", "value": 1}, {"from": "for", "to": "college", "value": 1}, {"from": "for", "to": "##iu r", "value": 1}, {"from": "for", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "for", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "for", "to": "##i a", "value": 1}, {"from": "for", "to": "##i h", "value": 1}, {"from": "for", "to": "##iu x", "value": 1}, {"from": "for", "to": "-", "value": 1}, {"from": "for", "to": "related", "value": 1}, {"from": "for", "to": "##ine kinase 2", "value": 1}, {"from": "for", "to": "induced protein", "value": 1}, {"from": "for", "to": "l", "value": 1}, {"from": "for", "to": "2", "value": 1}, {"from": "for", "to": "is", "value": 1}, {"from": "for", "to": "competitively", "value": 1}, {"from": "for", "to": "ch", "value": 1}, {"from": "for", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "for", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "for", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "for", "to": "x", "value": 1}, {"from": "for", "to": "r", "value": 1}, {"from": "for", "to": "10", "value": 1}, {"from": "for", "to": "##rna", "value": 1}, {"from": "for", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "for", "to": "binding protein 1", "value": 1}, {"from": "for", "to": "i", "value": 1}, {"from": "for", "to": "##emota", "value": 1}, {"from": "for", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "for", "to": "##na -", "value": 1}, {"from": "for", "to": "antagonist", "value": 1}, {"from": "college", "to": "##iu r", "value": 1}, {"from": "college", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "college", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "college", "to": "##i a", "value": 1}, {"from": "college", "to": "##i h", "value": 1}, {"from": "college", "to": "##iu x", "value": 1}, {"from": "college", "to": "-", "value": 1}, {"from": "college", "to": "related", "value": 1}, {"from": "college", "to": "##ine kinase 2", "value": 1}, {"from": "college", "to": "induced protein", "value": 1}, {"from": "college", "to": "l", "value": 1}, {"from": "college", "to": "2", "value": 1}, {"from": "college", "to": "is", "value": 2}, {"from": "college", "to": "competitively", "value": 1}, {"from": "college", "to": "ch", "value": 1}, {"from": "college", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "college", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "college", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "college", "to": "x", "value": 1}, {"from": "college", "to": "r", "value": 1}, {"from": "college", "to": "10", "value": 1}, {"from": "college", "to": "##rna", "value": 1}, {"from": "college", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "college", "to": "binding protein 1", "value": 1}, {"from": "college", "to": "i", "value": 1}, {"from": "college", "to": "##emota", "value": 1}, {"from": "college", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "college", "to": "##na -", "value": 1}, {"from": "college", "to": "antagonist", "value": 1}, {"from": "college", "to": "box l", "value": 1}, {"from": "college", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "college", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "college", "to": "of medical sciences, c.", "value": 1}, {"from": "college", "to": "these two conditions which", "value": 1}, {"from": "college", "to": "box", "value": 1}, {"from": "college", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "college", "to": "sciences", "value": 1}, {"from": "college", "to": "care", "value": 1}, {"from": "college", "to": ",", "value": 1}, {"from": "college", "to": "##ra", "value": 1}, {"from": "college", "to": "00", "value": 1}, {"from": "college", "to": "in", "value": 1}, {"from": "college", "to": "233, ghana.", "value": 1}, {"from": "college", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "college", "to": "##g 77, a", "value": 1}, {"from": "college", "to": "5", "value": 1}, {"from": "college", "to": "k", "value": 1}, {"from": "college", "to": ") west african genetic medicine centre", "value": 1}, {"from": "college", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "college", "to": "of health", "value": 1}, {"from": "college", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "college", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "college", "to": "been observed", "value": 1}, {"from": "college", "to": "school", "value": 1}, {"from": "college", "to": ", university of ghana, p. o.", "value": 1}, {"from": "college", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "college", "to": "between", "value": 1}, {"from": "college", "to": "of anaesthesia and intensive", "value": 1}, {"from": "college", "to": "##233, ghana.", "value": 1}, {"from": "college", "to": "incidence", "value": 1}, {"from": "college", "to": "4", "value": 1}, {"from": "college", "to": "cancer and ad", "value": 1}, {"from": "college", "to": "were formerly", "value": 1}, {"from": "college", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "college", "to": ")", "value": 1}, {"from": "college", "to": "has", "value": 1}, {"from": "college", "to": "department", "value": 1}, {"from": "college", "to": "inverse relationship between", "value": 1}, {"from": "college", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "college", "to": "##cc", "value": 1}, {"from": "##iu r", "to": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "value": 1}, {"from": "##iu r", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##iu r", "to": "##i a", "value": 1}, {"from": "##iu r", "to": "##i h", "value": 1}, {"from": "##iu r", "to": "##iu x", "value": 1}, {"from": "##iu r", "to": "-", "value": 1}, {"from": "##iu r", "to": "related", "value": 1}, {"from": "##iu r", "to": "##ine kinase 2", "value": 1}, {"from": "##iu r", "to": "induced protein", "value": 1}, {"from": "##iu r", "to": "l", "value": 1}, {"from": "##iu r", "to": "2", "value": 1}, {"from": "##iu r", "to": "is", "value": 1}, {"from": "##iu r", "to": "competitively", "value": 1}, {"from": "##iu r", "to": "ch", "value": 1}, {"from": "##iu r", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##iu r", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##iu r", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##iu r", "to": "x", "value": 1}, {"from": "##iu r", "to": "r", "value": 1}, {"from": "##iu r", "to": "10", "value": 1}, {"from": "##iu r", "to": "##rna", "value": 1}, {"from": "##iu r", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##iu r", "to": "binding protein 1", "value": 1}, {"from": "##iu r", "to": "i", "value": 1}, {"from": "##iu r", "to": "##emota", "value": 1}, {"from": "##iu r", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##iu r", "to": "##na -", "value": 1}, {"from": "##iu r", "to": "antagonist", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##gf2bp1 ) function as a pair of", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##i a", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##i h", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##iu x", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "-", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "related", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##ine kinase 2", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "induced protein", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "l", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "2", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "is", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "competitively", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "ch", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "x", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "r", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "10", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##rna", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "binding protein 1", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "i", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##emota", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "##na -", "value": 1}, {"from": "##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l", "to": "antagonist", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##i a", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##i h", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##iu x", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "-", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "related", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##ine kinase 2", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "induced protein", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "l", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "2", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "is", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "competitively", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "ch", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "x", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "r", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "10", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##rna", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "binding protein 1", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "i", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##emota", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "##na -", "value": 1}, {"from": "##gf2bp1 ) function as a pair of", "to": "antagonist", "value": 1}, {"from": "##i a", "to": "##i h", "value": 1}, {"from": "##i a", "to": "##iu x", "value": 1}, {"from": "##i a", "to": "-", "value": 1}, {"from": "##i a", "to": "related", "value": 1}, {"from": "##i a", "to": "##ine kinase 2", "value": 1}, {"from": "##i a", "to": "induced protein", "value": 1}, {"from": "##i a", "to": "l", "value": 1}, {"from": "##i a", "to": "2", "value": 1}, {"from": "##i a", "to": "is", "value": 1}, {"from": "##i a", "to": "competitively", "value": 1}, {"from": "##i a", "to": "ch", "value": 1}, {"from": "##i a", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##i a", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##i a", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##i a", "to": "x", "value": 1}, {"from": "##i a", "to": "r", "value": 1}, {"from": "##i a", "to": "10", "value": 1}, {"from": "##i a", "to": "##rna", "value": 1}, {"from": "##i a", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##i a", "to": "binding protein 1", "value": 1}, {"from": "##i a", "to": "i", "value": 1}, {"from": "##i a", "to": "##emota", "value": 1}, {"from": "##i a", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##i a", "to": "##na -", "value": 1}, {"from": "##i a", "to": "antagonist", "value": 1}, {"from": "##i h", "to": "##iu x", "value": 1}, {"from": "##i h", "to": "-", "value": 1}, {"from": "##i h", "to": "related", "value": 1}, {"from": "##i h", "to": "##ine kinase 2", "value": 1}, {"from": "##i h", "to": "induced protein", "value": 1}, {"from": "##i h", "to": "l", "value": 1}, {"from": "##i h", "to": "2", "value": 1}, {"from": "##i h", "to": "is", "value": 1}, {"from": "##i h", "to": "competitively", "value": 1}, {"from": "##i h", "to": "ch", "value": 1}, {"from": "##i h", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##i h", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##i h", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##i h", "to": "x", "value": 1}, {"from": "##i h", "to": "r", "value": 1}, {"from": "##i h", "to": "10", "value": 1}, {"from": "##i h", "to": "##rna", "value": 1}, {"from": "##i h", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##i h", "to": "binding protein 1", "value": 1}, {"from": "##i h", "to": "i", "value": 1}, {"from": "##i h", "to": "##emota", "value": 1}, {"from": "##i h", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##i h", "to": "##na -", "value": 1}, {"from": "##i h", "to": "antagonist", "value": 1}, {"from": "##iu x", "to": "-", "value": 1}, {"from": "##iu x", "to": "related", "value": 1}, {"from": "##iu x", "to": "##ine kinase 2", "value": 1}, {"from": "##iu x", "to": "induced protein", "value": 1}, {"from": "##iu x", "to": "l", "value": 1}, {"from": "##iu x", "to": "2", "value": 1}, {"from": "##iu x", "to": "is", "value": 1}, {"from": "##iu x", "to": "competitively", "value": 1}, {"from": "##iu x", "to": "ch", "value": 1}, {"from": "##iu x", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##iu x", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##iu x", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##iu x", "to": "x", "value": 1}, {"from": "##iu x", "to": "r", "value": 1}, {"from": "##iu x", "to": "10", "value": 1}, {"from": "##iu x", "to": "##rna", "value": 1}, {"from": "##iu x", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##iu x", "to": "binding protein 1", "value": 1}, {"from": "##iu x", "to": "i", "value": 1}, {"from": "##iu x", "to": "##emota", "value": 1}, {"from": "##iu x", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##iu x", "to": "##na -", "value": 1}, {"from": "##iu x", "to": "antagonist", "value": 1}, {"from": "-", "to": "related", "value": 1}, {"from": "-", "to": "##ine kinase 2", "value": 1}, {"from": "-", "to": "induced protein", "value": 1}, {"from": "-", "to": "l", "value": 1}, {"from": "-", "to": "2", "value": 1}, {"from": "-", "to": "is", "value": 3}, {"from": "-", "to": "competitively", "value": 1}, {"from": "-", "to": "ch", "value": 1}, {"from": "-", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "-", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "-", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "-", "to": "x", "value": 1}, {"from": "-", "to": "r", "value": 2}, {"from": "-", "to": "10", "value": 1}, {"from": "-", "to": "##rna", "value": 2}, {"from": "-", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "-", "to": "binding protein 1", "value": 1}, {"from": "-", "to": "i", "value": 2}, {"from": "-", "to": "##emota", "value": 1}, {"from": "-", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "-", "to": "##na -", "value": 1}, {"from": "-", "to": "antagonist", "value": 1}, {"from": "-", "to": "quantitative pcr", "value": 1}, {"from": "-", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "-", "to": "time", "value": 2}, {"from": "-", "to": "##sia", "value": 1}, {"from": "-", "to": "of medicine, univers", "value": 1}, {"from": "-", "to": "regulating the cell", "value": 1}, {"from": "-", "to": "ute,", "value": 1}, {"from": "-", "to": "##poptosis", "value": 1}, {"from": "-", "to": "##cence, making it", "value": 1}, {"from": "-", "to": "##itas in", "value": 1}, {"from": "-", "to": "proliferation", "value": 1}, {"from": "-", "to": "and se", "value": 1}, {"from": "-", "to": "a", "value": 2}, {"from": "-", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "-", "to": "in", "value": 6}, {"from": "-", "to": "target", "value": 1}, {"from": "-", "to": "##nes", "value": 1}, {"from": "-", "to": "##50 value", "value": 1}, {"from": "-", "to": "5", "value": 1}, {"from": "-", "to": "role in", "value": 1}, {"from": "-", "to": "##esi", "value": 1}, {"from": "-", "to": "real", "value": 2}, {"from": "-", "to": ". the p53 signaling pathway", "value": 1}, {"from": "-", "to": ", a", "value": 2}, {"from": "-", "to": "key", "value": 1}, {"from": "-", "to": ", and", "value": 1}, {"from": "-", "to": "plays", "value": 1}, {"from": "-", "to": "##a.", "value": 1}, {"from": "-", "to": "a critical", "value": 1}, {"from": "-", "to": "faculty", "value": 2}, {"from": "-", "to": "cycle", "value": 2}, {"from": "-", "to": "of downstream genes linked to cell", "value": 1}, {"from": "-", "to": "##a, jakarta,", "value": 1}, {"from": "-", "to": "##iti", "value": 1}, {"from": "-", "to": "of pharmacy, univers", "value": 1}, {"from": "-", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "-", "to": "##don", "value": 1}, {"from": "-", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "-", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "-", "to": "expression", "value": 3}, {"from": "-", "to": "##c", "value": 3}, {"from": "-", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "-", "to": "on the", "value": 1}, {"from": "-", "to": "##ia", "value": 3}, {"from": "-", "to": "senes", "value": 1}, {"from": "-", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "-", "to": "##ene", "value": 1}, {"from": "-", "to": "which was", "value": 1}, {"from": "-", "to": ": cyce or ccne1", "value": 1}, {"from": "-", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "-", "to": "c", "value": 1}, {"from": "-", "to": "##8 ), and e2f1", "value": 1}, {"from": "-", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "-", "to": "##1 ), rbl1", "value": 1}, {"from": "-", "to": "might", "value": 1}, {"from": "-", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "-", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "-", "to": "the native", "value": 1}, {"from": "-", "to": "ligan", "value": 1}, {"from": "-", "to": "00", "value": 1}, {"from": "-", "to": "im", "value": 1}, {"from": "-", "to": "p = 0. 01", "value": 1}, {"from": "-", "to": "##rank", "value": 1}, {"from": "-", "to": "##j", "value": 1}, {"from": "-", "to": "by", "value": 2}, {"from": "-", "to": "b", "value": 2}, {"from": "-", "to": "rerank score", "value": 1}, {"from": "-", "to": "##um", "value": 1}, {"from": "-", "to": "##d", "value": 1}, {"from": "-", "to": "of ad", "value": 1}, {"from": "-", "to": ".", "value": 4}, {"from": "-", "to": "re", "value": 1}, {"from": "-", "to": "##idodiph", "value": 1}, {"from": "-", "to": "p = 0", "value": 1}, {"from": "-", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "-", "to": "- 112. 70 k", "value": 1}, {"from": "-", "to": "score", "value": 1}, {"from": "-", "to": "##ine", "value": 1}, {"from": "-", "to": "##enyl", "value": 1}, {"from": "-", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "-", "to": "##osphate", "value": 1}, {"from": "-", "to": "- 110. 68 k", "value": 1}, {"from": "-", "to": "0", "value": 1}, {"from": "-", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "-", "to": "/ mol ), and nummular", "value": 1}, {"from": "-", "to": "squal", "value": 1}, {"from": "-", "to": "the decrease in p21", "value": 1}, {"from": "-", "to": "##mularia stem suggested that", "value": 1}, {"from": "-", "to": "prescribed chole", "value": 1}, {"from": "-", "to": "has recently", "value": 1}, {"from": "-", "to": "and its biological functions", "value": 1}, {"from": "-", "to": "of saida, saida, algeria.", "value": 1}, {"from": "-", "to": "shown", "value": 1}, {"from": "-", "to": "however", "value": 2}, {"from": "-", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "-", "to": "shown potential anti", "value": 1}, {"from": "-", "to": "genes", "value": 1}, {"from": "-", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "-", "to": "##in", "value": 1}, {"from": "-", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "-", "to": "particular breast cancer,", "value": 1}, {"from": "-", "to": "still", "value": 1}, {"from": "-", "to": "associated with atorvas", "value": 1}, {"from": "-", "to": "in breast", "value": 1}, {"from": "-", "to": "lowering", "value": 1}, {"from": "-", "to": "to be responsive to", "value": 1}, {"from": "-", "to": "interaction", "value": 1}, {"from": "-", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "-", "to": ") network and", "value": 1}, {"from": "-", "to": "in the protein - protein", "value": 1}, {"from": "-", "to": "drug,", "value": 1}, {"from": "-", "to": "##gu", "value": 1}, {"from": "-", "to": "hub gene", "value": 1}, {"from": "-", "to": ", its influence on gene", "value": 1}, {"from": "-", "to": "##lated", "value": 1}, {"from": "-", "to": "was", "value": 2}, {"from": "-", "to": "##in,", "value": 1}, {"from": "-", "to": "ppi", "value": 1}, {"from": "-", "to": "##oto", "value": 1}, {"from": "-", "to": "##tat", "value": 1}, {"from": "-", "to": "related pathways", "value": 1}, {"from": "-", "to": "cancer,", "value": 1}, {"from": "-", "to": "expressed", "value": 2}, {"from": "-", "to": "jun", "value": 1}, {"from": "-", "to": "##cer effects.", "value": 1}, {"from": "-", "to": "widely", "value": 1}, {"from": "-", "to": "atorvas", "value": 1}, {"from": "-", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "-", "to": "##ster", "value": 1}, {"from": "-", "to": "##ol", "value": 1}, {"from": "-", "to": "##can", "value": 1}, {"from": "-", "to": "cancer. atorvas", "value": 1}, {"from": "-", "to": "was identified as the", "value": 1}, {"from": "-", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "-", "to": "##r confirmed their down", "value": 1}, {"from": "-", "to": "four", "value": 1}, {"from": "-", "to": "prioriti", "value": 1}, {"from": "-", "to": "pc", "value": 1}, {"from": "-", "to": "##re", "value": 1}, {"from": "-", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "-", "to": "diagnosed", "value": 1}, {"from": "-", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "-", "to": "incomplete", "value": 1}, {"from": "-", "to": "ministry", "value": 1}, {"from": "-", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "-", "to": "diagnostic", "value": 1}, {"from": "-", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "-", "to": "##s and", "value": 1}, {"from": "-", "to": "##s.", "value": 1}, {"from": "-", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "-", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "-", "to": "treatment", "value": 2}, {"from": "-", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "-", "to": "- mi", "value": 1}, {"from": "-", "to": "##gna", "value": 1}, {"from": "-", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "-", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "-", "to": "##ncrna", "value": 1}, {"from": "-", "to": "##r", "value": 2}, {"from": "-", "to": "mrna", "value": 1}, {"from": "-", "to": "mali", "value": 1}, {"from": "-", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "-", "to": "), and the top", "value": 1}, {"from": "-", "to": "##0", "value": 1}, {"from": "-", "to": "), a parp", "value": 1}, {"from": "-", "to": "##point blockade", "value": 1}, {"from": "-", "to": "etop", "value": 1}, {"from": "-", "to": "##ide - on", "value": 1}, {"from": "-", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "-", "to": "##ide, a top", "value": 1}, {"from": "-", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "-", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "-", "to": "##ase ii", "value": 1}, {"from": "-", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "-", "to": "interfer", "value": 1}, {"from": "-", "to": "fails", "value": 1}, {"from": "-", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "-", "to": "type", "value": 1}, {"from": "-", "to": "if", "value": 1}, {"from": "-", "to": "##fi", "value": 1}, {"from": "-", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "-", "to": "##oisomer", "value": 1}, {"from": "-", "to": "##n ) signaling, with etop", "value": 1}, {"from": "-", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "-", "to": "##b", "value": 1}, {"from": "-", "to": "to encourage immune effector cell in", "value": 1}, {"from": "-", "to": "does", "value": 1}, {"from": "-", "to": "##ltration into tumors, and", "value": 1}, {"from": "-", "to": "##on - stimulated gene", "value": 1}, {"from": "-", "to": "check", "value": 1}, {"from": "-", "to": "##on", "value": 1}, {"from": "-", "to": "inhibitor", "value": 1}, {"from": "-", "to": "12", "value": 1}, {"from": "-", "to": "after net", "value": 1}, {"from": "-", "to": "a significant", "value": 1}, {"from": "-", "to": "offers the opportunity of", "value": 1}, {"from": "-", "to": "##ip", "value": 1}, {"from": "-", "to": "t", "value": 1}, {"from": "-", "to": ") health", "value": 1}, {"from": "-", "to": "background", "value": 1}, {"from": "-", "to": "##re population of", "value": 1}, {"from": "-", "to": "negative breast", "value": 1}, {"from": "-", "to": "barrier", "value": 1}, {"from": "-", "to": "##gipuzkoa", "value": 1}, {"from": "-", "to": "clinical", "value": 1}, {"from": "-", "to": "##2 -", "value": 1}, {"from": "-", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "-", "to": ",", "value": 2}, {"from": "-", "to": "##zkoa", "value": 1}, {"from": "-", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "-", "to": "##gi", "value": 1}, {"from": "-", "to": "##donostia ) health", "value": 1}, {"from": "-", "to": "##tian,", "value": 1}, {"from": "-", "to": "cancer", "value": 1}, {"from": "-", "to": "spain", "value": 1}, {"from": "-", "to": "##uzkoa. eus.", "value": 1}, {"from": "-", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "-", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "-", "to": "and", "value": 3}, {"from": "-", "to": "personal", "value": 1}, {"from": "-", "to": "##ised therapy.", "value": 1}, {"from": "-", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "-", "to": "bio", "value": 1}, {"from": "-", "to": "##donost", "value": 1}, {"from": "-", "to": "##cent", "value": 1}, {"from": "-", "to": "research institute", "value": 1}, {"from": "-", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "-", "to": "sa", "value": 1}, {"from": "-", "to": "sebas", "value": 1}, {"from": "-", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "-", "to": "her", "value": 1}, {"from": "-", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "-", "to": "##n sebastian,", "value": 1}, {"from": "-", "to": "##umour response", "value": 1}, {"from": "-", "to": "a,", "value": 1}, {"from": "-", "to": "##pu", "value": 1}, {"from": "-", "to": "##n", "value": 1}, {"from": "-", "to": "sebastian", "value": 1}, {"from": "-", "to": "##uc", "value": 1}, {"from": "-", "to": "13", "value": 1}, {"from": "-", "to": ", the lack of reprod", "value": 1}, {"from": "-", "to": ")", "value": 2}, {"from": "-", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "-", "to": "##c ) allows", "value": 1}, {"from": "-", "to": "##gnosis", "value": 1}, {"from": "-", "to": "- g", "value": 1}, {"from": "-", "to": "the", "value": 1}, {"from": "-", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "-", "to": "methods", "value": 1}, {"from": "-", "to": "hormone receptor positive", "value": 1}, {"from": "-", "to": "societal perspective", "value": 2}, {"from": "-", "to": "benefits", "value": 1}, {"from": "-", "to": "surgery", "value": 1}, {"from": "-", "to": "cost -", "value": 1}, {"from": "-", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "-", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "-", "to": "decision", "value": 1}, {"from": "-", "to": "to aid adjuvant treatment", "value": 1}, {"from": "-", "to": "##al", "value": 1}, {"from": "-", "to": "emit - 1 trial", "value": 1}, {"from": "-", "to": "post", "value": 1}, {"from": "-", "to": ". materials", "value": 1}, {"from": "-", "to": "model was", "value": 1}, {"from": "-", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "-", "to": "used", "value": 1}, {"from": "-", "to": "institute", "value": 1}, {"from": "-", "to": ": the", "value": 1}, {"from": "-", "to": "ki - 67", "value": 1}, {"from": "-", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "-", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "-", "to": "prosigna was tested", "value": 1}, {"from": "-", "to": "prospective", "value": 1}, {"from": "-", "to": "were measured", "value": 1}, {"from": "-", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "-", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "-", "to": "observation", "value": 1}, {"from": "-", "to": "division", "value": 1}, {"from": "-", "to": "decisions in", "value": 1}, {"from": "-", "to": "built", "value": 1}, {"from": "-", "to": "impact of", "value": 1}, {"from": "-", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "-", "to": "benefit", "value": 1}, {"from": "-", "to": "##26, 000 ;", "value": 1}, {"from": "-", "to": "effective", "value": 1}, {"from": "-", "to": "it was cost - saving", "value": 1}, {"from": "-", "to": "threshold", "value": 1}, {"from": "-", "to": "- 435, 677 )", "value": 1}, {"from": "-", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "-", "to": "##aly", "value": 1}, {"from": "-", "to": "in the", "value": 1}, {"from": "-", "to": "cost", "value": 1}, {"from": "-", "to": "\u20ac", "value": 1}, {"from": "-", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "-", "to": "- 620170,", "value": 1}, {"from": "-", "to": "##r )", "value": 1}, {"from": "-", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "-", "to": "candidates, the strategy", "value": 1}, {"from": "-", "to": "cost - effective", "value": 1}, {"from": "-", "to": "incre", "value": 1}, {"from": "-", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "-", "to": "##mental", "value": 1}, {"from": "-", "to": "the cost -", "value": 1}, {"from": "-", "to": "was cost - effective", "value": 1}, {"from": "-", "to": "above", "value": 1}, {"from": "-", "to": "respectively", "value": 1}, {"from": "-", "to": "results", "value": 1}, {"from": "-", "to": "was obtained from statistics norway.", "value": 1}, {"from": "-", "to": "per quality - adjusted life -", "value": 1}, {"from": "-", "to": "was cost - saving", "value": 1}, {"from": "-", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "-", "to": "chemotherapy", "value": 1}, {"from": "-", "to": "in both the healthcare", "value": 1}, {"from": "-", "to": "years", "value": 1}, {"from": "-", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "-", "to": "- per q", "value": 1}, {"from": "-", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "-", "to": ". conclusions", "value": 1}, {"from": "-", "to": ". selecting patient", "value": 1}, {"from": "-", "to": "ice", "value": 1}, {"from": "-", "to": "##8884 and", "value": 1}, {"from": "-", "to": "gained", "value": 1}, {"from": "-", "to": "the emit", "value": 1}, {"from": "-", "to": "records. including all pn0 patients", "value": 1}, {"from": "-", "to": "sector", "value": 1}, {"from": "-", "to": "not", "value": 1}, {"from": "related", "to": "##ine kinase 2", "value": 1}, {"from": "related", "to": "induced protein", "value": 1}, {"from": "related", "to": "l", "value": 1}, {"from": "related", "to": "2", "value": 1}, {"from": "related", "to": "is", "value": 1}, {"from": "related", "to": "competitively", "value": 1}, {"from": "related", "to": "ch", "value": 1}, {"from": "related", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "related", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "related", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "related", "to": "x", "value": 1}, {"from": "related", "to": "r", "value": 1}, {"from": "related", "to": "10", "value": 2}, {"from": "related", "to": "##rna", "value": 1}, {"from": "related", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "related", "to": "binding protein 1", "value": 1}, {"from": "related", "to": "i", "value": 1}, {"from": "related", "to": "##emota", "value": 1}, {"from": "related", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "related", "to": "##na -", "value": 1}, {"from": "related", "to": "antagonist", "value": 1}, {"from": "related", "to": "##t", "value": 1}, {"from": "related", "to": "of life", "value": 1}, {"from": "related", "to": "##k", "value": 1}, {"from": "related", "to": ") institute for brain sciences research,", "value": 1}, {"from": "related", "to": ":", "value": 1}, {"from": "related", "to": "index", "value": 1}, {"from": "related", "to": "##osu", "value": 1}, {"from": "related", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "related", "to": ". 1096 / fj. 202", "value": 1}, {"from": "related", "to": "may contribute to the", "value": 1}, {"from": "related", "to": "sciences", "value": 1}, {"from": "related", "to": "university", "value": 1}, {"from": "related", "to": "##lle", "value": 1}, {"from": "related", "to": "40", "value": 1}, {"from": "related", "to": ",", "value": 1}, {"from": "related", "to": "genes", "value": 1}, {"from": "related", "to": "##i", "value": 1}, {"from": "related", "to": "##f", "value": 1}, {"from": "related", "to": "we", "value": 1}, {"from": "related", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "related", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "related", "to": "3 )", "value": 1}, {"from": "related", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "related", "to": "##hie j", "value": 1}, {"from": "related", "to": "k", "value": 1}, {"from": "related", "to": "doi", "value": 1}, {"from": "related", "to": "b", "value": 1}, {"from": "related", "to": "102", "value": 1}, {"from": "related", "to": "j", "value": 1}, {"from": "related", "to": "##354028 [", "value": 1}, {"from": "related", "to": ".", "value": 1}, {"from": "related", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "related", "to": "school", "value": 1}, {"from": "related", "to": "), agegnehu sb", "value": 1}, {"from": "related", "to": "##ra 00", "value": 1}, {"from": "related", "to": "3 ), lamptey el", "value": 1}, {"from": "related", "to": "1", "value": 1}, {"from": "related", "to": "ka", "value": 1}, {"from": "related", "to": "4", "value": 1}, {"from": "related", "to": "of ghana, a", "value": 1}, {"from": "related", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "related", "to": "##461r pmid :", "value": 1}, {"from": "related", "to": "antiangiogenic therapy of", "value": 1}, {"from": "related", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "related", "to": ")", "value": 1}, {"from": "related", "to": "he", "value": 1}, {"from": "related", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "related", "to": "expression", "value": 1}, {"from": "related", "to": "breast", "value": 1}, {"from": "related", "to": "##500", "value": 1}, {"from": "related", "to": "in cancer", "value": 1}, {"from": "related", "to": "##mpo s", "value": 1}, {"from": "related", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "related", "to": "##cc", "value": 1}, {"from": "related", "to": "inverse", "value": 1}, {"from": "related", "to": "new insights into", "value": 1}, {"from": "##ine kinase 2", "to": "induced protein", "value": 1}, {"from": "##ine kinase 2", "to": "l", "value": 1}, {"from": "##ine kinase 2", "to": "2", "value": 1}, {"from": "##ine kinase 2", "to": "is", "value": 1}, {"from": "##ine kinase 2", "to": "competitively", "value": 1}, {"from": "##ine kinase 2", "to": "ch", "value": 1}, {"from": "##ine kinase 2", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "##ine kinase 2", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "##ine kinase 2", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "##ine kinase 2", "to": "x", "value": 1}, {"from": "##ine kinase 2", "to": "r", "value": 1}, {"from": "##ine kinase 2", "to": "10", "value": 1}, {"from": "##ine kinase 2", "to": "##rna", "value": 1}, {"from": "##ine kinase 2", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##ine kinase 2", "to": "binding protein 1", "value": 1}, {"from": "##ine kinase 2", "to": "i", "value": 1}, {"from": "##ine kinase 2", "to": "##emota", "value": 1}, {"from": "##ine kinase 2", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##ine kinase 2", "to": "##na -", "value": 1}, {"from": "##ine kinase 2", "to": "antagonist", "value": 1}, {"from": "induced protein", "to": "l", "value": 1}, {"from": "induced protein", "to": "2", "value": 1}, {"from": "induced protein", "to": "is", "value": 1}, {"from": "induced protein", "to": "competitively", "value": 1}, {"from": "induced protein", "to": "ch", "value": 1}, {"from": "induced protein", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "induced protein", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "induced protein", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "induced protein", "to": "x", "value": 1}, {"from": "induced protein", "to": "r", "value": 1}, {"from": "induced protein", "to": "10", "value": 1}, {"from": "induced protein", "to": "##rna", "value": 1}, {"from": "induced protein", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "induced protein", "to": "binding protein 1", "value": 1}, {"from": "induced protein", "to": "i", "value": 1}, {"from": "induced protein", "to": "##emota", "value": 1}, {"from": "induced protein", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "induced protein", "to": "##na -", "value": 1}, {"from": "induced protein", "to": "antagonist", "value": 1}, {"from": "l", "to": "2", "value": 1}, {"from": "l", "to": "is", "value": 1}, {"from": "l", "to": "competitively", "value": 1}, {"from": "l", "to": "ch", "value": 1}, {"from": "l", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "l", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "l", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "l", "to": "x", "value": 1}, {"from": "l", "to": "r", "value": 1}, {"from": "l", "to": "10", "value": 2}, {"from": "l", "to": "##rna", "value": 1}, {"from": "l", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "l", "to": "binding protein 1", "value": 1}, {"from": "l", "to": "i", "value": 1}, {"from": "l", "to": "##emota", "value": 1}, {"from": "l", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "l", "to": "##na -", "value": 1}, {"from": "l", "to": "antagonist", "value": 1}, {"from": "l", "to": "), huarte m", "value": 1}, {"from": "l", "to": "12", "value": 1}, {"from": "l", "to": "##407.", "value": 1}, {"from": "l", "to": "), par", "value": 1}, {"from": "l", "to": "ins", "value": 1}, {"from": "l", "to": ":", "value": 1}, {"from": "l", "to": "##or", "value": 1}, {"from": "l", "to": "##e", "value": 1}, {"from": "l", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "l", "to": "9", "value": 1}, {"from": "l", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "l", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "l", "to": "), aragon s", "value": 1}, {"from": "l", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "l", "to": "##ory", "value": 1}, {"from": "l", "to": "in", "value": 1}, {"from": "l", "to": "5", "value": 1}, {"from": "l", "to": "), gimenez j", "value": 1}, {"from": "l", "to": "doi", "value": 1}, {"from": "l", "to": "- lopez i", "value": 1}, {"from": "l", "to": "##rine", "value": 1}, {"from": "l", "to": "er + / her2 -", "value": 1}, {"from": "l", "to": "102", "value": 1}, {"from": "l", "to": "), prat a", "value": 1}, {"from": "l", "to": "research", "value": 1}, {"from": "l", "to": ".", "value": 1}, {"from": "l", "to": "##e. lg is /", "value": 1}, {"from": "l", "to": "), buch e", "value": 1}, {"from": "l", "to": "##roga v", "value": 1}, {"from": "l", "to": "been holding research", "value": 1}, {"from": "l", "to": "11", "value": 1}, {"from": "l", "to": "101", "value": 1}, {"from": "l", "to": "##riaga k", "value": 1}, {"from": "l", "to": "), etxabe i", "value": 1}, {"from": "l", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "l", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "l", "to": "13", "value": 1}, {"from": "l", "to": "4", "value": 1}, {"from": "l", "to": "therapy", "value": 1}, {"from": "l", "to": "##ui", "value": 1}, {"from": "l", "to": "##ez", "value": 1}, {"from": "l", "to": "##vita", "value": 1}, {"from": "l", "to": "contracts", "value": 1}, {"from": "l", "to": "has", "value": 1}, {"from": "l", "to": "6", "value": 1}, {"from": "l", "to": "breast", "value": 1}, {"from": "l", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "l", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "l", "to": "). author information :", "value": 1}, {"from": "l", "to": "), urruticoechea a", "value": 1}, {"from": "2", "to": "is", "value": 1}, {"from": "2", "to": "competitively", "value": 1}, {"from": "2", "to": "ch", "value": 1}, {"from": "2", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "2", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "2", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "2", "to": "x", "value": 1}, {"from": "2", "to": "r", "value": 1}, {"from": "2", "to": "10", "value": 1}, {"from": "2", "to": "##rna", "value": 1}, {"from": "2", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "2", "to": "binding protein 1", "value": 1}, {"from": "2", "to": "i", "value": 1}, {"from": "2", "to": "##emota", "value": 1}, {"from": "2", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "2", "to": "##na -", "value": 1}, {"from": "2", "to": "antagonist", "value": 1}, {"from": "is", "to": "competitively", "value": 1}, {"from": "is", "to": "ch", "value": 1}, {"from": "is", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "is", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "is", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "is", "to": "x", "value": 1}, {"from": "is", "to": "r", "value": 1}, {"from": "is", "to": "10", "value": 1}, {"from": "is", "to": "##rna", "value": 1}, {"from": "is", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "is", "to": "binding protein 1", "value": 1}, {"from": "is", "to": "i", "value": 2}, {"from": "is", "to": "##emota", "value": 1}, {"from": "is", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "is", "to": "##na -", "value": 1}, {"from": "is", "to": "antagonist", "value": 1}, {"from": "is", "to": "box l", "value": 1}, {"from": "is", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "is", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "is", "to": "of medical sciences, c.", "value": 1}, {"from": "is", "to": "these two conditions which", "value": 1}, {"from": "is", "to": "box", "value": 1}, {"from": "is", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "is", "to": "sciences", "value": 1}, {"from": "is", "to": "care", "value": 1}, {"from": "is", "to": ",", "value": 2}, {"from": "is", "to": "##ra", "value": 1}, {"from": "is", "to": "00", "value": 1}, {"from": "is", "to": "in", "value": 3}, {"from": "is", "to": "233, ghana.", "value": 1}, {"from": "is", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "is", "to": "##g 77, a", "value": 1}, {"from": "is", "to": "5", "value": 1}, {"from": "is", "to": "k", "value": 1}, {"from": "is", "to": ") west african genetic medicine centre", "value": 1}, {"from": "is", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "is", "to": "of health", "value": 1}, {"from": "is", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "is", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "is", "to": "been observed", "value": 1}, {"from": "is", "to": "school", "value": 1}, {"from": "is", "to": ", university of ghana, p. o.", "value": 1}, {"from": "is", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "is", "to": "between", "value": 1}, {"from": "is", "to": "of anaesthesia and intensive", "value": 1}, {"from": "is", "to": "##233, ghana.", "value": 1}, {"from": "is", "to": "incidence", "value": 1}, {"from": "is", "to": "4", "value": 1}, {"from": "is", "to": "cancer and ad", "value": 1}, {"from": "is", "to": "were formerly", "value": 1}, {"from": "is", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "is", "to": ")", "value": 2}, {"from": "is", "to": "has", "value": 1}, {"from": "is", "to": "department", "value": 1}, {"from": "is", "to": "inverse relationship between", "value": 1}, {"from": "is", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "is", "to": "##cc", "value": 1}, {"from": "is", "to": "), and the top", "value": 1}, {"from": "is", "to": "##0", "value": 1}, {"from": "is", "to": "), a parp", "value": 1}, {"from": "is", "to": "##point blockade", "value": 1}, {"from": "is", "to": "etop", "value": 1}, {"from": "is", "to": "##ide - on", "value": 1}, {"from": "is", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "is", "to": "##ide, a top", "value": 1}, {"from": "is", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "is", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "is", "to": "##ase ii", "value": 1}, {"from": "is", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "is", "to": "interfer", "value": 1}, {"from": "is", "to": "fails", "value": 1}, {"from": "is", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "is", "to": "type", "value": 1}, {"from": "is", "to": "if", "value": 1}, {"from": "is", "to": "##fi", "value": 1}, {"from": "is", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "is", "to": "##oisomer", "value": 1}, {"from": "is", "to": "##n ) signaling, with etop", "value": 1}, {"from": "is", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "is", "to": "##b", "value": 1}, {"from": "is", "to": "to encourage immune effector cell in", "value": 1}, {"from": "is", "to": "does", "value": 1}, {"from": "is", "to": "##ltration into tumors, and", "value": 1}, {"from": "is", "to": "##on - stimulated gene", "value": 1}, {"from": "is", "to": "check", "value": 1}, {"from": "is", "to": "##on", "value": 1}, {"from": "is", "to": "inhibitor", "value": 1}, {"from": "is", "to": "12", "value": 1}, {"from": "is", "to": "after net", "value": 1}, {"from": "is", "to": "a significant", "value": 1}, {"from": "is", "to": "time", "value": 1}, {"from": "is", "to": "offers the opportunity of", "value": 1}, {"from": "is", "to": "##ip", "value": 1}, {"from": "is", "to": "t", "value": 1}, {"from": "is", "to": "however", "value": 1}, {"from": "is", "to": ") health", "value": 1}, {"from": "is", "to": "background", "value": 1}, {"from": "is", "to": "##re population of", "value": 1}, {"from": "is", "to": "negative breast", "value": 1}, {"from": "is", "to": "barrier", "value": 1}, {"from": "is", "to": "##gipuzkoa", "value": 1}, {"from": "is", "to": "clinical", "value": 1}, {"from": "is", "to": "##2 -", "value": 1}, {"from": "is", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "is", "to": "##zkoa", "value": 1}, {"from": "is", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "is", "to": "##gi", "value": 1}, {"from": "is", "to": "##donostia ) health", "value": 1}, {"from": "is", "to": "##tian,", "value": 1}, {"from": "is", "to": "cancer", "value": 1}, {"from": "is", "to": "spain", "value": 1}, {"from": "is", "to": "##uzkoa. eus.", "value": 1}, {"from": "is", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "is", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "is", "to": "and", "value": 1}, {"from": "is", "to": "real", "value": 1}, {"from": "is", "to": "personal", "value": 1}, {"from": "is", "to": "b", "value": 1}, {"from": "is", "to": "##ised therapy.", "value": 1}, {"from": "is", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "is", "to": "bio", "value": 1}, {"from": "is", "to": "##donost", "value": 1}, {"from": "is", "to": "##cent", "value": 1}, {"from": "is", "to": "research institute", "value": 1}, {"from": "is", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "is", "to": ".", "value": 1}, {"from": "is", "to": "sa", "value": 1}, {"from": "is", "to": "sebas", "value": 1}, {"from": "is", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "is", "to": "her", "value": 1}, {"from": "is", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "is", "to": "##n sebastian,", "value": 1}, {"from": "is", "to": "##umour response", "value": 1}, {"from": "is", "to": "a,", "value": 1}, {"from": "is", "to": "##pu", "value": 1}, {"from": "is", "to": "##n", "value": 1}, {"from": "is", "to": "sebastian", "value": 1}, {"from": "is", "to": "##uc", "value": 1}, {"from": "is", "to": "13", "value": 1}, {"from": "is", "to": ", the lack of reprod", "value": 1}, {"from": "is", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "is", "to": "##c ) allows", "value": 1}, {"from": "is", "to": "##gnosis", "value": 1}, {"from": "is", "to": "- g", "value": 1}, {"from": "is", "to": "##ia", "value": 1}, {"from": "competitively", "to": "ch", "value": 1}, {"from": "competitively", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "competitively", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "competitively", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "competitively", "to": "x", "value": 1}, {"from": "competitively", "to": "r", "value": 1}, {"from": "competitively", "to": "10", "value": 1}, {"from": "competitively", "to": "##rna", "value": 1}, {"from": "competitively", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "competitively", "to": "binding protein 1", "value": 1}, {"from": "competitively", "to": "i", "value": 1}, {"from": "competitively", "to": "##emota", "value": 1}, {"from": "competitively", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "competitively", "to": "##na -", "value": 1}, {"from": "competitively", "to": "antagonist", "value": 1}, {"from": "ch", "to": ", beijing, china. tumor angiogenesis", "value": 1}, {"from": "ch", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": "ch", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "ch", "to": "x", "value": 1}, {"from": "ch", "to": "r", "value": 1}, {"from": "ch", "to": "10", "value": 1}, {"from": "ch", "to": "##rna", "value": 1}, {"from": "ch", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "ch", "to": "binding protein 1", "value": 1}, {"from": "ch", "to": "i", "value": 1}, {"from": "ch", "to": "##emota", "value": 1}, {"from": "ch", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "ch", "to": "##na -", "value": 1}, {"from": "ch", "to": "antagonist", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "1. faseb j. 2025 may 31 ; 39", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "x", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "r", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "10", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "##rna", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "binding protein 1", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "i", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "##emota", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "##na -", "value": 1}, {"from": ", beijing, china. tumor angiogenesis", "to": "antagonist", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "proteins mcpip2 and igf2b", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "x", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "r", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "10", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "##rna", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "binding protein 1", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "i", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "##emota", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "##na -", "value": 1}, {"from": "1. faseb j. 2025 may 31 ; 39", "to": "antagonist", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "x", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "r", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "10", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "##rna", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "binding protein 1", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "i", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "##emota", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "##na -", "value": 1}, {"from": "proteins mcpip2 and igf2b", "to": "antagonist", "value": 1}, {"from": "x", "to": "r", "value": 1}, {"from": "x", "to": "10", "value": 1}, {"from": "x", "to": "##rna", "value": 1}, {"from": "x", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "x", "to": "binding protein 1", "value": 1}, {"from": "x", "to": "i", "value": 1}, {"from": "x", "to": "##emota", "value": 1}, {"from": "x", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "x", "to": "##na -", "value": 1}, {"from": "x", "to": "antagonist", "value": 1}, {"from": "r", "to": "10", "value": 1}, {"from": "r", "to": "##rna", "value": 1}, {"from": "r", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "r", "to": "binding protein 1", "value": 1}, {"from": "r", "to": "i", "value": 1}, {"from": "r", "to": "##emota", "value": 1}, {"from": "r", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "r", "to": "##na -", "value": 1}, {"from": "r", "to": "antagonist", "value": 1}, {"from": "r", "to": "quantitative pcr", "value": 1}, {"from": "r", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "r", "to": "time", "value": 1}, {"from": "r", "to": "##sia", "value": 1}, {"from": "r", "to": "of medicine, univers", "value": 1}, {"from": "r", "to": "regulating the cell", "value": 1}, {"from": "r", "to": "ute,", "value": 1}, {"from": "r", "to": "##poptosis", "value": 1}, {"from": "r", "to": "##cence, making it", "value": 1}, {"from": "r", "to": "##itas in", "value": 1}, {"from": "r", "to": "proliferation", "value": 1}, {"from": "r", "to": "and se", "value": 1}, {"from": "r", "to": "a", "value": 1}, {"from": "r", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "r", "to": "in", "value": 2}, {"from": "r", "to": "target", "value": 1}, {"from": "r", "to": "##nes", "value": 2}, {"from": "r", "to": "##50 value", "value": 1}, {"from": "r", "to": "5", "value": 1}, {"from": "r", "to": "role in", "value": 1}, {"from": "r", "to": "##esi", "value": 1}, {"from": "r", "to": "real", "value": 1}, {"from": "r", "to": ". the p53 signaling pathway", "value": 1}, {"from": "r", "to": ", a", "value": 1}, {"from": "r", "to": "key", "value": 1}, {"from": "r", "to": ", and", "value": 1}, {"from": "r", "to": "plays", "value": 1}, {"from": "r", "to": "##a.", "value": 1}, {"from": "r", "to": "a critical", "value": 1}, {"from": "r", "to": "faculty", "value": 1}, {"from": "r", "to": "cycle", "value": 1}, {"from": "r", "to": "of downstream genes linked to cell", "value": 1}, {"from": "r", "to": "##a, jakarta,", "value": 1}, {"from": "r", "to": "##iti", "value": 1}, {"from": "r", "to": "of pharmacy, univers", "value": 1}, {"from": "r", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "r", "to": "##don", "value": 1}, {"from": "r", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "r", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "r", "to": "expression", "value": 1}, {"from": "r", "to": "##c", "value": 1}, {"from": "r", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "r", "to": "on the", "value": 1}, {"from": "r", "to": "##ia", "value": 1}, {"from": "r", "to": "senes", "value": 1}, {"from": "r", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "r", "to": "in ki", "value": 1}, {"from": "r", "to": "##cu", "value": 1}, {"from": "r", "to": "t", "value": 1}, {"from": "r", "to": "index", "value": 1}, {"from": "r", "to": "positive", "value": 1}, {"from": "r", "to": "##2 -", "value": 1}, {"from": "r", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "r", "to": "##type", "value": 1}, {"from": "r", "to": "##rrence", "value": 1}, {"from": "r", "to": "percentage", "value": 1}, {"from": "r", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "r", "to": "##i", "value": 1}, {"from": "r", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "r", "to": "from l", "value": 1}, {"from": "r", "to": "b", "value": 1}, {"from": "r", "to": "presented", "value": 1}, {"from": "r", "to": "re", "value": 1}, {"from": "r", "to": "results", "value": 1}, {"from": "r", "to": "pam50 - derived risk of", "value": 1}, {"from": "r", "to": "her", "value": 1}, {"from": "r", "to": "er + /", "value": 1}, {"from": "r", "to": "##nal a to normal - like", "value": 1}, {"from": "r", "to": "##umi", "value": 1}, {"from": "r", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "r", "to": "cells", "value": 1}, {"from": "r", "to": "score", "value": 1}, {"from": "r", "to": "change", "value": 1}, {"from": "r", "to": "after", "value": 1}, {"from": "r", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "r", "to": "of intrinsic sub", "value": 1}, {"from": "r", "to": "p53", "value": 1}, {"from": "r", "to": "##is.", "value": 1}, {"from": "r", "to": "biomark", "value": 1}, {"from": "r", "to": "subtype after", "value": 1}, {"from": "r", "to": "net", "value": 1}, {"from": "r", "to": "of", "value": 1}, {"from": "r", "to": "##c patients", "value": 1}, {"from": "r", "to": "net as a putative", "value": 1}, {"from": "r", "to": "##umour cellularity size", "value": 1}, {"from": "r", "to": "radio", "value": 1}, {"from": "r", "to": ") and lower", "value": 1}, {"from": "r", "to": "better", "value": 1}, {"from": "10", "to": "##rna", "value": 2}, {"from": "10", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "10", "to": "binding protein 1", "value": 1}, {"from": "10", "to": "i", "value": 3}, {"from": "10", "to": "##emota", "value": 1}, {"from": "10", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "10", "to": "##na -", "value": 1}, {"from": "10", "to": "antagonist", "value": 1}, {"from": "10", "to": "##t", "value": 1}, {"from": "10", "to": "of life", "value": 1}, {"from": "10", "to": "##k", "value": 1}, {"from": "10", "to": ") institute for brain sciences research,", "value": 1}, {"from": "10", "to": ":", "value": 9}, {"from": "10", "to": "index", "value": 1}, {"from": "10", "to": "##osu", "value": 1}, {"from": "10", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "10", "to": ". 1096 / fj. 202", "value": 1}, {"from": "10", "to": "may contribute to the", "value": 1}, {"from": "10", "to": "sciences", "value": 2}, {"from": "10", "to": "university", "value": 2}, {"from": "10", "to": "##lle", "value": 1}, {"from": "10", "to": "40", "value": 4}, {"from": "10", "to": ",", "value": 4}, {"from": "10", "to": "genes", "value": 1}, {"from": "10", "to": "##i", "value": 1}, {"from": "10", "to": "##f", "value": 1}, {"from": "10", "to": "we", "value": 1}, {"from": "10", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "10", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "10", "to": "3 )", "value": 1}, {"from": "10", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "10", "to": "##hie j", "value": 1}, {"from": "10", "to": "k", "value": 1}, {"from": "10", "to": "doi", "value": 9}, {"from": "10", "to": "b", "value": 5}, {"from": "10", "to": "102", "value": 2}, {"from": "10", "to": "j", "value": 4}, {"from": "10", "to": "##354028 [", "value": 1}, {"from": "10", "to": ".", "value": 9}, {"from": "10", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "10", "to": "school", "value": 1}, {"from": "10", "to": "), agegnehu sb", "value": 1}, {"from": "10", "to": "##ra 00", "value": 1}, {"from": "10", "to": "3 ), lamptey el", "value": 1}, {"from": "10", "to": "1", "value": 4}, {"from": "10", "to": "ka", "value": 1}, {"from": "10", "to": "4", "value": 3}, {"from": "10", "to": "of ghana, a", "value": 1}, {"from": "10", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "10", "to": "##461r pmid :", "value": 1}, {"from": "10", "to": "antiangiogenic therapy of", "value": 1}, {"from": "10", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "10", "to": ")", "value": 3}, {"from": "10", "to": "he", "value": 1}, {"from": "10", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "10", "to": "expression", "value": 2}, {"from": "10", "to": "breast", "value": 3}, {"from": "10", "to": "##500", "value": 1}, {"from": "10", "to": "in cancer", "value": 1}, {"from": "10", "to": "##mpo s", "value": 1}, {"from": "10", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "10", "to": "##cc", "value": 1}, {"from": "10", "to": "inverse", "value": 1}, {"from": "10", "to": "new insights into", "value": 1}, {"from": "10", "to": "risk", "value": 1}, {"from": "10", "to": "of cancer development while", "value": 1}, {"from": "10", "to": "c", "value": 1}, {"from": "10", "to": "reduced", "value": 1}, {"from": "10", "to": "##1 / acsomega. 4", "value": 1}, {"from": "10", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "10", "to": "##ve", "value": 1}, {"from": "10", "to": "##re", "value": 1}, {"from": "10", "to": "in", "value": 4}, {"from": "10", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "10", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "10", "to": "10. 102", "value": 1}, {"from": "10", "to": "##er and 5 genes down", "value": 1}, {"from": "10", "to": "upre", "value": 1}, {"from": "10", "to": "were downregulated", "value": 1}, {"from": "10", "to": "pm", "value": 1}, {"from": "10", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "10", "to": "##ida", "value": 2}, {"from": "10", "to": "##gulated", "value": 1}, {"from": "10", "to": "play an important role in", "value": 1}, {"from": "10", "to": "##12059893", "value": 1}, {"from": "10", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "10", "to": "##c", "value": 1}, {"from": "10", "to": "in all three cancers and may", "value": 1}, {"from": "10", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "10", "to": "##11571 pmcid : pm", "value": 1}, {"from": "10", "to": "##id :", "value": 1}, {"from": "10", "to": "classification of breast cancer : l", "value": 1}, {"from": "10", "to": ", h", "value": 1}, {"from": "10", "to": "##methylation", "value": 1}, {"from": "10", "to": "tion", "value": 1}, {"from": "10", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "10", "to": "the pt", "value": 1}, {"from": "10", "to": ". \u00a9 202", "value": 1}, {"from": "10", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "10", "to": "##rn2 gene", "value": 1}, {"from": "10", "to": "##type", "value": 1}, {"from": "10", "to": "##nal", "value": 1}, {"from": "10", "to": "##261 ), and tnbc", "value": 1}, {"from": "10", "to": "##p", "value": 1}, {"from": "10", "to": "the author", "value": 1}, {"from": "10", "to": "bio", "value": 2}, {"from": "10", "to": "respectively", "value": 1}, {"from": "10", "to": "##marker for each sub", "value": 1}, {"from": "10", "to": "##umi", "value": 1}, {"from": "10", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "10", "to": "##yper", "value": 1}, {"from": "10", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "10", "to": "improve", "value": 1}, {"from": "10", "to": "##10", "value": 1}, {"from": "10", "to": "##5", "value": 1}, {"from": "10", "to": "##nal a", "value": 1}, {"from": "10", "to": "52", "value": 3}, {"from": "10", "to": "), hashim", "value": 1}, {"from": "10", "to": "of medicine, univers", "value": 1}, {"from": "10", "to": "##rta", "value": 1}, {"from": "10", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "10", "to": ") drug development research cluster, indon", "value": 1}, {"from": "10", "to": "##an medical", "value": 1}, {"from": "10", "to": "indon", "value": 1}, {"from": "10", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "10", "to": "##hibit", "value": 1}, {"from": "10", "to": "na", "value": 1}, {"from": "10", "to": "master program in biomedical", "value": 1}, {"from": "10", "to": "education", "value": 1}, {"from": "10", "to": "n", "value": 1}, {"from": "10", "to": "3", "value": 1}, {"from": "10", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "10", "to": "##ajrin", "value": 1}, {"from": "10", "to": "), azizah", "value": 1}, {"from": "10", "to": "##esi", "value": 1}, {"from": "10", "to": "te", "value": 1}, {"from": "10", "to": "##a, jaka", "value": 1}, {"from": "10", "to": "##djo a", "value": 1}, {"from": "10", "to": "of medicine, universitas indon", "value": 1}, {"from": "10", "to": "##itas", "value": 1}, {"from": "10", "to": "##a.", "value": 1}, {"from": "10", "to": "faculty", "value": 3}, {"from": "10", "to": "##b", "value": 1}, {"from": "10", "to": "am", "value": 1}, {"from": "10", "to": "nn", "value": 1}, {"from": "10", "to": "of pharmacy, univers", "value": 1}, {"from": "10", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "10", "to": "##don", "value": 1}, {"from": "10", "to": "##a,", "value": 1}, {"from": "10", "to": ", indon", "value": 1}, {"from": "10", "to": "##aka", "value": 1}, {"from": "10", "to": "and research instit", "value": 1}, {"from": "10", "to": "), ramadanti", "value": 1}, {"from": "10", "to": "##life", "value": 1}, {"from": "10", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "10", "to": "##ion of p21", "value": 1}, {"from": "10", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "10", "to": "##in - mediated anti -", "value": 1}, {"from": "10", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "10", "to": "1 ), abdelkrim g", "value": 1}, {"from": "10", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "10", "to": "cancer effects. foda my", "value": 1}, {"from": "10", "to": "##press", "value": 1}, {"from": "10", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "10", "to": "##tat", "value": 1}, {"from": "10", "to": "jun", "value": 2}, {"from": "10", "to": "2 ), salem ml", "value": 1}, {"from": "10", "to": "in atorvas", "value": 1}, {"from": "10", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "10", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "10", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "10", "to": "##regulated", "value": 1}, {"from": "10", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "10", "to": ". 108", "value": 1}, {"from": "10", "to": "jun might", "value": 1}, {"from": "10", "to": "##0", "value": 1}, {"from": "10", "to": "expression.", "value": 1}, {"from": "10", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "10", "to": "##na ss", "value": 1}, {"from": "10", "to": "##v", "value": 1}, {"from": "10", "to": "##un", "value": 1}, {"from": "10", "to": "##gno", "value": 1}, {"from": "10", "to": "activity positively correlated with", "value": 1}, {"from": "10", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "10", "to": ". 17305 /", "value": 1}, {"from": "10", "to": "luki", "value": 1}, {"from": "10", "to": "##v vi", "value": 1}, {"from": "10", "to": "logino", "value": 1}, {"from": "10", "to": "was", "value": 1}, {"from": "10", "to": "may directly interact with", "value": 1}, {"from": "10", "to": "serve as a valuable pro", "value": 1}, {"from": "10", "to": "##tatin", "value": 1}, {"from": "10", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "10", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "10", "to": "expression. as such,", "value": 1}, {"from": "10", "to": "significantly", "value": 1}, {"from": "10", "to": "##nina", "value": 1}, {"from": "10", "to": "pro", "value": 1}, {"from": "10", "to": "down", "value": 2}, {"from": "10", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "10", "to": "=", "value": 1}, {"from": "10", "to": "##s,", "value": 1}, {"from": "10", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "10", "to": "which is involved in", "value": 1}, {"from": "10", "to": "- 0. 46,", "value": 1}, {"from": "10", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "10", "to": "mi", "value": 1}, {"from": "10", "to": "- 5p", "value": 1}, {"from": "10", "to": "##r - 17", "value": 1}, {"from": "10", "to": "a", "value": 1}, {"from": "10", "to": "5", "value": 3}, {"from": "10", "to": "##1", "value": 1}, {"from": "10", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "10", "to": ") : e010548.", "value": 1}, {"from": "10", "to": "5p", "value": 1}, {"from": "10", "to": "hand", "value": 1}, {"from": "10", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "10", "to": "03 ) and", "value": 1}, {"from": "10", "to": "p = 0", "value": 1}, {"from": "10", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "10", "to": "##r - 106a -", "value": 1}, {"from": "10", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "10", "to": "target gene", "value": 1}, {"from": "10", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "10", "to": "- 0. 41,", "value": 1}, {"from": "10", "to": "of these lnc", "value": 1}, {"from": "10", "to": "p = 0.", "value": 1}, {"from": "10", "to": "113", "value": 1}, {"from": "10", "to": "common", "value": 1}, {"from": "10", "to": "regulated", "value": 1}, {"from": "10", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "10", "to": "), huarte m", "value": 1}, {"from": "10", "to": "12", "value": 1}, {"from": "10", "to": "##407.", "value": 1}, {"from": "10", "to": "), par", "value": 1}, {"from": "10", "to": "ins", "value": 1}, {"from": "10", "to": "##or", "value": 1}, {"from": "10", "to": "##e", "value": 1}, {"from": "10", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "10", "to": "9", "value": 2}, {"from": "10", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "10", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "10", "to": "), aragon s", "value": 1}, {"from": "10", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "10", "to": "##ory", "value": 1}, {"from": "10", "to": "), gimenez j", "value": 1}, {"from": "10", "to": "- lopez i", "value": 1}, {"from": "10", "to": "##rine", "value": 1}, {"from": "10", "to": "er + / her2 -", "value": 1}, {"from": "10", "to": "), prat a", "value": 1}, {"from": "10", "to": "research", "value": 2}, {"from": "10", "to": "##e. lg is /", "value": 1}, {"from": "10", "to": "), buch e", "value": 1}, {"from": "10", "to": "##roga v", "value": 1}, {"from": "10", "to": "been holding research", "value": 1}, {"from": "10", "to": "11", "value": 2}, {"from": "10", "to": "101", "value": 3}, {"from": "10", "to": "##riaga k", "value": 1}, {"from": "10", "to": "), etxabe i", "value": 1}, {"from": "10", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "10", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "10", "to": "13", "value": 2}, {"from": "10", "to": "therapy", "value": 1}, {"from": "10", "to": "##ui", "value": 1}, {"from": "10", "to": "##ez", "value": 1}, {"from": "10", "to": "##vita", "value": 1}, {"from": "10", "to": "contracts", "value": 1}, {"from": "10", "to": "has", "value": 1}, {"from": "10", "to": "6", "value": 2}, {"from": "10", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "10", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "10", "to": "). author information :", "value": 1}, {"from": "10", "to": "), urruticoechea a", "value": 1}, {"from": "10", "to": "##rgen, norway.", "value": 1}, {"from": "10", "to": "##rgen, nor", "value": 1}, {"from": "10", "to": "t", "value": 1}, {"from": "10", "to": "economics", "value": 1}, {"from": "10", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "10", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "10", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "10", "to": "clinical trials", "value": 1}, {"from": "10", "to": "and", "value": 2}, {"from": "10", "to": "of health management and health", "value": 1}, {"from": "10", "to": "of health", "value": 1}, {"from": "10", "to": "institute", "value": 2}, {"from": "10", "to": ";", "value": 2}, {"from": "10", "to": ") department of p", "value": 1}, {"from": "10", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "10", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "10", "to": "), heie a", "value": 1}, {"from": "10", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "10", "to": "department", "value": 2}, {"from": "10", "to": "be", "value": 1}, {"from": "10", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "10", "to": "ug", "value": 1}, {"from": "10", "to": "##way", "value": 2}, {"from": "10", "to": ") department of", "value": 1}, {"from": "10", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "10", "to": "for cancer", "value": 1}, {"from": "10", "to": "##lia", "value": 1}, {"from": "10", "to": "##vanger,", "value": 1}, {"from": "10", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "10", "to": "##vanger university, s", "value": 1}, {"from": "10", "to": "8", "value": 1}, {"from": "10", "to": "of cancer genetics,", "value": 1}, {"from": "10", "to": "##ta", "value": 1}, {"from": "10", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "10", "to": "12 ) department", "value": 1}, {"from": "10", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "10", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "10", "to": "##vanger university hospital, s", "value": 1}, {"from": "10", "to": "ha", "value": 1}, {"from": "10", "to": "norway", "value": 1}, {"from": "10", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "10", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "10", "to": "of pathology, s", "value": 1}, {"from": "10", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "10", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "10", "to": "is cost - effective", "value": 1}, {"from": "10", "to": "of agriculture and natural", "value": 1}, {"from": "10", "to": ". ac.", "value": 1}, {"from": "10", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "10", "to": "resources", "value": 1}, {"from": "10", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "10", "to": "##za. he", "value": 1}, {"from": "10", "to": "##6 /", "value": 2}, {"from": "10", "to": "are", "value": 1}, {"from": "10", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "10", "to": "##ri - japelaghi r", "value": 1}, {"from": "10", "to": "##r.", "value": 1}, {"from": "10", "to": "who", "value": 1}, {"from": "10", "to": "inter", "value": 1}, {"from": "10", "to": "##vin", "value": 1}, {"from": "10", "to": "of tabriz,", "value": 1}, {"from": "10", "to": "@ org.", "value": 1}, {"from": "10", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "10", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "10", "to": "##idari", "value": 1}, {"from": "10", "to": "s", "value": 1}, {"from": "10", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "10", "to": "ta", "value": 1}, {"from": "10", "to": "##ran. electronic address :", "value": 1}, {"from": "10", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "10", "to": "re", "value": 1}, {"from": "10", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "10", "to": "perspectives", "value": 1}, {"from": "10", "to": "##briz,", "value": 1}, {"from": "10", "to": "of agriculture,", "value": 1}, {"from": "10", "to": "##fer", "value": 1}, {"from": "10", "to": "##on", "value": 1}, {"from": "10", "to": "##ki", "value": 1}, {"from": "10", "to": "from both", "value": 1}, {"from": "10", "to": "##ran.", "value": 1}, {"from": "10", "to": "- regulate", "value": 1}, {"from": "10", "to": "the", "value": 1}, {"from": "10", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "10", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "10", "to": "##tic", "value": 1}, {"from": "10", "to": "##6", "value": 1}, {"from": "10", "to": "##poptosis", "value": 1}, {"from": "10", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "10", "to": "##xic effect of", "value": 1}, {"from": "10", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "10", "to": "00", "value": 1}, {"from": "10", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "10", "to": "##xic efficacy of the", "value": 1}, {"from": "10", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "10", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "10", "to": "if", "value": 1}, {"from": "10", "to": "up -", "value": 1}, {"from": "10", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "10", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "10", "to": "development of tumor cells, a", "value": 1}, {"from": "10", "to": "##348089 conflict o", "value": 1}, {"from": "10", "to": "regulate", "value": 1}, {"from": "10", "to": "##oto", "value": 1}, {"from": "10", "to": "of pro", "value": 1}, {"from": "10", "to": "##cl -", "value": 1}, {"from": "10", "to": "##biotec. 2025.", "value": 1}, {"from": "10", "to": "04", "value": 1}, {"from": "10", "to": "##apopto", "value": 1}, {"from": "10", "to": "to", "value": 1}, {"from": "10", "to": "##cer and antiviral functions of", "value": 1}, {"from": "10", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "10", "to": "via", "value": 1}, {"from": "10", "to": "and p", "value": 1}, {"from": "10", "to": "##c cell line", "value": 1}, {"from": "10", "to": "hi", "value": 1}, {"from": "10", "to": "##can", "value": 1}, {"from": "10", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "10", "to": "##53", "value": 1}, {"from": "10", "to": ". 022 pmid :", "value": 1}, {"from": "10", "to": "bax", "value": 1}, {"from": "##rna", "to": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "value": 1}, {"from": "##rna", "to": "binding protein 1", "value": 1}, {"from": "##rna", "to": "i", "value": 1}, {"from": "##rna", "to": "##emota", "value": 1}, {"from": "##rna", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##rna", "to": "##na -", "value": 1}, {"from": "##rna", "to": "antagonist", "value": 1}, {"from": "##rna", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "##rna", "to": "##r confirmed their down", "value": 1}, {"from": "##rna", "to": "four", "value": 1}, {"from": "##rna", "to": "prioriti", "value": 1}, {"from": "##rna", "to": "pc", "value": 1}, {"from": "##rna", "to": "##re", "value": 1}, {"from": "##rna", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "##rna", "to": "diagnosed", "value": 1}, {"from": "##rna", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "##rna", "to": "incomplete", "value": 1}, {"from": "##rna", "to": "ministry", "value": 1}, {"from": "##rna", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##rna", "to": "diagnostic", "value": 1}, {"from": "##rna", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##rna", "to": "##s and", "value": 1}, {"from": "##rna", "to": "##s.", "value": 1}, {"from": "##rna", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##rna", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##rna", "to": "treatment", "value": 1}, {"from": "##rna", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##rna", "to": "- mi", "value": 1}, {"from": "##rna", "to": "##gna", "value": 1}, {"from": "##rna", "to": "expressed", "value": 1}, {"from": "##rna", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##rna", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##rna", "to": "##ncrna", "value": 1}, {"from": "##rna", "to": "##c", "value": 1}, {"from": "##rna", "to": "##r", "value": 1}, {"from": "##rna", "to": "##ia", "value": 1}, {"from": "##rna", "to": "mrna", "value": 1}, {"from": "##rna", "to": "mali", "value": 1}, {"from": "##rna", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##rna", "to": "=", "value": 1}, {"from": "##rna", "to": "##s,", "value": 1}, {"from": "##rna", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "##rna", "to": "which is involved in", "value": 1}, {"from": "##rna", "to": "- 0. 46,", "value": 1}, {"from": "##rna", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "##rna", "to": ":", "value": 1}, {"from": "##rna", "to": "mi", "value": 1}, {"from": "##rna", "to": "- 5p", "value": 1}, {"from": "##rna", "to": "##r - 17", "value": 1}, {"from": "##rna", "to": "a", "value": 1}, {"from": "##rna", "to": "5", "value": 1}, {"from": "##rna", "to": "##1", "value": 1}, {"from": "##rna", "to": "doi", "value": 1}, {"from": "##rna", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "##rna", "to": ") : e010548.", "value": 1}, {"from": "##rna", "to": "5p", "value": 1}, {"from": "##rna", "to": ".", "value": 1}, {"from": "##rna", "to": "hand", "value": 1}, {"from": "##rna", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##rna", "to": "03 ) and", "value": 1}, {"from": "##rna", "to": "p = 0", "value": 1}, {"from": "##rna", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##rna", "to": "##r - 106a -", "value": 1}, {"from": "##rna", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##rna", "to": "target gene", "value": 1}, {"from": "##rna", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##rna", "to": "- 0. 41,", "value": 1}, {"from": "##rna", "to": "of these lnc", "value": 1}, {"from": "##rna", "to": "p = 0.", "value": 1}, {"from": "##rna", "to": "113", "value": 1}, {"from": "##rna", "to": "common", "value": 1}, {"from": "##rna", "to": "regulated", "value": 1}, {"from": "##rna", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "binding protein 1", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "i", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "##emota", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "##na -", "value": 1}, {"from": "further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis -", "to": "antagonist", "value": 1}, {"from": "binding protein 1", "to": "i", "value": 1}, {"from": "binding protein 1", "to": "##emota", "value": 1}, {"from": "binding protein 1", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "binding protein 1", "to": "##na -", "value": 1}, {"from": "binding protein 1", "to": "antagonist", "value": 1}, {"from": "i", "to": "##emota", "value": 1}, {"from": "i", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "i", "to": "##na -", "value": 1}, {"from": "i", "to": "antagonist", "value": 1}, {"from": "i", "to": "##ibi", "value": 1}, {"from": "i", "to": "ri", "value": 1}, {"from": "i", "to": "##sana", "value": 1}, {"from": "i", "to": "doctoral program in biomedical", "value": 1}, {"from": "i", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "i", "to": "of medicine, univers", "value": 1}, {"from": "i", "to": "##g", "value": 1}, {"from": "i", "to": "##rta", "value": 1}, {"from": "i", "to": "sciences", "value": 1}, {"from": "i", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "i", "to": "##esia", "value": 1}, {"from": "i", "to": ",", "value": 2}, {"from": "i", "to": "##itas in", "value": 1}, {"from": "i", "to": "##nandi si", "value": 1}, {"from": "i", "to": "##eri", "value": 1}, {"from": "i", "to": "master program in biomedical", "value": 1}, {"from": "i", "to": "),", "value": 1}, {"from": "i", "to": "5", "value": 1}, {"from": "i", "to": "##esi", "value": 1}, {"from": "i", "to": "j", "value": 2}, {"from": "i", "to": "of medical chemistry,", "value": 1}, {"from": "i", "to": "##a.", "value": 1}, {"from": "i", "to": "faculty", "value": 3}, {"from": "i", "to": "wa", "value": 1}, {"from": "i", "to": "4", "value": 1}, {"from": "i", "to": "##don", "value": 1}, {"from": "i", "to": "##a,", "value": 1}, {"from": "i", "to": ")", "value": 1}, {"from": "i", "to": "6", "value": 1}, {"from": "i", "to": "##aka", "value": 1}, {"from": "i", "to": "department", "value": 1}, {"from": "i", "to": "indonesi", "value": 1}, {"from": "i", "to": "##itas indonesia", "value": 1}, {"from": "i", "to": "of surgery,", "value": 1}, {"from": "i", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "i", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "i", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "i", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "i", "to": "##regulated", "value": 1}, {"from": "i", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "i", "to": ". 108", "value": 1}, {"from": "i", "to": "jun might", "value": 1}, {"from": "i", "to": ":", "value": 2}, {"from": "i", "to": "##0", "value": 2}, {"from": "i", "to": "expression.", "value": 1}, {"from": "i", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "i", "to": "##na ss", "value": 1}, {"from": "i", "to": "##v", "value": 1}, {"from": "i", "to": "##un", "value": 1}, {"from": "i", "to": "##gno", "value": 1}, {"from": "i", "to": "activity positively correlated with", "value": 1}, {"from": "i", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "i", "to": ". 17305 /", "value": 1}, {"from": "i", "to": "doi", "value": 2}, {"from": "i", "to": "b", "value": 1}, {"from": "i", "to": "luki", "value": 1}, {"from": "i", "to": "bio", "value": 1}, {"from": "i", "to": "##v vi", "value": 1}, {"from": "i", "to": "logino", "value": 1}, {"from": "i", "to": "was", "value": 1}, {"from": "i", "to": "may directly interact with", "value": 1}, {"from": "i", "to": "serve as a valuable pro", "value": 1}, {"from": "i", "to": "##tatin", "value": 1}, {"from": "i", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "i", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "i", "to": "expression. as such,", "value": 1}, {"from": "i", "to": "significantly", "value": 1}, {"from": "i", "to": "jun", "value": 1}, {"from": "i", "to": "##nina", "value": 1}, {"from": "i", "to": "pro", "value": 1}, {"from": "i", "to": "down", "value": 1}, {"from": "i", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "i", "to": "), and the top", "value": 1}, {"from": "i", "to": "), a parp", "value": 1}, {"from": "i", "to": "##point blockade", "value": 1}, {"from": "i", "to": "etop", "value": 1}, {"from": "i", "to": "##ide - on", "value": 1}, {"from": "i", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "i", "to": "##ide, a top", "value": 1}, {"from": "i", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "i", "to": "in", "value": 2}, {"from": "i", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "i", "to": "##ase ii", "value": 1}, {"from": "i", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "i", "to": "interfer", "value": 1}, {"from": "i", "to": "fails", "value": 1}, {"from": "i", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "i", "to": "type", "value": 1}, {"from": "i", "to": "if", "value": 2}, {"from": "i", "to": "##fi", "value": 1}, {"from": "i", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "i", "to": "##oisomer", "value": 1}, {"from": "i", "to": "##n ) signaling, with etop", "value": 1}, {"from": "i", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "i", "to": "##b", "value": 1}, {"from": "i", "to": "to encourage immune effector cell in", "value": 1}, {"from": "i", "to": "does", "value": 1}, {"from": "i", "to": "##ltration into tumors, and", "value": 1}, {"from": "i", "to": "##on - stimulated gene", "value": 1}, {"from": "i", "to": "check", "value": 1}, {"from": "i", "to": "##on", "value": 2}, {"from": "i", "to": "inhibitor", "value": 1}, {"from": "i", "to": "is cost - effective", "value": 1}, {"from": "i", "to": "of agriculture and natural", "value": 1}, {"from": "i", "to": ". ac.", "value": 1}, {"from": "i", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "i", "to": "resources", "value": 1}, {"from": "i", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "i", "to": "##za. he", "value": 1}, {"from": "i", "to": "##6 /", "value": 1}, {"from": "i", "to": "are", "value": 1}, {"from": "i", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "i", "to": "##ri - japelaghi r", "value": 1}, {"from": "i", "to": "university", "value": 1}, {"from": "i", "to": "40", "value": 1}, {"from": "i", "to": "##r.", "value": 1}, {"from": "i", "to": "who", "value": 1}, {"from": "i", "to": "inter", "value": 1}, {"from": "i", "to": "##vin", "value": 1}, {"from": "i", "to": "of tabriz,", "value": 1}, {"from": "i", "to": "@ org.", "value": 1}, {"from": "i", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "i", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "i", "to": "##idari", "value": 1}, {"from": "i", "to": "s", "value": 1}, {"from": "i", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "i", "to": "ta", "value": 1}, {"from": "i", "to": "##ran. electronic address :", "value": 1}, {"from": "i", "to": ".", "value": 1}, {"from": "i", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "i", "to": "re", "value": 1}, {"from": "i", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "i", "to": "101", "value": 1}, {"from": "i", "to": "##ida", "value": 1}, {"from": "i", "to": "perspectives", "value": 1}, {"from": "i", "to": "##briz,", "value": 1}, {"from": "i", "to": "of agriculture,", "value": 1}, {"from": "i", "to": "##fer", "value": 1}, {"from": "i", "to": "##ki", "value": 1}, {"from": "i", "to": "from both", "value": 1}, {"from": "i", "to": "##ran.", "value": 1}, {"from": "i", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "i", "to": "##ifer", "value": 1}, {"from": "i", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "i", "to": "in the", "value": 1}, {"from": "i", "to": "##ne - c", "value": 1}, {"from": "i", "to": ", tnf signaling", "value": 1}, {"from": "i", "to": ", which", "value": 1}, {"from": "i", "to": "genes", "value": 1}, {"from": "i", "to": "down - regulated", "value": 1}, {"from": "i", "to": "including c", "value": 1}, {"from": "i", "to": "##ytoki", "value": 1}, {"from": "i", "to": "detected", "value": 1}, {"from": "i", "to": "cancer", "value": 1}, {"from": "i", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "i", "to": "vs", "value": 1}, {"from": "i", "to": "##cer assays. the", "value": 1}, {"from": "i", "to": "interaction", "value": 1}, {"from": "i", "to": "or", "value": 1}, {"from": "i", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "i", "to": "##ne receptor", "value": 1}, {"from": "i", "to": "##ap", "value": 1}, {"from": "i", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "i", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "i", "to": "via", "value": 1}, {"from": "i", "to": "anti", "value": 1}, {"from": "i", "to": "##n - \u03b3", "value": 1}, {"from": "i", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "i", "to": "f biotechnology engineering,", "value": 1}, {"from": "i", "to": "were up -", "value": 1}, {"from": "i", "to": ", nod - like receptor signaling", "value": 1}, {"from": "i", "to": "##ation, pro", "value": 1}, {"from": "i", "to": "breast", "value": 1}, {"from": "i", "to": "##can", "value": 1}, {"from": "i", "to": "pathways", "value": 1}, {"from": "i", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "i", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "i", "to": "pathway", "value": 1}, {"from": "i", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##emota", "to": "regulating mrna stability of proangiogenic gene", "value": 1}, {"from": "##emota", "to": "##na -", "value": 1}, {"from": "##emota", "to": "antagonist", "value": 1}, {"from": "regulating mrna stability of proangiogenic gene", "to": "##na -", "value": 1}, {"from": "regulating mrna stability of proangiogenic gene", "to": "antagonist", "value": 1}, {"from": "##na -", "to": "antagonist", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##osomal proteins might be required for mcpip2 - mediated des", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "- x - c motif chem", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "il", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "can", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "c", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "human", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "was re", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##2 expression", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "interleuki", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##d 1", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": ",", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##is", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##p2 physically", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "- untranslated region of proang", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "bb2 ),", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "stabilize the proang", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "in", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "\u0027", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "poor", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##ta", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##io", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##n - 8", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##oki", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "interacted", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "a reversed", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "associated with", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "tumors", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##pressed", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##cpip", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##bilize their mrnas.", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##igan", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "breast", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##8 ),", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##ne l", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##l", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##cpi", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "rib", "value": 1}, {"from": "correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan", "to": "survival", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "- x - c motif chem", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "il", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "can", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "c", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "human", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "was re", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##2 expression", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "interleuki", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##d 1", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": ",", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##is", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##p2 physically", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "- untranslated region of proang", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "bb2 ),", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "stabilize the proang", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "in", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "\u0027", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "poor", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##ta", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##io", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##n - 8", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##oki", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "interacted", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "a reversed", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "associated with", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "tumors", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##pressed", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##cpip", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##bilize their mrnas.", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##igan", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "breast", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##8 ),", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##ne l", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##l", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##cpi", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "rib", "value": 1}, {"from": "##osomal proteins might be required for mcpip2 - mediated des", "to": "survival", "value": 1}, {"from": "- x - c motif chem", "to": "il", "value": 1}, {"from": "- x - c motif chem", "to": "can", "value": 1}, {"from": "- x - c motif chem", "to": "c", "value": 1}, {"from": "- x - c motif chem", "to": "human", "value": 1}, {"from": "- x - c motif chem", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "- x - c motif chem", "to": "was re", "value": 1}, {"from": "- x - c motif chem", "to": "##2 expression", "value": 1}, {"from": "- x - c motif chem", "to": "interleuki", "value": 1}, {"from": "- x - c motif chem", "to": "##d 1", "value": 1}, {"from": "- x - c motif chem", "to": ",", "value": 1}, {"from": "- x - c motif chem", "to": "##is", "value": 1}, {"from": "- x - c motif chem", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "- x - c motif chem", "to": "##p2 physically", "value": 1}, {"from": "- x - c motif chem", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "- x - c motif chem", "to": "- untranslated region of proang", "value": 1}, {"from": "- x - c motif chem", "to": "bb2 ),", "value": 1}, {"from": "- x - c motif chem", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "- x - c motif chem", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "- x - c motif chem", "to": "stabilize the proang", "value": 1}, {"from": "- x - c motif chem", "to": "in", "value": 1}, {"from": "- x - c motif chem", "to": "\u0027", "value": 1}, {"from": "- x - c motif chem", "to": "poor", "value": 1}, {"from": "- x - c motif chem", "to": "##ta", "value": 1}, {"from": "- x - c motif chem", "to": "##io", "value": 1}, {"from": "- x - c motif chem", "to": "##n - 8", "value": 1}, {"from": "- x - c motif chem", "to": "##oki", "value": 1}, {"from": "- x - c motif chem", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "- x - c motif chem", "to": "interacted", "value": 1}, {"from": "- x - c motif chem", "to": "a reversed", "value": 1}, {"from": "- x - c motif chem", "to": "associated with", "value": 1}, {"from": "- x - c motif chem", "to": "tumors", "value": 1}, {"from": "- x - c motif chem", "to": "##pressed", "value": 1}, {"from": "- x - c motif chem", "to": "##cpip", "value": 1}, {"from": "- x - c motif chem", "to": "##bilize their mrnas.", "value": 1}, {"from": "- x - c motif chem", "to": "##igan", "value": 1}, {"from": "- x - c motif chem", "to": "breast", "value": 1}, {"from": "- x - c motif chem", "to": "##8 ),", "value": 1}, {"from": "- x - c motif chem", "to": "##ne l", "value": 1}, {"from": "- x - c motif chem", "to": "##l", "value": 1}, {"from": "- x - c motif chem", "to": "##cpi", "value": 1}, {"from": "- x - c motif chem", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "- x - c motif chem", "to": "rib", "value": 1}, {"from": "- x - c motif chem", "to": "survival", "value": 1}, {"from": "il", "to": "can", "value": 1}, {"from": "il", "to": "c", "value": 1}, {"from": "il", "to": "human", "value": 1}, {"from": "il", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "il", "to": "was re", "value": 1}, {"from": "il", "to": "##2 expression", "value": 1}, {"from": "il", "to": "interleuki", "value": 1}, {"from": "il", "to": "##d 1", "value": 1}, {"from": "il", "to": ",", "value": 1}, {"from": "il", "to": "##is", "value": 1}, {"from": "il", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "il", "to": "##p2 physically", "value": 1}, {"from": "il", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "il", "to": "- untranslated region of proang", "value": 1}, {"from": "il", "to": "bb2 ),", "value": 1}, {"from": "il", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "il", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "il", "to": "stabilize the proang", "value": 1}, {"from": "il", "to": "in", "value": 1}, {"from": "il", "to": "\u0027", "value": 1}, {"from": "il", "to": "poor", "value": 1}, {"from": "il", "to": "##ta", "value": 1}, {"from": "il", "to": "##io", "value": 1}, {"from": "il", "to": "##n - 8", "value": 1}, {"from": "il", "to": "##oki", "value": 1}, {"from": "il", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "il", "to": "interacted", "value": 1}, {"from": "il", "to": "a reversed", "value": 1}, {"from": "il", "to": "associated with", "value": 1}, {"from": "il", "to": "tumors", "value": 1}, {"from": "il", "to": "##pressed", "value": 1}, {"from": "il", "to": "##cpip", "value": 1}, {"from": "il", "to": "##bilize their mrnas.", "value": 1}, {"from": "il", "to": "##igan", "value": 1}, {"from": "il", "to": "breast", "value": 1}, {"from": "il", "to": "##8 ),", "value": 1}, {"from": "il", "to": "##ne l", "value": 1}, {"from": "il", "to": "##l", "value": 1}, {"from": "il", "to": "##cpi", "value": 1}, {"from": "il", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "il", "to": "rib", "value": 1}, {"from": "il", "to": "survival", "value": 1}, {"from": "can", "to": "c", "value": 1}, {"from": "can", "to": "human", "value": 1}, {"from": "can", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "can", "to": "was re", "value": 1}, {"from": "can", "to": "##2 expression", "value": 1}, {"from": "can", "to": "interleuki", "value": 1}, {"from": "can", "to": "##d 1", "value": 1}, {"from": "can", "to": ",", "value": 2}, {"from": "can", "to": "##is", "value": 1}, {"from": "can", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "can", "to": "##p2 physically", "value": 1}, {"from": "can", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "can", "to": "- untranslated region of proang", "value": 1}, {"from": "can", "to": "bb2 ),", "value": 1}, {"from": "can", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "can", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "can", "to": "stabilize the proang", "value": 1}, {"from": "can", "to": "in", "value": 2}, {"from": "can", "to": "\u0027", "value": 1}, {"from": "can", "to": "poor", "value": 1}, {"from": "can", "to": "##ta", "value": 1}, {"from": "can", "to": "##io", "value": 1}, {"from": "can", "to": "##n - 8", "value": 1}, {"from": "can", "to": "##oki", "value": 1}, {"from": "can", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "can", "to": "interacted", "value": 1}, {"from": "can", "to": "a reversed", "value": 1}, {"from": "can", "to": "associated with", "value": 1}, {"from": "can", "to": "tumors", "value": 1}, {"from": "can", "to": "##pressed", "value": 1}, {"from": "can", "to": "##cpip", "value": 1}, {"from": "can", "to": "##bilize their mrnas.", "value": 1}, {"from": "can", "to": "##igan", "value": 1}, {"from": "can", "to": "breast", "value": 1}, {"from": "can", "to": "##8 ),", "value": 1}, {"from": "can", "to": "##ne l", "value": 1}, {"from": "can", "to": "##l", "value": 1}, {"from": "can", "to": "##cpi", "value": 1}, {"from": "can", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "can", "to": "rib", "value": 1}, {"from": "can", "to": "survival", "value": 1}, {"from": "can", "to": "2 - positive", "value": 1}, {"from": "can", "to": "changes in the promoter region", "value": 1}, {"from": "can", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "can", "to": "##rta", "value": 1}, {"from": "can", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "can", "to": "receptor", "value": 1}, {"from": "can", "to": "is an", "value": 1}, {"from": "can", "to": "##type", "value": 1}, {"from": "can", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "can", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "can", "to": "- negative breast cancer", "value": 1}, {"from": "can", "to": "and", "value": 1}, {"from": "can", "to": "##esi", "value": 1}, {"from": "can", "to": "##a, jaka", "value": 1}, {"from": "can", "to": "lead", "value": 1}, {"from": "can", "to": "j", "value": 1}, {"from": "can", "to": "triple", "value": 1}, {"from": "can", "to": "of medicine, universitas indon", "value": 1}, {"from": "can", "to": "cilities - imeri,", "value": 1}, {"from": "can", "to": "##a. breast cancer sub", "value": 1}, {"from": "can", "to": "##umi", "value": 1}, {"from": "can", "to": "##a.", "value": 1}, {"from": "can", "to": "##ivers", "value": 1}, {"from": "can", "to": "faculty", "value": 1}, {"from": "can", "to": "to misclassification. dna methylation", "value": 1}, {"from": "can", "to": "##s", "value": 1}, {"from": "can", "to": "##don", "value": 1}, {"from": "can", "to": "##aka", "value": 1}, {"from": "can", "to": "un", "value": 1}, {"from": "can", "to": "##nal a, l", "value": 1}, {"from": "can", "to": "indonesi", "value": 1}, {"from": "can", "to": "##itas indonesia", "value": 1}, {"from": "can", "to": "epigenetic modification,", "value": 1}, {"from": "can", "to": "of medicine,", "value": 1}, {"from": "c", "to": "human", "value": 1}, {"from": "c", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "c", "to": "was re", "value": 1}, {"from": "c", "to": "##2 expression", "value": 1}, {"from": "c", "to": "interleuki", "value": 1}, {"from": "c", "to": "##d 1", "value": 1}, {"from": "c", "to": ",", "value": 1}, {"from": "c", "to": "##is", "value": 1}, {"from": "c", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "c", "to": "##p2 physically", "value": 1}, {"from": "c", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "c", "to": "- untranslated region of proang", "value": 1}, {"from": "c", "to": "bb2 ),", "value": 1}, {"from": "c", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "c", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "c", "to": "stabilize the proang", "value": 1}, {"from": "c", "to": "in", "value": 2}, {"from": "c", "to": "\u0027", "value": 1}, {"from": "c", "to": "poor", "value": 1}, {"from": "c", "to": "##ta", "value": 1}, {"from": "c", "to": "##io", "value": 1}, {"from": "c", "to": "##n - 8", "value": 1}, {"from": "c", "to": "##oki", "value": 1}, {"from": "c", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "c", "to": "interacted", "value": 1}, {"from": "c", "to": "a reversed", "value": 1}, {"from": "c", "to": "associated with", "value": 1}, {"from": "c", "to": "tumors", "value": 1}, {"from": "c", "to": "##pressed", "value": 1}, {"from": "c", "to": "##cpip", "value": 1}, {"from": "c", "to": "##bilize their mrnas.", "value": 1}, {"from": "c", "to": "##igan", "value": 1}, {"from": "c", "to": "breast", "value": 1}, {"from": "c", "to": "##8 ),", "value": 1}, {"from": "c", "to": "##ne l", "value": 1}, {"from": "c", "to": "##l", "value": 1}, {"from": "c", "to": "##cpi", "value": 1}, {"from": "c", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "c", "to": "rib", "value": 1}, {"from": "c", "to": "survival", "value": 1}, {"from": "c", "to": "risk", "value": 1}, {"from": "c", "to": "of cancer development while", "value": 1}, {"from": "c", "to": ":", "value": 1}, {"from": "c", "to": "reduced", "value": 1}, {"from": "c", "to": "##1 / acsomega. 4", "value": 1}, {"from": "c", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "c", "to": "40", "value": 1}, {"from": "c", "to": "##ve", "value": 1}, {"from": "c", "to": "##re", "value": 1}, {"from": "c", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "c", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "c", "to": "10. 102", "value": 1}, {"from": "c", "to": "##er and 5 genes down", "value": 1}, {"from": "c", "to": "upre", "value": 1}, {"from": "c", "to": "were downregulated", "value": 1}, {"from": "c", "to": "doi", "value": 1}, {"from": "c", "to": "pm", "value": 1}, {"from": "c", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "c", "to": "##ida", "value": 1}, {"from": "c", "to": "##gulated", "value": 1}, {"from": "c", "to": "play an important role in", "value": 1}, {"from": "c", "to": "##12059893", "value": 1}, {"from": "c", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "c", "to": "##c", "value": 2}, {"from": "c", "to": "in all three cancers and may", "value": 1}, {"from": "c", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "c", "to": "##11571 pmcid : pm", "value": 1}, {"from": "c", "to": "##id :", "value": 1}, {"from": "c", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "c", "to": "##ene", "value": 1}, {"from": "c", "to": "which was", "value": 1}, {"from": "c", "to": ": cyce or ccne1", "value": 1}, {"from": "c", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "c", "to": "##8 ), and e2f1", "value": 1}, {"from": "c", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "c", "to": "##1 ), rbl1", "value": 1}, {"from": "c", "to": "might", "value": 1}, {"from": "c", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "c", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "c", "to": "the native", "value": 1}, {"from": "c", "to": "ligan", "value": 1}, {"from": "c", "to": "00", "value": 1}, {"from": "c", "to": "im", "value": 1}, {"from": "c", "to": "p = 0. 01", "value": 1}, {"from": "c", "to": "##rank", "value": 1}, {"from": "c", "to": "##j", "value": 1}, {"from": "c", "to": "by", "value": 1}, {"from": "c", "to": "b", "value": 1}, {"from": "c", "to": "rerank score", "value": 1}, {"from": "c", "to": "##um", "value": 1}, {"from": "c", "to": "##d", "value": 1}, {"from": "c", "to": "of ad", "value": 1}, {"from": "c", "to": ".", "value": 1}, {"from": "c", "to": "re", "value": 1}, {"from": "c", "to": "##idodiph", "value": 1}, {"from": "c", "to": "p = 0", "value": 1}, {"from": "c", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "c", "to": "- 112. 70 k", "value": 1}, {"from": "c", "to": "score", "value": 1}, {"from": "c", "to": "##ine", "value": 1}, {"from": "c", "to": "##enyl", "value": 1}, {"from": "c", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "c", "to": "cycle", "value": 1}, {"from": "c", "to": "##osphate", "value": 1}, {"from": "c", "to": "- 110. 68 k", "value": 1}, {"from": "c", "to": "0", "value": 1}, {"from": "c", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "c", "to": "/ mol ), and nummular", "value": 1}, {"from": "c", "to": "squal", "value": 1}, {"from": "c", "to": "the decrease in p21", "value": 1}, {"from": "c", "to": "##mularia stem suggested that", "value": 1}, {"from": "human", "to": "with the stem - loop structures in the 3", "value": 1}, {"from": "human", "to": "was re", "value": 1}, {"from": "human", "to": "##2 expression", "value": 1}, {"from": "human", "to": "interleuki", "value": 1}, {"from": "human", "to": "##d 1", "value": 1}, {"from": "human", "to": ",", "value": 1}, {"from": "human", "to": "##is", "value": 1}, {"from": "human", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "human", "to": "##p2 physically", "value": 1}, {"from": "human", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "human", "to": "- untranslated region of proang", "value": 1}, {"from": "human", "to": "bb2 ),", "value": 1}, {"from": "human", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "human", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "human", "to": "stabilize the proang", "value": 1}, {"from": "human", "to": "in", "value": 1}, {"from": "human", "to": "\u0027", "value": 1}, {"from": "human", "to": "poor", "value": 1}, {"from": "human", "to": "##ta", "value": 1}, {"from": "human", "to": "##io", "value": 1}, {"from": "human", "to": "##n - 8", "value": 1}, {"from": "human", "to": "##oki", "value": 1}, {"from": "human", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "human", "to": "interacted", "value": 1}, {"from": "human", "to": "a reversed", "value": 1}, {"from": "human", "to": "associated with", "value": 1}, {"from": "human", "to": "tumors", "value": 1}, {"from": "human", "to": "##pressed", "value": 1}, {"from": "human", "to": "##cpip", "value": 1}, {"from": "human", "to": "##bilize their mrnas.", "value": 1}, {"from": "human", "to": "##igan", "value": 1}, {"from": "human", "to": "breast", "value": 1}, {"from": "human", "to": "##8 ),", "value": 1}, {"from": "human", "to": "##ne l", "value": 1}, {"from": "human", "to": "##l", "value": 1}, {"from": "human", "to": "##cpi", "value": 1}, {"from": "human", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "human", "to": "rib", "value": 1}, {"from": "human", "to": "survival", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "was re", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##2 expression", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "interleuki", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##d 1", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": ",", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##is", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##p2 physically", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "- untranslated region of proang", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "bb2 ),", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "stabilize the proang", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "in", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "\u0027", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "poor", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##ta", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##io", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##n - 8", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##oki", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "interacted", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "a reversed", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "associated with", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "tumors", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##pressed", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##cpip", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##bilize their mrnas.", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##igan", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "breast", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##8 ),", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##ne l", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##l", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##cpi", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "rib", "value": 1}, {"from": "with the stem - loop structures in the 3", "to": "survival", "value": 1}, {"from": "was re", "to": "##2 expression", "value": 1}, {"from": "was re", "to": "interleuki", "value": 1}, {"from": "was re", "to": "##d 1", "value": 1}, {"from": "was re", "to": ",", "value": 1}, {"from": "was re", "to": "##is", "value": 1}, {"from": "was re", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "was re", "to": "##p2 physically", "value": 1}, {"from": "was re", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "was re", "to": "- untranslated region of proang", "value": 1}, {"from": "was re", "to": "bb2 ),", "value": 1}, {"from": "was re", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "was re", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "was re", "to": "stabilize the proang", "value": 1}, {"from": "was re", "to": "in", "value": 1}, {"from": "was re", "to": "\u0027", "value": 1}, {"from": "was re", "to": "poor", "value": 1}, {"from": "was re", "to": "##ta", "value": 1}, {"from": "was re", "to": "##io", "value": 1}, {"from": "was re", "to": "##n - 8", "value": 1}, {"from": "was re", "to": "##oki", "value": 1}, {"from": "was re", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "was re", "to": "interacted", "value": 1}, {"from": "was re", "to": "a reversed", "value": 1}, {"from": "was re", "to": "associated with", "value": 1}, {"from": "was re", "to": "tumors", "value": 1}, {"from": "was re", "to": "##pressed", "value": 1}, {"from": "was re", "to": "##cpip", "value": 1}, {"from": "was re", "to": "##bilize their mrnas.", "value": 1}, {"from": "was re", "to": "##igan", "value": 1}, {"from": "was re", "to": "breast", "value": 1}, {"from": "was re", "to": "##8 ),", "value": 1}, {"from": "was re", "to": "##ne l", "value": 1}, {"from": "was re", "to": "##l", "value": 1}, {"from": "was re", "to": "##cpi", "value": 1}, {"from": "was re", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "was re", "to": "rib", "value": 1}, {"from": "was re", "to": "survival", "value": 1}, {"from": "##2 expression", "to": "interleuki", "value": 1}, {"from": "##2 expression", "to": "##d 1", "value": 1}, {"from": "##2 expression", "to": ",", "value": 1}, {"from": "##2 expression", "to": "##is", "value": 1}, {"from": "##2 expression", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "##2 expression", "to": "##p2 physically", "value": 1}, {"from": "##2 expression", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "##2 expression", "to": "- untranslated region of proang", "value": 1}, {"from": "##2 expression", "to": "bb2 ),", "value": 1}, {"from": "##2 expression", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##2 expression", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##2 expression", "to": "stabilize the proang", "value": 1}, {"from": "##2 expression", "to": "in", "value": 1}, {"from": "##2 expression", "to": "\u0027", "value": 1}, {"from": "##2 expression", "to": "poor", "value": 1}, {"from": "##2 expression", "to": "##ta", "value": 1}, {"from": "##2 expression", "to": "##io", "value": 1}, {"from": "##2 expression", "to": "##n - 8", "value": 1}, {"from": "##2 expression", "to": "##oki", "value": 1}, {"from": "##2 expression", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##2 expression", "to": "interacted", "value": 1}, {"from": "##2 expression", "to": "a reversed", "value": 1}, {"from": "##2 expression", "to": "associated with", "value": 1}, {"from": "##2 expression", "to": "tumors", "value": 1}, {"from": "##2 expression", "to": "##pressed", "value": 1}, {"from": "##2 expression", "to": "##cpip", "value": 1}, {"from": "##2 expression", "to": "##bilize their mrnas.", "value": 1}, {"from": "##2 expression", "to": "##igan", "value": 1}, {"from": "##2 expression", "to": "breast", "value": 1}, {"from": "##2 expression", "to": "##8 ),", "value": 1}, {"from": "##2 expression", "to": "##ne l", "value": 1}, {"from": "##2 expression", "to": "##l", "value": 1}, {"from": "##2 expression", "to": "##cpi", "value": 1}, {"from": "##2 expression", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##2 expression", "to": "rib", "value": 1}, {"from": "##2 expression", "to": "survival", "value": 1}, {"from": "interleuki", "to": "##d 1", "value": 1}, {"from": "interleuki", "to": ",", "value": 1}, {"from": "interleuki", "to": "##is", "value": 1}, {"from": "interleuki", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "interleuki", "to": "##p2 physically", "value": 1}, {"from": "interleuki", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "interleuki", "to": "- untranslated region of proang", "value": 1}, {"from": "interleuki", "to": "bb2 ),", "value": 1}, {"from": "interleuki", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "interleuki", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "interleuki", "to": "stabilize the proang", "value": 1}, {"from": "interleuki", "to": "in", "value": 1}, {"from": "interleuki", "to": "\u0027", "value": 1}, {"from": "interleuki", "to": "poor", "value": 1}, {"from": "interleuki", "to": "##ta", "value": 1}, {"from": "interleuki", "to": "##io", "value": 1}, {"from": "interleuki", "to": "##n - 8", "value": 1}, {"from": "interleuki", "to": "##oki", "value": 1}, {"from": "interleuki", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "interleuki", "to": "interacted", "value": 1}, {"from": "interleuki", "to": "a reversed", "value": 1}, {"from": "interleuki", "to": "associated with", "value": 1}, {"from": "interleuki", "to": "tumors", "value": 1}, {"from": "interleuki", "to": "##pressed", "value": 1}, {"from": "interleuki", "to": "##cpip", "value": 1}, {"from": "interleuki", "to": "##bilize their mrnas.", "value": 1}, {"from": "interleuki", "to": "##igan", "value": 1}, {"from": "interleuki", "to": "breast", "value": 1}, {"from": "interleuki", "to": "##8 ),", "value": 1}, {"from": "interleuki", "to": "##ne l", "value": 1}, {"from": "interleuki", "to": "##l", "value": 1}, {"from": "interleuki", "to": "##cpi", "value": 1}, {"from": "interleuki", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "interleuki", "to": "rib", "value": 1}, {"from": "interleuki", "to": "survival", "value": 1}, {"from": "##d 1", "to": ",", "value": 1}, {"from": "##d 1", "to": "##is", "value": 1}, {"from": "##d 1", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "##d 1", "to": "##p2 physically", "value": 1}, {"from": "##d 1", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "##d 1", "to": "- untranslated region of proang", "value": 1}, {"from": "##d 1", "to": "bb2 ),", "value": 1}, {"from": "##d 1", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##d 1", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##d 1", "to": "stabilize the proang", "value": 1}, {"from": "##d 1", "to": "in", "value": 1}, {"from": "##d 1", "to": "\u0027", "value": 1}, {"from": "##d 1", "to": "poor", "value": 1}, {"from": "##d 1", "to": "##ta", "value": 1}, {"from": "##d 1", "to": "##io", "value": 1}, {"from": "##d 1", "to": "##n - 8", "value": 1}, {"from": "##d 1", "to": "##oki", "value": 1}, {"from": "##d 1", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##d 1", "to": "interacted", "value": 1}, {"from": "##d 1", "to": "a reversed", "value": 1}, {"from": "##d 1", "to": "associated with", "value": 1}, {"from": "##d 1", "to": "tumors", "value": 1}, {"from": "##d 1", "to": "##pressed", "value": 1}, {"from": "##d 1", "to": "##cpip", "value": 1}, {"from": "##d 1", "to": "##bilize their mrnas.", "value": 1}, {"from": "##d 1", "to": "##igan", "value": 1}, {"from": "##d 1", "to": "breast", "value": 1}, {"from": "##d 1", "to": "##8 ),", "value": 1}, {"from": "##d 1", "to": "##ne l", "value": 1}, {"from": "##d 1", "to": "##l", "value": 1}, {"from": "##d 1", "to": "##cpi", "value": 1}, {"from": "##d 1", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##d 1", "to": "rib", "value": 1}, {"from": "##d 1", "to": "survival", "value": 1}, {"from": ",", "to": "##is", "value": 1}, {"from": ",", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": ",", "to": "##p2 physically", "value": 1}, {"from": ",", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": ",", "to": "- untranslated region of proang", "value": 1}, {"from": ",", "to": "bb2 ),", "value": 1}, {"from": ",", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": ",", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": ",", "to": "stabilize the proang", "value": 1}, {"from": ",", "to": "in", "value": 6}, {"from": ",", "to": "\u0027", "value": 1}, {"from": ",", "to": "poor", "value": 1}, {"from": ",", "to": "##ta", "value": 1}, {"from": ",", "to": "##io", "value": 1}, {"from": ",", "to": "##n - 8", "value": 1}, {"from": ",", "to": "##oki", "value": 1}, {"from": ",", "to": "##1 ), and ephrin a1", "value": 1}, {"from": ",", "to": "interacted", "value": 1}, {"from": ",", "to": "a reversed", "value": 1}, {"from": ",", "to": "associated with", "value": 1}, {"from": ",", "to": "tumors", "value": 1}, {"from": ",", "to": "##pressed", "value": 1}, {"from": ",", "to": "##cpip", "value": 1}, {"from": ",", "to": "##bilize their mrnas.", "value": 1}, {"from": ",", "to": "##igan", "value": 1}, {"from": ",", "to": "breast", "value": 2}, {"from": ",", "to": "##8 ),", "value": 1}, {"from": ",", "to": "##ne l", "value": 1}, {"from": ",", "to": "##l", "value": 1}, {"from": ",", "to": "##cpi", "value": 1}, {"from": ",", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": ",", "to": "rib", "value": 1}, {"from": ",", "to": "survival", "value": 1}, {"from": ",", "to": "##t", "value": 1}, {"from": ",", "to": "of life", "value": 1}, {"from": ",", "to": "##k", "value": 1}, {"from": ",", "to": ") institute for brain sciences research,", "value": 1}, {"from": ",", "to": ":", "value": 3}, {"from": ",", "to": "index", "value": 1}, {"from": ",", "to": "##osu", "value": 1}, {"from": ",", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": ",", "to": ". 1096 / fj. 202", "value": 1}, {"from": ",", "to": "may contribute to the", "value": 1}, {"from": ",", "to": "sciences", "value": 4}, {"from": ",", "to": "university", "value": 2}, {"from": ",", "to": "##lle", "value": 1}, {"from": ",", "to": "40", "value": 2}, {"from": ",", "to": "genes", "value": 1}, {"from": ",", "to": "##i", "value": 1}, {"from": ",", "to": "##f", "value": 1}, {"from": ",", "to": "we", "value": 1}, {"from": ",", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": ",", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": ",", "to": "3 )", "value": 1}, {"from": ",", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": ",", "to": "##hie j", "value": 1}, {"from": ",", "to": "k", "value": 3}, {"from": ",", "to": "doi", "value": 3}, {"from": ",", "to": "b", "value": 3}, {"from": ",", "to": "102", "value": 1}, {"from": ",", "to": "j", "value": 6}, {"from": ",", "to": "##354028 [", "value": 1}, {"from": ",", "to": ".", "value": 5}, {"from": ",", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": ",", "to": "school", "value": 2}, {"from": ",", "to": "), agegnehu sb", "value": 1}, {"from": ",", "to": "##ra 00", "value": 1}, {"from": ",", "to": "3 ), lamptey el", "value": 1}, {"from": ",", "to": "1", "value": 3}, {"from": ",", "to": "ka", "value": 1}, {"from": ",", "to": "4", "value": 5}, {"from": ",", "to": "of ghana, a", "value": 1}, {"from": ",", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": ",", "to": "##461r pmid :", "value": 1}, {"from": ",", "to": "antiangiogenic therapy of", "value": 1}, {"from": ",", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": ",", "to": ")", "value": 6}, {"from": ",", "to": "he", "value": 1}, {"from": ",", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ",", "to": "expression", "value": 2}, {"from": ",", "to": "##500", "value": 1}, {"from": ",", "to": "in cancer", "value": 1}, {"from": ",", "to": "##mpo s", "value": 1}, {"from": ",", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ",", "to": "##cc", "value": 2}, {"from": ",", "to": "inverse", "value": 1}, {"from": ",", "to": "new insights into", "value": 1}, {"from": ",", "to": "box l", "value": 1}, {"from": ",", "to": "associated with aging. interestingly, an", "value": 1}, {"from": ",", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": ",", "to": "of medical sciences, c.", "value": 1}, {"from": ",", "to": "these two conditions which", "value": 1}, {"from": ",", "to": "box", "value": 1}, {"from": ",", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": ",", "to": "care", "value": 1}, {"from": ",", "to": "##ra", "value": 1}, {"from": ",", "to": "00", "value": 1}, {"from": ",", "to": "233, ghana.", "value": 1}, {"from": ",", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": ",", "to": "##g 77, a", "value": 1}, {"from": ",", "to": "5", "value": 4}, {"from": ",", "to": ") west african genetic medicine centre", "value": 1}, {"from": ",", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": ",", "to": "of health", "value": 2}, {"from": ",", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": ",", "to": "##g 77, university of ghana, a", "value": 1}, {"from": ",", "to": "been observed", "value": 1}, {"from": ",", "to": ", university of ghana, p. o.", "value": 1}, {"from": ",", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": ",", "to": "between", "value": 1}, {"from": ",", "to": "of anaesthesia and intensive", "value": 1}, {"from": ",", "to": "##233, ghana.", "value": 1}, {"from": ",", "to": "incidence", "value": 1}, {"from": ",", "to": "cancer and ad", "value": 1}, {"from": ",", "to": "were formerly", "value": 1}, {"from": ",", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": ",", "to": "has", "value": 1}, {"from": ",", "to": "department", "value": 4}, {"from": ",", "to": "inverse relationship between", "value": 1}, {"from": ",", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": ",", "to": "##ibi", "value": 1}, {"from": ",", "to": "ri", "value": 1}, {"from": ",", "to": "##sana", "value": 1}, {"from": ",", "to": "doctoral program in biomedical", "value": 1}, {"from": ",", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": ",", "to": "of medicine, univers", "value": 2}, {"from": ",", "to": "##g", "value": 1}, {"from": ",", "to": "##rta", "value": 3}, {"from": ",", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": ",", "to": "##esia", "value": 1}, {"from": ",", "to": "##itas in", "value": 1}, {"from": ",", "to": "##nandi si", "value": 1}, {"from": ",", "to": "##eri", "value": 1}, {"from": ",", "to": "master program in biomedical", "value": 2}, {"from": ",", "to": "),", "value": 1}, {"from": ",", "to": "##esi", "value": 3}, {"from": ",", "to": "of medical chemistry,", "value": 1}, {"from": ",", "to": "##a.", "value": 4}, {"from": ",", "to": "faculty", "value": 4}, {"from": ",", "to": "wa", "value": 1}, {"from": ",", "to": "##don", "value": 3}, {"from": ",", "to": "##a,", "value": 2}, {"from": ",", "to": "6", "value": 1}, {"from": ",", "to": "##aka", "value": 3}, {"from": ",", "to": "indonesi", "value": 2}, {"from": ",", "to": "##itas indonesia", "value": 2}, {"from": ",", "to": "of surgery,", "value": 1}, {"from": ",", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": ",", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": ",", "to": "2 - positive", "value": 1}, {"from": ",", "to": "changes in the promoter region", "value": 1}, {"from": ",", "to": "9 ) department of internal medicine,", "value": 1}, {"from": ",", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": ",", "to": "receptor", "value": 1}, {"from": ",", "to": "is an", "value": 1}, {"from": ",", "to": "##type", "value": 1}, {"from": ",", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": ",", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": ",", "to": "- negative breast cancer", "value": 1}, {"from": ",", "to": "and", "value": 4}, {"from": ",", "to": "##a, jaka", "value": 2}, {"from": ",", "to": "lead", "value": 1}, {"from": ",", "to": "triple", "value": 1}, {"from": ",", "to": "of medicine, universitas indon", "value": 2}, {"from": ",", "to": "cilities - imeri,", "value": 1}, {"from": ",", "to": "##a. breast cancer sub", "value": 1}, {"from": ",", "to": "##umi", "value": 1}, {"from": ",", "to": "##ivers", "value": 1}, {"from": ",", "to": "to misclassification. dna methylation", "value": 1}, {"from": ",", "to": "##s", "value": 1}, {"from": ",", "to": "un", "value": 1}, {"from": ",", "to": "##nal a, l", "value": 1}, {"from": ",", "to": "epigenetic modification,", "value": 1}, {"from": ",", "to": "of medicine,", "value": 1}, {"from": ",", "to": "), hashim", "value": 1}, {"from": ",", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": ",", "to": ") drug development research cluster, indon", "value": 1}, {"from": ",", "to": "##an medical", "value": 1}, {"from": ",", "to": "indon", "value": 1}, {"from": ",", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": ",", "to": "##hibit", "value": 1}, {"from": ",", "to": "na", "value": 1}, {"from": ",", "to": "education", "value": 1}, {"from": ",", "to": "n", "value": 1}, {"from": ",", "to": "3", "value": 1}, {"from": ",", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": ",", "to": "##ajrin", "value": 1}, {"from": ",", "to": "), azizah", "value": 1}, {"from": ",", "to": "te", "value": 1}, {"from": ",", "to": "##djo a", "value": 1}, {"from": ",", "to": "##itas", "value": 1}, {"from": ",", "to": "##b", "value": 1}, {"from": ",", "to": "am", "value": 1}, {"from": ",", "to": "nn", "value": 1}, {"from": ",", "to": "of pharmacy, univers", "value": 1}, {"from": ",", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": ",", "to": ", indon", "value": 1}, {"from": ",", "to": "and research instit", "value": 1}, {"from": ",", "to": "), ramadanti", "value": 1}, {"from": ",", "to": "52", "value": 1}, {"from": ",", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": ",", "to": "), beltran - v", "value": 1}, {"from": ",", "to": ") department of pathology, co", "value": 1}, {"from": ",", "to": "##ulin", "value": 1}, {"from": ",", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": ",", "to": "f", "value": 1}, {"from": ",", "to": "new yo", "value": 1}, {"from": ",", "to": "sloan", "value": 1}, {"from": ",", "to": "la", "value": 1}, {"from": ",", "to": "center", "value": 1}, {"from": ",", "to": "us", "value": 1}, {"from": ",", "to": "##lum", "value": 1}, {"from": ",", "to": "##o m", "value": 1}, {"from": ",", "to": "9", "value": 1}, {"from": ",", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": ",", "to": "kette", "value": 1}, {"from": ",", "to": "yo", "value": 1}, {"from": ",", "to": "##ettering cancer", "value": 1}, {"from": ",", "to": "##rk, usa.", "value": 1}, {"from": ",", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": ",", "to": "re", "value": 2}, {"from": ",", "to": "new york", "value": 1}, {"from": ",", "to": "##bia university,", "value": 1}, {"from": ",", "to": "), shin e", "value": 1}, {"from": ",", "to": "##ring cancer", "value": 1}, {"from": ",", "to": "##rk, new", "value": 1}, {"from": ",", "to": "##urent, quebec, canada.", "value": 1}, {"from": ",", "to": "##isied", "value": 1}, {"from": ",", "to": "##pare therapeutics, saint -", "value": 1}, {"from": ",", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": ",", "to": "ancers. sinha s", "value": 1}, {"from": ",", "to": "##is - filho j", "value": 1}, {"from": ",", "to": "##rk,", "value": 1}, {"from": ",", "to": "), gardner r", "value": 1}, {"from": ",", "to": "##rio de v", "value": 1}, {"from": ",", "to": "t", "value": 3}, {"from": ",", "to": "##kolog", "value": 1}, {"from": ",", "to": ", san", "value": 1}, {"from": ",", "to": "##it", "value": 1}, {"from": ",", "to": ") health", "value": 2}, {"from": ",", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": ",", "to": "##iba", "value": 1}, {"from": ",", "to": "##ialdea", "value": 1}, {"from": ",", "to": "##gipuzkoa", "value": 2}, {"from": ",", "to": "##ko", "value": 1}, {"from": ",", "to": "##obe", "value": 1}, {"from": ",", "to": "se", "value": 1}, {"from": ",", "to": "##in", "value": 1}, {"from": ",", "to": "##gi", "value": 2}, {"from": ",", "to": "##tian,", "value": 2}, {"from": ",", "to": ") hospital clinico univers", "value": 1}, {"from": ",", "to": "##r 12, madrid,", "value": 1}, {"from": ",", "to": "spain", "value": 2}, {"from": ",", "to": "##ale", "value": 1}, {"from": ",", "to": "##a", "value": 1}, {"from": ",", "to": "##ute", "value": 1}, {"from": ",", "to": "##ikoa,", "value": 1}, {"from": ",", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ",", "to": "bio", "value": 2}, {"from": ",", "to": "##donost", "value": 2}, {"from": ",", "to": ") hospital oct", "value": 1}, {"from": ",", "to": "research institute", "value": 2}, {"from": ",", "to": "institute", "value": 3}, {"from": ",", "to": "sa", "value": 2}, {"from": ",", "to": "sebas", "value": 2}, {"from": ",", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ",", "to": "##ita", "value": 1}, {"from": ",", "to": ", v", "value": 1}, {"from": ",", "to": "11", "value": 1}, {"from": ",", "to": "##ps, barcelon", "value": 1}, {"from": ",", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ",", "to": "##n", "value": 2}, {"from": ",", "to": "##pu", "value": 2}, {"from": ",", "to": "sebastian", "value": 2}, {"from": ",", "to": "; gip", "value": 1}, {"from": ",", "to": "- on", "value": 1}, {"from": ",", "to": "7 ) valencia oncology", "value": 1}, {"from": ",", "to": "##ncia,", "value": 1}, {"from": ",", "to": "##uz", "value": 1}, {"from": ",", "to": "##ia", "value": 2}, {"from": ",", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ",", "to": "- onkologikoa, san", "value": 1}, {"from": ",", "to": "##z", "value": 1}, {"from": ",", "to": "##bastian, spa", "value": 1}, {"from": ",", "to": "12", "value": 1}, {"from": ",", "to": "after net", "value": 1}, {"from": ",", "to": "a significant", "value": 1}, {"from": ",", "to": "time", "value": 1}, {"from": ",", "to": "offers the opportunity of", "value": 1}, {"from": ",", "to": "##ip", "value": 1}, {"from": ",", "to": "however", "value": 1}, {"from": ",", "to": "background", "value": 1}, {"from": ",", "to": "##re population of", "value": 1}, {"from": ",", "to": "negative breast", "value": 1}, {"from": ",", "to": "barrier", "value": 1}, {"from": ",", "to": "clinical", "value": 1}, {"from": ",", "to": "##2 -", "value": 1}, {"from": ",", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": ",", "to": "##zkoa", "value": 1}, {"from": ",", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": ",", "to": "##donostia ) health", "value": 1}, {"from": ",", "to": "cancer", "value": 1}, {"from": ",", "to": "##uzkoa. eus.", "value": 1}, {"from": ",", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": ",", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": ",", "to": "real", "value": 1}, {"from": ",", "to": "personal", "value": 1}, {"from": ",", "to": "##ised therapy.", "value": 1}, {"from": ",", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ",", "to": "##cent", "value": 1}, {"from": ",", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ",", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ",", "to": "her", "value": 1}, {"from": ",", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ",", "to": "##n sebastian,", "value": 1}, {"from": ",", "to": "##umour response", "value": 1}, {"from": ",", "to": "a,", "value": 1}, {"from": ",", "to": "##uc", "value": 1}, {"from": ",", "to": "13", "value": 1}, {"from": ",", "to": ", the lack of reprod", "value": 1}, {"from": ",", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ",", "to": "##c ) allows", "value": 1}, {"from": ",", "to": "##gnosis", "value": 1}, {"from": ",", "to": "- g", "value": 1}, {"from": ",", "to": "##rgen, norway.", "value": 1}, {"from": ",", "to": "##rgen, nor", "value": 1}, {"from": ",", "to": "economics", "value": 1}, {"from": ",", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": ",", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": ",", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": ",", "to": "clinical trials", "value": 1}, {"from": ",", "to": "of health management and health", "value": 1}, {"from": ",", "to": ";", "value": 1}, {"from": ",", "to": ") department of p", "value": 1}, {"from": ",", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": ",", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": ",", "to": "), heie a", "value": 1}, {"from": ",", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": ",", "to": "be", "value": 1}, {"from": ",", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": ",", "to": "ug", "value": 1}, {"from": ",", "to": "##way", "value": 1}, {"from": ",", "to": "the", "value": 1}, {"from": ",", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": ",", "to": "methods", "value": 1}, {"from": ",", "to": "hormone receptor positive", "value": 1}, {"from": ",", "to": "societal perspective", "value": 1}, {"from": ",", "to": "benefits", "value": 1}, {"from": ",", "to": "surgery", "value": 1}, {"from": ",", "to": "cost -", "value": 1}, {"from": ",", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": ",", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": ",", "to": "decision", "value": 1}, {"from": ",", "to": "to aid adjuvant treatment", "value": 1}, {"from": ",", "to": "##al", "value": 1}, {"from": ",", "to": "emit - 1 trial", "value": 1}, {"from": ",", "to": "post", "value": 1}, {"from": ",", "to": ". materials", "value": 1}, {"from": ",", "to": "model was", "value": 1}, {"from": ",", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": ",", "to": "used", "value": 1}, {"from": ",", "to": ", a", "value": 1}, {"from": ",", "to": "treatment", "value": 1}, {"from": ",", "to": ": the", "value": 1}, {"from": ",", "to": "ki - 67", "value": 1}, {"from": ",", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": ",", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ",", "to": "prosigna was tested", "value": 1}, {"from": ",", "to": "prospective", "value": 1}, {"from": ",", "to": "were measured", "value": 1}, {"from": ",", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ",", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ",", "to": "observation", "value": 1}, {"from": ",", "to": "division", "value": 1}, {"from": ",", "to": "decisions in", "value": 1}, {"from": ",", "to": "built", "value": 1}, {"from": ",", "to": "impact of", "value": 1}, {"from": ",", "to": "is cost - effective", "value": 1}, {"from": ",", "to": "of agriculture and natural", "value": 1}, {"from": ",", "to": ". ac.", "value": 1}, {"from": ",", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": ",", "to": "resources", "value": 1}, {"from": ",", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": ",", "to": "##za. he", "value": 1}, {"from": ",", "to": "##6 /", "value": 1}, {"from": ",", "to": "are", "value": 1}, {"from": ",", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": ",", "to": "##ri - japelaghi r", "value": 1}, {"from": ",", "to": "##r.", "value": 1}, {"from": ",", "to": "who", "value": 1}, {"from": ",", "to": "inter", "value": 1}, {"from": ",", "to": "##vin", "value": 1}, {"from": ",", "to": "of tabriz,", "value": 1}, {"from": ",", "to": "@ org.", "value": 1}, {"from": ",", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": ",", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": ",", "to": "##idari", "value": 1}, {"from": ",", "to": "s", "value": 1}, {"from": ",", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": ",", "to": "ta", "value": 1}, {"from": ",", "to": "##ran. electronic address :", "value": 1}, {"from": ",", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": ",", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ",", "to": "101", "value": 1}, {"from": ",", "to": "##ida", "value": 1}, {"from": ",", "to": "perspectives", "value": 1}, {"from": ",", "to": "##briz,", "value": 1}, {"from": ",", "to": "of agriculture,", "value": 1}, {"from": ",", "to": "##fer", "value": 1}, {"from": ",", "to": "##on", "value": 1}, {"from": ",", "to": "##ki", "value": 1}, {"from": ",", "to": "from both", "value": 1}, {"from": ",", "to": "##ran.", "value": 1}, {"from": "##is", "to": "of breast cancer patients, respectively. notably, there was", "value": 1}, {"from": "##is", "to": "##p2 physically", "value": 1}, {"from": "##is", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "##is", "to": "- untranslated region of proang", "value": 1}, {"from": "##is", "to": "bb2 ),", "value": 1}, {"from": "##is", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##is", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##is", "to": "stabilize the proang", "value": 1}, {"from": "##is", "to": "in", "value": 1}, {"from": "##is", "to": "\u0027", "value": 1}, {"from": "##is", "to": "poor", "value": 1}, {"from": "##is", "to": "##ta", "value": 1}, {"from": "##is", "to": "##io", "value": 1}, {"from": "##is", "to": "##n - 8", "value": 1}, {"from": "##is", "to": "##oki", "value": 1}, {"from": "##is", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##is", "to": "interacted", "value": 1}, {"from": "##is", "to": "a reversed", "value": 1}, {"from": "##is", "to": "associated with", "value": 1}, {"from": "##is", "to": "tumors", "value": 1}, {"from": "##is", "to": "##pressed", "value": 1}, {"from": "##is", "to": "##cpip", "value": 1}, {"from": "##is", "to": "##bilize their mrnas.", "value": 1}, {"from": "##is", "to": "##igan", "value": 1}, {"from": "##is", "to": "breast", "value": 1}, {"from": "##is", "to": "##8 ),", "value": 1}, {"from": "##is", "to": "##ne l", "value": 1}, {"from": "##is", "to": "##l", "value": 1}, {"from": "##is", "to": "##cpi", "value": 1}, {"from": "##is", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##is", "to": "rib", "value": 1}, {"from": "##is", "to": "survival", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##p2 physically", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "- untranslated region of proang", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "bb2 ),", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "stabilize the proang", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "in", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "\u0027", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "poor", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##ta", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##io", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##n - 8", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##oki", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "interacted", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "a reversed", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "associated with", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "tumors", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##pressed", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##cpip", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##bilize their mrnas.", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##igan", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "breast", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##8 ),", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##ne l", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##l", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##cpi", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "rib", "value": 1}, {"from": "of breast cancer patients, respectively. notably, there was", "to": "survival", "value": 1}, {"from": "##p2 physically", "to": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "value": 1}, {"from": "##p2 physically", "to": "- untranslated region of proang", "value": 1}, {"from": "##p2 physically", "to": "bb2 ),", "value": 1}, {"from": "##p2 physically", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##p2 physically", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##p2 physically", "to": "stabilize the proang", "value": 1}, {"from": "##p2 physically", "to": "in", "value": 1}, {"from": "##p2 physically", "to": "\u0027", "value": 1}, {"from": "##p2 physically", "to": "poor", "value": 1}, {"from": "##p2 physically", "to": "##ta", "value": 1}, {"from": "##p2 physically", "to": "##io", "value": 1}, {"from": "##p2 physically", "to": "##n - 8", "value": 1}, {"from": "##p2 physically", "to": "##oki", "value": 1}, {"from": "##p2 physically", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##p2 physically", "to": "interacted", "value": 1}, {"from": "##p2 physically", "to": "a reversed", "value": 1}, {"from": "##p2 physically", "to": "associated with", "value": 1}, {"from": "##p2 physically", "to": "tumors", "value": 1}, {"from": "##p2 physically", "to": "##pressed", "value": 1}, {"from": "##p2 physically", "to": "##cpip", "value": 1}, {"from": "##p2 physically", "to": "##bilize their mrnas.", "value": 1}, {"from": "##p2 physically", "to": "##igan", "value": 1}, {"from": "##p2 physically", "to": "breast", "value": 1}, {"from": "##p2 physically", "to": "##8 ),", "value": 1}, {"from": "##p2 physically", "to": "##ne l", "value": 1}, {"from": "##p2 physically", "to": "##l", "value": 1}, {"from": "##p2 physically", "to": "##cpi", "value": 1}, {"from": "##p2 physically", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##p2 physically", "to": "rib", "value": 1}, {"from": "##p2 physically", "to": "survival", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "- untranslated region of proang", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "bb2 ),", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "stabilize the proang", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "in", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "\u0027", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "poor", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##ta", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##io", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##n - 8", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##oki", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "interacted", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "a reversed", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "associated with", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "tumors", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##pressed", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##cpip", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##bilize their mrnas.", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##igan", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "breast", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##8 ),", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##ne l", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##l", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##cpi", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "rib", "value": 1}, {"from": "##bilization of proangiogenic mrnas. on the other hand, igf2bp1", "to": "survival", "value": 1}, {"from": "- untranslated region of proang", "to": "bb2 ),", "value": 1}, {"from": "- untranslated region of proang", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "- untranslated region of proang", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "- untranslated region of proang", "to": "stabilize the proang", "value": 1}, {"from": "- untranslated region of proang", "to": "in", "value": 1}, {"from": "- untranslated region of proang", "to": "\u0027", "value": 1}, {"from": "- untranslated region of proang", "to": "poor", "value": 1}, {"from": "- untranslated region of proang", "to": "##ta", "value": 1}, {"from": "- untranslated region of proang", "to": "##io", "value": 1}, {"from": "- untranslated region of proang", "to": "##n - 8", "value": 1}, {"from": "- untranslated region of proang", "to": "##oki", "value": 1}, {"from": "- untranslated region of proang", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "- untranslated region of proang", "to": "interacted", "value": 1}, {"from": "- untranslated region of proang", "to": "a reversed", "value": 1}, {"from": "- untranslated region of proang", "to": "associated with", "value": 1}, {"from": "- untranslated region of proang", "to": "tumors", "value": 1}, {"from": "- untranslated region of proang", "to": "##pressed", "value": 1}, {"from": "- untranslated region of proang", "to": "##cpip", "value": 1}, {"from": "- untranslated region of proang", "to": "##bilize their mrnas.", "value": 1}, {"from": "- untranslated region of proang", "to": "##igan", "value": 1}, {"from": "- untranslated region of proang", "to": "breast", "value": 1}, {"from": "- untranslated region of proang", "to": "##8 ),", "value": 1}, {"from": "- untranslated region of proang", "to": "##ne l", "value": 1}, {"from": "- untranslated region of proang", "to": "##l", "value": 1}, {"from": "- untranslated region of proang", "to": "##cpi", "value": 1}, {"from": "- untranslated region of proang", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "- untranslated region of proang", "to": "rib", "value": 1}, {"from": "- untranslated region of proang", "to": "survival", "value": 1}, {"from": "bb2 ),", "to": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "value": 1}, {"from": "bb2 ),", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "bb2 ),", "to": "stabilize the proang", "value": 1}, {"from": "bb2 ),", "to": "in", "value": 1}, {"from": "bb2 ),", "to": "\u0027", "value": 1}, {"from": "bb2 ),", "to": "poor", "value": 1}, {"from": "bb2 ),", "to": "##ta", "value": 1}, {"from": "bb2 ),", "to": "##io", "value": 1}, {"from": "bb2 ),", "to": "##n - 8", "value": 1}, {"from": "bb2 ),", "to": "##oki", "value": 1}, {"from": "bb2 ),", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "bb2 ),", "to": "interacted", "value": 1}, {"from": "bb2 ),", "to": "a reversed", "value": 1}, {"from": "bb2 ),", "to": "associated with", "value": 1}, {"from": "bb2 ),", "to": "tumors", "value": 1}, {"from": "bb2 ),", "to": "##pressed", "value": 1}, {"from": "bb2 ),", "to": "##cpip", "value": 1}, {"from": "bb2 ),", "to": "##bilize their mrnas.", "value": 1}, {"from": "bb2 ),", "to": "##igan", "value": 1}, {"from": "bb2 ),", "to": "breast", "value": 1}, {"from": "bb2 ),", "to": "##8 ),", "value": 1}, {"from": "bb2 ),", "to": "##ne l", "value": 1}, {"from": "bb2 ),", "to": "##l", "value": 1}, {"from": "bb2 ),", "to": "##cpi", "value": 1}, {"from": "bb2 ),", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "bb2 ),", "to": "rib", "value": 1}, {"from": "bb2 ),", "to": "survival", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##genic transcripts through its rnase domain to des", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "stabilize the proang", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "in", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "\u0027", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "poor", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##ta", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##io", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##n - 8", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##oki", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "interacted", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "a reversed", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "associated with", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "tumors", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##pressed", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##cpip", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##bilize their mrnas.", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##igan", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "breast", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##8 ),", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##ne l", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##l", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##cpi", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "rib", "value": 1}, {"from": "whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly", "to": "survival", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "stabilize the proang", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "in", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "\u0027", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "poor", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##ta", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##io", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##n - 8", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##oki", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "interacted", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "a reversed", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "associated with", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "tumors", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##pressed", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##cpip", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##bilize their mrnas.", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##igan", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "breast", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##8 ),", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##ne l", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##l", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##cpi", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "rib", "value": 1}, {"from": "##genic transcripts through its rnase domain to des", "to": "survival", "value": 1}, {"from": "stabilize the proang", "to": "in", "value": 1}, {"from": "stabilize the proang", "to": "\u0027", "value": 1}, {"from": "stabilize the proang", "to": "poor", "value": 1}, {"from": "stabilize the proang", "to": "##ta", "value": 1}, {"from": "stabilize the proang", "to": "##io", "value": 1}, {"from": "stabilize the proang", "to": "##n - 8", "value": 1}, {"from": "stabilize the proang", "to": "##oki", "value": 1}, {"from": "stabilize the proang", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "stabilize the proang", "to": "interacted", "value": 1}, {"from": "stabilize the proang", "to": "a reversed", "value": 1}, {"from": "stabilize the proang", "to": "associated with", "value": 1}, {"from": "stabilize the proang", "to": "tumors", "value": 1}, {"from": "stabilize the proang", "to": "##pressed", "value": 1}, {"from": "stabilize the proang", "to": "##cpip", "value": 1}, {"from": "stabilize the proang", "to": "##bilize their mrnas.", "value": 1}, {"from": "stabilize the proang", "to": "##igan", "value": 1}, {"from": "stabilize the proang", "to": "breast", "value": 1}, {"from": "stabilize the proang", "to": "##8 ),", "value": 1}, {"from": "stabilize the proang", "to": "##ne l", "value": 1}, {"from": "stabilize the proang", "to": "##l", "value": 1}, {"from": "stabilize the proang", "to": "##cpi", "value": 1}, {"from": "stabilize the proang", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "stabilize the proang", "to": "rib", "value": 1}, {"from": "stabilize the proang", "to": "survival", "value": 1}, {"from": "in", "to": "\u0027", "value": 1}, {"from": "in", "to": "poor", "value": 1}, {"from": "in", "to": "##ta", "value": 1}, {"from": "in", "to": "##io", "value": 1}, {"from": "in", "to": "##n - 8", "value": 1}, {"from": "in", "to": "##oki", "value": 1}, {"from": "in", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "in", "to": "interacted", "value": 1}, {"from": "in", "to": "a reversed", "value": 1}, {"from": "in", "to": "associated with", "value": 1}, {"from": "in", "to": "tumors", "value": 1}, {"from": "in", "to": "##pressed", "value": 1}, {"from": "in", "to": "##cpip", "value": 1}, {"from": "in", "to": "##bilize their mrnas.", "value": 1}, {"from": "in", "to": "##igan", "value": 1}, {"from": "in", "to": "breast", "value": 3}, {"from": "in", "to": "##8 ),", "value": 1}, {"from": "in", "to": "##ne l", "value": 1}, {"from": "in", "to": "##l", "value": 1}, {"from": "in", "to": "##cpi", "value": 1}, {"from": "in", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "in", "to": "rib", "value": 1}, {"from": "in", "to": "survival", "value": 1}, {"from": "in", "to": "box l", "value": 1}, {"from": "in", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "in", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "in", "to": "of medical sciences, c.", "value": 1}, {"from": "in", "to": "these two conditions which", "value": 1}, {"from": "in", "to": "box", "value": 1}, {"from": "in", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "in", "to": "sciences", "value": 2}, {"from": "in", "to": "care", "value": 1}, {"from": "in", "to": "##ra", "value": 1}, {"from": "in", "to": "00", "value": 1}, {"from": "in", "to": "233, ghana.", "value": 1}, {"from": "in", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "in", "to": "##g 77, a", "value": 1}, {"from": "in", "to": "5", "value": 3}, {"from": "in", "to": "k", "value": 1}, {"from": "in", "to": ") west african genetic medicine centre", "value": 1}, {"from": "in", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "in", "to": "of health", "value": 1}, {"from": "in", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "in", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "in", "to": "been observed", "value": 1}, {"from": "in", "to": "school", "value": 1}, {"from": "in", "to": ", university of ghana, p. o.", "value": 1}, {"from": "in", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "in", "to": "between", "value": 1}, {"from": "in", "to": "of anaesthesia and intensive", "value": 1}, {"from": "in", "to": "##233, ghana.", "value": 1}, {"from": "in", "to": "incidence", "value": 1}, {"from": "in", "to": "4", "value": 3}, {"from": "in", "to": "cancer and ad", "value": 1}, {"from": "in", "to": "were formerly", "value": 1}, {"from": "in", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "in", "to": ")", "value": 3}, {"from": "in", "to": "has", "value": 2}, {"from": "in", "to": "department", "value": 1}, {"from": "in", "to": "inverse relationship between", "value": 1}, {"from": "in", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "in", "to": "##cc", "value": 1}, {"from": "in", "to": "risk", "value": 1}, {"from": "in", "to": "of cancer development while", "value": 1}, {"from": "in", "to": ":", "value": 4}, {"from": "in", "to": "reduced", "value": 1}, {"from": "in", "to": "##1 / acsomega. 4", "value": 1}, {"from": "in", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "in", "to": "40", "value": 1}, {"from": "in", "to": "##ve", "value": 1}, {"from": "in", "to": "##re", "value": 1}, {"from": "in", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "in", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "in", "to": "10. 102", "value": 1}, {"from": "in", "to": "##er and 5 genes down", "value": 1}, {"from": "in", "to": "upre", "value": 1}, {"from": "in", "to": "were downregulated", "value": 1}, {"from": "in", "to": "doi", "value": 4}, {"from": "in", "to": "pm", "value": 1}, {"from": "in", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "in", "to": "##ida", "value": 1}, {"from": "in", "to": "##gulated", "value": 1}, {"from": "in", "to": "play an important role in", "value": 1}, {"from": "in", "to": "##12059893", "value": 1}, {"from": "in", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "in", "to": "##c", "value": 2}, {"from": "in", "to": "in all three cancers and may", "value": 1}, {"from": "in", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "in", "to": "##11571 pmcid : pm", "value": 1}, {"from": "in", "to": "##id :", "value": 1}, {"from": "in", "to": "2 - positive", "value": 1}, {"from": "in", "to": "changes in the promoter region", "value": 1}, {"from": "in", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "in", "to": "##rta", "value": 2}, {"from": "in", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "in", "to": "receptor", "value": 1}, {"from": "in", "to": "is an", "value": 1}, {"from": "in", "to": "##type", "value": 3}, {"from": "in", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "in", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "in", "to": "- negative breast cancer", "value": 1}, {"from": "in", "to": "and", "value": 4}, {"from": "in", "to": "##esi", "value": 3}, {"from": "in", "to": "##a, jaka", "value": 2}, {"from": "in", "to": "lead", "value": 1}, {"from": "in", "to": "j", "value": 3}, {"from": "in", "to": "triple", "value": 1}, {"from": "in", "to": "of medicine, universitas indon", "value": 2}, {"from": "in", "to": "cilities - imeri,", "value": 1}, {"from": "in", "to": "##a. breast cancer sub", "value": 1}, {"from": "in", "to": "##umi", "value": 3}, {"from": "in", "to": "##a.", "value": 3}, {"from": "in", "to": "##ivers", "value": 1}, {"from": "in", "to": "faculty", "value": 5}, {"from": "in", "to": "to misclassification. dna methylation", "value": 1}, {"from": "in", "to": "##s", "value": 1}, {"from": "in", "to": "##don", "value": 3}, {"from": "in", "to": "##aka", "value": 2}, {"from": "in", "to": "un", "value": 1}, {"from": "in", "to": "##nal a, l", "value": 1}, {"from": "in", "to": "indonesi", "value": 1}, {"from": "in", "to": "##itas indonesia", "value": 1}, {"from": "in", "to": "epigenetic modification,", "value": 1}, {"from": "in", "to": "of medicine,", "value": 1}, {"from": "in", "to": "classification of breast cancer : l", "value": 1}, {"from": "in", "to": ", h", "value": 1}, {"from": "in", "to": "##methylation", "value": 1}, {"from": "in", "to": "tion", "value": 1}, {"from": "in", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "in", "to": "the pt", "value": 1}, {"from": "in", "to": ". \u00a9 202", "value": 1}, {"from": "in", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "in", "to": "##rn2 gene", "value": 1}, {"from": "in", "to": "##nal", "value": 1}, {"from": "in", "to": "##261 ), and tnbc", "value": 1}, {"from": "in", "to": "##p", "value": 1}, {"from": "in", "to": "the author", "value": 1}, {"from": "in", "to": "b", "value": 3}, {"from": "in", "to": "bio", "value": 2}, {"from": "in", "to": "respectively", "value": 2}, {"from": "in", "to": ".", "value": 7}, {"from": "in", "to": "##marker for each sub", "value": 1}, {"from": "in", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "in", "to": "##yper", "value": 1}, {"from": "in", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "in", "to": "improve", "value": 1}, {"from": "in", "to": "##10", "value": 1}, {"from": "in", "to": "##5", "value": 2}, {"from": "in", "to": "##nal a", "value": 1}, {"from": "in", "to": "52", "value": 2}, {"from": "in", "to": "), hashim", "value": 1}, {"from": "in", "to": "of medicine, univers", "value": 2}, {"from": "in", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "in", "to": ") drug development research cluster, indon", "value": 1}, {"from": "in", "to": "##an medical", "value": 1}, {"from": "in", "to": "indon", "value": 1}, {"from": "in", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "in", "to": "##hibit", "value": 1}, {"from": "in", "to": "na", "value": 1}, {"from": "in", "to": "master program in biomedical", "value": 1}, {"from": "in", "to": "education", "value": 1}, {"from": "in", "to": "n", "value": 1}, {"from": "in", "to": "3", "value": 1}, {"from": "in", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "in", "to": "##ajrin", "value": 1}, {"from": "in", "to": "), azizah", "value": 1}, {"from": "in", "to": "te", "value": 1}, {"from": "in", "to": "##djo a", "value": 1}, {"from": "in", "to": "##itas", "value": 1}, {"from": "in", "to": "##b", "value": 2}, {"from": "in", "to": "1", "value": 1}, {"from": "in", "to": "am", "value": 1}, {"from": "in", "to": "nn", "value": 1}, {"from": "in", "to": "of pharmacy, univers", "value": 2}, {"from": "in", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "in", "to": "##a,", "value": 1}, {"from": "in", "to": ", indon", "value": 1}, {"from": "in", "to": "and research instit", "value": 1}, {"from": "in", "to": "), ramadanti", "value": 1}, {"from": "in", "to": "quantitative pcr", "value": 1}, {"from": "in", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "in", "to": "time", "value": 2}, {"from": "in", "to": "##sia", "value": 1}, {"from": "in", "to": "regulating the cell", "value": 1}, {"from": "in", "to": "ute,", "value": 1}, {"from": "in", "to": "##poptosis", "value": 1}, {"from": "in", "to": "##cence, making it", "value": 1}, {"from": "in", "to": "##itas in", "value": 1}, {"from": "in", "to": "proliferation", "value": 1}, {"from": "in", "to": "and se", "value": 1}, {"from": "in", "to": "a", "value": 2}, {"from": "in", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "in", "to": "target", "value": 1}, {"from": "in", "to": "##nes", "value": 2}, {"from": "in", "to": "##50 value", "value": 1}, {"from": "in", "to": "role in", "value": 1}, {"from": "in", "to": "real", "value": 2}, {"from": "in", "to": ". the p53 signaling pathway", "value": 1}, {"from": "in", "to": ", a", "value": 2}, {"from": "in", "to": "key", "value": 1}, {"from": "in", "to": ", and", "value": 1}, {"from": "in", "to": "plays", "value": 1}, {"from": "in", "to": "a critical", "value": 1}, {"from": "in", "to": "cycle", "value": 1}, {"from": "in", "to": "of downstream genes linked to cell", "value": 1}, {"from": "in", "to": "##a, jakarta,", "value": 1}, {"from": "in", "to": "##iti", "value": 1}, {"from": "in", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "in", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "in", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "in", "to": "expression", "value": 3}, {"from": "in", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "in", "to": "on the", "value": 1}, {"from": "in", "to": "##ia", "value": 2}, {"from": "in", "to": "senes", "value": 1}, {"from": "in", "to": "prescribed chole", "value": 1}, {"from": "in", "to": "has recently", "value": 1}, {"from": "in", "to": "and its biological functions", "value": 1}, {"from": "in", "to": "of saida, saida, algeria.", "value": 1}, {"from": "in", "to": "shown", "value": 1}, {"from": "in", "to": "however", "value": 2}, {"from": "in", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "in", "to": "shown potential anti", "value": 1}, {"from": "in", "to": "genes", "value": 2}, {"from": "in", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "in", "to": "##in", "value": 1}, {"from": "in", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "in", "to": "particular breast cancer,", "value": 1}, {"from": "in", "to": "still", "value": 1}, {"from": "in", "to": "associated with atorvas", "value": 1}, {"from": "in", "to": "in breast", "value": 1}, {"from": "in", "to": "lowering", "value": 1}, {"from": "in", "to": "to be responsive to", "value": 1}, {"from": "in", "to": "interaction", "value": 2}, {"from": "in", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "in", "to": ") network and", "value": 1}, {"from": "in", "to": "in the protein - protein", "value": 1}, {"from": "in", "to": "drug,", "value": 1}, {"from": "in", "to": "##gu", "value": 1}, {"from": "in", "to": "hub gene", "value": 1}, {"from": "in", "to": ", its influence on gene", "value": 1}, {"from": "in", "to": "##lated", "value": 1}, {"from": "in", "to": "was", "value": 2}, {"from": "in", "to": "##in,", "value": 1}, {"from": "in", "to": "ppi", "value": 1}, {"from": "in", "to": "##oto", "value": 1}, {"from": "in", "to": "##tat", "value": 1}, {"from": "in", "to": "related pathways", "value": 1}, {"from": "in", "to": "cancer,", "value": 1}, {"from": "in", "to": "expressed", "value": 1}, {"from": "in", "to": "jun", "value": 1}, {"from": "in", "to": "##cer effects.", "value": 1}, {"from": "in", "to": "widely", "value": 1}, {"from": "in", "to": "atorvas", "value": 1}, {"from": "in", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "in", "to": "##ster", "value": 1}, {"from": "in", "to": "##ol", "value": 1}, {"from": "in", "to": "##can", "value": 2}, {"from": "in", "to": "cancer. atorvas", "value": 1}, {"from": "in", "to": "was identified as the", "value": 1}, {"from": "in", "to": "), and the top", "value": 1}, {"from": "in", "to": "##0", "value": 1}, {"from": "in", "to": "), a parp", "value": 1}, {"from": "in", "to": "##point blockade", "value": 1}, {"from": "in", "to": "etop", "value": 1}, {"from": "in", "to": "##ide - on", "value": 1}, {"from": "in", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "in", "to": "##ide, a top", "value": 1}, {"from": "in", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "in", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "in", "to": "##ase ii", "value": 1}, {"from": "in", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "in", "to": "interfer", "value": 1}, {"from": "in", "to": "fails", "value": 1}, {"from": "in", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "in", "to": "type", "value": 1}, {"from": "in", "to": "if", "value": 2}, {"from": "in", "to": "##fi", "value": 1}, {"from": "in", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "in", "to": "##oisomer", "value": 1}, {"from": "in", "to": "##n ) signaling, with etop", "value": 1}, {"from": "in", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "in", "to": "to encourage immune effector cell in", "value": 1}, {"from": "in", "to": "does", "value": 1}, {"from": "in", "to": "##ltration into tumors, and", "value": 1}, {"from": "in", "to": "##on - stimulated gene", "value": 1}, {"from": "in", "to": "check", "value": 1}, {"from": "in", "to": "##on", "value": 1}, {"from": "in", "to": "inhibitor", "value": 1}, {"from": "in", "to": "), huarte m", "value": 1}, {"from": "in", "to": "12", "value": 2}, {"from": "in", "to": "##407.", "value": 1}, {"from": "in", "to": "), par", "value": 1}, {"from": "in", "to": "ins", "value": 1}, {"from": "in", "to": "##or", "value": 1}, {"from": "in", "to": "##e", "value": 1}, {"from": "in", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "in", "to": "9", "value": 1}, {"from": "in", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "in", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "in", "to": "), aragon s", "value": 1}, {"from": "in", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "in", "to": "##ory", "value": 1}, {"from": "in", "to": "), gimenez j", "value": 1}, {"from": "in", "to": "- lopez i", "value": 1}, {"from": "in", "to": "##rine", "value": 1}, {"from": "in", "to": "er + / her2 -", "value": 1}, {"from": "in", "to": "102", "value": 2}, {"from": "in", "to": "), prat a", "value": 1}, {"from": "in", "to": "research", "value": 1}, {"from": "in", "to": "##e. lg is /", "value": 1}, {"from": "in", "to": "), buch e", "value": 1}, {"from": "in", "to": "##roga v", "value": 1}, {"from": "in", "to": "been holding research", "value": 1}, {"from": "in", "to": "11", "value": 1}, {"from": "in", "to": "101", "value": 1}, {"from": "in", "to": "##riaga k", "value": 1}, {"from": "in", "to": "), etxabe i", "value": 1}, {"from": "in", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "in", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "in", "to": "13", "value": 2}, {"from": "in", "to": "therapy", "value": 1}, {"from": "in", "to": "##ui", "value": 1}, {"from": "in", "to": "##ez", "value": 1}, {"from": "in", "to": "##vita", "value": 1}, {"from": "in", "to": "contracts", "value": 1}, {"from": "in", "to": "6", "value": 1}, {"from": "in", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "in", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "in", "to": "). author information :", "value": 1}, {"from": "in", "to": "), urruticoechea a", "value": 1}, {"from": "in", "to": "after net", "value": 1}, {"from": "in", "to": "a significant", "value": 1}, {"from": "in", "to": "offers the opportunity of", "value": 1}, {"from": "in", "to": "##ip", "value": 1}, {"from": "in", "to": "t", "value": 3}, {"from": "in", "to": ") health", "value": 1}, {"from": "in", "to": "background", "value": 1}, {"from": "in", "to": "##re population of", "value": 1}, {"from": "in", "to": "negative breast", "value": 1}, {"from": "in", "to": "barrier", "value": 1}, {"from": "in", "to": "##gipuzkoa", "value": 1}, {"from": "in", "to": "clinical", "value": 1}, {"from": "in", "to": "##2 -", "value": 2}, {"from": "in", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "in", "to": "##zkoa", "value": 1}, {"from": "in", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "in", "to": "##gi", "value": 1}, {"from": "in", "to": "##donostia ) health", "value": 1}, {"from": "in", "to": "##tian,", "value": 1}, {"from": "in", "to": "cancer", "value": 2}, {"from": "in", "to": "spain", "value": 1}, {"from": "in", "to": "##uzkoa. eus.", "value": 1}, {"from": "in", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "in", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "in", "to": "personal", "value": 1}, {"from": "in", "to": "##ised therapy.", "value": 1}, {"from": "in", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "in", "to": "##donost", "value": 1}, {"from": "in", "to": "##cent", "value": 1}, {"from": "in", "to": "research institute", "value": 1}, {"from": "in", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "in", "to": "sa", "value": 1}, {"from": "in", "to": "sebas", "value": 1}, {"from": "in", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "in", "to": "her", "value": 2}, {"from": "in", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "in", "to": "##n sebastian,", "value": 1}, {"from": "in", "to": "##umour response", "value": 1}, {"from": "in", "to": "a,", "value": 1}, {"from": "in", "to": "##pu", "value": 1}, {"from": "in", "to": "##n", "value": 1}, {"from": "in", "to": "sebastian", "value": 1}, {"from": "in", "to": "##uc", "value": 1}, {"from": "in", "to": ", the lack of reprod", "value": 1}, {"from": "in", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "in", "to": "##c ) allows", "value": 1}, {"from": "in", "to": "##gnosis", "value": 1}, {"from": "in", "to": "- g", "value": 1}, {"from": "in", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "in", "to": "in ki", "value": 1}, {"from": "in", "to": "##cu", "value": 1}, {"from": "in", "to": "index", "value": 1}, {"from": "in", "to": "positive", "value": 1}, {"from": "in", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "in", "to": "##rrence", "value": 1}, {"from": "in", "to": "percentage", "value": 1}, {"from": "in", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "in", "to": "##i", "value": 1}, {"from": "in", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "in", "to": "from l", "value": 1}, {"from": "in", "to": "presented", "value": 1}, {"from": "in", "to": "re", "value": 1}, {"from": "in", "to": "results", "value": 2}, {"from": "in", "to": "pam50 - derived risk of", "value": 1}, {"from": "in", "to": "er + /", "value": 1}, {"from": "in", "to": "##nal a to normal - like", "value": 1}, {"from": "in", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "in", "to": "cells", "value": 1}, {"from": "in", "to": "score", "value": 1}, {"from": "in", "to": "change", "value": 1}, {"from": "in", "to": "after", "value": 1}, {"from": "in", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "in", "to": "of intrinsic sub", "value": 1}, {"from": "in", "to": "p53", "value": 1}, {"from": "in", "to": "##is.", "value": 1}, {"from": "in", "to": "biomark", "value": 1}, {"from": "in", "to": "subtype after", "value": 1}, {"from": "in", "to": "net", "value": 1}, {"from": "in", "to": "of", "value": 1}, {"from": "in", "to": "##c patients", "value": 1}, {"from": "in", "to": "net as a putative", "value": 1}, {"from": "in", "to": "##umour cellularity size", "value": 1}, {"from": "in", "to": "radio", "value": 1}, {"from": "in", "to": ") and lower", "value": 1}, {"from": "in", "to": "better", "value": 1}, {"from": "in", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "in", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "in", "to": "##6 /", "value": 1}, {"from": "in", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "in", "to": "be validated in independent cohorts,", "value": 1}, {"from": "in", "to": "cost - effectiveness", "value": 1}, {"from": "in", "to": "##ers of response to net and pro", "value": 1}, {"from": "in", "to": "10. 101", "value": 1}, {"from": "in", "to": "help", "value": 1}, {"from": "in", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "in", "to": "##sis, which", "value": 1}, {"from": "in", "to": "##gno", "value": 1}, {"from": "in", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "in", "to": "##lin", "value": 1}, {"from": "in", "to": "should", "value": 1}, {"from": "in", "to": "202", "value": 1}, {"from": "in", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "in", "to": "helping to the", "value": 1}, {"from": "in", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "in", "to": "implementation of net", "value": 1}, {"from": "in", "to": "##mark", "value": 1}, {"from": "in", "to": "##ranon.", "value": 1}, {"from": "in", "to": ". clbc. 202", "value": 1}, {"from": "in", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "in", "to": "##5.", "value": 1}, {"from": "in", "to": "the", "value": 1}, {"from": "in", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "in", "to": "methods", "value": 1}, {"from": "in", "to": "hormone receptor positive", "value": 1}, {"from": "in", "to": "societal perspective", "value": 2}, {"from": "in", "to": "benefits", "value": 1}, {"from": "in", "to": "surgery", "value": 1}, {"from": "in", "to": "cost -", "value": 1}, {"from": "in", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "in", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "in", "to": "decision", "value": 1}, {"from": "in", "to": "to aid adjuvant treatment", "value": 1}, {"from": "in", "to": "##al", "value": 1}, {"from": "in", "to": "emit - 1 trial", "value": 1}, {"from": "in", "to": "post", "value": 1}, {"from": "in", "to": ". materials", "value": 1}, {"from": "in", "to": "model was", "value": 1}, {"from": "in", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "in", "to": "used", "value": 1}, {"from": "in", "to": "institute", "value": 1}, {"from": "in", "to": "treatment", "value": 1}, {"from": "in", "to": ": the", "value": 1}, {"from": "in", "to": "ki - 67", "value": 1}, {"from": "in", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "in", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "in", "to": "prosigna was tested", "value": 1}, {"from": "in", "to": "prospective", "value": 1}, {"from": "in", "to": "were measured", "value": 1}, {"from": "in", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "in", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "in", "to": "observation", "value": 1}, {"from": "in", "to": "division", "value": 1}, {"from": "in", "to": "decisions in", "value": 1}, {"from": "in", "to": "built", "value": 1}, {"from": "in", "to": "impact of", "value": 1}, {"from": "in", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "in", "to": "benefit", "value": 1}, {"from": "in", "to": "##26, 000 ;", "value": 1}, {"from": "in", "to": "effective", "value": 1}, {"from": "in", "to": "it was cost - saving", "value": 1}, {"from": "in", "to": "threshold", "value": 1}, {"from": "in", "to": "- 435, 677 )", "value": 1}, {"from": "in", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "in", "to": "##aly", "value": 1}, {"from": "in", "to": "in the", "value": 2}, {"from": "in", "to": "cost", "value": 1}, {"from": "in", "to": "\u20ac", "value": 1}, {"from": "in", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "in", "to": "- 620170,", "value": 1}, {"from": "in", "to": "##r )", "value": 1}, {"from": "in", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "in", "to": "candidates, the strategy", "value": 1}, {"from": "in", "to": "cost - effective", "value": 1}, {"from": "in", "to": "incre", "value": 1}, {"from": "in", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "in", "to": "by", "value": 1}, {"from": "in", "to": "##mental", "value": 1}, {"from": "in", "to": "the cost -", "value": 1}, {"from": "in", "to": "was cost - effective", "value": 1}, {"from": "in", "to": "above", "value": 1}, {"from": "in", "to": "was obtained from statistics norway.", "value": 1}, {"from": "in", "to": "per quality - adjusted life -", "value": 1}, {"from": "in", "to": "was cost - saving", "value": 1}, {"from": "in", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "in", "to": "chemotherapy", "value": 1}, {"from": "in", "to": "in both the healthcare", "value": 1}, {"from": "in", "to": "years", "value": 1}, {"from": "in", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "in", "to": "- per q", "value": 1}, {"from": "in", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "in", "to": ". conclusions", "value": 1}, {"from": "in", "to": ". selecting patient", "value": 1}, {"from": "in", "to": "ice", "value": 1}, {"from": "in", "to": "##r", "value": 1}, {"from": "in", "to": "##8884 and", "value": 1}, {"from": "in", "to": "gained", "value": 1}, {"from": "in", "to": "the emit", "value": 1}, {"from": "in", "to": "records. including all pn0 patients", "value": 1}, {"from": "in", "to": "sector", "value": 1}, {"from": "in", "to": "not", "value": 1}, {"from": "in", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "in", "to": "##ifer", "value": 1}, {"from": "in", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "in", "to": "##ne - c", "value": 1}, {"from": "in", "to": ", tnf signaling", "value": 1}, {"from": "in", "to": ", which", "value": 1}, {"from": "in", "to": "down - regulated", "value": 1}, {"from": "in", "to": "including c", "value": 1}, {"from": "in", "to": "##ytoki", "value": 1}, {"from": "in", "to": "detected", "value": 1}, {"from": "in", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "in", "to": "vs", "value": 1}, {"from": "in", "to": "##cer assays. the", "value": 1}, {"from": "in", "to": "or", "value": 1}, {"from": "in", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "in", "to": "##ne receptor", "value": 1}, {"from": "in", "to": "##ap", "value": 1}, {"from": "in", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "in", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "in", "to": "via", "value": 1}, {"from": "in", "to": "anti", "value": 1}, {"from": "in", "to": "##n - \u03b3", "value": 1}, {"from": "in", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "in", "to": "f biotechnology engineering,", "value": 1}, {"from": "in", "to": "were up -", "value": 1}, {"from": "in", "to": ", nod - like receptor signaling", "value": 1}, {"from": "in", "to": "##ation, pro", "value": 1}, {"from": "in", "to": "pathways", "value": 1}, {"from": "in", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "in", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "in", "to": "pathway", "value": 1}, {"from": "in", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "\u0027", "to": "poor", "value": 1}, {"from": "\u0027", "to": "##ta", "value": 1}, {"from": "\u0027", "to": "##io", "value": 1}, {"from": "\u0027", "to": "##n - 8", "value": 1}, {"from": "\u0027", "to": "##oki", "value": 1}, {"from": "\u0027", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "\u0027", "to": "interacted", "value": 1}, {"from": "\u0027", "to": "a reversed", "value": 1}, {"from": "\u0027", "to": "associated with", "value": 1}, {"from": "\u0027", "to": "tumors", "value": 1}, {"from": "\u0027", "to": "##pressed", "value": 1}, {"from": "\u0027", "to": "##cpip", "value": 1}, {"from": "\u0027", "to": "##bilize their mrnas.", "value": 1}, {"from": "\u0027", "to": "##igan", "value": 1}, {"from": "\u0027", "to": "breast", "value": 1}, {"from": "\u0027", "to": "##8 ),", "value": 1}, {"from": "\u0027", "to": "##ne l", "value": 1}, {"from": "\u0027", "to": "##l", "value": 1}, {"from": "\u0027", "to": "##cpi", "value": 1}, {"from": "\u0027", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "\u0027", "to": "rib", "value": 1}, {"from": "\u0027", "to": "survival", "value": 1}, {"from": "poor", "to": "##ta", "value": 1}, {"from": "poor", "to": "##io", "value": 1}, {"from": "poor", "to": "##n - 8", "value": 1}, {"from": "poor", "to": "##oki", "value": 1}, {"from": "poor", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "poor", "to": "interacted", "value": 1}, {"from": "poor", "to": "a reversed", "value": 1}, {"from": "poor", "to": "associated with", "value": 1}, {"from": "poor", "to": "tumors", "value": 1}, {"from": "poor", "to": "##pressed", "value": 1}, {"from": "poor", "to": "##cpip", "value": 1}, {"from": "poor", "to": "##bilize their mrnas.", "value": 1}, {"from": "poor", "to": "##igan", "value": 1}, {"from": "poor", "to": "breast", "value": 1}, {"from": "poor", "to": "##8 ),", "value": 1}, {"from": "poor", "to": "##ne l", "value": 1}, {"from": "poor", "to": "##l", "value": 1}, {"from": "poor", "to": "##cpi", "value": 1}, {"from": "poor", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "poor", "to": "rib", "value": 1}, {"from": "poor", "to": "survival", "value": 1}, {"from": "##ta", "to": "##io", "value": 1}, {"from": "##ta", "to": "##n - 8", "value": 1}, {"from": "##ta", "to": "##oki", "value": 1}, {"from": "##ta", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##ta", "to": "interacted", "value": 1}, {"from": "##ta", "to": "a reversed", "value": 1}, {"from": "##ta", "to": "associated with", "value": 1}, {"from": "##ta", "to": "tumors", "value": 1}, {"from": "##ta", "to": "##pressed", "value": 1}, {"from": "##ta", "to": "##cpip", "value": 1}, {"from": "##ta", "to": "##bilize their mrnas.", "value": 1}, {"from": "##ta", "to": "##igan", "value": 1}, {"from": "##ta", "to": "breast", "value": 1}, {"from": "##ta", "to": "##8 ),", "value": 1}, {"from": "##ta", "to": "##ne l", "value": 1}, {"from": "##ta", "to": "##l", "value": 1}, {"from": "##ta", "to": "##cpi", "value": 1}, {"from": "##ta", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##ta", "to": "rib", "value": 1}, {"from": "##ta", "to": "survival", "value": 1}, {"from": "##ta", "to": ") department of", "value": 1}, {"from": "##ta", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "##ta", "to": "for cancer", "value": 1}, {"from": "##ta", "to": "##lia", "value": 1}, {"from": "##ta", "to": "##vanger,", "value": 1}, {"from": "##ta", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "##ta", "to": "9", "value": 1}, {"from": "##ta", "to": "##vanger university, s", "value": 1}, {"from": "##ta", "to": "8", "value": 1}, {"from": "##ta", "to": "of cancer genetics,", "value": 1}, {"from": "##ta", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "##ta", "to": "12 ) department", "value": 1}, {"from": "##ta", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "##ta", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "##ta", "to": "##vanger university hospital, s", "value": 1}, {"from": "##ta", "to": "ha", "value": 1}, {"from": "##ta", "to": "norway", "value": 1}, {"from": "##ta", "to": "institute", "value": 1}, {"from": "##ta", "to": "research", "value": 1}, {"from": "##ta", "to": ".", "value": 1}, {"from": "##ta", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##ta", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##ta", "to": "of pathology, s", "value": 1}, {"from": "##ta", "to": ";", "value": 1}, {"from": "##ta", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##ta", "to": "11", "value": 1}, {"from": "##ta", "to": "13", "value": 1}, {"from": "##ta", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##ta", "to": "6", "value": 1}, {"from": "##ta", "to": ")", "value": 1}, {"from": "##ta", "to": "department", "value": 1}, {"from": "##ta", "to": "##way", "value": 1}, {"from": "##io", "to": "##n - 8", "value": 1}, {"from": "##io", "to": "##oki", "value": 1}, {"from": "##io", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##io", "to": "interacted", "value": 1}, {"from": "##io", "to": "a reversed", "value": 1}, {"from": "##io", "to": "associated with", "value": 1}, {"from": "##io", "to": "tumors", "value": 1}, {"from": "##io", "to": "##pressed", "value": 1}, {"from": "##io", "to": "##cpip", "value": 1}, {"from": "##io", "to": "##bilize their mrnas.", "value": 1}, {"from": "##io", "to": "##igan", "value": 1}, {"from": "##io", "to": "breast", "value": 1}, {"from": "##io", "to": "##8 ),", "value": 1}, {"from": "##io", "to": "##ne l", "value": 1}, {"from": "##io", "to": "##l", "value": 1}, {"from": "##io", "to": "##cpi", "value": 1}, {"from": "##io", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##io", "to": "rib", "value": 1}, {"from": "##io", "to": "survival", "value": 1}, {"from": "##n - 8", "to": "##oki", "value": 1}, {"from": "##n - 8", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##n - 8", "to": "interacted", "value": 1}, {"from": "##n - 8", "to": "a reversed", "value": 1}, {"from": "##n - 8", "to": "associated with", "value": 1}, {"from": "##n - 8", "to": "tumors", "value": 1}, {"from": "##n - 8", "to": "##pressed", "value": 1}, {"from": "##n - 8", "to": "##cpip", "value": 1}, {"from": "##n - 8", "to": "##bilize their mrnas.", "value": 1}, {"from": "##n - 8", "to": "##igan", "value": 1}, {"from": "##n - 8", "to": "breast", "value": 1}, {"from": "##n - 8", "to": "##8 ),", "value": 1}, {"from": "##n - 8", "to": "##ne l", "value": 1}, {"from": "##n - 8", "to": "##l", "value": 1}, {"from": "##n - 8", "to": "##cpi", "value": 1}, {"from": "##n - 8", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##n - 8", "to": "rib", "value": 1}, {"from": "##n - 8", "to": "survival", "value": 1}, {"from": "##oki", "to": "##1 ), and ephrin a1", "value": 1}, {"from": "##oki", "to": "interacted", "value": 1}, {"from": "##oki", "to": "a reversed", "value": 1}, {"from": "##oki", "to": "associated with", "value": 1}, {"from": "##oki", "to": "tumors", "value": 1}, {"from": "##oki", "to": "##pressed", "value": 1}, {"from": "##oki", "to": "##cpip", "value": 1}, {"from": "##oki", "to": "##bilize their mrnas.", "value": 1}, {"from": "##oki", "to": "##igan", "value": 1}, {"from": "##oki", "to": "breast", "value": 1}, {"from": "##oki", "to": "##8 ),", "value": 1}, {"from": "##oki", "to": "##ne l", "value": 1}, {"from": "##oki", "to": "##l", "value": 1}, {"from": "##oki", "to": "##cpi", "value": 1}, {"from": "##oki", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##oki", "to": "rib", "value": 1}, {"from": "##oki", "to": "survival", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "interacted", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "a reversed", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "associated with", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "tumors", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##pressed", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##cpip", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##bilize their mrnas.", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##igan", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "breast", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##8 ),", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##ne l", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##l", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##cpi", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "rib", "value": 1}, {"from": "##1 ), and ephrin a1", "to": "survival", "value": 1}, {"from": "interacted", "to": "a reversed", "value": 1}, {"from": "interacted", "to": "associated with", "value": 1}, {"from": "interacted", "to": "tumors", "value": 1}, {"from": "interacted", "to": "##pressed", "value": 1}, {"from": "interacted", "to": "##cpip", "value": 1}, {"from": "interacted", "to": "##bilize their mrnas.", "value": 1}, {"from": "interacted", "to": "##igan", "value": 1}, {"from": "interacted", "to": "breast", "value": 1}, {"from": "interacted", "to": "##8 ),", "value": 1}, {"from": "interacted", "to": "##ne l", "value": 1}, {"from": "interacted", "to": "##l", "value": 1}, {"from": "interacted", "to": "##cpi", "value": 1}, {"from": "interacted", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "interacted", "to": "rib", "value": 1}, {"from": "interacted", "to": "survival", "value": 1}, {"from": "a reversed", "to": "associated with", "value": 1}, {"from": "a reversed", "to": "tumors", "value": 1}, {"from": "a reversed", "to": "##pressed", "value": 1}, {"from": "a reversed", "to": "##cpip", "value": 1}, {"from": "a reversed", "to": "##bilize their mrnas.", "value": 1}, {"from": "a reversed", "to": "##igan", "value": 1}, {"from": "a reversed", "to": "breast", "value": 1}, {"from": "a reversed", "to": "##8 ),", "value": 1}, {"from": "a reversed", "to": "##ne l", "value": 1}, {"from": "a reversed", "to": "##l", "value": 1}, {"from": "a reversed", "to": "##cpi", "value": 1}, {"from": "a reversed", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "a reversed", "to": "rib", "value": 1}, {"from": "a reversed", "to": "survival", "value": 1}, {"from": "associated with", "to": "tumors", "value": 1}, {"from": "associated with", "to": "##pressed", "value": 1}, {"from": "associated with", "to": "##cpip", "value": 1}, {"from": "associated with", "to": "##bilize their mrnas.", "value": 1}, {"from": "associated with", "to": "##igan", "value": 1}, {"from": "associated with", "to": "breast", "value": 1}, {"from": "associated with", "to": "##8 ),", "value": 1}, {"from": "associated with", "to": "##ne l", "value": 1}, {"from": "associated with", "to": "##l", "value": 1}, {"from": "associated with", "to": "##cpi", "value": 1}, {"from": "associated with", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "associated with", "to": "rib", "value": 1}, {"from": "associated with", "to": "survival", "value": 1}, {"from": "tumors", "to": "##pressed", "value": 1}, {"from": "tumors", "to": "##cpip", "value": 1}, {"from": "tumors", "to": "##bilize their mrnas.", "value": 1}, {"from": "tumors", "to": "##igan", "value": 1}, {"from": "tumors", "to": "breast", "value": 1}, {"from": "tumors", "to": "##8 ),", "value": 1}, {"from": "tumors", "to": "##ne l", "value": 1}, {"from": "tumors", "to": "##l", "value": 1}, {"from": "tumors", "to": "##cpi", "value": 1}, {"from": "tumors", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "tumors", "to": "rib", "value": 1}, {"from": "tumors", "to": "survival", "value": 1}, {"from": "##pressed", "to": "##cpip", "value": 1}, {"from": "##pressed", "to": "##bilize their mrnas.", "value": 1}, {"from": "##pressed", "to": "##igan", "value": 1}, {"from": "##pressed", "to": "breast", "value": 1}, {"from": "##pressed", "to": "##8 ),", "value": 1}, {"from": "##pressed", "to": "##ne l", "value": 1}, {"from": "##pressed", "to": "##l", "value": 1}, {"from": "##pressed", "to": "##cpi", "value": 1}, {"from": "##pressed", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##pressed", "to": "rib", "value": 1}, {"from": "##pressed", "to": "survival", "value": 1}, {"from": "##cpip", "to": "##bilize their mrnas.", "value": 1}, {"from": "##cpip", "to": "##igan", "value": 1}, {"from": "##cpip", "to": "breast", "value": 1}, {"from": "##cpip", "to": "##8 ),", "value": 1}, {"from": "##cpip", "to": "##ne l", "value": 1}, {"from": "##cpip", "to": "##l", "value": 1}, {"from": "##cpip", "to": "##cpi", "value": 1}, {"from": "##cpip", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##cpip", "to": "rib", "value": 1}, {"from": "##cpip", "to": "survival", "value": 1}, {"from": "##bilize their mrnas.", "to": "##igan", "value": 1}, {"from": "##bilize their mrnas.", "to": "breast", "value": 1}, {"from": "##bilize their mrnas.", "to": "##8 ),", "value": 1}, {"from": "##bilize their mrnas.", "to": "##ne l", "value": 1}, {"from": "##bilize their mrnas.", "to": "##l", "value": 1}, {"from": "##bilize their mrnas.", "to": "##cpi", "value": 1}, {"from": "##bilize their mrnas.", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##bilize their mrnas.", "to": "rib", "value": 1}, {"from": "##bilize their mrnas.", "to": "survival", "value": 1}, {"from": "##igan", "to": "breast", "value": 1}, {"from": "##igan", "to": "##8 ),", "value": 1}, {"from": "##igan", "to": "##ne l", "value": 1}, {"from": "##igan", "to": "##l", "value": 1}, {"from": "##igan", "to": "##cpi", "value": 1}, {"from": "##igan", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##igan", "to": "rib", "value": 1}, {"from": "##igan", "to": "survival", "value": 1}, {"from": "breast", "to": "##8 ),", "value": 1}, {"from": "breast", "to": "##ne l", "value": 1}, {"from": "breast", "to": "##l", "value": 1}, {"from": "breast", "to": "##cpi", "value": 1}, {"from": "breast", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "breast", "to": "rib", "value": 1}, {"from": "breast", "to": "survival", "value": 1}, {"from": "breast", "to": "##t", "value": 2}, {"from": "breast", "to": "of life", "value": 1}, {"from": "breast", "to": "##k", "value": 1}, {"from": "breast", "to": ") institute for brain sciences research,", "value": 1}, {"from": "breast", "to": ":", "value": 3}, {"from": "breast", "to": "index", "value": 1}, {"from": "breast", "to": "##osu", "value": 1}, {"from": "breast", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "breast", "to": ". 1096 / fj. 202", "value": 1}, {"from": "breast", "to": "may contribute to the", "value": 1}, {"from": "breast", "to": "sciences", "value": 1}, {"from": "breast", "to": "university", "value": 1}, {"from": "breast", "to": "##lle", "value": 1}, {"from": "breast", "to": "40", "value": 1}, {"from": "breast", "to": "genes", "value": 2}, {"from": "breast", "to": "##i", "value": 1}, {"from": "breast", "to": "##f", "value": 1}, {"from": "breast", "to": "we", "value": 1}, {"from": "breast", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "breast", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "breast", "to": "3 )", "value": 1}, {"from": "breast", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "breast", "to": "##hie j", "value": 1}, {"from": "breast", "to": "k", "value": 1}, {"from": "breast", "to": "doi", "value": 3}, {"from": "breast", "to": "b", "value": 1}, {"from": "breast", "to": "102", "value": 2}, {"from": "breast", "to": "j", "value": 1}, {"from": "breast", "to": "##354028 [", "value": 1}, {"from": "breast", "to": ".", "value": 3}, {"from": "breast", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "breast", "to": "school", "value": 1}, {"from": "breast", "to": "), agegnehu sb", "value": 1}, {"from": "breast", "to": "##ra 00", "value": 1}, {"from": "breast", "to": "3 ), lamptey el", "value": 1}, {"from": "breast", "to": "1", "value": 2}, {"from": "breast", "to": "ka", "value": 1}, {"from": "breast", "to": "4", "value": 2}, {"from": "breast", "to": "of ghana, a", "value": 1}, {"from": "breast", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "breast", "to": "##461r pmid :", "value": 1}, {"from": "breast", "to": "antiangiogenic therapy of", "value": 1}, {"from": "breast", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "breast", "to": ")", "value": 1}, {"from": "breast", "to": "he", "value": 1}, {"from": "breast", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "breast", "to": "expression", "value": 1}, {"from": "breast", "to": "##500", "value": 1}, {"from": "breast", "to": "in cancer", "value": 1}, {"from": "breast", "to": "##mpo s", "value": 1}, {"from": "breast", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "breast", "to": "##cc", "value": 2}, {"from": "breast", "to": "inverse", "value": 1}, {"from": "breast", "to": "new insights into", "value": 1}, {"from": "breast", "to": "##life", "value": 1}, {"from": "breast", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "breast", "to": "##ion of p21", "value": 1}, {"from": "breast", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "breast", "to": "##in - mediated anti -", "value": 1}, {"from": "breast", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "breast", "to": "1 ), abdelkrim g", "value": 1}, {"from": "breast", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "breast", "to": "cancer effects. foda my", "value": 1}, {"from": "breast", "to": "##press", "value": 1}, {"from": "breast", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "breast", "to": "##tat", "value": 1}, {"from": "breast", "to": "faculty", "value": 2}, {"from": "breast", "to": "jun", "value": 1}, {"from": "breast", "to": "2 ), salem ml", "value": 1}, {"from": "breast", "to": "in atorvas", "value": 1}, {"from": "breast", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "breast", "to": "52", "value": 1}, {"from": "breast", "to": ": we generated isogenic atm - null models using", "value": 1}, {"from": "breast", "to": "##rates were assessed by flow c", "value": 1}, {"from": "breast", "to": ". org.", "value": 1}, {"from": "breast", "to": "regulator", "value": 1}, {"from": "breast", "to": "methods", "value": 1}, {"from": "breast", "to": ". org khana7 @ msk", "value": 1}, {"from": "breast", "to": "##yt", "value": 1}, {"from": "breast", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "breast", "to": "##ase functions,", "value": 1}, {"from": "breast", "to": "colorec", "value": 1}, {"from": "breast", "to": "are known", "value": 1}, {"from": "breast", "to": "polymer", "value": 1}, {"from": "breast", "to": "##r in murine triple -", "value": 1}, {"from": "breast", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "breast", "to": "##tal", "value": 1}, {"from": "breast", "to": "##lt", "value": 1}, {"from": "breast", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "breast", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "breast", "to": "mutated", "value": 1}, {"from": "breast", "to": "negative", "value": 1}, {"from": "breast", "to": "crisp", "value": 1}, {"from": "breast", "to": "##ometry and immunohis", "value": 1}, {"from": "breast", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "breast", "to": "##to", "value": 1}, {"from": "breast", "to": "), huarte m", "value": 1}, {"from": "breast", "to": "12", "value": 1}, {"from": "breast", "to": "##407.", "value": 1}, {"from": "breast", "to": "), par", "value": 1}, {"from": "breast", "to": "ins", "value": 1}, {"from": "breast", "to": "##or", "value": 1}, {"from": "breast", "to": "##e", "value": 1}, {"from": "breast", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "breast", "to": "9", "value": 1}, {"from": "breast", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "breast", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "breast", "to": "), aragon s", "value": 1}, {"from": "breast", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "breast", "to": "##ory", "value": 1}, {"from": "breast", "to": "5", "value": 1}, {"from": "breast", "to": "), gimenez j", "value": 1}, {"from": "breast", "to": "- lopez i", "value": 1}, {"from": "breast", "to": "##rine", "value": 1}, {"from": "breast", "to": "er + / her2 -", "value": 1}, {"from": "breast", "to": "), prat a", "value": 1}, {"from": "breast", "to": "research", "value": 1}, {"from": "breast", "to": "##e. lg is /", "value": 1}, {"from": "breast", "to": "), buch e", "value": 1}, {"from": "breast", "to": "##roga v", "value": 1}, {"from": "breast", "to": "been holding research", "value": 1}, {"from": "breast", "to": "11", "value": 1}, {"from": "breast", "to": "101", "value": 1}, {"from": "breast", "to": "##riaga k", "value": 1}, {"from": "breast", "to": "), etxabe i", "value": 1}, {"from": "breast", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "breast", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "breast", "to": "13", "value": 1}, {"from": "breast", "to": "therapy", "value": 1}, {"from": "breast", "to": "##ui", "value": 1}, {"from": "breast", "to": "##ez", "value": 1}, {"from": "breast", "to": "##vita", "value": 1}, {"from": "breast", "to": "contracts", "value": 1}, {"from": "breast", "to": "has", "value": 1}, {"from": "breast", "to": "6", "value": 1}, {"from": "breast", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "breast", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "breast", "to": "). author information :", "value": 1}, {"from": "breast", "to": "), urruticoechea a", "value": 1}, {"from": "breast", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "breast", "to": "##ifer", "value": 1}, {"from": "breast", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "breast", "to": "in the", "value": 1}, {"from": "breast", "to": "##ne - c", "value": 1}, {"from": "breast", "to": ", tnf signaling", "value": 1}, {"from": "breast", "to": ", which", "value": 1}, {"from": "breast", "to": "down - regulated", "value": 1}, {"from": "breast", "to": "including c", "value": 1}, {"from": "breast", "to": "##ytoki", "value": 1}, {"from": "breast", "to": "detected", "value": 1}, {"from": "breast", "to": "cancer", "value": 1}, {"from": "breast", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "breast", "to": "vs", "value": 1}, {"from": "breast", "to": "##cer assays. the", "value": 1}, {"from": "breast", "to": "interaction", "value": 1}, {"from": "breast", "to": "or", "value": 1}, {"from": "breast", "to": "if", "value": 1}, {"from": "breast", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "breast", "to": "##ne receptor", "value": 1}, {"from": "breast", "to": "##ap", "value": 1}, {"from": "breast", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "breast", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "breast", "to": "via", "value": 1}, {"from": "breast", "to": "anti", "value": 1}, {"from": "breast", "to": "##n - \u03b3", "value": 1}, {"from": "breast", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "breast", "to": "f biotechnology engineering,", "value": 1}, {"from": "breast", "to": "were up -", "value": 1}, {"from": "breast", "to": ", nod - like receptor signaling", "value": 1}, {"from": "breast", "to": "##ation, pro", "value": 1}, {"from": "breast", "to": "##can", "value": 1}, {"from": "breast", "to": "pathways", "value": 1}, {"from": "breast", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "breast", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "breast", "to": "pathway", "value": 1}, {"from": "breast", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##8 ),", "to": "##ne l", "value": 1}, {"from": "##8 ),", "to": "##l", "value": 1}, {"from": "##8 ),", "to": "##cpi", "value": 1}, {"from": "##8 ),", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##8 ),", "to": "rib", "value": 1}, {"from": "##8 ),", "to": "survival", "value": 1}, {"from": "##ne l", "to": "##l", "value": 1}, {"from": "##ne l", "to": "##cpi", "value": 1}, {"from": "##ne l", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##ne l", "to": "rib", "value": 1}, {"from": "##ne l", "to": "survival", "value": 1}, {"from": "##l", "to": "##cpi", "value": 1}, {"from": "##l", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##l", "to": "rib", "value": 1}, {"from": "##l", "to": "survival", "value": 1}, {"from": "##cpi", "to": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "value": 1}, {"from": "##cpi", "to": "rib", "value": 1}, {"from": "##cpi", "to": "survival", "value": 1}, {"from": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "to": "rib", "value": 1}, {"from": "##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m", "to": "survival", "value": 1}, {"from": "rib", "to": "survival", "value": 1}, {"from": "##t", "to": "of life", "value": 1}, {"from": "##t", "to": "##k", "value": 1}, {"from": "##t", "to": ") institute for brain sciences research,", "value": 1}, {"from": "##t", "to": ":", "value": 1}, {"from": "##t", "to": "index", "value": 1}, {"from": "##t", "to": "##osu", "value": 1}, {"from": "##t", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "##t", "to": ". 1096 / fj. 202", "value": 1}, {"from": "##t", "to": "may contribute to the", "value": 1}, {"from": "##t", "to": "sciences", "value": 1}, {"from": "##t", "to": "university", "value": 1}, {"from": "##t", "to": "##lle", "value": 1}, {"from": "##t", "to": "40", "value": 1}, {"from": "##t", "to": "genes", "value": 1}, {"from": "##t", "to": "##i", "value": 1}, {"from": "##t", "to": "##f", "value": 1}, {"from": "##t", "to": "we", "value": 1}, {"from": "##t", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##t", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##t", "to": "3 )", "value": 1}, {"from": "##t", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##t", "to": "##hie j", "value": 1}, {"from": "##t", "to": "k", "value": 1}, {"from": "##t", "to": "doi", "value": 1}, {"from": "##t", "to": "b", "value": 1}, {"from": "##t", "to": "102", "value": 1}, {"from": "##t", "to": "j", "value": 1}, {"from": "##t", "to": "##354028 [", "value": 1}, {"from": "##t", "to": ".", "value": 1}, {"from": "##t", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##t", "to": "school", "value": 1}, {"from": "##t", "to": "), agegnehu sb", "value": 1}, {"from": "##t", "to": "##ra 00", "value": 1}, {"from": "##t", "to": "3 ), lamptey el", "value": 1}, {"from": "##t", "to": "1", "value": 1}, {"from": "##t", "to": "ka", "value": 1}, {"from": "##t", "to": "4", "value": 1}, {"from": "##t", "to": "of ghana, a", "value": 1}, {"from": "##t", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##t", "to": "##461r pmid :", "value": 1}, {"from": "##t", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##t", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##t", "to": ")", "value": 1}, {"from": "##t", "to": "he", "value": 1}, {"from": "##t", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##t", "to": "expression", "value": 1}, {"from": "##t", "to": "##500", "value": 1}, {"from": "##t", "to": "in cancer", "value": 1}, {"from": "##t", "to": "##mpo s", "value": 1}, {"from": "##t", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##t", "to": "##cc", "value": 2}, {"from": "##t", "to": "inverse", "value": 1}, {"from": "##t", "to": "new insights into", "value": 1}, {"from": "##t", "to": ": we generated isogenic atm - null models using", "value": 1}, {"from": "##t", "to": "##rates were assessed by flow c", "value": 1}, {"from": "##t", "to": ". org.", "value": 1}, {"from": "##t", "to": "regulator", "value": 1}, {"from": "##t", "to": "methods", "value": 1}, {"from": "##t", "to": ". org khana7 @ msk", "value": 1}, {"from": "##t", "to": "##yt", "value": 1}, {"from": "##t", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "##t", "to": "##ase functions,", "value": 1}, {"from": "##t", "to": "colorec", "value": 1}, {"from": "##t", "to": "are known", "value": 1}, {"from": "##t", "to": "polymer", "value": 1}, {"from": "##t", "to": "##r in murine triple -", "value": 1}, {"from": "##t", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##t", "to": "##tal", "value": 1}, {"from": "##t", "to": "##lt", "value": 1}, {"from": "##t", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##t", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##t", "to": "mutated", "value": 1}, {"from": "##t", "to": "negative", "value": 1}, {"from": "##t", "to": "crisp", "value": 1}, {"from": "##t", "to": "##ometry and immunohis", "value": 1}, {"from": "##t", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##t", "to": "##to", "value": 1}, {"from": "of life", "to": "##k", "value": 1}, {"from": "of life", "to": ") institute for brain sciences research,", "value": 1}, {"from": "of life", "to": ":", "value": 1}, {"from": "of life", "to": "index", "value": 1}, {"from": "of life", "to": "##osu", "value": 1}, {"from": "of life", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "of life", "to": ". 1096 / fj. 202", "value": 1}, {"from": "of life", "to": "may contribute to the", "value": 1}, {"from": "of life", "to": "sciences", "value": 1}, {"from": "of life", "to": "university", "value": 1}, {"from": "of life", "to": "##lle", "value": 1}, {"from": "of life", "to": "40", "value": 1}, {"from": "of life", "to": "genes", "value": 1}, {"from": "of life", "to": "##i", "value": 1}, {"from": "of life", "to": "##f", "value": 1}, {"from": "of life", "to": "we", "value": 1}, {"from": "of life", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "of life", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "of life", "to": "3 )", "value": 1}, {"from": "of life", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "of life", "to": "##hie j", "value": 1}, {"from": "of life", "to": "k", "value": 1}, {"from": "of life", "to": "doi", "value": 1}, {"from": "of life", "to": "b", "value": 1}, {"from": "of life", "to": "102", "value": 1}, {"from": "of life", "to": "j", "value": 1}, {"from": "of life", "to": "##354028 [", "value": 1}, {"from": "of life", "to": ".", "value": 1}, {"from": "of life", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "of life", "to": "school", "value": 1}, {"from": "of life", "to": "), agegnehu sb", "value": 1}, {"from": "of life", "to": "##ra 00", "value": 1}, {"from": "of life", "to": "3 ), lamptey el", "value": 1}, {"from": "of life", "to": "1", "value": 1}, {"from": "of life", "to": "ka", "value": 1}, {"from": "of life", "to": "4", "value": 1}, {"from": "of life", "to": "of ghana, a", "value": 1}, {"from": "of life", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "of life", "to": "##461r pmid :", "value": 1}, {"from": "of life", "to": "antiangiogenic therapy of", "value": 1}, {"from": "of life", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "of life", "to": ")", "value": 1}, {"from": "of life", "to": "he", "value": 1}, {"from": "of life", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "of life", "to": "expression", "value": 1}, {"from": "of life", "to": "##500", "value": 1}, {"from": "of life", "to": "in cancer", "value": 1}, {"from": "of life", "to": "##mpo s", "value": 1}, {"from": "of life", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "of life", "to": "##cc", "value": 1}, {"from": "of life", "to": "inverse", "value": 1}, {"from": "of life", "to": "new insights into", "value": 1}, {"from": "##k", "to": ") institute for brain sciences research,", "value": 1}, {"from": "##k", "to": ":", "value": 1}, {"from": "##k", "to": "index", "value": 1}, {"from": "##k", "to": "##osu", "value": 1}, {"from": "##k", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "##k", "to": ". 1096 / fj. 202", "value": 1}, {"from": "##k", "to": "may contribute to the", "value": 1}, {"from": "##k", "to": "sciences", "value": 1}, {"from": "##k", "to": "university", "value": 1}, {"from": "##k", "to": "##lle", "value": 1}, {"from": "##k", "to": "40", "value": 1}, {"from": "##k", "to": "genes", "value": 1}, {"from": "##k", "to": "##i", "value": 1}, {"from": "##k", "to": "##f", "value": 1}, {"from": "##k", "to": "we", "value": 1}, {"from": "##k", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##k", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##k", "to": "3 )", "value": 1}, {"from": "##k", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##k", "to": "##hie j", "value": 1}, {"from": "##k", "to": "k", "value": 1}, {"from": "##k", "to": "doi", "value": 1}, {"from": "##k", "to": "b", "value": 1}, {"from": "##k", "to": "102", "value": 1}, {"from": "##k", "to": "j", "value": 1}, {"from": "##k", "to": "##354028 [", "value": 1}, {"from": "##k", "to": ".", "value": 1}, {"from": "##k", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##k", "to": "school", "value": 1}, {"from": "##k", "to": "), agegnehu sb", "value": 1}, {"from": "##k", "to": "##ra 00", "value": 1}, {"from": "##k", "to": "3 ), lamptey el", "value": 1}, {"from": "##k", "to": "1", "value": 1}, {"from": "##k", "to": "ka", "value": 1}, {"from": "##k", "to": "4", "value": 1}, {"from": "##k", "to": "of ghana, a", "value": 1}, {"from": "##k", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##k", "to": "##461r pmid :", "value": 1}, {"from": "##k", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##k", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##k", "to": ")", "value": 1}, {"from": "##k", "to": "he", "value": 1}, {"from": "##k", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##k", "to": "expression", "value": 1}, {"from": "##k", "to": "##500", "value": 1}, {"from": "##k", "to": "in cancer", "value": 1}, {"from": "##k", "to": "##mpo s", "value": 1}, {"from": "##k", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##k", "to": "##cc", "value": 1}, {"from": "##k", "to": "inverse", "value": 1}, {"from": "##k", "to": "new insights into", "value": 1}, {"from": ") institute for brain sciences research,", "to": ":", "value": 1}, {"from": ") institute for brain sciences research,", "to": "index", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##osu", "value": 1}, {"from": ") institute for brain sciences research,", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": ") institute for brain sciences research,", "to": ". 1096 / fj. 202", "value": 1}, {"from": ") institute for brain sciences research,", "to": "may contribute to the", "value": 1}, {"from": ") institute for brain sciences research,", "to": "sciences", "value": 1}, {"from": ") institute for brain sciences research,", "to": "university", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##lle", "value": 1}, {"from": ") institute for brain sciences research,", "to": "40", "value": 1}, {"from": ") institute for brain sciences research,", "to": "genes", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##i", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##f", "value": 1}, {"from": ") institute for brain sciences research,", "to": "we", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": ") institute for brain sciences research,", "to": "3 )", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##hie j", "value": 1}, {"from": ") institute for brain sciences research,", "to": "k", "value": 1}, {"from": ") institute for brain sciences research,", "to": "doi", "value": 1}, {"from": ") institute for brain sciences research,", "to": "b", "value": 1}, {"from": ") institute for brain sciences research,", "to": "102", "value": 1}, {"from": ") institute for brain sciences research,", "to": "j", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##354028 [", "value": 1}, {"from": ") institute for brain sciences research,", "to": ".", "value": 1}, {"from": ") institute for brain sciences research,", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": ") institute for brain sciences research,", "to": "school", "value": 1}, {"from": ") institute for brain sciences research,", "to": "), agegnehu sb", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##ra 00", "value": 1}, {"from": ") institute for brain sciences research,", "to": "3 ), lamptey el", "value": 1}, {"from": ") institute for brain sciences research,", "to": "1", "value": 1}, {"from": ") institute for brain sciences research,", "to": "ka", "value": 1}, {"from": ") institute for brain sciences research,", "to": "4", "value": 1}, {"from": ") institute for brain sciences research,", "to": "of ghana, a", "value": 1}, {"from": ") institute for brain sciences research,", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##461r pmid :", "value": 1}, {"from": ") institute for brain sciences research,", "to": "antiangiogenic therapy of", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": ") institute for brain sciences research,", "to": ")", "value": 1}, {"from": ") institute for brain sciences research,", "to": "he", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ") institute for brain sciences research,", "to": "expression", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##500", "value": 1}, {"from": ") institute for brain sciences research,", "to": "in cancer", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##mpo s", "value": 1}, {"from": ") institute for brain sciences research,", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ") institute for brain sciences research,", "to": "##cc", "value": 1}, {"from": ") institute for brain sciences research,", "to": "inverse", "value": 1}, {"from": ") institute for brain sciences research,", "to": "new insights into", "value": 1}, {"from": ":", "to": "index", "value": 2}, {"from": ":", "to": "##osu", "value": 1}, {"from": ":", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": ":", "to": ". 1096 / fj. 202", "value": 1}, {"from": ":", "to": "may contribute to the", "value": 1}, {"from": ":", "to": "sciences", "value": 2}, {"from": ":", "to": "university", "value": 2}, {"from": ":", "to": "##lle", "value": 1}, {"from": ":", "to": "40", "value": 4}, {"from": ":", "to": "genes", "value": 1}, {"from": ":", "to": "##i", "value": 1}, {"from": ":", "to": "##f", "value": 1}, {"from": ":", "to": "we", "value": 1}, {"from": ":", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": ":", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": ":", "to": "3 )", "value": 1}, {"from": ":", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": ":", "to": "##hie j", "value": 1}, {"from": ":", "to": "k", "value": 1}, {"from": ":", "to": "doi", "value": 11}, {"from": ":", "to": "b", "value": 3}, {"from": ":", "to": "102", "value": 3}, {"from": ":", "to": "j", "value": 5}, {"from": ":", "to": "##354028 [", "value": 1}, {"from": ":", "to": ".", "value": 8}, {"from": ":", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": ":", "to": "school", "value": 1}, {"from": ":", "to": "), agegnehu sb", "value": 1}, {"from": ":", "to": "##ra 00", "value": 1}, {"from": ":", "to": "3 ), lamptey el", "value": 1}, {"from": ":", "to": "1", "value": 3}, {"from": ":", "to": "ka", "value": 1}, {"from": ":", "to": "4", "value": 3}, {"from": ":", "to": "of ghana, a", "value": 1}, {"from": ":", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": ":", "to": "##461r pmid :", "value": 1}, {"from": ":", "to": "antiangiogenic therapy of", "value": 1}, {"from": ":", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": ":", "to": ")", "value": 1}, {"from": ":", "to": "he", "value": 1}, {"from": ":", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ":", "to": "expression", "value": 2}, {"from": ":", "to": "##500", "value": 1}, {"from": ":", "to": "in cancer", "value": 1}, {"from": ":", "to": "##mpo s", "value": 1}, {"from": ":", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ":", "to": "##cc", "value": 1}, {"from": ":", "to": "inverse", "value": 1}, {"from": ":", "to": "new insights into", "value": 1}, {"from": ":", "to": "risk", "value": 1}, {"from": ":", "to": "of cancer development while", "value": 1}, {"from": ":", "to": "reduced", "value": 1}, {"from": ":", "to": "##1 / acsomega. 4", "value": 1}, {"from": ":", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": ":", "to": "##ve", "value": 1}, {"from": ":", "to": "##re", "value": 1}, {"from": ":", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": ":", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": ":", "to": "10. 102", "value": 1}, {"from": ":", "to": "##er and 5 genes down", "value": 1}, {"from": ":", "to": "upre", "value": 1}, {"from": ":", "to": "were downregulated", "value": 1}, {"from": ":", "to": "pm", "value": 1}, {"from": ":", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": ":", "to": "##ida", "value": 2}, {"from": ":", "to": "##gulated", "value": 1}, {"from": ":", "to": "play an important role in", "value": 1}, {"from": ":", "to": "##12059893", "value": 1}, {"from": ":", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": ":", "to": "##c", "value": 2}, {"from": ":", "to": "in all three cancers and may", "value": 1}, {"from": ":", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": ":", "to": "##11571 pmcid : pm", "value": 1}, {"from": ":", "to": "##id :", "value": 1}, {"from": ":", "to": "), hashim", "value": 1}, {"from": ":", "to": "of medicine, univers", "value": 1}, {"from": ":", "to": "##rta", "value": 1}, {"from": ":", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": ":", "to": ") drug development research cluster, indon", "value": 1}, {"from": ":", "to": "##an medical", "value": 1}, {"from": ":", "to": "indon", "value": 1}, {"from": ":", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": ":", "to": "##hibit", "value": 1}, {"from": ":", "to": "na", "value": 1}, {"from": ":", "to": "master program in biomedical", "value": 1}, {"from": ":", "to": "education", "value": 1}, {"from": ":", "to": "n", "value": 1}, {"from": ":", "to": "3", "value": 1}, {"from": ":", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": ":", "to": "##ajrin", "value": 1}, {"from": ":", "to": "), azizah", "value": 1}, {"from": ":", "to": "##esi", "value": 1}, {"from": ":", "to": "te", "value": 1}, {"from": ":", "to": "##a, jaka", "value": 1}, {"from": ":", "to": "##djo a", "value": 1}, {"from": ":", "to": "of medicine, universitas indon", "value": 1}, {"from": ":", "to": "##itas", "value": 1}, {"from": ":", "to": "##a.", "value": 1}, {"from": ":", "to": "faculty", "value": 3}, {"from": ":", "to": "##b", "value": 1}, {"from": ":", "to": "am", "value": 1}, {"from": ":", "to": "nn", "value": 1}, {"from": ":", "to": "of pharmacy, univers", "value": 1}, {"from": ":", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": ":", "to": "##don", "value": 1}, {"from": ":", "to": "##a,", "value": 1}, {"from": ":", "to": ", indon", "value": 1}, {"from": ":", "to": "##aka", "value": 1}, {"from": ":", "to": "and research instit", "value": 1}, {"from": ":", "to": "), ramadanti", "value": 1}, {"from": ":", "to": "52", "value": 2}, {"from": ":", "to": "##life", "value": 1}, {"from": ":", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": ":", "to": "##ion of p21", "value": 1}, {"from": ":", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": ":", "to": "##in - mediated anti -", "value": 1}, {"from": ":", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": ":", "to": "1 ), abdelkrim g", "value": 1}, {"from": ":", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": ":", "to": "cancer effects. foda my", "value": 1}, {"from": ":", "to": "##press", "value": 1}, {"from": ":", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": ":", "to": "##tat", "value": 1}, {"from": ":", "to": "jun", "value": 2}, {"from": ":", "to": "2 ), salem ml", "value": 1}, {"from": ":", "to": "in atorvas", "value": 1}, {"from": ":", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": ":", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": ":", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": ":", "to": "##regulated", "value": 1}, {"from": ":", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": ":", "to": ". 108", "value": 1}, {"from": ":", "to": "jun might", "value": 1}, {"from": ":", "to": "##0", "value": 1}, {"from": ":", "to": "expression.", "value": 1}, {"from": ":", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": ":", "to": "##na ss", "value": 1}, {"from": ":", "to": "##v", "value": 1}, {"from": ":", "to": "##un", "value": 1}, {"from": ":", "to": "##gno", "value": 2}, {"from": ":", "to": "activity positively correlated with", "value": 1}, {"from": ":", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": ":", "to": ". 17305 /", "value": 1}, {"from": ":", "to": "luki", "value": 1}, {"from": ":", "to": "bio", "value": 1}, {"from": ":", "to": "##v vi", "value": 1}, {"from": ":", "to": "logino", "value": 1}, {"from": ":", "to": "was", "value": 1}, {"from": ":", "to": "may directly interact with", "value": 1}, {"from": ":", "to": "serve as a valuable pro", "value": 1}, {"from": ":", "to": "##tatin", "value": 1}, {"from": ":", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": ":", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": ":", "to": "expression. as such,", "value": 1}, {"from": ":", "to": "significantly", "value": 1}, {"from": ":", "to": "##nina", "value": 1}, {"from": ":", "to": "pro", "value": 1}, {"from": ":", "to": "down", "value": 2}, {"from": ":", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": ":", "to": "=", "value": 1}, {"from": ":", "to": "##s,", "value": 1}, {"from": ":", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": ":", "to": "which is involved in", "value": 1}, {"from": ":", "to": "- 0. 46,", "value": 1}, {"from": ":", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": ":", "to": "mi", "value": 1}, {"from": ":", "to": "- 5p", "value": 1}, {"from": ":", "to": "##r - 17", "value": 1}, {"from": ":", "to": "a", "value": 1}, {"from": ":", "to": "5", "value": 2}, {"from": ":", "to": "##1", "value": 1}, {"from": ":", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": ":", "to": ") : e010548.", "value": 1}, {"from": ":", "to": "5p", "value": 1}, {"from": ":", "to": "hand", "value": 1}, {"from": ":", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": ":", "to": "03 ) and", "value": 1}, {"from": ":", "to": "p = 0", "value": 1}, {"from": ":", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": ":", "to": "##r - 106a -", "value": 1}, {"from": ":", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": ":", "to": "target gene", "value": 1}, {"from": ":", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": ":", "to": "- 0. 41,", "value": 1}, {"from": ":", "to": "of these lnc", "value": 1}, {"from": ":", "to": "p = 0.", "value": 1}, {"from": ":", "to": "113", "value": 1}, {"from": ":", "to": "common", "value": 1}, {"from": ":", "to": "regulated", "value": 1}, {"from": ":", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ":", "to": "conclusions", "value": 1}, {"from": ":", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": ":", "to": "10. 113", "value": 1}, {"from": ":", "to": "interests", "value": 1}, {"from": ":", "to": ". no commercial re -", "value": 1}, {"from": ":", "to": "##p", "value": 1}, {"from": ":", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": ":", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": ":", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": ":", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": ":", "to": ": nr receives research support from bm", "value": 1}, {"from": ":", "to": "use", "value": 1}, {"from": ":", "to": ": atm deficiency, while com", "value": 1}, {"from": ":", "to": "does", "value": 1}, {"from": ":", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": ":", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": ":", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": ":", "to": "), huarte m", "value": 1}, {"from": ":", "to": "12", "value": 1}, {"from": ":", "to": "##407.", "value": 1}, {"from": ":", "to": "), par", "value": 1}, {"from": ":", "to": "ins", "value": 1}, {"from": ":", "to": "##or", "value": 1}, {"from": ":", "to": "##e", "value": 1}, {"from": ":", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": ":", "to": "9", "value": 1}, {"from": ":", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": ":", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": ":", "to": "), aragon s", "value": 1}, {"from": ":", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": ":", "to": "##ory", "value": 1}, {"from": ":", "to": "), gimenez j", "value": 1}, {"from": ":", "to": "- lopez i", "value": 1}, {"from": ":", "to": "##rine", "value": 1}, {"from": ":", "to": "er + / her2 -", "value": 1}, {"from": ":", "to": "), prat a", "value": 1}, {"from": ":", "to": "research", "value": 1}, {"from": ":", "to": "##e. lg is /", "value": 1}, {"from": ":", "to": "), buch e", "value": 1}, {"from": ":", "to": "##roga v", "value": 1}, {"from": ":", "to": "been holding research", "value": 1}, {"from": ":", "to": "11", "value": 1}, {"from": ":", "to": "101", "value": 3}, {"from": ":", "to": "##riaga k", "value": 1}, {"from": ":", "to": "), etxabe i", "value": 1}, {"from": ":", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": ":", "to": "1 ) biogipuzkoa", "value": 1}, {"from": ":", "to": "13", "value": 1}, {"from": ":", "to": "therapy", "value": 1}, {"from": ":", "to": "##ui", "value": 1}, {"from": ":", "to": "##ez", "value": 1}, {"from": ":", "to": "##vita", "value": 1}, {"from": ":", "to": "contracts", "value": 1}, {"from": ":", "to": "has", "value": 1}, {"from": ":", "to": "6", "value": 1}, {"from": ":", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": ":", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": ":", "to": "). author information :", "value": 1}, {"from": ":", "to": "), urruticoechea a", "value": 1}, {"from": ":", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": ":", "to": "t", "value": 1}, {"from": ":", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": ":", "to": "##6 /", "value": 3}, {"from": ":", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": ":", "to": "be validated in independent cohorts,", "value": 1}, {"from": ":", "to": "cost - effectiveness", "value": 1}, {"from": ":", "to": "##ers of response to net and pro", "value": 1}, {"from": ":", "to": "10. 101", "value": 1}, {"from": ":", "to": "help", "value": 1}, {"from": ":", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": ":", "to": "##sis, which", "value": 1}, {"from": ":", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": ":", "to": "##lin", "value": 1}, {"from": ":", "to": "should", "value": 1}, {"from": ":", "to": "202", "value": 1}, {"from": ":", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": ":", "to": "helping to the", "value": 1}, {"from": ":", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": ":", "to": "implementation of net", "value": 1}, {"from": ":", "to": "##mark", "value": 1}, {"from": ":", "to": "##ranon.", "value": 1}, {"from": ":", "to": "##5", "value": 1}, {"from": ":", "to": ". clbc. 202", "value": 1}, {"from": ":", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": ":", "to": "##5.", "value": 1}, {"from": ":", "to": "is cost - effective", "value": 1}, {"from": ":", "to": "of agriculture and natural", "value": 1}, {"from": ":", "to": ". ac.", "value": 1}, {"from": ":", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": ":", "to": "resources", "value": 1}, {"from": ":", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": ":", "to": "##za. he", "value": 1}, {"from": ":", "to": "are", "value": 1}, {"from": ":", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": ":", "to": "##ri - japelaghi r", "value": 1}, {"from": ":", "to": "##r.", "value": 1}, {"from": ":", "to": "who", "value": 1}, {"from": ":", "to": "inter", "value": 1}, {"from": ":", "to": "##vin", "value": 1}, {"from": ":", "to": "of tabriz,", "value": 1}, {"from": ":", "to": "@ org.", "value": 1}, {"from": ":", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": ":", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": ":", "to": "##idari", "value": 1}, {"from": ":", "to": "s", "value": 1}, {"from": ":", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": ":", "to": "ta", "value": 1}, {"from": ":", "to": "##ran. electronic address :", "value": 1}, {"from": ":", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": ":", "to": "re", "value": 1}, {"from": ":", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ":", "to": "perspectives", "value": 1}, {"from": ":", "to": "##briz,", "value": 1}, {"from": ":", "to": "of agriculture,", "value": 1}, {"from": ":", "to": "##fer", "value": 1}, {"from": ":", "to": "##on", "value": 1}, {"from": ":", "to": "##ki", "value": 1}, {"from": ":", "to": "from both", "value": 1}, {"from": ":", "to": "##ran.", "value": 1}, {"from": ":", "to": "- regulate", "value": 1}, {"from": ":", "to": "the", "value": 1}, {"from": ":", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": ":", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": ":", "to": "##tic", "value": 1}, {"from": ":", "to": "##6", "value": 1}, {"from": ":", "to": "##poptosis", "value": 1}, {"from": ":", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": ":", "to": "##xic effect of", "value": 1}, {"from": ":", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": ":", "to": "00", "value": 1}, {"from": ":", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": ":", "to": "##xic efficacy of the", "value": 1}, {"from": ":", "to": "and", "value": 1}, {"from": ":", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": ":", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": ":", "to": "if", "value": 1}, {"from": ":", "to": "up -", "value": 1}, {"from": ":", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": ":", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": ":", "to": "development of tumor cells, a", "value": 1}, {"from": ":", "to": "##348089 conflict o", "value": 1}, {"from": ":", "to": "regulate", "value": 1}, {"from": ":", "to": "##oto", "value": 1}, {"from": ":", "to": "of pro", "value": 1}, {"from": ":", "to": "##cl -", "value": 1}, {"from": ":", "to": "##biotec. 2025.", "value": 1}, {"from": ":", "to": "04", "value": 1}, {"from": ":", "to": "##apopto", "value": 1}, {"from": ":", "to": "to", "value": 1}, {"from": ":", "to": "##cer and antiviral functions of", "value": 1}, {"from": ":", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": ":", "to": "via", "value": 1}, {"from": ":", "to": "and p", "value": 1}, {"from": ":", "to": "##c cell line", "value": 1}, {"from": ":", "to": "hi", "value": 1}, {"from": ":", "to": "##can", "value": 1}, {"from": ":", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": ":", "to": "##53", "value": 1}, {"from": ":", "to": ". 022 pmid :", "value": 1}, {"from": ":", "to": "bax", "value": 1}, {"from": "index", "to": "##osu", "value": 1}, {"from": "index", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "index", "to": ". 1096 / fj. 202", "value": 1}, {"from": "index", "to": "may contribute to the", "value": 1}, {"from": "index", "to": "sciences", "value": 1}, {"from": "index", "to": "university", "value": 1}, {"from": "index", "to": "##lle", "value": 1}, {"from": "index", "to": "40", "value": 1}, {"from": "index", "to": "genes", "value": 1}, {"from": "index", "to": "##i", "value": 2}, {"from": "index", "to": "##f", "value": 1}, {"from": "index", "to": "we", "value": 1}, {"from": "index", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "index", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "index", "to": "3 )", "value": 1}, {"from": "index", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "index", "to": "##hie j", "value": 1}, {"from": "index", "to": "k", "value": 1}, {"from": "index", "to": "doi", "value": 2}, {"from": "index", "to": "b", "value": 2}, {"from": "index", "to": "102", "value": 1}, {"from": "index", "to": "j", "value": 1}, {"from": "index", "to": "##354028 [", "value": 1}, {"from": "index", "to": ".", "value": 1}, {"from": "index", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "index", "to": "school", "value": 1}, {"from": "index", "to": "), agegnehu sb", "value": 1}, {"from": "index", "to": "##ra 00", "value": 1}, {"from": "index", "to": "3 ), lamptey el", "value": 1}, {"from": "index", "to": "1", "value": 1}, {"from": "index", "to": "ka", "value": 1}, {"from": "index", "to": "4", "value": 1}, {"from": "index", "to": "of ghana, a", "value": 1}, {"from": "index", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "index", "to": "##461r pmid :", "value": 1}, {"from": "index", "to": "antiangiogenic therapy of", "value": 1}, {"from": "index", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "index", "to": ")", "value": 1}, {"from": "index", "to": "he", "value": 1}, {"from": "index", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "index", "to": "expression", "value": 1}, {"from": "index", "to": "##500", "value": 1}, {"from": "index", "to": "in cancer", "value": 1}, {"from": "index", "to": "##mpo s", "value": 1}, {"from": "index", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "index", "to": "##cc", "value": 1}, {"from": "index", "to": "inverse", "value": 1}, {"from": "index", "to": "new insights into", "value": 1}, {"from": "index", "to": "conclusions", "value": 1}, {"from": "index", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "index", "to": "10. 113", "value": 1}, {"from": "index", "to": "interests", "value": 1}, {"from": "index", "to": ". no commercial re -", "value": 1}, {"from": "index", "to": "##p", "value": 1}, {"from": "index", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "index", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "index", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "index", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "index", "to": ": nr receives research support from bm", "value": 1}, {"from": "index", "to": "use", "value": 1}, {"from": "index", "to": ": atm deficiency, while com", "value": 1}, {"from": "index", "to": "does", "value": 1}, {"from": "index", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "index", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "index", "to": "##c", "value": 1}, {"from": "index", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "index", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "index", "to": "in ki", "value": 1}, {"from": "index", "to": "##cu", "value": 1}, {"from": "index", "to": "t", "value": 1}, {"from": "index", "to": "positive", "value": 1}, {"from": "index", "to": "##2 -", "value": 1}, {"from": "index", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "index", "to": "##type", "value": 1}, {"from": "index", "to": "##rrence", "value": 1}, {"from": "index", "to": "percentage", "value": 1}, {"from": "index", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "index", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "index", "to": "##nes", "value": 1}, {"from": "index", "to": "from l", "value": 1}, {"from": "index", "to": "presented", "value": 1}, {"from": "index", "to": "re", "value": 1}, {"from": "index", "to": "results", "value": 1}, {"from": "index", "to": "pam50 - derived risk of", "value": 1}, {"from": "index", "to": "her", "value": 1}, {"from": "index", "to": "er + /", "value": 1}, {"from": "index", "to": "##nal a to normal - like", "value": 1}, {"from": "index", "to": "##umi", "value": 1}, {"from": "index", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "index", "to": "cells", "value": 1}, {"from": "index", "to": "score", "value": 1}, {"from": "index", "to": "change", "value": 1}, {"from": "index", "to": "after", "value": 1}, {"from": "index", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "index", "to": "of intrinsic sub", "value": 1}, {"from": "index", "to": "p53", "value": 1}, {"from": "index", "to": "##is.", "value": 1}, {"from": "index", "to": "biomark", "value": 1}, {"from": "index", "to": "subtype after", "value": 1}, {"from": "index", "to": "net", "value": 1}, {"from": "index", "to": "of", "value": 1}, {"from": "index", "to": "##c patients", "value": 1}, {"from": "index", "to": "net as a putative", "value": 1}, {"from": "index", "to": "##umour cellularity size", "value": 1}, {"from": "index", "to": "radio", "value": 1}, {"from": "index", "to": ") and lower", "value": 1}, {"from": "index", "to": "better", "value": 1}, {"from": "##osu", "to": "of alzheimer \u0027 s disease -", "value": 1}, {"from": "##osu", "to": ". 1096 / fj. 202", "value": 1}, {"from": "##osu", "to": "may contribute to the", "value": 1}, {"from": "##osu", "to": "sciences", "value": 1}, {"from": "##osu", "to": "university", "value": 1}, {"from": "##osu", "to": "##lle", "value": 1}, {"from": "##osu", "to": "40", "value": 1}, {"from": "##osu", "to": "genes", "value": 1}, {"from": "##osu", "to": "##i", "value": 1}, {"from": "##osu", "to": "##f", "value": 1}, {"from": "##osu", "to": "we", "value": 1}, {"from": "##osu", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##osu", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##osu", "to": "3 )", "value": 1}, {"from": "##osu", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##osu", "to": "##hie j", "value": 1}, {"from": "##osu", "to": "k", "value": 1}, {"from": "##osu", "to": "doi", "value": 1}, {"from": "##osu", "to": "b", "value": 1}, {"from": "##osu", "to": "102", "value": 1}, {"from": "##osu", "to": "j", "value": 1}, {"from": "##osu", "to": "##354028 [", "value": 1}, {"from": "##osu", "to": ".", "value": 1}, {"from": "##osu", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##osu", "to": "school", "value": 1}, {"from": "##osu", "to": "), agegnehu sb", "value": 1}, {"from": "##osu", "to": "##ra 00", "value": 1}, {"from": "##osu", "to": "3 ), lamptey el", "value": 1}, {"from": "##osu", "to": "1", "value": 1}, {"from": "##osu", "to": "ka", "value": 1}, {"from": "##osu", "to": "4", "value": 1}, {"from": "##osu", "to": "of ghana, a", "value": 1}, {"from": "##osu", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##osu", "to": "##461r pmid :", "value": 1}, {"from": "##osu", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##osu", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##osu", "to": ")", "value": 1}, {"from": "##osu", "to": "he", "value": 1}, {"from": "##osu", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##osu", "to": "expression", "value": 1}, {"from": "##osu", "to": "##500", "value": 1}, {"from": "##osu", "to": "in cancer", "value": 1}, {"from": "##osu", "to": "##mpo s", "value": 1}, {"from": "##osu", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##osu", "to": "##cc", "value": 1}, {"from": "##osu", "to": "inverse", "value": 1}, {"from": "##osu", "to": "new insights into", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": ". 1096 / fj. 202", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "may contribute to the", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "sciences", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "university", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##lle", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "40", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "genes", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##i", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##f", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "we", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "3 )", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##hie j", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "k", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "doi", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "b", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "102", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "j", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##354028 [", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": ".", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "school", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "), agegnehu sb", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##ra 00", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "3 ), lamptey el", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "1", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "ka", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "4", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "of ghana, a", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##461r pmid :", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "antiangiogenic therapy of", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": ")", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "he", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "expression", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##500", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "in cancer", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##mpo s", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "##cc", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "inverse", "value": 1}, {"from": "of alzheimer \u0027 s disease -", "to": "new insights into", "value": 1}, {"from": ". 1096 / fj. 202", "to": "may contribute to the", "value": 1}, {"from": ". 1096 / fj. 202", "to": "sciences", "value": 1}, {"from": ". 1096 / fj. 202", "to": "university", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##lle", "value": 1}, {"from": ". 1096 / fj. 202", "to": "40", "value": 1}, {"from": ". 1096 / fj. 202", "to": "genes", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##i", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##f", "value": 1}, {"from": ". 1096 / fj. 202", "to": "we", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": ". 1096 / fj. 202", "to": "3 )", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##hie j", "value": 1}, {"from": ". 1096 / fj. 202", "to": "k", "value": 1}, {"from": ". 1096 / fj. 202", "to": "doi", "value": 1}, {"from": ". 1096 / fj. 202", "to": "b", "value": 1}, {"from": ". 1096 / fj. 202", "to": "102", "value": 1}, {"from": ". 1096 / fj. 202", "to": "j", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##354028 [", "value": 1}, {"from": ". 1096 / fj. 202", "to": ".", "value": 1}, {"from": ". 1096 / fj. 202", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": ". 1096 / fj. 202", "to": "school", "value": 1}, {"from": ". 1096 / fj. 202", "to": "), agegnehu sb", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##ra 00", "value": 1}, {"from": ". 1096 / fj. 202", "to": "3 ), lamptey el", "value": 1}, {"from": ". 1096 / fj. 202", "to": "1", "value": 1}, {"from": ". 1096 / fj. 202", "to": "ka", "value": 1}, {"from": ". 1096 / fj. 202", "to": "4", "value": 1}, {"from": ". 1096 / fj. 202", "to": "of ghana, a", "value": 1}, {"from": ". 1096 / fj. 202", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##461r pmid :", "value": 1}, {"from": ". 1096 / fj. 202", "to": "antiangiogenic therapy of", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": ". 1096 / fj. 202", "to": ")", "value": 1}, {"from": ". 1096 / fj. 202", "to": "he", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ". 1096 / fj. 202", "to": "expression", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##500", "value": 1}, {"from": ". 1096 / fj. 202", "to": "in cancer", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##mpo s", "value": 1}, {"from": ". 1096 / fj. 202", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ". 1096 / fj. 202", "to": "##cc", "value": 1}, {"from": ". 1096 / fj. 202", "to": "inverse", "value": 1}, {"from": ". 1096 / fj. 202", "to": "new insights into", "value": 1}, {"from": "may contribute to the", "to": "sciences", "value": 1}, {"from": "may contribute to the", "to": "university", "value": 1}, {"from": "may contribute to the", "to": "##lle", "value": 1}, {"from": "may contribute to the", "to": "40", "value": 1}, {"from": "may contribute to the", "to": "genes", "value": 1}, {"from": "may contribute to the", "to": "##i", "value": 1}, {"from": "may contribute to the", "to": "##f", "value": 1}, {"from": "may contribute to the", "to": "we", "value": 1}, {"from": "may contribute to the", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "may contribute to the", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "may contribute to the", "to": "3 )", "value": 1}, {"from": "may contribute to the", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "may contribute to the", "to": "##hie j", "value": 1}, {"from": "may contribute to the", "to": "k", "value": 1}, {"from": "may contribute to the", "to": "doi", "value": 1}, {"from": "may contribute to the", "to": "b", "value": 1}, {"from": "may contribute to the", "to": "102", "value": 1}, {"from": "may contribute to the", "to": "j", "value": 1}, {"from": "may contribute to the", "to": "##354028 [", "value": 1}, {"from": "may contribute to the", "to": ".", "value": 1}, {"from": "may contribute to the", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "may contribute to the", "to": "school", "value": 1}, {"from": "may contribute to the", "to": "), agegnehu sb", "value": 1}, {"from": "may contribute to the", "to": "##ra 00", "value": 1}, {"from": "may contribute to the", "to": "3 ), lamptey el", "value": 1}, {"from": "may contribute to the", "to": "1", "value": 1}, {"from": "may contribute to the", "to": "ka", "value": 1}, {"from": "may contribute to the", "to": "4", "value": 1}, {"from": "may contribute to the", "to": "of ghana, a", "value": 1}, {"from": "may contribute to the", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "may contribute to the", "to": "##461r pmid :", "value": 1}, {"from": "may contribute to the", "to": "antiangiogenic therapy of", "value": 1}, {"from": "may contribute to the", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "may contribute to the", "to": ")", "value": 1}, {"from": "may contribute to the", "to": "he", "value": 1}, {"from": "may contribute to the", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "may contribute to the", "to": "expression", "value": 1}, {"from": "may contribute to the", "to": "##500", "value": 1}, {"from": "may contribute to the", "to": "in cancer", "value": 1}, {"from": "may contribute to the", "to": "##mpo s", "value": 1}, {"from": "may contribute to the", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "may contribute to the", "to": "##cc", "value": 1}, {"from": "may contribute to the", "to": "inverse", "value": 1}, {"from": "may contribute to the", "to": "new insights into", "value": 1}, {"from": "sciences", "to": "university", "value": 1}, {"from": "sciences", "to": "##lle", "value": 1}, {"from": "sciences", "to": "40", "value": 1}, {"from": "sciences", "to": "genes", "value": 1}, {"from": "sciences", "to": "##i", "value": 1}, {"from": "sciences", "to": "##f", "value": 1}, {"from": "sciences", "to": "we", "value": 1}, {"from": "sciences", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "sciences", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "sciences", "to": "3 )", "value": 1}, {"from": "sciences", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "sciences", "to": "##hie j", "value": 1}, {"from": "sciences", "to": "k", "value": 2}, {"from": "sciences", "to": "doi", "value": 2}, {"from": "sciences", "to": "b", "value": 1}, {"from": "sciences", "to": "102", "value": 1}, {"from": "sciences", "to": "j", "value": 3}, {"from": "sciences", "to": "##354028 [", "value": 1}, {"from": "sciences", "to": ".", "value": 2}, {"from": "sciences", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "sciences", "to": "school", "value": 2}, {"from": "sciences", "to": "), agegnehu sb", "value": 1}, {"from": "sciences", "to": "##ra 00", "value": 1}, {"from": "sciences", "to": "3 ), lamptey el", "value": 1}, {"from": "sciences", "to": "1", "value": 2}, {"from": "sciences", "to": "ka", "value": 1}, {"from": "sciences", "to": "4", "value": 4}, {"from": "sciences", "to": "of ghana, a", "value": 1}, {"from": "sciences", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "sciences", "to": "##461r pmid :", "value": 1}, {"from": "sciences", "to": "antiangiogenic therapy of", "value": 1}, {"from": "sciences", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "sciences", "to": ")", "value": 3}, {"from": "sciences", "to": "he", "value": 1}, {"from": "sciences", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "sciences", "to": "expression", "value": 1}, {"from": "sciences", "to": "##500", "value": 1}, {"from": "sciences", "to": "in cancer", "value": 1}, {"from": "sciences", "to": "##mpo s", "value": 1}, {"from": "sciences", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "sciences", "to": "##cc", "value": 2}, {"from": "sciences", "to": "inverse", "value": 1}, {"from": "sciences", "to": "new insights into", "value": 1}, {"from": "sciences", "to": "box l", "value": 1}, {"from": "sciences", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "sciences", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "sciences", "to": "of medical sciences, c.", "value": 1}, {"from": "sciences", "to": "these two conditions which", "value": 1}, {"from": "sciences", "to": "box", "value": 1}, {"from": "sciences", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "sciences", "to": "care", "value": 1}, {"from": "sciences", "to": "##ra", "value": 1}, {"from": "sciences", "to": "00", "value": 1}, {"from": "sciences", "to": "233, ghana.", "value": 1}, {"from": "sciences", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "sciences", "to": "##g 77, a", "value": 1}, {"from": "sciences", "to": "5", "value": 2}, {"from": "sciences", "to": ") west african genetic medicine centre", "value": 1}, {"from": "sciences", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "sciences", "to": "of health", "value": 1}, {"from": "sciences", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "sciences", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "sciences", "to": "been observed", "value": 1}, {"from": "sciences", "to": ", university of ghana, p. o.", "value": 1}, {"from": "sciences", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "sciences", "to": "between", "value": 1}, {"from": "sciences", "to": "of anaesthesia and intensive", "value": 1}, {"from": "sciences", "to": "##233, ghana.", "value": 1}, {"from": "sciences", "to": "incidence", "value": 1}, {"from": "sciences", "to": "cancer and ad", "value": 1}, {"from": "sciences", "to": "were formerly", "value": 1}, {"from": "sciences", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "sciences", "to": "has", "value": 1}, {"from": "sciences", "to": "department", "value": 2}, {"from": "sciences", "to": "inverse relationship between", "value": 1}, {"from": "sciences", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "sciences", "to": "##ibi", "value": 1}, {"from": "sciences", "to": "ri", "value": 1}, {"from": "sciences", "to": "##sana", "value": 1}, {"from": "sciences", "to": "doctoral program in biomedical", "value": 1}, {"from": "sciences", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "sciences", "to": "of medicine, univers", "value": 2}, {"from": "sciences", "to": "##g", "value": 1}, {"from": "sciences", "to": "##rta", "value": 2}, {"from": "sciences", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "sciences", "to": "##esia", "value": 1}, {"from": "sciences", "to": "##itas in", "value": 1}, {"from": "sciences", "to": "##nandi si", "value": 1}, {"from": "sciences", "to": "##eri", "value": 1}, {"from": "sciences", "to": "master program in biomedical", "value": 2}, {"from": "sciences", "to": "),", "value": 1}, {"from": "sciences", "to": "##esi", "value": 2}, {"from": "sciences", "to": "of medical chemistry,", "value": 1}, {"from": "sciences", "to": "##a.", "value": 2}, {"from": "sciences", "to": "faculty", "value": 2}, {"from": "sciences", "to": "wa", "value": 1}, {"from": "sciences", "to": "##don", "value": 2}, {"from": "sciences", "to": "##a,", "value": 2}, {"from": "sciences", "to": "6", "value": 1}, {"from": "sciences", "to": "##aka", "value": 2}, {"from": "sciences", "to": "indonesi", "value": 1}, {"from": "sciences", "to": "##itas indonesia", "value": 1}, {"from": "sciences", "to": "of surgery,", "value": 1}, {"from": "sciences", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "sciences", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "sciences", "to": "), hashim", "value": 1}, {"from": "sciences", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "sciences", "to": ") drug development research cluster, indon", "value": 1}, {"from": "sciences", "to": "##an medical", "value": 1}, {"from": "sciences", "to": "indon", "value": 1}, {"from": "sciences", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "sciences", "to": "##hibit", "value": 1}, {"from": "sciences", "to": "na", "value": 1}, {"from": "sciences", "to": "education", "value": 1}, {"from": "sciences", "to": "n", "value": 1}, {"from": "sciences", "to": "3", "value": 1}, {"from": "sciences", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "sciences", "to": "##ajrin", "value": 1}, {"from": "sciences", "to": "), azizah", "value": 1}, {"from": "sciences", "to": "te", "value": 1}, {"from": "sciences", "to": "##a, jaka", "value": 1}, {"from": "sciences", "to": "##djo a", "value": 1}, {"from": "sciences", "to": "of medicine, universitas indon", "value": 1}, {"from": "sciences", "to": "##itas", "value": 1}, {"from": "sciences", "to": "##b", "value": 1}, {"from": "sciences", "to": "am", "value": 1}, {"from": "sciences", "to": "nn", "value": 1}, {"from": "sciences", "to": "of pharmacy, univers", "value": 1}, {"from": "sciences", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "sciences", "to": ", indon", "value": 1}, {"from": "sciences", "to": "and research instit", "value": 1}, {"from": "sciences", "to": "), ramadanti", "value": 1}, {"from": "sciences", "to": "52", "value": 1}, {"from": "university", "to": "##lle", "value": 1}, {"from": "university", "to": "40", "value": 2}, {"from": "university", "to": "genes", "value": 1}, {"from": "university", "to": "##i", "value": 1}, {"from": "university", "to": "##f", "value": 1}, {"from": "university", "to": "we", "value": 1}, {"from": "university", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "university", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "university", "to": "3 )", "value": 1}, {"from": "university", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "university", "to": "##hie j", "value": 1}, {"from": "university", "to": "k", "value": 1}, {"from": "university", "to": "doi", "value": 2}, {"from": "university", "to": "b", "value": 1}, {"from": "university", "to": "102", "value": 1}, {"from": "university", "to": "j", "value": 2}, {"from": "university", "to": "##354028 [", "value": 1}, {"from": "university", "to": ".", "value": 3}, {"from": "university", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "university", "to": "school", "value": 1}, {"from": "university", "to": "), agegnehu sb", "value": 1}, {"from": "university", "to": "##ra 00", "value": 1}, {"from": "university", "to": "3 ), lamptey el", "value": 1}, {"from": "university", "to": "1", "value": 1}, {"from": "university", "to": "ka", "value": 1}, {"from": "university", "to": "4", "value": 1}, {"from": "university", "to": "of ghana, a", "value": 1}, {"from": "university", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "university", "to": "##461r pmid :", "value": 1}, {"from": "university", "to": "antiangiogenic therapy of", "value": 1}, {"from": "university", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "university", "to": ")", "value": 1}, {"from": "university", "to": "he", "value": 1}, {"from": "university", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "university", "to": "expression", "value": 1}, {"from": "university", "to": "##500", "value": 1}, {"from": "university", "to": "in cancer", "value": 1}, {"from": "university", "to": "##mpo s", "value": 1}, {"from": "university", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "university", "to": "##cc", "value": 1}, {"from": "university", "to": "inverse", "value": 1}, {"from": "university", "to": "new insights into", "value": 1}, {"from": "university", "to": ", drammen, norway.", "value": 1}, {"from": "university", "to": "of clinical medicine,", "value": 1}, {"from": "university", "to": "##dheim, norway.", "value": 1}, {"from": "university", "to": "25", "value": 1}, {"from": "university", "to": "trust", "value": 1}, {"from": "university", "to": "of cancer genetics,", "value": 1}, {"from": "university", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "university", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "university", "to": "institute", "value": 1}, {"from": "university", "to": ";", "value": 1}, {"from": "university", "to": ", hamar, norway.", "value": 1}, {"from": "university", "to": ", kalnes, norway.", "value": 1}, {"from": "university", "to": ", skien, norway.", "value": 1}, {"from": "university", "to": "of oslo, oslo, nor", "value": 1}, {"from": "university", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "university", "to": "department", "value": 1}, {"from": "university", "to": ") department of oncolog", "value": 1}, {"from": "university", "to": "##ron", "value": 1}, {"from": "university", "to": "##way", "value": 1}, {"from": "university", "to": "is cost - effective", "value": 1}, {"from": "university", "to": "of agriculture and natural", "value": 1}, {"from": "university", "to": ". ac.", "value": 1}, {"from": "university", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "university", "to": "resources", "value": 1}, {"from": "university", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "university", "to": "##za. he", "value": 1}, {"from": "university", "to": "##6 /", "value": 1}, {"from": "university", "to": "are", "value": 1}, {"from": "university", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "university", "to": "##ri - japelaghi r", "value": 1}, {"from": "university", "to": "##r.", "value": 1}, {"from": "university", "to": "who", "value": 1}, {"from": "university", "to": "inter", "value": 1}, {"from": "university", "to": "##vin", "value": 1}, {"from": "university", "to": "of tabriz,", "value": 1}, {"from": "university", "to": "@ org.", "value": 1}, {"from": "university", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "university", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "university", "to": "##idari", "value": 1}, {"from": "university", "to": "s", "value": 1}, {"from": "university", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "university", "to": "ta", "value": 1}, {"from": "university", "to": "##ran. electronic address :", "value": 1}, {"from": "university", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "university", "to": "re", "value": 1}, {"from": "university", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "university", "to": "101", "value": 1}, {"from": "university", "to": "##ida", "value": 1}, {"from": "university", "to": "perspectives", "value": 1}, {"from": "university", "to": "##briz,", "value": 1}, {"from": "university", "to": "faculty", "value": 1}, {"from": "university", "to": "of agriculture,", "value": 1}, {"from": "university", "to": "##fer", "value": 1}, {"from": "university", "to": "##on", "value": 1}, {"from": "university", "to": "##ki", "value": 1}, {"from": "university", "to": "from both", "value": 1}, {"from": "university", "to": "##ran.", "value": 1}, {"from": "##lle", "to": "40", "value": 1}, {"from": "##lle", "to": "genes", "value": 1}, {"from": "##lle", "to": "##i", "value": 1}, {"from": "##lle", "to": "##f", "value": 1}, {"from": "##lle", "to": "we", "value": 1}, {"from": "##lle", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##lle", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##lle", "to": "3 )", "value": 1}, {"from": "##lle", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##lle", "to": "##hie j", "value": 1}, {"from": "##lle", "to": "k", "value": 1}, {"from": "##lle", "to": "doi", "value": 1}, {"from": "##lle", "to": "b", "value": 1}, {"from": "##lle", "to": "102", "value": 1}, {"from": "##lle", "to": "j", "value": 1}, {"from": "##lle", "to": "##354028 [", "value": 1}, {"from": "##lle", "to": ".", "value": 1}, {"from": "##lle", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##lle", "to": "school", "value": 1}, {"from": "##lle", "to": "), agegnehu sb", "value": 1}, {"from": "##lle", "to": "##ra 00", "value": 1}, {"from": "##lle", "to": "3 ), lamptey el", "value": 1}, {"from": "##lle", "to": "1", "value": 1}, {"from": "##lle", "to": "ka", "value": 1}, {"from": "##lle", "to": "4", "value": 1}, {"from": "##lle", "to": "of ghana, a", "value": 1}, {"from": "##lle", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##lle", "to": "##461r pmid :", "value": 1}, {"from": "##lle", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##lle", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##lle", "to": ")", "value": 1}, {"from": "##lle", "to": "he", "value": 1}, {"from": "##lle", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##lle", "to": "expression", "value": 1}, {"from": "##lle", "to": "##500", "value": 1}, {"from": "##lle", "to": "in cancer", "value": 1}, {"from": "##lle", "to": "##mpo s", "value": 1}, {"from": "##lle", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##lle", "to": "##cc", "value": 1}, {"from": "##lle", "to": "inverse", "value": 1}, {"from": "##lle", "to": "new insights into", "value": 1}, {"from": "40", "to": "genes", "value": 1}, {"from": "40", "to": "##i", "value": 1}, {"from": "40", "to": "##f", "value": 1}, {"from": "40", "to": "we", "value": 1}, {"from": "40", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "40", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "40", "to": "3 )", "value": 1}, {"from": "40", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "40", "to": "##hie j", "value": 1}, {"from": "40", "to": "k", "value": 1}, {"from": "40", "to": "doi", "value": 4}, {"from": "40", "to": "b", "value": 2}, {"from": "40", "to": "102", "value": 1}, {"from": "40", "to": "j", "value": 3}, {"from": "40", "to": "##354028 [", "value": 1}, {"from": "40", "to": ".", "value": 3}, {"from": "40", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "40", "to": "school", "value": 1}, {"from": "40", "to": "), agegnehu sb", "value": 1}, {"from": "40", "to": "##ra 00", "value": 1}, {"from": "40", "to": "3 ), lamptey el", "value": 1}, {"from": "40", "to": "1", "value": 1}, {"from": "40", "to": "ka", "value": 1}, {"from": "40", "to": "4", "value": 1}, {"from": "40", "to": "of ghana, a", "value": 1}, {"from": "40", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "40", "to": "##461r pmid :", "value": 1}, {"from": "40", "to": "antiangiogenic therapy of", "value": 1}, {"from": "40", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "40", "to": ")", "value": 1}, {"from": "40", "to": "he", "value": 1}, {"from": "40", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "40", "to": "expression", "value": 2}, {"from": "40", "to": "##500", "value": 1}, {"from": "40", "to": "in cancer", "value": 1}, {"from": "40", "to": "##mpo s", "value": 1}, {"from": "40", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "40", "to": "##cc", "value": 1}, {"from": "40", "to": "inverse", "value": 1}, {"from": "40", "to": "new insights into", "value": 1}, {"from": "40", "to": "risk", "value": 1}, {"from": "40", "to": "of cancer development while", "value": 1}, {"from": "40", "to": "reduced", "value": 1}, {"from": "40", "to": "##1 / acsomega. 4", "value": 1}, {"from": "40", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "40", "to": "##ve", "value": 1}, {"from": "40", "to": "##re", "value": 1}, {"from": "40", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "40", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "40", "to": "10. 102", "value": 1}, {"from": "40", "to": "##er and 5 genes down", "value": 1}, {"from": "40", "to": "upre", "value": 1}, {"from": "40", "to": "were downregulated", "value": 1}, {"from": "40", "to": "pm", "value": 1}, {"from": "40", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "40", "to": "##ida", "value": 2}, {"from": "40", "to": "##gulated", "value": 1}, {"from": "40", "to": "play an important role in", "value": 1}, {"from": "40", "to": "##12059893", "value": 1}, {"from": "40", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "40", "to": "##c", "value": 1}, {"from": "40", "to": "in all three cancers and may", "value": 1}, {"from": "40", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "40", "to": "##11571 pmcid : pm", "value": 1}, {"from": "40", "to": "##id :", "value": 1}, {"from": "40", "to": "is cost - effective", "value": 1}, {"from": "40", "to": "of agriculture and natural", "value": 1}, {"from": "40", "to": ". ac.", "value": 1}, {"from": "40", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "40", "to": "resources", "value": 1}, {"from": "40", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "40", "to": "##za. he", "value": 1}, {"from": "40", "to": "##6 /", "value": 2}, {"from": "40", "to": "are", "value": 1}, {"from": "40", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "40", "to": "##ri - japelaghi r", "value": 1}, {"from": "40", "to": "##r.", "value": 1}, {"from": "40", "to": "who", "value": 1}, {"from": "40", "to": "inter", "value": 1}, {"from": "40", "to": "##vin", "value": 1}, {"from": "40", "to": "of tabriz,", "value": 1}, {"from": "40", "to": "@ org.", "value": 1}, {"from": "40", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "40", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "40", "to": "##idari", "value": 1}, {"from": "40", "to": "s", "value": 1}, {"from": "40", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "40", "to": "ta", "value": 1}, {"from": "40", "to": "##ran. electronic address :", "value": 1}, {"from": "40", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "40", "to": "re", "value": 1}, {"from": "40", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "40", "to": "101", "value": 2}, {"from": "40", "to": "perspectives", "value": 1}, {"from": "40", "to": "##briz,", "value": 1}, {"from": "40", "to": "faculty", "value": 1}, {"from": "40", "to": "of agriculture,", "value": 1}, {"from": "40", "to": "##fer", "value": 1}, {"from": "40", "to": "##on", "value": 1}, {"from": "40", "to": "##ki", "value": 1}, {"from": "40", "to": "from both", "value": 1}, {"from": "40", "to": "##ran.", "value": 1}, {"from": "40", "to": "- regulate", "value": 1}, {"from": "40", "to": "the", "value": 1}, {"from": "40", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "40", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "40", "to": "##tic", "value": 1}, {"from": "40", "to": "##6", "value": 1}, {"from": "40", "to": "##poptosis", "value": 1}, {"from": "40", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "40", "to": "##xic effect of", "value": 1}, {"from": "40", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "40", "to": "00", "value": 1}, {"from": "40", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "40", "to": "##xic efficacy of the", "value": 1}, {"from": "40", "to": "and", "value": 1}, {"from": "40", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "40", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "40", "to": "if", "value": 1}, {"from": "40", "to": "up -", "value": 1}, {"from": "40", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "40", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "40", "to": "development of tumor cells, a", "value": 1}, {"from": "40", "to": "##348089 conflict o", "value": 1}, {"from": "40", "to": "regulate", "value": 1}, {"from": "40", "to": "##oto", "value": 1}, {"from": "40", "to": "of pro", "value": 1}, {"from": "40", "to": "##cl -", "value": 1}, {"from": "40", "to": "##biotec. 2025.", "value": 1}, {"from": "40", "to": "04", "value": 1}, {"from": "40", "to": "##apopto", "value": 1}, {"from": "40", "to": "to", "value": 1}, {"from": "40", "to": "##cer and antiviral functions of", "value": 1}, {"from": "40", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "40", "to": "via", "value": 1}, {"from": "40", "to": "and p", "value": 1}, {"from": "40", "to": "##c cell line", "value": 1}, {"from": "40", "to": "hi", "value": 1}, {"from": "40", "to": "##can", "value": 1}, {"from": "40", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "40", "to": "down", "value": 1}, {"from": "40", "to": "##53", "value": 1}, {"from": "40", "to": ". 022 pmid :", "value": 1}, {"from": "40", "to": "bax", "value": 1}, {"from": "genes", "to": "##i", "value": 1}, {"from": "genes", "to": "##f", "value": 1}, {"from": "genes", "to": "we", "value": 1}, {"from": "genes", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "genes", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "genes", "to": "3 )", "value": 1}, {"from": "genes", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "genes", "to": "##hie j", "value": 1}, {"from": "genes", "to": "k", "value": 1}, {"from": "genes", "to": "doi", "value": 1}, {"from": "genes", "to": "b", "value": 1}, {"from": "genes", "to": "102", "value": 1}, {"from": "genes", "to": "j", "value": 1}, {"from": "genes", "to": "##354028 [", "value": 1}, {"from": "genes", "to": ".", "value": 2}, {"from": "genes", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "genes", "to": "school", "value": 1}, {"from": "genes", "to": "), agegnehu sb", "value": 1}, {"from": "genes", "to": "##ra 00", "value": 1}, {"from": "genes", "to": "3 ), lamptey el", "value": 1}, {"from": "genes", "to": "1", "value": 1}, {"from": "genes", "to": "ka", "value": 1}, {"from": "genes", "to": "4", "value": 1}, {"from": "genes", "to": "of ghana, a", "value": 1}, {"from": "genes", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "genes", "to": "##461r pmid :", "value": 1}, {"from": "genes", "to": "antiangiogenic therapy of", "value": 1}, {"from": "genes", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "genes", "to": ")", "value": 1}, {"from": "genes", "to": "he", "value": 1}, {"from": "genes", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "genes", "to": "expression", "value": 2}, {"from": "genes", "to": "##500", "value": 1}, {"from": "genes", "to": "in cancer", "value": 1}, {"from": "genes", "to": "##mpo s", "value": 1}, {"from": "genes", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "genes", "to": "##cc", "value": 1}, {"from": "genes", "to": "inverse", "value": 1}, {"from": "genes", "to": "new insights into", "value": 1}, {"from": "genes", "to": "prescribed chole", "value": 1}, {"from": "genes", "to": "has recently", "value": 1}, {"from": "genes", "to": "and its biological functions", "value": 1}, {"from": "genes", "to": "of saida, saida, algeria.", "value": 1}, {"from": "genes", "to": "shown", "value": 1}, {"from": "genes", "to": "however", "value": 1}, {"from": "genes", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "genes", "to": "shown potential anti", "value": 1}, {"from": "genes", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "genes", "to": "a", "value": 1}, {"from": "genes", "to": "##in", "value": 1}, {"from": "genes", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "genes", "to": "particular breast cancer,", "value": 1}, {"from": "genes", "to": "still", "value": 1}, {"from": "genes", "to": "associated with atorvas", "value": 1}, {"from": "genes", "to": "in breast", "value": 1}, {"from": "genes", "to": "lowering", "value": 1}, {"from": "genes", "to": "to be responsive to", "value": 1}, {"from": "genes", "to": "interaction", "value": 2}, {"from": "genes", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "genes", "to": ") network and", "value": 1}, {"from": "genes", "to": "in the protein - protein", "value": 1}, {"from": "genes", "to": "drug,", "value": 1}, {"from": "genes", "to": "##gu", "value": 1}, {"from": "genes", "to": "hub gene", "value": 1}, {"from": "genes", "to": ", its influence on gene", "value": 1}, {"from": "genes", "to": "##lated", "value": 1}, {"from": "genes", "to": "was", "value": 1}, {"from": "genes", "to": "##in,", "value": 1}, {"from": "genes", "to": "ppi", "value": 1}, {"from": "genes", "to": "##oto", "value": 1}, {"from": "genes", "to": "##tat", "value": 1}, {"from": "genes", "to": "related pathways", "value": 1}, {"from": "genes", "to": "faculty", "value": 2}, {"from": "genes", "to": "cancer,", "value": 1}, {"from": "genes", "to": "expressed", "value": 1}, {"from": "genes", "to": "jun", "value": 1}, {"from": "genes", "to": "##cer effects.", "value": 1}, {"from": "genes", "to": "widely", "value": 1}, {"from": "genes", "to": "atorvas", "value": 1}, {"from": "genes", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "genes", "to": "##ster", "value": 1}, {"from": "genes", "to": "##ol", "value": 1}, {"from": "genes", "to": "##can", "value": 2}, {"from": "genes", "to": "cancer. atorvas", "value": 1}, {"from": "genes", "to": "was identified as the", "value": 1}, {"from": "genes", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "genes", "to": "##ifer", "value": 1}, {"from": "genes", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "genes", "to": "in the", "value": 1}, {"from": "genes", "to": "##ne - c", "value": 1}, {"from": "genes", "to": ", tnf signaling", "value": 1}, {"from": "genes", "to": ", which", "value": 1}, {"from": "genes", "to": "down - regulated", "value": 1}, {"from": "genes", "to": "including c", "value": 1}, {"from": "genes", "to": "##ytoki", "value": 1}, {"from": "genes", "to": "detected", "value": 1}, {"from": "genes", "to": "cancer", "value": 1}, {"from": "genes", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "genes", "to": "vs", "value": 1}, {"from": "genes", "to": "##cer assays. the", "value": 1}, {"from": "genes", "to": "or", "value": 1}, {"from": "genes", "to": "if", "value": 1}, {"from": "genes", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "genes", "to": "##ne receptor", "value": 1}, {"from": "genes", "to": "##ap", "value": 1}, {"from": "genes", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "genes", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "genes", "to": "via", "value": 1}, {"from": "genes", "to": "anti", "value": 1}, {"from": "genes", "to": "##n - \u03b3", "value": 1}, {"from": "genes", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "genes", "to": "f biotechnology engineering,", "value": 1}, {"from": "genes", "to": "were up -", "value": 1}, {"from": "genes", "to": ", nod - like receptor signaling", "value": 1}, {"from": "genes", "to": "##ation, pro", "value": 1}, {"from": "genes", "to": "pathways", "value": 1}, {"from": "genes", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "genes", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "genes", "to": "pathway", "value": 1}, {"from": "genes", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##i", "to": "##f", "value": 1}, {"from": "##i", "to": "we", "value": 1}, {"from": "##i", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##i", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##i", "to": "3 )", "value": 1}, {"from": "##i", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##i", "to": "##hie j", "value": 1}, {"from": "##i", "to": "k", "value": 1}, {"from": "##i", "to": "doi", "value": 1}, {"from": "##i", "to": "b", "value": 2}, {"from": "##i", "to": "102", "value": 1}, {"from": "##i", "to": "j", "value": 1}, {"from": "##i", "to": "##354028 [", "value": 1}, {"from": "##i", "to": ".", "value": 1}, {"from": "##i", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##i", "to": "school", "value": 1}, {"from": "##i", "to": "), agegnehu sb", "value": 1}, {"from": "##i", "to": "##ra 00", "value": 1}, {"from": "##i", "to": "3 ), lamptey el", "value": 1}, {"from": "##i", "to": "1", "value": 1}, {"from": "##i", "to": "ka", "value": 1}, {"from": "##i", "to": "4", "value": 1}, {"from": "##i", "to": "of ghana, a", "value": 1}, {"from": "##i", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##i", "to": "##461r pmid :", "value": 1}, {"from": "##i", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##i", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##i", "to": ")", "value": 1}, {"from": "##i", "to": "he", "value": 1}, {"from": "##i", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##i", "to": "expression", "value": 1}, {"from": "##i", "to": "##500", "value": 1}, {"from": "##i", "to": "in cancer", "value": 1}, {"from": "##i", "to": "##mpo s", "value": 1}, {"from": "##i", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##i", "to": "##cc", "value": 1}, {"from": "##i", "to": "inverse", "value": 1}, {"from": "##i", "to": "new insights into", "value": 1}, {"from": "##i", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "##i", "to": "in ki", "value": 1}, {"from": "##i", "to": "##cu", "value": 1}, {"from": "##i", "to": "t", "value": 1}, {"from": "##i", "to": "positive", "value": 1}, {"from": "##i", "to": "##2 -", "value": 1}, {"from": "##i", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##i", "to": "##type", "value": 1}, {"from": "##i", "to": "##rrence", "value": 1}, {"from": "##i", "to": "percentage", "value": 1}, {"from": "##i", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##i", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##i", "to": "##nes", "value": 1}, {"from": "##i", "to": "from l", "value": 1}, {"from": "##i", "to": "presented", "value": 1}, {"from": "##i", "to": "re", "value": 1}, {"from": "##i", "to": "results", "value": 1}, {"from": "##i", "to": "pam50 - derived risk of", "value": 1}, {"from": "##i", "to": "her", "value": 1}, {"from": "##i", "to": "er + /", "value": 1}, {"from": "##i", "to": "##nal a to normal - like", "value": 1}, {"from": "##i", "to": "##umi", "value": 1}, {"from": "##i", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##i", "to": "cells", "value": 1}, {"from": "##i", "to": "score", "value": 1}, {"from": "##i", "to": "change", "value": 1}, {"from": "##i", "to": "after", "value": 1}, {"from": "##i", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##i", "to": "of intrinsic sub", "value": 1}, {"from": "##i", "to": "p53", "value": 1}, {"from": "##i", "to": "##is.", "value": 1}, {"from": "##i", "to": "biomark", "value": 1}, {"from": "##i", "to": "subtype after", "value": 1}, {"from": "##i", "to": "net", "value": 1}, {"from": "##i", "to": "of", "value": 1}, {"from": "##i", "to": "##c patients", "value": 1}, {"from": "##i", "to": "net as a putative", "value": 1}, {"from": "##i", "to": "##umour cellularity size", "value": 1}, {"from": "##i", "to": "radio", "value": 1}, {"from": "##i", "to": ") and lower", "value": 1}, {"from": "##i", "to": "better", "value": 1}, {"from": "##f", "to": "we", "value": 1}, {"from": "##f", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "##f", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##f", "to": "3 )", "value": 1}, {"from": "##f", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##f", "to": "##hie j", "value": 1}, {"from": "##f", "to": "k", "value": 1}, {"from": "##f", "to": "doi", "value": 1}, {"from": "##f", "to": "b", "value": 1}, {"from": "##f", "to": "102", "value": 1}, {"from": "##f", "to": "j", "value": 1}, {"from": "##f", "to": "##354028 [", "value": 1}, {"from": "##f", "to": ".", "value": 1}, {"from": "##f", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##f", "to": "school", "value": 1}, {"from": "##f", "to": "), agegnehu sb", "value": 1}, {"from": "##f", "to": "##ra 00", "value": 1}, {"from": "##f", "to": "3 ), lamptey el", "value": 1}, {"from": "##f", "to": "1", "value": 1}, {"from": "##f", "to": "ka", "value": 1}, {"from": "##f", "to": "4", "value": 1}, {"from": "##f", "to": "of ghana, a", "value": 1}, {"from": "##f", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##f", "to": "##461r pmid :", "value": 1}, {"from": "##f", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##f", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##f", "to": ")", "value": 1}, {"from": "##f", "to": "he", "value": 1}, {"from": "##f", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##f", "to": "expression", "value": 1}, {"from": "##f", "to": "##500", "value": 1}, {"from": "##f", "to": "in cancer", "value": 1}, {"from": "##f", "to": "##mpo s", "value": 1}, {"from": "##f", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##f", "to": "##cc", "value": 1}, {"from": "##f", "to": "inverse", "value": 1}, {"from": "##f", "to": "new insights into", "value": 1}, {"from": "we", "to": "##nan university, jinming avenue, kaifeng 475004, china.", "value": 1}, {"from": "we", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "we", "to": "3 )", "value": 1}, {"from": "we", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "we", "to": "##hie j", "value": 1}, {"from": "we", "to": "k", "value": 1}, {"from": "we", "to": "doi", "value": 1}, {"from": "we", "to": "b", "value": 1}, {"from": "we", "to": "102", "value": 1}, {"from": "we", "to": "j", "value": 1}, {"from": "we", "to": "##354028 [", "value": 1}, {"from": "we", "to": ".", "value": 1}, {"from": "we", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "we", "to": "school", "value": 1}, {"from": "we", "to": "), agegnehu sb", "value": 1}, {"from": "we", "to": "##ra 00", "value": 1}, {"from": "we", "to": "3 ), lamptey el", "value": 1}, {"from": "we", "to": "1", "value": 1}, {"from": "we", "to": "ka", "value": 1}, {"from": "we", "to": "4", "value": 1}, {"from": "we", "to": "of ghana, a", "value": 1}, {"from": "we", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "we", "to": "##461r pmid :", "value": 1}, {"from": "we", "to": "antiangiogenic therapy of", "value": 1}, {"from": "we", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "we", "to": ")", "value": 1}, {"from": "we", "to": "he", "value": 1}, {"from": "we", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "we", "to": "expression", "value": 1}, {"from": "we", "to": "##500", "value": 1}, {"from": "we", "to": "in cancer", "value": 1}, {"from": "we", "to": "##mpo s", "value": 1}, {"from": "we", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "we", "to": "##cc", "value": 1}, {"from": "we", "to": "inverse", "value": 1}, {"from": "we", "to": "new insights into", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##rican centre for cell biology of infectious pathogens", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "3 )", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##hie j", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "k", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "doi", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "b", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "102", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "j", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##354028 [", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": ".", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "school", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "), agegnehu sb", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##ra 00", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "3 ), lamptey el", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "1", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "ka", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "4", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "of ghana, a", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##461r pmid :", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": ")", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "he", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "expression", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##500", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "in cancer", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##mpo s", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "##cc", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "inverse", "value": 1}, {"from": "##nan university, jinming avenue, kaifeng 475004, china.", "to": "new insights into", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "3 )", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##hie j", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "k", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "doi", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "b", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "102", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "j", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##354028 [", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": ".", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "school", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "), agegnehu sb", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##ra 00", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "3 ), lamptey el", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "1", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "ka", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "4", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "of ghana, a", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##461r pmid :", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": ")", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "he", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "expression", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##500", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "in cancer", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##mpo s", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "##cc", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "inverse", "value": 1}, {"from": "##rican centre for cell biology of infectious pathogens", "to": "new insights into", "value": 1}, {"from": "3 )", "to": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "value": 1}, {"from": "3 )", "to": "##hie j", "value": 1}, {"from": "3 )", "to": "k", "value": 1}, {"from": "3 )", "to": "doi", "value": 1}, {"from": "3 )", "to": "b", "value": 1}, {"from": "3 )", "to": "102", "value": 1}, {"from": "3 )", "to": "j", "value": 1}, {"from": "3 )", "to": "##354028 [", "value": 1}, {"from": "3 )", "to": ".", "value": 1}, {"from": "3 )", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "3 )", "to": "school", "value": 1}, {"from": "3 )", "to": "), agegnehu sb", "value": 1}, {"from": "3 )", "to": "##ra 00", "value": 1}, {"from": "3 )", "to": "3 ), lamptey el", "value": 1}, {"from": "3 )", "to": "1", "value": 1}, {"from": "3 )", "to": "ka", "value": 1}, {"from": "3 )", "to": "4", "value": 1}, {"from": "3 )", "to": "of ghana, a", "value": 1}, {"from": "3 )", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "3 )", "to": "##461r pmid :", "value": 1}, {"from": "3 )", "to": "antiangiogenic therapy of", "value": 1}, {"from": "3 )", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "3 )", "to": ")", "value": 1}, {"from": "3 )", "to": "he", "value": 1}, {"from": "3 )", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "3 )", "to": "expression", "value": 1}, {"from": "3 )", "to": "##500", "value": 1}, {"from": "3 )", "to": "in cancer", "value": 1}, {"from": "3 )", "to": "##mpo s", "value": 1}, {"from": "3 )", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "3 )", "to": "##cc", "value": 1}, {"from": "3 )", "to": "inverse", "value": 1}, {"from": "3 )", "to": "new insights into", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##hie j", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "k", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "doi", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "b", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "102", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "j", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##354028 [", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": ".", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "school", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "), agegnehu sb", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##ra 00", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "3 ), lamptey el", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "1", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "ka", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "4", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "of ghana, a", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##461r pmid :", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": ")", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "he", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "expression", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##500", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "in cancer", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##mpo s", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "##cc", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "inverse", "value": 1}, {"from": "##ed for medline ] 2. acs omega. 2025 apr 24 ; 10", "to": "new insights into", "value": 1}, {"from": "##hie j", "to": "k", "value": 1}, {"from": "##hie j", "to": "doi", "value": 1}, {"from": "##hie j", "to": "b", "value": 1}, {"from": "##hie j", "to": "102", "value": 1}, {"from": "##hie j", "to": "j", "value": 1}, {"from": "##hie j", "to": "##354028 [", "value": 1}, {"from": "##hie j", "to": ".", "value": 1}, {"from": "##hie j", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##hie j", "to": "school", "value": 1}, {"from": "##hie j", "to": "), agegnehu sb", "value": 1}, {"from": "##hie j", "to": "##ra 00", "value": 1}, {"from": "##hie j", "to": "3 ), lamptey el", "value": 1}, {"from": "##hie j", "to": "1", "value": 1}, {"from": "##hie j", "to": "ka", "value": 1}, {"from": "##hie j", "to": "4", "value": 1}, {"from": "##hie j", "to": "of ghana, a", "value": 1}, {"from": "##hie j", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##hie j", "to": "##461r pmid :", "value": 1}, {"from": "##hie j", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##hie j", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##hie j", "to": ")", "value": 1}, {"from": "##hie j", "to": "he", "value": 1}, {"from": "##hie j", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##hie j", "to": "expression", "value": 1}, {"from": "##hie j", "to": "##500", "value": 1}, {"from": "##hie j", "to": "in cancer", "value": 1}, {"from": "##hie j", "to": "##mpo s", "value": 1}, {"from": "##hie j", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##hie j", "to": "##cc", "value": 1}, {"from": "##hie j", "to": "inverse", "value": 1}, {"from": "##hie j", "to": "new insights into", "value": 1}, {"from": "k", "to": "doi", "value": 1}, {"from": "k", "to": "b", "value": 1}, {"from": "k", "to": "102", "value": 1}, {"from": "k", "to": "j", "value": 2}, {"from": "k", "to": "##354028 [", "value": 1}, {"from": "k", "to": ".", "value": 1}, {"from": "k", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "k", "to": "school", "value": 2}, {"from": "k", "to": "), agegnehu sb", "value": 1}, {"from": "k", "to": "##ra 00", "value": 1}, {"from": "k", "to": "3 ), lamptey el", "value": 1}, {"from": "k", "to": "1", "value": 1}, {"from": "k", "to": "ka", "value": 1}, {"from": "k", "to": "4", "value": 3}, {"from": "k", "to": "of ghana, a", "value": 1}, {"from": "k", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "k", "to": "##461r pmid :", "value": 1}, {"from": "k", "to": "antiangiogenic therapy of", "value": 1}, {"from": "k", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "k", "to": ")", "value": 3}, {"from": "k", "to": "he", "value": 1}, {"from": "k", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "k", "to": "expression", "value": 1}, {"from": "k", "to": "##500", "value": 1}, {"from": "k", "to": "in cancer", "value": 1}, {"from": "k", "to": "##mpo s", "value": 1}, {"from": "k", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "k", "to": "##cc", "value": 2}, {"from": "k", "to": "inverse", "value": 1}, {"from": "k", "to": "new insights into", "value": 1}, {"from": "k", "to": "box l", "value": 1}, {"from": "k", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "k", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "k", "to": "of medical sciences, c.", "value": 1}, {"from": "k", "to": "these two conditions which", "value": 1}, {"from": "k", "to": "box", "value": 1}, {"from": "k", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "k", "to": "care", "value": 1}, {"from": "k", "to": "##ra", "value": 1}, {"from": "k", "to": "00", "value": 1}, {"from": "k", "to": "233, ghana.", "value": 1}, {"from": "k", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "k", "to": "##g 77, a", "value": 1}, {"from": "k", "to": "5", "value": 2}, {"from": "k", "to": ") west african genetic medicine centre", "value": 1}, {"from": "k", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "k", "to": "of health", "value": 1}, {"from": "k", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "k", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "k", "to": "been observed", "value": 1}, {"from": "k", "to": ", university of ghana, p. o.", "value": 1}, {"from": "k", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "k", "to": "between", "value": 1}, {"from": "k", "to": "of anaesthesia and intensive", "value": 1}, {"from": "k", "to": "##233, ghana.", "value": 1}, {"from": "k", "to": "incidence", "value": 1}, {"from": "k", "to": "cancer and ad", "value": 1}, {"from": "k", "to": "were formerly", "value": 1}, {"from": "k", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "k", "to": "has", "value": 1}, {"from": "k", "to": "department", "value": 2}, {"from": "k", "to": "inverse relationship between", "value": 1}, {"from": "k", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "k", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "k", "to": "), beltran - v", "value": 1}, {"from": "k", "to": ") department of pathology, co", "value": 1}, {"from": "k", "to": "##ulin", "value": 1}, {"from": "k", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "k", "to": "f", "value": 1}, {"from": "k", "to": "new yo", "value": 1}, {"from": "k", "to": "sloan", "value": 1}, {"from": "k", "to": "la", "value": 1}, {"from": "k", "to": "center", "value": 1}, {"from": "k", "to": "us", "value": 1}, {"from": "k", "to": "##lum", "value": 1}, {"from": "k", "to": "##o m", "value": 1}, {"from": "k", "to": "9", "value": 1}, {"from": "k", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "k", "to": "kette", "value": 1}, {"from": "k", "to": "yo", "value": 1}, {"from": "k", "to": "##ettering cancer", "value": 1}, {"from": "k", "to": "##rk, usa.", "value": 1}, {"from": "k", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "k", "to": "re", "value": 1}, {"from": "k", "to": "new york", "value": 1}, {"from": "k", "to": "##bia university,", "value": 1}, {"from": "k", "to": "), shin e", "value": 1}, {"from": "k", "to": "##a.", "value": 1}, {"from": "k", "to": "##ring cancer", "value": 1}, {"from": "k", "to": "##rk, new", "value": 1}, {"from": "k", "to": "##urent, quebec, canada.", "value": 1}, {"from": "k", "to": "##isied", "value": 1}, {"from": "k", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "k", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "k", "to": "ancers. sinha s", "value": 1}, {"from": "k", "to": "##is - filho j", "value": 1}, {"from": "k", "to": "##rk,", "value": 1}, {"from": "k", "to": "), gardner r", "value": 1}, {"from": "doi", "to": "b", "value": 3}, {"from": "doi", "to": "102", "value": 3}, {"from": "doi", "to": "j", "value": 5}, {"from": "doi", "to": "##354028 [", "value": 1}, {"from": "doi", "to": ".", "value": 8}, {"from": "doi", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "doi", "to": "school", "value": 1}, {"from": "doi", "to": "), agegnehu sb", "value": 1}, {"from": "doi", "to": "##ra 00", "value": 1}, {"from": "doi", "to": "3 ), lamptey el", "value": 1}, {"from": "doi", "to": "1", "value": 3}, {"from": "doi", "to": "ka", "value": 1}, {"from": "doi", "to": "4", "value": 3}, {"from": "doi", "to": "of ghana, a", "value": 1}, {"from": "doi", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "doi", "to": "##461r pmid :", "value": 1}, {"from": "doi", "to": "antiangiogenic therapy of", "value": 1}, {"from": "doi", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "doi", "to": ")", "value": 1}, {"from": "doi", "to": "he", "value": 1}, {"from": "doi", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "doi", "to": "expression", "value": 2}, {"from": "doi", "to": "##500", "value": 1}, {"from": "doi", "to": "in cancer", "value": 1}, {"from": "doi", "to": "##mpo s", "value": 1}, {"from": "doi", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "doi", "to": "##cc", "value": 1}, {"from": "doi", "to": "inverse", "value": 1}, {"from": "doi", "to": "new insights into", "value": 1}, {"from": "doi", "to": "risk", "value": 1}, {"from": "doi", "to": "of cancer development while", "value": 1}, {"from": "doi", "to": "reduced", "value": 1}, {"from": "doi", "to": "##1 / acsomega. 4", "value": 1}, {"from": "doi", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "doi", "to": "##ve", "value": 1}, {"from": "doi", "to": "##re", "value": 1}, {"from": "doi", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "doi", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "doi", "to": "10. 102", "value": 1}, {"from": "doi", "to": "##er and 5 genes down", "value": 1}, {"from": "doi", "to": "upre", "value": 1}, {"from": "doi", "to": "were downregulated", "value": 1}, {"from": "doi", "to": "pm", "value": 1}, {"from": "doi", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "doi", "to": "##ida", "value": 2}, {"from": "doi", "to": "##gulated", "value": 1}, {"from": "doi", "to": "play an important role in", "value": 1}, {"from": "doi", "to": "##12059893", "value": 1}, {"from": "doi", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "doi", "to": "##c", "value": 2}, {"from": "doi", "to": "in all three cancers and may", "value": 1}, {"from": "doi", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "doi", "to": "##11571 pmcid : pm", "value": 1}, {"from": "doi", "to": "##id :", "value": 1}, {"from": "doi", "to": "), hashim", "value": 1}, {"from": "doi", "to": "of medicine, univers", "value": 1}, {"from": "doi", "to": "##rta", "value": 1}, {"from": "doi", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "doi", "to": ") drug development research cluster, indon", "value": 1}, {"from": "doi", "to": "##an medical", "value": 1}, {"from": "doi", "to": "indon", "value": 1}, {"from": "doi", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "doi", "to": "##hibit", "value": 1}, {"from": "doi", "to": "na", "value": 1}, {"from": "doi", "to": "master program in biomedical", "value": 1}, {"from": "doi", "to": "education", "value": 1}, {"from": "doi", "to": "n", "value": 1}, {"from": "doi", "to": "3", "value": 1}, {"from": "doi", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "doi", "to": "##ajrin", "value": 1}, {"from": "doi", "to": "), azizah", "value": 1}, {"from": "doi", "to": "##esi", "value": 1}, {"from": "doi", "to": "te", "value": 1}, {"from": "doi", "to": "##a, jaka", "value": 1}, {"from": "doi", "to": "##djo a", "value": 1}, {"from": "doi", "to": "of medicine, universitas indon", "value": 1}, {"from": "doi", "to": "##itas", "value": 1}, {"from": "doi", "to": "##a.", "value": 1}, {"from": "doi", "to": "faculty", "value": 3}, {"from": "doi", "to": "##b", "value": 1}, {"from": "doi", "to": "am", "value": 1}, {"from": "doi", "to": "nn", "value": 1}, {"from": "doi", "to": "of pharmacy, univers", "value": 1}, {"from": "doi", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "doi", "to": "##don", "value": 1}, {"from": "doi", "to": "##a,", "value": 1}, {"from": "doi", "to": ", indon", "value": 1}, {"from": "doi", "to": "##aka", "value": 1}, {"from": "doi", "to": "and research instit", "value": 1}, {"from": "doi", "to": "), ramadanti", "value": 1}, {"from": "doi", "to": "52", "value": 2}, {"from": "doi", "to": "##life", "value": 1}, {"from": "doi", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "doi", "to": "##ion of p21", "value": 1}, {"from": "doi", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "doi", "to": "##in - mediated anti -", "value": 1}, {"from": "doi", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "doi", "to": "1 ), abdelkrim g", "value": 1}, {"from": "doi", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "doi", "to": "cancer effects. foda my", "value": 1}, {"from": "doi", "to": "##press", "value": 1}, {"from": "doi", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "doi", "to": "##tat", "value": 1}, {"from": "doi", "to": "jun", "value": 2}, {"from": "doi", "to": "2 ), salem ml", "value": 1}, {"from": "doi", "to": "in atorvas", "value": 1}, {"from": "doi", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "doi", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "doi", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "doi", "to": "##regulated", "value": 1}, {"from": "doi", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "doi", "to": ". 108", "value": 1}, {"from": "doi", "to": "jun might", "value": 1}, {"from": "doi", "to": "##0", "value": 1}, {"from": "doi", "to": "expression.", "value": 1}, {"from": "doi", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "doi", "to": "##na ss", "value": 1}, {"from": "doi", "to": "##v", "value": 1}, {"from": "doi", "to": "##un", "value": 1}, {"from": "doi", "to": "##gno", "value": 2}, {"from": "doi", "to": "activity positively correlated with", "value": 1}, {"from": "doi", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "doi", "to": ". 17305 /", "value": 1}, {"from": "doi", "to": "luki", "value": 1}, {"from": "doi", "to": "bio", "value": 1}, {"from": "doi", "to": "##v vi", "value": 1}, {"from": "doi", "to": "logino", "value": 1}, {"from": "doi", "to": "was", "value": 1}, {"from": "doi", "to": "may directly interact with", "value": 1}, {"from": "doi", "to": "serve as a valuable pro", "value": 1}, {"from": "doi", "to": "##tatin", "value": 1}, {"from": "doi", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "doi", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "doi", "to": "expression. as such,", "value": 1}, {"from": "doi", "to": "significantly", "value": 1}, {"from": "doi", "to": "##nina", "value": 1}, {"from": "doi", "to": "pro", "value": 1}, {"from": "doi", "to": "down", "value": 2}, {"from": "doi", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "doi", "to": "=", "value": 1}, {"from": "doi", "to": "##s,", "value": 1}, {"from": "doi", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "doi", "to": "which is involved in", "value": 1}, {"from": "doi", "to": "- 0. 46,", "value": 1}, {"from": "doi", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "doi", "to": "mi", "value": 1}, {"from": "doi", "to": "- 5p", "value": 1}, {"from": "doi", "to": "##r - 17", "value": 1}, {"from": "doi", "to": "a", "value": 1}, {"from": "doi", "to": "5", "value": 2}, {"from": "doi", "to": "##1", "value": 1}, {"from": "doi", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "doi", "to": ") : e010548.", "value": 1}, {"from": "doi", "to": "5p", "value": 1}, {"from": "doi", "to": "hand", "value": 1}, {"from": "doi", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "doi", "to": "03 ) and", "value": 1}, {"from": "doi", "to": "p = 0", "value": 1}, {"from": "doi", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "doi", "to": "##r - 106a -", "value": 1}, {"from": "doi", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "doi", "to": "target gene", "value": 1}, {"from": "doi", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "doi", "to": "- 0. 41,", "value": 1}, {"from": "doi", "to": "of these lnc", "value": 1}, {"from": "doi", "to": "p = 0.", "value": 1}, {"from": "doi", "to": "113", "value": 1}, {"from": "doi", "to": "common", "value": 1}, {"from": "doi", "to": "regulated", "value": 1}, {"from": "doi", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "doi", "to": "conclusions", "value": 1}, {"from": "doi", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "doi", "to": "10. 113", "value": 1}, {"from": "doi", "to": "interests", "value": 1}, {"from": "doi", "to": ". no commercial re -", "value": 1}, {"from": "doi", "to": "##p", "value": 1}, {"from": "doi", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "doi", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "doi", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "doi", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "doi", "to": ": nr receives research support from bm", "value": 1}, {"from": "doi", "to": "use", "value": 1}, {"from": "doi", "to": ": atm deficiency, while com", "value": 1}, {"from": "doi", "to": "does", "value": 1}, {"from": "doi", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "doi", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "doi", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "doi", "to": "), huarte m", "value": 1}, {"from": "doi", "to": "12", "value": 1}, {"from": "doi", "to": "##407.", "value": 1}, {"from": "doi", "to": "), par", "value": 1}, {"from": "doi", "to": "ins", "value": 1}, {"from": "doi", "to": "##or", "value": 1}, {"from": "doi", "to": "##e", "value": 1}, {"from": "doi", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "doi", "to": "9", "value": 1}, {"from": "doi", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "doi", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "doi", "to": "), aragon s", "value": 1}, {"from": "doi", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "doi", "to": "##ory", "value": 1}, {"from": "doi", "to": "), gimenez j", "value": 1}, {"from": "doi", "to": "- lopez i", "value": 1}, {"from": "doi", "to": "##rine", "value": 1}, {"from": "doi", "to": "er + / her2 -", "value": 1}, {"from": "doi", "to": "), prat a", "value": 1}, {"from": "doi", "to": "research", "value": 1}, {"from": "doi", "to": "##e. lg is /", "value": 1}, {"from": "doi", "to": "), buch e", "value": 1}, {"from": "doi", "to": "##roga v", "value": 1}, {"from": "doi", "to": "been holding research", "value": 1}, {"from": "doi", "to": "11", "value": 1}, {"from": "doi", "to": "101", "value": 3}, {"from": "doi", "to": "##riaga k", "value": 1}, {"from": "doi", "to": "), etxabe i", "value": 1}, {"from": "doi", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "doi", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "doi", "to": "13", "value": 1}, {"from": "doi", "to": "therapy", "value": 1}, {"from": "doi", "to": "##ui", "value": 1}, {"from": "doi", "to": "##ez", "value": 1}, {"from": "doi", "to": "##vita", "value": 1}, {"from": "doi", "to": "contracts", "value": 1}, {"from": "doi", "to": "has", "value": 1}, {"from": "doi", "to": "6", "value": 1}, {"from": "doi", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "doi", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "doi", "to": "). author information :", "value": 1}, {"from": "doi", "to": "), urruticoechea a", "value": 1}, {"from": "doi", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "doi", "to": "t", "value": 1}, {"from": "doi", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "doi", "to": "##6 /", "value": 3}, {"from": "doi", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "doi", "to": "be validated in independent cohorts,", "value": 1}, {"from": "doi", "to": "cost - effectiveness", "value": 1}, {"from": "doi", "to": "##ers of response to net and pro", "value": 1}, {"from": "doi", "to": "10. 101", "value": 1}, {"from": "doi", "to": "help", "value": 1}, {"from": "doi", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "doi", "to": "##sis, which", "value": 1}, {"from": "doi", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "doi", "to": "##lin", "value": 1}, {"from": "doi", "to": "should", "value": 1}, {"from": "doi", "to": "202", "value": 1}, {"from": "doi", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "doi", "to": "helping to the", "value": 1}, {"from": "doi", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "doi", "to": "implementation of net", "value": 1}, {"from": "doi", "to": "##mark", "value": 1}, {"from": "doi", "to": "##ranon.", "value": 1}, {"from": "doi", "to": "##5", "value": 1}, {"from": "doi", "to": ". clbc. 202", "value": 1}, {"from": "doi", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "doi", "to": "##5.", "value": 1}, {"from": "doi", "to": "is cost - effective", "value": 1}, {"from": "doi", "to": "of agriculture and natural", "value": 1}, {"from": "doi", "to": ". ac.", "value": 1}, {"from": "doi", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "doi", "to": "resources", "value": 1}, {"from": "doi", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "doi", "to": "##za. he", "value": 1}, {"from": "doi", "to": "are", "value": 1}, {"from": "doi", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "doi", "to": "##ri - japelaghi r", "value": 1}, {"from": "doi", "to": "##r.", "value": 1}, {"from": "doi", "to": "who", "value": 1}, {"from": "doi", "to": "inter", "value": 1}, {"from": "doi", "to": "##vin", "value": 1}, {"from": "doi", "to": "of tabriz,", "value": 1}, {"from": "doi", "to": "@ org.", "value": 1}, {"from": "doi", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "doi", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "doi", "to": "##idari", "value": 1}, {"from": "doi", "to": "s", "value": 1}, {"from": "doi", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "doi", "to": "ta", "value": 1}, {"from": "doi", "to": "##ran. electronic address :", "value": 1}, {"from": "doi", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "doi", "to": "re", "value": 1}, {"from": "doi", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "doi", "to": "perspectives", "value": 1}, {"from": "doi", "to": "##briz,", "value": 1}, {"from": "doi", "to": "of agriculture,", "value": 1}, {"from": "doi", "to": "##fer", "value": 1}, {"from": "doi", "to": "##on", "value": 1}, {"from": "doi", "to": "##ki", "value": 1}, {"from": "doi", "to": "from both", "value": 1}, {"from": "doi", "to": "##ran.", "value": 1}, {"from": "doi", "to": "- regulate", "value": 1}, {"from": "doi", "to": "the", "value": 1}, {"from": "doi", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "doi", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "doi", "to": "##tic", "value": 1}, {"from": "doi", "to": "##6", "value": 1}, {"from": "doi", "to": "##poptosis", "value": 1}, {"from": "doi", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "doi", "to": "##xic effect of", "value": 1}, {"from": "doi", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "doi", "to": "00", "value": 1}, {"from": "doi", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "doi", "to": "##xic efficacy of the", "value": 1}, {"from": "doi", "to": "and", "value": 1}, {"from": "doi", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "doi", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "doi", "to": "if", "value": 1}, {"from": "doi", "to": "up -", "value": 1}, {"from": "doi", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "doi", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "doi", "to": "development of tumor cells, a", "value": 1}, {"from": "doi", "to": "##348089 conflict o", "value": 1}, {"from": "doi", "to": "regulate", "value": 1}, {"from": "doi", "to": "##oto", "value": 1}, {"from": "doi", "to": "of pro", "value": 1}, {"from": "doi", "to": "##cl -", "value": 1}, {"from": "doi", "to": "##biotec. 2025.", "value": 1}, {"from": "doi", "to": "04", "value": 1}, {"from": "doi", "to": "##apopto", "value": 1}, {"from": "doi", "to": "to", "value": 1}, {"from": "doi", "to": "##cer and antiviral functions of", "value": 1}, {"from": "doi", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "doi", "to": "via", "value": 1}, {"from": "doi", "to": "and p", "value": 1}, {"from": "doi", "to": "##c cell line", "value": 1}, {"from": "doi", "to": "hi", "value": 1}, {"from": "doi", "to": "##can", "value": 1}, {"from": "doi", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "doi", "to": "##53", "value": 1}, {"from": "doi", "to": ". 022 pmid :", "value": 1}, {"from": "doi", "to": "bax", "value": 1}, {"from": "b", "to": "102", "value": 1}, {"from": "b", "to": "j", "value": 2}, {"from": "b", "to": "##354028 [", "value": 1}, {"from": "b", "to": ".", "value": 5}, {"from": "b", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "b", "to": "school", "value": 1}, {"from": "b", "to": "), agegnehu sb", "value": 1}, {"from": "b", "to": "##ra 00", "value": 1}, {"from": "b", "to": "3 ), lamptey el", "value": 1}, {"from": "b", "to": "1", "value": 2}, {"from": "b", "to": "ka", "value": 1}, {"from": "b", "to": "4", "value": 1}, {"from": "b", "to": "of ghana, a", "value": 1}, {"from": "b", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "b", "to": "##461r pmid :", "value": 1}, {"from": "b", "to": "antiangiogenic therapy of", "value": 1}, {"from": "b", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "b", "to": ")", "value": 3}, {"from": "b", "to": "he", "value": 1}, {"from": "b", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "b", "to": "expression", "value": 2}, {"from": "b", "to": "##500", "value": 1}, {"from": "b", "to": "in cancer", "value": 1}, {"from": "b", "to": "##mpo s", "value": 1}, {"from": "b", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "b", "to": "##cc", "value": 1}, {"from": "b", "to": "inverse", "value": 1}, {"from": "b", "to": "new insights into", "value": 1}, {"from": "b", "to": "classification of breast cancer : l", "value": 1}, {"from": "b", "to": ", h", "value": 1}, {"from": "b", "to": "##methylation", "value": 1}, {"from": "b", "to": "tion", "value": 1}, {"from": "b", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "b", "to": "the pt", "value": 1}, {"from": "b", "to": ". \u00a9 202", "value": 1}, {"from": "b", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "b", "to": "##rn2 gene", "value": 1}, {"from": "b", "to": "##type", "value": 2}, {"from": "b", "to": "##nal", "value": 1}, {"from": "b", "to": "##261 ), and tnbc", "value": 1}, {"from": "b", "to": "##p", "value": 1}, {"from": "b", "to": "the author", "value": 1}, {"from": "b", "to": "bio", "value": 3}, {"from": "b", "to": "respectively", "value": 1}, {"from": "b", "to": "##marker for each sub", "value": 1}, {"from": "b", "to": "##umi", "value": 2}, {"from": "b", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "b", "to": "##yper", "value": 1}, {"from": "b", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "b", "to": "improve", "value": 1}, {"from": "b", "to": "##10", "value": 1}, {"from": "b", "to": "##5", "value": 1}, {"from": "b", "to": "##nal a", "value": 1}, {"from": "b", "to": "52", "value": 1}, {"from": "b", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "b", "to": "##ene", "value": 1}, {"from": "b", "to": "which was", "value": 1}, {"from": "b", "to": ": cyce or ccne1", "value": 1}, {"from": "b", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "b", "to": "##8 ), and e2f1", "value": 1}, {"from": "b", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "b", "to": "##1 ), rbl1", "value": 1}, {"from": "b", "to": "might", "value": 1}, {"from": "b", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "b", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "b", "to": "the native", "value": 1}, {"from": "b", "to": "ligan", "value": 1}, {"from": "b", "to": "00", "value": 2}, {"from": "b", "to": "im", "value": 1}, {"from": "b", "to": "p = 0. 01", "value": 1}, {"from": "b", "to": "##rank", "value": 1}, {"from": "b", "to": "##j", "value": 1}, {"from": "b", "to": "by", "value": 1}, {"from": "b", "to": "rerank score", "value": 1}, {"from": "b", "to": "##um", "value": 1}, {"from": "b", "to": "##d", "value": 1}, {"from": "b", "to": "of ad", "value": 1}, {"from": "b", "to": "re", "value": 2}, {"from": "b", "to": "##idodiph", "value": 1}, {"from": "b", "to": "p = 0", "value": 1}, {"from": "b", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "b", "to": "- 112. 70 k", "value": 1}, {"from": "b", "to": "score", "value": 2}, {"from": "b", "to": "##ine", "value": 1}, {"from": "b", "to": "##enyl", "value": 1}, {"from": "b", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "b", "to": "cycle", "value": 1}, {"from": "b", "to": "##osphate", "value": 1}, {"from": "b", "to": "- 110. 68 k", "value": 1}, {"from": "b", "to": "0", "value": 1}, {"from": "b", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "b", "to": "##c", "value": 1}, {"from": "b", "to": "/ mol ), and nummular", "value": 1}, {"from": "b", "to": "squal", "value": 1}, {"from": "b", "to": "the decrease in p21", "value": 1}, {"from": "b", "to": "##mularia stem suggested that", "value": 1}, {"from": "b", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "b", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "b", "to": "##regulated", "value": 1}, {"from": "b", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "b", "to": ". 108", "value": 1}, {"from": "b", "to": "jun might", "value": 1}, {"from": "b", "to": "##0", "value": 1}, {"from": "b", "to": "expression.", "value": 1}, {"from": "b", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "b", "to": "##na ss", "value": 1}, {"from": "b", "to": "##v", "value": 1}, {"from": "b", "to": "##un", "value": 1}, {"from": "b", "to": "##gno", "value": 1}, {"from": "b", "to": "activity positively correlated with", "value": 1}, {"from": "b", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "b", "to": ". 17305 /", "value": 1}, {"from": "b", "to": "luki", "value": 1}, {"from": "b", "to": "##v vi", "value": 1}, {"from": "b", "to": "logino", "value": 1}, {"from": "b", "to": "was", "value": 1}, {"from": "b", "to": "may directly interact with", "value": 1}, {"from": "b", "to": "serve as a valuable pro", "value": 1}, {"from": "b", "to": "##tatin", "value": 1}, {"from": "b", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "b", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "b", "to": "expression. as such,", "value": 1}, {"from": "b", "to": "significantly", "value": 1}, {"from": "b", "to": "jun", "value": 1}, {"from": "b", "to": "##nina", "value": 1}, {"from": "b", "to": "pro", "value": 1}, {"from": "b", "to": "down", "value": 2}, {"from": "b", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "b", "to": "12", "value": 1}, {"from": "b", "to": "after net", "value": 1}, {"from": "b", "to": "a significant", "value": 1}, {"from": "b", "to": "time", "value": 1}, {"from": "b", "to": "offers the opportunity of", "value": 1}, {"from": "b", "to": "##ip", "value": 1}, {"from": "b", "to": "t", "value": 3}, {"from": "b", "to": "however", "value": 1}, {"from": "b", "to": ") health", "value": 1}, {"from": "b", "to": "background", "value": 1}, {"from": "b", "to": "##re population of", "value": 1}, {"from": "b", "to": "negative breast", "value": 1}, {"from": "b", "to": "barrier", "value": 1}, {"from": "b", "to": "##gipuzkoa", "value": 1}, {"from": "b", "to": "clinical", "value": 1}, {"from": "b", "to": "##2 -", "value": 2}, {"from": "b", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "b", "to": "##zkoa", "value": 1}, {"from": "b", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "b", "to": "##gi", "value": 1}, {"from": "b", "to": "##donostia ) health", "value": 1}, {"from": "b", "to": "##tian,", "value": 1}, {"from": "b", "to": "cancer", "value": 1}, {"from": "b", "to": "spain", "value": 1}, {"from": "b", "to": "##uzkoa. eus.", "value": 1}, {"from": "b", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "b", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "b", "to": "and", "value": 3}, {"from": "b", "to": "real", "value": 1}, {"from": "b", "to": "personal", "value": 1}, {"from": "b", "to": "##ised therapy.", "value": 1}, {"from": "b", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "b", "to": "##donost", "value": 1}, {"from": "b", "to": "##cent", "value": 1}, {"from": "b", "to": "research institute", "value": 1}, {"from": "b", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "b", "to": "sa", "value": 1}, {"from": "b", "to": "sebas", "value": 1}, {"from": "b", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "b", "to": "her", "value": 2}, {"from": "b", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "b", "to": "##n sebastian,", "value": 1}, {"from": "b", "to": "##umour response", "value": 1}, {"from": "b", "to": "a,", "value": 1}, {"from": "b", "to": "##pu", "value": 1}, {"from": "b", "to": "##n", "value": 1}, {"from": "b", "to": "sebastian", "value": 1}, {"from": "b", "to": "##uc", "value": 1}, {"from": "b", "to": "13", "value": 1}, {"from": "b", "to": ", the lack of reprod", "value": 1}, {"from": "b", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "b", "to": "##c ) allows", "value": 1}, {"from": "b", "to": "##gnosis", "value": 1}, {"from": "b", "to": "- g", "value": 1}, {"from": "b", "to": "##ia", "value": 1}, {"from": "b", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "b", "to": "in ki", "value": 1}, {"from": "b", "to": "##cu", "value": 1}, {"from": "b", "to": "positive", "value": 1}, {"from": "b", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "b", "to": "##rrence", "value": 1}, {"from": "b", "to": "percentage", "value": 1}, {"from": "b", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "b", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "b", "to": "##nes", "value": 1}, {"from": "b", "to": "from l", "value": 1}, {"from": "b", "to": "presented", "value": 1}, {"from": "b", "to": "results", "value": 1}, {"from": "b", "to": "pam50 - derived risk of", "value": 1}, {"from": "b", "to": "er + /", "value": 1}, {"from": "b", "to": "##nal a to normal - like", "value": 1}, {"from": "b", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "b", "to": "cells", "value": 1}, {"from": "b", "to": "change", "value": 1}, {"from": "b", "to": "after", "value": 1}, {"from": "b", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "b", "to": "of intrinsic sub", "value": 1}, {"from": "b", "to": "p53", "value": 1}, {"from": "b", "to": "##is.", "value": 1}, {"from": "b", "to": "biomark", "value": 1}, {"from": "b", "to": "subtype after", "value": 1}, {"from": "b", "to": "net", "value": 1}, {"from": "b", "to": "of", "value": 1}, {"from": "b", "to": "##c patients", "value": 1}, {"from": "b", "to": "net as a putative", "value": 1}, {"from": "b", "to": "##umour cellularity size", "value": 1}, {"from": "b", "to": "radio", "value": 1}, {"from": "b", "to": ") and lower", "value": 1}, {"from": "b", "to": "better", "value": 1}, {"from": "b", "to": "##rgen, norway.", "value": 1}, {"from": "b", "to": "##rgen, nor", "value": 1}, {"from": "b", "to": "economics", "value": 1}, {"from": "b", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "b", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "b", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "b", "to": "5", "value": 1}, {"from": "b", "to": "clinical trials", "value": 1}, {"from": "b", "to": "of health management and health", "value": 1}, {"from": "b", "to": "of health", "value": 1}, {"from": "b", "to": "institute", "value": 1}, {"from": "b", "to": ";", "value": 1}, {"from": "b", "to": ") department of p", "value": 1}, {"from": "b", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "b", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "b", "to": "), heie a", "value": 1}, {"from": "b", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "b", "to": "department", "value": 1}, {"from": "b", "to": "be", "value": 1}, {"from": "b", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "b", "to": "ug", "value": 1}, {"from": "b", "to": "##way", "value": 1}, {"from": "b", "to": "- regulate", "value": 1}, {"from": "b", "to": "the", "value": 1}, {"from": "b", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "b", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "b", "to": "##tic", "value": 1}, {"from": "b", "to": "##6 /", "value": 1}, {"from": "b", "to": "##6", "value": 1}, {"from": "b", "to": "##poptosis", "value": 1}, {"from": "b", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "b", "to": "##xic effect of", "value": 1}, {"from": "b", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "b", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "b", "to": "##xic efficacy of the", "value": 1}, {"from": "b", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "b", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "b", "to": "if", "value": 1}, {"from": "b", "to": "up -", "value": 1}, {"from": "b", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "b", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "b", "to": "development of tumor cells, a", "value": 1}, {"from": "b", "to": "##348089 conflict o", "value": 1}, {"from": "b", "to": "regulate", "value": 1}, {"from": "b", "to": "101", "value": 1}, {"from": "b", "to": "##oto", "value": 1}, {"from": "b", "to": "of pro", "value": 1}, {"from": "b", "to": "##cl -", "value": 1}, {"from": "b", "to": "##biotec. 2025.", "value": 1}, {"from": "b", "to": "04", "value": 1}, {"from": "b", "to": "##apopto", "value": 1}, {"from": "b", "to": "to", "value": 1}, {"from": "b", "to": "##cer and antiviral functions of", "value": 1}, {"from": "b", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "b", "to": "via", "value": 1}, {"from": "b", "to": "and p", "value": 1}, {"from": "b", "to": "##c cell line", "value": 1}, {"from": "b", "to": "hi", "value": 1}, {"from": "b", "to": "##can", "value": 1}, {"from": "b", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "b", "to": "##53", "value": 1}, {"from": "b", "to": ". 022 pmid :", "value": 1}, {"from": "b", "to": "bax", "value": 1}, {"from": "102", "to": "j", "value": 2}, {"from": "102", "to": "##354028 [", "value": 1}, {"from": "102", "to": ".", "value": 3}, {"from": "102", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "102", "to": "school", "value": 1}, {"from": "102", "to": "), agegnehu sb", "value": 1}, {"from": "102", "to": "##ra 00", "value": 1}, {"from": "102", "to": "3 ), lamptey el", "value": 1}, {"from": "102", "to": "1", "value": 1}, {"from": "102", "to": "ka", "value": 1}, {"from": "102", "to": "4", "value": 2}, {"from": "102", "to": "of ghana, a", "value": 1}, {"from": "102", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "102", "to": "##461r pmid :", "value": 1}, {"from": "102", "to": "antiangiogenic therapy of", "value": 1}, {"from": "102", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "102", "to": ")", "value": 1}, {"from": "102", "to": "he", "value": 1}, {"from": "102", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "102", "to": "expression", "value": 1}, {"from": "102", "to": "##500", "value": 1}, {"from": "102", "to": "in cancer", "value": 1}, {"from": "102", "to": "##mpo s", "value": 1}, {"from": "102", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "102", "to": "##cc", "value": 1}, {"from": "102", "to": "inverse", "value": 1}, {"from": "102", "to": "new insights into", "value": 1}, {"from": "102", "to": "), huarte m", "value": 1}, {"from": "102", "to": "12", "value": 1}, {"from": "102", "to": "##407.", "value": 1}, {"from": "102", "to": "), par", "value": 1}, {"from": "102", "to": "ins", "value": 1}, {"from": "102", "to": "##or", "value": 1}, {"from": "102", "to": "##e", "value": 1}, {"from": "102", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "102", "to": "9", "value": 1}, {"from": "102", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "102", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "102", "to": "), aragon s", "value": 1}, {"from": "102", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "102", "to": "##ory", "value": 1}, {"from": "102", "to": "5", "value": 1}, {"from": "102", "to": "), gimenez j", "value": 1}, {"from": "102", "to": "- lopez i", "value": 1}, {"from": "102", "to": "##rine", "value": 1}, {"from": "102", "to": "er + / her2 -", "value": 1}, {"from": "102", "to": "), prat a", "value": 1}, {"from": "102", "to": "research", "value": 1}, {"from": "102", "to": "##e. lg is /", "value": 1}, {"from": "102", "to": "), buch e", "value": 1}, {"from": "102", "to": "##roga v", "value": 1}, {"from": "102", "to": "been holding research", "value": 1}, {"from": "102", "to": "11", "value": 1}, {"from": "102", "to": "101", "value": 1}, {"from": "102", "to": "##riaga k", "value": 1}, {"from": "102", "to": "), etxabe i", "value": 1}, {"from": "102", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "102", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "102", "to": "13", "value": 1}, {"from": "102", "to": "therapy", "value": 1}, {"from": "102", "to": "##ui", "value": 1}, {"from": "102", "to": "##ez", "value": 1}, {"from": "102", "to": "##vita", "value": 1}, {"from": "102", "to": "contracts", "value": 1}, {"from": "102", "to": "has", "value": 1}, {"from": "102", "to": "6", "value": 1}, {"from": "102", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "102", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "102", "to": "). author information :", "value": 1}, {"from": "102", "to": "), urruticoechea a", "value": 1}, {"from": "102", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "102", "to": "t", "value": 1}, {"from": "102", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "102", "to": "##6 /", "value": 1}, {"from": "102", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "102", "to": "be validated in independent cohorts,", "value": 1}, {"from": "102", "to": "cost - effectiveness", "value": 1}, {"from": "102", "to": "##ers of response to net and pro", "value": 1}, {"from": "102", "to": "10. 101", "value": 1}, {"from": "102", "to": "help", "value": 1}, {"from": "102", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "102", "to": "##sis, which", "value": 1}, {"from": "102", "to": "##gno", "value": 1}, {"from": "102", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "102", "to": "##lin", "value": 1}, {"from": "102", "to": "should", "value": 1}, {"from": "102", "to": "202", "value": 1}, {"from": "102", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "102", "to": "helping to the", "value": 1}, {"from": "102", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "102", "to": "implementation of net", "value": 1}, {"from": "102", "to": "##mark", "value": 1}, {"from": "102", "to": "##ranon.", "value": 1}, {"from": "102", "to": "##5", "value": 1}, {"from": "102", "to": ". clbc. 202", "value": 1}, {"from": "102", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "102", "to": "##5.", "value": 1}, {"from": "j", "to": "##354028 [", "value": 1}, {"from": "j", "to": ".", "value": 5}, {"from": "j", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "j", "to": "school", "value": 1}, {"from": "j", "to": "), agegnehu sb", "value": 1}, {"from": "j", "to": "##ra 00", "value": 1}, {"from": "j", "to": "3 ), lamptey el", "value": 1}, {"from": "j", "to": "1", "value": 2}, {"from": "j", "to": "ka", "value": 1}, {"from": "j", "to": "4", "value": 4}, {"from": "j", "to": "of ghana, a", "value": 1}, {"from": "j", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "j", "to": "##461r pmid :", "value": 1}, {"from": "j", "to": "antiangiogenic therapy of", "value": 1}, {"from": "j", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "j", "to": ")", "value": 3}, {"from": "j", "to": "he", "value": 1}, {"from": "j", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "j", "to": "expression", "value": 2}, {"from": "j", "to": "##500", "value": 1}, {"from": "j", "to": "in cancer", "value": 1}, {"from": "j", "to": "##mpo s", "value": 1}, {"from": "j", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "j", "to": "##cc", "value": 1}, {"from": "j", "to": "inverse", "value": 1}, {"from": "j", "to": "new insights into", "value": 1}, {"from": "j", "to": "##ibi", "value": 1}, {"from": "j", "to": "ri", "value": 1}, {"from": "j", "to": "##sana", "value": 1}, {"from": "j", "to": "doctoral program in biomedical", "value": 1}, {"from": "j", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "j", "to": "of medicine, univers", "value": 2}, {"from": "j", "to": "##g", "value": 1}, {"from": "j", "to": "##rta", "value": 3}, {"from": "j", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "j", "to": "##esia", "value": 1}, {"from": "j", "to": "##itas in", "value": 1}, {"from": "j", "to": "##nandi si", "value": 1}, {"from": "j", "to": "##eri", "value": 1}, {"from": "j", "to": "master program in biomedical", "value": 2}, {"from": "j", "to": "),", "value": 1}, {"from": "j", "to": "5", "value": 2}, {"from": "j", "to": "##esi", "value": 3}, {"from": "j", "to": "of medical chemistry,", "value": 1}, {"from": "j", "to": "##a.", "value": 4}, {"from": "j", "to": "faculty", "value": 4}, {"from": "j", "to": "wa", "value": 1}, {"from": "j", "to": "##don", "value": 3}, {"from": "j", "to": "##a,", "value": 2}, {"from": "j", "to": "6", "value": 1}, {"from": "j", "to": "##aka", "value": 3}, {"from": "j", "to": "department", "value": 2}, {"from": "j", "to": "indonesi", "value": 2}, {"from": "j", "to": "##itas indonesia", "value": 2}, {"from": "j", "to": "of surgery,", "value": 1}, {"from": "j", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "j", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "j", "to": "2 - positive", "value": 1}, {"from": "j", "to": "changes in the promoter region", "value": 1}, {"from": "j", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "j", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "j", "to": "receptor", "value": 1}, {"from": "j", "to": "is an", "value": 1}, {"from": "j", "to": "##type", "value": 1}, {"from": "j", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "j", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "j", "to": "- negative breast cancer", "value": 1}, {"from": "j", "to": "and", "value": 2}, {"from": "j", "to": "##a, jaka", "value": 2}, {"from": "j", "to": "lead", "value": 1}, {"from": "j", "to": "triple", "value": 1}, {"from": "j", "to": "of medicine, universitas indon", "value": 2}, {"from": "j", "to": "cilities - imeri,", "value": 1}, {"from": "j", "to": "##a. breast cancer sub", "value": 1}, {"from": "j", "to": "##umi", "value": 1}, {"from": "j", "to": "##ivers", "value": 1}, {"from": "j", "to": "to misclassification. dna methylation", "value": 1}, {"from": "j", "to": "##s", "value": 1}, {"from": "j", "to": "un", "value": 1}, {"from": "j", "to": "##nal a, l", "value": 1}, {"from": "j", "to": "epigenetic modification,", "value": 1}, {"from": "j", "to": "of medicine,", "value": 1}, {"from": "j", "to": "), hashim", "value": 1}, {"from": "j", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "j", "to": ") drug development research cluster, indon", "value": 1}, {"from": "j", "to": "##an medical", "value": 1}, {"from": "j", "to": "indon", "value": 1}, {"from": "j", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "j", "to": "##hibit", "value": 1}, {"from": "j", "to": "na", "value": 1}, {"from": "j", "to": "education", "value": 1}, {"from": "j", "to": "n", "value": 1}, {"from": "j", "to": "3", "value": 1}, {"from": "j", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "j", "to": "##ajrin", "value": 1}, {"from": "j", "to": "), azizah", "value": 1}, {"from": "j", "to": "te", "value": 1}, {"from": "j", "to": "##djo a", "value": 1}, {"from": "j", "to": "##itas", "value": 1}, {"from": "j", "to": "##b", "value": 1}, {"from": "j", "to": "am", "value": 1}, {"from": "j", "to": "nn", "value": 1}, {"from": "j", "to": "of pharmacy, univers", "value": 1}, {"from": "j", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "j", "to": ", indon", "value": 1}, {"from": "j", "to": "and research instit", "value": 1}, {"from": "j", "to": "), ramadanti", "value": 1}, {"from": "j", "to": "52", "value": 1}, {"from": "j", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "j", "to": "), beltran - v", "value": 1}, {"from": "j", "to": ") department of pathology, co", "value": 1}, {"from": "j", "to": "##ulin", "value": 1}, {"from": "j", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "j", "to": "f", "value": 1}, {"from": "j", "to": "new yo", "value": 1}, {"from": "j", "to": "sloan", "value": 1}, {"from": "j", "to": "la", "value": 1}, {"from": "j", "to": "center", "value": 1}, {"from": "j", "to": "us", "value": 1}, {"from": "j", "to": "##lum", "value": 1}, {"from": "j", "to": "##o m", "value": 1}, {"from": "j", "to": "9", "value": 1}, {"from": "j", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "j", "to": "kette", "value": 1}, {"from": "j", "to": "yo", "value": 1}, {"from": "j", "to": "##ettering cancer", "value": 1}, {"from": "j", "to": "##rk, usa.", "value": 1}, {"from": "j", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "j", "to": "re", "value": 2}, {"from": "j", "to": "new york", "value": 1}, {"from": "j", "to": "##bia university,", "value": 1}, {"from": "j", "to": "), shin e", "value": 1}, {"from": "j", "to": "##ring cancer", "value": 1}, {"from": "j", "to": "##rk, new", "value": 1}, {"from": "j", "to": "##urent, quebec, canada.", "value": 1}, {"from": "j", "to": "##isied", "value": 1}, {"from": "j", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "j", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "j", "to": "ancers. sinha s", "value": 1}, {"from": "j", "to": "##is - filho j", "value": 1}, {"from": "j", "to": "##rk,", "value": 1}, {"from": "j", "to": "), gardner r", "value": 1}, {"from": "j", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "j", "to": "t", "value": 1}, {"from": "j", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "j", "to": "##6 /", "value": 3}, {"from": "j", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "j", "to": "be validated in independent cohorts,", "value": 1}, {"from": "j", "to": "cost - effectiveness", "value": 1}, {"from": "j", "to": "##ers of response to net and pro", "value": 1}, {"from": "j", "to": "10. 101", "value": 1}, {"from": "j", "to": "help", "value": 1}, {"from": "j", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "j", "to": "##sis, which", "value": 1}, {"from": "j", "to": "##gno", "value": 1}, {"from": "j", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "j", "to": "##lin", "value": 1}, {"from": "j", "to": "should", "value": 1}, {"from": "j", "to": "202", "value": 1}, {"from": "j", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "j", "to": "helping to the", "value": 1}, {"from": "j", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "j", "to": "implementation of net", "value": 1}, {"from": "j", "to": "##mark", "value": 1}, {"from": "j", "to": "##ranon.", "value": 1}, {"from": "j", "to": "##5", "value": 1}, {"from": "j", "to": ". clbc. 202", "value": 1}, {"from": "j", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "j", "to": "##5.", "value": 1}, {"from": "j", "to": "is cost - effective", "value": 1}, {"from": "j", "to": "of agriculture and natural", "value": 1}, {"from": "j", "to": ". ac.", "value": 1}, {"from": "j", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "j", "to": "resources", "value": 1}, {"from": "j", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "j", "to": "##za. he", "value": 1}, {"from": "j", "to": "are", "value": 1}, {"from": "j", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "j", "to": "##ri - japelaghi r", "value": 1}, {"from": "j", "to": "##r.", "value": 1}, {"from": "j", "to": "who", "value": 1}, {"from": "j", "to": "inter", "value": 1}, {"from": "j", "to": "##vin", "value": 1}, {"from": "j", "to": "of tabriz,", "value": 1}, {"from": "j", "to": "@ org.", "value": 1}, {"from": "j", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "j", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "j", "to": "##idari", "value": 1}, {"from": "j", "to": "s", "value": 1}, {"from": "j", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "j", "to": "ta", "value": 1}, {"from": "j", "to": "##ran. electronic address :", "value": 1}, {"from": "j", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "j", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "j", "to": "101", "value": 2}, {"from": "j", "to": "##ida", "value": 1}, {"from": "j", "to": "perspectives", "value": 1}, {"from": "j", "to": "##briz,", "value": 1}, {"from": "j", "to": "of agriculture,", "value": 1}, {"from": "j", "to": "##fer", "value": 1}, {"from": "j", "to": "##on", "value": 1}, {"from": "j", "to": "##ki", "value": 1}, {"from": "j", "to": "from both", "value": 1}, {"from": "j", "to": "##ran.", "value": 1}, {"from": "j", "to": "- regulate", "value": 1}, {"from": "j", "to": "the", "value": 1}, {"from": "j", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "j", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "j", "to": "##tic", "value": 1}, {"from": "j", "to": "##6", "value": 1}, {"from": "j", "to": "##poptosis", "value": 1}, {"from": "j", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "j", "to": "##xic effect of", "value": 1}, {"from": "j", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "j", "to": "00", "value": 1}, {"from": "j", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "j", "to": "##xic efficacy of the", "value": 1}, {"from": "j", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "j", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "j", "to": "if", "value": 1}, {"from": "j", "to": "up -", "value": 1}, {"from": "j", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "j", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "j", "to": "development of tumor cells, a", "value": 1}, {"from": "j", "to": "##348089 conflict o", "value": 1}, {"from": "j", "to": "regulate", "value": 1}, {"from": "j", "to": "##oto", "value": 1}, {"from": "j", "to": "of pro", "value": 1}, {"from": "j", "to": "##cl -", "value": 1}, {"from": "j", "to": "##biotec. 2025.", "value": 1}, {"from": "j", "to": "04", "value": 1}, {"from": "j", "to": "##apopto", "value": 1}, {"from": "j", "to": "to", "value": 1}, {"from": "j", "to": "##cer and antiviral functions of", "value": 1}, {"from": "j", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "j", "to": "via", "value": 1}, {"from": "j", "to": "and p", "value": 1}, {"from": "j", "to": "##c cell line", "value": 1}, {"from": "j", "to": "hi", "value": 1}, {"from": "j", "to": "##can", "value": 1}, {"from": "j", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "j", "to": "down", "value": 1}, {"from": "j", "to": "##53", "value": 1}, {"from": "j", "to": ". 022 pmid :", "value": 1}, {"from": "j", "to": "bax", "value": 1}, {"from": "##354028 [", "to": ".", "value": 1}, {"from": "##354028 [", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": "##354028 [", "to": "school", "value": 1}, {"from": "##354028 [", "to": "), agegnehu sb", "value": 1}, {"from": "##354028 [", "to": "##ra 00", "value": 1}, {"from": "##354028 [", "to": "3 ), lamptey el", "value": 1}, {"from": "##354028 [", "to": "1", "value": 1}, {"from": "##354028 [", "to": "ka", "value": 1}, {"from": "##354028 [", "to": "4", "value": 1}, {"from": "##354028 [", "to": "of ghana, a", "value": 1}, {"from": "##354028 [", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##354028 [", "to": "##461r pmid :", "value": 1}, {"from": "##354028 [", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##354028 [", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##354028 [", "to": ")", "value": 1}, {"from": "##354028 [", "to": "he", "value": 1}, {"from": "##354028 [", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##354028 [", "to": "expression", "value": 1}, {"from": "##354028 [", "to": "##500", "value": 1}, {"from": "##354028 [", "to": "in cancer", "value": 1}, {"from": "##354028 [", "to": "##mpo s", "value": 1}, {"from": "##354028 [", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##354028 [", "to": "##cc", "value": 1}, {"from": "##354028 [", "to": "inverse", "value": 1}, {"from": "##354028 [", "to": "new insights into", "value": 1}, {"from": ".", "to": "- relationship - a computational study. anyomi", "value": 1}, {"from": ".", "to": "school", "value": 1}, {"from": ".", "to": "), agegnehu sb", "value": 1}, {"from": ".", "to": "##ra 00", "value": 1}, {"from": ".", "to": "3 ), lamptey el", "value": 1}, {"from": ".", "to": "1", "value": 3}, {"from": ".", "to": "ka", "value": 1}, {"from": ".", "to": "4", "value": 3}, {"from": ".", "to": "of ghana, a", "value": 1}, {"from": ".", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": ".", "to": "##461r pmid :", "value": 1}, {"from": ".", "to": "antiangiogenic therapy of", "value": 1}, {"from": ".", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": ".", "to": ")", "value": 4}, {"from": ".", "to": "he", "value": 1}, {"from": ".", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ".", "to": "expression", "value": 3}, {"from": ".", "to": "##500", "value": 1}, {"from": ".", "to": "in cancer", "value": 1}, {"from": ".", "to": "##mpo s", "value": 1}, {"from": ".", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ".", "to": "##cc", "value": 1}, {"from": ".", "to": "inverse", "value": 1}, {"from": ".", "to": "new insights into", "value": 1}, {"from": ".", "to": "classification of breast cancer : l", "value": 1}, {"from": ".", "to": ", h", "value": 1}, {"from": ".", "to": "##methylation", "value": 1}, {"from": ".", "to": "tion", "value": 1}, {"from": ".", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": ".", "to": "the pt", "value": 1}, {"from": ".", "to": ". \u00a9 202", "value": 1}, {"from": ".", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": ".", "to": "##rn2 gene", "value": 1}, {"from": ".", "to": "##type", "value": 1}, {"from": ".", "to": "##nal", "value": 1}, {"from": ".", "to": "##261 ), and tnbc", "value": 1}, {"from": ".", "to": "##p", "value": 1}, {"from": ".", "to": "the author", "value": 1}, {"from": ".", "to": "bio", "value": 3}, {"from": ".", "to": "respectively", "value": 2}, {"from": ".", "to": "##marker for each sub", "value": 1}, {"from": ".", "to": "##umi", "value": 1}, {"from": ".", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": ".", "to": "##yper", "value": 1}, {"from": ".", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": ".", "to": "improve", "value": 1}, {"from": ".", "to": "##10", "value": 1}, {"from": ".", "to": "##5", "value": 2}, {"from": ".", "to": "##nal a", "value": 1}, {"from": ".", "to": "52", "value": 3}, {"from": ".", "to": "), hashim", "value": 1}, {"from": ".", "to": "of medicine, univers", "value": 1}, {"from": ".", "to": "##rta", "value": 1}, {"from": ".", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": ".", "to": ") drug development research cluster, indon", "value": 1}, {"from": ".", "to": "##an medical", "value": 1}, {"from": ".", "to": "indon", "value": 1}, {"from": ".", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": ".", "to": "##hibit", "value": 1}, {"from": ".", "to": "na", "value": 1}, {"from": ".", "to": "master program in biomedical", "value": 1}, {"from": ".", "to": "education", "value": 1}, {"from": ".", "to": "n", "value": 1}, {"from": ".", "to": "3", "value": 1}, {"from": ".", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": ".", "to": "##ajrin", "value": 1}, {"from": ".", "to": "), azizah", "value": 1}, {"from": ".", "to": "##esi", "value": 1}, {"from": ".", "to": "te", "value": 1}, {"from": ".", "to": "##a, jaka", "value": 1}, {"from": ".", "to": "##djo a", "value": 1}, {"from": ".", "to": "of medicine, universitas indon", "value": 1}, {"from": ".", "to": "##itas", "value": 1}, {"from": ".", "to": "##a.", "value": 1}, {"from": ".", "to": "faculty", "value": 4}, {"from": ".", "to": "##b", "value": 1}, {"from": ".", "to": "am", "value": 1}, {"from": ".", "to": "nn", "value": 1}, {"from": ".", "to": "of pharmacy, univers", "value": 1}, {"from": ".", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": ".", "to": "##don", "value": 1}, {"from": ".", "to": "##a,", "value": 1}, {"from": ".", "to": ", indon", "value": 1}, {"from": ".", "to": "##aka", "value": 1}, {"from": ".", "to": "and research instit", "value": 1}, {"from": ".", "to": "), ramadanti", "value": 1}, {"from": ".", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": ".", "to": "##ene", "value": 1}, {"from": ".", "to": "which was", "value": 1}, {"from": ".", "to": ": cyce or ccne1", "value": 1}, {"from": ".", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": ".", "to": "##8 ), and e2f1", "value": 1}, {"from": ".", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": ".", "to": "##1 ), rbl1", "value": 1}, {"from": ".", "to": "might", "value": 1}, {"from": ".", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": ".", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": ".", "to": "the native", "value": 1}, {"from": ".", "to": "ligan", "value": 1}, {"from": ".", "to": "00", "value": 2}, {"from": ".", "to": "im", "value": 1}, {"from": ".", "to": "p = 0. 01", "value": 1}, {"from": ".", "to": "##rank", "value": 1}, {"from": ".", "to": "##j", "value": 1}, {"from": ".", "to": "by", "value": 2}, {"from": ".", "to": "rerank score", "value": 1}, {"from": ".", "to": "##um", "value": 1}, {"from": ".", "to": "##d", "value": 1}, {"from": ".", "to": "of ad", "value": 1}, {"from": ".", "to": "re", "value": 2}, {"from": ".", "to": "##idodiph", "value": 1}, {"from": ".", "to": "p = 0", "value": 2}, {"from": ".", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": ".", "to": "- 112. 70 k", "value": 1}, {"from": ".", "to": "score", "value": 1}, {"from": ".", "to": "##ine", "value": 1}, {"from": ".", "to": "##enyl", "value": 1}, {"from": ".", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": ".", "to": "cycle", "value": 1}, {"from": ".", "to": "##osphate", "value": 1}, {"from": ".", "to": "- 110. 68 k", "value": 1}, {"from": ".", "to": "0", "value": 1}, {"from": ".", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": ".", "to": "##c", "value": 1}, {"from": ".", "to": "/ mol ), and nummular", "value": 1}, {"from": ".", "to": "squal", "value": 1}, {"from": ".", "to": "the decrease in p21", "value": 1}, {"from": ".", "to": "##mularia stem suggested that", "value": 1}, {"from": ".", "to": "##life", "value": 1}, {"from": ".", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": ".", "to": "##ion of p21", "value": 1}, {"from": ".", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": ".", "to": "##in - mediated anti -", "value": 1}, {"from": ".", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": ".", "to": "1 ), abdelkrim g", "value": 1}, {"from": ".", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": ".", "to": "cancer effects. foda my", "value": 1}, {"from": ".", "to": "##press", "value": 1}, {"from": ".", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": ".", "to": "##tat", "value": 2}, {"from": ".", "to": "jun", "value": 2}, {"from": ".", "to": "2 ), salem ml", "value": 1}, {"from": ".", "to": "in atorvas", "value": 1}, {"from": ".", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": ".", "to": "prescribed chole", "value": 1}, {"from": ".", "to": "has recently", "value": 1}, {"from": ".", "to": "and its biological functions", "value": 1}, {"from": ".", "to": "of saida, saida, algeria.", "value": 1}, {"from": ".", "to": "shown", "value": 1}, {"from": ".", "to": "however", "value": 2}, {"from": ".", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": ".", "to": "shown potential anti", "value": 1}, {"from": ".", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": ".", "to": "a", "value": 2}, {"from": ".", "to": "##in", "value": 2}, {"from": ".", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": ".", "to": "particular breast cancer,", "value": 1}, {"from": ".", "to": "still", "value": 1}, {"from": ".", "to": "associated with atorvas", "value": 1}, {"from": ".", "to": "in breast", "value": 1}, {"from": ".", "to": "lowering", "value": 1}, {"from": ".", "to": "to be responsive to", "value": 1}, {"from": ".", "to": "interaction", "value": 1}, {"from": ".", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": ".", "to": ") network and", "value": 1}, {"from": ".", "to": "in the protein - protein", "value": 1}, {"from": ".", "to": "drug,", "value": 1}, {"from": ".", "to": "##gu", "value": 1}, {"from": ".", "to": "hub gene", "value": 1}, {"from": ".", "to": ", its influence on gene", "value": 1}, {"from": ".", "to": "##lated", "value": 1}, {"from": ".", "to": "was", "value": 2}, {"from": ".", "to": "##in,", "value": 1}, {"from": ".", "to": "ppi", "value": 1}, {"from": ".", "to": "##oto", "value": 2}, {"from": ".", "to": "related pathways", "value": 1}, {"from": ".", "to": "cancer,", "value": 1}, {"from": ".", "to": "expressed", "value": 1}, {"from": ".", "to": "##cer effects.", "value": 1}, {"from": ".", "to": "widely", "value": 1}, {"from": ".", "to": "atorvas", "value": 1}, {"from": ".", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": ".", "to": "##ster", "value": 1}, {"from": ".", "to": "##ol", "value": 1}, {"from": ".", "to": "##can", "value": 2}, {"from": ".", "to": "cancer. atorvas", "value": 1}, {"from": ".", "to": "was identified as the", "value": 1}, {"from": ".", "to": "=", "value": 1}, {"from": ".", "to": "##s,", "value": 1}, {"from": ".", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": ".", "to": "which is involved in", "value": 1}, {"from": ".", "to": "- 0. 46,", "value": 1}, {"from": ".", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": ".", "to": "mi", "value": 1}, {"from": ".", "to": "- 5p", "value": 1}, {"from": ".", "to": "##r - 17", "value": 1}, {"from": ".", "to": "5", "value": 2}, {"from": ".", "to": "##1", "value": 1}, {"from": ".", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": ".", "to": ") : e010548.", "value": 1}, {"from": ".", "to": "5p", "value": 1}, {"from": ".", "to": "hand", "value": 1}, {"from": ".", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": ".", "to": "03 ) and", "value": 1}, {"from": ".", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": ".", "to": "##r - 106a -", "value": 1}, {"from": ".", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": ".", "to": "target gene", "value": 1}, {"from": ".", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": ".", "to": "- 0. 41,", "value": 1}, {"from": ".", "to": "of these lnc", "value": 1}, {"from": ".", "to": "p = 0.", "value": 1}, {"from": ".", "to": "113", "value": 1}, {"from": ".", "to": "common", "value": 1}, {"from": ".", "to": "regulated", "value": 1}, {"from": ".", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ".", "to": "), huarte m", "value": 1}, {"from": ".", "to": "12", "value": 2}, {"from": ".", "to": "##407.", "value": 1}, {"from": ".", "to": "), par", "value": 1}, {"from": ".", "to": "ins", "value": 1}, {"from": ".", "to": "##or", "value": 1}, {"from": ".", "to": "##e", "value": 1}, {"from": ".", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": ".", "to": "9", "value": 2}, {"from": ".", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": ".", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": ".", "to": "), aragon s", "value": 1}, {"from": ".", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": ".", "to": "##ory", "value": 1}, {"from": ".", "to": "), gimenez j", "value": 1}, {"from": ".", "to": "- lopez i", "value": 1}, {"from": ".", "to": "##rine", "value": 1}, {"from": ".", "to": "er + / her2 -", "value": 1}, {"from": ".", "to": "), prat a", "value": 1}, {"from": ".", "to": "research", "value": 2}, {"from": ".", "to": "##e. lg is /", "value": 1}, {"from": ".", "to": "), buch e", "value": 1}, {"from": ".", "to": "##roga v", "value": 1}, {"from": ".", "to": "been holding research", "value": 1}, {"from": ".", "to": "11", "value": 3}, {"from": ".", "to": "101", "value": 3}, {"from": ".", "to": "##riaga k", "value": 1}, {"from": ".", "to": "), etxabe i", "value": 1}, {"from": ".", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": ".", "to": "1 ) biogipuzkoa", "value": 1}, {"from": ".", "to": "13", "value": 3}, {"from": ".", "to": "therapy", "value": 1}, {"from": ".", "to": "##ui", "value": 1}, {"from": ".", "to": "##ez", "value": 1}, {"from": ".", "to": "##vita", "value": 1}, {"from": ".", "to": "contracts", "value": 1}, {"from": ".", "to": "has", "value": 1}, {"from": ".", "to": "6", "value": 2}, {"from": ".", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": ".", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": ".", "to": "). author information :", "value": 1}, {"from": ".", "to": "), urruticoechea a", "value": 1}, {"from": ".", "to": "##rio de v", "value": 1}, {"from": ".", "to": "t", "value": 3}, {"from": ".", "to": "##kolog", "value": 1}, {"from": ".", "to": ", san", "value": 1}, {"from": ".", "to": "##it", "value": 1}, {"from": ".", "to": ") health", "value": 2}, {"from": ".", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": ".", "to": "##iba", "value": 1}, {"from": ".", "to": "##ialdea", "value": 1}, {"from": ".", "to": "##gipuzkoa", "value": 2}, {"from": ".", "to": "##ko", "value": 1}, {"from": ".", "to": "##obe", "value": 1}, {"from": ".", "to": "se", "value": 1}, {"from": ".", "to": "##gi", "value": 2}, {"from": ".", "to": "##tian,", "value": 2}, {"from": ".", "to": ") hospital clinico univers", "value": 1}, {"from": ".", "to": "##r 12, madrid,", "value": 1}, {"from": ".", "to": "spain", "value": 2}, {"from": ".", "to": "##ale", "value": 1}, {"from": ".", "to": "##a", "value": 1}, {"from": ".", "to": "##ute", "value": 1}, {"from": ".", "to": "##ikoa,", "value": 1}, {"from": ".", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ".", "to": "##donost", "value": 2}, {"from": ".", "to": ") hospital oct", "value": 1}, {"from": ".", "to": "research institute", "value": 2}, {"from": ".", "to": "institute", "value": 3}, {"from": ".", "to": "sa", "value": 2}, {"from": ".", "to": "sebas", "value": 2}, {"from": ".", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ".", "to": "##ita", "value": 1}, {"from": ".", "to": ", v", "value": 1}, {"from": ".", "to": "##ps, barcelon", "value": 1}, {"from": ".", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ".", "to": "##n", "value": 2}, {"from": ".", "to": "##pu", "value": 2}, {"from": ".", "to": "sebastian", "value": 2}, {"from": ".", "to": "; gip", "value": 1}, {"from": ".", "to": "- on", "value": 1}, {"from": ".", "to": "7 ) valencia oncology", "value": 1}, {"from": ".", "to": "##ncia,", "value": 1}, {"from": ".", "to": "##uz", "value": 1}, {"from": ".", "to": "##ia", "value": 2}, {"from": ".", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ".", "to": "- onkologikoa, san", "value": 1}, {"from": ".", "to": "##z", "value": 1}, {"from": ".", "to": "##bastian, spa", "value": 1}, {"from": ".", "to": "after net", "value": 1}, {"from": ".", "to": "a significant", "value": 1}, {"from": ".", "to": "time", "value": 1}, {"from": ".", "to": "offers the opportunity of", "value": 1}, {"from": ".", "to": "##ip", "value": 1}, {"from": ".", "to": "background", "value": 1}, {"from": ".", "to": "##re population of", "value": 1}, {"from": ".", "to": "negative breast", "value": 1}, {"from": ".", "to": "barrier", "value": 1}, {"from": ".", "to": "clinical", "value": 1}, {"from": ".", "to": "##2 -", "value": 1}, {"from": ".", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": ".", "to": "##zkoa", "value": 1}, {"from": ".", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": ".", "to": "##donostia ) health", "value": 1}, {"from": ".", "to": "cancer", "value": 1}, {"from": ".", "to": "##uzkoa. eus.", "value": 1}, {"from": ".", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": ".", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": ".", "to": "and", "value": 3}, {"from": ".", "to": "real", "value": 1}, {"from": ".", "to": "personal", "value": 1}, {"from": ".", "to": "##ised therapy.", "value": 1}, {"from": ".", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ".", "to": "##cent", "value": 1}, {"from": ".", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ".", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ".", "to": "her", "value": 1}, {"from": ".", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ".", "to": "##n sebastian,", "value": 1}, {"from": ".", "to": "##umour response", "value": 1}, {"from": ".", "to": "a,", "value": 1}, {"from": ".", "to": "##uc", "value": 1}, {"from": ".", "to": ", the lack of reprod", "value": 1}, {"from": ".", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ".", "to": "##c ) allows", "value": 1}, {"from": ".", "to": "##gnosis", "value": 1}, {"from": ".", "to": "- g", "value": 1}, {"from": ".", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": ".", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": ".", "to": "##6 /", "value": 3}, {"from": ".", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": ".", "to": "be validated in independent cohorts,", "value": 1}, {"from": ".", "to": "cost - effectiveness", "value": 1}, {"from": ".", "to": "##ers of response to net and pro", "value": 1}, {"from": ".", "to": "10. 101", "value": 1}, {"from": ".", "to": "help", "value": 1}, {"from": ".", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": ".", "to": "##sis, which", "value": 1}, {"from": ".", "to": "##gno", "value": 1}, {"from": ".", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": ".", "to": "##lin", "value": 1}, {"from": ".", "to": "should", "value": 1}, {"from": ".", "to": "202", "value": 1}, {"from": ".", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": ".", "to": "helping to the", "value": 1}, {"from": ".", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": ".", "to": "implementation of net", "value": 1}, {"from": ".", "to": "##mark", "value": 1}, {"from": ".", "to": "##ranon.", "value": 1}, {"from": ".", "to": ". clbc. 202", "value": 1}, {"from": ".", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": ".", "to": "##5.", "value": 1}, {"from": ".", "to": ") department of", "value": 1}, {"from": ".", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": ".", "to": "for cancer", "value": 1}, {"from": ".", "to": "##lia", "value": 1}, {"from": ".", "to": "##vanger,", "value": 1}, {"from": ".", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": ".", "to": "##vanger university, s", "value": 1}, {"from": ".", "to": "8", "value": 1}, {"from": ".", "to": "of cancer genetics,", "value": 2}, {"from": ".", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": ".", "to": "12 ) department", "value": 1}, {"from": ".", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": ".", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ".", "to": "##vanger university hospital, s", "value": 1}, {"from": ".", "to": "ha", "value": 1}, {"from": ".", "to": "norway", "value": 1}, {"from": ".", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ".", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ".", "to": "of pathology, s", "value": 1}, {"from": ".", "to": ";", "value": 2}, {"from": ".", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ".", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ".", "to": "department", "value": 2}, {"from": ".", "to": "##way", "value": 2}, {"from": ".", "to": ", drammen, norway.", "value": 1}, {"from": ".", "to": "of clinical medicine,", "value": 1}, {"from": ".", "to": "##dheim, norway.", "value": 1}, {"from": ".", "to": "25", "value": 1}, {"from": ".", "to": "trust", "value": 1}, {"from": ".", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": ".", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": ".", "to": ", hamar, norway.", "value": 1}, {"from": ".", "to": ", kalnes, norway.", "value": 1}, {"from": ".", "to": ", skien, norway.", "value": 1}, {"from": ".", "to": "of oslo, oslo, nor", "value": 1}, {"from": ".", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ".", "to": ") department of oncolog", "value": 1}, {"from": ".", "to": "##ron", "value": 1}, {"from": ".", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": ".", "to": "benefit", "value": 1}, {"from": ".", "to": "##26, 000 ;", "value": 1}, {"from": ".", "to": "effective", "value": 1}, {"from": ".", "to": "it was cost - saving", "value": 1}, {"from": ".", "to": "threshold", "value": 1}, {"from": ".", "to": "- 435, 677 )", "value": 1}, {"from": ".", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": ".", "to": "##aly", "value": 1}, {"from": ".", "to": "in the", "value": 1}, {"from": ".", "to": "cost", "value": 1}, {"from": ".", "to": "\u20ac", "value": 1}, {"from": ".", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": ".", "to": "- 620170,", "value": 1}, {"from": ".", "to": "##r )", "value": 1}, {"from": ".", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": ".", "to": "societal perspective", "value": 1}, {"from": ".", "to": "candidates, the strategy", "value": 1}, {"from": ".", "to": "cost - effective", "value": 1}, {"from": ".", "to": "incre", "value": 1}, {"from": ".", "to": "prosigna - test strategy, the test", "value": 1}, {"from": ".", "to": "##mental", "value": 1}, {"from": ".", "to": "the cost -", "value": 1}, {"from": ".", "to": "was cost - effective", "value": 1}, {"from": ".", "to": "above", "value": 1}, {"from": ".", "to": "results", "value": 1}, {"from": ".", "to": "was obtained from statistics norway.", "value": 1}, {"from": ".", "to": "per quality - adjusted life -", "value": 1}, {"from": ".", "to": "was cost - saving", "value": 1}, {"from": ".", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": ".", "to": "chemotherapy", "value": 1}, {"from": ".", "to": "in both the healthcare", "value": 1}, {"from": ".", "to": "years", "value": 1}, {"from": ".", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": ".", "to": "- per q", "value": 1}, {"from": ".", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": ".", "to": ". conclusions", "value": 1}, {"from": ".", "to": ". selecting patient", "value": 1}, {"from": ".", "to": "ice", "value": 1}, {"from": ".", "to": "##r", "value": 1}, {"from": ".", "to": "##8884 and", "value": 1}, {"from": ".", "to": "gained", "value": 1}, {"from": ".", "to": "the emit", "value": 1}, {"from": ".", "to": "records. including all pn0 patients", "value": 1}, {"from": ".", "to": "sector", "value": 1}, {"from": ".", "to": "not", "value": 1}, {"from": ".", "to": "is cost - effective", "value": 1}, {"from": ".", "to": "of agriculture and natural", "value": 1}, {"from": ".", "to": ". ac.", "value": 1}, {"from": ".", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": ".", "to": "resources", "value": 1}, {"from": ".", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": ".", "to": "##za. he", "value": 1}, {"from": ".", "to": "are", "value": 1}, {"from": ".", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": ".", "to": "##ri - japelaghi r", "value": 1}, {"from": ".", "to": "##r.", "value": 1}, {"from": ".", "to": "who", "value": 1}, {"from": ".", "to": "inter", "value": 1}, {"from": ".", "to": "##vin", "value": 1}, {"from": ".", "to": "of tabriz,", "value": 1}, {"from": ".", "to": "@ org.", "value": 1}, {"from": ".", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": ".", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": ".", "to": "##idari", "value": 1}, {"from": ".", "to": "s", "value": 1}, {"from": ".", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": ".", "to": "ta", "value": 1}, {"from": ".", "to": "##ran. electronic address :", "value": 1}, {"from": ".", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": ".", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ".", "to": "##ida", "value": 1}, {"from": ".", "to": "perspectives", "value": 1}, {"from": ".", "to": "##briz,", "value": 1}, {"from": ".", "to": "of agriculture,", "value": 1}, {"from": ".", "to": "##fer", "value": 1}, {"from": ".", "to": "##on", "value": 1}, {"from": ".", "to": "##ki", "value": 1}, {"from": ".", "to": "from both", "value": 1}, {"from": ".", "to": "##ran.", "value": 1}, {"from": ".", "to": "- regulate", "value": 1}, {"from": ".", "to": "the", "value": 1}, {"from": ".", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": ".", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": ".", "to": "##tic", "value": 1}, {"from": ".", "to": "##6", "value": 1}, {"from": ".", "to": "##poptosis", "value": 1}, {"from": ".", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": ".", "to": "##xic effect of", "value": 1}, {"from": ".", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": ".", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": ".", "to": "##xic efficacy of the", "value": 1}, {"from": ".", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": ".", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": ".", "to": "if", "value": 1}, {"from": ".", "to": "up -", "value": 1}, {"from": ".", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": ".", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": ".", "to": "development of tumor cells, a", "value": 1}, {"from": ".", "to": "##348089 conflict o", "value": 1}, {"from": ".", "to": "regulate", "value": 1}, {"from": ".", "to": "of pro", "value": 1}, {"from": ".", "to": "##cl -", "value": 1}, {"from": ".", "to": "##biotec. 2025.", "value": 1}, {"from": ".", "to": "04", "value": 1}, {"from": ".", "to": "##apopto", "value": 1}, {"from": ".", "to": "to", "value": 1}, {"from": ".", "to": "##cer and antiviral functions of", "value": 1}, {"from": ".", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": ".", "to": "via", "value": 1}, {"from": ".", "to": "and p", "value": 1}, {"from": ".", "to": "##c cell line", "value": 1}, {"from": ".", "to": "hi", "value": 1}, {"from": ".", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": ".", "to": "down", "value": 1}, {"from": ".", "to": "##53", "value": 1}, {"from": ".", "to": ". 022 pmid :", "value": 1}, {"from": ".", "to": "bax", "value": 1}, {"from": ".", "to": "f interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "school", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "), agegnehu sb", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##ra 00", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "3 ), lamptey el", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "1", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "ka", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "4", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "of ghana, a", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##461r pmid :", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "antiangiogenic therapy of", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": ")", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "he", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "expression", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##500", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "in cancer", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##mpo s", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "##cc", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "inverse", "value": 1}, {"from": "- relationship - a computational study. anyomi", "to": "new insights into", "value": 1}, {"from": "school", "to": "), agegnehu sb", "value": 1}, {"from": "school", "to": "##ra 00", "value": 1}, {"from": "school", "to": "3 ), lamptey el", "value": 1}, {"from": "school", "to": "1", "value": 1}, {"from": "school", "to": "ka", "value": 1}, {"from": "school", "to": "4", "value": 2}, {"from": "school", "to": "of ghana, a", "value": 1}, {"from": "school", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "school", "to": "##461r pmid :", "value": 1}, {"from": "school", "to": "antiangiogenic therapy of", "value": 1}, {"from": "school", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "school", "to": ")", "value": 2}, {"from": "school", "to": "he", "value": 1}, {"from": "school", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "school", "to": "expression", "value": 1}, {"from": "school", "to": "##500", "value": 1}, {"from": "school", "to": "in cancer", "value": 1}, {"from": "school", "to": "##mpo s", "value": 1}, {"from": "school", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "school", "to": "##cc", "value": 2}, {"from": "school", "to": "inverse", "value": 1}, {"from": "school", "to": "new insights into", "value": 1}, {"from": "school", "to": "box l", "value": 1}, {"from": "school", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "school", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "school", "to": "of medical sciences, c.", "value": 1}, {"from": "school", "to": "these two conditions which", "value": 1}, {"from": "school", "to": "box", "value": 1}, {"from": "school", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "school", "to": "care", "value": 1}, {"from": "school", "to": "##ra", "value": 1}, {"from": "school", "to": "00", "value": 1}, {"from": "school", "to": "233, ghana.", "value": 1}, {"from": "school", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "school", "to": "##g 77, a", "value": 1}, {"from": "school", "to": "5", "value": 1}, {"from": "school", "to": ") west african genetic medicine centre", "value": 1}, {"from": "school", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "school", "to": "of health", "value": 1}, {"from": "school", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "school", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "school", "to": "been observed", "value": 1}, {"from": "school", "to": ", university of ghana, p. o.", "value": 1}, {"from": "school", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "school", "to": "between", "value": 1}, {"from": "school", "to": "of anaesthesia and intensive", "value": 1}, {"from": "school", "to": "##233, ghana.", "value": 1}, {"from": "school", "to": "incidence", "value": 1}, {"from": "school", "to": "cancer and ad", "value": 1}, {"from": "school", "to": "were formerly", "value": 1}, {"from": "school", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "school", "to": "has", "value": 1}, {"from": "school", "to": "department", "value": 1}, {"from": "school", "to": "inverse relationship between", "value": 1}, {"from": "school", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "), agegnehu sb", "to": "##ra 00", "value": 1}, {"from": "), agegnehu sb", "to": "3 ), lamptey el", "value": 1}, {"from": "), agegnehu sb", "to": "1", "value": 1}, {"from": "), agegnehu sb", "to": "ka", "value": 1}, {"from": "), agegnehu sb", "to": "4", "value": 1}, {"from": "), agegnehu sb", "to": "of ghana, a", "value": 1}, {"from": "), agegnehu sb", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "), agegnehu sb", "to": "##461r pmid :", "value": 1}, {"from": "), agegnehu sb", "to": "antiangiogenic therapy of", "value": 1}, {"from": "), agegnehu sb", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "), agegnehu sb", "to": ")", "value": 1}, {"from": "), agegnehu sb", "to": "he", "value": 1}, {"from": "), agegnehu sb", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "), agegnehu sb", "to": "expression", "value": 1}, {"from": "), agegnehu sb", "to": "##500", "value": 1}, {"from": "), agegnehu sb", "to": "in cancer", "value": 1}, {"from": "), agegnehu sb", "to": "##mpo s", "value": 1}, {"from": "), agegnehu sb", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "), agegnehu sb", "to": "##cc", "value": 1}, {"from": "), agegnehu sb", "to": "inverse", "value": 1}, {"from": "), agegnehu sb", "to": "new insights into", "value": 1}, {"from": "##ra 00", "to": "3 ), lamptey el", "value": 1}, {"from": "##ra 00", "to": "1", "value": 1}, {"from": "##ra 00", "to": "ka", "value": 1}, {"from": "##ra 00", "to": "4", "value": 1}, {"from": "##ra 00", "to": "of ghana, a", "value": 1}, {"from": "##ra 00", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "##ra 00", "to": "##461r pmid :", "value": 1}, {"from": "##ra 00", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##ra 00", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##ra 00", "to": ")", "value": 1}, {"from": "##ra 00", "to": "he", "value": 1}, {"from": "##ra 00", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##ra 00", "to": "expression", "value": 1}, {"from": "##ra 00", "to": "##500", "value": 1}, {"from": "##ra 00", "to": "in cancer", "value": 1}, {"from": "##ra 00", "to": "##mpo s", "value": 1}, {"from": "##ra 00", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##ra 00", "to": "##cc", "value": 1}, {"from": "##ra 00", "to": "inverse", "value": 1}, {"from": "##ra 00", "to": "new insights into", "value": 1}, {"from": "3 ), lamptey el", "to": "1", "value": 1}, {"from": "3 ), lamptey el", "to": "ka", "value": 1}, {"from": "3 ), lamptey el", "to": "4", "value": 1}, {"from": "3 ), lamptey el", "to": "of ghana, a", "value": 1}, {"from": "3 ), lamptey el", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "3 ), lamptey el", "to": "##461r pmid :", "value": 1}, {"from": "3 ), lamptey el", "to": "antiangiogenic therapy of", "value": 1}, {"from": "3 ), lamptey el", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "3 ), lamptey el", "to": ")", "value": 1}, {"from": "3 ), lamptey el", "to": "he", "value": 1}, {"from": "3 ), lamptey el", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "3 ), lamptey el", "to": "expression", "value": 1}, {"from": "3 ), lamptey el", "to": "##500", "value": 1}, {"from": "3 ), lamptey el", "to": "in cancer", "value": 1}, {"from": "3 ), lamptey el", "to": "##mpo s", "value": 1}, {"from": "3 ), lamptey el", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "3 ), lamptey el", "to": "##cc", "value": 1}, {"from": "3 ), lamptey el", "to": "inverse", "value": 1}, {"from": "3 ), lamptey el", "to": "new insights into", "value": 1}, {"from": "1", "to": "ka", "value": 1}, {"from": "1", "to": "4", "value": 2}, {"from": "1", "to": "of ghana, a", "value": 1}, {"from": "1", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "1", "to": "##461r pmid :", "value": 1}, {"from": "1", "to": "antiangiogenic therapy of", "value": 1}, {"from": "1", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "1", "to": ")", "value": 2}, {"from": "1", "to": "he", "value": 1}, {"from": "1", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "1", "to": "expression", "value": 1}, {"from": "1", "to": "##500", "value": 1}, {"from": "1", "to": "in cancer", "value": 1}, {"from": "1", "to": "##mpo s", "value": 1}, {"from": "1", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "1", "to": "##cc", "value": 1}, {"from": "1", "to": "inverse", "value": 1}, {"from": "1", "to": "new insights into", "value": 1}, {"from": "1", "to": "), hashim", "value": 1}, {"from": "1", "to": "of medicine, univers", "value": 1}, {"from": "1", "to": "##rta", "value": 1}, {"from": "1", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "1", "to": ") drug development research cluster, indon", "value": 1}, {"from": "1", "to": "##an medical", "value": 1}, {"from": "1", "to": "indon", "value": 1}, {"from": "1", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "1", "to": "##hibit", "value": 1}, {"from": "1", "to": "na", "value": 1}, {"from": "1", "to": "master program in biomedical", "value": 1}, {"from": "1", "to": "education", "value": 1}, {"from": "1", "to": "n", "value": 1}, {"from": "1", "to": "3", "value": 1}, {"from": "1", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "1", "to": "##ajrin", "value": 1}, {"from": "1", "to": "), azizah", "value": 1}, {"from": "1", "to": "##esi", "value": 1}, {"from": "1", "to": "te", "value": 1}, {"from": "1", "to": "##a, jaka", "value": 1}, {"from": "1", "to": "##djo a", "value": 1}, {"from": "1", "to": "of medicine, universitas indon", "value": 1}, {"from": "1", "to": "##itas", "value": 1}, {"from": "1", "to": "##a.", "value": 1}, {"from": "1", "to": "faculty", "value": 2}, {"from": "1", "to": "##b", "value": 1}, {"from": "1", "to": "am", "value": 1}, {"from": "1", "to": "nn", "value": 1}, {"from": "1", "to": "of pharmacy, univers", "value": 1}, {"from": "1", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "1", "to": "##don", "value": 1}, {"from": "1", "to": "##a,", "value": 1}, {"from": "1", "to": ", indon", "value": 1}, {"from": "1", "to": "##aka", "value": 1}, {"from": "1", "to": "and research instit", "value": 1}, {"from": "1", "to": "), ramadanti", "value": 1}, {"from": "1", "to": "52", "value": 2}, {"from": "1", "to": "##life", "value": 1}, {"from": "1", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "1", "to": "##ion of p21", "value": 1}, {"from": "1", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "1", "to": "##in - mediated anti -", "value": 1}, {"from": "1", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "1", "to": "1 ), abdelkrim g", "value": 1}, {"from": "1", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "1", "to": "cancer effects. foda my", "value": 1}, {"from": "1", "to": "##press", "value": 1}, {"from": "1", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "1", "to": "##tat", "value": 1}, {"from": "1", "to": "jun", "value": 1}, {"from": "1", "to": "2 ), salem ml", "value": 1}, {"from": "1", "to": "in atorvas", "value": 1}, {"from": "1", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "1", "to": "##rgen, norway.", "value": 1}, {"from": "1", "to": "##rgen, nor", "value": 1}, {"from": "1", "to": "t", "value": 1}, {"from": "1", "to": "economics", "value": 1}, {"from": "1", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "1", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "1", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "1", "to": "5", "value": 1}, {"from": "1", "to": "clinical trials", "value": 1}, {"from": "1", "to": "and", "value": 1}, {"from": "1", "to": "of health management and health", "value": 1}, {"from": "1", "to": "of health", "value": 1}, {"from": "1", "to": "institute", "value": 1}, {"from": "1", "to": ";", "value": 1}, {"from": "1", "to": ") department of p", "value": 1}, {"from": "1", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "1", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "1", "to": "), heie a", "value": 1}, {"from": "1", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "1", "to": "department", "value": 1}, {"from": "1", "to": "be", "value": 1}, {"from": "1", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "1", "to": "ug", "value": 1}, {"from": "1", "to": "##way", "value": 1}, {"from": "ka", "to": "4", "value": 1}, {"from": "ka", "to": "of ghana, a", "value": 1}, {"from": "ka", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "ka", "to": "##461r pmid :", "value": 1}, {"from": "ka", "to": "antiangiogenic therapy of", "value": 1}, {"from": "ka", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "ka", "to": ")", "value": 1}, {"from": "ka", "to": "he", "value": 1}, {"from": "ka", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "ka", "to": "expression", "value": 1}, {"from": "ka", "to": "##500", "value": 1}, {"from": "ka", "to": "in cancer", "value": 1}, {"from": "ka", "to": "##mpo s", "value": 1}, {"from": "ka", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "ka", "to": "##cc", "value": 1}, {"from": "ka", "to": "inverse", "value": 1}, {"from": "ka", "to": "new insights into", "value": 1}, {"from": "4", "to": "of ghana, a", "value": 1}, {"from": "4", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "4", "to": "##461r pmid :", "value": 1}, {"from": "4", "to": "antiangiogenic therapy of", "value": 1}, {"from": "4", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "4", "to": ")", "value": 4}, {"from": "4", "to": "he", "value": 1}, {"from": "4", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "4", "to": "expression", "value": 1}, {"from": "4", "to": "##500", "value": 1}, {"from": "4", "to": "in cancer", "value": 1}, {"from": "4", "to": "##mpo s", "value": 1}, {"from": "4", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "4", "to": "##cc", "value": 2}, {"from": "4", "to": "inverse", "value": 1}, {"from": "4", "to": "new insights into", "value": 1}, {"from": "4", "to": "box l", "value": 1}, {"from": "4", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "4", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "4", "to": "of medical sciences, c.", "value": 1}, {"from": "4", "to": "these two conditions which", "value": 1}, {"from": "4", "to": "box", "value": 1}, {"from": "4", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "4", "to": "care", "value": 1}, {"from": "4", "to": "##ra", "value": 1}, {"from": "4", "to": "00", "value": 1}, {"from": "4", "to": "233, ghana.", "value": 1}, {"from": "4", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "4", "to": "##g 77, a", "value": 1}, {"from": "4", "to": "5", "value": 4}, {"from": "4", "to": ") west african genetic medicine centre", "value": 1}, {"from": "4", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "4", "to": "of health", "value": 1}, {"from": "4", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "4", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "4", "to": "been observed", "value": 1}, {"from": "4", "to": ", university of ghana, p. o.", "value": 1}, {"from": "4", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "4", "to": "between", "value": 1}, {"from": "4", "to": "of anaesthesia and intensive", "value": 1}, {"from": "4", "to": "##233, ghana.", "value": 1}, {"from": "4", "to": "incidence", "value": 1}, {"from": "4", "to": "cancer and ad", "value": 1}, {"from": "4", "to": "were formerly", "value": 1}, {"from": "4", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "4", "to": "has", "value": 2}, {"from": "4", "to": "department", "value": 3}, {"from": "4", "to": "inverse relationship between", "value": 1}, {"from": "4", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "4", "to": "##ibi", "value": 1}, {"from": "4", "to": "ri", "value": 1}, {"from": "4", "to": "##sana", "value": 1}, {"from": "4", "to": "doctoral program in biomedical", "value": 1}, {"from": "4", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "4", "to": "of medicine, univers", "value": 2}, {"from": "4", "to": "##g", "value": 1}, {"from": "4", "to": "##rta", "value": 2}, {"from": "4", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "4", "to": "##esia", "value": 1}, {"from": "4", "to": "##itas in", "value": 1}, {"from": "4", "to": "##nandi si", "value": 1}, {"from": "4", "to": "##eri", "value": 1}, {"from": "4", "to": "master program in biomedical", "value": 2}, {"from": "4", "to": "),", "value": 1}, {"from": "4", "to": "##esi", "value": 2}, {"from": "4", "to": "of medical chemistry,", "value": 1}, {"from": "4", "to": "##a.", "value": 3}, {"from": "4", "to": "faculty", "value": 2}, {"from": "4", "to": "wa", "value": 1}, {"from": "4", "to": "##don", "value": 2}, {"from": "4", "to": "##a,", "value": 2}, {"from": "4", "to": "6", "value": 2}, {"from": "4", "to": "##aka", "value": 2}, {"from": "4", "to": "indonesi", "value": 1}, {"from": "4", "to": "##itas indonesia", "value": 1}, {"from": "4", "to": "of surgery,", "value": 1}, {"from": "4", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "4", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "4", "to": "), hashim", "value": 1}, {"from": "4", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "4", "to": ") drug development research cluster, indon", "value": 1}, {"from": "4", "to": "##an medical", "value": 1}, {"from": "4", "to": "indon", "value": 1}, {"from": "4", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "4", "to": "##hibit", "value": 1}, {"from": "4", "to": "na", "value": 1}, {"from": "4", "to": "education", "value": 1}, {"from": "4", "to": "n", "value": 1}, {"from": "4", "to": "3", "value": 1}, {"from": "4", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "4", "to": "##ajrin", "value": 1}, {"from": "4", "to": "), azizah", "value": 1}, {"from": "4", "to": "te", "value": 1}, {"from": "4", "to": "##a, jaka", "value": 1}, {"from": "4", "to": "##djo a", "value": 1}, {"from": "4", "to": "of medicine, universitas indon", "value": 1}, {"from": "4", "to": "##itas", "value": 1}, {"from": "4", "to": "##b", "value": 1}, {"from": "4", "to": "am", "value": 1}, {"from": "4", "to": "nn", "value": 1}, {"from": "4", "to": "of pharmacy, univers", "value": 1}, {"from": "4", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "4", "to": ", indon", "value": 1}, {"from": "4", "to": "and research instit", "value": 1}, {"from": "4", "to": "), ramadanti", "value": 1}, {"from": "4", "to": "52", "value": 1}, {"from": "4", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "4", "to": "), beltran - v", "value": 1}, {"from": "4", "to": ") department of pathology, co", "value": 1}, {"from": "4", "to": "##ulin", "value": 1}, {"from": "4", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "4", "to": "f", "value": 1}, {"from": "4", "to": "new yo", "value": 1}, {"from": "4", "to": "sloan", "value": 1}, {"from": "4", "to": "la", "value": 1}, {"from": "4", "to": "center", "value": 1}, {"from": "4", "to": "us", "value": 1}, {"from": "4", "to": "##lum", "value": 1}, {"from": "4", "to": "##o m", "value": 1}, {"from": "4", "to": "9", "value": 2}, {"from": "4", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "4", "to": "kette", "value": 1}, {"from": "4", "to": "yo", "value": 1}, {"from": "4", "to": "##ettering cancer", "value": 1}, {"from": "4", "to": "##rk, usa.", "value": 1}, {"from": "4", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "4", "to": "re", "value": 1}, {"from": "4", "to": "new york", "value": 1}, {"from": "4", "to": "##bia university,", "value": 1}, {"from": "4", "to": "), shin e", "value": 1}, {"from": "4", "to": "##ring cancer", "value": 1}, {"from": "4", "to": "##rk, new", "value": 1}, {"from": "4", "to": "##urent, quebec, canada.", "value": 1}, {"from": "4", "to": "##isied", "value": 1}, {"from": "4", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "4", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "4", "to": "ancers. sinha s", "value": 1}, {"from": "4", "to": "##is - filho j", "value": 1}, {"from": "4", "to": "##rk,", "value": 1}, {"from": "4", "to": "), gardner r", "value": 1}, {"from": "4", "to": "), huarte m", "value": 1}, {"from": "4", "to": "12", "value": 1}, {"from": "4", "to": "##407.", "value": 1}, {"from": "4", "to": "), par", "value": 1}, {"from": "4", "to": "ins", "value": 1}, {"from": "4", "to": "##or", "value": 1}, {"from": "4", "to": "##e", "value": 1}, {"from": "4", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "4", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "4", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "4", "to": "), aragon s", "value": 1}, {"from": "4", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "4", "to": "##ory", "value": 1}, {"from": "4", "to": "), gimenez j", "value": 1}, {"from": "4", "to": "- lopez i", "value": 1}, {"from": "4", "to": "##rine", "value": 1}, {"from": "4", "to": "er + / her2 -", "value": 1}, {"from": "4", "to": "), prat a", "value": 1}, {"from": "4", "to": "research", "value": 1}, {"from": "4", "to": "##e. lg is /", "value": 1}, {"from": "4", "to": "), buch e", "value": 1}, {"from": "4", "to": "##roga v", "value": 1}, {"from": "4", "to": "been holding research", "value": 1}, {"from": "4", "to": "11", "value": 1}, {"from": "4", "to": "101", "value": 1}, {"from": "4", "to": "##riaga k", "value": 1}, {"from": "4", "to": "), etxabe i", "value": 1}, {"from": "4", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "4", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "4", "to": "13", "value": 1}, {"from": "4", "to": "therapy", "value": 1}, {"from": "4", "to": "##ui", "value": 1}, {"from": "4", "to": "##ez", "value": 1}, {"from": "4", "to": "##vita", "value": 1}, {"from": "4", "to": "contracts", "value": 1}, {"from": "4", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "4", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "4", "to": "). author information :", "value": 1}, {"from": "4", "to": "), urruticoechea a", "value": 1}, {"from": "of ghana, a", "to": "cancer. \u00a9 2025 the author", "value": 1}, {"from": "of ghana, a", "to": "##461r pmid :", "value": 1}, {"from": "of ghana, a", "to": "antiangiogenic therapy of", "value": 1}, {"from": "of ghana, a", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "of ghana, a", "to": ")", "value": 1}, {"from": "of ghana, a", "to": "he", "value": 1}, {"from": "of ghana, a", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "of ghana, a", "to": "expression", "value": 1}, {"from": "of ghana, a", "to": "##500", "value": 1}, {"from": "of ghana, a", "to": "in cancer", "value": 1}, {"from": "of ghana, a", "to": "##mpo s", "value": 1}, {"from": "of ghana, a", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "of ghana, a", "to": "##cc", "value": 1}, {"from": "of ghana, a", "to": "inverse", "value": 1}, {"from": "of ghana, a", "to": "new insights into", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##461r pmid :", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "antiangiogenic therapy of", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": ")", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "he", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "expression", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##500", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "in cancer", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##mpo s", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "##cc", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "inverse", "value": 1}, {"from": "cancer. \u00a9 2025 the author", "to": "new insights into", "value": 1}, {"from": "##461r pmid :", "to": "antiangiogenic therapy of", "value": 1}, {"from": "##461r pmid :", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "##461r pmid :", "to": ")", "value": 1}, {"from": "##461r pmid :", "to": "he", "value": 1}, {"from": "##461r pmid :", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##461r pmid :", "to": "expression", "value": 1}, {"from": "##461r pmid :", "to": "##500", "value": 1}, {"from": "##461r pmid :", "to": "in cancer", "value": 1}, {"from": "##461r pmid :", "to": "##mpo s", "value": 1}, {"from": "##461r pmid :", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##461r pmid :", "to": "##cc", "value": 1}, {"from": "##461r pmid :", "to": "inverse", "value": 1}, {"from": "##461r pmid :", "to": "new insights into", "value": 1}, {"from": "antiangiogenic therapy of", "to": "##1 / acsomega. 4c11571. eco", "value": 1}, {"from": "antiangiogenic therapy of", "to": ")", "value": 1}, {"from": "antiangiogenic therapy of", "to": "he", "value": 1}, {"from": "antiangiogenic therapy of", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "antiangiogenic therapy of", "to": "expression", "value": 1}, {"from": "antiangiogenic therapy of", "to": "##500", "value": 1}, {"from": "antiangiogenic therapy of", "to": "in cancer", "value": 1}, {"from": "antiangiogenic therapy of", "to": "##mpo s", "value": 1}, {"from": "antiangiogenic therapy of", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "antiangiogenic therapy of", "to": "##cc", "value": 1}, {"from": "antiangiogenic therapy of", "to": "inverse", "value": 1}, {"from": "antiangiogenic therapy of", "to": "new insights into", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": ")", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "he", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "expression", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "##500", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "in cancer", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "##mpo s", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "##cc", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "inverse", "value": 1}, {"from": "##1 / acsomega. 4c11571. eco", "to": "new insights into", "value": 1}, {"from": ")", "to": "he", "value": 1}, {"from": ")", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": ")", "to": "expression", "value": 1}, {"from": ")", "to": "##500", "value": 1}, {"from": ")", "to": "in cancer", "value": 1}, {"from": ")", "to": "##mpo s", "value": 1}, {"from": ")", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": ")", "to": "##cc", "value": 2}, {"from": ")", "to": "inverse", "value": 1}, {"from": ")", "to": "new insights into", "value": 1}, {"from": ")", "to": "box l", "value": 1}, {"from": ")", "to": "associated with aging. interestingly, an", "value": 1}, {"from": ")", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": ")", "to": "of medical sciences, c.", "value": 1}, {"from": ")", "to": "these two conditions which", "value": 1}, {"from": ")", "to": "box", "value": 1}, {"from": ")", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": ")", "to": "care", "value": 1}, {"from": ")", "to": "##ra", "value": 1}, {"from": ")", "to": "00", "value": 1}, {"from": ")", "to": "233, ghana.", "value": 1}, {"from": ")", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": ")", "to": "##g 77, a", "value": 1}, {"from": ")", "to": "5", "value": 4}, {"from": ")", "to": ") west african genetic medicine centre", "value": 1}, {"from": ")", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": ")", "to": "of health", "value": 2}, {"from": ")", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": ")", "to": "##g 77, university of ghana, a", "value": 1}, {"from": ")", "to": "been observed", "value": 1}, {"from": ")", "to": ", university of ghana, p. o.", "value": 1}, {"from": ")", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": ")", "to": "between", "value": 1}, {"from": ")", "to": "of anaesthesia and intensive", "value": 1}, {"from": ")", "to": "##233, ghana.", "value": 1}, {"from": ")", "to": "incidence", "value": 1}, {"from": ")", "to": "cancer and ad", "value": 1}, {"from": ")", "to": "were formerly", "value": 1}, {"from": ")", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": ")", "to": "has", "value": 1}, {"from": ")", "to": "department", "value": 5}, {"from": ")", "to": "inverse relationship between", "value": 1}, {"from": ")", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": ")", "to": "##ibi", "value": 1}, {"from": ")", "to": "ri", "value": 1}, {"from": ")", "to": "##sana", "value": 1}, {"from": ")", "to": "doctoral program in biomedical", "value": 1}, {"from": ")", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": ")", "to": "of medicine, univers", "value": 1}, {"from": ")", "to": "##g", "value": 1}, {"from": ")", "to": "##rta", "value": 1}, {"from": ")", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": ")", "to": "##esia", "value": 1}, {"from": ")", "to": "##itas in", "value": 1}, {"from": ")", "to": "##nandi si", "value": 1}, {"from": ")", "to": "##eri", "value": 1}, {"from": ")", "to": "master program in biomedical", "value": 1}, {"from": ")", "to": "),", "value": 1}, {"from": ")", "to": "##esi", "value": 1}, {"from": ")", "to": "of medical chemistry,", "value": 1}, {"from": ")", "to": "##a.", "value": 2}, {"from": ")", "to": "faculty", "value": 1}, {"from": ")", "to": "wa", "value": 1}, {"from": ")", "to": "##don", "value": 1}, {"from": ")", "to": "##a,", "value": 1}, {"from": ")", "to": "6", "value": 2}, {"from": ")", "to": "##aka", "value": 1}, {"from": ")", "to": "indonesi", "value": 1}, {"from": ")", "to": "##itas indonesia", "value": 1}, {"from": ")", "to": "of surgery,", "value": 1}, {"from": ")", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": ")", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": ")", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": ")", "to": "), beltran - v", "value": 1}, {"from": ")", "to": ") department of pathology, co", "value": 1}, {"from": ")", "to": "##ulin", "value": 1}, {"from": ")", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": ")", "to": "f", "value": 1}, {"from": ")", "to": "new yo", "value": 1}, {"from": ")", "to": "sloan", "value": 1}, {"from": ")", "to": "la", "value": 1}, {"from": ")", "to": "center", "value": 1}, {"from": ")", "to": "us", "value": 1}, {"from": ")", "to": "##lum", "value": 1}, {"from": ")", "to": "##o m", "value": 1}, {"from": ")", "to": "9", "value": 2}, {"from": ")", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": ")", "to": "kette", "value": 1}, {"from": ")", "to": "yo", "value": 1}, {"from": ")", "to": "##ettering cancer", "value": 1}, {"from": ")", "to": "##rk, usa.", "value": 1}, {"from": ")", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": ")", "to": "re", "value": 1}, {"from": ")", "to": "new york", "value": 1}, {"from": ")", "to": "##bia university,", "value": 1}, {"from": ")", "to": "), shin e", "value": 1}, {"from": ")", "to": "##ring cancer", "value": 1}, {"from": ")", "to": "##rk, new", "value": 1}, {"from": ")", "to": "##urent, quebec, canada.", "value": 1}, {"from": ")", "to": "##isied", "value": 1}, {"from": ")", "to": "##pare therapeutics, saint -", "value": 1}, {"from": ")", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": ")", "to": "ancers. sinha s", "value": 1}, {"from": ")", "to": "##is - filho j", "value": 1}, {"from": ")", "to": "##rk,", "value": 1}, {"from": ")", "to": "), gardner r", "value": 1}, {"from": ")", "to": "12", "value": 1}, {"from": ")", "to": "after net", "value": 1}, {"from": ")", "to": "a significant", "value": 1}, {"from": ")", "to": "time", "value": 1}, {"from": ")", "to": "offers the opportunity of", "value": 1}, {"from": ")", "to": "##ip", "value": 1}, {"from": ")", "to": "t", "value": 2}, {"from": ")", "to": "however", "value": 1}, {"from": ")", "to": ") health", "value": 1}, {"from": ")", "to": "background", "value": 1}, {"from": ")", "to": "##re population of", "value": 1}, {"from": ")", "to": "negative breast", "value": 1}, {"from": ")", "to": "barrier", "value": 1}, {"from": ")", "to": "##gipuzkoa", "value": 1}, {"from": ")", "to": "clinical", "value": 1}, {"from": ")", "to": "##2 -", "value": 1}, {"from": ")", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": ")", "to": "##zkoa", "value": 1}, {"from": ")", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": ")", "to": "##gi", "value": 1}, {"from": ")", "to": "##donostia ) health", "value": 1}, {"from": ")", "to": "##tian,", "value": 1}, {"from": ")", "to": "cancer", "value": 1}, {"from": ")", "to": "spain", "value": 1}, {"from": ")", "to": "##uzkoa. eus.", "value": 1}, {"from": ")", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": ")", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": ")", "to": "and", "value": 3}, {"from": ")", "to": "real", "value": 1}, {"from": ")", "to": "personal", "value": 1}, {"from": ")", "to": "##ised therapy.", "value": 1}, {"from": ")", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ")", "to": "bio", "value": 1}, {"from": ")", "to": "##donost", "value": 1}, {"from": ")", "to": "##cent", "value": 1}, {"from": ")", "to": "research institute", "value": 1}, {"from": ")", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ")", "to": "sa", "value": 1}, {"from": ")", "to": "sebas", "value": 1}, {"from": ")", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ")", "to": "her", "value": 1}, {"from": ")", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ")", "to": "##n sebastian,", "value": 1}, {"from": ")", "to": "##umour response", "value": 1}, {"from": ")", "to": "a,", "value": 1}, {"from": ")", "to": "##pu", "value": 1}, {"from": ")", "to": "##n", "value": 1}, {"from": ")", "to": "sebastian", "value": 1}, {"from": ")", "to": "##uc", "value": 1}, {"from": ")", "to": "13", "value": 2}, {"from": ")", "to": ", the lack of reprod", "value": 1}, {"from": ")", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ")", "to": "##c ) allows", "value": 1}, {"from": ")", "to": "##gnosis", "value": 1}, {"from": ")", "to": "- g", "value": 1}, {"from": ")", "to": "##ia", "value": 1}, {"from": ")", "to": "##rgen, norway.", "value": 1}, {"from": ")", "to": "##rgen, nor", "value": 1}, {"from": ")", "to": "economics", "value": 1}, {"from": ")", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": ")", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": ")", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": ")", "to": "clinical trials", "value": 1}, {"from": ")", "to": "of health management and health", "value": 1}, {"from": ")", "to": "institute", "value": 2}, {"from": ")", "to": ";", "value": 2}, {"from": ")", "to": ") department of p", "value": 1}, {"from": ")", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": ")", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": ")", "to": "), heie a", "value": 1}, {"from": ")", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": ")", "to": "be", "value": 1}, {"from": ")", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": ")", "to": "ug", "value": 1}, {"from": ")", "to": "##way", "value": 2}, {"from": ")", "to": ") department of", "value": 1}, {"from": ")", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": ")", "to": "for cancer", "value": 1}, {"from": ")", "to": "##lia", "value": 1}, {"from": ")", "to": "##vanger,", "value": 1}, {"from": ")", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": ")", "to": "##vanger university, s", "value": 1}, {"from": ")", "to": "8", "value": 1}, {"from": ")", "to": "of cancer genetics,", "value": 1}, {"from": ")", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": ")", "to": "12 ) department", "value": 1}, {"from": ")", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": ")", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ")", "to": "##vanger university hospital, s", "value": 1}, {"from": ")", "to": "ha", "value": 1}, {"from": ")", "to": "norway", "value": 1}, {"from": ")", "to": "research", "value": 1}, {"from": ")", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ")", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ")", "to": "of pathology, s", "value": 1}, {"from": ")", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ")", "to": "11", "value": 1}, {"from": ")", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ")", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": ")", "to": "benefit", "value": 1}, {"from": ")", "to": "##26, 000 ;", "value": 1}, {"from": ")", "to": "effective", "value": 1}, {"from": ")", "to": "it was cost - saving", "value": 1}, {"from": ")", "to": "threshold", "value": 1}, {"from": ")", "to": "- 435, 677 )", "value": 1}, {"from": ")", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": ")", "to": "##aly", "value": 1}, {"from": ")", "to": "in the", "value": 1}, {"from": ")", "to": "cost", "value": 1}, {"from": ")", "to": "\u20ac", "value": 1}, {"from": ")", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": ")", "to": "- 620170,", "value": 1}, {"from": ")", "to": "##r )", "value": 1}, {"from": ")", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": ")", "to": "societal perspective", "value": 1}, {"from": ")", "to": "candidates, the strategy", "value": 1}, {"from": ")", "to": "cost - effective", "value": 1}, {"from": ")", "to": "incre", "value": 1}, {"from": ")", "to": "prosigna - test strategy, the test", "value": 1}, {"from": ")", "to": "by", "value": 1}, {"from": ")", "to": "##mental", "value": 1}, {"from": ")", "to": "the cost -", "value": 1}, {"from": ")", "to": "was cost - effective", "value": 1}, {"from": ")", "to": "above", "value": 1}, {"from": ")", "to": "respectively", "value": 1}, {"from": ")", "to": "results", "value": 1}, {"from": ")", "to": "was", "value": 1}, {"from": ")", "to": "was obtained from statistics norway.", "value": 1}, {"from": ")", "to": "per quality - adjusted life -", "value": 1}, {"from": ")", "to": "was cost - saving", "value": 1}, {"from": ")", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": ")", "to": "chemotherapy", "value": 1}, {"from": ")", "to": "in both the healthcare", "value": 1}, {"from": ")", "to": "years", "value": 1}, {"from": ")", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": ")", "to": "- per q", "value": 1}, {"from": ")", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": ")", "to": ". conclusions", "value": 1}, {"from": ")", "to": ". selecting patient", "value": 1}, {"from": ")", "to": "ice", "value": 1}, {"from": ")", "to": "##r", "value": 1}, {"from": ")", "to": "##8884 and", "value": 1}, {"from": ")", "to": "gained", "value": 1}, {"from": ")", "to": "the emit", "value": 1}, {"from": ")", "to": "records. including all pn0 patients", "value": 1}, {"from": ")", "to": "sector", "value": 1}, {"from": ")", "to": "not", "value": 1}, {"from": "he", "to": "##ction 2025 may 6. decreased", "value": 1}, {"from": "he", "to": "expression", "value": 1}, {"from": "he", "to": "##500", "value": 1}, {"from": "he", "to": "in cancer", "value": 1}, {"from": "he", "to": "##mpo s", "value": 1}, {"from": "he", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "he", "to": "##cc", "value": 1}, {"from": "he", "to": "inverse", "value": 1}, {"from": "he", "to": "new insights into", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "expression", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "##500", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "in cancer", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "##mpo s", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "##cc", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "inverse", "value": 1}, {"from": "##ction 2025 may 6. decreased", "to": "new insights into", "value": 1}, {"from": "expression", "to": "##500", "value": 1}, {"from": "expression", "to": "in cancer", "value": 1}, {"from": "expression", "to": "##mpo s", "value": 1}, {"from": "expression", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "expression", "to": "##cc", "value": 1}, {"from": "expression", "to": "inverse", "value": 1}, {"from": "expression", "to": "new insights into", "value": 1}, {"from": "expression", "to": "##regulated", "value": 1}, {"from": "expression", "to": "ad but significantly down", "value": 1}, {"from": "expression", "to": "##ly", "value": 1}, {"from": "expression", "to": "##2", "value": 1}, {"from": "expression", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "expression", "to": "##re", "value": 1}, {"from": "expression", "to": "differential", "value": 1}, {"from": "expression", "to": "##gulated in prostate can", "value": 1}, {"from": "expression", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "expression", "to": "##gulated in", "value": 1}, {"from": "expression", "to": "##gu", "value": 2}, {"from": "expression", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "expression", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "expression", "to": "expressed genes", "value": 1}, {"from": "expression", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "expression", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "expression", "to": "de", "value": 1}, {"from": "expression", "to": "quantitative pcr", "value": 1}, {"from": "expression", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "expression", "to": "time", "value": 1}, {"from": "expression", "to": "##sia", "value": 1}, {"from": "expression", "to": "of medicine, univers", "value": 1}, {"from": "expression", "to": "regulating the cell", "value": 1}, {"from": "expression", "to": "ute,", "value": 1}, {"from": "expression", "to": "##poptosis", "value": 2}, {"from": "expression", "to": "##cence, making it", "value": 1}, {"from": "expression", "to": "##itas in", "value": 1}, {"from": "expression", "to": "proliferation", "value": 1}, {"from": "expression", "to": "and se", "value": 1}, {"from": "expression", "to": "a", "value": 2}, {"from": "expression", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "expression", "to": "target", "value": 1}, {"from": "expression", "to": "##nes", "value": 1}, {"from": "expression", "to": "##50 value", "value": 1}, {"from": "expression", "to": "5", "value": 1}, {"from": "expression", "to": "role in", "value": 1}, {"from": "expression", "to": "##esi", "value": 1}, {"from": "expression", "to": "real", "value": 1}, {"from": "expression", "to": ". the p53 signaling pathway", "value": 1}, {"from": "expression", "to": ", a", "value": 2}, {"from": "expression", "to": "key", "value": 1}, {"from": "expression", "to": ", and", "value": 1}, {"from": "expression", "to": "plays", "value": 1}, {"from": "expression", "to": "##a.", "value": 1}, {"from": "expression", "to": "a critical", "value": 1}, {"from": "expression", "to": "faculty", "value": 2}, {"from": "expression", "to": "cycle", "value": 1}, {"from": "expression", "to": "of downstream genes linked to cell", "value": 1}, {"from": "expression", "to": "##a, jakarta,", "value": 1}, {"from": "expression", "to": "##iti", "value": 1}, {"from": "expression", "to": "of pharmacy, univers", "value": 1}, {"from": "expression", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "expression", "to": "##don", "value": 1}, {"from": "expression", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "expression", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "expression", "to": "##c", "value": 1}, {"from": "expression", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "expression", "to": "on the", "value": 1}, {"from": "expression", "to": "##ia", "value": 1}, {"from": "expression", "to": "senes", "value": 1}, {"from": "expression", "to": "prescribed chole", "value": 1}, {"from": "expression", "to": "has recently", "value": 1}, {"from": "expression", "to": "and its biological functions", "value": 1}, {"from": "expression", "to": "of saida, saida, algeria.", "value": 1}, {"from": "expression", "to": "shown", "value": 1}, {"from": "expression", "to": "however", "value": 1}, {"from": "expression", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "expression", "to": "shown potential anti", "value": 1}, {"from": "expression", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "expression", "to": "##in", "value": 1}, {"from": "expression", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "expression", "to": "particular breast cancer,", "value": 1}, {"from": "expression", "to": "still", "value": 1}, {"from": "expression", "to": "associated with atorvas", "value": 1}, {"from": "expression", "to": "in breast", "value": 1}, {"from": "expression", "to": "lowering", "value": 1}, {"from": "expression", "to": "to be responsive to", "value": 1}, {"from": "expression", "to": "interaction", "value": 1}, {"from": "expression", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "expression", "to": ") network and", "value": 1}, {"from": "expression", "to": "in the protein - protein", "value": 1}, {"from": "expression", "to": "drug,", "value": 1}, {"from": "expression", "to": "hub gene", "value": 1}, {"from": "expression", "to": ", its influence on gene", "value": 1}, {"from": "expression", "to": "##lated", "value": 1}, {"from": "expression", "to": "was", "value": 1}, {"from": "expression", "to": "##in,", "value": 1}, {"from": "expression", "to": "ppi", "value": 1}, {"from": "expression", "to": "##oto", "value": 2}, {"from": "expression", "to": "##tat", "value": 1}, {"from": "expression", "to": "related pathways", "value": 1}, {"from": "expression", "to": "cancer,", "value": 1}, {"from": "expression", "to": "expressed", "value": 1}, {"from": "expression", "to": "jun", "value": 1}, {"from": "expression", "to": "##cer effects.", "value": 1}, {"from": "expression", "to": "widely", "value": 1}, {"from": "expression", "to": "atorvas", "value": 1}, {"from": "expression", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "expression", "to": "##ster", "value": 1}, {"from": "expression", "to": "##ol", "value": 1}, {"from": "expression", "to": "##can", "value": 2}, {"from": "expression", "to": "cancer. atorvas", "value": 1}, {"from": "expression", "to": "was identified as the", "value": 1}, {"from": "expression", "to": "the", "value": 2}, {"from": "expression", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "expression", "to": "methods", "value": 1}, {"from": "expression", "to": "hormone receptor positive", "value": 1}, {"from": "expression", "to": "societal perspective", "value": 1}, {"from": "expression", "to": "benefits", "value": 1}, {"from": "expression", "to": "surgery", "value": 1}, {"from": "expression", "to": "cost -", "value": 1}, {"from": "expression", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "expression", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "expression", "to": "decision", "value": 1}, {"from": "expression", "to": "and", "value": 2}, {"from": "expression", "to": "to aid adjuvant treatment", "value": 1}, {"from": "expression", "to": "##al", "value": 1}, {"from": "expression", "to": "emit - 1 trial", "value": 1}, {"from": "expression", "to": "post", "value": 1}, {"from": "expression", "to": ". materials", "value": 1}, {"from": "expression", "to": "model was", "value": 1}, {"from": "expression", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "expression", "to": "used", "value": 1}, {"from": "expression", "to": "institute", "value": 1}, {"from": "expression", "to": "treatment", "value": 1}, {"from": "expression", "to": ": the", "value": 1}, {"from": "expression", "to": "ki - 67", "value": 1}, {"from": "expression", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "expression", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "expression", "to": "prosigna was tested", "value": 1}, {"from": "expression", "to": "prospective", "value": 1}, {"from": "expression", "to": "were measured", "value": 1}, {"from": "expression", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "expression", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "expression", "to": "observation", "value": 1}, {"from": "expression", "to": "division", "value": 1}, {"from": "expression", "to": "decisions in", "value": 1}, {"from": "expression", "to": "built", "value": 1}, {"from": "expression", "to": "impact of", "value": 1}, {"from": "expression", "to": "- regulate", "value": 1}, {"from": "expression", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "expression", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "expression", "to": "##tic", "value": 1}, {"from": "expression", "to": "##6 /", "value": 1}, {"from": "expression", "to": "##6", "value": 1}, {"from": "expression", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "expression", "to": "##xic effect of", "value": 1}, {"from": "expression", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "expression", "to": "00", "value": 1}, {"from": "expression", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "expression", "to": "##xic efficacy of the", "value": 1}, {"from": "expression", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "expression", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "expression", "to": "if", "value": 1}, {"from": "expression", "to": "up -", "value": 1}, {"from": "expression", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "expression", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "expression", "to": "development of tumor cells, a", "value": 1}, {"from": "expression", "to": "##348089 conflict o", "value": 1}, {"from": "expression", "to": "regulate", "value": 1}, {"from": "expression", "to": "101", "value": 1}, {"from": "expression", "to": "of pro", "value": 1}, {"from": "expression", "to": "##cl -", "value": 1}, {"from": "expression", "to": "##biotec. 2025.", "value": 1}, {"from": "expression", "to": "04", "value": 1}, {"from": "expression", "to": "##apopto", "value": 1}, {"from": "expression", "to": "to", "value": 1}, {"from": "expression", "to": "##cer and antiviral functions of", "value": 1}, {"from": "expression", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "expression", "to": "via", "value": 1}, {"from": "expression", "to": "and p", "value": 1}, {"from": "expression", "to": "##c cell line", "value": 1}, {"from": "expression", "to": "hi", "value": 1}, {"from": "expression", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "expression", "to": "down", "value": 1}, {"from": "expression", "to": "##53", "value": 1}, {"from": "expression", "to": ". 022 pmid :", "value": 1}, {"from": "expression", "to": "bax", "value": 1}, {"from": "##500", "to": "in cancer", "value": 1}, {"from": "##500", "to": "##mpo s", "value": 1}, {"from": "##500", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##500", "to": "##cc", "value": 1}, {"from": "##500", "to": "inverse", "value": 1}, {"from": "##500", "to": "new insights into", "value": 1}, {"from": "in cancer", "to": "##mpo s", "value": 1}, {"from": "in cancer", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "in cancer", "to": "##cc", "value": 1}, {"from": "in cancer", "to": "inverse", "value": 1}, {"from": "in cancer", "to": "new insights into", "value": 1}, {"from": "##mpo s", "to": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "value": 1}, {"from": "##mpo s", "to": "##cc", "value": 1}, {"from": "##mpo s", "to": "inverse", "value": 1}, {"from": "##mpo s", "to": "new insights into", "value": 1}, {"from": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "to": "##cc", "value": 1}, {"from": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "to": "inverse", "value": 1}, {"from": "m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides", "to": "new insights into", "value": 1}, {"from": "##cc", "to": "inverse", "value": 1}, {"from": "##cc", "to": "new insights into", "value": 1}, {"from": "##cc", "to": "box l", "value": 1}, {"from": "##cc", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "##cc", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "##cc", "to": "of medical sciences, c.", "value": 1}, {"from": "##cc", "to": "these two conditions which", "value": 1}, {"from": "##cc", "to": "box", "value": 1}, {"from": "##cc", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "##cc", "to": "care", "value": 1}, {"from": "##cc", "to": "##ra", "value": 1}, {"from": "##cc", "to": "00", "value": 1}, {"from": "##cc", "to": "233, ghana.", "value": 1}, {"from": "##cc", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "##cc", "to": "##g 77, a", "value": 1}, {"from": "##cc", "to": "5", "value": 1}, {"from": "##cc", "to": ") west african genetic medicine centre", "value": 1}, {"from": "##cc", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "##cc", "to": "of health", "value": 1}, {"from": "##cc", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "##cc", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "##cc", "to": "been observed", "value": 1}, {"from": "##cc", "to": ", university of ghana, p. o.", "value": 1}, {"from": "##cc", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "##cc", "to": "between", "value": 1}, {"from": "##cc", "to": "of anaesthesia and intensive", "value": 1}, {"from": "##cc", "to": "##233, ghana.", "value": 1}, {"from": "##cc", "to": "incidence", "value": 1}, {"from": "##cc", "to": "cancer and ad", "value": 1}, {"from": "##cc", "to": "were formerly", "value": 1}, {"from": "##cc", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##cc", "to": "has", "value": 1}, {"from": "##cc", "to": "department", "value": 1}, {"from": "##cc", "to": "inverse relationship between", "value": 1}, {"from": "##cc", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##cc", "to": ": we generated isogenic atm - null models using", "value": 1}, {"from": "##cc", "to": "##rates were assessed by flow c", "value": 1}, {"from": "##cc", "to": ". org.", "value": 1}, {"from": "##cc", "to": "regulator", "value": 1}, {"from": "##cc", "to": "methods", "value": 1}, {"from": "##cc", "to": ". org khana7 @ msk", "value": 1}, {"from": "##cc", "to": "##yt", "value": 1}, {"from": "##cc", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "##cc", "to": "##ase functions,", "value": 1}, {"from": "##cc", "to": "colorec", "value": 1}, {"from": "##cc", "to": "are known", "value": 1}, {"from": "##cc", "to": "polymer", "value": 1}, {"from": "##cc", "to": "##r in murine triple -", "value": 1}, {"from": "##cc", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##cc", "to": "##tal", "value": 1}, {"from": "##cc", "to": "##lt", "value": 1}, {"from": "##cc", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##cc", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##cc", "to": "mutated", "value": 1}, {"from": "##cc", "to": "negative", "value": 1}, {"from": "##cc", "to": "crisp", "value": 1}, {"from": "##cc", "to": "##ometry and immunohis", "value": 1}, {"from": "##cc", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##cc", "to": "##to", "value": 1}, {"from": "inverse", "to": "new insights into", "value": 1}, {"from": "box l", "to": "associated with aging. interestingly, an", "value": 1}, {"from": "box l", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "box l", "to": "of medical sciences, c.", "value": 1}, {"from": "box l", "to": "these two conditions which", "value": 1}, {"from": "box l", "to": "box", "value": 1}, {"from": "box l", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "box l", "to": "care", "value": 1}, {"from": "box l", "to": "##ra", "value": 1}, {"from": "box l", "to": "00", "value": 1}, {"from": "box l", "to": "233, ghana.", "value": 1}, {"from": "box l", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "box l", "to": "##g 77, a", "value": 1}, {"from": "box l", "to": "5", "value": 1}, {"from": "box l", "to": ") west african genetic medicine centre", "value": 1}, {"from": "box l", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "box l", "to": "of health", "value": 1}, {"from": "box l", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "box l", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "box l", "to": "been observed", "value": 1}, {"from": "box l", "to": ", university of ghana, p. o.", "value": 1}, {"from": "box l", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "box l", "to": "between", "value": 1}, {"from": "box l", "to": "of anaesthesia and intensive", "value": 1}, {"from": "box l", "to": "##233, ghana.", "value": 1}, {"from": "box l", "to": "incidence", "value": 1}, {"from": "box l", "to": "cancer and ad", "value": 1}, {"from": "box l", "to": "were formerly", "value": 1}, {"from": "box l", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "box l", "to": "has", "value": 1}, {"from": "box l", "to": "department", "value": 1}, {"from": "box l", "to": "inverse relationship between", "value": 1}, {"from": "box l", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "of biochemistry cell and molecular biology, p. o.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "of medical sciences, c.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "these two conditions which", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "box", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "care", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "##ra", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "00", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "233, ghana.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "##g 77, a", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "5", "value": 1}, {"from": "associated with aging. interestingly, an", "to": ") west african genetic medicine centre", "value": 1}, {"from": "associated with aging. interestingly, an", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "of health", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "been observed", "value": 1}, {"from": "associated with aging. interestingly, an", "to": ", university of ghana, p. o.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "between", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "of anaesthesia and intensive", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "##233, ghana.", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "incidence", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "cancer and ad", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "were formerly", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "has", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "department", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "inverse relationship between", "value": 1}, {"from": "associated with aging. interestingly, an", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "of medical sciences, c.", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "these two conditions which", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "box", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "care", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "##ra", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "00", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "233, ghana.", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "##g 77, a", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "5", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": ") west african genetic medicine centre", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "of health", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "been observed", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": ", university of ghana, p. o.", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "between", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "of anaesthesia and intensive", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "##233, ghana.", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "incidence", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "cancer and ad", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "were formerly", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "has", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "department", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "inverse relationship between", "value": 1}, {"from": "of biochemistry cell and molecular biology, p. o.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "of medical sciences, c.", "to": "these two conditions which", "value": 1}, {"from": "of medical sciences, c.", "to": "box", "value": 1}, {"from": "of medical sciences, c.", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "of medical sciences, c.", "to": "care", "value": 1}, {"from": "of medical sciences, c.", "to": "##ra", "value": 1}, {"from": "of medical sciences, c.", "to": "00", "value": 1}, {"from": "of medical sciences, c.", "to": "233, ghana.", "value": 1}, {"from": "of medical sciences, c.", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "of medical sciences, c.", "to": "##g 77, a", "value": 1}, {"from": "of medical sciences, c.", "to": "5", "value": 1}, {"from": "of medical sciences, c.", "to": ") west african genetic medicine centre", "value": 1}, {"from": "of medical sciences, c.", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "of medical sciences, c.", "to": "of health", "value": 1}, {"from": "of medical sciences, c.", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "of medical sciences, c.", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "of medical sciences, c.", "to": "been observed", "value": 1}, {"from": "of medical sciences, c.", "to": ", university of ghana, p. o.", "value": 1}, {"from": "of medical sciences, c.", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "of medical sciences, c.", "to": "between", "value": 1}, {"from": "of medical sciences, c.", "to": "of anaesthesia and intensive", "value": 1}, {"from": "of medical sciences, c.", "to": "##233, ghana.", "value": 1}, {"from": "of medical sciences, c.", "to": "incidence", "value": 1}, {"from": "of medical sciences, c.", "to": "cancer and ad", "value": 1}, {"from": "of medical sciences, c.", "to": "were formerly", "value": 1}, {"from": "of medical sciences, c.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "of medical sciences, c.", "to": "has", "value": 1}, {"from": "of medical sciences, c.", "to": "department", "value": 1}, {"from": "of medical sciences, c.", "to": "inverse relationship between", "value": 1}, {"from": "of medical sciences, c.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "these two conditions which", "to": "box", "value": 1}, {"from": "these two conditions which", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "these two conditions which", "to": "care", "value": 1}, {"from": "these two conditions which", "to": "##ra", "value": 1}, {"from": "these two conditions which", "to": "00", "value": 1}, {"from": "these two conditions which", "to": "233, ghana.", "value": 1}, {"from": "these two conditions which", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "these two conditions which", "to": "##g 77, a", "value": 1}, {"from": "these two conditions which", "to": "5", "value": 1}, {"from": "these two conditions which", "to": ") west african genetic medicine centre", "value": 1}, {"from": "these two conditions which", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "these two conditions which", "to": "of health", "value": 1}, {"from": "these two conditions which", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "these two conditions which", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "these two conditions which", "to": "been observed", "value": 1}, {"from": "these two conditions which", "to": ", university of ghana, p. o.", "value": 1}, {"from": "these two conditions which", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "these two conditions which", "to": "between", "value": 1}, {"from": "these two conditions which", "to": "of anaesthesia and intensive", "value": 1}, {"from": "these two conditions which", "to": "##233, ghana.", "value": 1}, {"from": "these two conditions which", "to": "incidence", "value": 1}, {"from": "these two conditions which", "to": "cancer and ad", "value": 1}, {"from": "these two conditions which", "to": "were formerly", "value": 1}, {"from": "these two conditions which", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "these two conditions which", "to": "has", "value": 1}, {"from": "these two conditions which", "to": "department", "value": 1}, {"from": "these two conditions which", "to": "inverse relationship between", "value": 1}, {"from": "these two conditions which", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "box", "to": "been largely prevalent among the older population. with the increasing", "value": 1}, {"from": "box", "to": "care", "value": 1}, {"from": "box", "to": "##ra", "value": 1}, {"from": "box", "to": "00", "value": 1}, {"from": "box", "to": "233, ghana.", "value": 1}, {"from": "box", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "box", "to": "##g 77, a", "value": 1}, {"from": "box", "to": "5", "value": 1}, {"from": "box", "to": ") west african genetic medicine centre", "value": 1}, {"from": "box", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "box", "to": "of health", "value": 1}, {"from": "box", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "box", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "box", "to": "been observed", "value": 1}, {"from": "box", "to": ", university of ghana, p. o.", "value": 1}, {"from": "box", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "box", "to": "between", "value": 1}, {"from": "box", "to": "of anaesthesia and intensive", "value": 1}, {"from": "box", "to": "##233, ghana.", "value": 1}, {"from": "box", "to": "incidence", "value": 1}, {"from": "box", "to": "cancer and ad", "value": 1}, {"from": "box", "to": "were formerly", "value": 1}, {"from": "box", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "box", "to": "has", "value": 1}, {"from": "box", "to": "department", "value": 1}, {"from": "box", "to": "inverse relationship between", "value": 1}, {"from": "box", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "care", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "##ra", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "00", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "233, ghana.", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "##g 77, a", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "5", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": ") west african genetic medicine centre", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "of health", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "been observed", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": ", university of ghana, p. o.", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "between", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "of anaesthesia and intensive", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "##233, ghana.", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "incidence", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "cancer and ad", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "were formerly", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "has", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "department", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "inverse relationship between", "value": 1}, {"from": "been largely prevalent among the older population. with the increasing", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "care", "to": "##ra", "value": 1}, {"from": "care", "to": "00", "value": 1}, {"from": "care", "to": "233, ghana.", "value": 1}, {"from": "care", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "care", "to": "##g 77, a", "value": 1}, {"from": "care", "to": "5", "value": 1}, {"from": "care", "to": ") west african genetic medicine centre", "value": 1}, {"from": "care", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "care", "to": "of health", "value": 1}, {"from": "care", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "care", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "care", "to": "been observed", "value": 1}, {"from": "care", "to": ", university of ghana, p. o.", "value": 1}, {"from": "care", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "care", "to": "between", "value": 1}, {"from": "care", "to": "of anaesthesia and intensive", "value": 1}, {"from": "care", "to": "##233, ghana.", "value": 1}, {"from": "care", "to": "incidence", "value": 1}, {"from": "care", "to": "cancer and ad", "value": 1}, {"from": "care", "to": "were formerly", "value": 1}, {"from": "care", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "care", "to": "has", "value": 1}, {"from": "care", "to": "department", "value": 1}, {"from": "care", "to": "inverse relationship between", "value": 1}, {"from": "care", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##ra", "to": "00", "value": 1}, {"from": "##ra", "to": "233, ghana.", "value": 1}, {"from": "##ra", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "##ra", "to": "##g 77, a", "value": 1}, {"from": "##ra", "to": "5", "value": 1}, {"from": "##ra", "to": ") west african genetic medicine centre", "value": 1}, {"from": "##ra", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "##ra", "to": "of health", "value": 1}, {"from": "##ra", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "##ra", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "##ra", "to": "been observed", "value": 1}, {"from": "##ra", "to": ", university of ghana, p. o.", "value": 1}, {"from": "##ra", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "##ra", "to": "between", "value": 1}, {"from": "##ra", "to": "of anaesthesia and intensive", "value": 1}, {"from": "##ra", "to": "##233, ghana.", "value": 1}, {"from": "##ra", "to": "incidence", "value": 1}, {"from": "##ra", "to": "cancer and ad", "value": 1}, {"from": "##ra", "to": "were formerly", "value": 1}, {"from": "##ra", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##ra", "to": "has", "value": 1}, {"from": "##ra", "to": "department", "value": 1}, {"from": "##ra", "to": "inverse relationship between", "value": 1}, {"from": "##ra", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "00", "to": "233, ghana.", "value": 1}, {"from": "00", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "00", "to": "##g 77, a", "value": 1}, {"from": "00", "to": "5", "value": 1}, {"from": "00", "to": ") west african genetic medicine centre", "value": 1}, {"from": "00", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "00", "to": "of health", "value": 1}, {"from": "00", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "00", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "00", "to": "been observed", "value": 1}, {"from": "00", "to": ", university of ghana, p. o.", "value": 1}, {"from": "00", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "00", "to": "between", "value": 1}, {"from": "00", "to": "of anaesthesia and intensive", "value": 1}, {"from": "00", "to": "##233, ghana.", "value": 1}, {"from": "00", "to": "incidence", "value": 1}, {"from": "00", "to": "cancer and ad", "value": 1}, {"from": "00", "to": "were formerly", "value": 1}, {"from": "00", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "00", "to": "has", "value": 1}, {"from": "00", "to": "department", "value": 1}, {"from": "00", "to": "inverse relationship between", "value": 1}, {"from": "00", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "00", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "00", "to": "##ene", "value": 1}, {"from": "00", "to": "which was", "value": 1}, {"from": "00", "to": ": cyce or ccne1", "value": 1}, {"from": "00", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "00", "to": "##8 ), and e2f1", "value": 1}, {"from": "00", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "00", "to": "##1 ), rbl1", "value": 1}, {"from": "00", "to": "might", "value": 1}, {"from": "00", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "00", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "00", "to": "the native", "value": 1}, {"from": "00", "to": "ligan", "value": 1}, {"from": "00", "to": "im", "value": 1}, {"from": "00", "to": "p = 0. 01", "value": 1}, {"from": "00", "to": "##rank", "value": 1}, {"from": "00", "to": "##j", "value": 1}, {"from": "00", "to": "by", "value": 1}, {"from": "00", "to": "rerank score", "value": 1}, {"from": "00", "to": "##um", "value": 1}, {"from": "00", "to": "##d", "value": 1}, {"from": "00", "to": "of ad", "value": 1}, {"from": "00", "to": "re", "value": 1}, {"from": "00", "to": "##idodiph", "value": 1}, {"from": "00", "to": "p = 0", "value": 1}, {"from": "00", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "00", "to": "- 112. 70 k", "value": 1}, {"from": "00", "to": "score", "value": 1}, {"from": "00", "to": "##ine", "value": 1}, {"from": "00", "to": "##enyl", "value": 1}, {"from": "00", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "00", "to": "cycle", "value": 1}, {"from": "00", "to": "##osphate", "value": 1}, {"from": "00", "to": "- 110. 68 k", "value": 1}, {"from": "00", "to": "0", "value": 1}, {"from": "00", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "00", "to": "##c", "value": 1}, {"from": "00", "to": "/ mol ), and nummular", "value": 1}, {"from": "00", "to": "squal", "value": 1}, {"from": "00", "to": "the decrease in p21", "value": 1}, {"from": "00", "to": "##mularia stem suggested that", "value": 1}, {"from": "00", "to": "- regulate", "value": 1}, {"from": "00", "to": "the", "value": 1}, {"from": "00", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "00", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "00", "to": "##tic", "value": 1}, {"from": "00", "to": "##6 /", "value": 1}, {"from": "00", "to": "##6", "value": 1}, {"from": "00", "to": "##poptosis", "value": 1}, {"from": "00", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "00", "to": "##xic effect of", "value": 1}, {"from": "00", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "00", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "00", "to": "##xic efficacy of the", "value": 1}, {"from": "00", "to": "and", "value": 1}, {"from": "00", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "00", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "00", "to": "if", "value": 1}, {"from": "00", "to": "up -", "value": 1}, {"from": "00", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "00", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "00", "to": "development of tumor cells, a", "value": 1}, {"from": "00", "to": "##348089 conflict o", "value": 1}, {"from": "00", "to": "regulate", "value": 1}, {"from": "00", "to": "101", "value": 1}, {"from": "00", "to": "##oto", "value": 1}, {"from": "00", "to": "of pro", "value": 1}, {"from": "00", "to": "##cl -", "value": 1}, {"from": "00", "to": "##biotec. 2025.", "value": 1}, {"from": "00", "to": "04", "value": 1}, {"from": "00", "to": "##apopto", "value": 1}, {"from": "00", "to": "to", "value": 1}, {"from": "00", "to": "##cer and antiviral functions of", "value": 1}, {"from": "00", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "00", "to": "via", "value": 1}, {"from": "00", "to": "and p", "value": 1}, {"from": "00", "to": "##c cell line", "value": 1}, {"from": "00", "to": "hi", "value": 1}, {"from": "00", "to": "##can", "value": 1}, {"from": "00", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "00", "to": "down", "value": 1}, {"from": "00", "to": "##53", "value": 1}, {"from": "00", "to": ". 022 pmid :", "value": 1}, {"from": "00", "to": "bax", "value": 1}, {"from": "233, ghana.", "to": "limited data on the molecular mechanisms that govern this", "value": 1}, {"from": "233, ghana.", "to": "##g 77, a", "value": 1}, {"from": "233, ghana.", "to": "5", "value": 1}, {"from": "233, ghana.", "to": ") west african genetic medicine centre", "value": 1}, {"from": "233, ghana.", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "233, ghana.", "to": "of health", "value": 1}, {"from": "233, ghana.", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "233, ghana.", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "233, ghana.", "to": "been observed", "value": 1}, {"from": "233, ghana.", "to": ", university of ghana, p. o.", "value": 1}, {"from": "233, ghana.", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "233, ghana.", "to": "between", "value": 1}, {"from": "233, ghana.", "to": "of anaesthesia and intensive", "value": 1}, {"from": "233, ghana.", "to": "##233, ghana.", "value": 1}, {"from": "233, ghana.", "to": "incidence", "value": 1}, {"from": "233, ghana.", "to": "cancer and ad", "value": 1}, {"from": "233, ghana.", "to": "were formerly", "value": 1}, {"from": "233, ghana.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "233, ghana.", "to": "has", "value": 1}, {"from": "233, ghana.", "to": "department", "value": 1}, {"from": "233, ghana.", "to": "inverse relationship between", "value": 1}, {"from": "233, ghana.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "##g 77, a", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "5", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": ") west african genetic medicine centre", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "of health", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "been observed", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": ", university of ghana, p. o.", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "between", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "of anaesthesia and intensive", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "##233, ghana.", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "incidence", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "cancer and ad", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "were formerly", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "has", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "department", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "inverse relationship between", "value": 1}, {"from": "limited data on the molecular mechanisms that govern this", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##g 77, a", "to": "5", "value": 1}, {"from": "##g 77, a", "to": ") west african genetic medicine centre", "value": 1}, {"from": "##g 77, a", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "##g 77, a", "to": "of health", "value": 1}, {"from": "##g 77, a", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "##g 77, a", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "##g 77, a", "to": "been observed", "value": 1}, {"from": "##g 77, a", "to": ", university of ghana, p. o.", "value": 1}, {"from": "##g 77, a", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "##g 77, a", "to": "between", "value": 1}, {"from": "##g 77, a", "to": "of anaesthesia and intensive", "value": 1}, {"from": "##g 77, a", "to": "##233, ghana.", "value": 1}, {"from": "##g 77, a", "to": "incidence", "value": 1}, {"from": "##g 77, a", "to": "cancer and ad", "value": 1}, {"from": "##g 77, a", "to": "were formerly", "value": 1}, {"from": "##g 77, a", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##g 77, a", "to": "has", "value": 1}, {"from": "##g 77, a", "to": "department", "value": 1}, {"from": "##g 77, a", "to": "inverse relationship between", "value": 1}, {"from": "##g 77, a", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "5", "to": ") west african genetic medicine centre", "value": 1}, {"from": "5", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": "5", "to": "of health", "value": 2}, {"from": "5", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "5", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "5", "to": "been observed", "value": 1}, {"from": "5", "to": ", university of ghana, p. o.", "value": 1}, {"from": "5", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "5", "to": "between", "value": 1}, {"from": "5", "to": "of anaesthesia and intensive", "value": 1}, {"from": "5", "to": "##233, ghana.", "value": 1}, {"from": "5", "to": "incidence", "value": 1}, {"from": "5", "to": "cancer and ad", "value": 1}, {"from": "5", "to": "were formerly", "value": 1}, {"from": "5", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "5", "to": "has", "value": 2}, {"from": "5", "to": "department", "value": 4}, {"from": "5", "to": "inverse relationship between", "value": 1}, {"from": "5", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "5", "to": "##ibi", "value": 1}, {"from": "5", "to": "ri", "value": 1}, {"from": "5", "to": "##sana", "value": 1}, {"from": "5", "to": "doctoral program in biomedical", "value": 1}, {"from": "5", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "5", "to": "of medicine, univers", "value": 2}, {"from": "5", "to": "##g", "value": 1}, {"from": "5", "to": "##rta", "value": 1}, {"from": "5", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "5", "to": "##esia", "value": 1}, {"from": "5", "to": "##itas in", "value": 2}, {"from": "5", "to": "##nandi si", "value": 1}, {"from": "5", "to": "##eri", "value": 1}, {"from": "5", "to": "master program in biomedical", "value": 1}, {"from": "5", "to": "),", "value": 1}, {"from": "5", "to": "##esi", "value": 2}, {"from": "5", "to": "of medical chemistry,", "value": 1}, {"from": "5", "to": "##a.", "value": 3}, {"from": "5", "to": "faculty", "value": 2}, {"from": "5", "to": "wa", "value": 1}, {"from": "5", "to": "##don", "value": 2}, {"from": "5", "to": "##a,", "value": 1}, {"from": "5", "to": "6", "value": 2}, {"from": "5", "to": "##aka", "value": 1}, {"from": "5", "to": "indonesi", "value": 1}, {"from": "5", "to": "##itas indonesia", "value": 1}, {"from": "5", "to": "of surgery,", "value": 1}, {"from": "5", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "5", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "5", "to": "quantitative pcr", "value": 1}, {"from": "5", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "5", "to": "time", "value": 1}, {"from": "5", "to": "##sia", "value": 1}, {"from": "5", "to": "regulating the cell", "value": 1}, {"from": "5", "to": "ute,", "value": 1}, {"from": "5", "to": "##poptosis", "value": 1}, {"from": "5", "to": "##cence, making it", "value": 1}, {"from": "5", "to": "proliferation", "value": 1}, {"from": "5", "to": "and se", "value": 1}, {"from": "5", "to": "a", "value": 2}, {"from": "5", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "5", "to": "target", "value": 1}, {"from": "5", "to": "##nes", "value": 1}, {"from": "5", "to": "##50 value", "value": 1}, {"from": "5", "to": "role in", "value": 1}, {"from": "5", "to": "real", "value": 1}, {"from": "5", "to": ". the p53 signaling pathway", "value": 1}, {"from": "5", "to": ", a", "value": 1}, {"from": "5", "to": "key", "value": 1}, {"from": "5", "to": ", and", "value": 1}, {"from": "5", "to": "plays", "value": 1}, {"from": "5", "to": "a critical", "value": 1}, {"from": "5", "to": "cycle", "value": 1}, {"from": "5", "to": "of downstream genes linked to cell", "value": 1}, {"from": "5", "to": "##a, jakarta,", "value": 1}, {"from": "5", "to": "##iti", "value": 1}, {"from": "5", "to": "of pharmacy, univers", "value": 1}, {"from": "5", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "5", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "5", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "5", "to": "##c", "value": 1}, {"from": "5", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "5", "to": "on the", "value": 1}, {"from": "5", "to": "##ia", "value": 1}, {"from": "5", "to": "senes", "value": 1}, {"from": "5", "to": "=", "value": 1}, {"from": "5", "to": "##s,", "value": 1}, {"from": "5", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "5", "to": "which is involved in", "value": 1}, {"from": "5", "to": "- 0. 46,", "value": 1}, {"from": "5", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "5", "to": "mi", "value": 1}, {"from": "5", "to": "- 5p", "value": 1}, {"from": "5", "to": "##r - 17", "value": 1}, {"from": "5", "to": "##1", "value": 1}, {"from": "5", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "5", "to": ") : e010548.", "value": 1}, {"from": "5", "to": "5p", "value": 1}, {"from": "5", "to": "hand", "value": 1}, {"from": "5", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "5", "to": "03 ) and", "value": 1}, {"from": "5", "to": "p = 0", "value": 1}, {"from": "5", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "5", "to": "##r - 106a -", "value": 1}, {"from": "5", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "5", "to": "target gene", "value": 1}, {"from": "5", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "5", "to": "- 0. 41,", "value": 1}, {"from": "5", "to": "of these lnc", "value": 1}, {"from": "5", "to": "p = 0.", "value": 1}, {"from": "5", "to": "113", "value": 1}, {"from": "5", "to": "common", "value": 1}, {"from": "5", "to": "regulated", "value": 1}, {"from": "5", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "5", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "5", "to": "), beltran - v", "value": 1}, {"from": "5", "to": ") department of pathology, co", "value": 1}, {"from": "5", "to": "##ulin", "value": 1}, {"from": "5", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "5", "to": "f", "value": 1}, {"from": "5", "to": "new yo", "value": 1}, {"from": "5", "to": "sloan", "value": 1}, {"from": "5", "to": "la", "value": 1}, {"from": "5", "to": "center", "value": 1}, {"from": "5", "to": "us", "value": 1}, {"from": "5", "to": "##lum", "value": 1}, {"from": "5", "to": "##o m", "value": 1}, {"from": "5", "to": "9", "value": 2}, {"from": "5", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "5", "to": "kette", "value": 1}, {"from": "5", "to": "yo", "value": 1}, {"from": "5", "to": "##ettering cancer", "value": 1}, {"from": "5", "to": "##rk, usa.", "value": 1}, {"from": "5", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "5", "to": "re", "value": 1}, {"from": "5", "to": "new york", "value": 1}, {"from": "5", "to": "##bia university,", "value": 1}, {"from": "5", "to": "), shin e", "value": 1}, {"from": "5", "to": "##ring cancer", "value": 1}, {"from": "5", "to": "##rk, new", "value": 1}, {"from": "5", "to": "##urent, quebec, canada.", "value": 1}, {"from": "5", "to": "##isied", "value": 1}, {"from": "5", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "5", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "5", "to": "ancers. sinha s", "value": 1}, {"from": "5", "to": "##is - filho j", "value": 1}, {"from": "5", "to": "##rk,", "value": 1}, {"from": "5", "to": "), gardner r", "value": 1}, {"from": "5", "to": "), huarte m", "value": 1}, {"from": "5", "to": "12", "value": 1}, {"from": "5", "to": "##407.", "value": 1}, {"from": "5", "to": "), par", "value": 1}, {"from": "5", "to": "ins", "value": 1}, {"from": "5", "to": "##or", "value": 1}, {"from": "5", "to": "##e", "value": 1}, {"from": "5", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "5", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "5", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "5", "to": "), aragon s", "value": 1}, {"from": "5", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "5", "to": "##ory", "value": 1}, {"from": "5", "to": "), gimenez j", "value": 1}, {"from": "5", "to": "- lopez i", "value": 1}, {"from": "5", "to": "##rine", "value": 1}, {"from": "5", "to": "er + / her2 -", "value": 1}, {"from": "5", "to": "), prat a", "value": 1}, {"from": "5", "to": "research", "value": 1}, {"from": "5", "to": "##e. lg is /", "value": 1}, {"from": "5", "to": "), buch e", "value": 1}, {"from": "5", "to": "##roga v", "value": 1}, {"from": "5", "to": "been holding research", "value": 1}, {"from": "5", "to": "11", "value": 1}, {"from": "5", "to": "101", "value": 1}, {"from": "5", "to": "##riaga k", "value": 1}, {"from": "5", "to": "), etxabe i", "value": 1}, {"from": "5", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "5", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "5", "to": "13", "value": 1}, {"from": "5", "to": "therapy", "value": 1}, {"from": "5", "to": "##ui", "value": 1}, {"from": "5", "to": "##ez", "value": 1}, {"from": "5", "to": "##vita", "value": 1}, {"from": "5", "to": "contracts", "value": 1}, {"from": "5", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "5", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "5", "to": "). author information :", "value": 1}, {"from": "5", "to": "), urruticoechea a", "value": 1}, {"from": "5", "to": "##rgen, norway.", "value": 1}, {"from": "5", "to": "##rgen, nor", "value": 1}, {"from": "5", "to": "t", "value": 1}, {"from": "5", "to": "economics", "value": 1}, {"from": "5", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "5", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "5", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "5", "to": "clinical trials", "value": 1}, {"from": "5", "to": "and", "value": 1}, {"from": "5", "to": "of health management and health", "value": 1}, {"from": "5", "to": "institute", "value": 1}, {"from": "5", "to": ";", "value": 1}, {"from": "5", "to": ") department of p", "value": 1}, {"from": "5", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "5", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "5", "to": "), heie a", "value": 1}, {"from": "5", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "5", "to": "be", "value": 1}, {"from": "5", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "5", "to": "ug", "value": 1}, {"from": "5", "to": "##way", "value": 1}, {"from": ") west african genetic medicine centre", "to": ". tedam university of technology and applied sciences, p. o.", "value": 1}, {"from": ") west african genetic medicine centre", "to": "of health", "value": 1}, {"from": ") west african genetic medicine centre", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": ") west african genetic medicine centre", "to": "##g 77, university of ghana, a", "value": 1}, {"from": ") west african genetic medicine centre", "to": "been observed", "value": 1}, {"from": ") west african genetic medicine centre", "to": ", university of ghana, p. o.", "value": 1}, {"from": ") west african genetic medicine centre", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": ") west african genetic medicine centre", "to": "between", "value": 1}, {"from": ") west african genetic medicine centre", "to": "of anaesthesia and intensive", "value": 1}, {"from": ") west african genetic medicine centre", "to": "##233, ghana.", "value": 1}, {"from": ") west african genetic medicine centre", "to": "incidence", "value": 1}, {"from": ") west african genetic medicine centre", "to": "cancer and ad", "value": 1}, {"from": ") west african genetic medicine centre", "to": "were formerly", "value": 1}, {"from": ") west african genetic medicine centre", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": ") west african genetic medicine centre", "to": "has", "value": 1}, {"from": ") west african genetic medicine centre", "to": "department", "value": 1}, {"from": ") west african genetic medicine centre", "to": "inverse relationship between", "value": 1}, {"from": ") west african genetic medicine centre", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "of health", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "##g 77, university of ghana, a", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "been observed", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": ", university of ghana, p. o.", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "between", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "of anaesthesia and intensive", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "##233, ghana.", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "incidence", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "cancer and ad", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "were formerly", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "has", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "department", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "inverse relationship between", "value": 1}, {"from": ". tedam university of technology and applied sciences, p. o.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "of health", "to": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "value": 1}, {"from": "of health", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "of health", "to": "been observed", "value": 1}, {"from": "of health", "to": ", university of ghana, p. o.", "value": 1}, {"from": "of health", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "of health", "to": "between", "value": 1}, {"from": "of health", "to": "of anaesthesia and intensive", "value": 1}, {"from": "of health", "to": "##233, ghana.", "value": 1}, {"from": "of health", "to": "incidence", "value": 1}, {"from": "of health", "to": "cancer and ad", "value": 1}, {"from": "of health", "to": "were formerly", "value": 1}, {"from": "of health", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "of health", "to": "has", "value": 1}, {"from": "of health", "to": "department", "value": 2}, {"from": "of health", "to": "inverse relationship between", "value": 1}, {"from": "of health", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "of health", "to": "##rgen, norway.", "value": 1}, {"from": "of health", "to": "##rgen, nor", "value": 1}, {"from": "of health", "to": "t", "value": 1}, {"from": "of health", "to": "economics", "value": 1}, {"from": "of health", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "of health", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "of health", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "of health", "to": "clinical trials", "value": 1}, {"from": "of health", "to": "and", "value": 1}, {"from": "of health", "to": "of health management and health", "value": 1}, {"from": "of health", "to": "institute", "value": 1}, {"from": "of health", "to": ";", "value": 1}, {"from": "of health", "to": ") department of p", "value": 1}, {"from": "of health", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "of health", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "of health", "to": "), heie a", "value": 1}, {"from": "of health", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "of health", "to": "be", "value": 1}, {"from": "of health", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "of health", "to": "ug", "value": 1}, {"from": "of health", "to": "##way", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "##g 77, university of ghana, a", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "been observed", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": ", university of ghana, p. o.", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "between", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "of anaesthesia and intensive", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "##233, ghana.", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "incidence", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "cancer and ad", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "were formerly", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "has", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "department", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "inverse relationship between", "value": 1}, {"from": "large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "been observed", "value": 1}, {"from": "##g 77, university of ghana, a", "to": ", university of ghana, p. o.", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "between", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "of anaesthesia and intensive", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "##233, ghana.", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "incidence", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "cancer and ad", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "were formerly", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "has", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "department", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "inverse relationship between", "value": 1}, {"from": "##g 77, university of ghana, a", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "been observed", "to": ", university of ghana, p. o.", "value": 1}, {"from": "been observed", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": "been observed", "to": "between", "value": 1}, {"from": "been observed", "to": "of anaesthesia and intensive", "value": 1}, {"from": "been observed", "to": "##233, ghana.", "value": 1}, {"from": "been observed", "to": "incidence", "value": 1}, {"from": "been observed", "to": "cancer and ad", "value": 1}, {"from": "been observed", "to": "were formerly", "value": 1}, {"from": "been observed", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "been observed", "to": "has", "value": 1}, {"from": "been observed", "to": "department", "value": 1}, {"from": "been observed", "to": "inverse relationship between", "value": 1}, {"from": "been observed", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": ", university of ghana, p. o.", "to": "##233, ghana. alzheimer \u0027 s disease", "value": 1}, {"from": ", university of ghana, p. o.", "to": "between", "value": 1}, {"from": ", university of ghana, p. o.", "to": "of anaesthesia and intensive", "value": 1}, {"from": ", university of ghana, p. o.", "to": "##233, ghana.", "value": 1}, {"from": ", university of ghana, p. o.", "to": "incidence", "value": 1}, {"from": ", university of ghana, p. o.", "to": "cancer and ad", "value": 1}, {"from": ", university of ghana, p. o.", "to": "were formerly", "value": 1}, {"from": ", university of ghana, p. o.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": ", university of ghana, p. o.", "to": "has", "value": 1}, {"from": ", university of ghana, p. o.", "to": "department", "value": 1}, {"from": ", university of ghana, p. o.", "to": "inverse relationship between", "value": 1}, {"from": ", university of ghana, p. o.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "between", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "of anaesthesia and intensive", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "##233, ghana.", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "incidence", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "cancer and ad", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "were formerly", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "has", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "department", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "inverse relationship between", "value": 1}, {"from": "##233, ghana. alzheimer \u0027 s disease", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "between", "to": "of anaesthesia and intensive", "value": 1}, {"from": "between", "to": "##233, ghana.", "value": 1}, {"from": "between", "to": "incidence", "value": 1}, {"from": "between", "to": "cancer and ad", "value": 1}, {"from": "between", "to": "were formerly", "value": 1}, {"from": "between", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "between", "to": "has", "value": 1}, {"from": "between", "to": "department", "value": 1}, {"from": "between", "to": "inverse relationship between", "value": 1}, {"from": "between", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "of anaesthesia and intensive", "to": "##233, ghana.", "value": 1}, {"from": "of anaesthesia and intensive", "to": "incidence", "value": 1}, {"from": "of anaesthesia and intensive", "to": "cancer and ad", "value": 1}, {"from": "of anaesthesia and intensive", "to": "were formerly", "value": 1}, {"from": "of anaesthesia and intensive", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "of anaesthesia and intensive", "to": "has", "value": 1}, {"from": "of anaesthesia and intensive", "to": "department", "value": 1}, {"from": "of anaesthesia and intensive", "to": "inverse relationship between", "value": 1}, {"from": "of anaesthesia and intensive", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##233, ghana.", "to": "incidence", "value": 1}, {"from": "##233, ghana.", "to": "cancer and ad", "value": 1}, {"from": "##233, ghana.", "to": "were formerly", "value": 1}, {"from": "##233, ghana.", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "##233, ghana.", "to": "has", "value": 1}, {"from": "##233, ghana.", "to": "department", "value": 1}, {"from": "##233, ghana.", "to": "inverse relationship between", "value": 1}, {"from": "##233, ghana.", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "incidence", "to": "cancer and ad", "value": 1}, {"from": "incidence", "to": "were formerly", "value": 1}, {"from": "incidence", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "incidence", "to": "has", "value": 1}, {"from": "incidence", "to": "department", "value": 1}, {"from": "incidence", "to": "inverse relationship between", "value": 1}, {"from": "incidence", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "cancer and ad", "to": "were formerly", "value": 1}, {"from": "cancer and ad", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "cancer and ad", "to": "has", "value": 1}, {"from": "cancer and ad", "to": "department", "value": 1}, {"from": "cancer and ad", "to": "inverse relationship between", "value": 1}, {"from": "cancer and ad", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "were formerly", "to": "24, am133 coffee street, navrongo", "value": 1}, {"from": "were formerly", "to": "has", "value": 1}, {"from": "were formerly", "to": "department", "value": 1}, {"from": "were formerly", "to": "inverse relationship between", "value": 1}, {"from": "were formerly", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "24, am133 coffee street, navrongo", "to": "has", "value": 1}, {"from": "24, am133 coffee street, navrongo", "to": "department", "value": 1}, {"from": "24, am133 coffee street, navrongo", "to": "inverse relationship between", "value": 1}, {"from": "24, am133 coffee street, navrongo", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "has", "to": "department", "value": 1}, {"from": "has", "to": "inverse relationship between", "value": 1}, {"from": "has", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "has", "to": "), huarte m", "value": 1}, {"from": "has", "to": "12", "value": 1}, {"from": "has", "to": "##407.", "value": 1}, {"from": "has", "to": "), par", "value": 1}, {"from": "has", "to": "ins", "value": 1}, {"from": "has", "to": "##or", "value": 1}, {"from": "has", "to": "##e", "value": 1}, {"from": "has", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "has", "to": "9", "value": 1}, {"from": "has", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "has", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "has", "to": "), aragon s", "value": 1}, {"from": "has", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "has", "to": "##ory", "value": 1}, {"from": "has", "to": "), gimenez j", "value": 1}, {"from": "has", "to": "- lopez i", "value": 1}, {"from": "has", "to": "##rine", "value": 1}, {"from": "has", "to": "er + / her2 -", "value": 1}, {"from": "has", "to": "), prat a", "value": 1}, {"from": "has", "to": "research", "value": 1}, {"from": "has", "to": "##e. lg is /", "value": 1}, {"from": "has", "to": "), buch e", "value": 1}, {"from": "has", "to": "##roga v", "value": 1}, {"from": "has", "to": "been holding research", "value": 1}, {"from": "has", "to": "11", "value": 1}, {"from": "has", "to": "101", "value": 1}, {"from": "has", "to": "##riaga k", "value": 1}, {"from": "has", "to": "), etxabe i", "value": 1}, {"from": "has", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "has", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "has", "to": "13", "value": 1}, {"from": "has", "to": "therapy", "value": 1}, {"from": "has", "to": "##ui", "value": 1}, {"from": "has", "to": "##ez", "value": 1}, {"from": "has", "to": "##vita", "value": 1}, {"from": "has", "to": "contracts", "value": 1}, {"from": "has", "to": "6", "value": 1}, {"from": "has", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "has", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "has", "to": "). author information :", "value": 1}, {"from": "has", "to": "), urruticoechea a", "value": 1}, {"from": "department", "to": "inverse relationship between", "value": 1}, {"from": "department", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "department", "to": "##ibi", "value": 1}, {"from": "department", "to": "ri", "value": 1}, {"from": "department", "to": "##sana", "value": 1}, {"from": "department", "to": "doctoral program in biomedical", "value": 1}, {"from": "department", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "department", "to": "of medicine, univers", "value": 1}, {"from": "department", "to": "##g", "value": 1}, {"from": "department", "to": "##rta", "value": 1}, {"from": "department", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "department", "to": "##esia", "value": 1}, {"from": "department", "to": "##itas in", "value": 1}, {"from": "department", "to": "##nandi si", "value": 1}, {"from": "department", "to": "##eri", "value": 1}, {"from": "department", "to": "master program in biomedical", "value": 1}, {"from": "department", "to": "),", "value": 1}, {"from": "department", "to": "##esi", "value": 1}, {"from": "department", "to": "of medical chemistry,", "value": 1}, {"from": "department", "to": "##a.", "value": 2}, {"from": "department", "to": "faculty", "value": 1}, {"from": "department", "to": "wa", "value": 1}, {"from": "department", "to": "##don", "value": 1}, {"from": "department", "to": "##a,", "value": 1}, {"from": "department", "to": "6", "value": 2}, {"from": "department", "to": "##aka", "value": 1}, {"from": "department", "to": "indonesi", "value": 1}, {"from": "department", "to": "##itas indonesia", "value": 1}, {"from": "department", "to": "of surgery,", "value": 1}, {"from": "department", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "department", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "department", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "department", "to": "), beltran - v", "value": 1}, {"from": "department", "to": ") department of pathology, co", "value": 1}, {"from": "department", "to": "##ulin", "value": 1}, {"from": "department", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "department", "to": "f", "value": 1}, {"from": "department", "to": "new yo", "value": 1}, {"from": "department", "to": "sloan", "value": 1}, {"from": "department", "to": "la", "value": 1}, {"from": "department", "to": "center", "value": 1}, {"from": "department", "to": "us", "value": 1}, {"from": "department", "to": "##lum", "value": 1}, {"from": "department", "to": "##o m", "value": 1}, {"from": "department", "to": "9", "value": 2}, {"from": "department", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "department", "to": "kette", "value": 1}, {"from": "department", "to": "yo", "value": 1}, {"from": "department", "to": "##ettering cancer", "value": 1}, {"from": "department", "to": "##rk, usa.", "value": 1}, {"from": "department", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "department", "to": "re", "value": 1}, {"from": "department", "to": "new york", "value": 1}, {"from": "department", "to": "##bia university,", "value": 1}, {"from": "department", "to": "), shin e", "value": 1}, {"from": "department", "to": "##ring cancer", "value": 1}, {"from": "department", "to": "##rk, new", "value": 1}, {"from": "department", "to": "##urent, quebec, canada.", "value": 1}, {"from": "department", "to": "##isied", "value": 1}, {"from": "department", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "department", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "department", "to": "ancers. sinha s", "value": 1}, {"from": "department", "to": "##is - filho j", "value": 1}, {"from": "department", "to": "##rk,", "value": 1}, {"from": "department", "to": "), gardner r", "value": 1}, {"from": "department", "to": "##rgen, norway.", "value": 1}, {"from": "department", "to": "##rgen, nor", "value": 1}, {"from": "department", "to": "t", "value": 1}, {"from": "department", "to": "economics", "value": 1}, {"from": "department", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "department", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "department", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "department", "to": "clinical trials", "value": 1}, {"from": "department", "to": "and", "value": 1}, {"from": "department", "to": "of health management and health", "value": 1}, {"from": "department", "to": "institute", "value": 3}, {"from": "department", "to": ";", "value": 3}, {"from": "department", "to": ") department of p", "value": 1}, {"from": "department", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "department", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "department", "to": "), heie a", "value": 1}, {"from": "department", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": "be", "value": 1}, {"from": "department", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "department", "to": "ug", "value": 1}, {"from": "department", "to": "##way", "value": 3}, {"from": "department", "to": ") department of", "value": 1}, {"from": "department", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "department", "to": "for cancer", "value": 1}, {"from": "department", "to": "##lia", "value": 1}, {"from": "department", "to": "##vanger,", "value": 1}, {"from": "department", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "department", "to": "##vanger university, s", "value": 1}, {"from": "department", "to": "8", "value": 1}, {"from": "department", "to": "of cancer genetics,", "value": 2}, {"from": "department", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "department", "to": "12 ) department", "value": 1}, {"from": "department", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "department", "to": "##vanger university hospital, s", "value": 1}, {"from": "department", "to": "ha", "value": 1}, {"from": "department", "to": "norway", "value": 1}, {"from": "department", "to": "research", "value": 1}, {"from": "department", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "department", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "department", "to": "of pathology, s", "value": 1}, {"from": "department", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": "11", "value": 1}, {"from": "department", "to": "13", "value": 1}, {"from": "department", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": ", drammen, norway.", "value": 1}, {"from": "department", "to": "of clinical medicine,", "value": 1}, {"from": "department", "to": "##dheim, norway.", "value": 1}, {"from": "department", "to": "25", "value": 1}, {"from": "department", "to": "trust", "value": 1}, {"from": "department", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "department", "to": ", hamar, norway.", "value": 1}, {"from": "department", "to": ", kalnes, norway.", "value": 1}, {"from": "department", "to": ", skien, norway.", "value": 1}, {"from": "department", "to": "of oslo, oslo, nor", "value": 1}, {"from": "department", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "department", "to": ") department of oncolog", "value": 1}, {"from": "department", "to": "##ron", "value": 1}, {"from": "inverse relationship between", "to": "of cancer over the years, scientists have explored the relationship", "value": 1}, {"from": "##regulated", "to": "ad but significantly down", "value": 1}, {"from": "##regulated", "to": "##ly", "value": 1}, {"from": "##regulated", "to": "##2", "value": 1}, {"from": "##regulated", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "##regulated", "to": "##re", "value": 1}, {"from": "##regulated", "to": "differential", "value": 1}, {"from": "##regulated", "to": "##gulated in prostate can", "value": 1}, {"from": "##regulated", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##regulated", "to": "##gulated in", "value": 1}, {"from": "##regulated", "to": "##gu", "value": 1}, {"from": "##regulated", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##regulated", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##regulated", "to": "expressed genes", "value": 1}, {"from": "##regulated", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##regulated", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##regulated", "to": "de", "value": 1}, {"from": "##regulated", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "##regulated", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "##regulated", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "##regulated", "to": ". 108", "value": 1}, {"from": "##regulated", "to": "jun might", "value": 1}, {"from": "##regulated", "to": "##0", "value": 1}, {"from": "##regulated", "to": "expression.", "value": 1}, {"from": "##regulated", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "##regulated", "to": "##na ss", "value": 1}, {"from": "##regulated", "to": "##v", "value": 1}, {"from": "##regulated", "to": "##un", "value": 1}, {"from": "##regulated", "to": "##gno", "value": 1}, {"from": "##regulated", "to": "activity positively correlated with", "value": 1}, {"from": "##regulated", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##regulated", "to": ". 17305 /", "value": 1}, {"from": "##regulated", "to": "luki", "value": 1}, {"from": "##regulated", "to": "bio", "value": 1}, {"from": "##regulated", "to": "##v vi", "value": 1}, {"from": "##regulated", "to": "logino", "value": 1}, {"from": "##regulated", "to": "was", "value": 1}, {"from": "##regulated", "to": "may directly interact with", "value": 1}, {"from": "##regulated", "to": "serve as a valuable pro", "value": 1}, {"from": "##regulated", "to": "##tatin", "value": 1}, {"from": "##regulated", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##regulated", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##regulated", "to": "expression. as such,", "value": 1}, {"from": "##regulated", "to": "significantly", "value": 1}, {"from": "##regulated", "to": "jun", "value": 1}, {"from": "##regulated", "to": "##nina", "value": 1}, {"from": "##regulated", "to": "pro", "value": 1}, {"from": "##regulated", "to": "down", "value": 1}, {"from": "##regulated", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "ad but significantly down", "to": "##ly", "value": 1}, {"from": "ad but significantly down", "to": "##2", "value": 1}, {"from": "ad but significantly down", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "ad but significantly down", "to": "##re", "value": 1}, {"from": "ad but significantly down", "to": "differential", "value": 1}, {"from": "ad but significantly down", "to": "##gulated in prostate can", "value": 1}, {"from": "ad but significantly down", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "ad but significantly down", "to": "##gulated in", "value": 1}, {"from": "ad but significantly down", "to": "##gu", "value": 1}, {"from": "ad but significantly down", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "ad but significantly down", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "ad but significantly down", "to": "expressed genes", "value": 1}, {"from": "ad but significantly down", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "ad but significantly down", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "ad but significantly down", "to": "de", "value": 1}, {"from": "##ly", "to": "##2", "value": 1}, {"from": "##ly", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "##ly", "to": "##re", "value": 1}, {"from": "##ly", "to": "differential", "value": 1}, {"from": "##ly", "to": "##gulated in prostate can", "value": 1}, {"from": "##ly", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##ly", "to": "##gulated in", "value": 1}, {"from": "##ly", "to": "##gu", "value": 1}, {"from": "##ly", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##ly", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##ly", "to": "expressed genes", "value": 1}, {"from": "##ly", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##ly", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##ly", "to": "de", "value": 1}, {"from": "##2", "to": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "value": 1}, {"from": "##2", "to": "##re", "value": 1}, {"from": "##2", "to": "differential", "value": 1}, {"from": "##2", "to": "##gulated in prostate can", "value": 1}, {"from": "##2", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##2", "to": "##gulated in", "value": 1}, {"from": "##2", "to": "##gu", "value": 1}, {"from": "##2", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##2", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##2", "to": "expressed genes", "value": 1}, {"from": "##2", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##2", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##2", "to": "de", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##re", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "differential", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##gulated in prostate can", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##gulated in", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##gu", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "expressed genes", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna", "to": "de", "value": 1}, {"from": "##re", "to": "differential", "value": 1}, {"from": "##re", "to": "##gulated in prostate can", "value": 1}, {"from": "##re", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##re", "to": "##gulated in", "value": 1}, {"from": "##re", "to": "##gu", "value": 1}, {"from": "##re", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##re", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##re", "to": "expressed genes", "value": 1}, {"from": "##re", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##re", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##re", "to": "de", "value": 1}, {"from": "##re", "to": "risk", "value": 1}, {"from": "##re", "to": "of cancer development while", "value": 1}, {"from": "##re", "to": "reduced", "value": 1}, {"from": "##re", "to": "##1 / acsomega. 4", "value": 1}, {"from": "##re", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "##re", "to": "##ve", "value": 1}, {"from": "##re", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "##re", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "##re", "to": "10. 102", "value": 1}, {"from": "##re", "to": "##er and 5 genes down", "value": 1}, {"from": "##re", "to": "upre", "value": 1}, {"from": "##re", "to": "were downregulated", "value": 1}, {"from": "##re", "to": "pm", "value": 1}, {"from": "##re", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##re", "to": "##ida", "value": 1}, {"from": "##re", "to": "##gulated", "value": 1}, {"from": "##re", "to": "play an important role in", "value": 1}, {"from": "##re", "to": "##12059893", "value": 1}, {"from": "##re", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##re", "to": "##c", "value": 2}, {"from": "##re", "to": "in all three cancers and may", "value": 1}, {"from": "##re", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##re", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##re", "to": "##id :", "value": 1}, {"from": "##re", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "##re", "to": "##r confirmed their down", "value": 1}, {"from": "##re", "to": "four", "value": 1}, {"from": "##re", "to": "prioriti", "value": 1}, {"from": "##re", "to": "pc", "value": 1}, {"from": "##re", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "##re", "to": "diagnosed", "value": 1}, {"from": "##re", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "##re", "to": "incomplete", "value": 1}, {"from": "##re", "to": "ministry", "value": 1}, {"from": "##re", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##re", "to": "diagnostic", "value": 1}, {"from": "##re", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##re", "to": "##s and", "value": 1}, {"from": "##re", "to": "##s.", "value": 1}, {"from": "##re", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##re", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##re", "to": "treatment", "value": 1}, {"from": "##re", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##re", "to": "- mi", "value": 1}, {"from": "##re", "to": "##gna", "value": 1}, {"from": "##re", "to": "expressed", "value": 1}, {"from": "##re", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##re", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##re", "to": "##ncrna", "value": 1}, {"from": "##re", "to": "##r", "value": 1}, {"from": "##re", "to": "##ia", "value": 1}, {"from": "##re", "to": "mrna", "value": 1}, {"from": "##re", "to": "mali", "value": 1}, {"from": "##re", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "differential", "to": "##gulated in prostate can", "value": 1}, {"from": "differential", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "differential", "to": "##gulated in", "value": 1}, {"from": "differential", "to": "##gu", "value": 1}, {"from": "differential", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "differential", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "differential", "to": "expressed genes", "value": 1}, {"from": "differential", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "differential", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "differential", "to": "de", "value": 1}, {"from": "##gulated in prostate can", "to": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "value": 1}, {"from": "##gulated in prostate can", "to": "##gulated in", "value": 1}, {"from": "##gulated in prostate can", "to": "##gu", "value": 1}, {"from": "##gulated in prostate can", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##gulated in prostate can", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##gulated in prostate can", "to": "expressed genes", "value": 1}, {"from": "##gulated in prostate can", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##gulated in prostate can", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##gulated in prostate can", "to": "de", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "##gulated in", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "##gu", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "expressed genes", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre", "to": "de", "value": 1}, {"from": "##gulated in", "to": "##gu", "value": 1}, {"from": "##gulated in", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##gulated in", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##gulated in", "to": "expressed genes", "value": 1}, {"from": "##gulated in", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##gulated in", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##gulated in", "to": "de", "value": 1}, {"from": "##gu", "to": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "value": 1}, {"from": "##gu", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##gu", "to": "expressed genes", "value": 1}, {"from": "##gu", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##gu", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##gu", "to": "de", "value": 1}, {"from": "##gu", "to": "prescribed chole", "value": 1}, {"from": "##gu", "to": "has recently", "value": 1}, {"from": "##gu", "to": "and its biological functions", "value": 1}, {"from": "##gu", "to": "of saida, saida, algeria.", "value": 1}, {"from": "##gu", "to": "shown", "value": 1}, {"from": "##gu", "to": "however", "value": 1}, {"from": "##gu", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "##gu", "to": "shown potential anti", "value": 1}, {"from": "##gu", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "##gu", "to": "a", "value": 1}, {"from": "##gu", "to": "##in", "value": 1}, {"from": "##gu", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "##gu", "to": "particular breast cancer,", "value": 1}, {"from": "##gu", "to": "still", "value": 1}, {"from": "##gu", "to": "associated with atorvas", "value": 1}, {"from": "##gu", "to": "in breast", "value": 1}, {"from": "##gu", "to": "lowering", "value": 1}, {"from": "##gu", "to": "to be responsive to", "value": 1}, {"from": "##gu", "to": "interaction", "value": 1}, {"from": "##gu", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "##gu", "to": ") network and", "value": 1}, {"from": "##gu", "to": "in the protein - protein", "value": 1}, {"from": "##gu", "to": "drug,", "value": 1}, {"from": "##gu", "to": "hub gene", "value": 1}, {"from": "##gu", "to": ", its influence on gene", "value": 1}, {"from": "##gu", "to": "##lated", "value": 1}, {"from": "##gu", "to": "was", "value": 1}, {"from": "##gu", "to": "##in,", "value": 1}, {"from": "##gu", "to": "ppi", "value": 1}, {"from": "##gu", "to": "##oto", "value": 1}, {"from": "##gu", "to": "##tat", "value": 1}, {"from": "##gu", "to": "related pathways", "value": 1}, {"from": "##gu", "to": "faculty", "value": 1}, {"from": "##gu", "to": "cancer,", "value": 1}, {"from": "##gu", "to": "expressed", "value": 1}, {"from": "##gu", "to": "jun", "value": 1}, {"from": "##gu", "to": "##cer effects.", "value": 1}, {"from": "##gu", "to": "widely", "value": 1}, {"from": "##gu", "to": "atorvas", "value": 1}, {"from": "##gu", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##gu", "to": "##ster", "value": 1}, {"from": "##gu", "to": "##ol", "value": 1}, {"from": "##gu", "to": "##can", "value": 1}, {"from": "##gu", "to": "cancer. atorvas", "value": 1}, {"from": "##gu", "to": "was identified as the", "value": 1}, {"from": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "to": "##gs ) between ad and nondemented controls were identified using the geo", "value": 1}, {"from": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "to": "expressed genes", "value": 1}, {"from": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre", "to": "de", "value": 1}, {"from": "##gs ) between ad and nondemented controls were identified using the geo", "to": "expressed genes", "value": 1}, {"from": "##gs ) between ad and nondemented controls were identified using the geo", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "##gs ) between ad and nondemented controls were identified using the geo", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "##gs ) between ad and nondemented controls were identified using the geo", "to": "de", "value": 1}, {"from": "expressed genes", "to": "in breast cancer, 11 significantly down", "value": 1}, {"from": "expressed genes", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "expressed genes", "to": "de", "value": 1}, {"from": "in breast cancer, 11 significantly down", "to": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "value": 1}, {"from": "in breast cancer, 11 significantly down", "to": "de", "value": 1}, {"from": "phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus", "to": "de", "value": 1}, {"from": "risk", "to": "of cancer development while", "value": 1}, {"from": "risk", "to": "reduced", "value": 1}, {"from": "risk", "to": "##1 / acsomega. 4", "value": 1}, {"from": "risk", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "risk", "to": "##ve", "value": 1}, {"from": "risk", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "risk", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "risk", "to": "10. 102", "value": 1}, {"from": "risk", "to": "##er and 5 genes down", "value": 1}, {"from": "risk", "to": "upre", "value": 1}, {"from": "risk", "to": "were downregulated", "value": 1}, {"from": "risk", "to": "pm", "value": 1}, {"from": "risk", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "risk", "to": "##ida", "value": 1}, {"from": "risk", "to": "##gulated", "value": 1}, {"from": "risk", "to": "play an important role in", "value": 1}, {"from": "risk", "to": "##12059893", "value": 1}, {"from": "risk", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "risk", "to": "##c", "value": 1}, {"from": "risk", "to": "in all three cancers and may", "value": 1}, {"from": "risk", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "risk", "to": "##11571 pmcid : pm", "value": 1}, {"from": "risk", "to": "##id :", "value": 1}, {"from": "of cancer development while", "to": "reduced", "value": 1}, {"from": "of cancer development while", "to": "##1 / acsomega. 4", "value": 1}, {"from": "of cancer development while", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "of cancer development while", "to": "##ve", "value": 1}, {"from": "of cancer development while", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "of cancer development while", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "of cancer development while", "to": "10. 102", "value": 1}, {"from": "of cancer development while", "to": "##er and 5 genes down", "value": 1}, {"from": "of cancer development while", "to": "upre", "value": 1}, {"from": "of cancer development while", "to": "were downregulated", "value": 1}, {"from": "of cancer development while", "to": "pm", "value": 1}, {"from": "of cancer development while", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "of cancer development while", "to": "##ida", "value": 1}, {"from": "of cancer development while", "to": "##gulated", "value": 1}, {"from": "of cancer development while", "to": "play an important role in", "value": 1}, {"from": "of cancer development while", "to": "##12059893", "value": 1}, {"from": "of cancer development while", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "of cancer development while", "to": "##c", "value": 1}, {"from": "of cancer development while", "to": "in all three cancers and may", "value": 1}, {"from": "of cancer development while", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "of cancer development while", "to": "##11571 pmcid : pm", "value": 1}, {"from": "of cancer development while", "to": "##id :", "value": 1}, {"from": "reduced", "to": "##1 / acsomega. 4", "value": 1}, {"from": "reduced", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "reduced", "to": "##ve", "value": 1}, {"from": "reduced", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "reduced", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "reduced", "to": "10. 102", "value": 1}, {"from": "reduced", "to": "##er and 5 genes down", "value": 1}, {"from": "reduced", "to": "upre", "value": 1}, {"from": "reduced", "to": "were downregulated", "value": 1}, {"from": "reduced", "to": "pm", "value": 1}, {"from": "reduced", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "reduced", "to": "##ida", "value": 1}, {"from": "reduced", "to": "##gulated", "value": 1}, {"from": "reduced", "to": "play an important role in", "value": 1}, {"from": "reduced", "to": "##12059893", "value": 1}, {"from": "reduced", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "reduced", "to": "##c", "value": 1}, {"from": "reduced", "to": "in all three cancers and may", "value": 1}, {"from": "reduced", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "reduced", "to": "##11571 pmcid : pm", "value": 1}, {"from": "reduced", "to": "##id :", "value": 1}, {"from": "##1 / acsomega. 4", "to": ". 52225 / narra. v5i1. 1364. ep", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##ve", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "##1 / acsomega. 4", "to": "10. 102", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##er and 5 genes down", "value": 1}, {"from": "##1 / acsomega. 4", "to": "upre", "value": 1}, {"from": "##1 / acsomega. 4", "to": "were downregulated", "value": 1}, {"from": "##1 / acsomega. 4", "to": "pm", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##ida", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##gulated", "value": 1}, {"from": "##1 / acsomega. 4", "to": "play an important role in", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##12059893", "value": 1}, {"from": "##1 / acsomega. 4", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##c", "value": 1}, {"from": "##1 / acsomega. 4", "to": "in all three cancers and may", "value": 1}, {"from": "##1 / acsomega. 4", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##1 / acsomega. 4", "to": "##id :", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##ve", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "10. 102", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##er and 5 genes down", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "upre", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "were downregulated", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "pm", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##ida", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##gulated", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "play an important role in", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##12059893", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##c", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "in all three cancers and may", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##11571 pmcid : pm", "value": 1}, {"from": ". 52225 / narra. v5i1. 1364. ep", "to": "##id :", "value": 1}, {"from": "##ve", "to": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "value": 1}, {"from": "##ve", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "##ve", "to": "10. 102", "value": 1}, {"from": "##ve", "to": "##er and 5 genes down", "value": 1}, {"from": "##ve", "to": "upre", "value": 1}, {"from": "##ve", "to": "were downregulated", "value": 1}, {"from": "##ve", "to": "pm", "value": 1}, {"from": "##ve", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##ve", "to": "##ida", "value": 1}, {"from": "##ve", "to": "##gulated", "value": 1}, {"from": "##ve", "to": "play an important role in", "value": 1}, {"from": "##ve", "to": "##12059893", "value": 1}, {"from": "##ve", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##ve", "to": "##c", "value": 1}, {"from": "##ve", "to": "in all three cancers and may", "value": 1}, {"from": "##ve", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##ve", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##ve", "to": "##id :", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "10. 102", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##er and 5 genes down", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "upre", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "were downregulated", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "pm", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##ida", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##gulated", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "play an important role in", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##12059893", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##c", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "in all three cancers and may", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. \u00a9 2025 the authors. published by american chemical society.", "to": "##id :", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "10. 102", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##er and 5 genes down", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "upre", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "were downregulated", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "pm", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##ida", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##gulated", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "play an important role in", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##12059893", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##c", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "in all three cancers and may", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three", "to": "##id :", "value": 1}, {"from": "10. 102", "to": "##er and 5 genes down", "value": 1}, {"from": "10. 102", "to": "upre", "value": 1}, {"from": "10. 102", "to": "were downregulated", "value": 1}, {"from": "10. 102", "to": "pm", "value": 1}, {"from": "10. 102", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "10. 102", "to": "##ida", "value": 1}, {"from": "10. 102", "to": "##gulated", "value": 1}, {"from": "10. 102", "to": "play an important role in", "value": 1}, {"from": "10. 102", "to": "##12059893", "value": 1}, {"from": "10. 102", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "10. 102", "to": "##c", "value": 1}, {"from": "10. 102", "to": "in all three cancers and may", "value": 1}, {"from": "10. 102", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "10. 102", "to": "##11571 pmcid : pm", "value": 1}, {"from": "10. 102", "to": "##id :", "value": 1}, {"from": "##er and 5 genes down", "to": "upre", "value": 1}, {"from": "##er and 5 genes down", "to": "were downregulated", "value": 1}, {"from": "##er and 5 genes down", "to": "pm", "value": 1}, {"from": "##er and 5 genes down", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "##er and 5 genes down", "to": "##ida", "value": 1}, {"from": "##er and 5 genes down", "to": "##gulated", "value": 1}, {"from": "##er and 5 genes down", "to": "play an important role in", "value": 1}, {"from": "##er and 5 genes down", "to": "##12059893", "value": 1}, {"from": "##er and 5 genes down", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##er and 5 genes down", "to": "##c", "value": 1}, {"from": "##er and 5 genes down", "to": "in all three cancers and may", "value": 1}, {"from": "##er and 5 genes down", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##er and 5 genes down", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##er and 5 genes down", "to": "##id :", "value": 1}, {"from": "upre", "to": "were downregulated", "value": 1}, {"from": "upre", "to": "pm", "value": 1}, {"from": "upre", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "upre", "to": "##ida", "value": 1}, {"from": "upre", "to": "##gulated", "value": 1}, {"from": "upre", "to": "play an important role in", "value": 1}, {"from": "upre", "to": "##12059893", "value": 1}, {"from": "upre", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "upre", "to": "##c", "value": 1}, {"from": "upre", "to": "in all three cancers and may", "value": 1}, {"from": "upre", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "upre", "to": "##11571 pmcid : pm", "value": 1}, {"from": "upre", "to": "##id :", "value": 1}, {"from": "were downregulated", "to": "pm", "value": 1}, {"from": "were downregulated", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "were downregulated", "to": "##ida", "value": 1}, {"from": "were downregulated", "to": "##gulated", "value": 1}, {"from": "were downregulated", "to": "play an important role in", "value": 1}, {"from": "were downregulated", "to": "##12059893", "value": 1}, {"from": "were downregulated", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "were downregulated", "to": "##c", "value": 1}, {"from": "were downregulated", "to": "in all three cancers and may", "value": 1}, {"from": "were downregulated", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "were downregulated", "to": "##11571 pmcid : pm", "value": 1}, {"from": "were downregulated", "to": "##id :", "value": 1}, {"from": "pm", "to": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "value": 1}, {"from": "pm", "to": "##ida", "value": 1}, {"from": "pm", "to": "##gulated", "value": 1}, {"from": "pm", "to": "play an important role in", "value": 1}, {"from": "pm", "to": "##12059893", "value": 1}, {"from": "pm", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "pm", "to": "##c", "value": 1}, {"from": "pm", "to": "in all three cancers and may", "value": 1}, {"from": "pm", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "pm", "to": "##11571 pmcid : pm", "value": 1}, {"from": "pm", "to": "##id :", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##ida", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##gulated", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "play an important role in", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##12059893", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##c", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "in all three cancers and may", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5", "to": "##id :", "value": 1}, {"from": "##ida", "to": "##gulated", "value": 1}, {"from": "##ida", "to": "play an important role in", "value": 1}, {"from": "##ida", "to": "##12059893", "value": 1}, {"from": "##ida", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##ida", "to": "##c", "value": 1}, {"from": "##ida", "to": "in all three cancers and may", "value": 1}, {"from": "##ida", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##ida", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##ida", "to": "##id :", "value": 1}, {"from": "##ida", "to": "is cost - effective", "value": 1}, {"from": "##ida", "to": "of agriculture and natural", "value": 1}, {"from": "##ida", "to": ". ac.", "value": 1}, {"from": "##ida", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "##ida", "to": "resources", "value": 1}, {"from": "##ida", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "##ida", "to": "##za. he", "value": 1}, {"from": "##ida", "to": "##6 /", "value": 1}, {"from": "##ida", "to": "are", "value": 1}, {"from": "##ida", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##ida", "to": "##ri - japelaghi r", "value": 1}, {"from": "##ida", "to": "##r.", "value": 1}, {"from": "##ida", "to": "who", "value": 1}, {"from": "##ida", "to": "inter", "value": 1}, {"from": "##ida", "to": "##vin", "value": 1}, {"from": "##ida", "to": "of tabriz,", "value": 1}, {"from": "##ida", "to": "@ org.", "value": 1}, {"from": "##ida", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##ida", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##ida", "to": "##idari", "value": 1}, {"from": "##ida", "to": "s", "value": 1}, {"from": "##ida", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##ida", "to": "ta", "value": 1}, {"from": "##ida", "to": "##ran. electronic address :", "value": 1}, {"from": "##ida", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##ida", "to": "re", "value": 1}, {"from": "##ida", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##ida", "to": "101", "value": 1}, {"from": "##ida", "to": "perspectives", "value": 1}, {"from": "##ida", "to": "##briz,", "value": 1}, {"from": "##ida", "to": "faculty", "value": 1}, {"from": "##ida", "to": "of agriculture,", "value": 1}, {"from": "##ida", "to": "##fer", "value": 1}, {"from": "##ida", "to": "##on", "value": 1}, {"from": "##ida", "to": "##ki", "value": 1}, {"from": "##ida", "to": "from both", "value": 1}, {"from": "##ida", "to": "##ran.", "value": 1}, {"from": "##gulated", "to": "play an important role in", "value": 1}, {"from": "##gulated", "to": "##12059893", "value": 1}, {"from": "##gulated", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##gulated", "to": "##c", "value": 1}, {"from": "##gulated", "to": "in all three cancers and may", "value": 1}, {"from": "##gulated", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##gulated", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##gulated", "to": "##id :", "value": 1}, {"from": "play an important role in", "to": "##12059893", "value": 1}, {"from": "play an important role in", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "play an important role in", "to": "##c", "value": 1}, {"from": "play an important role in", "to": "in all three cancers and may", "value": 1}, {"from": "play an important role in", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "play an important role in", "to": "##11571 pmcid : pm", "value": 1}, {"from": "play an important role in", "to": "##id :", "value": 1}, {"from": "##12059893", "to": "ad. this study serves as a foundational effort to del", "value": 1}, {"from": "##12059893", "to": "##c", "value": 1}, {"from": "##12059893", "to": "in all three cancers and may", "value": 1}, {"from": "##12059893", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##12059893", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##12059893", "to": "##id :", "value": 1}, {"from": "ad. this study serves as a foundational effort to del", "to": "##c", "value": 1}, {"from": "ad. this study serves as a foundational effort to del", "to": "in all three cancers and may", "value": 1}, {"from": "ad. this study serves as a foundational effort to del", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "ad. this study serves as a foundational effort to del", "to": "##11571 pmcid : pm", "value": 1}, {"from": "ad. this study serves as a foundational effort to del", "to": "##id :", "value": 1}, {"from": "##c", "to": "in all three cancers and may", "value": 1}, {"from": "##c", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "##c", "to": "##11571 pmcid : pm", "value": 1}, {"from": "##c", "to": "##id :", "value": 1}, {"from": "##c", "to": "quantitative pcr", "value": 1}, {"from": "##c", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "##c", "to": "time", "value": 1}, {"from": "##c", "to": "##sia", "value": 1}, {"from": "##c", "to": "of medicine, univers", "value": 1}, {"from": "##c", "to": "regulating the cell", "value": 1}, {"from": "##c", "to": "ute,", "value": 1}, {"from": "##c", "to": "##poptosis", "value": 1}, {"from": "##c", "to": "##cence, making it", "value": 1}, {"from": "##c", "to": "##itas in", "value": 1}, {"from": "##c", "to": "proliferation", "value": 1}, {"from": "##c", "to": "and se", "value": 1}, {"from": "##c", "to": "a", "value": 1}, {"from": "##c", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##c", "to": "target", "value": 1}, {"from": "##c", "to": "##nes", "value": 1}, {"from": "##c", "to": "##50 value", "value": 1}, {"from": "##c", "to": "role in", "value": 1}, {"from": "##c", "to": "##esi", "value": 1}, {"from": "##c", "to": "real", "value": 1}, {"from": "##c", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##c", "to": ", a", "value": 1}, {"from": "##c", "to": "key", "value": 1}, {"from": "##c", "to": ", and", "value": 1}, {"from": "##c", "to": "plays", "value": 1}, {"from": "##c", "to": "##a.", "value": 1}, {"from": "##c", "to": "a critical", "value": 1}, {"from": "##c", "to": "faculty", "value": 1}, {"from": "##c", "to": "cycle", "value": 2}, {"from": "##c", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##c", "to": "##a, jakarta,", "value": 1}, {"from": "##c", "to": "##iti", "value": 1}, {"from": "##c", "to": "of pharmacy, univers", "value": 1}, {"from": "##c", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##c", "to": "##don", "value": 1}, {"from": "##c", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##c", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##c", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##c", "to": "on the", "value": 1}, {"from": "##c", "to": "##ia", "value": 2}, {"from": "##c", "to": "senes", "value": 1}, {"from": "##c", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "##c", "to": "##ene", "value": 1}, {"from": "##c", "to": "which was", "value": 1}, {"from": "##c", "to": ": cyce or ccne1", "value": 1}, {"from": "##c", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "##c", "to": "##8 ), and e2f1", "value": 1}, {"from": "##c", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "##c", "to": "##1 ), rbl1", "value": 1}, {"from": "##c", "to": "might", "value": 1}, {"from": "##c", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "##c", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "##c", "to": "the native", "value": 1}, {"from": "##c", "to": "ligan", "value": 1}, {"from": "##c", "to": "im", "value": 1}, {"from": "##c", "to": "p = 0. 01", "value": 1}, {"from": "##c", "to": "##rank", "value": 1}, {"from": "##c", "to": "##j", "value": 1}, {"from": "##c", "to": "by", "value": 1}, {"from": "##c", "to": "rerank score", "value": 1}, {"from": "##c", "to": "##um", "value": 1}, {"from": "##c", "to": "##d", "value": 1}, {"from": "##c", "to": "of ad", "value": 1}, {"from": "##c", "to": "re", "value": 1}, {"from": "##c", "to": "##idodiph", "value": 1}, {"from": "##c", "to": "p = 0", "value": 1}, {"from": "##c", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##c", "to": "- 112. 70 k", "value": 1}, {"from": "##c", "to": "score", "value": 1}, {"from": "##c", "to": "##ine", "value": 1}, {"from": "##c", "to": "##enyl", "value": 1}, {"from": "##c", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##c", "to": "##osphate", "value": 1}, {"from": "##c", "to": "- 110. 68 k", "value": 1}, {"from": "##c", "to": "0", "value": 1}, {"from": "##c", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##c", "to": "/ mol ), and nummular", "value": 1}, {"from": "##c", "to": "squal", "value": 1}, {"from": "##c", "to": "the decrease in p21", "value": 1}, {"from": "##c", "to": "##mularia stem suggested that", "value": 1}, {"from": "##c", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "##c", "to": "##r confirmed their down", "value": 1}, {"from": "##c", "to": "four", "value": 1}, {"from": "##c", "to": "prioriti", "value": 1}, {"from": "##c", "to": "pc", "value": 1}, {"from": "##c", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "##c", "to": "diagnosed", "value": 1}, {"from": "##c", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "##c", "to": "incomplete", "value": 1}, {"from": "##c", "to": "ministry", "value": 1}, {"from": "##c", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##c", "to": "diagnostic", "value": 1}, {"from": "##c", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##c", "to": "##s and", "value": 1}, {"from": "##c", "to": "##s.", "value": 1}, {"from": "##c", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##c", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##c", "to": "treatment", "value": 1}, {"from": "##c", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##c", "to": "- mi", "value": 1}, {"from": "##c", "to": "##gna", "value": 1}, {"from": "##c", "to": "expressed", "value": 1}, {"from": "##c", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##c", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##c", "to": "##ncrna", "value": 1}, {"from": "##c", "to": "##r", "value": 1}, {"from": "##c", "to": "mrna", "value": 1}, {"from": "##c", "to": "mali", "value": 1}, {"from": "##c", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##c", "to": "conclusions", "value": 1}, {"from": "##c", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "##c", "to": "10. 113", "value": 1}, {"from": "##c", "to": "interests", "value": 1}, {"from": "##c", "to": ". no commercial re -", "value": 1}, {"from": "##c", "to": "##p", "value": 1}, {"from": "##c", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "##c", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "##c", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "##c", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "##c", "to": ": nr receives research support from bm", "value": 1}, {"from": "##c", "to": "use", "value": 1}, {"from": "##c", "to": ": atm deficiency, while com", "value": 1}, {"from": "##c", "to": "does", "value": 1}, {"from": "##c", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "##c", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##c", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "in all three cancers and may", "to": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "value": 1}, {"from": "in all three cancers and may", "to": "##11571 pmcid : pm", "value": 1}, {"from": "in all three cancers and may", "to": "##id :", "value": 1}, {"from": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "to": "##11571 pmcid : pm", "value": 1}, {"from": "deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc", "to": "##id :", "value": 1}, {"from": "##11571 pmcid : pm", "to": "##id :", "value": 1}, {"from": "##ibi", "to": "ri", "value": 1}, {"from": "##ibi", "to": "##sana", "value": 1}, {"from": "##ibi", "to": "doctoral program in biomedical", "value": 1}, {"from": "##ibi", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "##ibi", "to": "of medicine, univers", "value": 1}, {"from": "##ibi", "to": "##g", "value": 1}, {"from": "##ibi", "to": "##rta", "value": 1}, {"from": "##ibi", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "##ibi", "to": "##esia", "value": 1}, {"from": "##ibi", "to": "##itas in", "value": 1}, {"from": "##ibi", "to": "##nandi si", "value": 1}, {"from": "##ibi", "to": "##eri", "value": 1}, {"from": "##ibi", "to": "master program in biomedical", "value": 1}, {"from": "##ibi", "to": "),", "value": 1}, {"from": "##ibi", "to": "##esi", "value": 1}, {"from": "##ibi", "to": "of medical chemistry,", "value": 1}, {"from": "##ibi", "to": "##a.", "value": 1}, {"from": "##ibi", "to": "faculty", "value": 1}, {"from": "##ibi", "to": "wa", "value": 1}, {"from": "##ibi", "to": "##don", "value": 1}, {"from": "##ibi", "to": "##a,", "value": 1}, {"from": "##ibi", "to": "6", "value": 1}, {"from": "##ibi", "to": "##aka", "value": 1}, {"from": "##ibi", "to": "indonesi", "value": 1}, {"from": "##ibi", "to": "##itas indonesia", "value": 1}, {"from": "##ibi", "to": "of surgery,", "value": 1}, {"from": "##ibi", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##ibi", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "ri", "to": "##sana", "value": 1}, {"from": "ri", "to": "doctoral program in biomedical", "value": 1}, {"from": "ri", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "ri", "to": "of medicine, univers", "value": 1}, {"from": "ri", "to": "##g", "value": 1}, {"from": "ri", "to": "##rta", "value": 1}, {"from": "ri", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "ri", "to": "##esia", "value": 1}, {"from": "ri", "to": "##itas in", "value": 1}, {"from": "ri", "to": "##nandi si", "value": 1}, {"from": "ri", "to": "##eri", "value": 1}, {"from": "ri", "to": "master program in biomedical", "value": 1}, {"from": "ri", "to": "),", "value": 1}, {"from": "ri", "to": "##esi", "value": 1}, {"from": "ri", "to": "of medical chemistry,", "value": 1}, {"from": "ri", "to": "##a.", "value": 1}, {"from": "ri", "to": "faculty", "value": 1}, {"from": "ri", "to": "wa", "value": 1}, {"from": "ri", "to": "##don", "value": 1}, {"from": "ri", "to": "##a,", "value": 1}, {"from": "ri", "to": "6", "value": 1}, {"from": "ri", "to": "##aka", "value": 1}, {"from": "ri", "to": "indonesi", "value": 1}, {"from": "ri", "to": "##itas indonesia", "value": 1}, {"from": "ri", "to": "of surgery,", "value": 1}, {"from": "ri", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "ri", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##sana", "to": "doctoral program in biomedical", "value": 1}, {"from": "##sana", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "##sana", "to": "of medicine, univers", "value": 1}, {"from": "##sana", "to": "##g", "value": 1}, {"from": "##sana", "to": "##rta", "value": 1}, {"from": "##sana", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "##sana", "to": "##esia", "value": 1}, {"from": "##sana", "to": "##itas in", "value": 1}, {"from": "##sana", "to": "##nandi si", "value": 1}, {"from": "##sana", "to": "##eri", "value": 1}, {"from": "##sana", "to": "master program in biomedical", "value": 1}, {"from": "##sana", "to": "),", "value": 1}, {"from": "##sana", "to": "##esi", "value": 1}, {"from": "##sana", "to": "of medical chemistry,", "value": 1}, {"from": "##sana", "to": "##a.", "value": 1}, {"from": "##sana", "to": "faculty", "value": 1}, {"from": "##sana", "to": "wa", "value": 1}, {"from": "##sana", "to": "##don", "value": 1}, {"from": "##sana", "to": "##a,", "value": 1}, {"from": "##sana", "to": "6", "value": 1}, {"from": "##sana", "to": "##aka", "value": 1}, {"from": "##sana", "to": "indonesi", "value": 1}, {"from": "##sana", "to": "##itas indonesia", "value": 1}, {"from": "##sana", "to": "of surgery,", "value": 1}, {"from": "##sana", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##sana", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "doctoral program in biomedical", "to": "of biochemistry and molecular biology,", "value": 1}, {"from": "doctoral program in biomedical", "to": "of medicine, univers", "value": 1}, {"from": "doctoral program in biomedical", "to": "##g", "value": 1}, {"from": "doctoral program in biomedical", "to": "##rta", "value": 1}, {"from": "doctoral program in biomedical", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "doctoral program in biomedical", "to": "##esia", "value": 1}, {"from": "doctoral program in biomedical", "to": "##itas in", "value": 1}, {"from": "doctoral program in biomedical", "to": "##nandi si", "value": 1}, {"from": "doctoral program in biomedical", "to": "##eri", "value": 1}, {"from": "doctoral program in biomedical", "to": "master program in biomedical", "value": 1}, {"from": "doctoral program in biomedical", "to": "),", "value": 1}, {"from": "doctoral program in biomedical", "to": "##esi", "value": 1}, {"from": "doctoral program in biomedical", "to": "of medical chemistry,", "value": 1}, {"from": "doctoral program in biomedical", "to": "##a.", "value": 1}, {"from": "doctoral program in biomedical", "to": "faculty", "value": 1}, {"from": "doctoral program in biomedical", "to": "wa", "value": 1}, {"from": "doctoral program in biomedical", "to": "##don", "value": 1}, {"from": "doctoral program in biomedical", "to": "##a,", "value": 1}, {"from": "doctoral program in biomedical", "to": "6", "value": 1}, {"from": "doctoral program in biomedical", "to": "##aka", "value": 1}, {"from": "doctoral program in biomedical", "to": "indonesi", "value": 1}, {"from": "doctoral program in biomedical", "to": "##itas indonesia", "value": 1}, {"from": "doctoral program in biomedical", "to": "of surgery,", "value": 1}, {"from": "doctoral program in biomedical", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "doctoral program in biomedical", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "of medicine, univers", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##g", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##rta", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##esia", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##itas in", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##nandi si", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##eri", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "master program in biomedical", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "),", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##esi", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "of medical chemistry,", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##a.", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "faculty", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "wa", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##don", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##a,", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "6", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##aka", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "indonesi", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "##itas indonesia", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "of surgery,", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "of biochemistry and molecular biology,", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "of medicine, univers", "to": "##g", "value": 1}, {"from": "of medicine, univers", "to": "##rta", "value": 2}, {"from": "of medicine, univers", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "of medicine, univers", "to": "##esia", "value": 1}, {"from": "of medicine, univers", "to": "##itas in", "value": 2}, {"from": "of medicine, univers", "to": "##nandi si", "value": 1}, {"from": "of medicine, univers", "to": "##eri", "value": 1}, {"from": "of medicine, univers", "to": "master program in biomedical", "value": 2}, {"from": "of medicine, univers", "to": "),", "value": 1}, {"from": "of medicine, univers", "to": "##esi", "value": 3}, {"from": "of medicine, univers", "to": "of medical chemistry,", "value": 1}, {"from": "of medicine, univers", "to": "##a.", "value": 3}, {"from": "of medicine, univers", "to": "faculty", "value": 3}, {"from": "of medicine, univers", "to": "wa", "value": 1}, {"from": "of medicine, univers", "to": "##don", "value": 3}, {"from": "of medicine, univers", "to": "##a,", "value": 2}, {"from": "of medicine, univers", "to": "6", "value": 1}, {"from": "of medicine, univers", "to": "##aka", "value": 2}, {"from": "of medicine, univers", "to": "indonesi", "value": 1}, {"from": "of medicine, univers", "to": "##itas indonesia", "value": 1}, {"from": "of medicine, univers", "to": "of surgery,", "value": 1}, {"from": "of medicine, univers", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "of medicine, univers", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "of medicine, univers", "to": "), hashim", "value": 1}, {"from": "of medicine, univers", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "of medicine, univers", "to": ") drug development research cluster, indon", "value": 1}, {"from": "of medicine, univers", "to": "##an medical", "value": 1}, {"from": "of medicine, univers", "to": "indon", "value": 1}, {"from": "of medicine, univers", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "of medicine, univers", "to": "##hibit", "value": 1}, {"from": "of medicine, univers", "to": "na", "value": 1}, {"from": "of medicine, univers", "to": "education", "value": 1}, {"from": "of medicine, univers", "to": "n", "value": 1}, {"from": "of medicine, univers", "to": "3", "value": 1}, {"from": "of medicine, univers", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "of medicine, univers", "to": "##ajrin", "value": 1}, {"from": "of medicine, univers", "to": "), azizah", "value": 1}, {"from": "of medicine, univers", "to": "te", "value": 1}, {"from": "of medicine, univers", "to": "##a, jaka", "value": 1}, {"from": "of medicine, univers", "to": "##djo a", "value": 1}, {"from": "of medicine, univers", "to": "of medicine, universitas indon", "value": 1}, {"from": "of medicine, univers", "to": "##itas", "value": 1}, {"from": "of medicine, univers", "to": "##b", "value": 1}, {"from": "of medicine, univers", "to": "am", "value": 1}, {"from": "of medicine, univers", "to": "nn", "value": 1}, {"from": "of medicine, univers", "to": "of pharmacy, univers", "value": 2}, {"from": "of medicine, univers", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "of medicine, univers", "to": ", indon", "value": 1}, {"from": "of medicine, univers", "to": "and research instit", "value": 1}, {"from": "of medicine, univers", "to": "), ramadanti", "value": 1}, {"from": "of medicine, univers", "to": "52", "value": 1}, {"from": "of medicine, univers", "to": "quantitative pcr", "value": 1}, {"from": "of medicine, univers", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "of medicine, univers", "to": "time", "value": 1}, {"from": "of medicine, univers", "to": "##sia", "value": 1}, {"from": "of medicine, univers", "to": "regulating the cell", "value": 1}, {"from": "of medicine, univers", "to": "ute,", "value": 1}, {"from": "of medicine, univers", "to": "##poptosis", "value": 1}, {"from": "of medicine, univers", "to": "##cence, making it", "value": 1}, {"from": "of medicine, univers", "to": "proliferation", "value": 1}, {"from": "of medicine, univers", "to": "and se", "value": 1}, {"from": "of medicine, univers", "to": "a", "value": 1}, {"from": "of medicine, univers", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "of medicine, univers", "to": "target", "value": 1}, {"from": "of medicine, univers", "to": "##nes", "value": 1}, {"from": "of medicine, univers", "to": "##50 value", "value": 1}, {"from": "of medicine, univers", "to": "role in", "value": 1}, {"from": "of medicine, univers", "to": "real", "value": 1}, {"from": "of medicine, univers", "to": ". the p53 signaling pathway", "value": 1}, {"from": "of medicine, univers", "to": ", a", "value": 1}, {"from": "of medicine, univers", "to": "key", "value": 1}, {"from": "of medicine, univers", "to": ", and", "value": 1}, {"from": "of medicine, univers", "to": "plays", "value": 1}, {"from": "of medicine, univers", "to": "a critical", "value": 1}, {"from": "of medicine, univers", "to": "cycle", "value": 1}, {"from": "of medicine, univers", "to": "of downstream genes linked to cell", "value": 1}, {"from": "of medicine, univers", "to": "##a, jakarta,", "value": 1}, {"from": "of medicine, univers", "to": "##iti", "value": 1}, {"from": "of medicine, univers", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "of medicine, univers", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "of medicine, univers", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "of medicine, univers", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "of medicine, univers", "to": "on the", "value": 1}, {"from": "of medicine, univers", "to": "##ia", "value": 1}, {"from": "of medicine, univers", "to": "senes", "value": 1}, {"from": "##g", "to": "##rta", "value": 1}, {"from": "##g", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "##g", "to": "##esia", "value": 1}, {"from": "##g", "to": "##itas in", "value": 1}, {"from": "##g", "to": "##nandi si", "value": 1}, {"from": "##g", "to": "##eri", "value": 1}, {"from": "##g", "to": "master program in biomedical", "value": 1}, {"from": "##g", "to": "),", "value": 1}, {"from": "##g", "to": "##esi", "value": 1}, {"from": "##g", "to": "of medical chemistry,", "value": 1}, {"from": "##g", "to": "##a.", "value": 1}, {"from": "##g", "to": "faculty", "value": 1}, {"from": "##g", "to": "wa", "value": 1}, {"from": "##g", "to": "##don", "value": 1}, {"from": "##g", "to": "##a,", "value": 1}, {"from": "##g", "to": "6", "value": 1}, {"from": "##g", "to": "##aka", "value": 1}, {"from": "##g", "to": "indonesi", "value": 1}, {"from": "##g", "to": "##itas indonesia", "value": 1}, {"from": "##g", "to": "of surgery,", "value": 1}, {"from": "##g", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##g", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##rta", "to": ") bioinformatics core facilities - im", "value": 1}, {"from": "##rta", "to": "##esia", "value": 1}, {"from": "##rta", "to": "##itas in", "value": 1}, {"from": "##rta", "to": "##nandi si", "value": 1}, {"from": "##rta", "to": "##eri", "value": 1}, {"from": "##rta", "to": "master program in biomedical", "value": 2}, {"from": "##rta", "to": "),", "value": 1}, {"from": "##rta", "to": "##esi", "value": 3}, {"from": "##rta", "to": "of medical chemistry,", "value": 1}, {"from": "##rta", "to": "##a.", "value": 3}, {"from": "##rta", "to": "faculty", "value": 3}, {"from": "##rta", "to": "wa", "value": 1}, {"from": "##rta", "to": "##don", "value": 3}, {"from": "##rta", "to": "##a,", "value": 2}, {"from": "##rta", "to": "6", "value": 1}, {"from": "##rta", "to": "##aka", "value": 3}, {"from": "##rta", "to": "indonesi", "value": 2}, {"from": "##rta", "to": "##itas indonesia", "value": 2}, {"from": "##rta", "to": "of surgery,", "value": 1}, {"from": "##rta", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##rta", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##rta", "to": "2 - positive", "value": 1}, {"from": "##rta", "to": "changes in the promoter region", "value": 1}, {"from": "##rta", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##rta", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##rta", "to": "receptor", "value": 1}, {"from": "##rta", "to": "is an", "value": 1}, {"from": "##rta", "to": "##type", "value": 1}, {"from": "##rta", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##rta", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##rta", "to": "- negative breast cancer", "value": 1}, {"from": "##rta", "to": "and", "value": 1}, {"from": "##rta", "to": "##a, jaka", "value": 2}, {"from": "##rta", "to": "lead", "value": 1}, {"from": "##rta", "to": "triple", "value": 1}, {"from": "##rta", "to": "of medicine, universitas indon", "value": 2}, {"from": "##rta", "to": "cilities - imeri,", "value": 1}, {"from": "##rta", "to": "##a. breast cancer sub", "value": 1}, {"from": "##rta", "to": "##umi", "value": 1}, {"from": "##rta", "to": "##ivers", "value": 1}, {"from": "##rta", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##rta", "to": "##s", "value": 1}, {"from": "##rta", "to": "un", "value": 1}, {"from": "##rta", "to": "##nal a, l", "value": 1}, {"from": "##rta", "to": "epigenetic modification,", "value": 1}, {"from": "##rta", "to": "of medicine,", "value": 1}, {"from": "##rta", "to": "), hashim", "value": 1}, {"from": "##rta", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##rta", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##rta", "to": "##an medical", "value": 1}, {"from": "##rta", "to": "indon", "value": 1}, {"from": "##rta", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##rta", "to": "##hibit", "value": 1}, {"from": "##rta", "to": "na", "value": 1}, {"from": "##rta", "to": "education", "value": 1}, {"from": "##rta", "to": "n", "value": 1}, {"from": "##rta", "to": "3", "value": 1}, {"from": "##rta", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##rta", "to": "##ajrin", "value": 1}, {"from": "##rta", "to": "), azizah", "value": 1}, {"from": "##rta", "to": "te", "value": 1}, {"from": "##rta", "to": "##djo a", "value": 1}, {"from": "##rta", "to": "##itas", "value": 1}, {"from": "##rta", "to": "##b", "value": 1}, {"from": "##rta", "to": "am", "value": 1}, {"from": "##rta", "to": "nn", "value": 1}, {"from": "##rta", "to": "of pharmacy, univers", "value": 1}, {"from": "##rta", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##rta", "to": ", indon", "value": 1}, {"from": "##rta", "to": "and research instit", "value": 1}, {"from": "##rta", "to": "), ramadanti", "value": 1}, {"from": "##rta", "to": "52", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##esia", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##itas in", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##nandi si", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##eri", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "master program in biomedical", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "),", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##esi", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "of medical chemistry,", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##a.", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "faculty", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "wa", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##don", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##a,", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "6", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##aka", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "indonesi", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "##itas indonesia", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "of surgery,", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": ") bioinformatics core facilities - im", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##esia", "to": "##itas in", "value": 1}, {"from": "##esia", "to": "##nandi si", "value": 1}, {"from": "##esia", "to": "##eri", "value": 1}, {"from": "##esia", "to": "master program in biomedical", "value": 1}, {"from": "##esia", "to": "),", "value": 1}, {"from": "##esia", "to": "##esi", "value": 1}, {"from": "##esia", "to": "of medical chemistry,", "value": 1}, {"from": "##esia", "to": "##a.", "value": 1}, {"from": "##esia", "to": "faculty", "value": 1}, {"from": "##esia", "to": "wa", "value": 1}, {"from": "##esia", "to": "##don", "value": 1}, {"from": "##esia", "to": "##a,", "value": 1}, {"from": "##esia", "to": "6", "value": 1}, {"from": "##esia", "to": "##aka", "value": 1}, {"from": "##esia", "to": "indonesi", "value": 1}, {"from": "##esia", "to": "##itas indonesia", "value": 1}, {"from": "##esia", "to": "of surgery,", "value": 1}, {"from": "##esia", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##esia", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##itas in", "to": "##nandi si", "value": 1}, {"from": "##itas in", "to": "##eri", "value": 1}, {"from": "##itas in", "to": "master program in biomedical", "value": 1}, {"from": "##itas in", "to": "),", "value": 1}, {"from": "##itas in", "to": "##esi", "value": 2}, {"from": "##itas in", "to": "of medical chemistry,", "value": 1}, {"from": "##itas in", "to": "##a.", "value": 2}, {"from": "##itas in", "to": "faculty", "value": 2}, {"from": "##itas in", "to": "wa", "value": 1}, {"from": "##itas in", "to": "##don", "value": 2}, {"from": "##itas in", "to": "##a,", "value": 1}, {"from": "##itas in", "to": "6", "value": 1}, {"from": "##itas in", "to": "##aka", "value": 1}, {"from": "##itas in", "to": "indonesi", "value": 1}, {"from": "##itas in", "to": "##itas indonesia", "value": 1}, {"from": "##itas in", "to": "of surgery,", "value": 1}, {"from": "##itas in", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##itas in", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##itas in", "to": "quantitative pcr", "value": 1}, {"from": "##itas in", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "##itas in", "to": "time", "value": 1}, {"from": "##itas in", "to": "##sia", "value": 1}, {"from": "##itas in", "to": "regulating the cell", "value": 1}, {"from": "##itas in", "to": "ute,", "value": 1}, {"from": "##itas in", "to": "##poptosis", "value": 1}, {"from": "##itas in", "to": "##cence, making it", "value": 1}, {"from": "##itas in", "to": "proliferation", "value": 1}, {"from": "##itas in", "to": "and se", "value": 1}, {"from": "##itas in", "to": "a", "value": 1}, {"from": "##itas in", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##itas in", "to": "target", "value": 1}, {"from": "##itas in", "to": "##nes", "value": 1}, {"from": "##itas in", "to": "##50 value", "value": 1}, {"from": "##itas in", "to": "role in", "value": 1}, {"from": "##itas in", "to": "real", "value": 1}, {"from": "##itas in", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##itas in", "to": ", a", "value": 1}, {"from": "##itas in", "to": "key", "value": 1}, {"from": "##itas in", "to": ", and", "value": 1}, {"from": "##itas in", "to": "plays", "value": 1}, {"from": "##itas in", "to": "a critical", "value": 1}, {"from": "##itas in", "to": "cycle", "value": 1}, {"from": "##itas in", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##itas in", "to": "##a, jakarta,", "value": 1}, {"from": "##itas in", "to": "##iti", "value": 1}, {"from": "##itas in", "to": "of pharmacy, univers", "value": 1}, {"from": "##itas in", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##itas in", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##itas in", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##itas in", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##itas in", "to": "on the", "value": 1}, {"from": "##itas in", "to": "##ia", "value": 1}, {"from": "##itas in", "to": "senes", "value": 1}, {"from": "##nandi si", "to": "##eri", "value": 1}, {"from": "##nandi si", "to": "master program in biomedical", "value": 1}, {"from": "##nandi si", "to": "),", "value": 1}, {"from": "##nandi si", "to": "##esi", "value": 1}, {"from": "##nandi si", "to": "of medical chemistry,", "value": 1}, {"from": "##nandi si", "to": "##a.", "value": 1}, {"from": "##nandi si", "to": "faculty", "value": 1}, {"from": "##nandi si", "to": "wa", "value": 1}, {"from": "##nandi si", "to": "##don", "value": 1}, {"from": "##nandi si", "to": "##a,", "value": 1}, {"from": "##nandi si", "to": "6", "value": 1}, {"from": "##nandi si", "to": "##aka", "value": 1}, {"from": "##nandi si", "to": "indonesi", "value": 1}, {"from": "##nandi si", "to": "##itas indonesia", "value": 1}, {"from": "##nandi si", "to": "of surgery,", "value": 1}, {"from": "##nandi si", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##nandi si", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##eri", "to": "master program in biomedical", "value": 1}, {"from": "##eri", "to": "),", "value": 1}, {"from": "##eri", "to": "##esi", "value": 1}, {"from": "##eri", "to": "of medical chemistry,", "value": 1}, {"from": "##eri", "to": "##a.", "value": 1}, {"from": "##eri", "to": "faculty", "value": 1}, {"from": "##eri", "to": "wa", "value": 1}, {"from": "##eri", "to": "##don", "value": 1}, {"from": "##eri", "to": "##a,", "value": 1}, {"from": "##eri", "to": "6", "value": 1}, {"from": "##eri", "to": "##aka", "value": 1}, {"from": "##eri", "to": "indonesi", "value": 1}, {"from": "##eri", "to": "##itas indonesia", "value": 1}, {"from": "##eri", "to": "of surgery,", "value": 1}, {"from": "##eri", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##eri", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "master program in biomedical", "to": "),", "value": 1}, {"from": "master program in biomedical", "to": "##esi", "value": 2}, {"from": "master program in biomedical", "to": "of medical chemistry,", "value": 1}, {"from": "master program in biomedical", "to": "##a.", "value": 2}, {"from": "master program in biomedical", "to": "faculty", "value": 2}, {"from": "master program in biomedical", "to": "wa", "value": 1}, {"from": "master program in biomedical", "to": "##don", "value": 2}, {"from": "master program in biomedical", "to": "##a,", "value": 2}, {"from": "master program in biomedical", "to": "6", "value": 1}, {"from": "master program in biomedical", "to": "##aka", "value": 2}, {"from": "master program in biomedical", "to": "indonesi", "value": 1}, {"from": "master program in biomedical", "to": "##itas indonesia", "value": 1}, {"from": "master program in biomedical", "to": "of surgery,", "value": 1}, {"from": "master program in biomedical", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "master program in biomedical", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "master program in biomedical", "to": "), hashim", "value": 1}, {"from": "master program in biomedical", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "master program in biomedical", "to": ") drug development research cluster, indon", "value": 1}, {"from": "master program in biomedical", "to": "##an medical", "value": 1}, {"from": "master program in biomedical", "to": "indon", "value": 1}, {"from": "master program in biomedical", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "master program in biomedical", "to": "##hibit", "value": 1}, {"from": "master program in biomedical", "to": "na", "value": 1}, {"from": "master program in biomedical", "to": "education", "value": 1}, {"from": "master program in biomedical", "to": "n", "value": 1}, {"from": "master program in biomedical", "to": "3", "value": 1}, {"from": "master program in biomedical", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "master program in biomedical", "to": "##ajrin", "value": 1}, {"from": "master program in biomedical", "to": "), azizah", "value": 1}, {"from": "master program in biomedical", "to": "te", "value": 1}, {"from": "master program in biomedical", "to": "##a, jaka", "value": 1}, {"from": "master program in biomedical", "to": "##djo a", "value": 1}, {"from": "master program in biomedical", "to": "of medicine, universitas indon", "value": 1}, {"from": "master program in biomedical", "to": "##itas", "value": 1}, {"from": "master program in biomedical", "to": "##b", "value": 1}, {"from": "master program in biomedical", "to": "am", "value": 1}, {"from": "master program in biomedical", "to": "nn", "value": 1}, {"from": "master program in biomedical", "to": "of pharmacy, univers", "value": 1}, {"from": "master program in biomedical", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "master program in biomedical", "to": ", indon", "value": 1}, {"from": "master program in biomedical", "to": "and research instit", "value": 1}, {"from": "master program in biomedical", "to": "), ramadanti", "value": 1}, {"from": "master program in biomedical", "to": "52", "value": 1}, {"from": "),", "to": "##esi", "value": 1}, {"from": "),", "to": "of medical chemistry,", "value": 1}, {"from": "),", "to": "##a.", "value": 1}, {"from": "),", "to": "faculty", "value": 1}, {"from": "),", "to": "wa", "value": 1}, {"from": "),", "to": "##don", "value": 1}, {"from": "),", "to": "##a,", "value": 1}, {"from": "),", "to": "6", "value": 1}, {"from": "),", "to": "##aka", "value": 1}, {"from": "),", "to": "indonesi", "value": 1}, {"from": "),", "to": "##itas indonesia", "value": 1}, {"from": "),", "to": "of surgery,", "value": 1}, {"from": "),", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "),", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##esi", "to": "of medical chemistry,", "value": 1}, {"from": "##esi", "to": "##a.", "value": 4}, {"from": "##esi", "to": "faculty", "value": 4}, {"from": "##esi", "to": "wa", "value": 1}, {"from": "##esi", "to": "##don", "value": 4}, {"from": "##esi", "to": "##a,", "value": 2}, {"from": "##esi", "to": "6", "value": 1}, {"from": "##esi", "to": "##aka", "value": 3}, {"from": "##esi", "to": "indonesi", "value": 2}, {"from": "##esi", "to": "##itas indonesia", "value": 2}, {"from": "##esi", "to": "of surgery,", "value": 1}, {"from": "##esi", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##esi", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##esi", "to": "2 - positive", "value": 1}, {"from": "##esi", "to": "changes in the promoter region", "value": 1}, {"from": "##esi", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##esi", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##esi", "to": "receptor", "value": 1}, {"from": "##esi", "to": "is an", "value": 1}, {"from": "##esi", "to": "##type", "value": 1}, {"from": "##esi", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##esi", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##esi", "to": "- negative breast cancer", "value": 1}, {"from": "##esi", "to": "and", "value": 1}, {"from": "##esi", "to": "##a, jaka", "value": 2}, {"from": "##esi", "to": "lead", "value": 1}, {"from": "##esi", "to": "triple", "value": 1}, {"from": "##esi", "to": "of medicine, universitas indon", "value": 2}, {"from": "##esi", "to": "cilities - imeri,", "value": 1}, {"from": "##esi", "to": "##a. breast cancer sub", "value": 1}, {"from": "##esi", "to": "##umi", "value": 1}, {"from": "##esi", "to": "##ivers", "value": 1}, {"from": "##esi", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##esi", "to": "##s", "value": 1}, {"from": "##esi", "to": "un", "value": 1}, {"from": "##esi", "to": "##nal a, l", "value": 1}, {"from": "##esi", "to": "epigenetic modification,", "value": 1}, {"from": "##esi", "to": "of medicine,", "value": 1}, {"from": "##esi", "to": "), hashim", "value": 1}, {"from": "##esi", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##esi", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##esi", "to": "##an medical", "value": 1}, {"from": "##esi", "to": "indon", "value": 1}, {"from": "##esi", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##esi", "to": "##hibit", "value": 1}, {"from": "##esi", "to": "na", "value": 1}, {"from": "##esi", "to": "education", "value": 1}, {"from": "##esi", "to": "n", "value": 1}, {"from": "##esi", "to": "3", "value": 1}, {"from": "##esi", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##esi", "to": "##ajrin", "value": 1}, {"from": "##esi", "to": "), azizah", "value": 1}, {"from": "##esi", "to": "te", "value": 1}, {"from": "##esi", "to": "##djo a", "value": 1}, {"from": "##esi", "to": "##itas", "value": 1}, {"from": "##esi", "to": "##b", "value": 1}, {"from": "##esi", "to": "am", "value": 1}, {"from": "##esi", "to": "nn", "value": 1}, {"from": "##esi", "to": "of pharmacy, univers", "value": 2}, {"from": "##esi", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##esi", "to": ", indon", "value": 1}, {"from": "##esi", "to": "and research instit", "value": 1}, {"from": "##esi", "to": "), ramadanti", "value": 1}, {"from": "##esi", "to": "52", "value": 1}, {"from": "##esi", "to": "quantitative pcr", "value": 1}, {"from": "##esi", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "##esi", "to": "time", "value": 1}, {"from": "##esi", "to": "##sia", "value": 1}, {"from": "##esi", "to": "regulating the cell", "value": 1}, {"from": "##esi", "to": "ute,", "value": 1}, {"from": "##esi", "to": "##poptosis", "value": 1}, {"from": "##esi", "to": "##cence, making it", "value": 1}, {"from": "##esi", "to": "proliferation", "value": 1}, {"from": "##esi", "to": "and se", "value": 1}, {"from": "##esi", "to": "a", "value": 1}, {"from": "##esi", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##esi", "to": "target", "value": 1}, {"from": "##esi", "to": "##nes", "value": 1}, {"from": "##esi", "to": "##50 value", "value": 1}, {"from": "##esi", "to": "role in", "value": 1}, {"from": "##esi", "to": "real", "value": 1}, {"from": "##esi", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##esi", "to": ", a", "value": 1}, {"from": "##esi", "to": "key", "value": 1}, {"from": "##esi", "to": ", and", "value": 1}, {"from": "##esi", "to": "plays", "value": 1}, {"from": "##esi", "to": "a critical", "value": 1}, {"from": "##esi", "to": "cycle", "value": 1}, {"from": "##esi", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##esi", "to": "##a, jakarta,", "value": 1}, {"from": "##esi", "to": "##iti", "value": 1}, {"from": "##esi", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##esi", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##esi", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##esi", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##esi", "to": "on the", "value": 1}, {"from": "##esi", "to": "##ia", "value": 1}, {"from": "##esi", "to": "senes", "value": 1}, {"from": "of medical chemistry,", "to": "##a.", "value": 1}, {"from": "of medical chemistry,", "to": "faculty", "value": 1}, {"from": "of medical chemistry,", "to": "wa", "value": 1}, {"from": "of medical chemistry,", "to": "##don", "value": 1}, {"from": "of medical chemistry,", "to": "##a,", "value": 1}, {"from": "of medical chemistry,", "to": "6", "value": 1}, {"from": "of medical chemistry,", "to": "##aka", "value": 1}, {"from": "of medical chemistry,", "to": "indonesi", "value": 1}, {"from": "of medical chemistry,", "to": "##itas indonesia", "value": 1}, {"from": "of medical chemistry,", "to": "of surgery,", "value": 1}, {"from": "of medical chemistry,", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "of medical chemistry,", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##a.", "to": "faculty", "value": 4}, {"from": "##a.", "to": "wa", "value": 1}, {"from": "##a.", "to": "##don", "value": 4}, {"from": "##a.", "to": "##a,", "value": 2}, {"from": "##a.", "to": "6", "value": 1}, {"from": "##a.", "to": "##aka", "value": 3}, {"from": "##a.", "to": "indonesi", "value": 2}, {"from": "##a.", "to": "##itas indonesia", "value": 2}, {"from": "##a.", "to": "of surgery,", "value": 1}, {"from": "##a.", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##a.", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##a.", "to": "2 - positive", "value": 1}, {"from": "##a.", "to": "changes in the promoter region", "value": 1}, {"from": "##a.", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##a.", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##a.", "to": "receptor", "value": 1}, {"from": "##a.", "to": "is an", "value": 1}, {"from": "##a.", "to": "##type", "value": 1}, {"from": "##a.", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##a.", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##a.", "to": "- negative breast cancer", "value": 1}, {"from": "##a.", "to": "and", "value": 1}, {"from": "##a.", "to": "##a, jaka", "value": 2}, {"from": "##a.", "to": "lead", "value": 1}, {"from": "##a.", "to": "triple", "value": 1}, {"from": "##a.", "to": "of medicine, universitas indon", "value": 2}, {"from": "##a.", "to": "cilities - imeri,", "value": 1}, {"from": "##a.", "to": "##a. breast cancer sub", "value": 1}, {"from": "##a.", "to": "##umi", "value": 1}, {"from": "##a.", "to": "##ivers", "value": 1}, {"from": "##a.", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##a.", "to": "##s", "value": 1}, {"from": "##a.", "to": "un", "value": 1}, {"from": "##a.", "to": "##nal a, l", "value": 1}, {"from": "##a.", "to": "epigenetic modification,", "value": 1}, {"from": "##a.", "to": "of medicine,", "value": 1}, {"from": "##a.", "to": "), hashim", "value": 1}, {"from": "##a.", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##a.", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##a.", "to": "##an medical", "value": 1}, {"from": "##a.", "to": "indon", "value": 1}, {"from": "##a.", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##a.", "to": "##hibit", "value": 1}, {"from": "##a.", "to": "na", "value": 1}, {"from": "##a.", "to": "education", "value": 1}, {"from": "##a.", "to": "n", "value": 1}, {"from": "##a.", "to": "3", "value": 1}, {"from": "##a.", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##a.", "to": "##ajrin", "value": 1}, {"from": "##a.", "to": "), azizah", "value": 1}, {"from": "##a.", "to": "te", "value": 1}, {"from": "##a.", "to": "##djo a", "value": 1}, {"from": "##a.", "to": "##itas", "value": 1}, {"from": "##a.", "to": "##b", "value": 1}, {"from": "##a.", "to": "am", "value": 1}, {"from": "##a.", "to": "nn", "value": 1}, {"from": "##a.", "to": "of pharmacy, univers", "value": 2}, {"from": "##a.", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##a.", "to": ", indon", "value": 1}, {"from": "##a.", "to": "and research instit", "value": 1}, {"from": "##a.", "to": "), ramadanti", "value": 1}, {"from": "##a.", "to": "52", "value": 1}, {"from": "##a.", "to": "quantitative pcr", "value": 1}, {"from": "##a.", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "##a.", "to": "time", "value": 1}, {"from": "##a.", "to": "##sia", "value": 1}, {"from": "##a.", "to": "regulating the cell", "value": 1}, {"from": "##a.", "to": "ute,", "value": 1}, {"from": "##a.", "to": "##poptosis", "value": 1}, {"from": "##a.", "to": "##cence, making it", "value": 1}, {"from": "##a.", "to": "proliferation", "value": 1}, {"from": "##a.", "to": "and se", "value": 1}, {"from": "##a.", "to": "a", "value": 1}, {"from": "##a.", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##a.", "to": "target", "value": 1}, {"from": "##a.", "to": "##nes", "value": 1}, {"from": "##a.", "to": "##50 value", "value": 1}, {"from": "##a.", "to": "role in", "value": 1}, {"from": "##a.", "to": "real", "value": 1}, {"from": "##a.", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##a.", "to": ", a", "value": 1}, {"from": "##a.", "to": "key", "value": 1}, {"from": "##a.", "to": ", and", "value": 1}, {"from": "##a.", "to": "plays", "value": 1}, {"from": "##a.", "to": "a critical", "value": 1}, {"from": "##a.", "to": "cycle", "value": 1}, {"from": "##a.", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##a.", "to": "##a, jakarta,", "value": 1}, {"from": "##a.", "to": "##iti", "value": 1}, {"from": "##a.", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##a.", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##a.", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##a.", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##a.", "to": "on the", "value": 1}, {"from": "##a.", "to": "##ia", "value": 1}, {"from": "##a.", "to": "senes", "value": 1}, {"from": "##a.", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "##a.", "to": "), beltran - v", "value": 1}, {"from": "##a.", "to": ") department of pathology, co", "value": 1}, {"from": "##a.", "to": "##ulin", "value": 1}, {"from": "##a.", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "##a.", "to": "f", "value": 1}, {"from": "##a.", "to": "new yo", "value": 1}, {"from": "##a.", "to": "sloan", "value": 1}, {"from": "##a.", "to": "la", "value": 1}, {"from": "##a.", "to": "center", "value": 1}, {"from": "##a.", "to": "us", "value": 1}, {"from": "##a.", "to": "##lum", "value": 1}, {"from": "##a.", "to": "##o m", "value": 1}, {"from": "##a.", "to": "9", "value": 1}, {"from": "##a.", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "##a.", "to": "kette", "value": 1}, {"from": "##a.", "to": "yo", "value": 1}, {"from": "##a.", "to": "##ettering cancer", "value": 1}, {"from": "##a.", "to": "##rk, usa.", "value": 1}, {"from": "##a.", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##a.", "to": "re", "value": 1}, {"from": "##a.", "to": "new york", "value": 1}, {"from": "##a.", "to": "##bia university,", "value": 1}, {"from": "##a.", "to": "), shin e", "value": 1}, {"from": "##a.", "to": "##ring cancer", "value": 1}, {"from": "##a.", "to": "##rk, new", "value": 1}, {"from": "##a.", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##a.", "to": "##isied", "value": 1}, {"from": "##a.", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##a.", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##a.", "to": "ancers. sinha s", "value": 1}, {"from": "##a.", "to": "##is - filho j", "value": 1}, {"from": "##a.", "to": "##rk,", "value": 1}, {"from": "##a.", "to": "), gardner r", "value": 1}, {"from": "faculty", "to": "wa", "value": 1}, {"from": "faculty", "to": "##don", "value": 4}, {"from": "faculty", "to": "##a,", "value": 2}, {"from": "faculty", "to": "6", "value": 1}, {"from": "faculty", "to": "##aka", "value": 3}, {"from": "faculty", "to": "indonesi", "value": 2}, {"from": "faculty", "to": "##itas indonesia", "value": 2}, {"from": "faculty", "to": "of surgery,", "value": 1}, {"from": "faculty", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "faculty", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "faculty", "to": "2 - positive", "value": 1}, {"from": "faculty", "to": "changes in the promoter region", "value": 1}, {"from": "faculty", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "faculty", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "faculty", "to": "receptor", "value": 1}, {"from": "faculty", "to": "is an", "value": 1}, {"from": "faculty", "to": "##type", "value": 1}, {"from": "faculty", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "faculty", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "faculty", "to": "- negative breast cancer", "value": 1}, {"from": "faculty", "to": "and", "value": 1}, {"from": "faculty", "to": "##a, jaka", "value": 2}, {"from": "faculty", "to": "lead", "value": 1}, {"from": "faculty", "to": "triple", "value": 1}, {"from": "faculty", "to": "of medicine, universitas indon", "value": 2}, {"from": "faculty", "to": "cilities - imeri,", "value": 1}, {"from": "faculty", "to": "##a. breast cancer sub", "value": 1}, {"from": "faculty", "to": "##umi", "value": 1}, {"from": "faculty", "to": "##ivers", "value": 1}, {"from": "faculty", "to": "to misclassification. dna methylation", "value": 1}, {"from": "faculty", "to": "##s", "value": 1}, {"from": "faculty", "to": "un", "value": 1}, {"from": "faculty", "to": "##nal a, l", "value": 1}, {"from": "faculty", "to": "epigenetic modification,", "value": 1}, {"from": "faculty", "to": "of medicine,", "value": 1}, {"from": "faculty", "to": "), hashim", "value": 1}, {"from": "faculty", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "faculty", "to": ") drug development research cluster, indon", "value": 1}, {"from": "faculty", "to": "##an medical", "value": 1}, {"from": "faculty", "to": "indon", "value": 1}, {"from": "faculty", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "faculty", "to": "##hibit", "value": 1}, {"from": "faculty", "to": "na", "value": 1}, {"from": "faculty", "to": "education", "value": 1}, {"from": "faculty", "to": "n", "value": 1}, {"from": "faculty", "to": "3", "value": 1}, {"from": "faculty", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "faculty", "to": "##ajrin", "value": 1}, {"from": "faculty", "to": "), azizah", "value": 1}, {"from": "faculty", "to": "te", "value": 1}, {"from": "faculty", "to": "##djo a", "value": 1}, {"from": "faculty", "to": "##itas", "value": 1}, {"from": "faculty", "to": "##b", "value": 1}, {"from": "faculty", "to": "am", "value": 1}, {"from": "faculty", "to": "nn", "value": 1}, {"from": "faculty", "to": "of pharmacy, univers", "value": 2}, {"from": "faculty", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "faculty", "to": ", indon", "value": 1}, {"from": "faculty", "to": "and research instit", "value": 1}, {"from": "faculty", "to": "), ramadanti", "value": 1}, {"from": "faculty", "to": "52", "value": 2}, {"from": "faculty", "to": "quantitative pcr", "value": 1}, {"from": "faculty", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "faculty", "to": "time", "value": 1}, {"from": "faculty", "to": "##sia", "value": 1}, {"from": "faculty", "to": "regulating the cell", "value": 1}, {"from": "faculty", "to": "ute,", "value": 1}, {"from": "faculty", "to": "##poptosis", "value": 1}, {"from": "faculty", "to": "##cence, making it", "value": 1}, {"from": "faculty", "to": "proliferation", "value": 1}, {"from": "faculty", "to": "and se", "value": 1}, {"from": "faculty", "to": "a", "value": 2}, {"from": "faculty", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "faculty", "to": "target", "value": 1}, {"from": "faculty", "to": "##nes", "value": 1}, {"from": "faculty", "to": "##50 value", "value": 1}, {"from": "faculty", "to": "role in", "value": 1}, {"from": "faculty", "to": "real", "value": 1}, {"from": "faculty", "to": ". the p53 signaling pathway", "value": 1}, {"from": "faculty", "to": ", a", "value": 1}, {"from": "faculty", "to": "key", "value": 1}, {"from": "faculty", "to": ", and", "value": 1}, {"from": "faculty", "to": "plays", "value": 1}, {"from": "faculty", "to": "a critical", "value": 1}, {"from": "faculty", "to": "cycle", "value": 1}, {"from": "faculty", "to": "of downstream genes linked to cell", "value": 1}, {"from": "faculty", "to": "##a, jakarta,", "value": 1}, {"from": "faculty", "to": "##iti", "value": 1}, {"from": "faculty", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "faculty", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "faculty", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "faculty", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "faculty", "to": "on the", "value": 1}, {"from": "faculty", "to": "##ia", "value": 1}, {"from": "faculty", "to": "senes", "value": 1}, {"from": "faculty", "to": "##life", "value": 1}, {"from": "faculty", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "faculty", "to": "##ion of p21", "value": 1}, {"from": "faculty", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "faculty", "to": "##in - mediated anti -", "value": 1}, {"from": "faculty", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "faculty", "to": "1 ), abdelkrim g", "value": 1}, {"from": "faculty", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "faculty", "to": "cancer effects. foda my", "value": 1}, {"from": "faculty", "to": "##press", "value": 1}, {"from": "faculty", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "faculty", "to": "##tat", "value": 2}, {"from": "faculty", "to": "jun", "value": 2}, {"from": "faculty", "to": "2 ), salem ml", "value": 1}, {"from": "faculty", "to": "in atorvas", "value": 1}, {"from": "faculty", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "faculty", "to": "prescribed chole", "value": 1}, {"from": "faculty", "to": "has recently", "value": 1}, {"from": "faculty", "to": "and its biological functions", "value": 1}, {"from": "faculty", "to": "of saida, saida, algeria.", "value": 1}, {"from": "faculty", "to": "shown", "value": 1}, {"from": "faculty", "to": "however", "value": 1}, {"from": "faculty", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "faculty", "to": "shown potential anti", "value": 1}, {"from": "faculty", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "faculty", "to": "##in", "value": 1}, {"from": "faculty", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "faculty", "to": "particular breast cancer,", "value": 1}, {"from": "faculty", "to": "still", "value": 1}, {"from": "faculty", "to": "associated with atorvas", "value": 1}, {"from": "faculty", "to": "in breast", "value": 1}, {"from": "faculty", "to": "lowering", "value": 1}, {"from": "faculty", "to": "to be responsive to", "value": 1}, {"from": "faculty", "to": "interaction", "value": 2}, {"from": "faculty", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "faculty", "to": ") network and", "value": 1}, {"from": "faculty", "to": "in the protein - protein", "value": 1}, {"from": "faculty", "to": "drug,", "value": 1}, {"from": "faculty", "to": "hub gene", "value": 1}, {"from": "faculty", "to": ", its influence on gene", "value": 1}, {"from": "faculty", "to": "##lated", "value": 1}, {"from": "faculty", "to": "was", "value": 1}, {"from": "faculty", "to": "##in,", "value": 1}, {"from": "faculty", "to": "ppi", "value": 1}, {"from": "faculty", "to": "##oto", "value": 1}, {"from": "faculty", "to": "related pathways", "value": 1}, {"from": "faculty", "to": "cancer,", "value": 1}, {"from": "faculty", "to": "expressed", "value": 1}, {"from": "faculty", "to": "##cer effects.", "value": 1}, {"from": "faculty", "to": "widely", "value": 1}, {"from": "faculty", "to": "atorvas", "value": 1}, {"from": "faculty", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "faculty", "to": "##ster", "value": 1}, {"from": "faculty", "to": "##ol", "value": 1}, {"from": "faculty", "to": "##can", "value": 2}, {"from": "faculty", "to": "cancer. atorvas", "value": 1}, {"from": "faculty", "to": "was identified as the", "value": 1}, {"from": "faculty", "to": "is cost - effective", "value": 1}, {"from": "faculty", "to": "of agriculture and natural", "value": 1}, {"from": "faculty", "to": ". ac.", "value": 1}, {"from": "faculty", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "faculty", "to": "resources", "value": 1}, {"from": "faculty", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "faculty", "to": "##za. he", "value": 1}, {"from": "faculty", "to": "##6 /", "value": 1}, {"from": "faculty", "to": "are", "value": 1}, {"from": "faculty", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "faculty", "to": "##ri - japelaghi r", "value": 1}, {"from": "faculty", "to": "##r.", "value": 1}, {"from": "faculty", "to": "who", "value": 1}, {"from": "faculty", "to": "inter", "value": 1}, {"from": "faculty", "to": "##vin", "value": 1}, {"from": "faculty", "to": "of tabriz,", "value": 1}, {"from": "faculty", "to": "@ org.", "value": 1}, {"from": "faculty", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "faculty", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "faculty", "to": "##idari", "value": 1}, {"from": "faculty", "to": "s", "value": 1}, {"from": "faculty", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "faculty", "to": "ta", "value": 1}, {"from": "faculty", "to": "##ran. electronic address :", "value": 1}, {"from": "faculty", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "faculty", "to": "re", "value": 1}, {"from": "faculty", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "faculty", "to": "101", "value": 1}, {"from": "faculty", "to": "perspectives", "value": 1}, {"from": "faculty", "to": "##briz,", "value": 1}, {"from": "faculty", "to": "of agriculture,", "value": 1}, {"from": "faculty", "to": "##fer", "value": 1}, {"from": "faculty", "to": "##on", "value": 1}, {"from": "faculty", "to": "##ki", "value": 1}, {"from": "faculty", "to": "from both", "value": 1}, {"from": "faculty", "to": "##ran.", "value": 1}, {"from": "faculty", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "faculty", "to": "##ifer", "value": 1}, {"from": "faculty", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "faculty", "to": "in the", "value": 1}, {"from": "faculty", "to": "##ne - c", "value": 1}, {"from": "faculty", "to": ", tnf signaling", "value": 1}, {"from": "faculty", "to": ", which", "value": 1}, {"from": "faculty", "to": "down - regulated", "value": 1}, {"from": "faculty", "to": "including c", "value": 1}, {"from": "faculty", "to": "##ytoki", "value": 1}, {"from": "faculty", "to": "detected", "value": 1}, {"from": "faculty", "to": "cancer", "value": 1}, {"from": "faculty", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "faculty", "to": "vs", "value": 1}, {"from": "faculty", "to": "##cer assays. the", "value": 1}, {"from": "faculty", "to": "or", "value": 1}, {"from": "faculty", "to": "if", "value": 1}, {"from": "faculty", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "faculty", "to": "##ne receptor", "value": 1}, {"from": "faculty", "to": "##ap", "value": 1}, {"from": "faculty", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "faculty", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "faculty", "to": "via", "value": 1}, {"from": "faculty", "to": "anti", "value": 1}, {"from": "faculty", "to": "##n - \u03b3", "value": 1}, {"from": "faculty", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "faculty", "to": "f biotechnology engineering,", "value": 1}, {"from": "faculty", "to": "were up -", "value": 1}, {"from": "faculty", "to": ", nod - like receptor signaling", "value": 1}, {"from": "faculty", "to": "##ation, pro", "value": 1}, {"from": "faculty", "to": "pathways", "value": 1}, {"from": "faculty", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "faculty", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "faculty", "to": "pathway", "value": 1}, {"from": "faculty", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "wa", "to": "##don", "value": 1}, {"from": "wa", "to": "##a,", "value": 1}, {"from": "wa", "to": "6", "value": 1}, {"from": "wa", "to": "##aka", "value": 1}, {"from": "wa", "to": "indonesi", "value": 1}, {"from": "wa", "to": "##itas indonesia", "value": 1}, {"from": "wa", "to": "of surgery,", "value": 1}, {"from": "wa", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "wa", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##don", "to": "##a,", "value": 2}, {"from": "##don", "to": "6", "value": 1}, {"from": "##don", "to": "##aka", "value": 3}, {"from": "##don", "to": "indonesi", "value": 2}, {"from": "##don", "to": "##itas indonesia", "value": 2}, {"from": "##don", "to": "of surgery,", "value": 1}, {"from": "##don", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##don", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##don", "to": "2 - positive", "value": 1}, {"from": "##don", "to": "changes in the promoter region", "value": 1}, {"from": "##don", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##don", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##don", "to": "receptor", "value": 1}, {"from": "##don", "to": "is an", "value": 1}, {"from": "##don", "to": "##type", "value": 1}, {"from": "##don", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##don", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##don", "to": "- negative breast cancer", "value": 1}, {"from": "##don", "to": "and", "value": 1}, {"from": "##don", "to": "##a, jaka", "value": 2}, {"from": "##don", "to": "lead", "value": 1}, {"from": "##don", "to": "triple", "value": 1}, {"from": "##don", "to": "of medicine, universitas indon", "value": 2}, {"from": "##don", "to": "cilities - imeri,", "value": 1}, {"from": "##don", "to": "##a. breast cancer sub", "value": 1}, {"from": "##don", "to": "##umi", "value": 1}, {"from": "##don", "to": "##ivers", "value": 1}, {"from": "##don", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##don", "to": "##s", "value": 1}, {"from": "##don", "to": "un", "value": 1}, {"from": "##don", "to": "##nal a, l", "value": 1}, {"from": "##don", "to": "epigenetic modification,", "value": 1}, {"from": "##don", "to": "of medicine,", "value": 1}, {"from": "##don", "to": "), hashim", "value": 1}, {"from": "##don", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##don", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##don", "to": "##an medical", "value": 1}, {"from": "##don", "to": "indon", "value": 1}, {"from": "##don", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##don", "to": "##hibit", "value": 1}, {"from": "##don", "to": "na", "value": 1}, {"from": "##don", "to": "education", "value": 1}, {"from": "##don", "to": "n", "value": 1}, {"from": "##don", "to": "3", "value": 1}, {"from": "##don", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##don", "to": "##ajrin", "value": 1}, {"from": "##don", "to": "), azizah", "value": 1}, {"from": "##don", "to": "te", "value": 1}, {"from": "##don", "to": "##djo a", "value": 1}, {"from": "##don", "to": "##itas", "value": 1}, {"from": "##don", "to": "##b", "value": 1}, {"from": "##don", "to": "am", "value": 1}, {"from": "##don", "to": "nn", "value": 1}, {"from": "##don", "to": "of pharmacy, univers", "value": 2}, {"from": "##don", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##don", "to": ", indon", "value": 1}, {"from": "##don", "to": "and research instit", "value": 1}, {"from": "##don", "to": "), ramadanti", "value": 1}, {"from": "##don", "to": "52", "value": 1}, {"from": "##don", "to": "quantitative pcr", "value": 1}, {"from": "##don", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "##don", "to": "time", "value": 1}, {"from": "##don", "to": "##sia", "value": 1}, {"from": "##don", "to": "regulating the cell", "value": 1}, {"from": "##don", "to": "ute,", "value": 1}, {"from": "##don", "to": "##poptosis", "value": 1}, {"from": "##don", "to": "##cence, making it", "value": 1}, {"from": "##don", "to": "proliferation", "value": 1}, {"from": "##don", "to": "and se", "value": 1}, {"from": "##don", "to": "a", "value": 1}, {"from": "##don", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##don", "to": "target", "value": 1}, {"from": "##don", "to": "##nes", "value": 1}, {"from": "##don", "to": "##50 value", "value": 1}, {"from": "##don", "to": "role in", "value": 1}, {"from": "##don", "to": "real", "value": 1}, {"from": "##don", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##don", "to": ", a", "value": 1}, {"from": "##don", "to": "key", "value": 1}, {"from": "##don", "to": ", and", "value": 1}, {"from": "##don", "to": "plays", "value": 1}, {"from": "##don", "to": "a critical", "value": 1}, {"from": "##don", "to": "cycle", "value": 1}, {"from": "##don", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##don", "to": "##a, jakarta,", "value": 1}, {"from": "##don", "to": "##iti", "value": 1}, {"from": "##don", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##don", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##don", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##don", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##don", "to": "on the", "value": 1}, {"from": "##don", "to": "##ia", "value": 1}, {"from": "##don", "to": "senes", "value": 1}, {"from": "##a,", "to": "6", "value": 1}, {"from": "##a,", "to": "##aka", "value": 2}, {"from": "##a,", "to": "indonesi", "value": 1}, {"from": "##a,", "to": "##itas indonesia", "value": 1}, {"from": "##a,", "to": "of surgery,", "value": 1}, {"from": "##a,", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##a,", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##a,", "to": "), hashim", "value": 1}, {"from": "##a,", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##a,", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##a,", "to": "##an medical", "value": 1}, {"from": "##a,", "to": "indon", "value": 1}, {"from": "##a,", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##a,", "to": "##hibit", "value": 1}, {"from": "##a,", "to": "na", "value": 1}, {"from": "##a,", "to": "education", "value": 1}, {"from": "##a,", "to": "n", "value": 1}, {"from": "##a,", "to": "3", "value": 1}, {"from": "##a,", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##a,", "to": "##ajrin", "value": 1}, {"from": "##a,", "to": "), azizah", "value": 1}, {"from": "##a,", "to": "te", "value": 1}, {"from": "##a,", "to": "##a, jaka", "value": 1}, {"from": "##a,", "to": "##djo a", "value": 1}, {"from": "##a,", "to": "of medicine, universitas indon", "value": 1}, {"from": "##a,", "to": "##itas", "value": 1}, {"from": "##a,", "to": "##b", "value": 1}, {"from": "##a,", "to": "am", "value": 1}, {"from": "##a,", "to": "nn", "value": 1}, {"from": "##a,", "to": "of pharmacy, univers", "value": 1}, {"from": "##a,", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##a,", "to": ", indon", "value": 1}, {"from": "##a,", "to": "and research instit", "value": 1}, {"from": "##a,", "to": "), ramadanti", "value": 1}, {"from": "##a,", "to": "52", "value": 1}, {"from": "6", "to": "##aka", "value": 1}, {"from": "6", "to": "indonesi", "value": 1}, {"from": "6", "to": "##itas indonesia", "value": 1}, {"from": "6", "to": "of surgery,", "value": 1}, {"from": "6", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "6", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "6", "to": "), huarte m", "value": 1}, {"from": "6", "to": "12", "value": 1}, {"from": "6", "to": "##407.", "value": 1}, {"from": "6", "to": "), par", "value": 1}, {"from": "6", "to": "ins", "value": 1}, {"from": "6", "to": "##or", "value": 1}, {"from": "6", "to": "##e", "value": 1}, {"from": "6", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "6", "to": "9", "value": 2}, {"from": "6", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "6", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "6", "to": "), aragon s", "value": 1}, {"from": "6", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "6", "to": "##ory", "value": 1}, {"from": "6", "to": "), gimenez j", "value": 1}, {"from": "6", "to": "- lopez i", "value": 1}, {"from": "6", "to": "##rine", "value": 1}, {"from": "6", "to": "er + / her2 -", "value": 1}, {"from": "6", "to": "), prat a", "value": 1}, {"from": "6", "to": "research", "value": 2}, {"from": "6", "to": "##e. lg is /", "value": 1}, {"from": "6", "to": "), buch e", "value": 1}, {"from": "6", "to": "##roga v", "value": 1}, {"from": "6", "to": "been holding research", "value": 1}, {"from": "6", "to": "11", "value": 2}, {"from": "6", "to": "101", "value": 1}, {"from": "6", "to": "##riaga k", "value": 1}, {"from": "6", "to": "), etxabe i", "value": 1}, {"from": "6", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "6", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "6", "to": "13", "value": 2}, {"from": "6", "to": "therapy", "value": 1}, {"from": "6", "to": "##ui", "value": 1}, {"from": "6", "to": "##ez", "value": 1}, {"from": "6", "to": "##vita", "value": 1}, {"from": "6", "to": "contracts", "value": 1}, {"from": "6", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "6", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "6", "to": "). author information :", "value": 1}, {"from": "6", "to": "), urruticoechea a", "value": 1}, {"from": "6", "to": ") department of", "value": 1}, {"from": "6", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "6", "to": "for cancer", "value": 1}, {"from": "6", "to": "##lia", "value": 1}, {"from": "6", "to": "##vanger,", "value": 1}, {"from": "6", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "6", "to": "##vanger university, s", "value": 1}, {"from": "6", "to": "8", "value": 1}, {"from": "6", "to": "of cancer genetics,", "value": 1}, {"from": "6", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "6", "to": "12 ) department", "value": 1}, {"from": "6", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "6", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "6", "to": "##vanger university hospital, s", "value": 1}, {"from": "6", "to": "ha", "value": 1}, {"from": "6", "to": "norway", "value": 1}, {"from": "6", "to": "institute", "value": 1}, {"from": "6", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "6", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "6", "to": "of pathology, s", "value": 1}, {"from": "6", "to": ";", "value": 1}, {"from": "6", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "6", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "6", "to": "##way", "value": 1}, {"from": "##aka", "to": "indonesi", "value": 2}, {"from": "##aka", "to": "##itas indonesia", "value": 2}, {"from": "##aka", "to": "of surgery,", "value": 1}, {"from": "##aka", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##aka", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##aka", "to": "2 - positive", "value": 1}, {"from": "##aka", "to": "changes in the promoter region", "value": 1}, {"from": "##aka", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##aka", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##aka", "to": "receptor", "value": 1}, {"from": "##aka", "to": "is an", "value": 1}, {"from": "##aka", "to": "##type", "value": 1}, {"from": "##aka", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##aka", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##aka", "to": "- negative breast cancer", "value": 1}, {"from": "##aka", "to": "and", "value": 1}, {"from": "##aka", "to": "##a, jaka", "value": 2}, {"from": "##aka", "to": "lead", "value": 1}, {"from": "##aka", "to": "triple", "value": 1}, {"from": "##aka", "to": "of medicine, universitas indon", "value": 2}, {"from": "##aka", "to": "cilities - imeri,", "value": 1}, {"from": "##aka", "to": "##a. breast cancer sub", "value": 1}, {"from": "##aka", "to": "##umi", "value": 1}, {"from": "##aka", "to": "##ivers", "value": 1}, {"from": "##aka", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##aka", "to": "##s", "value": 1}, {"from": "##aka", "to": "un", "value": 1}, {"from": "##aka", "to": "##nal a, l", "value": 1}, {"from": "##aka", "to": "epigenetic modification,", "value": 1}, {"from": "##aka", "to": "of medicine,", "value": 1}, {"from": "##aka", "to": "), hashim", "value": 1}, {"from": "##aka", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##aka", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##aka", "to": "##an medical", "value": 1}, {"from": "##aka", "to": "indon", "value": 1}, {"from": "##aka", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##aka", "to": "##hibit", "value": 1}, {"from": "##aka", "to": "na", "value": 1}, {"from": "##aka", "to": "education", "value": 1}, {"from": "##aka", "to": "n", "value": 1}, {"from": "##aka", "to": "3", "value": 1}, {"from": "##aka", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##aka", "to": "##ajrin", "value": 1}, {"from": "##aka", "to": "), azizah", "value": 1}, {"from": "##aka", "to": "te", "value": 1}, {"from": "##aka", "to": "##djo a", "value": 1}, {"from": "##aka", "to": "##itas", "value": 1}, {"from": "##aka", "to": "##b", "value": 1}, {"from": "##aka", "to": "am", "value": 1}, {"from": "##aka", "to": "nn", "value": 1}, {"from": "##aka", "to": "of pharmacy, univers", "value": 1}, {"from": "##aka", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##aka", "to": ", indon", "value": 1}, {"from": "##aka", "to": "and research instit", "value": 1}, {"from": "##aka", "to": "), ramadanti", "value": 1}, {"from": "##aka", "to": "52", "value": 1}, {"from": "indonesi", "to": "##itas indonesia", "value": 2}, {"from": "indonesi", "to": "of surgery,", "value": 1}, {"from": "indonesi", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "indonesi", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "indonesi", "to": "2 - positive", "value": 1}, {"from": "indonesi", "to": "changes in the promoter region", "value": 1}, {"from": "indonesi", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "indonesi", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "indonesi", "to": "receptor", "value": 1}, {"from": "indonesi", "to": "is an", "value": 1}, {"from": "indonesi", "to": "##type", "value": 1}, {"from": "indonesi", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "indonesi", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "indonesi", "to": "- negative breast cancer", "value": 1}, {"from": "indonesi", "to": "and", "value": 1}, {"from": "indonesi", "to": "##a, jaka", "value": 1}, {"from": "indonesi", "to": "lead", "value": 1}, {"from": "indonesi", "to": "triple", "value": 1}, {"from": "indonesi", "to": "of medicine, universitas indon", "value": 1}, {"from": "indonesi", "to": "cilities - imeri,", "value": 1}, {"from": "indonesi", "to": "##a. breast cancer sub", "value": 1}, {"from": "indonesi", "to": "##umi", "value": 1}, {"from": "indonesi", "to": "##ivers", "value": 1}, {"from": "indonesi", "to": "to misclassification. dna methylation", "value": 1}, {"from": "indonesi", "to": "##s", "value": 1}, {"from": "indonesi", "to": "un", "value": 1}, {"from": "indonesi", "to": "##nal a, l", "value": 1}, {"from": "indonesi", "to": "epigenetic modification,", "value": 1}, {"from": "indonesi", "to": "of medicine,", "value": 1}, {"from": "##itas indonesia", "to": "of surgery,", "value": 1}, {"from": "##itas indonesia", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "##itas indonesia", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "##itas indonesia", "to": "2 - positive", "value": 1}, {"from": "##itas indonesia", "to": "changes in the promoter region", "value": 1}, {"from": "##itas indonesia", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "##itas indonesia", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "##itas indonesia", "to": "receptor", "value": 1}, {"from": "##itas indonesia", "to": "is an", "value": 1}, {"from": "##itas indonesia", "to": "##type", "value": 1}, {"from": "##itas indonesia", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##itas indonesia", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##itas indonesia", "to": "- negative breast cancer", "value": 1}, {"from": "##itas indonesia", "to": "and", "value": 1}, {"from": "##itas indonesia", "to": "##a, jaka", "value": 1}, {"from": "##itas indonesia", "to": "lead", "value": 1}, {"from": "##itas indonesia", "to": "triple", "value": 1}, {"from": "##itas indonesia", "to": "of medicine, universitas indon", "value": 1}, {"from": "##itas indonesia", "to": "cilities - imeri,", "value": 1}, {"from": "##itas indonesia", "to": "##a. breast cancer sub", "value": 1}, {"from": "##itas indonesia", "to": "##umi", "value": 1}, {"from": "##itas indonesia", "to": "##ivers", "value": 1}, {"from": "##itas indonesia", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##itas indonesia", "to": "##s", "value": 1}, {"from": "##itas indonesia", "to": "un", "value": 1}, {"from": "##itas indonesia", "to": "##nal a, l", "value": 1}, {"from": "##itas indonesia", "to": "epigenetic modification,", "value": 1}, {"from": "##itas indonesia", "to": "of medicine,", "value": 1}, {"from": "of surgery,", "to": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "value": 1}, {"from": "of surgery,", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr", "to": "7 ) molecular biology and proteomics core fa", "value": 1}, {"from": "2 - positive", "to": "changes in the promoter region", "value": 1}, {"from": "2 - positive", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "2 - positive", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "2 - positive", "to": "receptor", "value": 1}, {"from": "2 - positive", "to": "is an", "value": 1}, {"from": "2 - positive", "to": "##type", "value": 1}, {"from": "2 - positive", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "2 - positive", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "2 - positive", "to": "- negative breast cancer", "value": 1}, {"from": "2 - positive", "to": "and", "value": 1}, {"from": "2 - positive", "to": "##a, jaka", "value": 1}, {"from": "2 - positive", "to": "lead", "value": 1}, {"from": "2 - positive", "to": "triple", "value": 1}, {"from": "2 - positive", "to": "of medicine, universitas indon", "value": 1}, {"from": "2 - positive", "to": "cilities - imeri,", "value": 1}, {"from": "2 - positive", "to": "##a. breast cancer sub", "value": 1}, {"from": "2 - positive", "to": "##umi", "value": 1}, {"from": "2 - positive", "to": "##ivers", "value": 1}, {"from": "2 - positive", "to": "to misclassification. dna methylation", "value": 1}, {"from": "2 - positive", "to": "##s", "value": 1}, {"from": "2 - positive", "to": "un", "value": 1}, {"from": "2 - positive", "to": "##nal a, l", "value": 1}, {"from": "2 - positive", "to": "epigenetic modification,", "value": 1}, {"from": "2 - positive", "to": "of medicine,", "value": 1}, {"from": "changes in the promoter region", "to": "9 ) department of internal medicine,", "value": 1}, {"from": "changes in the promoter region", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "changes in the promoter region", "to": "receptor", "value": 1}, {"from": "changes in the promoter region", "to": "is an", "value": 1}, {"from": "changes in the promoter region", "to": "##type", "value": 1}, {"from": "changes in the promoter region", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "changes in the promoter region", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "changes in the promoter region", "to": "- negative breast cancer", "value": 1}, {"from": "changes in the promoter region", "to": "and", "value": 1}, {"from": "changes in the promoter region", "to": "##a, jaka", "value": 1}, {"from": "changes in the promoter region", "to": "lead", "value": 1}, {"from": "changes in the promoter region", "to": "triple", "value": 1}, {"from": "changes in the promoter region", "to": "of medicine, universitas indon", "value": 1}, {"from": "changes in the promoter region", "to": "cilities - imeri,", "value": 1}, {"from": "changes in the promoter region", "to": "##a. breast cancer sub", "value": 1}, {"from": "changes in the promoter region", "to": "##umi", "value": 1}, {"from": "changes in the promoter region", "to": "##ivers", "value": 1}, {"from": "changes in the promoter region", "to": "to misclassification. dna methylation", "value": 1}, {"from": "changes in the promoter region", "to": "##s", "value": 1}, {"from": "changes in the promoter region", "to": "un", "value": 1}, {"from": "changes in the promoter region", "to": "##nal a, l", "value": 1}, {"from": "changes in the promoter region", "to": "epigenetic modification,", "value": 1}, {"from": "changes in the promoter region", "to": "of medicine,", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "receptor", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "is an", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##type", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "- negative breast cancer", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "and", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##a, jaka", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "lead", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "triple", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "of medicine, universitas indon", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "cilities - imeri,", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##a. breast cancer sub", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##umi", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##ivers", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "to misclassification. dna methylation", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##s", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "un", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "##nal a, l", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "epigenetic modification,", "value": 1}, {"from": "9 ) department of internal medicine,", "to": "of medicine,", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "receptor", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "is an", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##type", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "- negative breast cancer", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "and", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##a, jaka", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "lead", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "triple", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "of medicine, universitas indon", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "cilities - imeri,", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##a. breast cancer sub", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##umi", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##ivers", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "to misclassification. dna methylation", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##s", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "un", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "##nal a, l", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "epigenetic modification,", "value": 1}, {"from": "alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac", "to": "of medicine,", "value": 1}, {"from": "receptor", "to": "is an", "value": 1}, {"from": "receptor", "to": "##type", "value": 1}, {"from": "receptor", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "receptor", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "receptor", "to": "- negative breast cancer", "value": 1}, {"from": "receptor", "to": "and", "value": 1}, {"from": "receptor", "to": "##a, jaka", "value": 1}, {"from": "receptor", "to": "lead", "value": 1}, {"from": "receptor", "to": "triple", "value": 1}, {"from": "receptor", "to": "of medicine, universitas indon", "value": 1}, {"from": "receptor", "to": "cilities - imeri,", "value": 1}, {"from": "receptor", "to": "##a. breast cancer sub", "value": 1}, {"from": "receptor", "to": "##umi", "value": 1}, {"from": "receptor", "to": "##ivers", "value": 1}, {"from": "receptor", "to": "to misclassification. dna methylation", "value": 1}, {"from": "receptor", "to": "##s", "value": 1}, {"from": "receptor", "to": "un", "value": 1}, {"from": "receptor", "to": "##nal a, l", "value": 1}, {"from": "receptor", "to": "epigenetic modification,", "value": 1}, {"from": "receptor", "to": "of medicine,", "value": 1}, {"from": "is an", "to": "##type", "value": 1}, {"from": "is an", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "is an", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "is an", "to": "- negative breast cancer", "value": 1}, {"from": "is an", "to": "and", "value": 1}, {"from": "is an", "to": "##a, jaka", "value": 1}, {"from": "is an", "to": "lead", "value": 1}, {"from": "is an", "to": "triple", "value": 1}, {"from": "is an", "to": "of medicine, universitas indon", "value": 1}, {"from": "is an", "to": "cilities - imeri,", "value": 1}, {"from": "is an", "to": "##a. breast cancer sub", "value": 1}, {"from": "is an", "to": "##umi", "value": 1}, {"from": "is an", "to": "##ivers", "value": 1}, {"from": "is an", "to": "to misclassification. dna methylation", "value": 1}, {"from": "is an", "to": "##s", "value": 1}, {"from": "is an", "to": "un", "value": 1}, {"from": "is an", "to": "##nal a, l", "value": 1}, {"from": "is an", "to": "epigenetic modification,", "value": 1}, {"from": "is an", "to": "of medicine,", "value": 1}, {"from": "##type", "to": "##nal b, human epidermal growth factor", "value": 1}, {"from": "##type", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##type", "to": "- negative breast cancer", "value": 1}, {"from": "##type", "to": "and", "value": 1}, {"from": "##type", "to": "##a, jaka", "value": 1}, {"from": "##type", "to": "lead", "value": 1}, {"from": "##type", "to": "triple", "value": 1}, {"from": "##type", "to": "of medicine, universitas indon", "value": 1}, {"from": "##type", "to": "cilities - imeri,", "value": 1}, {"from": "##type", "to": "##a. breast cancer sub", "value": 1}, {"from": "##type", "to": "##umi", "value": 3}, {"from": "##type", "to": "##ivers", "value": 1}, {"from": "##type", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##type", "to": "##s", "value": 1}, {"from": "##type", "to": "un", "value": 1}, {"from": "##type", "to": "##nal a, l", "value": 1}, {"from": "##type", "to": "epigenetic modification,", "value": 1}, {"from": "##type", "to": "of medicine,", "value": 1}, {"from": "##type", "to": "classification of breast cancer : l", "value": 1}, {"from": "##type", "to": ", h", "value": 1}, {"from": "##type", "to": "##methylation", "value": 1}, {"from": "##type", "to": "tion", "value": 1}, {"from": "##type", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "##type", "to": "the pt", "value": 1}, {"from": "##type", "to": ". \u00a9 202", "value": 1}, {"from": "##type", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "##type", "to": "##rn2 gene", "value": 1}, {"from": "##type", "to": "##nal", "value": 1}, {"from": "##type", "to": "##261 ), and tnbc", "value": 1}, {"from": "##type", "to": "##p", "value": 1}, {"from": "##type", "to": "the author", "value": 1}, {"from": "##type", "to": "bio", "value": 1}, {"from": "##type", "to": "respectively", "value": 1}, {"from": "##type", "to": "##marker for each sub", "value": 1}, {"from": "##type", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##type", "to": "##yper", "value": 1}, {"from": "##type", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##type", "to": "improve", "value": 1}, {"from": "##type", "to": "##10", "value": 1}, {"from": "##type", "to": "##5", "value": 1}, {"from": "##type", "to": "##nal a", "value": 1}, {"from": "##type", "to": "52", "value": 1}, {"from": "##type", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "##type", "to": "in ki", "value": 1}, {"from": "##type", "to": "##cu", "value": 1}, {"from": "##type", "to": "t", "value": 1}, {"from": "##type", "to": "positive", "value": 1}, {"from": "##type", "to": "##2 -", "value": 1}, {"from": "##type", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##type", "to": "##rrence", "value": 1}, {"from": "##type", "to": "percentage", "value": 1}, {"from": "##type", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##type", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##type", "to": "##nes", "value": 1}, {"from": "##type", "to": "from l", "value": 1}, {"from": "##type", "to": "presented", "value": 1}, {"from": "##type", "to": "re", "value": 1}, {"from": "##type", "to": "results", "value": 1}, {"from": "##type", "to": "pam50 - derived risk of", "value": 1}, {"from": "##type", "to": "her", "value": 1}, {"from": "##type", "to": "er + /", "value": 1}, {"from": "##type", "to": "##nal a to normal - like", "value": 1}, {"from": "##type", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##type", "to": "cells", "value": 1}, {"from": "##type", "to": "score", "value": 1}, {"from": "##type", "to": "change", "value": 1}, {"from": "##type", "to": "after", "value": 1}, {"from": "##type", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##type", "to": "of intrinsic sub", "value": 1}, {"from": "##type", "to": "p53", "value": 1}, {"from": "##type", "to": "##is.", "value": 1}, {"from": "##type", "to": "biomark", "value": 1}, {"from": "##type", "to": "subtype after", "value": 1}, {"from": "##type", "to": "net", "value": 1}, {"from": "##type", "to": "of", "value": 1}, {"from": "##type", "to": "##c patients", "value": 1}, {"from": "##type", "to": "net as a putative", "value": 1}, {"from": "##type", "to": "##umour cellularity size", "value": 1}, {"from": "##type", "to": "radio", "value": 1}, {"from": "##type", "to": ") and lower", "value": 1}, {"from": "##type", "to": "better", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "be categorized based on their gene expression profiles using immunohistochemistry into l", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "- negative breast cancer", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "and", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##a, jaka", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "lead", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "triple", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "of medicine, universitas indon", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "cilities - imeri,", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##a. breast cancer sub", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##umi", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##ivers", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##s", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "un", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "##nal a, l", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "epigenetic modification,", "value": 1}, {"from": "##nal b, human epidermal growth factor", "to": "of medicine,", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "- negative breast cancer", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "and", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##a, jaka", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "lead", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "triple", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "of medicine, universitas indon", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "cilities - imeri,", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##a. breast cancer sub", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##umi", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##ivers", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "to misclassification. dna methylation", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##s", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "un", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "##nal a, l", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "epigenetic modification,", "value": 1}, {"from": "be categorized based on their gene expression profiles using immunohistochemistry into l", "to": "of medicine,", "value": 1}, {"from": "- negative breast cancer", "to": "and", "value": 1}, {"from": "- negative breast cancer", "to": "##a, jaka", "value": 1}, {"from": "- negative breast cancer", "to": "lead", "value": 1}, {"from": "- negative breast cancer", "to": "triple", "value": 1}, {"from": "- negative breast cancer", "to": "of medicine, universitas indon", "value": 1}, {"from": "- negative breast cancer", "to": "cilities - imeri,", "value": 1}, {"from": "- negative breast cancer", "to": "##a. breast cancer sub", "value": 1}, {"from": "- negative breast cancer", "to": "##umi", "value": 1}, {"from": "- negative breast cancer", "to": "##ivers", "value": 1}, {"from": "- negative breast cancer", "to": "to misclassification. dna methylation", "value": 1}, {"from": "- negative breast cancer", "to": "##s", "value": 1}, {"from": "- negative breast cancer", "to": "un", "value": 1}, {"from": "- negative breast cancer", "to": "##nal a, l", "value": 1}, {"from": "- negative breast cancer", "to": "epigenetic modification,", "value": 1}, {"from": "- negative breast cancer", "to": "of medicine,", "value": 1}, {"from": "and", "to": "##a, jaka", "value": 1}, {"from": "and", "to": "lead", "value": 1}, {"from": "and", "to": "triple", "value": 1}, {"from": "and", "to": "of medicine, universitas indon", "value": 1}, {"from": "and", "to": "cilities - imeri,", "value": 1}, {"from": "and", "to": "##a. breast cancer sub", "value": 1}, {"from": "and", "to": "##umi", "value": 1}, {"from": "and", "to": "##ivers", "value": 1}, {"from": "and", "to": "to misclassification. dna methylation", "value": 1}, {"from": "and", "to": "##s", "value": 1}, {"from": "and", "to": "un", "value": 1}, {"from": "and", "to": "##nal a, l", "value": 1}, {"from": "and", "to": "epigenetic modification,", "value": 1}, {"from": "and", "to": "of medicine,", "value": 1}, {"from": "and", "to": "12", "value": 1}, {"from": "and", "to": "after net", "value": 1}, {"from": "and", "to": "a significant", "value": 1}, {"from": "and", "to": "time", "value": 1}, {"from": "and", "to": "offers the opportunity of", "value": 1}, {"from": "and", "to": "##ip", "value": 1}, {"from": "and", "to": "t", "value": 2}, {"from": "and", "to": "however", "value": 1}, {"from": "and", "to": ") health", "value": 1}, {"from": "and", "to": "background", "value": 1}, {"from": "and", "to": "##re population of", "value": 1}, {"from": "and", "to": "negative breast", "value": 1}, {"from": "and", "to": "barrier", "value": 1}, {"from": "and", "to": "##gipuzkoa", "value": 1}, {"from": "and", "to": "clinical", "value": 1}, {"from": "and", "to": "##2 -", "value": 1}, {"from": "and", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "and", "to": "##zkoa", "value": 1}, {"from": "and", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "and", "to": "##gi", "value": 1}, {"from": "and", "to": "##donostia ) health", "value": 1}, {"from": "and", "to": "##tian,", "value": 1}, {"from": "and", "to": "cancer", "value": 1}, {"from": "and", "to": "spain", "value": 1}, {"from": "and", "to": "##uzkoa. eus.", "value": 1}, {"from": "and", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "and", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "and", "to": "real", "value": 1}, {"from": "and", "to": "personal", "value": 1}, {"from": "and", "to": "##ised therapy.", "value": 1}, {"from": "and", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "and", "to": "bio", "value": 1}, {"from": "and", "to": "##donost", "value": 1}, {"from": "and", "to": "##cent", "value": 1}, {"from": "and", "to": "research institute", "value": 1}, {"from": "and", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "and", "to": "sa", "value": 1}, {"from": "and", "to": "sebas", "value": 1}, {"from": "and", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "and", "to": "her", "value": 1}, {"from": "and", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "and", "to": "##n sebastian,", "value": 1}, {"from": "and", "to": "##umour response", "value": 1}, {"from": "and", "to": "a,", "value": 1}, {"from": "and", "to": "##pu", "value": 1}, {"from": "and", "to": "##n", "value": 1}, {"from": "and", "to": "sebastian", "value": 1}, {"from": "and", "to": "##uc", "value": 1}, {"from": "and", "to": "13", "value": 1}, {"from": "and", "to": ", the lack of reprod", "value": 1}, {"from": "and", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "and", "to": "##c ) allows", "value": 1}, {"from": "and", "to": "##gnosis", "value": 1}, {"from": "and", "to": "- g", "value": 1}, {"from": "and", "to": "##ia", "value": 1}, {"from": "and", "to": "##rgen, norway.", "value": 1}, {"from": "and", "to": "##rgen, nor", "value": 1}, {"from": "and", "to": "economics", "value": 1}, {"from": "and", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "and", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "and", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "and", "to": "clinical trials", "value": 1}, {"from": "and", "to": "of health management and health", "value": 1}, {"from": "and", "to": "institute", "value": 2}, {"from": "and", "to": ";", "value": 1}, {"from": "and", "to": ") department of p", "value": 1}, {"from": "and", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "and", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "and", "to": "), heie a", "value": 1}, {"from": "and", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "and", "to": "be", "value": 1}, {"from": "and", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "and", "to": "ug", "value": 1}, {"from": "and", "to": "##way", "value": 1}, {"from": "and", "to": "the", "value": 2}, {"from": "and", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "and", "to": "methods", "value": 1}, {"from": "and", "to": "hormone receptor positive", "value": 1}, {"from": "and", "to": "societal perspective", "value": 2}, {"from": "and", "to": "benefits", "value": 1}, {"from": "and", "to": "surgery", "value": 1}, {"from": "and", "to": "cost -", "value": 1}, {"from": "and", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "and", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "and", "to": "decision", "value": 1}, {"from": "and", "to": "to aid adjuvant treatment", "value": 1}, {"from": "and", "to": "##al", "value": 1}, {"from": "and", "to": "emit - 1 trial", "value": 1}, {"from": "and", "to": "post", "value": 1}, {"from": "and", "to": ". materials", "value": 1}, {"from": "and", "to": "model was", "value": 1}, {"from": "and", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "and", "to": "used", "value": 1}, {"from": "and", "to": ", a", "value": 1}, {"from": "and", "to": "treatment", "value": 1}, {"from": "and", "to": ": the", "value": 1}, {"from": "and", "to": "ki - 67", "value": 1}, {"from": "and", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "and", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "and", "to": "prosigna was tested", "value": 1}, {"from": "and", "to": "prospective", "value": 1}, {"from": "and", "to": "were measured", "value": 1}, {"from": "and", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "and", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "and", "to": "observation", "value": 1}, {"from": "and", "to": "division", "value": 1}, {"from": "and", "to": "decisions in", "value": 1}, {"from": "and", "to": "built", "value": 1}, {"from": "and", "to": "impact of", "value": 1}, {"from": "and", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "and", "to": "benefit", "value": 1}, {"from": "and", "to": "##26, 000 ;", "value": 1}, {"from": "and", "to": "effective", "value": 1}, {"from": "and", "to": "it was cost - saving", "value": 1}, {"from": "and", "to": "threshold", "value": 1}, {"from": "and", "to": "- 435, 677 )", "value": 1}, {"from": "and", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "and", "to": "##aly", "value": 1}, {"from": "and", "to": "in the", "value": 1}, {"from": "and", "to": "cost", "value": 1}, {"from": "and", "to": "\u20ac", "value": 1}, {"from": "and", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "and", "to": "- 620170,", "value": 1}, {"from": "and", "to": "##r )", "value": 1}, {"from": "and", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "and", "to": "candidates, the strategy", "value": 1}, {"from": "and", "to": "cost - effective", "value": 1}, {"from": "and", "to": "incre", "value": 1}, {"from": "and", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "and", "to": "by", "value": 1}, {"from": "and", "to": "##mental", "value": 1}, {"from": "and", "to": "the cost -", "value": 1}, {"from": "and", "to": "was cost - effective", "value": 1}, {"from": "and", "to": "above", "value": 1}, {"from": "and", "to": "respectively", "value": 1}, {"from": "and", "to": "results", "value": 1}, {"from": "and", "to": "was", "value": 1}, {"from": "and", "to": "was obtained from statistics norway.", "value": 1}, {"from": "and", "to": "per quality - adjusted life -", "value": 1}, {"from": "and", "to": "was cost - saving", "value": 1}, {"from": "and", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "and", "to": "chemotherapy", "value": 1}, {"from": "and", "to": "in both the healthcare", "value": 1}, {"from": "and", "to": "years", "value": 1}, {"from": "and", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "and", "to": "- per q", "value": 1}, {"from": "and", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "and", "to": ". conclusions", "value": 1}, {"from": "and", "to": ". selecting patient", "value": 1}, {"from": "and", "to": "ice", "value": 1}, {"from": "and", "to": "##r", "value": 1}, {"from": "and", "to": "##8884 and", "value": 1}, {"from": "and", "to": "gained", "value": 1}, {"from": "and", "to": "the emit", "value": 1}, {"from": "and", "to": "records. including all pn0 patients", "value": 1}, {"from": "and", "to": "sector", "value": 1}, {"from": "and", "to": "not", "value": 1}, {"from": "and", "to": "- regulate", "value": 1}, {"from": "and", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "and", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "and", "to": "##tic", "value": 1}, {"from": "and", "to": "##6 /", "value": 1}, {"from": "and", "to": "##6", "value": 1}, {"from": "and", "to": "##poptosis", "value": 1}, {"from": "and", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "and", "to": "##xic effect of", "value": 1}, {"from": "and", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "and", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "and", "to": "##xic efficacy of the", "value": 1}, {"from": "and", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "and", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "and", "to": "if", "value": 1}, {"from": "and", "to": "up -", "value": 1}, {"from": "and", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "and", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "and", "to": "development of tumor cells, a", "value": 1}, {"from": "and", "to": "##348089 conflict o", "value": 1}, {"from": "and", "to": "regulate", "value": 1}, {"from": "and", "to": "101", "value": 1}, {"from": "and", "to": "##oto", "value": 1}, {"from": "and", "to": "of pro", "value": 1}, {"from": "and", "to": "##cl -", "value": 1}, {"from": "and", "to": "##biotec. 2025.", "value": 1}, {"from": "and", "to": "04", "value": 1}, {"from": "and", "to": "##apopto", "value": 1}, {"from": "and", "to": "to", "value": 1}, {"from": "and", "to": "##cer and antiviral functions of", "value": 1}, {"from": "and", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "and", "to": "via", "value": 1}, {"from": "and", "to": "and p", "value": 1}, {"from": "and", "to": "##c cell line", "value": 1}, {"from": "and", "to": "hi", "value": 1}, {"from": "and", "to": "##can", "value": 1}, {"from": "and", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "and", "to": "down", "value": 1}, {"from": "and", "to": "##53", "value": 1}, {"from": "and", "to": ". 022 pmid :", "value": 1}, {"from": "and", "to": "bax", "value": 1}, {"from": "##a, jaka", "to": "lead", "value": 1}, {"from": "##a, jaka", "to": "triple", "value": 1}, {"from": "##a, jaka", "to": "of medicine, universitas indon", "value": 2}, {"from": "##a, jaka", "to": "cilities - imeri,", "value": 1}, {"from": "##a, jaka", "to": "##a. breast cancer sub", "value": 1}, {"from": "##a, jaka", "to": "##umi", "value": 1}, {"from": "##a, jaka", "to": "##ivers", "value": 1}, {"from": "##a, jaka", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##a, jaka", "to": "##s", "value": 1}, {"from": "##a, jaka", "to": "un", "value": 1}, {"from": "##a, jaka", "to": "##nal a, l", "value": 1}, {"from": "##a, jaka", "to": "epigenetic modification,", "value": 1}, {"from": "##a, jaka", "to": "of medicine,", "value": 1}, {"from": "##a, jaka", "to": "), hashim", "value": 1}, {"from": "##a, jaka", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "##a, jaka", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##a, jaka", "to": "##an medical", "value": 1}, {"from": "##a, jaka", "to": "indon", "value": 1}, {"from": "##a, jaka", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##a, jaka", "to": "##hibit", "value": 1}, {"from": "##a, jaka", "to": "na", "value": 1}, {"from": "##a, jaka", "to": "education", "value": 1}, {"from": "##a, jaka", "to": "n", "value": 1}, {"from": "##a, jaka", "to": "3", "value": 1}, {"from": "##a, jaka", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##a, jaka", "to": "##ajrin", "value": 1}, {"from": "##a, jaka", "to": "), azizah", "value": 1}, {"from": "##a, jaka", "to": "te", "value": 1}, {"from": "##a, jaka", "to": "##djo a", "value": 1}, {"from": "##a, jaka", "to": "##itas", "value": 1}, {"from": "##a, jaka", "to": "##b", "value": 1}, {"from": "##a, jaka", "to": "am", "value": 1}, {"from": "##a, jaka", "to": "nn", "value": 1}, {"from": "##a, jaka", "to": "of pharmacy, univers", "value": 1}, {"from": "##a, jaka", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##a, jaka", "to": ", indon", "value": 1}, {"from": "##a, jaka", "to": "and research instit", "value": 1}, {"from": "##a, jaka", "to": "), ramadanti", "value": 1}, {"from": "##a, jaka", "to": "52", "value": 1}, {"from": "lead", "to": "triple", "value": 1}, {"from": "lead", "to": "of medicine, universitas indon", "value": 1}, {"from": "lead", "to": "cilities - imeri,", "value": 1}, {"from": "lead", "to": "##a. breast cancer sub", "value": 1}, {"from": "lead", "to": "##umi", "value": 1}, {"from": "lead", "to": "##ivers", "value": 1}, {"from": "lead", "to": "to misclassification. dna methylation", "value": 1}, {"from": "lead", "to": "##s", "value": 1}, {"from": "lead", "to": "un", "value": 1}, {"from": "lead", "to": "##nal a, l", "value": 1}, {"from": "lead", "to": "epigenetic modification,", "value": 1}, {"from": "lead", "to": "of medicine,", "value": 1}, {"from": "triple", "to": "of medicine, universitas indon", "value": 1}, {"from": "triple", "to": "cilities - imeri,", "value": 1}, {"from": "triple", "to": "##a. breast cancer sub", "value": 1}, {"from": "triple", "to": "##umi", "value": 1}, {"from": "triple", "to": "##ivers", "value": 1}, {"from": "triple", "to": "to misclassification. dna methylation", "value": 1}, {"from": "triple", "to": "##s", "value": 1}, {"from": "triple", "to": "un", "value": 1}, {"from": "triple", "to": "##nal a, l", "value": 1}, {"from": "triple", "to": "epigenetic modification,", "value": 1}, {"from": "triple", "to": "of medicine,", "value": 1}, {"from": "of medicine, universitas indon", "to": "cilities - imeri,", "value": 1}, {"from": "of medicine, universitas indon", "to": "##a. breast cancer sub", "value": 1}, {"from": "of medicine, universitas indon", "to": "##umi", "value": 1}, {"from": "of medicine, universitas indon", "to": "##ivers", "value": 1}, {"from": "of medicine, universitas indon", "to": "to misclassification. dna methylation", "value": 1}, {"from": "of medicine, universitas indon", "to": "##s", "value": 1}, {"from": "of medicine, universitas indon", "to": "un", "value": 1}, {"from": "of medicine, universitas indon", "to": "##nal a, l", "value": 1}, {"from": "of medicine, universitas indon", "to": "epigenetic modification,", "value": 1}, {"from": "of medicine, universitas indon", "to": "of medicine,", "value": 1}, {"from": "of medicine, universitas indon", "to": "), hashim", "value": 1}, {"from": "of medicine, universitas indon", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "of medicine, universitas indon", "to": ") drug development research cluster, indon", "value": 1}, {"from": "of medicine, universitas indon", "to": "##an medical", "value": 1}, {"from": "of medicine, universitas indon", "to": "indon", "value": 1}, {"from": "of medicine, universitas indon", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "of medicine, universitas indon", "to": "##hibit", "value": 1}, {"from": "of medicine, universitas indon", "to": "na", "value": 1}, {"from": "of medicine, universitas indon", "to": "education", "value": 1}, {"from": "of medicine, universitas indon", "to": "n", "value": 1}, {"from": "of medicine, universitas indon", "to": "3", "value": 1}, {"from": "of medicine, universitas indon", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "of medicine, universitas indon", "to": "##ajrin", "value": 1}, {"from": "of medicine, universitas indon", "to": "), azizah", "value": 1}, {"from": "of medicine, universitas indon", "to": "te", "value": 1}, {"from": "of medicine, universitas indon", "to": "##djo a", "value": 1}, {"from": "of medicine, universitas indon", "to": "##itas", "value": 1}, {"from": "of medicine, universitas indon", "to": "##b", "value": 1}, {"from": "of medicine, universitas indon", "to": "am", "value": 1}, {"from": "of medicine, universitas indon", "to": "nn", "value": 1}, {"from": "of medicine, universitas indon", "to": "of pharmacy, univers", "value": 1}, {"from": "of medicine, universitas indon", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "of medicine, universitas indon", "to": ", indon", "value": 1}, {"from": "of medicine, universitas indon", "to": "and research instit", "value": 1}, {"from": "of medicine, universitas indon", "to": "), ramadanti", "value": 1}, {"from": "of medicine, universitas indon", "to": "52", "value": 1}, {"from": "cilities - imeri,", "to": "##a. breast cancer sub", "value": 1}, {"from": "cilities - imeri,", "to": "##umi", "value": 1}, {"from": "cilities - imeri,", "to": "##ivers", "value": 1}, {"from": "cilities - imeri,", "to": "to misclassification. dna methylation", "value": 1}, {"from": "cilities - imeri,", "to": "##s", "value": 1}, {"from": "cilities - imeri,", "to": "un", "value": 1}, {"from": "cilities - imeri,", "to": "##nal a, l", "value": 1}, {"from": "cilities - imeri,", "to": "epigenetic modification,", "value": 1}, {"from": "cilities - imeri,", "to": "of medicine,", "value": 1}, {"from": "##a. breast cancer sub", "to": "##umi", "value": 1}, {"from": "##a. breast cancer sub", "to": "##ivers", "value": 1}, {"from": "##a. breast cancer sub", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##a. breast cancer sub", "to": "##s", "value": 1}, {"from": "##a. breast cancer sub", "to": "un", "value": 1}, {"from": "##a. breast cancer sub", "to": "##nal a, l", "value": 1}, {"from": "##a. breast cancer sub", "to": "epigenetic modification,", "value": 1}, {"from": "##a. breast cancer sub", "to": "of medicine,", "value": 1}, {"from": "##umi", "to": "##ivers", "value": 1}, {"from": "##umi", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##umi", "to": "##s", "value": 1}, {"from": "##umi", "to": "un", "value": 1}, {"from": "##umi", "to": "##nal a, l", "value": 1}, {"from": "##umi", "to": "epigenetic modification,", "value": 1}, {"from": "##umi", "to": "of medicine,", "value": 1}, {"from": "##umi", "to": "classification of breast cancer : l", "value": 1}, {"from": "##umi", "to": ", h", "value": 1}, {"from": "##umi", "to": "##methylation", "value": 1}, {"from": "##umi", "to": "tion", "value": 1}, {"from": "##umi", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "##umi", "to": "the pt", "value": 1}, {"from": "##umi", "to": ". \u00a9 202", "value": 1}, {"from": "##umi", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "##umi", "to": "##rn2 gene", "value": 1}, {"from": "##umi", "to": "##nal", "value": 1}, {"from": "##umi", "to": "##261 ), and tnbc", "value": 1}, {"from": "##umi", "to": "##p", "value": 1}, {"from": "##umi", "to": "the author", "value": 1}, {"from": "##umi", "to": "bio", "value": 1}, {"from": "##umi", "to": "respectively", "value": 1}, {"from": "##umi", "to": "##marker for each sub", "value": 1}, {"from": "##umi", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##umi", "to": "##yper", "value": 1}, {"from": "##umi", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##umi", "to": "improve", "value": 1}, {"from": "##umi", "to": "##10", "value": 1}, {"from": "##umi", "to": "##5", "value": 1}, {"from": "##umi", "to": "##nal a", "value": 1}, {"from": "##umi", "to": "52", "value": 1}, {"from": "##umi", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "##umi", "to": "in ki", "value": 1}, {"from": "##umi", "to": "##cu", "value": 1}, {"from": "##umi", "to": "t", "value": 1}, {"from": "##umi", "to": "positive", "value": 1}, {"from": "##umi", "to": "##2 -", "value": 1}, {"from": "##umi", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##umi", "to": "##rrence", "value": 1}, {"from": "##umi", "to": "percentage", "value": 1}, {"from": "##umi", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##umi", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##umi", "to": "##nes", "value": 1}, {"from": "##umi", "to": "from l", "value": 1}, {"from": "##umi", "to": "presented", "value": 1}, {"from": "##umi", "to": "re", "value": 1}, {"from": "##umi", "to": "results", "value": 1}, {"from": "##umi", "to": "pam50 - derived risk of", "value": 1}, {"from": "##umi", "to": "her", "value": 1}, {"from": "##umi", "to": "er + /", "value": 1}, {"from": "##umi", "to": "##nal a to normal - like", "value": 1}, {"from": "##umi", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##umi", "to": "cells", "value": 1}, {"from": "##umi", "to": "score", "value": 1}, {"from": "##umi", "to": "change", "value": 1}, {"from": "##umi", "to": "after", "value": 1}, {"from": "##umi", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##umi", "to": "of intrinsic sub", "value": 1}, {"from": "##umi", "to": "p53", "value": 1}, {"from": "##umi", "to": "##is.", "value": 1}, {"from": "##umi", "to": "biomark", "value": 1}, {"from": "##umi", "to": "subtype after", "value": 1}, {"from": "##umi", "to": "net", "value": 1}, {"from": "##umi", "to": "of", "value": 1}, {"from": "##umi", "to": "##c patients", "value": 1}, {"from": "##umi", "to": "net as a putative", "value": 1}, {"from": "##umi", "to": "##umour cellularity size", "value": 1}, {"from": "##umi", "to": "radio", "value": 1}, {"from": "##umi", "to": ") and lower", "value": 1}, {"from": "##umi", "to": "better", "value": 1}, {"from": "##ivers", "to": "to misclassification. dna methylation", "value": 1}, {"from": "##ivers", "to": "##s", "value": 1}, {"from": "##ivers", "to": "un", "value": 1}, {"from": "##ivers", "to": "##nal a, l", "value": 1}, {"from": "##ivers", "to": "epigenetic modification,", "value": 1}, {"from": "##ivers", "to": "of medicine,", "value": 1}, {"from": "to misclassification. dna methylation", "to": "##s", "value": 1}, {"from": "to misclassification. dna methylation", "to": "un", "value": 1}, {"from": "to misclassification. dna methylation", "to": "##nal a, l", "value": 1}, {"from": "to misclassification. dna methylation", "to": "epigenetic modification,", "value": 1}, {"from": "to misclassification. dna methylation", "to": "of medicine,", "value": 1}, {"from": "##s", "to": "un", "value": 1}, {"from": "##s", "to": "##nal a, l", "value": 1}, {"from": "##s", "to": "epigenetic modification,", "value": 1}, {"from": "##s", "to": "of medicine,", "value": 1}, {"from": "un", "to": "##nal a, l", "value": 1}, {"from": "un", "to": "epigenetic modification,", "value": 1}, {"from": "un", "to": "of medicine,", "value": 1}, {"from": "##nal a, l", "to": "epigenetic modification,", "value": 1}, {"from": "##nal a, l", "to": "of medicine,", "value": 1}, {"from": "epigenetic modification,", "to": "of medicine,", "value": 1}, {"from": "classification of breast cancer : l", "to": ", h", "value": 1}, {"from": "classification of breast cancer : l", "to": "##methylation", "value": 1}, {"from": "classification of breast cancer : l", "to": "tion", "value": 1}, {"from": "classification of breast cancer : l", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "classification of breast cancer : l", "to": "the pt", "value": 1}, {"from": "classification of breast cancer : l", "to": ". \u00a9 202", "value": 1}, {"from": "classification of breast cancer : l", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "classification of breast cancer : l", "to": "##rn2 gene", "value": 1}, {"from": "classification of breast cancer : l", "to": "##nal", "value": 1}, {"from": "classification of breast cancer : l", "to": "##261 ), and tnbc", "value": 1}, {"from": "classification of breast cancer : l", "to": "##p", "value": 1}, {"from": "classification of breast cancer : l", "to": "the author", "value": 1}, {"from": "classification of breast cancer : l", "to": "bio", "value": 1}, {"from": "classification of breast cancer : l", "to": "respectively", "value": 1}, {"from": "classification of breast cancer : l", "to": "##marker for each sub", "value": 1}, {"from": "classification of breast cancer : l", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "classification of breast cancer : l", "to": "##yper", "value": 1}, {"from": "classification of breast cancer : l", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "classification of breast cancer : l", "to": "improve", "value": 1}, {"from": "classification of breast cancer : l", "to": "##10", "value": 1}, {"from": "classification of breast cancer : l", "to": "##5", "value": 1}, {"from": "classification of breast cancer : l", "to": "##nal a", "value": 1}, {"from": "classification of breast cancer : l", "to": "52", "value": 1}, {"from": ", h", "to": "##methylation", "value": 1}, {"from": ", h", "to": "tion", "value": 1}, {"from": ", h", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": ", h", "to": "the pt", "value": 1}, {"from": ", h", "to": ". \u00a9 202", "value": 1}, {"from": ", h", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": ", h", "to": "##rn2 gene", "value": 1}, {"from": ", h", "to": "##nal", "value": 1}, {"from": ", h", "to": "##261 ), and tnbc", "value": 1}, {"from": ", h", "to": "##p", "value": 1}, {"from": ", h", "to": "the author", "value": 1}, {"from": ", h", "to": "bio", "value": 1}, {"from": ", h", "to": "respectively", "value": 1}, {"from": ", h", "to": "##marker for each sub", "value": 1}, {"from": ", h", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": ", h", "to": "##yper", "value": 1}, {"from": ", h", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": ", h", "to": "improve", "value": 1}, {"from": ", h", "to": "##10", "value": 1}, {"from": ", h", "to": "##5", "value": 1}, {"from": ", h", "to": "##nal a", "value": 1}, {"from": ", h", "to": "52", "value": 1}, {"from": "##methylation", "to": "tion", "value": 1}, {"from": "##methylation", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "##methylation", "to": "the pt", "value": 1}, {"from": "##methylation", "to": ". \u00a9 202", "value": 1}, {"from": "##methylation", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "##methylation", "to": "##rn2 gene", "value": 1}, {"from": "##methylation", "to": "##nal", "value": 1}, {"from": "##methylation", "to": "##261 ), and tnbc", "value": 1}, {"from": "##methylation", "to": "##p", "value": 1}, {"from": "##methylation", "to": "the author", "value": 1}, {"from": "##methylation", "to": "bio", "value": 1}, {"from": "##methylation", "to": "respectively", "value": 1}, {"from": "##methylation", "to": "##marker for each sub", "value": 1}, {"from": "##methylation", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##methylation", "to": "##yper", "value": 1}, {"from": "##methylation", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##methylation", "to": "improve", "value": 1}, {"from": "##methylation", "to": "##10", "value": 1}, {"from": "##methylation", "to": "##5", "value": 1}, {"from": "##methylation", "to": "##nal a", "value": 1}, {"from": "##methylation", "to": "52", "value": 1}, {"from": "tion", "to": "##nal b subtypes, with accuracies of 75 % and 76 %,", "value": 1}, {"from": "tion", "to": "the pt", "value": 1}, {"from": "tion", "to": ". \u00a9 202", "value": 1}, {"from": "tion", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "tion", "to": "##rn2 gene", "value": 1}, {"from": "tion", "to": "##nal", "value": 1}, {"from": "tion", "to": "##261 ), and tnbc", "value": 1}, {"from": "tion", "to": "##p", "value": 1}, {"from": "tion", "to": "the author", "value": 1}, {"from": "tion", "to": "bio", "value": 1}, {"from": "tion", "to": "respectively", "value": 1}, {"from": "tion", "to": "##marker for each sub", "value": 1}, {"from": "tion", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "tion", "to": "##yper", "value": 1}, {"from": "tion", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "tion", "to": "improve", "value": 1}, {"from": "tion", "to": "##10", "value": 1}, {"from": "tion", "to": "##5", "value": 1}, {"from": "tion", "to": "##nal a", "value": 1}, {"from": "tion", "to": "52", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "the pt", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": ". \u00a9 202", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##rn2 gene", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##nal", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##261 ), and tnbc", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##p", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "the author", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "bio", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "respectively", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##marker for each sub", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##yper", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "improve", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##10", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##5", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "##nal a", "value": 1}, {"from": "##nal b subtypes, with accuracies of 75 % and 76 %,", "to": "52", "value": 1}, {"from": "the pt", "to": ". \u00a9 202", "value": 1}, {"from": "the pt", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": "the pt", "to": "##rn2 gene", "value": 1}, {"from": "the pt", "to": "##nal", "value": 1}, {"from": "the pt", "to": "##261 ), and tnbc", "value": 1}, {"from": "the pt", "to": "##p", "value": 1}, {"from": "the pt", "to": "the author", "value": 1}, {"from": "the pt", "to": "bio", "value": 1}, {"from": "the pt", "to": "respectively", "value": 1}, {"from": "the pt", "to": "##marker for each sub", "value": 1}, {"from": "the pt", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "the pt", "to": "##yper", "value": 1}, {"from": "the pt", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "the pt", "to": "improve", "value": 1}, {"from": "the pt", "to": "##10", "value": 1}, {"from": "the pt", "to": "##5", "value": 1}, {"from": "the pt", "to": "##nal a", "value": 1}, {"from": "the pt", "to": "52", "value": 1}, {"from": ". \u00a9 202", "to": "##225 / narra. v5i1. 1364 pmcid", "value": 1}, {"from": ". \u00a9 202", "to": "##rn2 gene", "value": 1}, {"from": ". \u00a9 202", "to": "##nal", "value": 1}, {"from": ". \u00a9 202", "to": "##261 ), and tnbc", "value": 1}, {"from": ". \u00a9 202", "to": "##p", "value": 1}, {"from": ". \u00a9 202", "to": "the author", "value": 1}, {"from": ". \u00a9 202", "to": "bio", "value": 1}, {"from": ". \u00a9 202", "to": "respectively", "value": 1}, {"from": ". \u00a9 202", "to": "##marker for each sub", "value": 1}, {"from": ". \u00a9 202", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": ". \u00a9 202", "to": "##yper", "value": 1}, {"from": ". \u00a9 202", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": ". \u00a9 202", "to": "improve", "value": 1}, {"from": ". \u00a9 202", "to": "##10", "value": 1}, {"from": ". \u00a9 202", "to": "##5", "value": 1}, {"from": ". \u00a9 202", "to": "##nal a", "value": 1}, {"from": ". \u00a9 202", "to": "52", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##rn2 gene", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##nal", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##261 ), and tnbc", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##p", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "the author", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "bio", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "respectively", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##marker for each sub", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##yper", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "improve", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##10", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##5", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "##nal a", "value": 1}, {"from": "##225 / narra. v5i1. 1364 pmcid", "to": "52", "value": 1}, {"from": "##rn2 gene", "to": "##nal", "value": 1}, {"from": "##rn2 gene", "to": "##261 ), and tnbc", "value": 1}, {"from": "##rn2 gene", "to": "##p", "value": 1}, {"from": "##rn2 gene", "to": "the author", "value": 1}, {"from": "##rn2 gene", "to": "bio", "value": 1}, {"from": "##rn2 gene", "to": "respectively", "value": 1}, {"from": "##rn2 gene", "to": "##marker for each sub", "value": 1}, {"from": "##rn2 gene", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##rn2 gene", "to": "##yper", "value": 1}, {"from": "##rn2 gene", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##rn2 gene", "to": "improve", "value": 1}, {"from": "##rn2 gene", "to": "##10", "value": 1}, {"from": "##rn2 gene", "to": "##5", "value": 1}, {"from": "##rn2 gene", "to": "##nal a", "value": 1}, {"from": "##rn2 gene", "to": "52", "value": 1}, {"from": "##nal", "to": "##261 ), and tnbc", "value": 1}, {"from": "##nal", "to": "##p", "value": 1}, {"from": "##nal", "to": "the author", "value": 1}, {"from": "##nal", "to": "bio", "value": 1}, {"from": "##nal", "to": "respectively", "value": 1}, {"from": "##nal", "to": "##marker for each sub", "value": 1}, {"from": "##nal", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##nal", "to": "##yper", "value": 1}, {"from": "##nal", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##nal", "to": "improve", "value": 1}, {"from": "##nal", "to": "##10", "value": 1}, {"from": "##nal", "to": "##5", "value": 1}, {"from": "##nal", "to": "##nal a", "value": 1}, {"from": "##nal", "to": "52", "value": 1}, {"from": "##261 ), and tnbc", "to": "##p", "value": 1}, {"from": "##261 ), and tnbc", "to": "the author", "value": 1}, {"from": "##261 ), and tnbc", "to": "bio", "value": 1}, {"from": "##261 ), and tnbc", "to": "respectively", "value": 1}, {"from": "##261 ), and tnbc", "to": "##marker for each sub", "value": 1}, {"from": "##261 ), and tnbc", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##261 ), and tnbc", "to": "##yper", "value": 1}, {"from": "##261 ), and tnbc", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##261 ), and tnbc", "to": "improve", "value": 1}, {"from": "##261 ), and tnbc", "to": "##10", "value": 1}, {"from": "##261 ), and tnbc", "to": "##5", "value": 1}, {"from": "##261 ), and tnbc", "to": "##nal a", "value": 1}, {"from": "##261 ), and tnbc", "to": "52", "value": 1}, {"from": "##p", "to": "the author", "value": 1}, {"from": "##p", "to": "bio", "value": 1}, {"from": "##p", "to": "respectively", "value": 1}, {"from": "##p", "to": "##marker for each sub", "value": 1}, {"from": "##p", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##p", "to": "##yper", "value": 1}, {"from": "##p", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##p", "to": "improve", "value": 1}, {"from": "##p", "to": "##10", "value": 1}, {"from": "##p", "to": "##5", "value": 1}, {"from": "##p", "to": "##nal a", "value": 1}, {"from": "##p", "to": "52", "value": 1}, {"from": "##p", "to": "conclusions", "value": 1}, {"from": "##p", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "##p", "to": "10. 113", "value": 1}, {"from": "##p", "to": "interests", "value": 1}, {"from": "##p", "to": ". no commercial re -", "value": 1}, {"from": "##p", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "##p", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "##p", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "##p", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "##p", "to": ": nr receives research support from bm", "value": 1}, {"from": "##p", "to": "use", "value": 1}, {"from": "##p", "to": ": atm deficiency, while com", "value": 1}, {"from": "##p", "to": "does", "value": 1}, {"from": "##p", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "##p", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##p", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "the author", "to": "bio", "value": 1}, {"from": "the author", "to": "respectively", "value": 1}, {"from": "the author", "to": "##marker for each sub", "value": 1}, {"from": "the author", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "the author", "to": "##yper", "value": 1}, {"from": "the author", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "the author", "to": "improve", "value": 1}, {"from": "the author", "to": "##10", "value": 1}, {"from": "the author", "to": "##5", "value": 1}, {"from": "the author", "to": "##nal a", "value": 1}, {"from": "the author", "to": "52", "value": 1}, {"from": "bio", "to": "respectively", "value": 1}, {"from": "bio", "to": "##marker for each sub", "value": 1}, {"from": "bio", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "bio", "to": "##yper", "value": 1}, {"from": "bio", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "bio", "to": "improve", "value": 1}, {"from": "bio", "to": "##10", "value": 1}, {"from": "bio", "to": "##5", "value": 1}, {"from": "bio", "to": "##nal a", "value": 1}, {"from": "bio", "to": "52", "value": 1}, {"from": "bio", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "bio", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "bio", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "bio", "to": ". 108", "value": 1}, {"from": "bio", "to": "jun might", "value": 1}, {"from": "bio", "to": "##0", "value": 1}, {"from": "bio", "to": "expression.", "value": 1}, {"from": "bio", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "bio", "to": "##na ss", "value": 1}, {"from": "bio", "to": "##v", "value": 1}, {"from": "bio", "to": "##un", "value": 1}, {"from": "bio", "to": "##gno", "value": 1}, {"from": "bio", "to": "activity positively correlated with", "value": 1}, {"from": "bio", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "bio", "to": ". 17305 /", "value": 1}, {"from": "bio", "to": "luki", "value": 1}, {"from": "bio", "to": "##v vi", "value": 1}, {"from": "bio", "to": "logino", "value": 1}, {"from": "bio", "to": "was", "value": 1}, {"from": "bio", "to": "may directly interact with", "value": 1}, {"from": "bio", "to": "serve as a valuable pro", "value": 1}, {"from": "bio", "to": "##tatin", "value": 1}, {"from": "bio", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "bio", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "bio", "to": "expression. as such,", "value": 1}, {"from": "bio", "to": "significantly", "value": 1}, {"from": "bio", "to": "jun", "value": 1}, {"from": "bio", "to": "##nina", "value": 1}, {"from": "bio", "to": "pro", "value": 1}, {"from": "bio", "to": "down", "value": 1}, {"from": "bio", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "bio", "to": "##rio de v", "value": 1}, {"from": "bio", "to": "t", "value": 2}, {"from": "bio", "to": "##kolog", "value": 1}, {"from": "bio", "to": ", san", "value": 1}, {"from": "bio", "to": "##it", "value": 1}, {"from": "bio", "to": ") health", "value": 2}, {"from": "bio", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "bio", "to": "##iba", "value": 1}, {"from": "bio", "to": "##ialdea", "value": 1}, {"from": "bio", "to": "##gipuzkoa", "value": 2}, {"from": "bio", "to": "##ko", "value": 1}, {"from": "bio", "to": "##obe", "value": 1}, {"from": "bio", "to": "se", "value": 1}, {"from": "bio", "to": "##in", "value": 1}, {"from": "bio", "to": "##gi", "value": 2}, {"from": "bio", "to": "##tian,", "value": 2}, {"from": "bio", "to": ") hospital clinico univers", "value": 1}, {"from": "bio", "to": "##r 12, madrid,", "value": 1}, {"from": "bio", "to": "spain", "value": 2}, {"from": "bio", "to": "##ale", "value": 1}, {"from": "bio", "to": "##a", "value": 1}, {"from": "bio", "to": "##ute", "value": 1}, {"from": "bio", "to": "##ikoa,", "value": 1}, {"from": "bio", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "bio", "to": "##donost", "value": 2}, {"from": "bio", "to": ") hospital oct", "value": 1}, {"from": "bio", "to": "research institute", "value": 2}, {"from": "bio", "to": "institute", "value": 1}, {"from": "bio", "to": "sa", "value": 2}, {"from": "bio", "to": "sebas", "value": 2}, {"from": "bio", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "bio", "to": "##ita", "value": 1}, {"from": "bio", "to": ", v", "value": 1}, {"from": "bio", "to": "11", "value": 1}, {"from": "bio", "to": "##ps, barcelon", "value": 1}, {"from": "bio", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "bio", "to": "##n", "value": 2}, {"from": "bio", "to": "##pu", "value": 2}, {"from": "bio", "to": "sebastian", "value": 2}, {"from": "bio", "to": "; gip", "value": 1}, {"from": "bio", "to": "- on", "value": 1}, {"from": "bio", "to": "7 ) valencia oncology", "value": 1}, {"from": "bio", "to": "##ncia,", "value": 1}, {"from": "bio", "to": "##uz", "value": 1}, {"from": "bio", "to": "##ia", "value": 2}, {"from": "bio", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "bio", "to": "- onkologikoa, san", "value": 1}, {"from": "bio", "to": "##z", "value": 1}, {"from": "bio", "to": "##bastian, spa", "value": 1}, {"from": "bio", "to": "12", "value": 1}, {"from": "bio", "to": "after net", "value": 1}, {"from": "bio", "to": "a significant", "value": 1}, {"from": "bio", "to": "time", "value": 1}, {"from": "bio", "to": "offers the opportunity of", "value": 1}, {"from": "bio", "to": "##ip", "value": 1}, {"from": "bio", "to": "however", "value": 1}, {"from": "bio", "to": "background", "value": 1}, {"from": "bio", "to": "##re population of", "value": 1}, {"from": "bio", "to": "negative breast", "value": 1}, {"from": "bio", "to": "barrier", "value": 1}, {"from": "bio", "to": "clinical", "value": 1}, {"from": "bio", "to": "##2 -", "value": 1}, {"from": "bio", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "bio", "to": "##zkoa", "value": 1}, {"from": "bio", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "bio", "to": "##donostia ) health", "value": 1}, {"from": "bio", "to": "cancer", "value": 1}, {"from": "bio", "to": "##uzkoa. eus.", "value": 1}, {"from": "bio", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "bio", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "bio", "to": "real", "value": 1}, {"from": "bio", "to": "personal", "value": 1}, {"from": "bio", "to": "##ised therapy.", "value": 1}, {"from": "bio", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "bio", "to": "##cent", "value": 1}, {"from": "bio", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "bio", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "bio", "to": "her", "value": 1}, {"from": "bio", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "bio", "to": "##n sebastian,", "value": 1}, {"from": "bio", "to": "##umour response", "value": 1}, {"from": "bio", "to": "a,", "value": 1}, {"from": "bio", "to": "##uc", "value": 1}, {"from": "bio", "to": "13", "value": 1}, {"from": "bio", "to": ", the lack of reprod", "value": 1}, {"from": "bio", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "bio", "to": "##c ) allows", "value": 1}, {"from": "bio", "to": "##gnosis", "value": 1}, {"from": "bio", "to": "- g", "value": 1}, {"from": "respectively", "to": "##marker for each sub", "value": 1}, {"from": "respectively", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "respectively", "to": "##yper", "value": 1}, {"from": "respectively", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "respectively", "to": "improve", "value": 1}, {"from": "respectively", "to": "##10", "value": 1}, {"from": "respectively", "to": "##5", "value": 1}, {"from": "respectively", "to": "##nal a", "value": 1}, {"from": "respectively", "to": "52", "value": 1}, {"from": "respectively", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "respectively", "to": "benefit", "value": 1}, {"from": "respectively", "to": "##26, 000 ;", "value": 1}, {"from": "respectively", "to": "effective", "value": 1}, {"from": "respectively", "to": "it was cost - saving", "value": 1}, {"from": "respectively", "to": "threshold", "value": 1}, {"from": "respectively", "to": "- 435, 677 )", "value": 1}, {"from": "respectively", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "respectively", "to": "##aly", "value": 1}, {"from": "respectively", "to": "in the", "value": 1}, {"from": "respectively", "to": "cost", "value": 1}, {"from": "respectively", "to": "\u20ac", "value": 1}, {"from": "respectively", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "respectively", "to": "- 620170,", "value": 1}, {"from": "respectively", "to": "##r )", "value": 1}, {"from": "respectively", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "respectively", "to": "societal perspective", "value": 1}, {"from": "respectively", "to": "candidates, the strategy", "value": 1}, {"from": "respectively", "to": "cost - effective", "value": 1}, {"from": "respectively", "to": "incre", "value": 1}, {"from": "respectively", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "respectively", "to": "by", "value": 1}, {"from": "respectively", "to": "##mental", "value": 1}, {"from": "respectively", "to": "the cost -", "value": 1}, {"from": "respectively", "to": "was cost - effective", "value": 1}, {"from": "respectively", "to": "above", "value": 1}, {"from": "respectively", "to": "results", "value": 1}, {"from": "respectively", "to": "was", "value": 1}, {"from": "respectively", "to": "was obtained from statistics norway.", "value": 1}, {"from": "respectively", "to": "per quality - adjusted life -", "value": 1}, {"from": "respectively", "to": "was cost - saving", "value": 1}, {"from": "respectively", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "respectively", "to": "chemotherapy", "value": 1}, {"from": "respectively", "to": "in both the healthcare", "value": 1}, {"from": "respectively", "to": "years", "value": 1}, {"from": "respectively", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "respectively", "to": "- per q", "value": 1}, {"from": "respectively", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "respectively", "to": ". conclusions", "value": 1}, {"from": "respectively", "to": ". selecting patient", "value": 1}, {"from": "respectively", "to": "ice", "value": 1}, {"from": "respectively", "to": "##r", "value": 1}, {"from": "respectively", "to": "##8884 and", "value": 1}, {"from": "respectively", "to": "gained", "value": 1}, {"from": "respectively", "to": "the emit", "value": 1}, {"from": "respectively", "to": "records. including all pn0 patients", "value": 1}, {"from": "respectively", "to": "sector", "value": 1}, {"from": "respectively", "to": "not", "value": 1}, {"from": "##marker for each sub", "to": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "value": 1}, {"from": "##marker for each sub", "to": "##yper", "value": 1}, {"from": "##marker for each sub", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##marker for each sub", "to": "improve", "value": 1}, {"from": "##marker for each sub", "to": "##10", "value": 1}, {"from": "##marker for each sub", "to": "##5", "value": 1}, {"from": "##marker for each sub", "to": "##nal a", "value": 1}, {"from": "##marker for each sub", "to": "52", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "##yper", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "improve", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "##10", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "##5", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "##nal a", "value": 1}, {"from": "the patient \u0027 s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l", "to": "52", "value": 1}, {"from": "##yper", "to": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "value": 1}, {"from": "##yper", "to": "improve", "value": 1}, {"from": "##yper", "to": "##10", "value": 1}, {"from": "##yper", "to": "##5", "value": 1}, {"from": "##yper", "to": "##nal a", "value": 1}, {"from": "##yper", "to": "52", "value": 1}, {"from": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "to": "improve", "value": 1}, {"from": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "to": "##10", "value": 1}, {"from": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "to": "##5", "value": 1}, {"from": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "to": "##nal a", "value": 1}, {"from": "##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to", "to": "52", "value": 1}, {"from": "improve", "to": "##10", "value": 1}, {"from": "improve", "to": "##5", "value": 1}, {"from": "improve", "to": "##nal a", "value": 1}, {"from": "improve", "to": "52", "value": 1}, {"from": "##10", "to": "##5", "value": 1}, {"from": "##10", "to": "##nal a", "value": 1}, {"from": "##10", "to": "52", "value": 1}, {"from": "##5", "to": "##nal a", "value": 1}, {"from": "##5", "to": "52", "value": 1}, {"from": "##5", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "##5", "to": "t", "value": 1}, {"from": "##5", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "##5", "to": "##6 /", "value": 1}, {"from": "##5", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "##5", "to": "be validated in independent cohorts,", "value": 1}, {"from": "##5", "to": "cost - effectiveness", "value": 1}, {"from": "##5", "to": "##ers of response to net and pro", "value": 1}, {"from": "##5", "to": "10. 101", "value": 1}, {"from": "##5", "to": "help", "value": 1}, {"from": "##5", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "##5", "to": "##sis, which", "value": 1}, {"from": "##5", "to": "##gno", "value": 1}, {"from": "##5", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "##5", "to": "##lin", "value": 1}, {"from": "##5", "to": "should", "value": 1}, {"from": "##5", "to": "202", "value": 1}, {"from": "##5", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##5", "to": "helping to the", "value": 1}, {"from": "##5", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##5", "to": "implementation of net", "value": 1}, {"from": "##5", "to": "##mark", "value": 1}, {"from": "##5", "to": "##ranon.", "value": 1}, {"from": "##5", "to": ". clbc. 202", "value": 1}, {"from": "##5", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##5", "to": "##5.", "value": 1}, {"from": "##nal a", "to": "52", "value": 1}, {"from": "52", "to": "), hashim", "value": 1}, {"from": "52", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "52", "to": ") drug development research cluster, indon", "value": 1}, {"from": "52", "to": "##an medical", "value": 1}, {"from": "52", "to": "indon", "value": 1}, {"from": "52", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "52", "to": "##hibit", "value": 1}, {"from": "52", "to": "na", "value": 1}, {"from": "52", "to": "education", "value": 1}, {"from": "52", "to": "n", "value": 1}, {"from": "52", "to": "3", "value": 1}, {"from": "52", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "52", "to": "##ajrin", "value": 1}, {"from": "52", "to": "), azizah", "value": 1}, {"from": "52", "to": "te", "value": 1}, {"from": "52", "to": "##djo a", "value": 1}, {"from": "52", "to": "##itas", "value": 1}, {"from": "52", "to": "##b", "value": 1}, {"from": "52", "to": "am", "value": 1}, {"from": "52", "to": "nn", "value": 1}, {"from": "52", "to": "of pharmacy, univers", "value": 1}, {"from": "52", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "52", "to": ", indon", "value": 1}, {"from": "52", "to": "and research instit", "value": 1}, {"from": "52", "to": "), ramadanti", "value": 1}, {"from": "52", "to": "##life", "value": 1}, {"from": "52", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "52", "to": "##ion of p21", "value": 1}, {"from": "52", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "52", "to": "##in - mediated anti -", "value": 1}, {"from": "52", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "52", "to": "1 ), abdelkrim g", "value": 1}, {"from": "52", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "52", "to": "cancer effects. foda my", "value": 1}, {"from": "52", "to": "##press", "value": 1}, {"from": "52", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "52", "to": "##tat", "value": 1}, {"from": "52", "to": "jun", "value": 1}, {"from": "52", "to": "2 ), salem ml", "value": 1}, {"from": "52", "to": "in atorvas", "value": 1}, {"from": "52", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "), hashim", "to": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "value": 1}, {"from": "), hashim", "to": ") drug development research cluster, indon", "value": 1}, {"from": "), hashim", "to": "##an medical", "value": 1}, {"from": "), hashim", "to": "indon", "value": 1}, {"from": "), hashim", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "), hashim", "to": "##hibit", "value": 1}, {"from": "), hashim", "to": "na", "value": 1}, {"from": "), hashim", "to": "education", "value": 1}, {"from": "), hashim", "to": "n", "value": 1}, {"from": "), hashim", "to": "3", "value": 1}, {"from": "), hashim", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "), hashim", "to": "##ajrin", "value": 1}, {"from": "), hashim", "to": "), azizah", "value": 1}, {"from": "), hashim", "to": "te", "value": 1}, {"from": "), hashim", "to": "##djo a", "value": 1}, {"from": "), hashim", "to": "##itas", "value": 1}, {"from": "), hashim", "to": "##b", "value": 1}, {"from": "), hashim", "to": "am", "value": 1}, {"from": "), hashim", "to": "nn", "value": 1}, {"from": "), hashim", "to": "of pharmacy, univers", "value": 1}, {"from": "), hashim", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "), hashim", "to": ", indon", "value": 1}, {"from": "), hashim", "to": "and research instit", "value": 1}, {"from": "), hashim", "to": "), ramadanti", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": ") drug development research cluster, indon", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##an medical", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "indon", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##hibit", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "na", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "education", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "n", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "3", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##ajrin", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "), azizah", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "te", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##djo a", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##itas", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "##b", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "am", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "nn", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "of pharmacy, univers", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": ", indon", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "and research instit", "value": 1}, {"from": "##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase", "to": "), ramadanti", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##an medical", "value": 1}, {"from": ") drug development research cluster, indon", "to": "indon", "value": 1}, {"from": ") drug development research cluster, indon", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##hibit", "value": 1}, {"from": ") drug development research cluster, indon", "to": "na", "value": 1}, {"from": ") drug development research cluster, indon", "to": "education", "value": 1}, {"from": ") drug development research cluster, indon", "to": "n", "value": 1}, {"from": ") drug development research cluster, indon", "to": "3", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##ajrin", "value": 1}, {"from": ") drug development research cluster, indon", "to": "), azizah", "value": 1}, {"from": ") drug development research cluster, indon", "to": "te", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##djo a", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##itas", "value": 1}, {"from": ") drug development research cluster, indon", "to": "##b", "value": 1}, {"from": ") drug development research cluster, indon", "to": "am", "value": 1}, {"from": ") drug development research cluster, indon", "to": "nn", "value": 1}, {"from": ") drug development research cluster, indon", "to": "of pharmacy, univers", "value": 1}, {"from": ") drug development research cluster, indon", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": ") drug development research cluster, indon", "to": ", indon", "value": 1}, {"from": ") drug development research cluster, indon", "to": "and research instit", "value": 1}, {"from": ") drug development research cluster, indon", "to": "), ramadanti", "value": 1}, {"from": "##an medical", "to": "indon", "value": 1}, {"from": "##an medical", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "##an medical", "to": "##hibit", "value": 1}, {"from": "##an medical", "to": "na", "value": 1}, {"from": "##an medical", "to": "education", "value": 1}, {"from": "##an medical", "to": "n", "value": 1}, {"from": "##an medical", "to": "3", "value": 1}, {"from": "##an medical", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##an medical", "to": "##ajrin", "value": 1}, {"from": "##an medical", "to": "), azizah", "value": 1}, {"from": "##an medical", "to": "te", "value": 1}, {"from": "##an medical", "to": "##djo a", "value": 1}, {"from": "##an medical", "to": "##itas", "value": 1}, {"from": "##an medical", "to": "##b", "value": 1}, {"from": "##an medical", "to": "am", "value": 1}, {"from": "##an medical", "to": "nn", "value": 1}, {"from": "##an medical", "to": "of pharmacy, univers", "value": 1}, {"from": "##an medical", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##an medical", "to": ", indon", "value": 1}, {"from": "##an medical", "to": "and research instit", "value": 1}, {"from": "##an medical", "to": "), ramadanti", "value": 1}, {"from": "indon", "to": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "value": 1}, {"from": "indon", "to": "##hibit", "value": 1}, {"from": "indon", "to": "na", "value": 1}, {"from": "indon", "to": "education", "value": 1}, {"from": "indon", "to": "n", "value": 1}, {"from": "indon", "to": "3", "value": 1}, {"from": "indon", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "indon", "to": "##ajrin", "value": 1}, {"from": "indon", "to": "), azizah", "value": 1}, {"from": "indon", "to": "te", "value": 1}, {"from": "indon", "to": "##djo a", "value": 1}, {"from": "indon", "to": "##itas", "value": 1}, {"from": "indon", "to": "##b", "value": 1}, {"from": "indon", "to": "am", "value": 1}, {"from": "indon", "to": "nn", "value": 1}, {"from": "indon", "to": "of pharmacy, univers", "value": 1}, {"from": "indon", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "indon", "to": ", indon", "value": 1}, {"from": "indon", "to": "and research instit", "value": 1}, {"from": "indon", "to": "), ramadanti", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##hibit", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "na", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "education", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "n", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "3", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##ajrin", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "), azizah", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "te", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##djo a", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##itas", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "##b", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "am", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "nn", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "of pharmacy, univers", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": ", indon", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "and research instit", "value": 1}, {"from": ": pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5", "to": "), ramadanti", "value": 1}, {"from": "##hibit", "to": "na", "value": 1}, {"from": "##hibit", "to": "education", "value": 1}, {"from": "##hibit", "to": "n", "value": 1}, {"from": "##hibit", "to": "3", "value": 1}, {"from": "##hibit", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "##hibit", "to": "##ajrin", "value": 1}, {"from": "##hibit", "to": "), azizah", "value": 1}, {"from": "##hibit", "to": "te", "value": 1}, {"from": "##hibit", "to": "##djo a", "value": 1}, {"from": "##hibit", "to": "##itas", "value": 1}, {"from": "##hibit", "to": "##b", "value": 1}, {"from": "##hibit", "to": "am", "value": 1}, {"from": "##hibit", "to": "nn", "value": 1}, {"from": "##hibit", "to": "of pharmacy, univers", "value": 1}, {"from": "##hibit", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##hibit", "to": ", indon", "value": 1}, {"from": "##hibit", "to": "and research instit", "value": 1}, {"from": "##hibit", "to": "), ramadanti", "value": 1}, {"from": "na", "to": "education", "value": 1}, {"from": "na", "to": "n", "value": 1}, {"from": "na", "to": "3", "value": 1}, {"from": "na", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "na", "to": "##ajrin", "value": 1}, {"from": "na", "to": "), azizah", "value": 1}, {"from": "na", "to": "te", "value": 1}, {"from": "na", "to": "##djo a", "value": 1}, {"from": "na", "to": "##itas", "value": 1}, {"from": "na", "to": "##b", "value": 1}, {"from": "na", "to": "am", "value": 1}, {"from": "na", "to": "nn", "value": 1}, {"from": "na", "to": "of pharmacy, univers", "value": 1}, {"from": "na", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "na", "to": ", indon", "value": 1}, {"from": "na", "to": "and research instit", "value": 1}, {"from": "na", "to": "), ramadanti", "value": 1}, {"from": "education", "to": "n", "value": 1}, {"from": "education", "to": "3", "value": 1}, {"from": "education", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "education", "to": "##ajrin", "value": 1}, {"from": "education", "to": "), azizah", "value": 1}, {"from": "education", "to": "te", "value": 1}, {"from": "education", "to": "##djo a", "value": 1}, {"from": "education", "to": "##itas", "value": 1}, {"from": "education", "to": "##b", "value": 1}, {"from": "education", "to": "am", "value": 1}, {"from": "education", "to": "nn", "value": 1}, {"from": "education", "to": "of pharmacy, univers", "value": 1}, {"from": "education", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "education", "to": ", indon", "value": 1}, {"from": "education", "to": "and research instit", "value": 1}, {"from": "education", "to": "), ramadanti", "value": 1}, {"from": "n", "to": "3", "value": 1}, {"from": "n", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "n", "to": "##ajrin", "value": 1}, {"from": "n", "to": "), azizah", "value": 1}, {"from": "n", "to": "te", "value": 1}, {"from": "n", "to": "##djo a", "value": 1}, {"from": "n", "to": "##itas", "value": 1}, {"from": "n", "to": "##b", "value": 1}, {"from": "n", "to": "am", "value": 1}, {"from": "n", "to": "nn", "value": 1}, {"from": "n", "to": "of pharmacy, univers", "value": 1}, {"from": "n", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "n", "to": ", indon", "value": 1}, {"from": "n", "to": "and research instit", "value": 1}, {"from": "n", "to": "), ramadanti", "value": 1}, {"from": "3", "to": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "value": 1}, {"from": "3", "to": "##ajrin", "value": 1}, {"from": "3", "to": "), azizah", "value": 1}, {"from": "3", "to": "te", "value": 1}, {"from": "3", "to": "##djo a", "value": 1}, {"from": "3", "to": "##itas", "value": 1}, {"from": "3", "to": "##b", "value": 1}, {"from": "3", "to": "am", "value": 1}, {"from": "3", "to": "nn", "value": 1}, {"from": "3", "to": "of pharmacy, univers", "value": 1}, {"from": "3", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "3", "to": ", indon", "value": 1}, {"from": "3", "to": "and research instit", "value": 1}, {"from": "3", "to": "), ramadanti", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "##ajrin", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "), azizah", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "te", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "##djo a", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "##itas", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "##b", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "am", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "nn", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "of pharmacy, univers", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": ", indon", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "and research instit", "value": 1}, {"from": "##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in", "to": "), ramadanti", "value": 1}, {"from": "##ajrin", "to": "), azizah", "value": 1}, {"from": "##ajrin", "to": "te", "value": 1}, {"from": "##ajrin", "to": "##djo a", "value": 1}, {"from": "##ajrin", "to": "##itas", "value": 1}, {"from": "##ajrin", "to": "##b", "value": 1}, {"from": "##ajrin", "to": "am", "value": 1}, {"from": "##ajrin", "to": "nn", "value": 1}, {"from": "##ajrin", "to": "of pharmacy, univers", "value": 1}, {"from": "##ajrin", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##ajrin", "to": ", indon", "value": 1}, {"from": "##ajrin", "to": "and research instit", "value": 1}, {"from": "##ajrin", "to": "), ramadanti", "value": 1}, {"from": "), azizah", "to": "te", "value": 1}, {"from": "), azizah", "to": "##djo a", "value": 1}, {"from": "), azizah", "to": "##itas", "value": 1}, {"from": "), azizah", "to": "##b", "value": 1}, {"from": "), azizah", "to": "am", "value": 1}, {"from": "), azizah", "to": "nn", "value": 1}, {"from": "), azizah", "to": "of pharmacy, univers", "value": 1}, {"from": "), azizah", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "), azizah", "to": ", indon", "value": 1}, {"from": "), azizah", "to": "and research instit", "value": 1}, {"from": "), azizah", "to": "), ramadanti", "value": 1}, {"from": "te", "to": "##djo a", "value": 1}, {"from": "te", "to": "##itas", "value": 1}, {"from": "te", "to": "##b", "value": 1}, {"from": "te", "to": "am", "value": 1}, {"from": "te", "to": "nn", "value": 1}, {"from": "te", "to": "of pharmacy, univers", "value": 1}, {"from": "te", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "te", "to": ", indon", "value": 1}, {"from": "te", "to": "and research instit", "value": 1}, {"from": "te", "to": "), ramadanti", "value": 1}, {"from": "##djo a", "to": "##itas", "value": 1}, {"from": "##djo a", "to": "##b", "value": 1}, {"from": "##djo a", "to": "am", "value": 1}, {"from": "##djo a", "to": "nn", "value": 1}, {"from": "##djo a", "to": "of pharmacy, univers", "value": 1}, {"from": "##djo a", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##djo a", "to": ", indon", "value": 1}, {"from": "##djo a", "to": "and research instit", "value": 1}, {"from": "##djo a", "to": "), ramadanti", "value": 1}, {"from": "##itas", "to": "##b", "value": 1}, {"from": "##itas", "to": "am", "value": 1}, {"from": "##itas", "to": "nn", "value": 1}, {"from": "##itas", "to": "of pharmacy, univers", "value": 1}, {"from": "##itas", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##itas", "to": ", indon", "value": 1}, {"from": "##itas", "to": "and research instit", "value": 1}, {"from": "##itas", "to": "), ramadanti", "value": 1}, {"from": "##b", "to": "am", "value": 1}, {"from": "##b", "to": "nn", "value": 1}, {"from": "##b", "to": "of pharmacy, univers", "value": 1}, {"from": "##b", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "##b", "to": ", indon", "value": 1}, {"from": "##b", "to": "and research instit", "value": 1}, {"from": "##b", "to": "), ramadanti", "value": 1}, {"from": "##b", "to": "), and the top", "value": 1}, {"from": "##b", "to": "##0", "value": 1}, {"from": "##b", "to": "), a parp", "value": 1}, {"from": "##b", "to": "##point blockade", "value": 1}, {"from": "##b", "to": "etop", "value": 1}, {"from": "##b", "to": "##ide - on", "value": 1}, {"from": "##b", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "##b", "to": "##ide, a top", "value": 1}, {"from": "##b", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##b", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##b", "to": "##ase ii", "value": 1}, {"from": "##b", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##b", "to": "interfer", "value": 1}, {"from": "##b", "to": "fails", "value": 1}, {"from": "##b", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##b", "to": "type", "value": 1}, {"from": "##b", "to": "if", "value": 1}, {"from": "##b", "to": "##fi", "value": 1}, {"from": "##b", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##b", "to": "##oisomer", "value": 1}, {"from": "##b", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##b", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##b", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##b", "to": "does", "value": 1}, {"from": "##b", "to": "##ltration into tumors, and", "value": 1}, {"from": "##b", "to": "##on - stimulated gene", "value": 1}, {"from": "##b", "to": "check", "value": 1}, {"from": "##b", "to": "##on", "value": 1}, {"from": "##b", "to": "inhibitor", "value": 1}, {"from": "am", "to": "nn", "value": 1}, {"from": "am", "to": "of pharmacy, univers", "value": 1}, {"from": "am", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "am", "to": ", indon", "value": 1}, {"from": "am", "to": "and research instit", "value": 1}, {"from": "am", "to": "), ramadanti", "value": 1}, {"from": "nn", "to": "of pharmacy, univers", "value": 1}, {"from": "nn", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "nn", "to": ", indon", "value": 1}, {"from": "nn", "to": "and research instit", "value": 1}, {"from": "nn", "to": "), ramadanti", "value": 1}, {"from": "of pharmacy, univers", "to": ") department of pharmacognosy, phytochemistry, and natural products,", "value": 1}, {"from": "of pharmacy, univers", "to": ", indon", "value": 1}, {"from": "of pharmacy, univers", "to": "and research instit", "value": 1}, {"from": "of pharmacy, univers", "to": "), ramadanti", "value": 1}, {"from": "of pharmacy, univers", "to": "quantitative pcr", "value": 1}, {"from": "of pharmacy, univers", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "of pharmacy, univers", "to": "time", "value": 1}, {"from": "of pharmacy, univers", "to": "##sia", "value": 1}, {"from": "of pharmacy, univers", "to": "regulating the cell", "value": 1}, {"from": "of pharmacy, univers", "to": "ute,", "value": 1}, {"from": "of pharmacy, univers", "to": "##poptosis", "value": 1}, {"from": "of pharmacy, univers", "to": "##cence, making it", "value": 1}, {"from": "of pharmacy, univers", "to": "proliferation", "value": 1}, {"from": "of pharmacy, univers", "to": "and se", "value": 1}, {"from": "of pharmacy, univers", "to": "a", "value": 1}, {"from": "of pharmacy, univers", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "of pharmacy, univers", "to": "target", "value": 1}, {"from": "of pharmacy, univers", "to": "##nes", "value": 1}, {"from": "of pharmacy, univers", "to": "##50 value", "value": 1}, {"from": "of pharmacy, univers", "to": "role in", "value": 1}, {"from": "of pharmacy, univers", "to": "real", "value": 1}, {"from": "of pharmacy, univers", "to": ". the p53 signaling pathway", "value": 1}, {"from": "of pharmacy, univers", "to": ", a", "value": 1}, {"from": "of pharmacy, univers", "to": "key", "value": 1}, {"from": "of pharmacy, univers", "to": ", and", "value": 1}, {"from": "of pharmacy, univers", "to": "plays", "value": 1}, {"from": "of pharmacy, univers", "to": "a critical", "value": 1}, {"from": "of pharmacy, univers", "to": "cycle", "value": 1}, {"from": "of pharmacy, univers", "to": "of downstream genes linked to cell", "value": 1}, {"from": "of pharmacy, univers", "to": "##a, jakarta,", "value": 1}, {"from": "of pharmacy, univers", "to": "##iti", "value": 1}, {"from": "of pharmacy, univers", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "of pharmacy, univers", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "of pharmacy, univers", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "of pharmacy, univers", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "of pharmacy, univers", "to": "on the", "value": 1}, {"from": "of pharmacy, univers", "to": "##ia", "value": 1}, {"from": "of pharmacy, univers", "to": "senes", "value": 1}, {"from": ") department of pharmacognosy, phytochemistry, and natural products,", "to": ", indon", "value": 1}, {"from": ") department of pharmacognosy, phytochemistry, and natural products,", "to": "and research instit", "value": 1}, {"from": ") department of pharmacognosy, phytochemistry, and natural products,", "to": "), ramadanti", "value": 1}, {"from": ", indon", "to": "and research instit", "value": 1}, {"from": ", indon", "to": "), ramadanti", "value": 1}, {"from": "and research instit", "to": "), ramadanti", "value": 1}, {"from": "quantitative pcr", "to": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "value": 1}, {"from": "quantitative pcr", "to": "time", "value": 1}, {"from": "quantitative pcr", "to": "##sia", "value": 1}, {"from": "quantitative pcr", "to": "regulating the cell", "value": 1}, {"from": "quantitative pcr", "to": "ute,", "value": 1}, {"from": "quantitative pcr", "to": "##poptosis", "value": 1}, {"from": "quantitative pcr", "to": "##cence, making it", "value": 1}, {"from": "quantitative pcr", "to": "proliferation", "value": 1}, {"from": "quantitative pcr", "to": "and se", "value": 1}, {"from": "quantitative pcr", "to": "a", "value": 1}, {"from": "quantitative pcr", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "quantitative pcr", "to": "target", "value": 1}, {"from": "quantitative pcr", "to": "##nes", "value": 1}, {"from": "quantitative pcr", "to": "##50 value", "value": 1}, {"from": "quantitative pcr", "to": "role in", "value": 1}, {"from": "quantitative pcr", "to": "real", "value": 1}, {"from": "quantitative pcr", "to": ". the p53 signaling pathway", "value": 1}, {"from": "quantitative pcr", "to": ", a", "value": 1}, {"from": "quantitative pcr", "to": "key", "value": 1}, {"from": "quantitative pcr", "to": ", and", "value": 1}, {"from": "quantitative pcr", "to": "plays", "value": 1}, {"from": "quantitative pcr", "to": "a critical", "value": 1}, {"from": "quantitative pcr", "to": "cycle", "value": 1}, {"from": "quantitative pcr", "to": "of downstream genes linked to cell", "value": 1}, {"from": "quantitative pcr", "to": "##a, jakarta,", "value": 1}, {"from": "quantitative pcr", "to": "##iti", "value": 1}, {"from": "quantitative pcr", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "quantitative pcr", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "quantitative pcr", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "quantitative pcr", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "quantitative pcr", "to": "on the", "value": 1}, {"from": "quantitative pcr", "to": "##ia", "value": 1}, {"from": "quantitative pcr", "to": "senes", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "time", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##sia", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "regulating the cell", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "ute,", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##poptosis", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##cence, making it", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "proliferation", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "and se", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "a", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "target", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##nes", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##50 value", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "role in", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "real", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": ". the p53 signaling pathway", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": ", a", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "key", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": ", and", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "plays", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "a critical", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "cycle", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "of downstream genes linked to cell", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##a, jakarta,", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##iti", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "on the", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "##ia", "value": 1}, {"from": "in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular", "to": "senes", "value": 1}, {"from": "time", "to": "##sia", "value": 1}, {"from": "time", "to": "regulating the cell", "value": 1}, {"from": "time", "to": "ute,", "value": 1}, {"from": "time", "to": "##poptosis", "value": 1}, {"from": "time", "to": "##cence, making it", "value": 1}, {"from": "time", "to": "proliferation", "value": 1}, {"from": "time", "to": "and se", "value": 1}, {"from": "time", "to": "a", "value": 1}, {"from": "time", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "time", "to": "target", "value": 1}, {"from": "time", "to": "##nes", "value": 1}, {"from": "time", "to": "##50 value", "value": 1}, {"from": "time", "to": "role in", "value": 1}, {"from": "time", "to": "real", "value": 2}, {"from": "time", "to": ". the p53 signaling pathway", "value": 1}, {"from": "time", "to": ", a", "value": 1}, {"from": "time", "to": "key", "value": 1}, {"from": "time", "to": ", and", "value": 1}, {"from": "time", "to": "plays", "value": 1}, {"from": "time", "to": "a critical", "value": 1}, {"from": "time", "to": "cycle", "value": 1}, {"from": "time", "to": "of downstream genes linked to cell", "value": 1}, {"from": "time", "to": "##a, jakarta,", "value": 1}, {"from": "time", "to": "##iti", "value": 1}, {"from": "time", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "time", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "time", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "time", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "time", "to": "on the", "value": 1}, {"from": "time", "to": "##ia", "value": 2}, {"from": "time", "to": "senes", "value": 1}, {"from": "time", "to": "12", "value": 1}, {"from": "time", "to": "after net", "value": 1}, {"from": "time", "to": "a significant", "value": 1}, {"from": "time", "to": "offers the opportunity of", "value": 1}, {"from": "time", "to": "##ip", "value": 1}, {"from": "time", "to": "t", "value": 1}, {"from": "time", "to": "however", "value": 1}, {"from": "time", "to": ") health", "value": 1}, {"from": "time", "to": "background", "value": 1}, {"from": "time", "to": "##re population of", "value": 1}, {"from": "time", "to": "negative breast", "value": 1}, {"from": "time", "to": "barrier", "value": 1}, {"from": "time", "to": "##gipuzkoa", "value": 1}, {"from": "time", "to": "clinical", "value": 1}, {"from": "time", "to": "##2 -", "value": 1}, {"from": "time", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "time", "to": "##zkoa", "value": 1}, {"from": "time", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "time", "to": "##gi", "value": 1}, {"from": "time", "to": "##donostia ) health", "value": 1}, {"from": "time", "to": "##tian,", "value": 1}, {"from": "time", "to": "cancer", "value": 1}, {"from": "time", "to": "spain", "value": 1}, {"from": "time", "to": "##uzkoa. eus.", "value": 1}, {"from": "time", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "time", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "time", "to": "personal", "value": 1}, {"from": "time", "to": "##ised therapy.", "value": 1}, {"from": "time", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "time", "to": "##donost", "value": 1}, {"from": "time", "to": "##cent", "value": 1}, {"from": "time", "to": "research institute", "value": 1}, {"from": "time", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "time", "to": "sa", "value": 1}, {"from": "time", "to": "sebas", "value": 1}, {"from": "time", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "time", "to": "her", "value": 1}, {"from": "time", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "time", "to": "##n sebastian,", "value": 1}, {"from": "time", "to": "##umour response", "value": 1}, {"from": "time", "to": "a,", "value": 1}, {"from": "time", "to": "##pu", "value": 1}, {"from": "time", "to": "##n", "value": 1}, {"from": "time", "to": "sebastian", "value": 1}, {"from": "time", "to": "##uc", "value": 1}, {"from": "time", "to": "13", "value": 1}, {"from": "time", "to": ", the lack of reprod", "value": 1}, {"from": "time", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "time", "to": "##c ) allows", "value": 1}, {"from": "time", "to": "##gnosis", "value": 1}, {"from": "time", "to": "- g", "value": 1}, {"from": "##sia", "to": "regulating the cell", "value": 1}, {"from": "##sia", "to": "ute,", "value": 1}, {"from": "##sia", "to": "##poptosis", "value": 1}, {"from": "##sia", "to": "##cence, making it", "value": 1}, {"from": "##sia", "to": "proliferation", "value": 1}, {"from": "##sia", "to": "and se", "value": 1}, {"from": "##sia", "to": "a", "value": 1}, {"from": "##sia", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##sia", "to": "target", "value": 1}, {"from": "##sia", "to": "##nes", "value": 1}, {"from": "##sia", "to": "##50 value", "value": 1}, {"from": "##sia", "to": "role in", "value": 1}, {"from": "##sia", "to": "real", "value": 1}, {"from": "##sia", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##sia", "to": ", a", "value": 1}, {"from": "##sia", "to": "key", "value": 1}, {"from": "##sia", "to": ", and", "value": 1}, {"from": "##sia", "to": "plays", "value": 1}, {"from": "##sia", "to": "a critical", "value": 1}, {"from": "##sia", "to": "cycle", "value": 1}, {"from": "##sia", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##sia", "to": "##a, jakarta,", "value": 1}, {"from": "##sia", "to": "##iti", "value": 1}, {"from": "##sia", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##sia", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##sia", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##sia", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##sia", "to": "on the", "value": 1}, {"from": "##sia", "to": "##ia", "value": 1}, {"from": "##sia", "to": "senes", "value": 1}, {"from": "regulating the cell", "to": "ute,", "value": 1}, {"from": "regulating the cell", "to": "##poptosis", "value": 1}, {"from": "regulating the cell", "to": "##cence, making it", "value": 1}, {"from": "regulating the cell", "to": "proliferation", "value": 1}, {"from": "regulating the cell", "to": "and se", "value": 1}, {"from": "regulating the cell", "to": "a", "value": 1}, {"from": "regulating the cell", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "regulating the cell", "to": "target", "value": 1}, {"from": "regulating the cell", "to": "##nes", "value": 1}, {"from": "regulating the cell", "to": "##50 value", "value": 1}, {"from": "regulating the cell", "to": "role in", "value": 1}, {"from": "regulating the cell", "to": "real", "value": 1}, {"from": "regulating the cell", "to": ". the p53 signaling pathway", "value": 1}, {"from": "regulating the cell", "to": ", a", "value": 1}, {"from": "regulating the cell", "to": "key", "value": 1}, {"from": "regulating the cell", "to": ", and", "value": 1}, {"from": "regulating the cell", "to": "plays", "value": 1}, {"from": "regulating the cell", "to": "a critical", "value": 1}, {"from": "regulating the cell", "to": "cycle", "value": 1}, {"from": "regulating the cell", "to": "of downstream genes linked to cell", "value": 1}, {"from": "regulating the cell", "to": "##a, jakarta,", "value": 1}, {"from": "regulating the cell", "to": "##iti", "value": 1}, {"from": "regulating the cell", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "regulating the cell", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "regulating the cell", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "regulating the cell", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "regulating the cell", "to": "on the", "value": 1}, {"from": "regulating the cell", "to": "##ia", "value": 1}, {"from": "regulating the cell", "to": "senes", "value": 1}, {"from": "ute,", "to": "##poptosis", "value": 1}, {"from": "ute,", "to": "##cence, making it", "value": 1}, {"from": "ute,", "to": "proliferation", "value": 1}, {"from": "ute,", "to": "and se", "value": 1}, {"from": "ute,", "to": "a", "value": 1}, {"from": "ute,", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "ute,", "to": "target", "value": 1}, {"from": "ute,", "to": "##nes", "value": 1}, {"from": "ute,", "to": "##50 value", "value": 1}, {"from": "ute,", "to": "role in", "value": 1}, {"from": "ute,", "to": "real", "value": 1}, {"from": "ute,", "to": ". the p53 signaling pathway", "value": 1}, {"from": "ute,", "to": ", a", "value": 1}, {"from": "ute,", "to": "key", "value": 1}, {"from": "ute,", "to": ", and", "value": 1}, {"from": "ute,", "to": "plays", "value": 1}, {"from": "ute,", "to": "a critical", "value": 1}, {"from": "ute,", "to": "cycle", "value": 1}, {"from": "ute,", "to": "of downstream genes linked to cell", "value": 1}, {"from": "ute,", "to": "##a, jakarta,", "value": 1}, {"from": "ute,", "to": "##iti", "value": 1}, {"from": "ute,", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "ute,", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "ute,", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "ute,", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "ute,", "to": "on the", "value": 1}, {"from": "ute,", "to": "##ia", "value": 1}, {"from": "ute,", "to": "senes", "value": 1}, {"from": "##poptosis", "to": "##cence, making it", "value": 1}, {"from": "##poptosis", "to": "proliferation", "value": 1}, {"from": "##poptosis", "to": "and se", "value": 1}, {"from": "##poptosis", "to": "a", "value": 1}, {"from": "##poptosis", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##poptosis", "to": "target", "value": 1}, {"from": "##poptosis", "to": "##nes", "value": 1}, {"from": "##poptosis", "to": "##50 value", "value": 1}, {"from": "##poptosis", "to": "role in", "value": 1}, {"from": "##poptosis", "to": "real", "value": 1}, {"from": "##poptosis", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##poptosis", "to": ", a", "value": 1}, {"from": "##poptosis", "to": "key", "value": 1}, {"from": "##poptosis", "to": ", and", "value": 1}, {"from": "##poptosis", "to": "plays", "value": 1}, {"from": "##poptosis", "to": "a critical", "value": 1}, {"from": "##poptosis", "to": "cycle", "value": 1}, {"from": "##poptosis", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##poptosis", "to": "##a, jakarta,", "value": 1}, {"from": "##poptosis", "to": "##iti", "value": 1}, {"from": "##poptosis", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##poptosis", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##poptosis", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##poptosis", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##poptosis", "to": "on the", "value": 1}, {"from": "##poptosis", "to": "##ia", "value": 1}, {"from": "##poptosis", "to": "senes", "value": 1}, {"from": "##poptosis", "to": "- regulate", "value": 1}, {"from": "##poptosis", "to": "the", "value": 1}, {"from": "##poptosis", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "##poptosis", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "##poptosis", "to": "##tic", "value": 1}, {"from": "##poptosis", "to": "##6 /", "value": 1}, {"from": "##poptosis", "to": "##6", "value": 1}, {"from": "##poptosis", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##poptosis", "to": "##xic effect of", "value": 1}, {"from": "##poptosis", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##poptosis", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##poptosis", "to": "##xic efficacy of the", "value": 1}, {"from": "##poptosis", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##poptosis", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##poptosis", "to": "if", "value": 1}, {"from": "##poptosis", "to": "up -", "value": 1}, {"from": "##poptosis", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##poptosis", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##poptosis", "to": "development of tumor cells, a", "value": 1}, {"from": "##poptosis", "to": "##348089 conflict o", "value": 1}, {"from": "##poptosis", "to": "regulate", "value": 1}, {"from": "##poptosis", "to": "101", "value": 1}, {"from": "##poptosis", "to": "##oto", "value": 1}, {"from": "##poptosis", "to": "of pro", "value": 1}, {"from": "##poptosis", "to": "##cl -", "value": 1}, {"from": "##poptosis", "to": "##biotec. 2025.", "value": 1}, {"from": "##poptosis", "to": "04", "value": 1}, {"from": "##poptosis", "to": "##apopto", "value": 1}, {"from": "##poptosis", "to": "to", "value": 1}, {"from": "##poptosis", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##poptosis", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##poptosis", "to": "via", "value": 1}, {"from": "##poptosis", "to": "and p", "value": 1}, {"from": "##poptosis", "to": "##c cell line", "value": 1}, {"from": "##poptosis", "to": "hi", "value": 1}, {"from": "##poptosis", "to": "##can", "value": 1}, {"from": "##poptosis", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##poptosis", "to": "down", "value": 1}, {"from": "##poptosis", "to": "##53", "value": 1}, {"from": "##poptosis", "to": ". 022 pmid :", "value": 1}, {"from": "##poptosis", "to": "bax", "value": 1}, {"from": "##cence, making it", "to": "proliferation", "value": 1}, {"from": "##cence, making it", "to": "and se", "value": 1}, {"from": "##cence, making it", "to": "a", "value": 1}, {"from": "##cence, making it", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "##cence, making it", "to": "target", "value": 1}, {"from": "##cence, making it", "to": "##nes", "value": 1}, {"from": "##cence, making it", "to": "##50 value", "value": 1}, {"from": "##cence, making it", "to": "role in", "value": 1}, {"from": "##cence, making it", "to": "real", "value": 1}, {"from": "##cence, making it", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##cence, making it", "to": ", a", "value": 1}, {"from": "##cence, making it", "to": "key", "value": 1}, {"from": "##cence, making it", "to": ", and", "value": 1}, {"from": "##cence, making it", "to": "plays", "value": 1}, {"from": "##cence, making it", "to": "a critical", "value": 1}, {"from": "##cence, making it", "to": "cycle", "value": 1}, {"from": "##cence, making it", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##cence, making it", "to": "##a, jakarta,", "value": 1}, {"from": "##cence, making it", "to": "##iti", "value": 1}, {"from": "##cence, making it", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##cence, making it", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##cence, making it", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##cence, making it", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##cence, making it", "to": "on the", "value": 1}, {"from": "##cence, making it", "to": "##ia", "value": 1}, {"from": "##cence, making it", "to": "senes", "value": 1}, {"from": "proliferation", "to": "and se", "value": 1}, {"from": "proliferation", "to": "a", "value": 1}, {"from": "proliferation", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "proliferation", "to": "target", "value": 1}, {"from": "proliferation", "to": "##nes", "value": 1}, {"from": "proliferation", "to": "##50 value", "value": 1}, {"from": "proliferation", "to": "role in", "value": 1}, {"from": "proliferation", "to": "real", "value": 1}, {"from": "proliferation", "to": ". the p53 signaling pathway", "value": 1}, {"from": "proliferation", "to": ", a", "value": 1}, {"from": "proliferation", "to": "key", "value": 1}, {"from": "proliferation", "to": ", and", "value": 1}, {"from": "proliferation", "to": "plays", "value": 1}, {"from": "proliferation", "to": "a critical", "value": 1}, {"from": "proliferation", "to": "cycle", "value": 1}, {"from": "proliferation", "to": "of downstream genes linked to cell", "value": 1}, {"from": "proliferation", "to": "##a, jakarta,", "value": 1}, {"from": "proliferation", "to": "##iti", "value": 1}, {"from": "proliferation", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "proliferation", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "proliferation", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "proliferation", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "proliferation", "to": "on the", "value": 1}, {"from": "proliferation", "to": "##ia", "value": 1}, {"from": "proliferation", "to": "senes", "value": 1}, {"from": "and se", "to": "a", "value": 1}, {"from": "and se", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "and se", "to": "target", "value": 1}, {"from": "and se", "to": "##nes", "value": 1}, {"from": "and se", "to": "##50 value", "value": 1}, {"from": "and se", "to": "role in", "value": 1}, {"from": "and se", "to": "real", "value": 1}, {"from": "and se", "to": ". the p53 signaling pathway", "value": 1}, {"from": "and se", "to": ", a", "value": 1}, {"from": "and se", "to": "key", "value": 1}, {"from": "and se", "to": ", and", "value": 1}, {"from": "and se", "to": "plays", "value": 1}, {"from": "and se", "to": "a critical", "value": 1}, {"from": "and se", "to": "cycle", "value": 1}, {"from": "and se", "to": "of downstream genes linked to cell", "value": 1}, {"from": "and se", "to": "##a, jakarta,", "value": 1}, {"from": "and se", "to": "##iti", "value": 1}, {"from": "and se", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "and se", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "and se", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "and se", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "and se", "to": "on the", "value": 1}, {"from": "and se", "to": "##ia", "value": 1}, {"from": "and se", "to": "senes", "value": 1}, {"from": "a", "to": "malaya, kuala lumpur, malay", "value": 1}, {"from": "a", "to": "target", "value": 1}, {"from": "a", "to": "##nes", "value": 1}, {"from": "a", "to": "##50 value", "value": 1}, {"from": "a", "to": "role in", "value": 1}, {"from": "a", "to": "real", "value": 1}, {"from": "a", "to": ". the p53 signaling pathway", "value": 1}, {"from": "a", "to": ", a", "value": 1}, {"from": "a", "to": "key", "value": 1}, {"from": "a", "to": ", and", "value": 1}, {"from": "a", "to": "plays", "value": 1}, {"from": "a", "to": "a critical", "value": 1}, {"from": "a", "to": "cycle", "value": 1}, {"from": "a", "to": "of downstream genes linked to cell", "value": 1}, {"from": "a", "to": "##a, jakarta,", "value": 1}, {"from": "a", "to": "##iti", "value": 1}, {"from": "a", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "a", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "a", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "a", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "a", "to": "on the", "value": 1}, {"from": "a", "to": "##ia", "value": 1}, {"from": "a", "to": "senes", "value": 1}, {"from": "a", "to": "prescribed chole", "value": 1}, {"from": "a", "to": "has recently", "value": 1}, {"from": "a", "to": "and its biological functions", "value": 1}, {"from": "a", "to": "of saida, saida, algeria.", "value": 1}, {"from": "a", "to": "shown", "value": 1}, {"from": "a", "to": "however", "value": 1}, {"from": "a", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "a", "to": "shown potential anti", "value": 1}, {"from": "a", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "a", "to": "##in", "value": 1}, {"from": "a", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "a", "to": "particular breast cancer,", "value": 1}, {"from": "a", "to": "still", "value": 1}, {"from": "a", "to": "associated with atorvas", "value": 1}, {"from": "a", "to": "in breast", "value": 1}, {"from": "a", "to": "lowering", "value": 1}, {"from": "a", "to": "to be responsive to", "value": 1}, {"from": "a", "to": "interaction", "value": 1}, {"from": "a", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "a", "to": ") network and", "value": 1}, {"from": "a", "to": "in the protein - protein", "value": 1}, {"from": "a", "to": "drug,", "value": 1}, {"from": "a", "to": "hub gene", "value": 1}, {"from": "a", "to": ", its influence on gene", "value": 1}, {"from": "a", "to": "##lated", "value": 1}, {"from": "a", "to": "was", "value": 1}, {"from": "a", "to": "##in,", "value": 1}, {"from": "a", "to": "ppi", "value": 1}, {"from": "a", "to": "##oto", "value": 1}, {"from": "a", "to": "##tat", "value": 1}, {"from": "a", "to": "related pathways", "value": 1}, {"from": "a", "to": "cancer,", "value": 1}, {"from": "a", "to": "expressed", "value": 1}, {"from": "a", "to": "jun", "value": 1}, {"from": "a", "to": "##cer effects.", "value": 1}, {"from": "a", "to": "widely", "value": 1}, {"from": "a", "to": "atorvas", "value": 1}, {"from": "a", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "a", "to": "##ster", "value": 1}, {"from": "a", "to": "##ol", "value": 1}, {"from": "a", "to": "##can", "value": 1}, {"from": "a", "to": "cancer. atorvas", "value": 1}, {"from": "a", "to": "was identified as the", "value": 1}, {"from": "a", "to": "=", "value": 1}, {"from": "a", "to": "##s,", "value": 1}, {"from": "a", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "a", "to": "which is involved in", "value": 1}, {"from": "a", "to": "- 0. 46,", "value": 1}, {"from": "a", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "a", "to": "mi", "value": 1}, {"from": "a", "to": "- 5p", "value": 1}, {"from": "a", "to": "##r - 17", "value": 1}, {"from": "a", "to": "##1", "value": 1}, {"from": "a", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "a", "to": ") : e010548.", "value": 1}, {"from": "a", "to": "5p", "value": 1}, {"from": "a", "to": "hand", "value": 1}, {"from": "a", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "a", "to": "03 ) and", "value": 1}, {"from": "a", "to": "p = 0", "value": 1}, {"from": "a", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "a", "to": "##r - 106a -", "value": 1}, {"from": "a", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "a", "to": "target gene", "value": 1}, {"from": "a", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "a", "to": "- 0. 41,", "value": 1}, {"from": "a", "to": "of these lnc", "value": 1}, {"from": "a", "to": "p = 0.", "value": 1}, {"from": "a", "to": "113", "value": 1}, {"from": "a", "to": "common", "value": 1}, {"from": "a", "to": "regulated", "value": 1}, {"from": "a", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "target", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##nes", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##50 value", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "role in", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "real", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": ". the p53 signaling pathway", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": ", a", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "key", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": ", and", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "plays", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "a critical", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "cycle", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "of downstream genes linked to cell", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##a, jakarta,", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##iti", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "on the", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "##ia", "value": 1}, {"from": "malaya, kuala lumpur, malay", "to": "senes", "value": 1}, {"from": "target", "to": "##nes", "value": 1}, {"from": "target", "to": "##50 value", "value": 1}, {"from": "target", "to": "role in", "value": 1}, {"from": "target", "to": "real", "value": 1}, {"from": "target", "to": ". the p53 signaling pathway", "value": 1}, {"from": "target", "to": ", a", "value": 1}, {"from": "target", "to": "key", "value": 1}, {"from": "target", "to": ", and", "value": 1}, {"from": "target", "to": "plays", "value": 1}, {"from": "target", "to": "a critical", "value": 1}, {"from": "target", "to": "cycle", "value": 1}, {"from": "target", "to": "of downstream genes linked to cell", "value": 1}, {"from": "target", "to": "##a, jakarta,", "value": 1}, {"from": "target", "to": "##iti", "value": 1}, {"from": "target", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "target", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "target", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "target", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "target", "to": "on the", "value": 1}, {"from": "target", "to": "##ia", "value": 1}, {"from": "target", "to": "senes", "value": 1}, {"from": "##nes", "to": "##50 value", "value": 1}, {"from": "##nes", "to": "role in", "value": 1}, {"from": "##nes", "to": "real", "value": 1}, {"from": "##nes", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##nes", "to": ", a", "value": 1}, {"from": "##nes", "to": "key", "value": 1}, {"from": "##nes", "to": ", and", "value": 1}, {"from": "##nes", "to": "plays", "value": 1}, {"from": "##nes", "to": "a critical", "value": 1}, {"from": "##nes", "to": "cycle", "value": 1}, {"from": "##nes", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##nes", "to": "##a, jakarta,", "value": 1}, {"from": "##nes", "to": "##iti", "value": 1}, {"from": "##nes", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##nes", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##nes", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##nes", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##nes", "to": "on the", "value": 1}, {"from": "##nes", "to": "##ia", "value": 1}, {"from": "##nes", "to": "senes", "value": 1}, {"from": "##nes", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "##nes", "to": "in ki", "value": 1}, {"from": "##nes", "to": "##cu", "value": 1}, {"from": "##nes", "to": "t", "value": 1}, {"from": "##nes", "to": "positive", "value": 1}, {"from": "##nes", "to": "##2 -", "value": 1}, {"from": "##nes", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##nes", "to": "##rrence", "value": 1}, {"from": "##nes", "to": "percentage", "value": 1}, {"from": "##nes", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##nes", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##nes", "to": "from l", "value": 1}, {"from": "##nes", "to": "presented", "value": 1}, {"from": "##nes", "to": "re", "value": 1}, {"from": "##nes", "to": "results", "value": 1}, {"from": "##nes", "to": "pam50 - derived risk of", "value": 1}, {"from": "##nes", "to": "her", "value": 1}, {"from": "##nes", "to": "er + /", "value": 1}, {"from": "##nes", "to": "##nal a to normal - like", "value": 1}, {"from": "##nes", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##nes", "to": "cells", "value": 1}, {"from": "##nes", "to": "score", "value": 1}, {"from": "##nes", "to": "change", "value": 1}, {"from": "##nes", "to": "after", "value": 1}, {"from": "##nes", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##nes", "to": "of intrinsic sub", "value": 1}, {"from": "##nes", "to": "p53", "value": 1}, {"from": "##nes", "to": "##is.", "value": 1}, {"from": "##nes", "to": "biomark", "value": 1}, {"from": "##nes", "to": "subtype after", "value": 1}, {"from": "##nes", "to": "net", "value": 1}, {"from": "##nes", "to": "of", "value": 1}, {"from": "##nes", "to": "##c patients", "value": 1}, {"from": "##nes", "to": "net as a putative", "value": 1}, {"from": "##nes", "to": "##umour cellularity size", "value": 1}, {"from": "##nes", "to": "radio", "value": 1}, {"from": "##nes", "to": ") and lower", "value": 1}, {"from": "##nes", "to": "better", "value": 1}, {"from": "##50 value", "to": "role in", "value": 1}, {"from": "##50 value", "to": "real", "value": 1}, {"from": "##50 value", "to": ". the p53 signaling pathway", "value": 1}, {"from": "##50 value", "to": ", a", "value": 1}, {"from": "##50 value", "to": "key", "value": 1}, {"from": "##50 value", "to": ", and", "value": 1}, {"from": "##50 value", "to": "plays", "value": 1}, {"from": "##50 value", "to": "a critical", "value": 1}, {"from": "##50 value", "to": "cycle", "value": 1}, {"from": "##50 value", "to": "of downstream genes linked to cell", "value": 1}, {"from": "##50 value", "to": "##a, jakarta,", "value": 1}, {"from": "##50 value", "to": "##iti", "value": 1}, {"from": "##50 value", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##50 value", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##50 value", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##50 value", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##50 value", "to": "on the", "value": 1}, {"from": "##50 value", "to": "##ia", "value": 1}, {"from": "##50 value", "to": "senes", "value": 1}, {"from": "role in", "to": "real", "value": 1}, {"from": "role in", "to": ". the p53 signaling pathway", "value": 1}, {"from": "role in", "to": ", a", "value": 1}, {"from": "role in", "to": "key", "value": 1}, {"from": "role in", "to": ", and", "value": 1}, {"from": "role in", "to": "plays", "value": 1}, {"from": "role in", "to": "a critical", "value": 1}, {"from": "role in", "to": "cycle", "value": 1}, {"from": "role in", "to": "of downstream genes linked to cell", "value": 1}, {"from": "role in", "to": "##a, jakarta,", "value": 1}, {"from": "role in", "to": "##iti", "value": 1}, {"from": "role in", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "role in", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "role in", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "role in", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "role in", "to": "on the", "value": 1}, {"from": "role in", "to": "##ia", "value": 1}, {"from": "role in", "to": "senes", "value": 1}, {"from": "real", "to": ". the p53 signaling pathway", "value": 1}, {"from": "real", "to": ", a", "value": 1}, {"from": "real", "to": "key", "value": 1}, {"from": "real", "to": ", and", "value": 1}, {"from": "real", "to": "plays", "value": 1}, {"from": "real", "to": "a critical", "value": 1}, {"from": "real", "to": "cycle", "value": 1}, {"from": "real", "to": "of downstream genes linked to cell", "value": 1}, {"from": "real", "to": "##a, jakarta,", "value": 1}, {"from": "real", "to": "##iti", "value": 1}, {"from": "real", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "real", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "real", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "real", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "real", "to": "on the", "value": 1}, {"from": "real", "to": "##ia", "value": 2}, {"from": "real", "to": "senes", "value": 1}, {"from": "real", "to": "12", "value": 1}, {"from": "real", "to": "after net", "value": 1}, {"from": "real", "to": "a significant", "value": 1}, {"from": "real", "to": "offers the opportunity of", "value": 1}, {"from": "real", "to": "##ip", "value": 1}, {"from": "real", "to": "t", "value": 1}, {"from": "real", "to": "however", "value": 1}, {"from": "real", "to": ") health", "value": 1}, {"from": "real", "to": "background", "value": 1}, {"from": "real", "to": "##re population of", "value": 1}, {"from": "real", "to": "negative breast", "value": 1}, {"from": "real", "to": "barrier", "value": 1}, {"from": "real", "to": "##gipuzkoa", "value": 1}, {"from": "real", "to": "clinical", "value": 1}, {"from": "real", "to": "##2 -", "value": 1}, {"from": "real", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "real", "to": "##zkoa", "value": 1}, {"from": "real", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "real", "to": "##gi", "value": 1}, {"from": "real", "to": "##donostia ) health", "value": 1}, {"from": "real", "to": "##tian,", "value": 1}, {"from": "real", "to": "cancer", "value": 1}, {"from": "real", "to": "spain", "value": 1}, {"from": "real", "to": "##uzkoa. eus.", "value": 1}, {"from": "real", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "real", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "real", "to": "personal", "value": 1}, {"from": "real", "to": "##ised therapy.", "value": 1}, {"from": "real", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "real", "to": "##donost", "value": 1}, {"from": "real", "to": "##cent", "value": 1}, {"from": "real", "to": "research institute", "value": 1}, {"from": "real", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "real", "to": "sa", "value": 1}, {"from": "real", "to": "sebas", "value": 1}, {"from": "real", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "real", "to": "her", "value": 1}, {"from": "real", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "real", "to": "##n sebastian,", "value": 1}, {"from": "real", "to": "##umour response", "value": 1}, {"from": "real", "to": "a,", "value": 1}, {"from": "real", "to": "##pu", "value": 1}, {"from": "real", "to": "##n", "value": 1}, {"from": "real", "to": "sebastian", "value": 1}, {"from": "real", "to": "##uc", "value": 1}, {"from": "real", "to": "13", "value": 1}, {"from": "real", "to": ", the lack of reprod", "value": 1}, {"from": "real", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "real", "to": "##c ) allows", "value": 1}, {"from": "real", "to": "##gnosis", "value": 1}, {"from": "real", "to": "- g", "value": 1}, {"from": ". the p53 signaling pathway", "to": ", a", "value": 1}, {"from": ". the p53 signaling pathway", "to": "key", "value": 1}, {"from": ". the p53 signaling pathway", "to": ", and", "value": 1}, {"from": ". the p53 signaling pathway", "to": "plays", "value": 1}, {"from": ". the p53 signaling pathway", "to": "a critical", "value": 1}, {"from": ". the p53 signaling pathway", "to": "cycle", "value": 1}, {"from": ". the p53 signaling pathway", "to": "of downstream genes linked to cell", "value": 1}, {"from": ". the p53 signaling pathway", "to": "##a, jakarta,", "value": 1}, {"from": ". the p53 signaling pathway", "to": "##iti", "value": 1}, {"from": ". the p53 signaling pathway", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": ". the p53 signaling pathway", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": ". the p53 signaling pathway", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": ". the p53 signaling pathway", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": ". the p53 signaling pathway", "to": "on the", "value": 1}, {"from": ". the p53 signaling pathway", "to": "##ia", "value": 1}, {"from": ". the p53 signaling pathway", "to": "senes", "value": 1}, {"from": ", a", "to": "key", "value": 1}, {"from": ", a", "to": ", and", "value": 1}, {"from": ", a", "to": "plays", "value": 1}, {"from": ", a", "to": "a critical", "value": 1}, {"from": ", a", "to": "cycle", "value": 1}, {"from": ", a", "to": "of downstream genes linked to cell", "value": 1}, {"from": ", a", "to": "##a, jakarta,", "value": 1}, {"from": ", a", "to": "##iti", "value": 1}, {"from": ", a", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": ", a", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": ", a", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": ", a", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": ", a", "to": "on the", "value": 1}, {"from": ", a", "to": "##ia", "value": 1}, {"from": ", a", "to": "senes", "value": 1}, {"from": ", a", "to": "the", "value": 1}, {"from": ", a", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": ", a", "to": "methods", "value": 1}, {"from": ", a", "to": "hormone receptor positive", "value": 1}, {"from": ", a", "to": "societal perspective", "value": 1}, {"from": ", a", "to": "benefits", "value": 1}, {"from": ", a", "to": "surgery", "value": 1}, {"from": ", a", "to": "cost -", "value": 1}, {"from": ", a", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": ", a", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": ", a", "to": "decision", "value": 1}, {"from": ", a", "to": "to aid adjuvant treatment", "value": 1}, {"from": ", a", "to": "##al", "value": 1}, {"from": ", a", "to": "emit - 1 trial", "value": 1}, {"from": ", a", "to": "post", "value": 1}, {"from": ", a", "to": ". materials", "value": 1}, {"from": ", a", "to": "model was", "value": 1}, {"from": ", a", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": ", a", "to": "used", "value": 1}, {"from": ", a", "to": "institute", "value": 1}, {"from": ", a", "to": "treatment", "value": 1}, {"from": ", a", "to": ": the", "value": 1}, {"from": ", a", "to": "ki - 67", "value": 1}, {"from": ", a", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": ", a", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ", a", "to": "prosigna was tested", "value": 1}, {"from": ", a", "to": "prospective", "value": 1}, {"from": ", a", "to": "were measured", "value": 1}, {"from": ", a", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ", a", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ", a", "to": "observation", "value": 1}, {"from": ", a", "to": "division", "value": 1}, {"from": ", a", "to": "decisions in", "value": 1}, {"from": ", a", "to": "built", "value": 1}, {"from": ", a", "to": "impact of", "value": 1}, {"from": "key", "to": ", and", "value": 1}, {"from": "key", "to": "plays", "value": 1}, {"from": "key", "to": "a critical", "value": 1}, {"from": "key", "to": "cycle", "value": 1}, {"from": "key", "to": "of downstream genes linked to cell", "value": 1}, {"from": "key", "to": "##a, jakarta,", "value": 1}, {"from": "key", "to": "##iti", "value": 1}, {"from": "key", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "key", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "key", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "key", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "key", "to": "on the", "value": 1}, {"from": "key", "to": "##ia", "value": 1}, {"from": "key", "to": "senes", "value": 1}, {"from": ", and", "to": "plays", "value": 1}, {"from": ", and", "to": "a critical", "value": 1}, {"from": ", and", "to": "cycle", "value": 1}, {"from": ", and", "to": "of downstream genes linked to cell", "value": 1}, {"from": ", and", "to": "##a, jakarta,", "value": 1}, {"from": ", and", "to": "##iti", "value": 1}, {"from": ", and", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": ", and", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": ", and", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": ", and", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": ", and", "to": "on the", "value": 1}, {"from": ", and", "to": "##ia", "value": 1}, {"from": ", and", "to": "senes", "value": 1}, {"from": "plays", "to": "a critical", "value": 1}, {"from": "plays", "to": "cycle", "value": 1}, {"from": "plays", "to": "of downstream genes linked to cell", "value": 1}, {"from": "plays", "to": "##a, jakarta,", "value": 1}, {"from": "plays", "to": "##iti", "value": 1}, {"from": "plays", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "plays", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "plays", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "plays", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "plays", "to": "on the", "value": 1}, {"from": "plays", "to": "##ia", "value": 1}, {"from": "plays", "to": "senes", "value": 1}, {"from": "a critical", "to": "cycle", "value": 1}, {"from": "a critical", "to": "of downstream genes linked to cell", "value": 1}, {"from": "a critical", "to": "##a, jakarta,", "value": 1}, {"from": "a critical", "to": "##iti", "value": 1}, {"from": "a critical", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "a critical", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "a critical", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "a critical", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "a critical", "to": "on the", "value": 1}, {"from": "a critical", "to": "##ia", "value": 1}, {"from": "a critical", "to": "senes", "value": 1}, {"from": "cycle", "to": "of downstream genes linked to cell", "value": 1}, {"from": "cycle", "to": "##a, jakarta,", "value": 1}, {"from": "cycle", "to": "##iti", "value": 1}, {"from": "cycle", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "cycle", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "cycle", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "cycle", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "cycle", "to": "on the", "value": 1}, {"from": "cycle", "to": "##ia", "value": 1}, {"from": "cycle", "to": "senes", "value": 1}, {"from": "cycle", "to": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "value": 1}, {"from": "cycle", "to": "##ene", "value": 1}, {"from": "cycle", "to": "which was", "value": 1}, {"from": "cycle", "to": ": cyce or ccne1", "value": 1}, {"from": "cycle", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "cycle", "to": "##8 ), and e2f1", "value": 1}, {"from": "cycle", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "cycle", "to": "##1 ), rbl1", "value": 1}, {"from": "cycle", "to": "might", "value": 1}, {"from": "cycle", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "cycle", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "cycle", "to": "the native", "value": 1}, {"from": "cycle", "to": "ligan", "value": 1}, {"from": "cycle", "to": "im", "value": 1}, {"from": "cycle", "to": "p = 0. 01", "value": 1}, {"from": "cycle", "to": "##rank", "value": 1}, {"from": "cycle", "to": "##j", "value": 1}, {"from": "cycle", "to": "by", "value": 1}, {"from": "cycle", "to": "rerank score", "value": 1}, {"from": "cycle", "to": "##um", "value": 1}, {"from": "cycle", "to": "##d", "value": 1}, {"from": "cycle", "to": "of ad", "value": 1}, {"from": "cycle", "to": "re", "value": 1}, {"from": "cycle", "to": "##idodiph", "value": 1}, {"from": "cycle", "to": "p = 0", "value": 1}, {"from": "cycle", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "cycle", "to": "- 112. 70 k", "value": 1}, {"from": "cycle", "to": "score", "value": 1}, {"from": "cycle", "to": "##ine", "value": 1}, {"from": "cycle", "to": "##enyl", "value": 1}, {"from": "cycle", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "cycle", "to": "##osphate", "value": 1}, {"from": "cycle", "to": "- 110. 68 k", "value": 1}, {"from": "cycle", "to": "0", "value": 1}, {"from": "cycle", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "cycle", "to": "/ mol ), and nummular", "value": 1}, {"from": "cycle", "to": "squal", "value": 1}, {"from": "cycle", "to": "the decrease in p21", "value": 1}, {"from": "cycle", "to": "##mularia stem suggested that", "value": 1}, {"from": "of downstream genes linked to cell", "to": "##a, jakarta,", "value": 1}, {"from": "of downstream genes linked to cell", "to": "##iti", "value": 1}, {"from": "of downstream genes linked to cell", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "of downstream genes linked to cell", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "of downstream genes linked to cell", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "of downstream genes linked to cell", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "of downstream genes linked to cell", "to": "on the", "value": 1}, {"from": "of downstream genes linked to cell", "to": "##ia", "value": 1}, {"from": "of downstream genes linked to cell", "to": "senes", "value": 1}, {"from": "##a, jakarta,", "to": "##iti", "value": 1}, {"from": "##a, jakarta,", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##a, jakarta,", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##a, jakarta,", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##a, jakarta,", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##a, jakarta,", "to": "on the", "value": 1}, {"from": "##a, jakarta,", "to": "##ia", "value": 1}, {"from": "##a, jakarta,", "to": "senes", "value": 1}, {"from": "##iti", "to": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "value": 1}, {"from": "##iti", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##iti", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##iti", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##iti", "to": "on the", "value": 1}, {"from": "##iti", "to": "##ia", "value": 1}, {"from": "##iti", "to": "senes", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": "on the", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": "##ia", "value": 1}, {"from": "##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker", "to": "senes", "value": 1}, {"from": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "to": ") department of pharmaceutical chemistry,", "value": 1}, {"from": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "to": "on the", "value": 1}, {"from": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "to": "##ia", "value": 1}, {"from": "and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this,", "to": "senes", "value": 1}, {"from": ") department of pharmaceutical chemistry,", "to": "##t - qpcr ) was used to evaluate the mrna", "value": 1}, {"from": ") department of pharmaceutical chemistry,", "to": "on the", "value": 1}, {"from": ") department of pharmaceutical chemistry,", "to": "##ia", "value": 1}, {"from": ") department of pharmaceutical chemistry,", "to": "senes", "value": 1}, {"from": "##t - qpcr ) was used to evaluate the mrna", "to": "on the", "value": 1}, {"from": "##t - qpcr ) was used to evaluate the mrna", "to": "##ia", "value": 1}, {"from": "##t - qpcr ) was used to evaluate the mrna", "to": "senes", "value": 1}, {"from": "on the", "to": "##ia", "value": 1}, {"from": "on the", "to": "senes", "value": 1}, {"from": "##ia", "to": "senes", "value": 1}, {"from": "##ia", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "##ia", "to": "##r confirmed their down", "value": 1}, {"from": "##ia", "to": "four", "value": 1}, {"from": "##ia", "to": "prioriti", "value": 1}, {"from": "##ia", "to": "pc", "value": 1}, {"from": "##ia", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "##ia", "to": "diagnosed", "value": 1}, {"from": "##ia", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "##ia", "to": "incomplete", "value": 1}, {"from": "##ia", "to": "ministry", "value": 1}, {"from": "##ia", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##ia", "to": "diagnostic", "value": 1}, {"from": "##ia", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##ia", "to": "##s and", "value": 1}, {"from": "##ia", "to": "##s.", "value": 1}, {"from": "##ia", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##ia", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##ia", "to": "treatment", "value": 1}, {"from": "##ia", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##ia", "to": "- mi", "value": 1}, {"from": "##ia", "to": "##gna", "value": 1}, {"from": "##ia", "to": "expressed", "value": 1}, {"from": "##ia", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##ia", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##ia", "to": "##ncrna", "value": 1}, {"from": "##ia", "to": "##r", "value": 1}, {"from": "##ia", "to": "mrna", "value": 1}, {"from": "##ia", "to": "mali", "value": 1}, {"from": "##ia", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##ia", "to": "##rio de v", "value": 1}, {"from": "##ia", "to": "t", "value": 2}, {"from": "##ia", "to": "##kolog", "value": 1}, {"from": "##ia", "to": ", san", "value": 1}, {"from": "##ia", "to": "##it", "value": 1}, {"from": "##ia", "to": ") health", "value": 2}, {"from": "##ia", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "##ia", "to": "##iba", "value": 1}, {"from": "##ia", "to": "##ialdea", "value": 1}, {"from": "##ia", "to": "##gipuzkoa", "value": 2}, {"from": "##ia", "to": "##ko", "value": 1}, {"from": "##ia", "to": "##obe", "value": 1}, {"from": "##ia", "to": "se", "value": 1}, {"from": "##ia", "to": "##in", "value": 1}, {"from": "##ia", "to": "##gi", "value": 2}, {"from": "##ia", "to": "##tian,", "value": 2}, {"from": "##ia", "to": ") hospital clinico univers", "value": 1}, {"from": "##ia", "to": "##r 12, madrid,", "value": 1}, {"from": "##ia", "to": "spain", "value": 2}, {"from": "##ia", "to": "##ale", "value": 1}, {"from": "##ia", "to": "##a", "value": 1}, {"from": "##ia", "to": "##ute", "value": 1}, {"from": "##ia", "to": "##ikoa,", "value": 1}, {"from": "##ia", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ia", "to": "##donost", "value": 2}, {"from": "##ia", "to": ") hospital oct", "value": 1}, {"from": "##ia", "to": "research institute", "value": 2}, {"from": "##ia", "to": "institute", "value": 1}, {"from": "##ia", "to": "sa", "value": 2}, {"from": "##ia", "to": "sebas", "value": 2}, {"from": "##ia", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ia", "to": "##ita", "value": 1}, {"from": "##ia", "to": ", v", "value": 1}, {"from": "##ia", "to": "11", "value": 1}, {"from": "##ia", "to": "##ps, barcelon", "value": 1}, {"from": "##ia", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ia", "to": "##n", "value": 2}, {"from": "##ia", "to": "##pu", "value": 2}, {"from": "##ia", "to": "sebastian", "value": 2}, {"from": "##ia", "to": "; gip", "value": 1}, {"from": "##ia", "to": "- on", "value": 1}, {"from": "##ia", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ia", "to": "##ncia,", "value": 1}, {"from": "##ia", "to": "##uz", "value": 1}, {"from": "##ia", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ia", "to": "- onkologikoa, san", "value": 1}, {"from": "##ia", "to": "##z", "value": 1}, {"from": "##ia", "to": "##bastian, spa", "value": 1}, {"from": "##ia", "to": "12", "value": 1}, {"from": "##ia", "to": "after net", "value": 1}, {"from": "##ia", "to": "a significant", "value": 1}, {"from": "##ia", "to": "offers the opportunity of", "value": 1}, {"from": "##ia", "to": "##ip", "value": 1}, {"from": "##ia", "to": "however", "value": 1}, {"from": "##ia", "to": "background", "value": 1}, {"from": "##ia", "to": "##re population of", "value": 1}, {"from": "##ia", "to": "negative breast", "value": 1}, {"from": "##ia", "to": "barrier", "value": 1}, {"from": "##ia", "to": "clinical", "value": 1}, {"from": "##ia", "to": "##2 -", "value": 1}, {"from": "##ia", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##ia", "to": "##zkoa", "value": 1}, {"from": "##ia", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##ia", "to": "##donostia ) health", "value": 1}, {"from": "##ia", "to": "cancer", "value": 1}, {"from": "##ia", "to": "##uzkoa. eus.", "value": 1}, {"from": "##ia", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##ia", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##ia", "to": "personal", "value": 1}, {"from": "##ia", "to": "##ised therapy.", "value": 1}, {"from": "##ia", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##ia", "to": "##cent", "value": 1}, {"from": "##ia", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##ia", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##ia", "to": "her", "value": 1}, {"from": "##ia", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##ia", "to": "##n sebastian,", "value": 1}, {"from": "##ia", "to": "##umour response", "value": 1}, {"from": "##ia", "to": "a,", "value": 1}, {"from": "##ia", "to": "##uc", "value": 1}, {"from": "##ia", "to": "13", "value": 1}, {"from": "##ia", "to": ", the lack of reprod", "value": 1}, {"from": "##ia", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##ia", "to": "##c ) allows", "value": 1}, {"from": "##ia", "to": "##gnosis", "value": 1}, {"from": "##ia", "to": "- g", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##ene", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "which was", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": ": cyce or ccne1", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##8 ), and e2f1", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##1 ), rbl1", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "might", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "the native", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "ligan", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "im", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "p = 0. 01", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##rank", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##j", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "by", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "rerank score", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##um", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##d", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "of ad", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "re", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##idodiph", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "p = 0", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "- 112. 70 k", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "score", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##ine", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##enyl", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##osphate", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "- 110. 68 k", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "0", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "/ mol ), and nummular", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "squal", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "the decrease in p21", "value": 1}, {"from": "##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem", "to": "##mularia stem suggested that", "value": 1}, {"from": "##ene", "to": "which was", "value": 1}, {"from": "##ene", "to": ": cyce or ccne1", "value": 1}, {"from": "##ene", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "##ene", "to": "##8 ), and e2f1", "value": 1}, {"from": "##ene", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "##ene", "to": "##1 ), rbl1", "value": 1}, {"from": "##ene", "to": "might", "value": 1}, {"from": "##ene", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "##ene", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "##ene", "to": "the native", "value": 1}, {"from": "##ene", "to": "ligan", "value": 1}, {"from": "##ene", "to": "im", "value": 1}, {"from": "##ene", "to": "p = 0. 01", "value": 1}, {"from": "##ene", "to": "##rank", "value": 1}, {"from": "##ene", "to": "##j", "value": 1}, {"from": "##ene", "to": "by", "value": 1}, {"from": "##ene", "to": "rerank score", "value": 1}, {"from": "##ene", "to": "##um", "value": 1}, {"from": "##ene", "to": "##d", "value": 1}, {"from": "##ene", "to": "of ad", "value": 1}, {"from": "##ene", "to": "re", "value": 1}, {"from": "##ene", "to": "##idodiph", "value": 1}, {"from": "##ene", "to": "p = 0", "value": 1}, {"from": "##ene", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##ene", "to": "- 112. 70 k", "value": 1}, {"from": "##ene", "to": "score", "value": 1}, {"from": "##ene", "to": "##ine", "value": 1}, {"from": "##ene", "to": "##enyl", "value": 1}, {"from": "##ene", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##ene", "to": "##osphate", "value": 1}, {"from": "##ene", "to": "- 110. 68 k", "value": 1}, {"from": "##ene", "to": "0", "value": 1}, {"from": "##ene", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##ene", "to": "/ mol ), and nummular", "value": 1}, {"from": "##ene", "to": "squal", "value": 1}, {"from": "##ene", "to": "the decrease in p21", "value": 1}, {"from": "##ene", "to": "##mularia stem suggested that", "value": 1}, {"from": "which was", "to": ": cyce or ccne1", "value": 1}, {"from": "which was", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": "which was", "to": "##8 ), and e2f1", "value": 1}, {"from": "which was", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "which was", "to": "##1 ), rbl1", "value": 1}, {"from": "which was", "to": "might", "value": 1}, {"from": "which was", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "which was", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "which was", "to": "the native", "value": 1}, {"from": "which was", "to": "ligan", "value": 1}, {"from": "which was", "to": "im", "value": 1}, {"from": "which was", "to": "p = 0. 01", "value": 1}, {"from": "which was", "to": "##rank", "value": 1}, {"from": "which was", "to": "##j", "value": 1}, {"from": "which was", "to": "by", "value": 1}, {"from": "which was", "to": "rerank score", "value": 1}, {"from": "which was", "to": "##um", "value": 1}, {"from": "which was", "to": "##d", "value": 1}, {"from": "which was", "to": "of ad", "value": 1}, {"from": "which was", "to": "re", "value": 1}, {"from": "which was", "to": "##idodiph", "value": 1}, {"from": "which was", "to": "p = 0", "value": 1}, {"from": "which was", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "which was", "to": "- 112. 70 k", "value": 1}, {"from": "which was", "to": "score", "value": 1}, {"from": "which was", "to": "##ine", "value": 1}, {"from": "which was", "to": "##enyl", "value": 1}, {"from": "which was", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "which was", "to": "##osphate", "value": 1}, {"from": "which was", "to": "- 110. 68 k", "value": 1}, {"from": "which was", "to": "0", "value": 1}, {"from": "which was", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "which was", "to": "/ mol ), and nummular", "value": 1}, {"from": "which was", "to": "squal", "value": 1}, {"from": "which was", "to": "the decrease in p21", "value": 1}, {"from": "which was", "to": "##mularia stem suggested that", "value": 1}, {"from": ": cyce or ccne1", "to": "occur via pathways associated with cell senescence and cell", "value": 1}, {"from": ": cyce or ccne1", "to": "##8 ), and e2f1", "value": 1}, {"from": ": cyce or ccne1", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": ": cyce or ccne1", "to": "##1 ), rbl1", "value": 1}, {"from": ": cyce or ccne1", "to": "might", "value": 1}, {"from": ": cyce or ccne1", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": ": cyce or ccne1", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": ": cyce or ccne1", "to": "the native", "value": 1}, {"from": ": cyce or ccne1", "to": "ligan", "value": 1}, {"from": ": cyce or ccne1", "to": "im", "value": 1}, {"from": ": cyce or ccne1", "to": "p = 0. 01", "value": 1}, {"from": ": cyce or ccne1", "to": "##rank", "value": 1}, {"from": ": cyce or ccne1", "to": "##j", "value": 1}, {"from": ": cyce or ccne1", "to": "by", "value": 1}, {"from": ": cyce or ccne1", "to": "rerank score", "value": 1}, {"from": ": cyce or ccne1", "to": "##um", "value": 1}, {"from": ": cyce or ccne1", "to": "##d", "value": 1}, {"from": ": cyce or ccne1", "to": "of ad", "value": 1}, {"from": ": cyce or ccne1", "to": "re", "value": 1}, {"from": ": cyce or ccne1", "to": "##idodiph", "value": 1}, {"from": ": cyce or ccne1", "to": "p = 0", "value": 1}, {"from": ": cyce or ccne1", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": ": cyce or ccne1", "to": "- 112. 70 k", "value": 1}, {"from": ": cyce or ccne1", "to": "score", "value": 1}, {"from": ": cyce or ccne1", "to": "##ine", "value": 1}, {"from": ": cyce or ccne1", "to": "##enyl", "value": 1}, {"from": ": cyce or ccne1", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": ": cyce or ccne1", "to": "##osphate", "value": 1}, {"from": ": cyce or ccne1", "to": "- 110. 68 k", "value": 1}, {"from": ": cyce or ccne1", "to": "0", "value": 1}, {"from": ": cyce or ccne1", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": ": cyce or ccne1", "to": "/ mol ), and nummular", "value": 1}, {"from": ": cyce or ccne1", "to": "squal", "value": 1}, {"from": ": cyce or ccne1", "to": "the decrease in p21", "value": 1}, {"from": ": cyce or ccne1", "to": "##mularia stem suggested that", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##8 ), and e2f1", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##1 ), rbl1", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "might", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "the native", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "ligan", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "im", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "p = 0. 01", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##rank", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##j", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "by", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "rerank score", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##um", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##d", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "of ad", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "re", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##idodiph", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "p = 0", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "- 112. 70 k", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "score", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##ine", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##enyl", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##osphate", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "- 110. 68 k", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "0", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "/ mol ), and nummular", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "squal", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "the decrease in p21", "value": 1}, {"from": "occur via pathways associated with cell senescence and cell", "to": "##mularia stem suggested that", "value": 1}, {"from": "##8 ), and e2f1", "to": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "value": 1}, {"from": "##8 ), and e2f1", "to": "##1 ), rbl1", "value": 1}, {"from": "##8 ), and e2f1", "to": "might", "value": 1}, {"from": "##8 ), and e2f1", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "##8 ), and e2f1", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "##8 ), and e2f1", "to": "the native", "value": 1}, {"from": "##8 ), and e2f1", "to": "ligan", "value": 1}, {"from": "##8 ), and e2f1", "to": "im", "value": 1}, {"from": "##8 ), and e2f1", "to": "p = 0. 01", "value": 1}, {"from": "##8 ), and e2f1", "to": "##rank", "value": 1}, {"from": "##8 ), and e2f1", "to": "##j", "value": 1}, {"from": "##8 ), and e2f1", "to": "by", "value": 1}, {"from": "##8 ), and e2f1", "to": "rerank score", "value": 1}, {"from": "##8 ), and e2f1", "to": "##um", "value": 1}, {"from": "##8 ), and e2f1", "to": "##d", "value": 1}, {"from": "##8 ), and e2f1", "to": "of ad", "value": 1}, {"from": "##8 ), and e2f1", "to": "re", "value": 1}, {"from": "##8 ), and e2f1", "to": "##idodiph", "value": 1}, {"from": "##8 ), and e2f1", "to": "p = 0", "value": 1}, {"from": "##8 ), and e2f1", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##8 ), and e2f1", "to": "- 112. 70 k", "value": 1}, {"from": "##8 ), and e2f1", "to": "score", "value": 1}, {"from": "##8 ), and e2f1", "to": "##ine", "value": 1}, {"from": "##8 ), and e2f1", "to": "##enyl", "value": 1}, {"from": "##8 ), and e2f1", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##8 ), and e2f1", "to": "##osphate", "value": 1}, {"from": "##8 ), and e2f1", "to": "- 110. 68 k", "value": 1}, {"from": "##8 ), and e2f1", "to": "0", "value": 1}, {"from": "##8 ), and e2f1", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##8 ), and e2f1", "to": "/ mol ), and nummular", "value": 1}, {"from": "##8 ), and e2f1", "to": "squal", "value": 1}, {"from": "##8 ), and e2f1", "to": "the decrease in p21", "value": 1}, {"from": "##8 ), and e2f1", "to": "##mularia stem suggested that", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##1 ), rbl1", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "might", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "the native", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "ligan", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "im", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "p = 0. 01", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##rank", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##j", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "by", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "rerank score", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##um", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##d", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "of ad", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "re", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##idodiph", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "p = 0", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "- 112. 70 k", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "score", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##ine", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##enyl", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##osphate", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "- 110. 68 k", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "0", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "/ mol ), and nummular", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "squal", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "the decrease in p21", "value": 1}, {"from": ". 72 \u03bcg / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell", "to": "##mularia stem suggested that", "value": 1}, {"from": "##1 ), rbl1", "to": "might", "value": 1}, {"from": "##1 ), rbl1", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "##1 ), rbl1", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "##1 ), rbl1", "to": "the native", "value": 1}, {"from": "##1 ), rbl1", "to": "ligan", "value": 1}, {"from": "##1 ), rbl1", "to": "im", "value": 1}, {"from": "##1 ), rbl1", "to": "p = 0. 01", "value": 1}, {"from": "##1 ), rbl1", "to": "##rank", "value": 1}, {"from": "##1 ), rbl1", "to": "##j", "value": 1}, {"from": "##1 ), rbl1", "to": "by", "value": 1}, {"from": "##1 ), rbl1", "to": "rerank score", "value": 1}, {"from": "##1 ), rbl1", "to": "##um", "value": 1}, {"from": "##1 ), rbl1", "to": "##d", "value": 1}, {"from": "##1 ), rbl1", "to": "of ad", "value": 1}, {"from": "##1 ), rbl1", "to": "re", "value": 1}, {"from": "##1 ), rbl1", "to": "##idodiph", "value": 1}, {"from": "##1 ), rbl1", "to": "p = 0", "value": 1}, {"from": "##1 ), rbl1", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##1 ), rbl1", "to": "- 112. 70 k", "value": 1}, {"from": "##1 ), rbl1", "to": "score", "value": 1}, {"from": "##1 ), rbl1", "to": "##ine", "value": 1}, {"from": "##1 ), rbl1", "to": "##enyl", "value": 1}, {"from": "##1 ), rbl1", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##1 ), rbl1", "to": "##osphate", "value": 1}, {"from": "##1 ), rbl1", "to": "- 110. 68 k", "value": 1}, {"from": "##1 ), rbl1", "to": "0", "value": 1}, {"from": "##1 ), rbl1", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##1 ), rbl1", "to": "/ mol ), and nummular", "value": 1}, {"from": "##1 ), rbl1", "to": "squal", "value": 1}, {"from": "##1 ), rbl1", "to": "the decrease in p21", "value": 1}, {"from": "##1 ), rbl1", "to": "##mularia stem suggested that", "value": 1}, {"from": "might", "to": "arrest. molecular docking results of metabolite compounds from z. n", "value": 1}, {"from": "might", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "might", "to": "the native", "value": 1}, {"from": "might", "to": "ligan", "value": 1}, {"from": "might", "to": "im", "value": 1}, {"from": "might", "to": "p = 0. 01", "value": 1}, {"from": "might", "to": "##rank", "value": 1}, {"from": "might", "to": "##j", "value": 1}, {"from": "might", "to": "by", "value": 1}, {"from": "might", "to": "rerank score", "value": 1}, {"from": "might", "to": "##um", "value": 1}, {"from": "might", "to": "##d", "value": 1}, {"from": "might", "to": "of ad", "value": 1}, {"from": "might", "to": "re", "value": 1}, {"from": "might", "to": "##idodiph", "value": 1}, {"from": "might", "to": "p = 0", "value": 1}, {"from": "might", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "might", "to": "- 112. 70 k", "value": 1}, {"from": "might", "to": "score", "value": 1}, {"from": "might", "to": "##ine", "value": 1}, {"from": "might", "to": "##enyl", "value": 1}, {"from": "might", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "might", "to": "##osphate", "value": 1}, {"from": "might", "to": "- 110. 68 k", "value": 1}, {"from": "might", "to": "0", "value": 1}, {"from": "might", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "might", "to": "/ mol ), and nummular", "value": 1}, {"from": "might", "to": "squal", "value": 1}, {"from": "might", "to": "the decrease in p21", "value": 1}, {"from": "might", "to": "##mularia stem suggested that", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "the native", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "ligan", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "im", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "p = 0. 01", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##rank", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##j", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "by", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "rerank score", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##um", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##d", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "of ad", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "re", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##idodiph", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "p = 0", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "- 112. 70 k", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "score", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##ine", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##enyl", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##osphate", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "- 110. 68 k", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "0", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "/ mol ), and nummular", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "squal", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "the decrease in p21", "value": 1}, {"from": "arrest. molecular docking results of metabolite compounds from z. n", "to": "##mularia stem suggested that", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "the native", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "ligan", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "im", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "p = 0. 01", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##rank", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##j", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "by", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "rerank score", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##um", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##d", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "of ad", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "re", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##idodiph", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "p = 0", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "- 112. 70 k", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "score", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##ine", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##enyl", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##osphate", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "- 110. 68 k", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "0", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "/ mol ), and nummular", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "squal", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "the decrease in p21", "value": 1}, {"from": "##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed", "to": "##mularia stem suggested that", "value": 1}, {"from": "the native", "to": "ligan", "value": 1}, {"from": "the native", "to": "im", "value": 1}, {"from": "the native", "to": "p = 0. 01", "value": 1}, {"from": "the native", "to": "##rank", "value": 1}, {"from": "the native", "to": "##j", "value": 1}, {"from": "the native", "to": "by", "value": 1}, {"from": "the native", "to": "rerank score", "value": 1}, {"from": "the native", "to": "##um", "value": 1}, {"from": "the native", "to": "##d", "value": 1}, {"from": "the native", "to": "of ad", "value": 1}, {"from": "the native", "to": "re", "value": 1}, {"from": "the native", "to": "##idodiph", "value": 1}, {"from": "the native", "to": "p = 0", "value": 1}, {"from": "the native", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "the native", "to": "- 112. 70 k", "value": 1}, {"from": "the native", "to": "score", "value": 1}, {"from": "the native", "to": "##ine", "value": 1}, {"from": "the native", "to": "##enyl", "value": 1}, {"from": "the native", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "the native", "to": "##osphate", "value": 1}, {"from": "the native", "to": "- 110. 68 k", "value": 1}, {"from": "the native", "to": "0", "value": 1}, {"from": "the native", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "the native", "to": "/ mol ), and nummular", "value": 1}, {"from": "the native", "to": "squal", "value": 1}, {"from": "the native", "to": "the decrease in p21", "value": 1}, {"from": "the native", "to": "##mularia stem suggested that", "value": 1}, {"from": "ligan", "to": "im", "value": 1}, {"from": "ligan", "to": "p = 0. 01", "value": 1}, {"from": "ligan", "to": "##rank", "value": 1}, {"from": "ligan", "to": "##j", "value": 1}, {"from": "ligan", "to": "by", "value": 1}, {"from": "ligan", "to": "rerank score", "value": 1}, {"from": "ligan", "to": "##um", "value": 1}, {"from": "ligan", "to": "##d", "value": 1}, {"from": "ligan", "to": "of ad", "value": 1}, {"from": "ligan", "to": "re", "value": 1}, {"from": "ligan", "to": "##idodiph", "value": 1}, {"from": "ligan", "to": "p = 0", "value": 1}, {"from": "ligan", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "ligan", "to": "- 112. 70 k", "value": 1}, {"from": "ligan", "to": "score", "value": 1}, {"from": "ligan", "to": "##ine", "value": 1}, {"from": "ligan", "to": "##enyl", "value": 1}, {"from": "ligan", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "ligan", "to": "##osphate", "value": 1}, {"from": "ligan", "to": "- 110. 68 k", "value": 1}, {"from": "ligan", "to": "0", "value": 1}, {"from": "ligan", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "ligan", "to": "/ mol ), and nummular", "value": 1}, {"from": "ligan", "to": "squal", "value": 1}, {"from": "ligan", "to": "the decrease in p21", "value": 1}, {"from": "ligan", "to": "##mularia stem suggested that", "value": 1}, {"from": "im", "to": "p = 0. 01", "value": 1}, {"from": "im", "to": "##rank", "value": 1}, {"from": "im", "to": "##j", "value": 1}, {"from": "im", "to": "by", "value": 1}, {"from": "im", "to": "rerank score", "value": 1}, {"from": "im", "to": "##um", "value": 1}, {"from": "im", "to": "##d", "value": 1}, {"from": "im", "to": "of ad", "value": 1}, {"from": "im", "to": "re", "value": 1}, {"from": "im", "to": "##idodiph", "value": 1}, {"from": "im", "to": "p = 0", "value": 1}, {"from": "im", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "im", "to": "- 112. 70 k", "value": 1}, {"from": "im", "to": "score", "value": 1}, {"from": "im", "to": "##ine", "value": 1}, {"from": "im", "to": "##enyl", "value": 1}, {"from": "im", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "im", "to": "##osphate", "value": 1}, {"from": "im", "to": "- 110. 68 k", "value": 1}, {"from": "im", "to": "0", "value": 1}, {"from": "im", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "im", "to": "/ mol ), and nummular", "value": 1}, {"from": "im", "to": "squal", "value": 1}, {"from": "im", "to": "the decrease in p21", "value": 1}, {"from": "im", "to": "##mularia stem suggested that", "value": 1}, {"from": "p = 0. 01", "to": "##rank", "value": 1}, {"from": "p = 0. 01", "to": "##j", "value": 1}, {"from": "p = 0. 01", "to": "by", "value": 1}, {"from": "p = 0. 01", "to": "rerank score", "value": 1}, {"from": "p = 0. 01", "to": "##um", "value": 1}, {"from": "p = 0. 01", "to": "##d", "value": 1}, {"from": "p = 0. 01", "to": "of ad", "value": 1}, {"from": "p = 0. 01", "to": "re", "value": 1}, {"from": "p = 0. 01", "to": "##idodiph", "value": 1}, {"from": "p = 0. 01", "to": "p = 0", "value": 1}, {"from": "p = 0. 01", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "p = 0. 01", "to": "- 112. 70 k", "value": 1}, {"from": "p = 0. 01", "to": "score", "value": 1}, {"from": "p = 0. 01", "to": "##ine", "value": 1}, {"from": "p = 0. 01", "to": "##enyl", "value": 1}, {"from": "p = 0. 01", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "p = 0. 01", "to": "##osphate", "value": 1}, {"from": "p = 0. 01", "to": "- 110. 68 k", "value": 1}, {"from": "p = 0. 01", "to": "0", "value": 1}, {"from": "p = 0. 01", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "p = 0. 01", "to": "/ mol ), and nummular", "value": 1}, {"from": "p = 0. 01", "to": "squal", "value": 1}, {"from": "p = 0. 01", "to": "the decrease in p21", "value": 1}, {"from": "p = 0. 01", "to": "##mularia stem suggested that", "value": 1}, {"from": "##rank", "to": "##j", "value": 1}, {"from": "##rank", "to": "by", "value": 1}, {"from": "##rank", "to": "rerank score", "value": 1}, {"from": "##rank", "to": "##um", "value": 1}, {"from": "##rank", "to": "##d", "value": 1}, {"from": "##rank", "to": "of ad", "value": 1}, {"from": "##rank", "to": "re", "value": 1}, {"from": "##rank", "to": "##idodiph", "value": 1}, {"from": "##rank", "to": "p = 0", "value": 1}, {"from": "##rank", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##rank", "to": "- 112. 70 k", "value": 1}, {"from": "##rank", "to": "score", "value": 1}, {"from": "##rank", "to": "##ine", "value": 1}, {"from": "##rank", "to": "##enyl", "value": 1}, {"from": "##rank", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##rank", "to": "##osphate", "value": 1}, {"from": "##rank", "to": "- 110. 68 k", "value": 1}, {"from": "##rank", "to": "0", "value": 1}, {"from": "##rank", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##rank", "to": "/ mol ), and nummular", "value": 1}, {"from": "##rank", "to": "squal", "value": 1}, {"from": "##rank", "to": "the decrease in p21", "value": 1}, {"from": "##rank", "to": "##mularia stem suggested that", "value": 1}, {"from": "##j", "to": "by", "value": 1}, {"from": "##j", "to": "rerank score", "value": 1}, {"from": "##j", "to": "##um", "value": 1}, {"from": "##j", "to": "##d", "value": 1}, {"from": "##j", "to": "of ad", "value": 1}, {"from": "##j", "to": "re", "value": 1}, {"from": "##j", "to": "##idodiph", "value": 1}, {"from": "##j", "to": "p = 0", "value": 1}, {"from": "##j", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##j", "to": "- 112. 70 k", "value": 1}, {"from": "##j", "to": "score", "value": 1}, {"from": "##j", "to": "##ine", "value": 1}, {"from": "##j", "to": "##enyl", "value": 1}, {"from": "##j", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##j", "to": "##osphate", "value": 1}, {"from": "##j", "to": "- 110. 68 k", "value": 1}, {"from": "##j", "to": "0", "value": 1}, {"from": "##j", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##j", "to": "/ mol ), and nummular", "value": 1}, {"from": "##j", "to": "squal", "value": 1}, {"from": "##j", "to": "the decrease in p21", "value": 1}, {"from": "##j", "to": "##mularia stem suggested that", "value": 1}, {"from": "by", "to": "rerank score", "value": 1}, {"from": "by", "to": "##um", "value": 1}, {"from": "by", "to": "##d", "value": 1}, {"from": "by", "to": "of ad", "value": 1}, {"from": "by", "to": "re", "value": 1}, {"from": "by", "to": "##idodiph", "value": 1}, {"from": "by", "to": "p = 0", "value": 1}, {"from": "by", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "by", "to": "- 112. 70 k", "value": 1}, {"from": "by", "to": "score", "value": 1}, {"from": "by", "to": "##ine", "value": 1}, {"from": "by", "to": "##enyl", "value": 1}, {"from": "by", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "by", "to": "##osphate", "value": 1}, {"from": "by", "to": "- 110. 68 k", "value": 1}, {"from": "by", "to": "0", "value": 1}, {"from": "by", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "by", "to": "/ mol ), and nummular", "value": 1}, {"from": "by", "to": "squal", "value": 1}, {"from": "by", "to": "the decrease in p21", "value": 1}, {"from": "by", "to": "##mularia stem suggested that", "value": 1}, {"from": "by", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "by", "to": "benefit", "value": 1}, {"from": "by", "to": "##26, 000 ;", "value": 1}, {"from": "by", "to": "effective", "value": 1}, {"from": "by", "to": "it was cost - saving", "value": 1}, {"from": "by", "to": "threshold", "value": 1}, {"from": "by", "to": "- 435, 677 )", "value": 1}, {"from": "by", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "by", "to": "##aly", "value": 1}, {"from": "by", "to": "in the", "value": 1}, {"from": "by", "to": "cost", "value": 1}, {"from": "by", "to": "\u20ac", "value": 1}, {"from": "by", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "by", "to": "- 620170,", "value": 1}, {"from": "by", "to": "##r )", "value": 1}, {"from": "by", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "by", "to": "societal perspective", "value": 1}, {"from": "by", "to": "candidates, the strategy", "value": 1}, {"from": "by", "to": "cost - effective", "value": 1}, {"from": "by", "to": "incre", "value": 1}, {"from": "by", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "by", "to": "##mental", "value": 1}, {"from": "by", "to": "the cost -", "value": 1}, {"from": "by", "to": "was cost - effective", "value": 1}, {"from": "by", "to": "above", "value": 1}, {"from": "by", "to": "results", "value": 1}, {"from": "by", "to": "was", "value": 1}, {"from": "by", "to": "was obtained from statistics norway.", "value": 1}, {"from": "by", "to": "per quality - adjusted life -", "value": 1}, {"from": "by", "to": "was cost - saving", "value": 1}, {"from": "by", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "by", "to": "chemotherapy", "value": 1}, {"from": "by", "to": "in both the healthcare", "value": 1}, {"from": "by", "to": "years", "value": 1}, {"from": "by", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "by", "to": "- per q", "value": 1}, {"from": "by", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "by", "to": ". conclusions", "value": 1}, {"from": "by", "to": ". selecting patient", "value": 1}, {"from": "by", "to": "ice", "value": 1}, {"from": "by", "to": "##r", "value": 1}, {"from": "by", "to": "##8884 and", "value": 1}, {"from": "by", "to": "gained", "value": 1}, {"from": "by", "to": "the emit", "value": 1}, {"from": "by", "to": "records. including all pn0 patients", "value": 1}, {"from": "by", "to": "sector", "value": 1}, {"from": "by", "to": "not", "value": 1}, {"from": "rerank score", "to": "##um", "value": 1}, {"from": "rerank score", "to": "##d", "value": 1}, {"from": "rerank score", "to": "of ad", "value": 1}, {"from": "rerank score", "to": "re", "value": 1}, {"from": "rerank score", "to": "##idodiph", "value": 1}, {"from": "rerank score", "to": "p = 0", "value": 1}, {"from": "rerank score", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "rerank score", "to": "- 112. 70 k", "value": 1}, {"from": "rerank score", "to": "score", "value": 1}, {"from": "rerank score", "to": "##ine", "value": 1}, {"from": "rerank score", "to": "##enyl", "value": 1}, {"from": "rerank score", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "rerank score", "to": "##osphate", "value": 1}, {"from": "rerank score", "to": "- 110. 68 k", "value": 1}, {"from": "rerank score", "to": "0", "value": 1}, {"from": "rerank score", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "rerank score", "to": "/ mol ), and nummular", "value": 1}, {"from": "rerank score", "to": "squal", "value": 1}, {"from": "rerank score", "to": "the decrease in p21", "value": 1}, {"from": "rerank score", "to": "##mularia stem suggested that", "value": 1}, {"from": "##um", "to": "##d", "value": 1}, {"from": "##um", "to": "of ad", "value": 1}, {"from": "##um", "to": "re", "value": 1}, {"from": "##um", "to": "##idodiph", "value": 1}, {"from": "##um", "to": "p = 0", "value": 1}, {"from": "##um", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##um", "to": "- 112. 70 k", "value": 1}, {"from": "##um", "to": "score", "value": 1}, {"from": "##um", "to": "##ine", "value": 1}, {"from": "##um", "to": "##enyl", "value": 1}, {"from": "##um", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##um", "to": "##osphate", "value": 1}, {"from": "##um", "to": "- 110. 68 k", "value": 1}, {"from": "##um", "to": "0", "value": 1}, {"from": "##um", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##um", "to": "/ mol ), and nummular", "value": 1}, {"from": "##um", "to": "squal", "value": 1}, {"from": "##um", "to": "the decrease in p21", "value": 1}, {"from": "##um", "to": "##mularia stem suggested that", "value": 1}, {"from": "##d", "to": "of ad", "value": 1}, {"from": "##d", "to": "re", "value": 1}, {"from": "##d", "to": "##idodiph", "value": 1}, {"from": "##d", "to": "p = 0", "value": 1}, {"from": "##d", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##d", "to": "- 112. 70 k", "value": 1}, {"from": "##d", "to": "score", "value": 1}, {"from": "##d", "to": "##ine", "value": 1}, {"from": "##d", "to": "##enyl", "value": 1}, {"from": "##d", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##d", "to": "##osphate", "value": 1}, {"from": "##d", "to": "- 110. 68 k", "value": 1}, {"from": "##d", "to": "0", "value": 1}, {"from": "##d", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##d", "to": "/ mol ), and nummular", "value": 1}, {"from": "##d", "to": "squal", "value": 1}, {"from": "##d", "to": "the decrease in p21", "value": 1}, {"from": "##d", "to": "##mularia stem suggested that", "value": 1}, {"from": "of ad", "to": "re", "value": 1}, {"from": "of ad", "to": "##idodiph", "value": 1}, {"from": "of ad", "to": "p = 0", "value": 1}, {"from": "of ad", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "of ad", "to": "- 112. 70 k", "value": 1}, {"from": "of ad", "to": "score", "value": 1}, {"from": "of ad", "to": "##ine", "value": 1}, {"from": "of ad", "to": "##enyl", "value": 1}, {"from": "of ad", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "of ad", "to": "##osphate", "value": 1}, {"from": "of ad", "to": "- 110. 68 k", "value": 1}, {"from": "of ad", "to": "0", "value": 1}, {"from": "of ad", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "of ad", "to": "/ mol ), and nummular", "value": 1}, {"from": "of ad", "to": "squal", "value": 1}, {"from": "of ad", "to": "the decrease in p21", "value": 1}, {"from": "of ad", "to": "##mularia stem suggested that", "value": 1}, {"from": "re", "to": "##idodiph", "value": 1}, {"from": "re", "to": "p = 0", "value": 1}, {"from": "re", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "re", "to": "- 112. 70 k", "value": 1}, {"from": "re", "to": "score", "value": 2}, {"from": "re", "to": "##ine", "value": 1}, {"from": "re", "to": "##enyl", "value": 1}, {"from": "re", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "re", "to": "##osphate", "value": 1}, {"from": "re", "to": "- 110. 68 k", "value": 1}, {"from": "re", "to": "0", "value": 1}, {"from": "re", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "re", "to": "/ mol ), and nummular", "value": 1}, {"from": "re", "to": "squal", "value": 1}, {"from": "re", "to": "the decrease in p21", "value": 1}, {"from": "re", "to": "##mularia stem suggested that", "value": 1}, {"from": "re", "to": "2 ) department of pathology, memorial sloan kettering cancer center,", "value": 1}, {"from": "re", "to": "), beltran - v", "value": 1}, {"from": "re", "to": ") department of pathology, co", "value": 1}, {"from": "re", "to": "##ulin", "value": 1}, {"from": "re", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "re", "to": "f", "value": 1}, {"from": "re", "to": "new yo", "value": 1}, {"from": "re", "to": "sloan", "value": 1}, {"from": "re", "to": "la", "value": 1}, {"from": "re", "to": "center", "value": 1}, {"from": "re", "to": "us", "value": 1}, {"from": "re", "to": "##lum", "value": 1}, {"from": "re", "to": "##o m", "value": 1}, {"from": "re", "to": "9", "value": 1}, {"from": "re", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "re", "to": "kette", "value": 1}, {"from": "re", "to": "yo", "value": 1}, {"from": "re", "to": "##ettering cancer", "value": 1}, {"from": "re", "to": "##rk, usa.", "value": 1}, {"from": "re", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "re", "to": "new york", "value": 1}, {"from": "re", "to": "##bia university,", "value": 1}, {"from": "re", "to": "), shin e", "value": 1}, {"from": "re", "to": "##ring cancer", "value": 1}, {"from": "re", "to": "##rk, new", "value": 1}, {"from": "re", "to": "##urent, quebec, canada.", "value": 1}, {"from": "re", "to": "##isied", "value": 1}, {"from": "re", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "re", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "re", "to": "ancers. sinha s", "value": 1}, {"from": "re", "to": "##is - filho j", "value": 1}, {"from": "re", "to": "##rk,", "value": 1}, {"from": "re", "to": "), gardner r", "value": 1}, {"from": "re", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "re", "to": "in ki", "value": 1}, {"from": "re", "to": "##cu", "value": 1}, {"from": "re", "to": "t", "value": 1}, {"from": "re", "to": "positive", "value": 1}, {"from": "re", "to": "##2 -", "value": 1}, {"from": "re", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "re", "to": "##rrence", "value": 1}, {"from": "re", "to": "percentage", "value": 1}, {"from": "re", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "re", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "re", "to": "from l", "value": 1}, {"from": "re", "to": "presented", "value": 1}, {"from": "re", "to": "results", "value": 1}, {"from": "re", "to": "pam50 - derived risk of", "value": 1}, {"from": "re", "to": "her", "value": 1}, {"from": "re", "to": "er + /", "value": 1}, {"from": "re", "to": "##nal a to normal - like", "value": 1}, {"from": "re", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "re", "to": "cells", "value": 1}, {"from": "re", "to": "change", "value": 1}, {"from": "re", "to": "after", "value": 1}, {"from": "re", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "re", "to": "of intrinsic sub", "value": 1}, {"from": "re", "to": "p53", "value": 1}, {"from": "re", "to": "##is.", "value": 1}, {"from": "re", "to": "biomark", "value": 1}, {"from": "re", "to": "subtype after", "value": 1}, {"from": "re", "to": "net", "value": 1}, {"from": "re", "to": "of", "value": 1}, {"from": "re", "to": "##c patients", "value": 1}, {"from": "re", "to": "net as a putative", "value": 1}, {"from": "re", "to": "##umour cellularity size", "value": 1}, {"from": "re", "to": "radio", "value": 1}, {"from": "re", "to": ") and lower", "value": 1}, {"from": "re", "to": "better", "value": 1}, {"from": "re", "to": "is cost - effective", "value": 1}, {"from": "re", "to": "of agriculture and natural", "value": 1}, {"from": "re", "to": ". ac.", "value": 1}, {"from": "re", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "re", "to": "resources", "value": 1}, {"from": "re", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "re", "to": "##za. he", "value": 1}, {"from": "re", "to": "##6 /", "value": 1}, {"from": "re", "to": "are", "value": 1}, {"from": "re", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "re", "to": "##ri - japelaghi r", "value": 1}, {"from": "re", "to": "##r.", "value": 1}, {"from": "re", "to": "who", "value": 1}, {"from": "re", "to": "inter", "value": 1}, {"from": "re", "to": "##vin", "value": 1}, {"from": "re", "to": "of tabriz,", "value": 1}, {"from": "re", "to": "@ org.", "value": 1}, {"from": "re", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "re", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "re", "to": "##idari", "value": 1}, {"from": "re", "to": "s", "value": 1}, {"from": "re", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "re", "to": "ta", "value": 1}, {"from": "re", "to": "##ran. electronic address :", "value": 1}, {"from": "re", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "re", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "re", "to": "101", "value": 1}, {"from": "re", "to": "perspectives", "value": 1}, {"from": "re", "to": "##briz,", "value": 1}, {"from": "re", "to": "of agriculture,", "value": 1}, {"from": "re", "to": "##fer", "value": 1}, {"from": "re", "to": "##on", "value": 1}, {"from": "re", "to": "##ki", "value": 1}, {"from": "re", "to": "from both", "value": 1}, {"from": "re", "to": "##ran.", "value": 1}, {"from": "##idodiph", "to": "p = 0", "value": 1}, {"from": "##idodiph", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "##idodiph", "to": "- 112. 70 k", "value": 1}, {"from": "##idodiph", "to": "score", "value": 1}, {"from": "##idodiph", "to": "##ine", "value": 1}, {"from": "##idodiph", "to": "##enyl", "value": 1}, {"from": "##idodiph", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##idodiph", "to": "##osphate", "value": 1}, {"from": "##idodiph", "to": "- 110. 68 k", "value": 1}, {"from": "##idodiph", "to": "0", "value": 1}, {"from": "##idodiph", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##idodiph", "to": "/ mol ), and nummular", "value": 1}, {"from": "##idodiph", "to": "squal", "value": 1}, {"from": "##idodiph", "to": "the decrease in p21", "value": 1}, {"from": "##idodiph", "to": "##mularia stem suggested that", "value": 1}, {"from": "p = 0", "to": "##5 ), which was observed through rt - qp", "value": 1}, {"from": "p = 0", "to": "- 112. 70 k", "value": 1}, {"from": "p = 0", "to": "score", "value": 1}, {"from": "p = 0", "to": "##ine", "value": 1}, {"from": "p = 0", "to": "##enyl", "value": 1}, {"from": "p = 0", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "p = 0", "to": "##osphate", "value": 1}, {"from": "p = 0", "to": "- 110. 68 k", "value": 1}, {"from": "p = 0", "to": "0", "value": 1}, {"from": "p = 0", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "p = 0", "to": "/ mol ), and nummular", "value": 1}, {"from": "p = 0", "to": "squal", "value": 1}, {"from": "p = 0", "to": "the decrease in p21", "value": 1}, {"from": "p = 0", "to": "##mularia stem suggested that", "value": 1}, {"from": "p = 0", "to": "=", "value": 1}, {"from": "p = 0", "to": "##s,", "value": 1}, {"from": "p = 0", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "p = 0", "to": "which is involved in", "value": 1}, {"from": "p = 0", "to": "- 0. 46,", "value": 1}, {"from": "p = 0", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "p = 0", "to": "mi", "value": 1}, {"from": "p = 0", "to": "- 5p", "value": 1}, {"from": "p = 0", "to": "##r - 17", "value": 1}, {"from": "p = 0", "to": "##1", "value": 1}, {"from": "p = 0", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "p = 0", "to": ") : e010548.", "value": 1}, {"from": "p = 0", "to": "5p", "value": 1}, {"from": "p = 0", "to": "hand", "value": 1}, {"from": "p = 0", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "p = 0", "to": "03 ) and", "value": 1}, {"from": "p = 0", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "p = 0", "to": "##r - 106a -", "value": 1}, {"from": "p = 0", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "p = 0", "to": "target gene", "value": 1}, {"from": "p = 0", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "p = 0", "to": "- 0. 41,", "value": 1}, {"from": "p = 0", "to": "of these lnc", "value": 1}, {"from": "p = 0", "to": "p = 0.", "value": 1}, {"from": "p = 0", "to": "113", "value": 1}, {"from": "p = 0", "to": "common", "value": 1}, {"from": "p = 0", "to": "regulated", "value": 1}, {"from": "p = 0", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "- 112. 70 k", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "score", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "##ine", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "##enyl", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "##osphate", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "- 110. 68 k", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "0", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "/ mol ), and nummular", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "squal", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "the decrease in p21", "value": 1}, {"from": "##5 ), which was observed through rt - qp", "to": "##mularia stem suggested that", "value": 1}, {"from": "- 112. 70 k", "to": "score", "value": 1}, {"from": "- 112. 70 k", "to": "##ine", "value": 1}, {"from": "- 112. 70 k", "to": "##enyl", "value": 1}, {"from": "- 112. 70 k", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "- 112. 70 k", "to": "##osphate", "value": 1}, {"from": "- 112. 70 k", "to": "- 110. 68 k", "value": 1}, {"from": "- 112. 70 k", "to": "0", "value": 1}, {"from": "- 112. 70 k", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "- 112. 70 k", "to": "/ mol ), and nummular", "value": 1}, {"from": "- 112. 70 k", "to": "squal", "value": 1}, {"from": "- 112. 70 k", "to": "the decrease in p21", "value": 1}, {"from": "- 112. 70 k", "to": "##mularia stem suggested that", "value": 1}, {"from": "score", "to": "##ine", "value": 1}, {"from": "score", "to": "##enyl", "value": 1}, {"from": "score", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "score", "to": "##osphate", "value": 1}, {"from": "score", "to": "- 110. 68 k", "value": 1}, {"from": "score", "to": "0", "value": 1}, {"from": "score", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "score", "to": "/ mol ), and nummular", "value": 1}, {"from": "score", "to": "squal", "value": 1}, {"from": "score", "to": "the decrease in p21", "value": 1}, {"from": "score", "to": "##mularia stem suggested that", "value": 1}, {"from": "score", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "score", "to": "in ki", "value": 1}, {"from": "score", "to": "##cu", "value": 1}, {"from": "score", "to": "t", "value": 1}, {"from": "score", "to": "positive", "value": 1}, {"from": "score", "to": "##2 -", "value": 1}, {"from": "score", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "score", "to": "##rrence", "value": 1}, {"from": "score", "to": "percentage", "value": 1}, {"from": "score", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "score", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "score", "to": "from l", "value": 1}, {"from": "score", "to": "presented", "value": 1}, {"from": "score", "to": "results", "value": 1}, {"from": "score", "to": "pam50 - derived risk of", "value": 1}, {"from": "score", "to": "her", "value": 1}, {"from": "score", "to": "er + /", "value": 1}, {"from": "score", "to": "##nal a to normal - like", "value": 1}, {"from": "score", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "score", "to": "cells", "value": 1}, {"from": "score", "to": "change", "value": 1}, {"from": "score", "to": "after", "value": 1}, {"from": "score", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "score", "to": "of intrinsic sub", "value": 1}, {"from": "score", "to": "p53", "value": 1}, {"from": "score", "to": "##is.", "value": 1}, {"from": "score", "to": "biomark", "value": 1}, {"from": "score", "to": "subtype after", "value": 1}, {"from": "score", "to": "net", "value": 1}, {"from": "score", "to": "of", "value": 1}, {"from": "score", "to": "##c patients", "value": 1}, {"from": "score", "to": "net as a putative", "value": 1}, {"from": "score", "to": "##umour cellularity size", "value": 1}, {"from": "score", "to": "radio", "value": 1}, {"from": "score", "to": ") and lower", "value": 1}, {"from": "score", "to": "better", "value": 1}, {"from": "##ine", "to": "##enyl", "value": 1}, {"from": "##ine", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##ine", "to": "##osphate", "value": 1}, {"from": "##ine", "to": "- 110. 68 k", "value": 1}, {"from": "##ine", "to": "0", "value": 1}, {"from": "##ine", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##ine", "to": "/ mol ), and nummular", "value": 1}, {"from": "##ine", "to": "squal", "value": 1}, {"from": "##ine", "to": "the decrease in p21", "value": 1}, {"from": "##ine", "to": "##mularia stem suggested that", "value": 1}, {"from": "##enyl", "to": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "value": 1}, {"from": "##enyl", "to": "##osphate", "value": 1}, {"from": "##enyl", "to": "- 110. 68 k", "value": 1}, {"from": "##enyl", "to": "0", "value": 1}, {"from": "##enyl", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##enyl", "to": "/ mol ), and nummular", "value": 1}, {"from": "##enyl", "to": "squal", "value": 1}, {"from": "##enyl", "to": "the decrease in p21", "value": 1}, {"from": "##enyl", "to": "##mularia stem suggested that", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "##osphate", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "- 110. 68 k", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "0", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "/ mol ), and nummular", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "squal", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "the decrease in p21", "value": 1}, {"from": "of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 \u00b1", "to": "##mularia stem suggested that", "value": 1}, {"from": "##osphate", "to": "- 110. 68 k", "value": 1}, {"from": "##osphate", "to": "0", "value": 1}, {"from": "##osphate", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "##osphate", "to": "/ mol ), and nummular", "value": 1}, {"from": "##osphate", "to": "squal", "value": 1}, {"from": "##osphate", "to": "the decrease in p21", "value": 1}, {"from": "##osphate", "to": "##mularia stem suggested that", "value": 1}, {"from": "- 110. 68 k", "to": "0", "value": 1}, {"from": "- 110. 68 k", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "- 110. 68 k", "to": "/ mol ), and nummular", "value": 1}, {"from": "- 110. 68 k", "to": "squal", "value": 1}, {"from": "- 110. 68 k", "to": "the decrease in p21", "value": 1}, {"from": "- 110. 68 k", "to": "##mularia stem suggested that", "value": 1}, {"from": "0", "to": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "value": 1}, {"from": "0", "to": "/ mol ), and nummular", "value": 1}, {"from": "0", "to": "squal", "value": 1}, {"from": "0", "to": "the decrease in p21", "value": 1}, {"from": "0", "to": "##mularia stem suggested that", "value": 1}, {"from": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "to": "/ mol ), and nummular", "value": 1}, {"from": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "to": "squal", "value": 1}, {"from": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "to": "the decrease in p21", "value": 1}, {"from": "/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the", "to": "##mularia stem suggested that", "value": 1}, {"from": "/ mol ), and nummular", "to": "squal", "value": 1}, {"from": "/ mol ), and nummular", "to": "the decrease in p21", "value": 1}, {"from": "/ mol ), and nummular", "to": "##mularia stem suggested that", "value": 1}, {"from": "squal", "to": "the decrease in p21", "value": 1}, {"from": "squal", "to": "##mularia stem suggested that", "value": 1}, {"from": "the decrease in p21", "to": "##mularia stem suggested that", "value": 1}, {"from": "##life", "to": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "value": 1}, {"from": "##life", "to": "##ion of p21", "value": 1}, {"from": "##life", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "##life", "to": "##in - mediated anti -", "value": 1}, {"from": "##life", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "##life", "to": "1 ), abdelkrim g", "value": 1}, {"from": "##life", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "##life", "to": "cancer effects. foda my", "value": 1}, {"from": "##life", "to": "##press", "value": 1}, {"from": "##life", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "##life", "to": "##tat", "value": 1}, {"from": "##life", "to": "jun", "value": 1}, {"from": "##life", "to": "2 ), salem ml", "value": 1}, {"from": "##life", "to": "in atorvas", "value": 1}, {"from": "##life", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "##ion of p21", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "##in - mediated anti -", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "1 ), abdelkrim g", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "cancer effects. foda my", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "##press", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "##tat", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "jun", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "2 ), salem ml", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "in atorvas", "value": 1}, {"from": "##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21.", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##ion of p21", "to": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "value": 1}, {"from": "##ion of p21", "to": "##in - mediated anti -", "value": 1}, {"from": "##ion of p21", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "##ion of p21", "to": "1 ), abdelkrim g", "value": 1}, {"from": "##ion of p21", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "##ion of p21", "to": "cancer effects. foda my", "value": 1}, {"from": "##ion of p21", "to": "##press", "value": 1}, {"from": "##ion of p21", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "##ion of p21", "to": "##tat", "value": 1}, {"from": "##ion of p21", "to": "jun", "value": 1}, {"from": "##ion of p21", "to": "2 ), salem ml", "value": 1}, {"from": "##ion of p21", "to": "in atorvas", "value": 1}, {"from": "##ion of p21", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "##in - mediated anti -", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "1 ), abdelkrim g", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "cancer effects. foda my", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "##press", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "##tat", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "jun", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "2 ), salem ml", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "in atorvas", "value": 1}, {"from": ". 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##in - mediated anti -", "to": ") biochemistry division, chemistry department,", "value": 1}, {"from": "##in - mediated anti -", "to": "1 ), abdelkrim g", "value": 1}, {"from": "##in - mediated anti -", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "##in - mediated anti -", "to": "cancer effects. foda my", "value": 1}, {"from": "##in - mediated anti -", "to": "##press", "value": 1}, {"from": "##in - mediated anti -", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "##in - mediated anti -", "to": "##tat", "value": 1}, {"from": "##in - mediated anti -", "to": "jun", "value": 1}, {"from": "##in - mediated anti -", "to": "2 ), salem ml", "value": 1}, {"from": "##in - mediated anti -", "to": "in atorvas", "value": 1}, {"from": "##in - mediated anti -", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "1 ), abdelkrim g", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "cancer effects. foda my", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "##press", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "##tat", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "jun", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "2 ), salem ml", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "in atorvas", "value": 1}, {"from": ") biochemistry division, chemistry department,", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "1 ), abdelkrim g", "to": "kn1a ) mrna expression. in conclusion, the anti - pro", "value": 1}, {"from": "1 ), abdelkrim g", "to": "cancer effects. foda my", "value": 1}, {"from": "1 ), abdelkrim g", "to": "##press", "value": 1}, {"from": "1 ), abdelkrim g", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "1 ), abdelkrim g", "to": "##tat", "value": 1}, {"from": "1 ), abdelkrim g", "to": "jun", "value": 1}, {"from": "1 ), abdelkrim g", "to": "2 ), salem ml", "value": 1}, {"from": "1 ), abdelkrim g", "to": "in atorvas", "value": 1}, {"from": "1 ), abdelkrim g", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "cancer effects. foda my", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "##press", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "##tat", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "jun", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "2 ), salem ml", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "in atorvas", "value": 1}, {"from": "kn1a ) mrna expression. in conclusion, the anti - pro", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "cancer effects. foda my", "to": "##press", "value": 1}, {"from": "cancer effects. foda my", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "cancer effects. foda my", "to": "##tat", "value": 1}, {"from": "cancer effects. foda my", "to": "jun", "value": 1}, {"from": "cancer effects. foda my", "to": "2 ), salem ml", "value": 1}, {"from": "cancer effects. foda my", "to": "in atorvas", "value": 1}, {"from": "cancer effects. foda my", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##press", "to": "of science, mansoura university, mansoura, egypt.", "value": 1}, {"from": "##press", "to": "##tat", "value": 1}, {"from": "##press", "to": "jun", "value": 1}, {"from": "##press", "to": "2 ), salem ml", "value": 1}, {"from": "##press", "to": "in atorvas", "value": 1}, {"from": "##press", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "of science, mansoura university, mansoura, egypt.", "to": "##tat", "value": 1}, {"from": "of science, mansoura university, mansoura, egypt.", "to": "jun", "value": 1}, {"from": "of science, mansoura university, mansoura, egypt.", "to": "2 ), salem ml", "value": 1}, {"from": "of science, mansoura university, mansoura, egypt.", "to": "in atorvas", "value": 1}, {"from": "of science, mansoura university, mansoura, egypt.", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##tat", "to": "jun", "value": 2}, {"from": "##tat", "to": "2 ), salem ml", "value": 1}, {"from": "##tat", "to": "in atorvas", "value": 1}, {"from": "##tat", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "##tat", "to": "prescribed chole", "value": 1}, {"from": "##tat", "to": "has recently", "value": 1}, {"from": "##tat", "to": "and its biological functions", "value": 1}, {"from": "##tat", "to": "of saida, saida, algeria.", "value": 1}, {"from": "##tat", "to": "shown", "value": 1}, {"from": "##tat", "to": "however", "value": 1}, {"from": "##tat", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "##tat", "to": "shown potential anti", "value": 1}, {"from": "##tat", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "##tat", "to": "##in", "value": 1}, {"from": "##tat", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "##tat", "to": "particular breast cancer,", "value": 1}, {"from": "##tat", "to": "still", "value": 1}, {"from": "##tat", "to": "associated with atorvas", "value": 1}, {"from": "##tat", "to": "in breast", "value": 1}, {"from": "##tat", "to": "lowering", "value": 1}, {"from": "##tat", "to": "to be responsive to", "value": 1}, {"from": "##tat", "to": "interaction", "value": 1}, {"from": "##tat", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "##tat", "to": ") network and", "value": 1}, {"from": "##tat", "to": "in the protein - protein", "value": 1}, {"from": "##tat", "to": "drug,", "value": 1}, {"from": "##tat", "to": "hub gene", "value": 1}, {"from": "##tat", "to": ", its influence on gene", "value": 1}, {"from": "##tat", "to": "##lated", "value": 1}, {"from": "##tat", "to": "was", "value": 1}, {"from": "##tat", "to": "##in,", "value": 1}, {"from": "##tat", "to": "ppi", "value": 1}, {"from": "##tat", "to": "##oto", "value": 1}, {"from": "##tat", "to": "related pathways", "value": 1}, {"from": "##tat", "to": "cancer,", "value": 1}, {"from": "##tat", "to": "expressed", "value": 1}, {"from": "##tat", "to": "##cer effects.", "value": 1}, {"from": "##tat", "to": "widely", "value": 1}, {"from": "##tat", "to": "atorvas", "value": 1}, {"from": "##tat", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##tat", "to": "##ster", "value": 1}, {"from": "##tat", "to": "##ol", "value": 1}, {"from": "##tat", "to": "##can", "value": 1}, {"from": "##tat", "to": "cancer. atorvas", "value": 1}, {"from": "##tat", "to": "was identified as the", "value": 1}, {"from": "jun", "to": "2 ), salem ml", "value": 1}, {"from": "jun", "to": "in atorvas", "value": 1}, {"from": "jun", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "jun", "to": "prescribed chole", "value": 1}, {"from": "jun", "to": "has recently", "value": 1}, {"from": "jun", "to": "and its biological functions", "value": 1}, {"from": "jun", "to": "of saida, saida, algeria.", "value": 1}, {"from": "jun", "to": "shown", "value": 1}, {"from": "jun", "to": "however", "value": 1}, {"from": "jun", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "jun", "to": "shown potential anti", "value": 1}, {"from": "jun", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "jun", "to": "##in", "value": 1}, {"from": "jun", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "jun", "to": "particular breast cancer,", "value": 1}, {"from": "jun", "to": "still", "value": 1}, {"from": "jun", "to": "associated with atorvas", "value": 1}, {"from": "jun", "to": "in breast", "value": 1}, {"from": "jun", "to": "lowering", "value": 1}, {"from": "jun", "to": "to be responsive to", "value": 1}, {"from": "jun", "to": "interaction", "value": 1}, {"from": "jun", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "jun", "to": ") network and", "value": 1}, {"from": "jun", "to": "in the protein - protein", "value": 1}, {"from": "jun", "to": "drug,", "value": 1}, {"from": "jun", "to": "hub gene", "value": 1}, {"from": "jun", "to": ", its influence on gene", "value": 1}, {"from": "jun", "to": "##lated", "value": 1}, {"from": "jun", "to": "was", "value": 2}, {"from": "jun", "to": "##in,", "value": 1}, {"from": "jun", "to": "ppi", "value": 1}, {"from": "jun", "to": "##oto", "value": 1}, {"from": "jun", "to": "related pathways", "value": 1}, {"from": "jun", "to": "cancer,", "value": 1}, {"from": "jun", "to": "expressed", "value": 1}, {"from": "jun", "to": "##cer effects.", "value": 1}, {"from": "jun", "to": "widely", "value": 1}, {"from": "jun", "to": "atorvas", "value": 1}, {"from": "jun", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "jun", "to": "##ster", "value": 1}, {"from": "jun", "to": "##ol", "value": 1}, {"from": "jun", "to": "##can", "value": 1}, {"from": "jun", "to": "cancer. atorvas", "value": 1}, {"from": "jun", "to": "was identified as the", "value": 1}, {"from": "jun", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "jun", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "jun", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "jun", "to": ". 108", "value": 1}, {"from": "jun", "to": "jun might", "value": 1}, {"from": "jun", "to": "##0", "value": 1}, {"from": "jun", "to": "expression.", "value": 1}, {"from": "jun", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "jun", "to": "##na ss", "value": 1}, {"from": "jun", "to": "##v", "value": 1}, {"from": "jun", "to": "##un", "value": 1}, {"from": "jun", "to": "##gno", "value": 1}, {"from": "jun", "to": "activity positively correlated with", "value": 1}, {"from": "jun", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "jun", "to": ". 17305 /", "value": 1}, {"from": "jun", "to": "luki", "value": 1}, {"from": "jun", "to": "##v vi", "value": 1}, {"from": "jun", "to": "logino", "value": 1}, {"from": "jun", "to": "may directly interact with", "value": 1}, {"from": "jun", "to": "serve as a valuable pro", "value": 1}, {"from": "jun", "to": "##tatin", "value": 1}, {"from": "jun", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "jun", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "jun", "to": "expression. as such,", "value": 1}, {"from": "jun", "to": "significantly", "value": 1}, {"from": "jun", "to": "##nina", "value": 1}, {"from": "jun", "to": "pro", "value": 1}, {"from": "jun", "to": "down", "value": 1}, {"from": "jun", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "2 ), salem ml", "to": "in atorvas", "value": 1}, {"from": "2 ), salem ml", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "in atorvas", "to": "##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex", "value": 1}, {"from": "prescribed chole", "to": "has recently", "value": 1}, {"from": "prescribed chole", "to": "and its biological functions", "value": 1}, {"from": "prescribed chole", "to": "of saida, saida, algeria.", "value": 1}, {"from": "prescribed chole", "to": "shown", "value": 1}, {"from": "prescribed chole", "to": "however", "value": 1}, {"from": "prescribed chole", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "prescribed chole", "to": "shown potential anti", "value": 1}, {"from": "prescribed chole", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "prescribed chole", "to": "##in", "value": 1}, {"from": "prescribed chole", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "prescribed chole", "to": "particular breast cancer,", "value": 1}, {"from": "prescribed chole", "to": "still", "value": 1}, {"from": "prescribed chole", "to": "associated with atorvas", "value": 1}, {"from": "prescribed chole", "to": "in breast", "value": 1}, {"from": "prescribed chole", "to": "lowering", "value": 1}, {"from": "prescribed chole", "to": "to be responsive to", "value": 1}, {"from": "prescribed chole", "to": "interaction", "value": 1}, {"from": "prescribed chole", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "prescribed chole", "to": ") network and", "value": 1}, {"from": "prescribed chole", "to": "in the protein - protein", "value": 1}, {"from": "prescribed chole", "to": "drug,", "value": 1}, {"from": "prescribed chole", "to": "hub gene", "value": 1}, {"from": "prescribed chole", "to": ", its influence on gene", "value": 1}, {"from": "prescribed chole", "to": "##lated", "value": 1}, {"from": "prescribed chole", "to": "was", "value": 1}, {"from": "prescribed chole", "to": "##in,", "value": 1}, {"from": "prescribed chole", "to": "ppi", "value": 1}, {"from": "prescribed chole", "to": "##oto", "value": 1}, {"from": "prescribed chole", "to": "related pathways", "value": 1}, {"from": "prescribed chole", "to": "cancer,", "value": 1}, {"from": "prescribed chole", "to": "expressed", "value": 1}, {"from": "prescribed chole", "to": "##cer effects.", "value": 1}, {"from": "prescribed chole", "to": "widely", "value": 1}, {"from": "prescribed chole", "to": "atorvas", "value": 1}, {"from": "prescribed chole", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "prescribed chole", "to": "##ster", "value": 1}, {"from": "prescribed chole", "to": "##ol", "value": 1}, {"from": "prescribed chole", "to": "##can", "value": 1}, {"from": "prescribed chole", "to": "cancer. atorvas", "value": 1}, {"from": "prescribed chole", "to": "was identified as the", "value": 1}, {"from": "has recently", "to": "and its biological functions", "value": 1}, {"from": "has recently", "to": "of saida, saida, algeria.", "value": 1}, {"from": "has recently", "to": "shown", "value": 1}, {"from": "has recently", "to": "however", "value": 1}, {"from": "has recently", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "has recently", "to": "shown potential anti", "value": 1}, {"from": "has recently", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "has recently", "to": "##in", "value": 1}, {"from": "has recently", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "has recently", "to": "particular breast cancer,", "value": 1}, {"from": "has recently", "to": "still", "value": 1}, {"from": "has recently", "to": "associated with atorvas", "value": 1}, {"from": "has recently", "to": "in breast", "value": 1}, {"from": "has recently", "to": "lowering", "value": 1}, {"from": "has recently", "to": "to be responsive to", "value": 1}, {"from": "has recently", "to": "interaction", "value": 1}, {"from": "has recently", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "has recently", "to": ") network and", "value": 1}, {"from": "has recently", "to": "in the protein - protein", "value": 1}, {"from": "has recently", "to": "drug,", "value": 1}, {"from": "has recently", "to": "hub gene", "value": 1}, {"from": "has recently", "to": ", its influence on gene", "value": 1}, {"from": "has recently", "to": "##lated", "value": 1}, {"from": "has recently", "to": "was", "value": 1}, {"from": "has recently", "to": "##in,", "value": 1}, {"from": "has recently", "to": "ppi", "value": 1}, {"from": "has recently", "to": "##oto", "value": 1}, {"from": "has recently", "to": "related pathways", "value": 1}, {"from": "has recently", "to": "cancer,", "value": 1}, {"from": "has recently", "to": "expressed", "value": 1}, {"from": "has recently", "to": "##cer effects.", "value": 1}, {"from": "has recently", "to": "widely", "value": 1}, {"from": "has recently", "to": "atorvas", "value": 1}, {"from": "has recently", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "has recently", "to": "##ster", "value": 1}, {"from": "has recently", "to": "##ol", "value": 1}, {"from": "has recently", "to": "##can", "value": 1}, {"from": "has recently", "to": "cancer. atorvas", "value": 1}, {"from": "has recently", "to": "was identified as the", "value": 1}, {"from": "and its biological functions", "to": "of saida, saida, algeria.", "value": 1}, {"from": "and its biological functions", "to": "shown", "value": 1}, {"from": "and its biological functions", "to": "however", "value": 1}, {"from": "and its biological functions", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "and its biological functions", "to": "shown potential anti", "value": 1}, {"from": "and its biological functions", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "and its biological functions", "to": "##in", "value": 1}, {"from": "and its biological functions", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "and its biological functions", "to": "particular breast cancer,", "value": 1}, {"from": "and its biological functions", "to": "still", "value": 1}, {"from": "and its biological functions", "to": "associated with atorvas", "value": 1}, {"from": "and its biological functions", "to": "in breast", "value": 1}, {"from": "and its biological functions", "to": "lowering", "value": 1}, {"from": "and its biological functions", "to": "to be responsive to", "value": 1}, {"from": "and its biological functions", "to": "interaction", "value": 1}, {"from": "and its biological functions", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "and its biological functions", "to": ") network and", "value": 1}, {"from": "and its biological functions", "to": "in the protein - protein", "value": 1}, {"from": "and its biological functions", "to": "drug,", "value": 1}, {"from": "and its biological functions", "to": "hub gene", "value": 1}, {"from": "and its biological functions", "to": ", its influence on gene", "value": 1}, {"from": "and its biological functions", "to": "##lated", "value": 1}, {"from": "and its biological functions", "to": "was", "value": 1}, {"from": "and its biological functions", "to": "##in,", "value": 1}, {"from": "and its biological functions", "to": "ppi", "value": 1}, {"from": "and its biological functions", "to": "##oto", "value": 1}, {"from": "and its biological functions", "to": "related pathways", "value": 1}, {"from": "and its biological functions", "to": "cancer,", "value": 1}, {"from": "and its biological functions", "to": "expressed", "value": 1}, {"from": "and its biological functions", "to": "##cer effects.", "value": 1}, {"from": "and its biological functions", "to": "widely", "value": 1}, {"from": "and its biological functions", "to": "atorvas", "value": 1}, {"from": "and its biological functions", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "and its biological functions", "to": "##ster", "value": 1}, {"from": "and its biological functions", "to": "##ol", "value": 1}, {"from": "and its biological functions", "to": "##can", "value": 1}, {"from": "and its biological functions", "to": "cancer. atorvas", "value": 1}, {"from": "and its biological functions", "to": "was identified as the", "value": 1}, {"from": "of saida, saida, algeria.", "to": "shown", "value": 1}, {"from": "of saida, saida, algeria.", "to": "however", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "of saida, saida, algeria.", "to": "shown potential anti", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##in", "value": 1}, {"from": "of saida, saida, algeria.", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "of saida, saida, algeria.", "to": "particular breast cancer,", "value": 1}, {"from": "of saida, saida, algeria.", "to": "still", "value": 1}, {"from": "of saida, saida, algeria.", "to": "associated with atorvas", "value": 1}, {"from": "of saida, saida, algeria.", "to": "in breast", "value": 1}, {"from": "of saida, saida, algeria.", "to": "lowering", "value": 1}, {"from": "of saida, saida, algeria.", "to": "to be responsive to", "value": 1}, {"from": "of saida, saida, algeria.", "to": "interaction", "value": 1}, {"from": "of saida, saida, algeria.", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "of saida, saida, algeria.", "to": ") network and", "value": 1}, {"from": "of saida, saida, algeria.", "to": "in the protein - protein", "value": 1}, {"from": "of saida, saida, algeria.", "to": "drug,", "value": 1}, {"from": "of saida, saida, algeria.", "to": "hub gene", "value": 1}, {"from": "of saida, saida, algeria.", "to": ", its influence on gene", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##lated", "value": 1}, {"from": "of saida, saida, algeria.", "to": "was", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##in,", "value": 1}, {"from": "of saida, saida, algeria.", "to": "ppi", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##oto", "value": 1}, {"from": "of saida, saida, algeria.", "to": "related pathways", "value": 1}, {"from": "of saida, saida, algeria.", "to": "cancer,", "value": 1}, {"from": "of saida, saida, algeria.", "to": "expressed", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##cer effects.", "value": 1}, {"from": "of saida, saida, algeria.", "to": "widely", "value": 1}, {"from": "of saida, saida, algeria.", "to": "atorvas", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##ster", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##ol", "value": 1}, {"from": "of saida, saida, algeria.", "to": "##can", "value": 1}, {"from": "of saida, saida, algeria.", "to": "cancer. atorvas", "value": 1}, {"from": "of saida, saida, algeria.", "to": "was identified as the", "value": 1}, {"from": "shown", "to": "however", "value": 1}, {"from": "shown", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "shown", "to": "shown potential anti", "value": 1}, {"from": "shown", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "shown", "to": "##in", "value": 1}, {"from": "shown", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "shown", "to": "particular breast cancer,", "value": 1}, {"from": "shown", "to": "still", "value": 1}, {"from": "shown", "to": "associated with atorvas", "value": 1}, {"from": "shown", "to": "in breast", "value": 1}, {"from": "shown", "to": "lowering", "value": 1}, {"from": "shown", "to": "to be responsive to", "value": 1}, {"from": "shown", "to": "interaction", "value": 1}, {"from": "shown", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "shown", "to": ") network and", "value": 1}, {"from": "shown", "to": "in the protein - protein", "value": 1}, {"from": "shown", "to": "drug,", "value": 1}, {"from": "shown", "to": "hub gene", "value": 1}, {"from": "shown", "to": ", its influence on gene", "value": 1}, {"from": "shown", "to": "##lated", "value": 1}, {"from": "shown", "to": "was", "value": 1}, {"from": "shown", "to": "##in,", "value": 1}, {"from": "shown", "to": "ppi", "value": 1}, {"from": "shown", "to": "##oto", "value": 1}, {"from": "shown", "to": "related pathways", "value": 1}, {"from": "shown", "to": "cancer,", "value": 1}, {"from": "shown", "to": "expressed", "value": 1}, {"from": "shown", "to": "##cer effects.", "value": 1}, {"from": "shown", "to": "widely", "value": 1}, {"from": "shown", "to": "atorvas", "value": 1}, {"from": "shown", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "shown", "to": "##ster", "value": 1}, {"from": "shown", "to": "##ol", "value": 1}, {"from": "shown", "to": "##can", "value": 1}, {"from": "shown", "to": "cancer. atorvas", "value": 1}, {"from": "shown", "to": "was identified as the", "value": 1}, {"from": "however", "to": "##xicity against breast cancer lines, with the", "value": 1}, {"from": "however", "to": "shown potential anti", "value": 1}, {"from": "however", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "however", "to": "##in", "value": 1}, {"from": "however", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "however", "to": "particular breast cancer,", "value": 1}, {"from": "however", "to": "still", "value": 1}, {"from": "however", "to": "associated with atorvas", "value": 1}, {"from": "however", "to": "in breast", "value": 1}, {"from": "however", "to": "lowering", "value": 1}, {"from": "however", "to": "to be responsive to", "value": 1}, {"from": "however", "to": "interaction", "value": 1}, {"from": "however", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "however", "to": ") network and", "value": 1}, {"from": "however", "to": "in the protein - protein", "value": 1}, {"from": "however", "to": "drug,", "value": 1}, {"from": "however", "to": "hub gene", "value": 1}, {"from": "however", "to": ", its influence on gene", "value": 1}, {"from": "however", "to": "##lated", "value": 1}, {"from": "however", "to": "was", "value": 1}, {"from": "however", "to": "##in,", "value": 1}, {"from": "however", "to": "ppi", "value": 1}, {"from": "however", "to": "##oto", "value": 1}, {"from": "however", "to": "related pathways", "value": 1}, {"from": "however", "to": "cancer,", "value": 1}, {"from": "however", "to": "expressed", "value": 1}, {"from": "however", "to": "##cer effects.", "value": 1}, {"from": "however", "to": "widely", "value": 1}, {"from": "however", "to": "atorvas", "value": 1}, {"from": "however", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "however", "to": "##ster", "value": 1}, {"from": "however", "to": "##ol", "value": 1}, {"from": "however", "to": "##can", "value": 1}, {"from": "however", "to": "cancer. atorvas", "value": 1}, {"from": "however", "to": "was identified as the", "value": 1}, {"from": "however", "to": "12", "value": 1}, {"from": "however", "to": "after net", "value": 1}, {"from": "however", "to": "a significant", "value": 1}, {"from": "however", "to": "offers the opportunity of", "value": 1}, {"from": "however", "to": "##ip", "value": 1}, {"from": "however", "to": "t", "value": 1}, {"from": "however", "to": ") health", "value": 1}, {"from": "however", "to": "background", "value": 1}, {"from": "however", "to": "##re population of", "value": 1}, {"from": "however", "to": "negative breast", "value": 1}, {"from": "however", "to": "barrier", "value": 1}, {"from": "however", "to": "##gipuzkoa", "value": 1}, {"from": "however", "to": "clinical", "value": 1}, {"from": "however", "to": "##2 -", "value": 1}, {"from": "however", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "however", "to": "##zkoa", "value": 1}, {"from": "however", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "however", "to": "##gi", "value": 1}, {"from": "however", "to": "##donostia ) health", "value": 1}, {"from": "however", "to": "##tian,", "value": 1}, {"from": "however", "to": "cancer", "value": 1}, {"from": "however", "to": "spain", "value": 1}, {"from": "however", "to": "##uzkoa. eus.", "value": 1}, {"from": "however", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "however", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "however", "to": "personal", "value": 1}, {"from": "however", "to": "##ised therapy.", "value": 1}, {"from": "however", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "however", "to": "##donost", "value": 1}, {"from": "however", "to": "##cent", "value": 1}, {"from": "however", "to": "research institute", "value": 1}, {"from": "however", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "however", "to": "sa", "value": 1}, {"from": "however", "to": "sebas", "value": 1}, {"from": "however", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "however", "to": "her", "value": 1}, {"from": "however", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "however", "to": "##n sebastian,", "value": 1}, {"from": "however", "to": "##umour response", "value": 1}, {"from": "however", "to": "a,", "value": 1}, {"from": "however", "to": "##pu", "value": 1}, {"from": "however", "to": "##n", "value": 1}, {"from": "however", "to": "sebastian", "value": 1}, {"from": "however", "to": "##uc", "value": 1}, {"from": "however", "to": "13", "value": 1}, {"from": "however", "to": ", the lack of reprod", "value": 1}, {"from": "however", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "however", "to": "##c ) allows", "value": 1}, {"from": "however", "to": "##gnosis", "value": 1}, {"from": "however", "to": "- g", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "shown potential anti", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##in", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "particular breast cancer,", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "still", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "associated with atorvas", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "in breast", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "lowering", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "to be responsive to", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "interaction", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": ") network and", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "in the protein - protein", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "drug,", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "hub gene", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": ", its influence on gene", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##lated", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "was", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##in,", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "ppi", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##oto", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "related pathways", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "cancer,", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "expressed", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##cer effects.", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "widely", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "atorvas", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##ster", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##ol", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "##can", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "cancer. atorvas", "value": 1}, {"from": "##xicity against breast cancer lines, with the", "to": "was identified as the", "value": 1}, {"from": "shown potential anti", "to": "##in exhibited notable predicted cyt", "value": 1}, {"from": "shown potential anti", "to": "##in", "value": 1}, {"from": "shown potential anti", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "shown potential anti", "to": "particular breast cancer,", "value": 1}, {"from": "shown potential anti", "to": "still", "value": 1}, {"from": "shown potential anti", "to": "associated with atorvas", "value": 1}, {"from": "shown potential anti", "to": "in breast", "value": 1}, {"from": "shown potential anti", "to": "lowering", "value": 1}, {"from": "shown potential anti", "to": "to be responsive to", "value": 1}, {"from": "shown potential anti", "to": "interaction", "value": 1}, {"from": "shown potential anti", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "shown potential anti", "to": ") network and", "value": 1}, {"from": "shown potential anti", "to": "in the protein - protein", "value": 1}, {"from": "shown potential anti", "to": "drug,", "value": 1}, {"from": "shown potential anti", "to": "hub gene", "value": 1}, {"from": "shown potential anti", "to": ", its influence on gene", "value": 1}, {"from": "shown potential anti", "to": "##lated", "value": 1}, {"from": "shown potential anti", "to": "was", "value": 1}, {"from": "shown potential anti", "to": "##in,", "value": 1}, {"from": "shown potential anti", "to": "ppi", "value": 1}, {"from": "shown potential anti", "to": "##oto", "value": 1}, {"from": "shown potential anti", "to": "related pathways", "value": 1}, {"from": "shown potential anti", "to": "cancer,", "value": 1}, {"from": "shown potential anti", "to": "expressed", "value": 1}, {"from": "shown potential anti", "to": "##cer effects.", "value": 1}, {"from": "shown potential anti", "to": "widely", "value": 1}, {"from": "shown potential anti", "to": "atorvas", "value": 1}, {"from": "shown potential anti", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "shown potential anti", "to": "##ster", "value": 1}, {"from": "shown potential anti", "to": "##ol", "value": 1}, {"from": "shown potential anti", "to": "##can", "value": 1}, {"from": "shown potential anti", "to": "cancer. atorvas", "value": 1}, {"from": "shown potential anti", "to": "was identified as the", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##in", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "particular breast cancer,", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "still", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "associated with atorvas", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "in breast", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "lowering", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "to be responsive to", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "interaction", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": ") network and", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "in the protein - protein", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "drug,", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "hub gene", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": ", its influence on gene", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##lated", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "was", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##in,", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "ppi", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##oto", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "related pathways", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "cancer,", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "expressed", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##cer effects.", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "widely", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "atorvas", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##ster", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##ol", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "##can", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "cancer. atorvas", "value": 1}, {"from": "##in exhibited notable predicted cyt", "to": "was identified as the", "value": 1}, {"from": "##in", "to": "unclear. we aim to identify the dysre", "value": 1}, {"from": "##in", "to": "particular breast cancer,", "value": 1}, {"from": "##in", "to": "still", "value": 1}, {"from": "##in", "to": "associated with atorvas", "value": 1}, {"from": "##in", "to": "in breast", "value": 1}, {"from": "##in", "to": "lowering", "value": 1}, {"from": "##in", "to": "to be responsive to", "value": 1}, {"from": "##in", "to": "interaction", "value": 1}, {"from": "##in", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "##in", "to": ") network and", "value": 1}, {"from": "##in", "to": "in the protein - protein", "value": 1}, {"from": "##in", "to": "drug,", "value": 1}, {"from": "##in", "to": "hub gene", "value": 1}, {"from": "##in", "to": ", its influence on gene", "value": 1}, {"from": "##in", "to": "##lated", "value": 1}, {"from": "##in", "to": "was", "value": 1}, {"from": "##in", "to": "##in,", "value": 1}, {"from": "##in", "to": "ppi", "value": 1}, {"from": "##in", "to": "##oto", "value": 1}, {"from": "##in", "to": "related pathways", "value": 1}, {"from": "##in", "to": "cancer,", "value": 1}, {"from": "##in", "to": "expressed", "value": 1}, {"from": "##in", "to": "##cer effects.", "value": 1}, {"from": "##in", "to": "widely", "value": 1}, {"from": "##in", "to": "atorvas", "value": 1}, {"from": "##in", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##in", "to": "##ster", "value": 1}, {"from": "##in", "to": "##ol", "value": 1}, {"from": "##in", "to": "##can", "value": 1}, {"from": "##in", "to": "cancer. atorvas", "value": 1}, {"from": "##in", "to": "was identified as the", "value": 1}, {"from": "##in", "to": "##rio de v", "value": 1}, {"from": "##in", "to": "t", "value": 1}, {"from": "##in", "to": "##kolog", "value": 1}, {"from": "##in", "to": ", san", "value": 1}, {"from": "##in", "to": "##it", "value": 1}, {"from": "##in", "to": ") health", "value": 1}, {"from": "##in", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "##in", "to": "##iba", "value": 1}, {"from": "##in", "to": "##ialdea", "value": 1}, {"from": "##in", "to": "##gipuzkoa", "value": 1}, {"from": "##in", "to": "##ko", "value": 1}, {"from": "##in", "to": "##obe", "value": 1}, {"from": "##in", "to": "se", "value": 1}, {"from": "##in", "to": "##gi", "value": 1}, {"from": "##in", "to": "##tian,", "value": 1}, {"from": "##in", "to": ") hospital clinico univers", "value": 1}, {"from": "##in", "to": "##r 12, madrid,", "value": 1}, {"from": "##in", "to": "spain", "value": 1}, {"from": "##in", "to": "##ale", "value": 1}, {"from": "##in", "to": "##a", "value": 1}, {"from": "##in", "to": "##ute", "value": 1}, {"from": "##in", "to": "##ikoa,", "value": 1}, {"from": "##in", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##in", "to": "##donost", "value": 1}, {"from": "##in", "to": ") hospital oct", "value": 1}, {"from": "##in", "to": "research institute", "value": 1}, {"from": "##in", "to": "institute", "value": 1}, {"from": "##in", "to": "sa", "value": 1}, {"from": "##in", "to": "sebas", "value": 1}, {"from": "##in", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##in", "to": "##ita", "value": 1}, {"from": "##in", "to": ", v", "value": 1}, {"from": "##in", "to": "11", "value": 1}, {"from": "##in", "to": "##ps, barcelon", "value": 1}, {"from": "##in", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##in", "to": "##n", "value": 1}, {"from": "##in", "to": "##pu", "value": 1}, {"from": "##in", "to": "sebastian", "value": 1}, {"from": "##in", "to": "; gip", "value": 1}, {"from": "##in", "to": "- on", "value": 1}, {"from": "##in", "to": "7 ) valencia oncology", "value": 1}, {"from": "##in", "to": "##ncia,", "value": 1}, {"from": "##in", "to": "##uz", "value": 1}, {"from": "##in", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##in", "to": "- onkologikoa, san", "value": 1}, {"from": "##in", "to": "##z", "value": 1}, {"from": "##in", "to": "##bastian, spa", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "particular breast cancer,", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "still", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "associated with atorvas", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "in breast", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "lowering", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "to be responsive to", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "interaction", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": ") network and", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "in the protein - protein", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "drug,", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "hub gene", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": ", its influence on gene", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##lated", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "was", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##in,", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "ppi", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##oto", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "related pathways", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "cancer,", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "expressed", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##cer effects.", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "widely", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "atorvas", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##ster", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##ol", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "##can", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "cancer. atorvas", "value": 1}, {"from": "unclear. we aim to identify the dysre", "to": "was identified as the", "value": 1}, {"from": "particular breast cancer,", "to": "still", "value": 1}, {"from": "particular breast cancer,", "to": "associated with atorvas", "value": 1}, {"from": "particular breast cancer,", "to": "in breast", "value": 1}, {"from": "particular breast cancer,", "to": "lowering", "value": 1}, {"from": "particular breast cancer,", "to": "to be responsive to", "value": 1}, {"from": "particular breast cancer,", "to": "interaction", "value": 1}, {"from": "particular breast cancer,", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "particular breast cancer,", "to": ") network and", "value": 1}, {"from": "particular breast cancer,", "to": "in the protein - protein", "value": 1}, {"from": "particular breast cancer,", "to": "drug,", "value": 1}, {"from": "particular breast cancer,", "to": "hub gene", "value": 1}, {"from": "particular breast cancer,", "to": ", its influence on gene", "value": 1}, {"from": "particular breast cancer,", "to": "##lated", "value": 1}, {"from": "particular breast cancer,", "to": "was", "value": 1}, {"from": "particular breast cancer,", "to": "##in,", "value": 1}, {"from": "particular breast cancer,", "to": "ppi", "value": 1}, {"from": "particular breast cancer,", "to": "##oto", "value": 1}, {"from": "particular breast cancer,", "to": "related pathways", "value": 1}, {"from": "particular breast cancer,", "to": "cancer,", "value": 1}, {"from": "particular breast cancer,", "to": "expressed", "value": 1}, {"from": "particular breast cancer,", "to": "##cer effects.", "value": 1}, {"from": "particular breast cancer,", "to": "widely", "value": 1}, {"from": "particular breast cancer,", "to": "atorvas", "value": 1}, {"from": "particular breast cancer,", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "particular breast cancer,", "to": "##ster", "value": 1}, {"from": "particular breast cancer,", "to": "##ol", "value": 1}, {"from": "particular breast cancer,", "to": "##can", "value": 1}, {"from": "particular breast cancer,", "to": "cancer. atorvas", "value": 1}, {"from": "particular breast cancer,", "to": "was identified as the", "value": 1}, {"from": "still", "to": "associated with atorvas", "value": 1}, {"from": "still", "to": "in breast", "value": 1}, {"from": "still", "to": "lowering", "value": 1}, {"from": "still", "to": "to be responsive to", "value": 1}, {"from": "still", "to": "interaction", "value": 1}, {"from": "still", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "still", "to": ") network and", "value": 1}, {"from": "still", "to": "in the protein - protein", "value": 1}, {"from": "still", "to": "drug,", "value": 1}, {"from": "still", "to": "hub gene", "value": 1}, {"from": "still", "to": ", its influence on gene", "value": 1}, {"from": "still", "to": "##lated", "value": 1}, {"from": "still", "to": "was", "value": 1}, {"from": "still", "to": "##in,", "value": 1}, {"from": "still", "to": "ppi", "value": 1}, {"from": "still", "to": "##oto", "value": 1}, {"from": "still", "to": "related pathways", "value": 1}, {"from": "still", "to": "cancer,", "value": 1}, {"from": "still", "to": "expressed", "value": 1}, {"from": "still", "to": "##cer effects.", "value": 1}, {"from": "still", "to": "widely", "value": 1}, {"from": "still", "to": "atorvas", "value": 1}, {"from": "still", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "still", "to": "##ster", "value": 1}, {"from": "still", "to": "##ol", "value": 1}, {"from": "still", "to": "##can", "value": 1}, {"from": "still", "to": "cancer. atorvas", "value": 1}, {"from": "still", "to": "was identified as the", "value": 1}, {"from": "associated with atorvas", "to": "in breast", "value": 1}, {"from": "associated with atorvas", "to": "lowering", "value": 1}, {"from": "associated with atorvas", "to": "to be responsive to", "value": 1}, {"from": "associated with atorvas", "to": "interaction", "value": 1}, {"from": "associated with atorvas", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "associated with atorvas", "to": ") network and", "value": 1}, {"from": "associated with atorvas", "to": "in the protein - protein", "value": 1}, {"from": "associated with atorvas", "to": "drug,", "value": 1}, {"from": "associated with atorvas", "to": "hub gene", "value": 1}, {"from": "associated with atorvas", "to": ", its influence on gene", "value": 1}, {"from": "associated with atorvas", "to": "##lated", "value": 1}, {"from": "associated with atorvas", "to": "was", "value": 1}, {"from": "associated with atorvas", "to": "##in,", "value": 1}, {"from": "associated with atorvas", "to": "ppi", "value": 1}, {"from": "associated with atorvas", "to": "##oto", "value": 1}, {"from": "associated with atorvas", "to": "related pathways", "value": 1}, {"from": "associated with atorvas", "to": "cancer,", "value": 1}, {"from": "associated with atorvas", "to": "expressed", "value": 1}, {"from": "associated with atorvas", "to": "##cer effects.", "value": 1}, {"from": "associated with atorvas", "to": "widely", "value": 1}, {"from": "associated with atorvas", "to": "atorvas", "value": 1}, {"from": "associated with atorvas", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "associated with atorvas", "to": "##ster", "value": 1}, {"from": "associated with atorvas", "to": "##ol", "value": 1}, {"from": "associated with atorvas", "to": "##can", "value": 1}, {"from": "associated with atorvas", "to": "cancer. atorvas", "value": 1}, {"from": "associated with atorvas", "to": "was identified as the", "value": 1}, {"from": "in breast", "to": "lowering", "value": 1}, {"from": "in breast", "to": "to be responsive to", "value": 1}, {"from": "in breast", "to": "interaction", "value": 1}, {"from": "in breast", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "in breast", "to": ") network and", "value": 1}, {"from": "in breast", "to": "in the protein - protein", "value": 1}, {"from": "in breast", "to": "drug,", "value": 1}, {"from": "in breast", "to": "hub gene", "value": 1}, {"from": "in breast", "to": ", its influence on gene", "value": 1}, {"from": "in breast", "to": "##lated", "value": 1}, {"from": "in breast", "to": "was", "value": 1}, {"from": "in breast", "to": "##in,", "value": 1}, {"from": "in breast", "to": "ppi", "value": 1}, {"from": "in breast", "to": "##oto", "value": 1}, {"from": "in breast", "to": "related pathways", "value": 1}, {"from": "in breast", "to": "cancer,", "value": 1}, {"from": "in breast", "to": "expressed", "value": 1}, {"from": "in breast", "to": "##cer effects.", "value": 1}, {"from": "in breast", "to": "widely", "value": 1}, {"from": "in breast", "to": "atorvas", "value": 1}, {"from": "in breast", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "in breast", "to": "##ster", "value": 1}, {"from": "in breast", "to": "##ol", "value": 1}, {"from": "in breast", "to": "##can", "value": 1}, {"from": "in breast", "to": "cancer. atorvas", "value": 1}, {"from": "in breast", "to": "was identified as the", "value": 1}, {"from": "lowering", "to": "to be responsive to", "value": 1}, {"from": "lowering", "to": "interaction", "value": 1}, {"from": "lowering", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "lowering", "to": ") network and", "value": 1}, {"from": "lowering", "to": "in the protein - protein", "value": 1}, {"from": "lowering", "to": "drug,", "value": 1}, {"from": "lowering", "to": "hub gene", "value": 1}, {"from": "lowering", "to": ", its influence on gene", "value": 1}, {"from": "lowering", "to": "##lated", "value": 1}, {"from": "lowering", "to": "was", "value": 1}, {"from": "lowering", "to": "##in,", "value": 1}, {"from": "lowering", "to": "ppi", "value": 1}, {"from": "lowering", "to": "##oto", "value": 1}, {"from": "lowering", "to": "related pathways", "value": 1}, {"from": "lowering", "to": "cancer,", "value": 1}, {"from": "lowering", "to": "expressed", "value": 1}, {"from": "lowering", "to": "##cer effects.", "value": 1}, {"from": "lowering", "to": "widely", "value": 1}, {"from": "lowering", "to": "atorvas", "value": 1}, {"from": "lowering", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "lowering", "to": "##ster", "value": 1}, {"from": "lowering", "to": "##ol", "value": 1}, {"from": "lowering", "to": "##can", "value": 1}, {"from": "lowering", "to": "cancer. atorvas", "value": 1}, {"from": "lowering", "to": "was identified as the", "value": 1}, {"from": "to be responsive to", "to": "interaction", "value": 1}, {"from": "to be responsive to", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "to be responsive to", "to": ") network and", "value": 1}, {"from": "to be responsive to", "to": "in the protein - protein", "value": 1}, {"from": "to be responsive to", "to": "drug,", "value": 1}, {"from": "to be responsive to", "to": "hub gene", "value": 1}, {"from": "to be responsive to", "to": ", its influence on gene", "value": 1}, {"from": "to be responsive to", "to": "##lated", "value": 1}, {"from": "to be responsive to", "to": "was", "value": 1}, {"from": "to be responsive to", "to": "##in,", "value": 1}, {"from": "to be responsive to", "to": "ppi", "value": 1}, {"from": "to be responsive to", "to": "##oto", "value": 1}, {"from": "to be responsive to", "to": "related pathways", "value": 1}, {"from": "to be responsive to", "to": "cancer,", "value": 1}, {"from": "to be responsive to", "to": "expressed", "value": 1}, {"from": "to be responsive to", "to": "##cer effects.", "value": 1}, {"from": "to be responsive to", "to": "widely", "value": 1}, {"from": "to be responsive to", "to": "atorvas", "value": 1}, {"from": "to be responsive to", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "to be responsive to", "to": "##ster", "value": 1}, {"from": "to be responsive to", "to": "##ol", "value": 1}, {"from": "to be responsive to", "to": "##can", "value": 1}, {"from": "to be responsive to", "to": "cancer. atorvas", "value": 1}, {"from": "to be responsive to", "to": "was identified as the", "value": 1}, {"from": "interaction", "to": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "value": 1}, {"from": "interaction", "to": ") network and", "value": 1}, {"from": "interaction", "to": "in the protein - protein", "value": 1}, {"from": "interaction", "to": "drug,", "value": 1}, {"from": "interaction", "to": "hub gene", "value": 1}, {"from": "interaction", "to": ", its influence on gene", "value": 1}, {"from": "interaction", "to": "##lated", "value": 1}, {"from": "interaction", "to": "was", "value": 1}, {"from": "interaction", "to": "##in,", "value": 1}, {"from": "interaction", "to": "ppi", "value": 1}, {"from": "interaction", "to": "##oto", "value": 1}, {"from": "interaction", "to": "related pathways", "value": 1}, {"from": "interaction", "to": "cancer,", "value": 1}, {"from": "interaction", "to": "expressed", "value": 1}, {"from": "interaction", "to": "##cer effects.", "value": 1}, {"from": "interaction", "to": "widely", "value": 1}, {"from": "interaction", "to": "atorvas", "value": 1}, {"from": "interaction", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "interaction", "to": "##ster", "value": 1}, {"from": "interaction", "to": "##ol", "value": 1}, {"from": "interaction", "to": "##can", "value": 2}, {"from": "interaction", "to": "cancer. atorvas", "value": 1}, {"from": "interaction", "to": "was identified as the", "value": 1}, {"from": "interaction", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "interaction", "to": "##ifer", "value": 1}, {"from": "interaction", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "interaction", "to": "in the", "value": 1}, {"from": "interaction", "to": "##ne - c", "value": 1}, {"from": "interaction", "to": ", tnf signaling", "value": 1}, {"from": "interaction", "to": ", which", "value": 1}, {"from": "interaction", "to": "down - regulated", "value": 1}, {"from": "interaction", "to": "including c", "value": 1}, {"from": "interaction", "to": "##ytoki", "value": 1}, {"from": "interaction", "to": "detected", "value": 1}, {"from": "interaction", "to": "cancer", "value": 1}, {"from": "interaction", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "interaction", "to": "vs", "value": 1}, {"from": "interaction", "to": "##cer assays. the", "value": 1}, {"from": "interaction", "to": "or", "value": 1}, {"from": "interaction", "to": "if", "value": 1}, {"from": "interaction", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "interaction", "to": "##ne receptor", "value": 1}, {"from": "interaction", "to": "##ap", "value": 1}, {"from": "interaction", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "interaction", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "interaction", "to": "via", "value": 1}, {"from": "interaction", "to": "anti", "value": 1}, {"from": "interaction", "to": "##n - \u03b3", "value": 1}, {"from": "interaction", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "interaction", "to": "f biotechnology engineering,", "value": 1}, {"from": "interaction", "to": "were up -", "value": 1}, {"from": "interaction", "to": ", nod - like receptor signaling", "value": 1}, {"from": "interaction", "to": "##ation, pro", "value": 1}, {"from": "interaction", "to": "pathways", "value": 1}, {"from": "interaction", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "interaction", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "interaction", "to": "pathway", "value": 1}, {"from": "interaction", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": ") network and", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "in the protein - protein", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "drug,", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "hub gene", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": ", its influence on gene", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##lated", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "was", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##in,", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "ppi", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##oto", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "related pathways", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "cancer,", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "expressed", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##cer effects.", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "widely", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "atorvas", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##ster", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##ol", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "##can", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "cancer. atorvas", "value": 1}, {"from": "of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas", "to": "was identified as the", "value": 1}, {"from": ") network and", "to": "in the protein - protein", "value": 1}, {"from": ") network and", "to": "drug,", "value": 1}, {"from": ") network and", "to": "hub gene", "value": 1}, {"from": ") network and", "to": ", its influence on gene", "value": 1}, {"from": ") network and", "to": "##lated", "value": 1}, {"from": ") network and", "to": "was", "value": 1}, {"from": ") network and", "to": "##in,", "value": 1}, {"from": ") network and", "to": "ppi", "value": 1}, {"from": ") network and", "to": "##oto", "value": 1}, {"from": ") network and", "to": "related pathways", "value": 1}, {"from": ") network and", "to": "cancer,", "value": 1}, {"from": ") network and", "to": "expressed", "value": 1}, {"from": ") network and", "to": "##cer effects.", "value": 1}, {"from": ") network and", "to": "widely", "value": 1}, {"from": ") network and", "to": "atorvas", "value": 1}, {"from": ") network and", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": ") network and", "to": "##ster", "value": 1}, {"from": ") network and", "to": "##ol", "value": 1}, {"from": ") network and", "to": "##can", "value": 1}, {"from": ") network and", "to": "cancer. atorvas", "value": 1}, {"from": ") network and", "to": "was identified as the", "value": 1}, {"from": "in the protein - protein", "to": "drug,", "value": 1}, {"from": "in the protein - protein", "to": "hub gene", "value": 1}, {"from": "in the protein - protein", "to": ", its influence on gene", "value": 1}, {"from": "in the protein - protein", "to": "##lated", "value": 1}, {"from": "in the protein - protein", "to": "was", "value": 1}, {"from": "in the protein - protein", "to": "##in,", "value": 1}, {"from": "in the protein - protein", "to": "ppi", "value": 1}, {"from": "in the protein - protein", "to": "##oto", "value": 1}, {"from": "in the protein - protein", "to": "related pathways", "value": 1}, {"from": "in the protein - protein", "to": "cancer,", "value": 1}, {"from": "in the protein - protein", "to": "expressed", "value": 1}, {"from": "in the protein - protein", "to": "##cer effects.", "value": 1}, {"from": "in the protein - protein", "to": "widely", "value": 1}, {"from": "in the protein - protein", "to": "atorvas", "value": 1}, {"from": "in the protein - protein", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "in the protein - protein", "to": "##ster", "value": 1}, {"from": "in the protein - protein", "to": "##ol", "value": 1}, {"from": "in the protein - protein", "to": "##can", "value": 1}, {"from": "in the protein - protein", "to": "cancer. atorvas", "value": 1}, {"from": "in the protein - protein", "to": "was identified as the", "value": 1}, {"from": "drug,", "to": "hub gene", "value": 1}, {"from": "drug,", "to": ", its influence on gene", "value": 1}, {"from": "drug,", "to": "##lated", "value": 1}, {"from": "drug,", "to": "was", "value": 1}, {"from": "drug,", "to": "##in,", "value": 1}, {"from": "drug,", "to": "ppi", "value": 1}, {"from": "drug,", "to": "##oto", "value": 1}, {"from": "drug,", "to": "related pathways", "value": 1}, {"from": "drug,", "to": "cancer,", "value": 1}, {"from": "drug,", "to": "expressed", "value": 1}, {"from": "drug,", "to": "##cer effects.", "value": 1}, {"from": "drug,", "to": "widely", "value": 1}, {"from": "drug,", "to": "atorvas", "value": 1}, {"from": "drug,", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "drug,", "to": "##ster", "value": 1}, {"from": "drug,", "to": "##ol", "value": 1}, {"from": "drug,", "to": "##can", "value": 1}, {"from": "drug,", "to": "cancer. atorvas", "value": 1}, {"from": "drug,", "to": "was identified as the", "value": 1}, {"from": "hub gene", "to": ", its influence on gene", "value": 1}, {"from": "hub gene", "to": "##lated", "value": 1}, {"from": "hub gene", "to": "was", "value": 1}, {"from": "hub gene", "to": "##in,", "value": 1}, {"from": "hub gene", "to": "ppi", "value": 1}, {"from": "hub gene", "to": "##oto", "value": 1}, {"from": "hub gene", "to": "related pathways", "value": 1}, {"from": "hub gene", "to": "cancer,", "value": 1}, {"from": "hub gene", "to": "expressed", "value": 1}, {"from": "hub gene", "to": "##cer effects.", "value": 1}, {"from": "hub gene", "to": "widely", "value": 1}, {"from": "hub gene", "to": "atorvas", "value": 1}, {"from": "hub gene", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "hub gene", "to": "##ster", "value": 1}, {"from": "hub gene", "to": "##ol", "value": 1}, {"from": "hub gene", "to": "##can", "value": 1}, {"from": "hub gene", "to": "cancer. atorvas", "value": 1}, {"from": "hub gene", "to": "was identified as the", "value": 1}, {"from": ", its influence on gene", "to": "##lated", "value": 1}, {"from": ", its influence on gene", "to": "was", "value": 1}, {"from": ", its influence on gene", "to": "##in,", "value": 1}, {"from": ", its influence on gene", "to": "ppi", "value": 1}, {"from": ", its influence on gene", "to": "##oto", "value": 1}, {"from": ", its influence on gene", "to": "related pathways", "value": 1}, {"from": ", its influence on gene", "to": "cancer,", "value": 1}, {"from": ", its influence on gene", "to": "expressed", "value": 1}, {"from": ", its influence on gene", "to": "##cer effects.", "value": 1}, {"from": ", its influence on gene", "to": "widely", "value": 1}, {"from": ", its influence on gene", "to": "atorvas", "value": 1}, {"from": ", its influence on gene", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": ", its influence on gene", "to": "##ster", "value": 1}, {"from": ", its influence on gene", "to": "##ol", "value": 1}, {"from": ", its influence on gene", "to": "##can", "value": 1}, {"from": ", its influence on gene", "to": "cancer. atorvas", "value": 1}, {"from": ", its influence on gene", "to": "was identified as the", "value": 1}, {"from": "##lated", "to": "was", "value": 1}, {"from": "##lated", "to": "##in,", "value": 1}, {"from": "##lated", "to": "ppi", "value": 1}, {"from": "##lated", "to": "##oto", "value": 1}, {"from": "##lated", "to": "related pathways", "value": 1}, {"from": "##lated", "to": "cancer,", "value": 1}, {"from": "##lated", "to": "expressed", "value": 1}, {"from": "##lated", "to": "##cer effects.", "value": 1}, {"from": "##lated", "to": "widely", "value": 1}, {"from": "##lated", "to": "atorvas", "value": 1}, {"from": "##lated", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##lated", "to": "##ster", "value": 1}, {"from": "##lated", "to": "##ol", "value": 1}, {"from": "##lated", "to": "##can", "value": 1}, {"from": "##lated", "to": "cancer. atorvas", "value": 1}, {"from": "##lated", "to": "was identified as the", "value": 1}, {"from": "was", "to": "##in,", "value": 1}, {"from": "was", "to": "ppi", "value": 1}, {"from": "was", "to": "##oto", "value": 1}, {"from": "was", "to": "related pathways", "value": 1}, {"from": "was", "to": "cancer,", "value": 1}, {"from": "was", "to": "expressed", "value": 1}, {"from": "was", "to": "##cer effects.", "value": 1}, {"from": "was", "to": "widely", "value": 1}, {"from": "was", "to": "atorvas", "value": 1}, {"from": "was", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "was", "to": "##ster", "value": 1}, {"from": "was", "to": "##ol", "value": 1}, {"from": "was", "to": "##can", "value": 1}, {"from": "was", "to": "cancer. atorvas", "value": 1}, {"from": "was", "to": "was identified as the", "value": 1}, {"from": "was", "to": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "value": 1}, {"from": "was", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "was", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "was", "to": ". 108", "value": 1}, {"from": "was", "to": "jun might", "value": 1}, {"from": "was", "to": "##0", "value": 1}, {"from": "was", "to": "expression.", "value": 1}, {"from": "was", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "was", "to": "##na ss", "value": 1}, {"from": "was", "to": "##v", "value": 1}, {"from": "was", "to": "##un", "value": 1}, {"from": "was", "to": "##gno", "value": 1}, {"from": "was", "to": "activity positively correlated with", "value": 1}, {"from": "was", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "was", "to": ". 17305 /", "value": 1}, {"from": "was", "to": "luki", "value": 1}, {"from": "was", "to": "##v vi", "value": 1}, {"from": "was", "to": "logino", "value": 1}, {"from": "was", "to": "may directly interact with", "value": 1}, {"from": "was", "to": "serve as a valuable pro", "value": 1}, {"from": "was", "to": "##tatin", "value": 1}, {"from": "was", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "was", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "was", "to": "expression. as such,", "value": 1}, {"from": "was", "to": "significantly", "value": 1}, {"from": "was", "to": "##nina", "value": 1}, {"from": "was", "to": "pro", "value": 1}, {"from": "was", "to": "down", "value": 1}, {"from": "was", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "was", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "was", "to": "benefit", "value": 1}, {"from": "was", "to": "##26, 000 ;", "value": 1}, {"from": "was", "to": "effective", "value": 1}, {"from": "was", "to": "it was cost - saving", "value": 1}, {"from": "was", "to": "threshold", "value": 1}, {"from": "was", "to": "- 435, 677 )", "value": 1}, {"from": "was", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "was", "to": "##aly", "value": 1}, {"from": "was", "to": "in the", "value": 1}, {"from": "was", "to": "cost", "value": 1}, {"from": "was", "to": "\u20ac", "value": 1}, {"from": "was", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "was", "to": "- 620170,", "value": 1}, {"from": "was", "to": "##r )", "value": 1}, {"from": "was", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "was", "to": "societal perspective", "value": 1}, {"from": "was", "to": "candidates, the strategy", "value": 1}, {"from": "was", "to": "cost - effective", "value": 1}, {"from": "was", "to": "incre", "value": 1}, {"from": "was", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "was", "to": "##mental", "value": 1}, {"from": "was", "to": "the cost -", "value": 1}, {"from": "was", "to": "was cost - effective", "value": 1}, {"from": "was", "to": "above", "value": 1}, {"from": "was", "to": "results", "value": 1}, {"from": "was", "to": "was obtained from statistics norway.", "value": 1}, {"from": "was", "to": "per quality - adjusted life -", "value": 1}, {"from": "was", "to": "was cost - saving", "value": 1}, {"from": "was", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "was", "to": "chemotherapy", "value": 1}, {"from": "was", "to": "in both the healthcare", "value": 1}, {"from": "was", "to": "years", "value": 1}, {"from": "was", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "was", "to": "- per q", "value": 1}, {"from": "was", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "was", "to": ". conclusions", "value": 1}, {"from": "was", "to": ". selecting patient", "value": 1}, {"from": "was", "to": "ice", "value": 1}, {"from": "was", "to": "##r", "value": 1}, {"from": "was", "to": "##8884 and", "value": 1}, {"from": "was", "to": "gained", "value": 1}, {"from": "was", "to": "the emit", "value": 1}, {"from": "was", "to": "records. including all pn0 patients", "value": 1}, {"from": "was", "to": "sector", "value": 1}, {"from": "was", "to": "not", "value": 1}, {"from": "##in,", "to": "ppi", "value": 1}, {"from": "##in,", "to": "##oto", "value": 1}, {"from": "##in,", "to": "related pathways", "value": 1}, {"from": "##in,", "to": "cancer,", "value": 1}, {"from": "##in,", "to": "expressed", "value": 1}, {"from": "##in,", "to": "##cer effects.", "value": 1}, {"from": "##in,", "to": "widely", "value": 1}, {"from": "##in,", "to": "atorvas", "value": 1}, {"from": "##in,", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##in,", "to": "##ster", "value": 1}, {"from": "##in,", "to": "##ol", "value": 1}, {"from": "##in,", "to": "##can", "value": 1}, {"from": "##in,", "to": "cancer. atorvas", "value": 1}, {"from": "##in,", "to": "was identified as the", "value": 1}, {"from": "ppi", "to": "##oto", "value": 1}, {"from": "ppi", "to": "related pathways", "value": 1}, {"from": "ppi", "to": "cancer,", "value": 1}, {"from": "ppi", "to": "expressed", "value": 1}, {"from": "ppi", "to": "##cer effects.", "value": 1}, {"from": "ppi", "to": "widely", "value": 1}, {"from": "ppi", "to": "atorvas", "value": 1}, {"from": "ppi", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "ppi", "to": "##ster", "value": 1}, {"from": "ppi", "to": "##ol", "value": 1}, {"from": "ppi", "to": "##can", "value": 1}, {"from": "ppi", "to": "cancer. atorvas", "value": 1}, {"from": "ppi", "to": "was identified as the", "value": 1}, {"from": "##oto", "to": "related pathways", "value": 1}, {"from": "##oto", "to": "cancer,", "value": 1}, {"from": "##oto", "to": "expressed", "value": 1}, {"from": "##oto", "to": "##cer effects.", "value": 1}, {"from": "##oto", "to": "widely", "value": 1}, {"from": "##oto", "to": "atorvas", "value": 1}, {"from": "##oto", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##oto", "to": "##ster", "value": 1}, {"from": "##oto", "to": "##ol", "value": 1}, {"from": "##oto", "to": "##can", "value": 2}, {"from": "##oto", "to": "cancer. atorvas", "value": 1}, {"from": "##oto", "to": "was identified as the", "value": 1}, {"from": "##oto", "to": "- regulate", "value": 1}, {"from": "##oto", "to": "the", "value": 1}, {"from": "##oto", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "##oto", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "##oto", "to": "##tic", "value": 1}, {"from": "##oto", "to": "##6 /", "value": 1}, {"from": "##oto", "to": "##6", "value": 1}, {"from": "##oto", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##oto", "to": "##xic effect of", "value": 1}, {"from": "##oto", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##oto", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##oto", "to": "##xic efficacy of the", "value": 1}, {"from": "##oto", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##oto", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##oto", "to": "if", "value": 1}, {"from": "##oto", "to": "up -", "value": 1}, {"from": "##oto", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##oto", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##oto", "to": "development of tumor cells, a", "value": 1}, {"from": "##oto", "to": "##348089 conflict o", "value": 1}, {"from": "##oto", "to": "regulate", "value": 1}, {"from": "##oto", "to": "101", "value": 1}, {"from": "##oto", "to": "of pro", "value": 1}, {"from": "##oto", "to": "##cl -", "value": 1}, {"from": "##oto", "to": "##biotec. 2025.", "value": 1}, {"from": "##oto", "to": "04", "value": 1}, {"from": "##oto", "to": "##apopto", "value": 1}, {"from": "##oto", "to": "to", "value": 1}, {"from": "##oto", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##oto", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##oto", "to": "via", "value": 1}, {"from": "##oto", "to": "and p", "value": 1}, {"from": "##oto", "to": "##c cell line", "value": 1}, {"from": "##oto", "to": "hi", "value": 1}, {"from": "##oto", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##oto", "to": "down", "value": 1}, {"from": "##oto", "to": "##53", "value": 1}, {"from": "##oto", "to": ". 022 pmid :", "value": 1}, {"from": "##oto", "to": "bax", "value": 1}, {"from": "related pathways", "to": "cancer,", "value": 1}, {"from": "related pathways", "to": "expressed", "value": 1}, {"from": "related pathways", "to": "##cer effects.", "value": 1}, {"from": "related pathways", "to": "widely", "value": 1}, {"from": "related pathways", "to": "atorvas", "value": 1}, {"from": "related pathways", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "related pathways", "to": "##ster", "value": 1}, {"from": "related pathways", "to": "##ol", "value": 1}, {"from": "related pathways", "to": "##can", "value": 1}, {"from": "related pathways", "to": "cancer. atorvas", "value": 1}, {"from": "related pathways", "to": "was identified as the", "value": 1}, {"from": "cancer,", "to": "expressed", "value": 1}, {"from": "cancer,", "to": "##cer effects.", "value": 1}, {"from": "cancer,", "to": "widely", "value": 1}, {"from": "cancer,", "to": "atorvas", "value": 1}, {"from": "cancer,", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "cancer,", "to": "##ster", "value": 1}, {"from": "cancer,", "to": "##ol", "value": 1}, {"from": "cancer,", "to": "##can", "value": 1}, {"from": "cancer,", "to": "cancer. atorvas", "value": 1}, {"from": "cancer,", "to": "was identified as the", "value": 1}, {"from": "expressed", "to": "##cer effects.", "value": 1}, {"from": "expressed", "to": "widely", "value": 1}, {"from": "expressed", "to": "atorvas", "value": 1}, {"from": "expressed", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "expressed", "to": "##ster", "value": 1}, {"from": "expressed", "to": "##ol", "value": 1}, {"from": "expressed", "to": "##can", "value": 1}, {"from": "expressed", "to": "cancer. atorvas", "value": 1}, {"from": "expressed", "to": "was identified as the", "value": 1}, {"from": "expressed", "to": "array and bioinformatic analysis, we identified seven differentially", "value": 1}, {"from": "expressed", "to": "##r confirmed their down", "value": 1}, {"from": "expressed", "to": "four", "value": 1}, {"from": "expressed", "to": "prioriti", "value": 1}, {"from": "expressed", "to": "pc", "value": 1}, {"from": "expressed", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "expressed", "to": "diagnosed", "value": 1}, {"from": "expressed", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "expressed", "to": "incomplete", "value": 1}, {"from": "expressed", "to": "ministry", "value": 1}, {"from": "expressed", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "expressed", "to": "diagnostic", "value": 1}, {"from": "expressed", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "expressed", "to": "##s and", "value": 1}, {"from": "expressed", "to": "##s.", "value": 1}, {"from": "expressed", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "expressed", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "expressed", "to": "treatment", "value": 1}, {"from": "expressed", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "expressed", "to": "- mi", "value": 1}, {"from": "expressed", "to": "##gna", "value": 1}, {"from": "expressed", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "expressed", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "expressed", "to": "##ncrna", "value": 1}, {"from": "expressed", "to": "##r", "value": 1}, {"from": "expressed", "to": "mrna", "value": 1}, {"from": "expressed", "to": "mali", "value": 1}, {"from": "expressed", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##cer effects.", "to": "widely", "value": 1}, {"from": "##cer effects.", "to": "atorvas", "value": 1}, {"from": "##cer effects.", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "##cer effects.", "to": "##ster", "value": 1}, {"from": "##cer effects.", "to": "##ol", "value": 1}, {"from": "##cer effects.", "to": "##can", "value": 1}, {"from": "##cer effects.", "to": "cancer. atorvas", "value": 1}, {"from": "##cer effects.", "to": "was identified as the", "value": 1}, {"from": "widely", "to": "atorvas", "value": 1}, {"from": "widely", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "widely", "to": "##ster", "value": 1}, {"from": "widely", "to": "##ol", "value": 1}, {"from": "widely", "to": "##can", "value": 1}, {"from": "widely", "to": "cancer. atorvas", "value": 1}, {"from": "widely", "to": "was identified as the", "value": 1}, {"from": "atorvas", "to": "##in treatment and the main players in their biological network. a total of 103 differentially", "value": 1}, {"from": "atorvas", "to": "##ster", "value": 1}, {"from": "atorvas", "to": "##ol", "value": 1}, {"from": "atorvas", "to": "##can", "value": 1}, {"from": "atorvas", "to": "cancer. atorvas", "value": 1}, {"from": "atorvas", "to": "was identified as the", "value": 1}, {"from": "##in treatment and the main players in their biological network. a total of 103 differentially", "to": "##ster", "value": 1}, {"from": "##in treatment and the main players in their biological network. a total of 103 differentially", "to": "##ol", "value": 1}, {"from": "##in treatment and the main players in their biological network. a total of 103 differentially", "to": "##can", "value": 1}, {"from": "##in treatment and the main players in their biological network. a total of 103 differentially", "to": "cancer. atorvas", "value": 1}, {"from": "##in treatment and the main players in their biological network. a total of 103 differentially", "to": "was identified as the", "value": 1}, {"from": "##ster", "to": "##ol", "value": 1}, {"from": "##ster", "to": "##can", "value": 1}, {"from": "##ster", "to": "cancer. atorvas", "value": 1}, {"from": "##ster", "to": "was identified as the", "value": 1}, {"from": "##ol", "to": "##can", "value": 1}, {"from": "##ol", "to": "cancer. atorvas", "value": 1}, {"from": "##ol", "to": "was identified as the", "value": 1}, {"from": "##can", "to": "cancer. atorvas", "value": 1}, {"from": "##can", "to": "was identified as the", "value": 1}, {"from": "##can", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "##can", "to": "##ifer", "value": 1}, {"from": "##can", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "##can", "to": "in the", "value": 1}, {"from": "##can", "to": "##ne - c", "value": 1}, {"from": "##can", "to": ", tnf signaling", "value": 1}, {"from": "##can", "to": ", which", "value": 1}, {"from": "##can", "to": "down - regulated", "value": 1}, {"from": "##can", "to": "including c", "value": 1}, {"from": "##can", "to": "##ytoki", "value": 1}, {"from": "##can", "to": "detected", "value": 1}, {"from": "##can", "to": "cancer", "value": 1}, {"from": "##can", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "##can", "to": "vs", "value": 1}, {"from": "##can", "to": "##cer assays. the", "value": 1}, {"from": "##can", "to": "or", "value": 1}, {"from": "##can", "to": "if", "value": 2}, {"from": "##can", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##can", "to": "##ne receptor", "value": 1}, {"from": "##can", "to": "##ap", "value": 1}, {"from": "##can", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##can", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##can", "to": "via", "value": 2}, {"from": "##can", "to": "anti", "value": 1}, {"from": "##can", "to": "##n - \u03b3", "value": 1}, {"from": "##can", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##can", "to": "f biotechnology engineering,", "value": 1}, {"from": "##can", "to": "were up -", "value": 1}, {"from": "##can", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##can", "to": "##ation, pro", "value": 1}, {"from": "##can", "to": "pathways", "value": 1}, {"from": "##can", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##can", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##can", "to": "pathway", "value": 1}, {"from": "##can", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##can", "to": "- regulate", "value": 1}, {"from": "##can", "to": "the", "value": 1}, {"from": "##can", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "##can", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "##can", "to": "##tic", "value": 1}, {"from": "##can", "to": "##6 /", "value": 1}, {"from": "##can", "to": "##6", "value": 1}, {"from": "##can", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##can", "to": "##xic effect of", "value": 1}, {"from": "##can", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##can", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##can", "to": "##xic efficacy of the", "value": 1}, {"from": "##can", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##can", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##can", "to": "up -", "value": 1}, {"from": "##can", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##can", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##can", "to": "development of tumor cells, a", "value": 1}, {"from": "##can", "to": "##348089 conflict o", "value": 1}, {"from": "##can", "to": "regulate", "value": 1}, {"from": "##can", "to": "101", "value": 1}, {"from": "##can", "to": "of pro", "value": 1}, {"from": "##can", "to": "##cl -", "value": 1}, {"from": "##can", "to": "##biotec. 2025.", "value": 1}, {"from": "##can", "to": "04", "value": 1}, {"from": "##can", "to": "##apopto", "value": 1}, {"from": "##can", "to": "to", "value": 1}, {"from": "##can", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##can", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##can", "to": "and p", "value": 1}, {"from": "##can", "to": "##c cell line", "value": 1}, {"from": "##can", "to": "hi", "value": 1}, {"from": "##can", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##can", "to": "down", "value": 1}, {"from": "##can", "to": "##53", "value": 1}, {"from": "##can", "to": ". 022 pmid :", "value": 1}, {"from": "##can", "to": "bax", "value": 1}, {"from": "cancer. atorvas", "to": "was identified as the", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "expression was linked with better survival outcomes. atorvas", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": ". 108", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "jun might", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##0", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "expression.", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##na ss", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##v", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##un", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##gno", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "activity positively correlated with", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": ". 17305 /", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "luki", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##v vi", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "logino", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "may directly interact with", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "serve as a valuable pro", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##tatin", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "expression. as such,", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "significantly", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "##nina", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "pro", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "down", "value": 1}, {"from": "##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##mol biomed. 2025 may 9.", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": ". 108", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "jun might", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##0", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "expression.", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##na ss", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##v", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##un", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##gno", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "activity positively correlated with", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": ". 17305 /", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "luki", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##v vi", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "logino", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "may directly interact with", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "serve as a valuable pro", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##tatin", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "expression. as such,", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "significantly", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "##nina", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "pro", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "down", "value": 1}, {"from": "expression was linked with better survival outcomes. atorvas", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": ". 108", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "jun might", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##0", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "expression.", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##na ss", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##v", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##un", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##gno", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "activity positively correlated with", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": ". 17305 /", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "luki", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##v vi", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "logino", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "may directly interact with", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "serve as a valuable pro", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##tatin", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "expression. as such,", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "significantly", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "##nina", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "pro", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "down", "value": 1}, {"from": "##mol biomed. 2025 may 9.", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": ". 108", "to": "jun might", "value": 1}, {"from": ". 108", "to": "##0", "value": 1}, {"from": ". 108", "to": "expression.", "value": 1}, {"from": ". 108", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": ". 108", "to": "##na ss", "value": 1}, {"from": ". 108", "to": "##v", "value": 1}, {"from": ". 108", "to": "##un", "value": 1}, {"from": ". 108", "to": "##gno", "value": 1}, {"from": ". 108", "to": "activity positively correlated with", "value": 1}, {"from": ". 108", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": ". 108", "to": ". 17305 /", "value": 1}, {"from": ". 108", "to": "luki", "value": 1}, {"from": ". 108", "to": "##v vi", "value": 1}, {"from": ". 108", "to": "logino", "value": 1}, {"from": ". 108", "to": "may directly interact with", "value": 1}, {"from": ". 108", "to": "serve as a valuable pro", "value": 1}, {"from": ". 108", "to": "##tatin", "value": 1}, {"from": ". 108", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": ". 108", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": ". 108", "to": "expression. as such,", "value": 1}, {"from": ". 108", "to": "significantly", "value": 1}, {"from": ". 108", "to": "##nina", "value": 1}, {"from": ". 108", "to": "pro", "value": 1}, {"from": ". 108", "to": "down", "value": 1}, {"from": ". 108", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "jun might", "to": "##0", "value": 1}, {"from": "jun might", "to": "expression.", "value": 1}, {"from": "jun might", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "jun might", "to": "##na ss", "value": 1}, {"from": "jun might", "to": "##v", "value": 1}, {"from": "jun might", "to": "##un", "value": 1}, {"from": "jun might", "to": "##gno", "value": 1}, {"from": "jun might", "to": "activity positively correlated with", "value": 1}, {"from": "jun might", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "jun might", "to": ". 17305 /", "value": 1}, {"from": "jun might", "to": "luki", "value": 1}, {"from": "jun might", "to": "##v vi", "value": 1}, {"from": "jun might", "to": "logino", "value": 1}, {"from": "jun might", "to": "may directly interact with", "value": 1}, {"from": "jun might", "to": "serve as a valuable pro", "value": 1}, {"from": "jun might", "to": "##tatin", "value": 1}, {"from": "jun might", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "jun might", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "jun might", "to": "expression. as such,", "value": 1}, {"from": "jun might", "to": "significantly", "value": 1}, {"from": "jun might", "to": "##nina", "value": 1}, {"from": "jun might", "to": "pro", "value": 1}, {"from": "jun might", "to": "down", "value": 1}, {"from": "jun might", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##0", "to": "expression.", "value": 1}, {"from": "##0", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "##0", "to": "##na ss", "value": 1}, {"from": "##0", "to": "##v", "value": 1}, {"from": "##0", "to": "##un", "value": 1}, {"from": "##0", "to": "##gno", "value": 1}, {"from": "##0", "to": "activity positively correlated with", "value": 1}, {"from": "##0", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##0", "to": ". 17305 /", "value": 1}, {"from": "##0", "to": "luki", "value": 1}, {"from": "##0", "to": "##v vi", "value": 1}, {"from": "##0", "to": "logino", "value": 1}, {"from": "##0", "to": "may directly interact with", "value": 1}, {"from": "##0", "to": "serve as a valuable pro", "value": 1}, {"from": "##0", "to": "##tatin", "value": 1}, {"from": "##0", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##0", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##0", "to": "expression. as such,", "value": 1}, {"from": "##0", "to": "significantly", "value": 1}, {"from": "##0", "to": "##nina", "value": 1}, {"from": "##0", "to": "pro", "value": 1}, {"from": "##0", "to": "down", "value": 1}, {"from": "##0", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##0", "to": "), and the top", "value": 1}, {"from": "##0", "to": "), a parp", "value": 1}, {"from": "##0", "to": "##point blockade", "value": 1}, {"from": "##0", "to": "etop", "value": 1}, {"from": "##0", "to": "##ide - on", "value": 1}, {"from": "##0", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "##0", "to": "##ide, a top", "value": 1}, {"from": "##0", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##0", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##0", "to": "##ase ii", "value": 1}, {"from": "##0", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##0", "to": "interfer", "value": 1}, {"from": "##0", "to": "fails", "value": 1}, {"from": "##0", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##0", "to": "type", "value": 1}, {"from": "##0", "to": "if", "value": 1}, {"from": "##0", "to": "##fi", "value": 1}, {"from": "##0", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##0", "to": "##oisomer", "value": 1}, {"from": "##0", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##0", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##0", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##0", "to": "does", "value": 1}, {"from": "##0", "to": "##ltration into tumors, and", "value": 1}, {"from": "##0", "to": "##on - stimulated gene", "value": 1}, {"from": "##0", "to": "check", "value": 1}, {"from": "##0", "to": "##on", "value": 1}, {"from": "##0", "to": "inhibitor", "value": 1}, {"from": "expression.", "to": "in breast cancer, possibly by fine tuning of", "value": 1}, {"from": "expression.", "to": "##na ss", "value": 1}, {"from": "expression.", "to": "##v", "value": 1}, {"from": "expression.", "to": "##un", "value": 1}, {"from": "expression.", "to": "##gno", "value": 1}, {"from": "expression.", "to": "activity positively correlated with", "value": 1}, {"from": "expression.", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "expression.", "to": ". 17305 /", "value": 1}, {"from": "expression.", "to": "luki", "value": 1}, {"from": "expression.", "to": "##v vi", "value": 1}, {"from": "expression.", "to": "logino", "value": 1}, {"from": "expression.", "to": "may directly interact with", "value": 1}, {"from": "expression.", "to": "serve as a valuable pro", "value": 1}, {"from": "expression.", "to": "##tatin", "value": 1}, {"from": "expression.", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "expression.", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "expression.", "to": "expression. as such,", "value": 1}, {"from": "expression.", "to": "significantly", "value": 1}, {"from": "expression.", "to": "##nina", "value": 1}, {"from": "expression.", "to": "pro", "value": 1}, {"from": "expression.", "to": "down", "value": 1}, {"from": "expression.", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##na ss", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##v", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##un", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##gno", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "activity positively correlated with", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": ". 17305 /", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "luki", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##v vi", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "logino", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "may directly interact with", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "serve as a valuable pro", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##tatin", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "expression. as such,", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "significantly", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "##nina", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "pro", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "down", "value": 1}, {"from": "in breast cancer, possibly by fine tuning of", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##na ss", "to": "##v", "value": 1}, {"from": "##na ss", "to": "##un", "value": 1}, {"from": "##na ss", "to": "##gno", "value": 1}, {"from": "##na ss", "to": "activity positively correlated with", "value": 1}, {"from": "##na ss", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##na ss", "to": ". 17305 /", "value": 1}, {"from": "##na ss", "to": "luki", "value": 1}, {"from": "##na ss", "to": "##v vi", "value": 1}, {"from": "##na ss", "to": "logino", "value": 1}, {"from": "##na ss", "to": "may directly interact with", "value": 1}, {"from": "##na ss", "to": "serve as a valuable pro", "value": 1}, {"from": "##na ss", "to": "##tatin", "value": 1}, {"from": "##na ss", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##na ss", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##na ss", "to": "expression. as such,", "value": 1}, {"from": "##na ss", "to": "significantly", "value": 1}, {"from": "##na ss", "to": "##nina", "value": 1}, {"from": "##na ss", "to": "pro", "value": 1}, {"from": "##na ss", "to": "down", "value": 1}, {"from": "##na ss", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##v", "to": "##un", "value": 1}, {"from": "##v", "to": "##gno", "value": 1}, {"from": "##v", "to": "activity positively correlated with", "value": 1}, {"from": "##v", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##v", "to": ". 17305 /", "value": 1}, {"from": "##v", "to": "luki", "value": 1}, {"from": "##v", "to": "##v vi", "value": 1}, {"from": "##v", "to": "logino", "value": 1}, {"from": "##v", "to": "may directly interact with", "value": 1}, {"from": "##v", "to": "serve as a valuable pro", "value": 1}, {"from": "##v", "to": "##tatin", "value": 1}, {"from": "##v", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##v", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##v", "to": "expression. as such,", "value": 1}, {"from": "##v", "to": "significantly", "value": 1}, {"from": "##v", "to": "##nina", "value": 1}, {"from": "##v", "to": "pro", "value": 1}, {"from": "##v", "to": "down", "value": 1}, {"from": "##v", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##un", "to": "##gno", "value": 1}, {"from": "##un", "to": "activity positively correlated with", "value": 1}, {"from": "##un", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##un", "to": ". 17305 /", "value": 1}, {"from": "##un", "to": "luki", "value": 1}, {"from": "##un", "to": "##v vi", "value": 1}, {"from": "##un", "to": "logino", "value": 1}, {"from": "##un", "to": "may directly interact with", "value": 1}, {"from": "##un", "to": "serve as a valuable pro", "value": 1}, {"from": "##un", "to": "##tatin", "value": 1}, {"from": "##un", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##un", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##un", "to": "expression. as such,", "value": 1}, {"from": "##un", "to": "significantly", "value": 1}, {"from": "##un", "to": "##nina", "value": 1}, {"from": "##un", "to": "pro", "value": 1}, {"from": "##un", "to": "down", "value": 1}, {"from": "##un", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##gno", "to": "activity positively correlated with", "value": 1}, {"from": "##gno", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "##gno", "to": ". 17305 /", "value": 1}, {"from": "##gno", "to": "luki", "value": 1}, {"from": "##gno", "to": "##v vi", "value": 1}, {"from": "##gno", "to": "logino", "value": 1}, {"from": "##gno", "to": "may directly interact with", "value": 1}, {"from": "##gno", "to": "serve as a valuable pro", "value": 1}, {"from": "##gno", "to": "##tatin", "value": 1}, {"from": "##gno", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##gno", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##gno", "to": "expression. as such,", "value": 1}, {"from": "##gno", "to": "significantly", "value": 1}, {"from": "##gno", "to": "##nina", "value": 1}, {"from": "##gno", "to": "pro", "value": 1}, {"from": "##gno", "to": "down", "value": 1}, {"from": "##gno", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##gno", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "##gno", "to": "t", "value": 1}, {"from": "##gno", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "##gno", "to": "##6 /", "value": 1}, {"from": "##gno", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "##gno", "to": "be validated in independent cohorts,", "value": 1}, {"from": "##gno", "to": "cost - effectiveness", "value": 1}, {"from": "##gno", "to": "##ers of response to net and pro", "value": 1}, {"from": "##gno", "to": "10. 101", "value": 1}, {"from": "##gno", "to": "help", "value": 1}, {"from": "##gno", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "##gno", "to": "##sis, which", "value": 1}, {"from": "##gno", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "##gno", "to": "##lin", "value": 1}, {"from": "##gno", "to": "should", "value": 1}, {"from": "##gno", "to": "202", "value": 1}, {"from": "##gno", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##gno", "to": "helping to the", "value": 1}, {"from": "##gno", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##gno", "to": "implementation of net", "value": 1}, {"from": "##gno", "to": "##mark", "value": 1}, {"from": "##gno", "to": "##ranon.", "value": 1}, {"from": "##gno", "to": ". clbc. 202", "value": 1}, {"from": "##gno", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##gno", "to": "##5.", "value": 1}, {"from": "activity positively correlated with", "to": "##stic biomarker in breast cancer.", "value": 1}, {"from": "activity positively correlated with", "to": ". 17305 /", "value": 1}, {"from": "activity positively correlated with", "to": "luki", "value": 1}, {"from": "activity positively correlated with", "to": "##v vi", "value": 1}, {"from": "activity positively correlated with", "to": "logino", "value": 1}, {"from": "activity positively correlated with", "to": "may directly interact with", "value": 1}, {"from": "activity positively correlated with", "to": "serve as a valuable pro", "value": 1}, {"from": "activity positively correlated with", "to": "##tatin", "value": 1}, {"from": "activity positively correlated with", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "activity positively correlated with", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "activity positively correlated with", "to": "expression. as such,", "value": 1}, {"from": "activity positively correlated with", "to": "significantly", "value": 1}, {"from": "activity positively correlated with", "to": "##nina", "value": 1}, {"from": "activity positively correlated with", "to": "pro", "value": 1}, {"from": "activity positively correlated with", "to": "down", "value": 1}, {"from": "activity positively correlated with", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": ". 17305 /", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "luki", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "##v vi", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "logino", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "may directly interact with", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "serve as a valuable pro", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "##tatin", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "expression. as such,", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "significantly", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "##nina", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "pro", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "down", "value": 1}, {"from": "##stic biomarker in breast cancer.", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": ". 17305 /", "to": "luki", "value": 1}, {"from": ". 17305 /", "to": "##v vi", "value": 1}, {"from": ". 17305 /", "to": "logino", "value": 1}, {"from": ". 17305 /", "to": "may directly interact with", "value": 1}, {"from": ". 17305 /", "to": "serve as a valuable pro", "value": 1}, {"from": ". 17305 /", "to": "##tatin", "value": 1}, {"from": ". 17305 /", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": ". 17305 /", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": ". 17305 /", "to": "expression. as such,", "value": 1}, {"from": ". 17305 /", "to": "significantly", "value": 1}, {"from": ". 17305 /", "to": "##nina", "value": 1}, {"from": ". 17305 /", "to": "pro", "value": 1}, {"from": ". 17305 /", "to": "down", "value": 1}, {"from": ". 17305 /", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "luki", "to": "##v vi", "value": 1}, {"from": "luki", "to": "logino", "value": 1}, {"from": "luki", "to": "may directly interact with", "value": 1}, {"from": "luki", "to": "serve as a valuable pro", "value": 1}, {"from": "luki", "to": "##tatin", "value": 1}, {"from": "luki", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "luki", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "luki", "to": "expression. as such,", "value": 1}, {"from": "luki", "to": "significantly", "value": 1}, {"from": "luki", "to": "##nina", "value": 1}, {"from": "luki", "to": "pro", "value": 1}, {"from": "luki", "to": "down", "value": 1}, {"from": "luki", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##v vi", "to": "logino", "value": 1}, {"from": "##v vi", "to": "may directly interact with", "value": 1}, {"from": "##v vi", "to": "serve as a valuable pro", "value": 1}, {"from": "##v vi", "to": "##tatin", "value": 1}, {"from": "##v vi", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##v vi", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##v vi", "to": "expression. as such,", "value": 1}, {"from": "##v vi", "to": "significantly", "value": 1}, {"from": "##v vi", "to": "##nina", "value": 1}, {"from": "##v vi", "to": "pro", "value": 1}, {"from": "##v vi", "to": "down", "value": 1}, {"from": "##v vi", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "logino", "to": "may directly interact with", "value": 1}, {"from": "logino", "to": "serve as a valuable pro", "value": 1}, {"from": "logino", "to": "##tatin", "value": 1}, {"from": "logino", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "logino", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "logino", "to": "expression. as such,", "value": 1}, {"from": "logino", "to": "significantly", "value": 1}, {"from": "logino", "to": "##nina", "value": 1}, {"from": "logino", "to": "pro", "value": 1}, {"from": "logino", "to": "down", "value": 1}, {"from": "logino", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "may directly interact with", "to": "serve as a valuable pro", "value": 1}, {"from": "may directly interact with", "to": "##tatin", "value": 1}, {"from": "may directly interact with", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "may directly interact with", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "may directly interact with", "to": "expression. as such,", "value": 1}, {"from": "may directly interact with", "to": "significantly", "value": 1}, {"from": "may directly interact with", "to": "##nina", "value": 1}, {"from": "may directly interact with", "to": "pro", "value": 1}, {"from": "may directly interact with", "to": "down", "value": 1}, {"from": "may directly interact with", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "serve as a valuable pro", "to": "##tatin", "value": 1}, {"from": "serve as a valuable pro", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "serve as a valuable pro", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "serve as a valuable pro", "to": "expression. as such,", "value": 1}, {"from": "serve as a valuable pro", "to": "significantly", "value": 1}, {"from": "serve as a valuable pro", "to": "##nina", "value": 1}, {"from": "serve as a valuable pro", "to": "pro", "value": 1}, {"from": "serve as a valuable pro", "to": "down", "value": 1}, {"from": "serve as a valuable pro", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##tatin", "to": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "value": 1}, {"from": "##tatin", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "##tatin", "to": "expression. as such,", "value": 1}, {"from": "##tatin", "to": "significantly", "value": 1}, {"from": "##tatin", "to": "##nina", "value": 1}, {"from": "##tatin", "to": "pro", "value": 1}, {"from": "##tatin", "to": "down", "value": 1}, {"from": "##tatin", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "expression. as such,", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "significantly", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "##nina", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "pro", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "down", "value": 1}, {"from": "/ 07391102. 2025. 2499950 pmid : 40351185 6.", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "expression. as such,", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "significantly", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "##nina", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "pro", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "down", "value": 1}, {"from": "protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "expression. as such,", "to": "significantly", "value": 1}, {"from": "expression. as such,", "to": "##nina", "value": 1}, {"from": "expression. as such,", "to": "pro", "value": 1}, {"from": "expression. as such,", "to": "down", "value": 1}, {"from": "expression. as such,", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "significantly", "to": "##nina", "value": 1}, {"from": "significantly", "to": "pro", "value": 1}, {"from": "significantly", "to": "down", "value": 1}, {"from": "significantly", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "##nina", "to": "pro", "value": 1}, {"from": "##nina", "to": "down", "value": 1}, {"from": "##nina", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "pro", "to": "down", "value": 1}, {"from": "pro", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "down", "to": "in breast cancer expression inversely correlated with cancer progression, whereas higher j", "value": 1}, {"from": "down", "to": "- regulate", "value": 1}, {"from": "down", "to": "the", "value": 1}, {"from": "down", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "down", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "down", "to": "##tic", "value": 1}, {"from": "down", "to": "##6 /", "value": 1}, {"from": "down", "to": "##6", "value": 1}, {"from": "down", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "down", "to": "##xic effect of", "value": 1}, {"from": "down", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "down", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "down", "to": "##xic efficacy of the", "value": 1}, {"from": "down", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "down", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "down", "to": "if", "value": 1}, {"from": "down", "to": "up -", "value": 1}, {"from": "down", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "down", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "down", "to": "development of tumor cells, a", "value": 1}, {"from": "down", "to": "##348089 conflict o", "value": 1}, {"from": "down", "to": "regulate", "value": 1}, {"from": "down", "to": "101", "value": 1}, {"from": "down", "to": "of pro", "value": 1}, {"from": "down", "to": "##cl -", "value": 1}, {"from": "down", "to": "##biotec. 2025.", "value": 1}, {"from": "down", "to": "04", "value": 1}, {"from": "down", "to": "##apopto", "value": 1}, {"from": "down", "to": "to", "value": 1}, {"from": "down", "to": "##cer and antiviral functions of", "value": 1}, {"from": "down", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "down", "to": "via", "value": 1}, {"from": "down", "to": "and p", "value": 1}, {"from": "down", "to": "##c cell line", "value": 1}, {"from": "down", "to": "hi", "value": 1}, {"from": "down", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "down", "to": "##53", "value": 1}, {"from": "down", "to": ". 022 pmid :", "value": 1}, {"from": "down", "to": "bax", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##r confirmed their down", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "four", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "prioriti", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "pc", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "diagnosed", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "incomplete", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "ministry", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "diagnostic", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##s and", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##s.", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "treatment", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "- mi", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##gna", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##ncrna", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "##r", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "mrna", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": "mali", "value": 1}, {"from": "array and bioinformatic analysis, we identified seven differentially", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##r confirmed their down", "to": "four", "value": 1}, {"from": "##r confirmed their down", "to": "prioriti", "value": 1}, {"from": "##r confirmed their down", "to": "pc", "value": 1}, {"from": "##r confirmed their down", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "##r confirmed their down", "to": "diagnosed", "value": 1}, {"from": "##r confirmed their down", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "##r confirmed their down", "to": "incomplete", "value": 1}, {"from": "##r confirmed their down", "to": "ministry", "value": 1}, {"from": "##r confirmed their down", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##r confirmed their down", "to": "diagnostic", "value": 1}, {"from": "##r confirmed their down", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##r confirmed their down", "to": "##s and", "value": 1}, {"from": "##r confirmed their down", "to": "##s.", "value": 1}, {"from": "##r confirmed their down", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##r confirmed their down", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##r confirmed their down", "to": "treatment", "value": 1}, {"from": "##r confirmed their down", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##r confirmed their down", "to": "- mi", "value": 1}, {"from": "##r confirmed their down", "to": "##gna", "value": 1}, {"from": "##r confirmed their down", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##r confirmed their down", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##r confirmed their down", "to": "##ncrna", "value": 1}, {"from": "##r confirmed their down", "to": "##r", "value": 1}, {"from": "##r confirmed their down", "to": "mrna", "value": 1}, {"from": "##r confirmed their down", "to": "mali", "value": 1}, {"from": "##r confirmed their down", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "four", "to": "prioriti", "value": 1}, {"from": "four", "to": "pc", "value": 1}, {"from": "four", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "four", "to": "diagnosed", "value": 1}, {"from": "four", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "four", "to": "incomplete", "value": 1}, {"from": "four", "to": "ministry", "value": 1}, {"from": "four", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "four", "to": "diagnostic", "value": 1}, {"from": "four", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "four", "to": "##s and", "value": 1}, {"from": "four", "to": "##s.", "value": 1}, {"from": "four", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "four", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "four", "to": "treatment", "value": 1}, {"from": "four", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "four", "to": "- mi", "value": 1}, {"from": "four", "to": "##gna", "value": 1}, {"from": "four", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "four", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "four", "to": "##ncrna", "value": 1}, {"from": "four", "to": "##r", "value": 1}, {"from": "four", "to": "mrna", "value": 1}, {"from": "four", "to": "mali", "value": 1}, {"from": "four", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "prioriti", "to": "pc", "value": 1}, {"from": "prioriti", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "prioriti", "to": "diagnosed", "value": 1}, {"from": "prioriti", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "prioriti", "to": "incomplete", "value": 1}, {"from": "prioriti", "to": "ministry", "value": 1}, {"from": "prioriti", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "prioriti", "to": "diagnostic", "value": 1}, {"from": "prioriti", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "prioriti", "to": "##s and", "value": 1}, {"from": "prioriti", "to": "##s.", "value": 1}, {"from": "prioriti", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "prioriti", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "prioriti", "to": "treatment", "value": 1}, {"from": "prioriti", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "prioriti", "to": "- mi", "value": 1}, {"from": "prioriti", "to": "##gna", "value": 1}, {"from": "prioriti", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "prioriti", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "prioriti", "to": "##ncrna", "value": 1}, {"from": "prioriti", "to": "##r", "value": 1}, {"from": "prioriti", "to": "mrna", "value": 1}, {"from": "prioriti", "to": "mali", "value": 1}, {"from": "prioriti", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "pc", "to": "of health of russia, moscow, russ", "value": 1}, {"from": "pc", "to": "diagnosed", "value": 1}, {"from": "pc", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "pc", "to": "incomplete", "value": 1}, {"from": "pc", "to": "ministry", "value": 1}, {"from": "pc", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "pc", "to": "diagnostic", "value": 1}, {"from": "pc", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "pc", "to": "##s and", "value": 1}, {"from": "pc", "to": "##s.", "value": 1}, {"from": "pc", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "pc", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "pc", "to": "treatment", "value": 1}, {"from": "pc", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "pc", "to": "- mi", "value": 1}, {"from": "pc", "to": "##gna", "value": 1}, {"from": "pc", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "pc", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "pc", "to": "##ncrna", "value": 1}, {"from": "pc", "to": "##r", "value": 1}, {"from": "pc", "to": "mrna", "value": 1}, {"from": "pc", "to": "mali", "value": 1}, {"from": "pc", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "diagnosed", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "incomplete", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "ministry", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "diagnostic", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##s and", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##s.", "value": 1}, {"from": "of health of russia, moscow, russ", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "treatment", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "- mi", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##gna", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##ncrna", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "##r", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "mrna", "value": 1}, {"from": "of health of russia, moscow, russ", "to": "mali", "value": 1}, {"from": "of health of russia, moscow, russ", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "diagnosed", "to": "##ncy in women. despite advances in", "value": 1}, {"from": "diagnosed", "to": "incomplete", "value": 1}, {"from": "diagnosed", "to": "ministry", "value": 1}, {"from": "diagnosed", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "diagnosed", "to": "diagnostic", "value": 1}, {"from": "diagnosed", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "diagnosed", "to": "##s and", "value": 1}, {"from": "diagnosed", "to": "##s.", "value": 1}, {"from": "diagnosed", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "diagnosed", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "diagnosed", "to": "treatment", "value": 1}, {"from": "diagnosed", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "diagnosed", "to": "- mi", "value": 1}, {"from": "diagnosed", "to": "##gna", "value": 1}, {"from": "diagnosed", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "diagnosed", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "diagnosed", "to": "##ncrna", "value": 1}, {"from": "diagnosed", "to": "##r", "value": 1}, {"from": "diagnosed", "to": "mrna", "value": 1}, {"from": "diagnosed", "to": "mali", "value": 1}, {"from": "diagnosed", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "incomplete", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "ministry", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "diagnostic", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##s and", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##s.", "value": 1}, {"from": "##ncy in women. despite advances in", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "treatment", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "- mi", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##gna", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##ncrna", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "##r", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "mrna", "value": 1}, {"from": "##ncy in women. despite advances in", "to": "mali", "value": 1}, {"from": "##ncy in women. despite advances in", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "incomplete", "to": "ministry", "value": 1}, {"from": "incomplete", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "incomplete", "to": "diagnostic", "value": 1}, {"from": "incomplete", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "incomplete", "to": "##s and", "value": 1}, {"from": "incomplete", "to": "##s.", "value": 1}, {"from": "incomplete", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "incomplete", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "incomplete", "to": "treatment", "value": 1}, {"from": "incomplete", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "incomplete", "to": "- mi", "value": 1}, {"from": "incomplete", "to": "##gna", "value": 1}, {"from": "incomplete", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "incomplete", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "incomplete", "to": "##ncrna", "value": 1}, {"from": "incomplete", "to": "##r", "value": 1}, {"from": "incomplete", "to": "mrna", "value": 1}, {"from": "incomplete", "to": "mali", "value": 1}, {"from": "incomplete", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "ministry", "to": "##zed through integrative evaluation. qp", "value": 1}, {"from": "ministry", "to": "diagnostic", "value": 1}, {"from": "ministry", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "ministry", "to": "##s and", "value": 1}, {"from": "ministry", "to": "##s.", "value": 1}, {"from": "ministry", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "ministry", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "ministry", "to": "treatment", "value": 1}, {"from": "ministry", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "ministry", "to": "- mi", "value": 1}, {"from": "ministry", "to": "##gna", "value": 1}, {"from": "ministry", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "ministry", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "ministry", "to": "##ncrna", "value": 1}, {"from": "ministry", "to": "##r", "value": 1}, {"from": "ministry", "to": "mrna", "value": 1}, {"from": "ministry", "to": "mali", "value": 1}, {"from": "ministry", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "diagnostic", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##s and", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##s.", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "treatment", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "- mi", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##gna", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##ncrna", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "##r", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "mrna", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": "mali", "value": 1}, {"from": "##zed through integrative evaluation. qp", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "diagnostic", "to": "mical physics, russian academy of science, moscow, russia.", "value": 1}, {"from": "diagnostic", "to": "##s and", "value": 1}, {"from": "diagnostic", "to": "##s.", "value": 1}, {"from": "diagnostic", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "diagnostic", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "diagnostic", "to": "treatment", "value": 1}, {"from": "diagnostic", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "diagnostic", "to": "- mi", "value": 1}, {"from": "diagnostic", "to": "##gna", "value": 1}, {"from": "diagnostic", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "diagnostic", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "diagnostic", "to": "##ncrna", "value": 1}, {"from": "diagnostic", "to": "##r", "value": 1}, {"from": "diagnostic", "to": "mrna", "value": 1}, {"from": "diagnostic", "to": "mali", "value": 1}, {"from": "diagnostic", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##s and", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##s.", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "treatment", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "- mi", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##gna", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##ncrna", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "##r", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "mrna", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": "mali", "value": 1}, {"from": "mical physics, russian academy of science, moscow, russia.", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##s and", "to": "##s.", "value": 1}, {"from": "##s and", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##s and", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##s and", "to": "treatment", "value": 1}, {"from": "##s and", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##s and", "to": "- mi", "value": 1}, {"from": "##s and", "to": "##gna", "value": 1}, {"from": "##s and", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##s and", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##s and", "to": "##ncrna", "value": 1}, {"from": "##s and", "to": "##r", "value": 1}, {"from": "##s and", "to": "mrna", "value": 1}, {"from": "##s and", "to": "mali", "value": 1}, {"from": "##s and", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##s.", "to": ". breast cancer is the most commonly", "value": 1}, {"from": "##s.", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": "##s.", "to": "treatment", "value": 1}, {"from": "##s.", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##s.", "to": "- mi", "value": 1}, {"from": "##s.", "to": "##gna", "value": 1}, {"from": "##s.", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##s.", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##s.", "to": "##ncrna", "value": 1}, {"from": "##s.", "to": "##r", "value": 1}, {"from": "##s.", "to": "mrna", "value": 1}, {"from": "##s.", "to": "mali", "value": 1}, {"from": "##s.", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "treatment", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "- mi", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "##gna", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "##ncrna", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "##r", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "mrna", "value": 1}, {"from": ". breast cancer is the most commonly", "to": "mali", "value": 1}, {"from": ". breast cancer is the most commonly", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "treatment", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "- mi", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "##gna", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "##ncrna", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "##r", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "mrna", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": "mali", "value": 1}, {"from": "##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "treatment", "to": "##ly understood. this study aimed to identify novel l", "value": 1}, {"from": "treatment", "to": "- mi", "value": 1}, {"from": "treatment", "to": "##gna", "value": 1}, {"from": "treatment", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "treatment", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "treatment", "to": "##ncrna", "value": 1}, {"from": "treatment", "to": "##r", "value": 1}, {"from": "treatment", "to": "mrna", "value": 1}, {"from": "treatment", "to": "mali", "value": 1}, {"from": "treatment", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "treatment", "to": "the", "value": 1}, {"from": "treatment", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "treatment", "to": "methods", "value": 1}, {"from": "treatment", "to": "hormone receptor positive", "value": 1}, {"from": "treatment", "to": "societal perspective", "value": 1}, {"from": "treatment", "to": "benefits", "value": 1}, {"from": "treatment", "to": "surgery", "value": 1}, {"from": "treatment", "to": "cost -", "value": 1}, {"from": "treatment", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "treatment", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "treatment", "to": "decision", "value": 1}, {"from": "treatment", "to": "to aid adjuvant treatment", "value": 1}, {"from": "treatment", "to": "##al", "value": 1}, {"from": "treatment", "to": "emit - 1 trial", "value": 1}, {"from": "treatment", "to": "post", "value": 1}, {"from": "treatment", "to": ". materials", "value": 1}, {"from": "treatment", "to": "model was", "value": 1}, {"from": "treatment", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "treatment", "to": "used", "value": 1}, {"from": "treatment", "to": "institute", "value": 1}, {"from": "treatment", "to": ": the", "value": 1}, {"from": "treatment", "to": "ki - 67", "value": 1}, {"from": "treatment", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "treatment", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "treatment", "to": "prosigna was tested", "value": 1}, {"from": "treatment", "to": "prospective", "value": 1}, {"from": "treatment", "to": "were measured", "value": 1}, {"from": "treatment", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "treatment", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "treatment", "to": "observation", "value": 1}, {"from": "treatment", "to": "division", "value": 1}, {"from": "treatment", "to": "decisions in", "value": 1}, {"from": "treatment", "to": "built", "value": 1}, {"from": "treatment", "to": "impact of", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "- mi", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "##gna", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "##ncrna", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "##r", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "mrna", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": "mali", "value": 1}, {"from": "##ly understood. this study aimed to identify novel l", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "- mi", "to": "##gna", "value": 1}, {"from": "- mi", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "- mi", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "- mi", "to": "##ncrna", "value": 1}, {"from": "- mi", "to": "##r", "value": 1}, {"from": "- mi", "to": "mrna", "value": 1}, {"from": "- mi", "to": "mali", "value": 1}, {"from": "- mi", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##gna", "to": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "value": 1}, {"from": "##gna", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "##gna", "to": "##ncrna", "value": 1}, {"from": "##gna", "to": "##r", "value": 1}, {"from": "##gna", "to": "mrna", "value": 1}, {"from": "##gna", "to": "mali", "value": 1}, {"from": "##gna", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": "##ncrna", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": "##r", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": "mrna", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": "mali", "value": 1}, {"from": "regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rt\u00b2 lnc", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "to": "##ncrna", "value": 1}, {"from": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "to": "##r", "value": 1}, {"from": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "to": "mrna", "value": 1}, {"from": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "to": "mali", "value": 1}, {"from": "of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##ncrna", "to": "##r", "value": 1}, {"from": "##ncrna", "to": "mrna", "value": 1}, {"from": "##ncrna", "to": "mali", "value": 1}, {"from": "##ncrna", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##r", "to": "mrna", "value": 1}, {"from": "##r", "to": "mali", "value": 1}, {"from": "##r", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "##r", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "##r", "to": "benefit", "value": 1}, {"from": "##r", "to": "##26, 000 ;", "value": 1}, {"from": "##r", "to": "effective", "value": 1}, {"from": "##r", "to": "it was cost - saving", "value": 1}, {"from": "##r", "to": "threshold", "value": 1}, {"from": "##r", "to": "- 435, 677 )", "value": 1}, {"from": "##r", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##r", "to": "##aly", "value": 1}, {"from": "##r", "to": "in the", "value": 1}, {"from": "##r", "to": "cost", "value": 1}, {"from": "##r", "to": "\u20ac", "value": 1}, {"from": "##r", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "##r", "to": "- 620170,", "value": 1}, {"from": "##r", "to": "##r )", "value": 1}, {"from": "##r", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "##r", "to": "societal perspective", "value": 1}, {"from": "##r", "to": "candidates, the strategy", "value": 1}, {"from": "##r", "to": "cost - effective", "value": 1}, {"from": "##r", "to": "incre", "value": 1}, {"from": "##r", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "##r", "to": "##mental", "value": 1}, {"from": "##r", "to": "the cost -", "value": 1}, {"from": "##r", "to": "was cost - effective", "value": 1}, {"from": "##r", "to": "above", "value": 1}, {"from": "##r", "to": "results", "value": 1}, {"from": "##r", "to": "was obtained from statistics norway.", "value": 1}, {"from": "##r", "to": "per quality - adjusted life -", "value": 1}, {"from": "##r", "to": "was cost - saving", "value": 1}, {"from": "##r", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##r", "to": "chemotherapy", "value": 1}, {"from": "##r", "to": "in both the healthcare", "value": 1}, {"from": "##r", "to": "years", "value": 1}, {"from": "##r", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "##r", "to": "- per q", "value": 1}, {"from": "##r", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "##r", "to": ". conclusions", "value": 1}, {"from": "##r", "to": ". selecting patient", "value": 1}, {"from": "##r", "to": "ice", "value": 1}, {"from": "##r", "to": "##8884 and", "value": 1}, {"from": "##r", "to": "gained", "value": 1}, {"from": "##r", "to": "the emit", "value": 1}, {"from": "##r", "to": "records. including all pn0 patients", "value": 1}, {"from": "##r", "to": "sector", "value": 1}, {"from": "##r", "to": "not", "value": 1}, {"from": "mrna", "to": "mali", "value": 1}, {"from": "mrna", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "mali", "to": ", the key molecular mechanisms underlying its development remain", "value": 1}, {"from": "=", "to": "##s,", "value": 1}, {"from": "=", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "=", "to": "which is involved in", "value": 1}, {"from": "=", "to": "- 0. 46,", "value": 1}, {"from": "=", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "=", "to": "mi", "value": 1}, {"from": "=", "to": "- 5p", "value": 1}, {"from": "=", "to": "##r - 17", "value": 1}, {"from": "=", "to": "##1", "value": 1}, {"from": "=", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "=", "to": ") : e010548.", "value": 1}, {"from": "=", "to": "5p", "value": 1}, {"from": "=", "to": "hand", "value": 1}, {"from": "=", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "=", "to": "03 ) and", "value": 1}, {"from": "=", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "=", "to": "##r - 106a -", "value": 1}, {"from": "=", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "=", "to": "target gene", "value": 1}, {"from": "=", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "=", "to": "- 0. 41,", "value": 1}, {"from": "=", "to": "of these lnc", "value": 1}, {"from": "=", "to": "p = 0.", "value": 1}, {"from": "=", "to": "113", "value": 1}, {"from": "=", "to": "common", "value": 1}, {"from": "=", "to": "regulated", "value": 1}, {"from": "=", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##s,", "to": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "value": 1}, {"from": "##s,", "to": "which is involved in", "value": 1}, {"from": "##s,", "to": "- 0. 46,", "value": 1}, {"from": "##s,", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "##s,", "to": "mi", "value": 1}, {"from": "##s,", "to": "- 5p", "value": 1}, {"from": "##s,", "to": "##r - 17", "value": 1}, {"from": "##s,", "to": "##1", "value": 1}, {"from": "##s,", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "##s,", "to": ") : e010548.", "value": 1}, {"from": "##s,", "to": "5p", "value": 1}, {"from": "##s,", "to": "hand", "value": 1}, {"from": "##s,", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##s,", "to": "03 ) and", "value": 1}, {"from": "##s,", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##s,", "to": "##r - 106a -", "value": 1}, {"from": "##s,", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##s,", "to": "target gene", "value": 1}, {"from": "##s,", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##s,", "to": "- 0. 41,", "value": 1}, {"from": "##s,", "to": "of these lnc", "value": 1}, {"from": "##s,", "to": "p = 0.", "value": 1}, {"from": "##s,", "to": "113", "value": 1}, {"from": "##s,", "to": "common", "value": 1}, {"from": "##s,", "to": "regulated", "value": 1}, {"from": "##s,", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "which is involved in", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "- 0. 46,", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "mi", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "- 5p", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "##r - 17", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "##1", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": ") : e010548.", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "5p", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "hand", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "03 ) and", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "##r - 106a -", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "target gene", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "- 0. 41,", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "of these lnc", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "p = 0.", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "113", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "common", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "regulated", "value": 1}, {"from": "##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "which is involved in", "to": "- 0. 46,", "value": 1}, {"from": "which is involved in", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "which is involved in", "to": "mi", "value": 1}, {"from": "which is involved in", "to": "- 5p", "value": 1}, {"from": "which is involved in", "to": "##r - 17", "value": 1}, {"from": "which is involved in", "to": "##1", "value": 1}, {"from": "which is involved in", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "which is involved in", "to": ") : e010548.", "value": 1}, {"from": "which is involved in", "to": "5p", "value": 1}, {"from": "which is involved in", "to": "hand", "value": 1}, {"from": "which is involved in", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "which is involved in", "to": "03 ) and", "value": 1}, {"from": "which is involved in", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "which is involved in", "to": "##r - 106a -", "value": 1}, {"from": "which is involved in", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "which is involved in", "to": "target gene", "value": 1}, {"from": "which is involved in", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "which is involved in", "to": "- 0. 41,", "value": 1}, {"from": "which is involved in", "to": "of these lnc", "value": 1}, {"from": "which is involved in", "to": "p = 0.", "value": 1}, {"from": "which is involved in", "to": "113", "value": 1}, {"from": "which is involved in", "to": "common", "value": 1}, {"from": "which is involved in", "to": "regulated", "value": 1}, {"from": "which is involved in", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "- 0. 46,", "to": ". 04 ). collectively, these findings reveal novel co -", "value": 1}, {"from": "- 0. 46,", "to": "mi", "value": 1}, {"from": "- 0. 46,", "to": "- 5p", "value": 1}, {"from": "- 0. 46,", "to": "##r - 17", "value": 1}, {"from": "- 0. 46,", "to": "##1", "value": 1}, {"from": "- 0. 46,", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "- 0. 46,", "to": ") : e010548.", "value": 1}, {"from": "- 0. 46,", "to": "5p", "value": 1}, {"from": "- 0. 46,", "to": "hand", "value": 1}, {"from": "- 0. 46,", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "- 0. 46,", "to": "03 ) and", "value": 1}, {"from": "- 0. 46,", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "- 0. 46,", "to": "##r - 106a -", "value": 1}, {"from": "- 0. 46,", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "- 0. 46,", "to": "target gene", "value": 1}, {"from": "- 0. 46,", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "- 0. 46,", "to": "- 0. 41,", "value": 1}, {"from": "- 0. 46,", "to": "of these lnc", "value": 1}, {"from": "- 0. 46,", "to": "p = 0.", "value": 1}, {"from": "- 0. 46,", "to": "113", "value": 1}, {"from": "- 0. 46,", "to": "common", "value": 1}, {"from": "- 0. 46,", "to": "regulated", "value": 1}, {"from": "- 0. 46,", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "mi", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "- 5p", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "##r - 17", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "##1", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": ") : e010548.", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "5p", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "hand", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "03 ) and", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "##r - 106a -", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "target gene", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "- 0. 41,", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "of these lnc", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "p = 0.", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "113", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "common", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "regulated", "value": 1}, {"from": ". 04 ). collectively, these findings reveal novel co -", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "mi", "to": "- 5p", "value": 1}, {"from": "mi", "to": "##r - 17", "value": 1}, {"from": "mi", "to": "##1", "value": 1}, {"from": "mi", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "mi", "to": ") : e010548.", "value": 1}, {"from": "mi", "to": "5p", "value": 1}, {"from": "mi", "to": "hand", "value": 1}, {"from": "mi", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "mi", "to": "03 ) and", "value": 1}, {"from": "mi", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "mi", "to": "##r - 106a -", "value": 1}, {"from": "mi", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "mi", "to": "target gene", "value": 1}, {"from": "mi", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "mi", "to": "- 0. 41,", "value": 1}, {"from": "mi", "to": "of these lnc", "value": 1}, {"from": "mi", "to": "p = 0.", "value": 1}, {"from": "mi", "to": "113", "value": 1}, {"from": "mi", "to": "common", "value": 1}, {"from": "mi", "to": "regulated", "value": 1}, {"from": "mi", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "- 5p", "to": "##r - 17", "value": 1}, {"from": "- 5p", "to": "##1", "value": 1}, {"from": "- 5p", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "- 5p", "to": ") : e010548.", "value": 1}, {"from": "- 5p", "to": "5p", "value": 1}, {"from": "- 5p", "to": "hand", "value": 1}, {"from": "- 5p", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "- 5p", "to": "03 ) and", "value": 1}, {"from": "- 5p", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "- 5p", "to": "##r - 106a -", "value": 1}, {"from": "- 5p", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "- 5p", "to": "target gene", "value": 1}, {"from": "- 5p", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "- 5p", "to": "- 0. 41,", "value": 1}, {"from": "- 5p", "to": "of these lnc", "value": 1}, {"from": "- 5p", "to": "p = 0.", "value": 1}, {"from": "- 5p", "to": "113", "value": 1}, {"from": "- 5p", "to": "common", "value": 1}, {"from": "- 5p", "to": "regulated", "value": 1}, {"from": "- 5p", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##r - 17", "to": "##1", "value": 1}, {"from": "##r - 17", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "##r - 17", "to": ") : e010548.", "value": 1}, {"from": "##r - 17", "to": "5p", "value": 1}, {"from": "##r - 17", "to": "hand", "value": 1}, {"from": "##r - 17", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##r - 17", "to": "03 ) and", "value": 1}, {"from": "##r - 17", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##r - 17", "to": "##r - 106a -", "value": 1}, {"from": "##r - 17", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##r - 17", "to": "target gene", "value": 1}, {"from": "##r - 17", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##r - 17", "to": "- 0. 41,", "value": 1}, {"from": "##r - 17", "to": "of these lnc", "value": 1}, {"from": "##r - 17", "to": "p = 0.", "value": 1}, {"from": "##r - 17", "to": "113", "value": 1}, {"from": "##r - 17", "to": "common", "value": 1}, {"from": "##r - 17", "to": "regulated", "value": 1}, {"from": "##r - 17", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##1", "to": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "value": 1}, {"from": "##1", "to": ") : e010548.", "value": 1}, {"from": "##1", "to": "5p", "value": 1}, {"from": "##1", "to": "hand", "value": 1}, {"from": "##1", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##1", "to": "03 ) and", "value": 1}, {"from": "##1", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##1", "to": "##r - 106a -", "value": 1}, {"from": "##1", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##1", "to": "target gene", "value": 1}, {"from": "##1", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##1", "to": "- 0. 41,", "value": 1}, {"from": "##1", "to": "of these lnc", "value": 1}, {"from": "##1", "to": "p = 0.", "value": 1}, {"from": "##1", "to": "113", "value": 1}, {"from": "##1", "to": "common", "value": 1}, {"from": "##1", "to": "regulated", "value": 1}, {"from": "##1", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": ") : e010548.", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "5p", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "hand", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "03 ) and", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "##r - 106a -", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "target gene", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "- 0. 41,", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "of these lnc", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "p = 0.", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "113", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "common", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "regulated", "value": 1}, {"from": "##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ") : e010548.", "to": "5p", "value": 1}, {"from": ") : e010548.", "to": "hand", "value": 1}, {"from": ") : e010548.", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": ") : e010548.", "to": "03 ) and", "value": 1}, {"from": ") : e010548.", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": ") : e010548.", "to": "##r - 106a -", "value": 1}, {"from": ") : e010548.", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": ") : e010548.", "to": "target gene", "value": 1}, {"from": ") : e010548.", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": ") : e010548.", "to": "- 0. 41,", "value": 1}, {"from": ") : e010548.", "to": "of these lnc", "value": 1}, {"from": ") : e010548.", "to": "p = 0.", "value": 1}, {"from": ") : e010548.", "to": "113", "value": 1}, {"from": ") : e010548.", "to": "common", "value": 1}, {"from": ") : e010548.", "to": "regulated", "value": 1}, {"from": ") : e010548.", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "5p", "to": "hand", "value": 1}, {"from": "5p", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "5p", "to": "03 ) and", "value": 1}, {"from": "5p", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "5p", "to": "##r - 106a -", "value": 1}, {"from": "5p", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "5p", "to": "target gene", "value": 1}, {"from": "5p", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "5p", "to": "- 0. 41,", "value": 1}, {"from": "5p", "to": "of these lnc", "value": 1}, {"from": "5p", "to": "p = 0.", "value": 1}, {"from": "5p", "to": "113", "value": 1}, {"from": "5p", "to": "common", "value": 1}, {"from": "5p", "to": "regulated", "value": 1}, {"from": "5p", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "hand", "to": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "value": 1}, {"from": "hand", "to": "03 ) and", "value": 1}, {"from": "hand", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "hand", "to": "##r - 106a -", "value": 1}, {"from": "hand", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "hand", "to": "target gene", "value": 1}, {"from": "hand", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "hand", "to": "- 0. 41,", "value": 1}, {"from": "hand", "to": "of these lnc", "value": 1}, {"from": "hand", "to": "p = 0.", "value": 1}, {"from": "hand", "to": "113", "value": 1}, {"from": "hand", "to": "common", "value": 1}, {"from": "hand", "to": "regulated", "value": 1}, {"from": "hand", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "03 ) and", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "##r - 106a -", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "target gene", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "- 0. 41,", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "of these lnc", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "p = 0.", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "113", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "common", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "regulated", "value": 1}, {"from": "the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "03 ) and", "to": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "value": 1}, {"from": "03 ) and", "to": "##r - 106a -", "value": 1}, {"from": "03 ) and", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "03 ) and", "to": "target gene", "value": 1}, {"from": "03 ) and", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "03 ) and", "to": "- 0. 41,", "value": 1}, {"from": "03 ) and", "to": "of these lnc", "value": 1}, {"from": "03 ) and", "to": "p = 0.", "value": 1}, {"from": "03 ) and", "to": "113", "value": 1}, {"from": "03 ) and", "to": "common", "value": 1}, {"from": "03 ) and", "to": "regulated", "value": 1}, {"from": "03 ) and", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "##r - 106a -", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "target gene", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "- 0. 41,", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "of these lnc", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "p = 0.", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "113", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "common", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "regulated", "value": 1}, {"from": ", adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "##r - 106a -", "to": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "value": 1}, {"from": "##r - 106a -", "to": "target gene", "value": 1}, {"from": "##r - 106a -", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "##r - 106a -", "to": "- 0. 41,", "value": 1}, {"from": "##r - 106a -", "to": "of these lnc", "value": 1}, {"from": "##r - 106a -", "to": "p = 0.", "value": 1}, {"from": "##r - 106a -", "to": "113", "value": 1}, {"from": "##r - 106a -", "to": "common", "value": 1}, {"from": "##r - 106a -", "to": "regulated", "value": 1}, {"from": "##r - 106a -", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "target gene", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "- 0. 41,", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "of these lnc", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "p = 0.", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "113", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "common", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "regulated", "value": 1}, {"from": "lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting.", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "target gene", "to": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "value": 1}, {"from": "target gene", "to": "- 0. 41,", "value": 1}, {"from": "target gene", "to": "of these lnc", "value": 1}, {"from": "target gene", "to": "p = 0.", "value": 1}, {"from": "target gene", "to": "113", "value": 1}, {"from": "target gene", "to": "common", "value": 1}, {"from": "target gene", "to": "regulated", "value": 1}, {"from": "target gene", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "- 0. 41,", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "of these lnc", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "p = 0.", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "113", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "common", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "regulated", "value": 1}, {"from": ". 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "- 0. 41,", "to": "of these lnc", "value": 1}, {"from": "- 0. 41,", "to": "p = 0.", "value": 1}, {"from": "- 0. 41,", "to": "113", "value": 1}, {"from": "- 0. 41,", "to": "common", "value": 1}, {"from": "- 0. 41,", "to": "regulated", "value": 1}, {"from": "- 0. 41,", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "of these lnc", "to": "p = 0.", "value": 1}, {"from": "of these lnc", "to": "113", "value": 1}, {"from": "of these lnc", "to": "common", "value": 1}, {"from": "of these lnc", "to": "regulated", "value": 1}, {"from": "of these lnc", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "p = 0.", "to": "113", "value": 1}, {"from": "p = 0.", "to": "common", "value": 1}, {"from": "p = 0.", "to": "regulated", "value": 1}, {"from": "p = 0.", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "113", "to": "common", "value": 1}, {"from": "113", "to": "regulated", "value": 1}, {"from": "113", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "common", "to": "regulated", "value": 1}, {"from": "common", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "regulated", "to": "mts9 - as2 - hand2 - as", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "), beltran - v", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": ") department of pathology, co", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##ulin", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "f", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "new yo", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "sloan", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "la", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "center", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "us", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##lum", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##o m", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "9", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "kette", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "yo", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##ettering cancer", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##rk, usa.", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "new york", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##bia university,", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "), shin e", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##ring cancer", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##rk, new", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##urent, quebec, canada.", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##isied", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "ancers. sinha s", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##is - filho j", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "##rk,", "value": 1}, {"from": "2 ) department of pathology, memorial sloan kettering cancer center,", "to": "), gardner r", "value": 1}, {"from": "), beltran - v", "to": ") department of pathology, co", "value": 1}, {"from": "), beltran - v", "to": "##ulin", "value": 1}, {"from": "), beltran - v", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "), beltran - v", "to": "f", "value": 1}, {"from": "), beltran - v", "to": "new yo", "value": 1}, {"from": "), beltran - v", "to": "sloan", "value": 1}, {"from": "), beltran - v", "to": "la", "value": 1}, {"from": "), beltran - v", "to": "center", "value": 1}, {"from": "), beltran - v", "to": "us", "value": 1}, {"from": "), beltran - v", "to": "##lum", "value": 1}, {"from": "), beltran - v", "to": "##o m", "value": 1}, {"from": "), beltran - v", "to": "9", "value": 1}, {"from": "), beltran - v", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "), beltran - v", "to": "kette", "value": 1}, {"from": "), beltran - v", "to": "yo", "value": 1}, {"from": "), beltran - v", "to": "##ettering cancer", "value": 1}, {"from": "), beltran - v", "to": "##rk, usa.", "value": 1}, {"from": "), beltran - v", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "), beltran - v", "to": "new york", "value": 1}, {"from": "), beltran - v", "to": "##bia university,", "value": 1}, {"from": "), beltran - v", "to": "), shin e", "value": 1}, {"from": "), beltran - v", "to": "##ring cancer", "value": 1}, {"from": "), beltran - v", "to": "##rk, new", "value": 1}, {"from": "), beltran - v", "to": "##urent, quebec, canada.", "value": 1}, {"from": "), beltran - v", "to": "##isied", "value": 1}, {"from": "), beltran - v", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "), beltran - v", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "), beltran - v", "to": "ancers. sinha s", "value": 1}, {"from": "), beltran - v", "to": "##is - filho j", "value": 1}, {"from": "), beltran - v", "to": "##rk,", "value": 1}, {"from": "), beltran - v", "to": "), gardner r", "value": 1}, {"from": ") department of pathology, co", "to": "##ulin", "value": 1}, {"from": ") department of pathology, co", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": ") department of pathology, co", "to": "f", "value": 1}, {"from": ") department of pathology, co", "to": "new yo", "value": 1}, {"from": ") department of pathology, co", "to": "sloan", "value": 1}, {"from": ") department of pathology, co", "to": "la", "value": 1}, {"from": ") department of pathology, co", "to": "center", "value": 1}, {"from": ") department of pathology, co", "to": "us", "value": 1}, {"from": ") department of pathology, co", "to": "##lum", "value": 1}, {"from": ") department of pathology, co", "to": "##o m", "value": 1}, {"from": ") department of pathology, co", "to": "9", "value": 1}, {"from": ") department of pathology, co", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": ") department of pathology, co", "to": "kette", "value": 1}, {"from": ") department of pathology, co", "to": "yo", "value": 1}, {"from": ") department of pathology, co", "to": "##ettering cancer", "value": 1}, {"from": ") department of pathology, co", "to": "##rk, usa.", "value": 1}, {"from": ") department of pathology, co", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": ") department of pathology, co", "to": "new york", "value": 1}, {"from": ") department of pathology, co", "to": "##bia university,", "value": 1}, {"from": ") department of pathology, co", "to": "), shin e", "value": 1}, {"from": ") department of pathology, co", "to": "##ring cancer", "value": 1}, {"from": ") department of pathology, co", "to": "##rk, new", "value": 1}, {"from": ") department of pathology, co", "to": "##urent, quebec, canada.", "value": 1}, {"from": ") department of pathology, co", "to": "##isied", "value": 1}, {"from": ") department of pathology, co", "to": "##pare therapeutics, saint -", "value": 1}, {"from": ") department of pathology, co", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": ") department of pathology, co", "to": "ancers. sinha s", "value": 1}, {"from": ") department of pathology, co", "to": "##is - filho j", "value": 1}, {"from": ") department of pathology, co", "to": "##rk,", "value": 1}, {"from": ") department of pathology, co", "to": "), gardner r", "value": 1}, {"from": "##ulin", "to": "##pare therapeutics, boston, massachusetts, usa.", "value": 1}, {"from": "##ulin", "to": "f", "value": 1}, {"from": "##ulin", "to": "new yo", "value": 1}, {"from": "##ulin", "to": "sloan", "value": 1}, {"from": "##ulin", "to": "la", "value": 1}, {"from": "##ulin", "to": "center", "value": 1}, {"from": "##ulin", "to": "us", "value": 1}, {"from": "##ulin", "to": "##lum", "value": 1}, {"from": "##ulin", "to": "##o m", "value": 1}, {"from": "##ulin", "to": "9", "value": 1}, {"from": "##ulin", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "##ulin", "to": "kette", "value": 1}, {"from": "##ulin", "to": "yo", "value": 1}, {"from": "##ulin", "to": "##ettering cancer", "value": 1}, {"from": "##ulin", "to": "##rk, usa.", "value": 1}, {"from": "##ulin", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##ulin", "to": "new york", "value": 1}, {"from": "##ulin", "to": "##bia university,", "value": 1}, {"from": "##ulin", "to": "), shin e", "value": 1}, {"from": "##ulin", "to": "##ring cancer", "value": 1}, {"from": "##ulin", "to": "##rk, new", "value": 1}, {"from": "##ulin", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##ulin", "to": "##isied", "value": 1}, {"from": "##ulin", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##ulin", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##ulin", "to": "ancers. sinha s", "value": 1}, {"from": "##ulin", "to": "##is - filho j", "value": 1}, {"from": "##ulin", "to": "##rk,", "value": 1}, {"from": "##ulin", "to": "), gardner r", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "f", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "new yo", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "sloan", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "la", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "center", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "us", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##lum", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##o m", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "9", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "kette", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "yo", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##ettering cancer", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##rk, usa.", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "new york", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##bia university,", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "), shin e", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##ring cancer", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##rk, new", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##isied", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "ancers. sinha s", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##is - filho j", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "##rk,", "value": 1}, {"from": "##pare therapeutics, boston, massachusetts, usa.", "to": "), gardner r", "value": 1}, {"from": "f", "to": "new yo", "value": 1}, {"from": "f", "to": "sloan", "value": 1}, {"from": "f", "to": "la", "value": 1}, {"from": "f", "to": "center", "value": 1}, {"from": "f", "to": "us", "value": 1}, {"from": "f", "to": "##lum", "value": 1}, {"from": "f", "to": "##o m", "value": 1}, {"from": "f", "to": "9", "value": 1}, {"from": "f", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "f", "to": "kette", "value": 1}, {"from": "f", "to": "yo", "value": 1}, {"from": "f", "to": "##ettering cancer", "value": 1}, {"from": "f", "to": "##rk, usa.", "value": 1}, {"from": "f", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "f", "to": "new york", "value": 1}, {"from": "f", "to": "##bia university,", "value": 1}, {"from": "f", "to": "), shin e", "value": 1}, {"from": "f", "to": "##ring cancer", "value": 1}, {"from": "f", "to": "##rk, new", "value": 1}, {"from": "f", "to": "##urent, quebec, canada.", "value": 1}, {"from": "f", "to": "##isied", "value": 1}, {"from": "f", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "f", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "f", "to": "ancers. sinha s", "value": 1}, {"from": "f", "to": "##is - filho j", "value": 1}, {"from": "f", "to": "##rk,", "value": 1}, {"from": "f", "to": "), gardner r", "value": 1}, {"from": "new yo", "to": "sloan", "value": 1}, {"from": "new yo", "to": "la", "value": 1}, {"from": "new yo", "to": "center", "value": 1}, {"from": "new yo", "to": "us", "value": 1}, {"from": "new yo", "to": "##lum", "value": 1}, {"from": "new yo", "to": "##o m", "value": 1}, {"from": "new yo", "to": "9", "value": 1}, {"from": "new yo", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "new yo", "to": "kette", "value": 1}, {"from": "new yo", "to": "yo", "value": 1}, {"from": "new yo", "to": "##ettering cancer", "value": 1}, {"from": "new yo", "to": "##rk, usa.", "value": 1}, {"from": "new yo", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "new yo", "to": "new york", "value": 1}, {"from": "new yo", "to": "##bia university,", "value": 1}, {"from": "new yo", "to": "), shin e", "value": 1}, {"from": "new yo", "to": "##ring cancer", "value": 1}, {"from": "new yo", "to": "##rk, new", "value": 1}, {"from": "new yo", "to": "##urent, quebec, canada.", "value": 1}, {"from": "new yo", "to": "##isied", "value": 1}, {"from": "new yo", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "new yo", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "new yo", "to": "ancers. sinha s", "value": 1}, {"from": "new yo", "to": "##is - filho j", "value": 1}, {"from": "new yo", "to": "##rk,", "value": 1}, {"from": "new yo", "to": "), gardner r", "value": 1}, {"from": "sloan", "to": "la", "value": 1}, {"from": "sloan", "to": "center", "value": 1}, {"from": "sloan", "to": "us", "value": 1}, {"from": "sloan", "to": "##lum", "value": 1}, {"from": "sloan", "to": "##o m", "value": 1}, {"from": "sloan", "to": "9", "value": 1}, {"from": "sloan", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "sloan", "to": "kette", "value": 1}, {"from": "sloan", "to": "yo", "value": 1}, {"from": "sloan", "to": "##ettering cancer", "value": 1}, {"from": "sloan", "to": "##rk, usa.", "value": 1}, {"from": "sloan", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "sloan", "to": "new york", "value": 1}, {"from": "sloan", "to": "##bia university,", "value": 1}, {"from": "sloan", "to": "), shin e", "value": 1}, {"from": "sloan", "to": "##ring cancer", "value": 1}, {"from": "sloan", "to": "##rk, new", "value": 1}, {"from": "sloan", "to": "##urent, quebec, canada.", "value": 1}, {"from": "sloan", "to": "##isied", "value": 1}, {"from": "sloan", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "sloan", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "sloan", "to": "ancers. sinha s", "value": 1}, {"from": "sloan", "to": "##is - filho j", "value": 1}, {"from": "sloan", "to": "##rk,", "value": 1}, {"from": "sloan", "to": "), gardner r", "value": 1}, {"from": "la", "to": "center", "value": 1}, {"from": "la", "to": "us", "value": 1}, {"from": "la", "to": "##lum", "value": 1}, {"from": "la", "to": "##o m", "value": 1}, {"from": "la", "to": "9", "value": 1}, {"from": "la", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "la", "to": "kette", "value": 1}, {"from": "la", "to": "yo", "value": 1}, {"from": "la", "to": "##ettering cancer", "value": 1}, {"from": "la", "to": "##rk, usa.", "value": 1}, {"from": "la", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "la", "to": "new york", "value": 1}, {"from": "la", "to": "##bia university,", "value": 1}, {"from": "la", "to": "), shin e", "value": 1}, {"from": "la", "to": "##ring cancer", "value": 1}, {"from": "la", "to": "##rk, new", "value": 1}, {"from": "la", "to": "##urent, quebec, canada.", "value": 1}, {"from": "la", "to": "##isied", "value": 1}, {"from": "la", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "la", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "la", "to": "ancers. sinha s", "value": 1}, {"from": "la", "to": "##is - filho j", "value": 1}, {"from": "la", "to": "##rk,", "value": 1}, {"from": "la", "to": "), gardner r", "value": 1}, {"from": "center", "to": "us", "value": 1}, {"from": "center", "to": "##lum", "value": 1}, {"from": "center", "to": "##o m", "value": 1}, {"from": "center", "to": "9", "value": 1}, {"from": "center", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "center", "to": "kette", "value": 1}, {"from": "center", "to": "yo", "value": 1}, {"from": "center", "to": "##ettering cancer", "value": 1}, {"from": "center", "to": "##rk, usa.", "value": 1}, {"from": "center", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "center", "to": "new york", "value": 1}, {"from": "center", "to": "##bia university,", "value": 1}, {"from": "center", "to": "), shin e", "value": 1}, {"from": "center", "to": "##ring cancer", "value": 1}, {"from": "center", "to": "##rk, new", "value": 1}, {"from": "center", "to": "##urent, quebec, canada.", "value": 1}, {"from": "center", "to": "##isied", "value": 1}, {"from": "center", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "center", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "center", "to": "ancers. sinha s", "value": 1}, {"from": "center", "to": "##is - filho j", "value": 1}, {"from": "center", "to": "##rk,", "value": 1}, {"from": "center", "to": "), gardner r", "value": 1}, {"from": "us", "to": "##lum", "value": 1}, {"from": "us", "to": "##o m", "value": 1}, {"from": "us", "to": "9", "value": 1}, {"from": "us", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "us", "to": "kette", "value": 1}, {"from": "us", "to": "yo", "value": 1}, {"from": "us", "to": "##ettering cancer", "value": 1}, {"from": "us", "to": "##rk, usa.", "value": 1}, {"from": "us", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "us", "to": "new york", "value": 1}, {"from": "us", "to": "##bia university,", "value": 1}, {"from": "us", "to": "), shin e", "value": 1}, {"from": "us", "to": "##ring cancer", "value": 1}, {"from": "us", "to": "##rk, new", "value": 1}, {"from": "us", "to": "##urent, quebec, canada.", "value": 1}, {"from": "us", "to": "##isied", "value": 1}, {"from": "us", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "us", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "us", "to": "ancers. sinha s", "value": 1}, {"from": "us", "to": "##is - filho j", "value": 1}, {"from": "us", "to": "##rk,", "value": 1}, {"from": "us", "to": "), gardner r", "value": 1}, {"from": "##lum", "to": "##o m", "value": 1}, {"from": "##lum", "to": "9", "value": 1}, {"from": "##lum", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "##lum", "to": "kette", "value": 1}, {"from": "##lum", "to": "yo", "value": 1}, {"from": "##lum", "to": "##ettering cancer", "value": 1}, {"from": "##lum", "to": "##rk, usa.", "value": 1}, {"from": "##lum", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##lum", "to": "new york", "value": 1}, {"from": "##lum", "to": "##bia university,", "value": 1}, {"from": "##lum", "to": "), shin e", "value": 1}, {"from": "##lum", "to": "##ring cancer", "value": 1}, {"from": "##lum", "to": "##rk, new", "value": 1}, {"from": "##lum", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##lum", "to": "##isied", "value": 1}, {"from": "##lum", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##lum", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##lum", "to": "ancers. sinha s", "value": 1}, {"from": "##lum", "to": "##is - filho j", "value": 1}, {"from": "##lum", "to": "##rk,", "value": 1}, {"from": "##lum", "to": "), gardner r", "value": 1}, {"from": "##o m", "to": "9", "value": 1}, {"from": "##o m", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "##o m", "to": "kette", "value": 1}, {"from": "##o m", "to": "yo", "value": 1}, {"from": "##o m", "to": "##ettering cancer", "value": 1}, {"from": "##o m", "to": "##rk, usa.", "value": 1}, {"from": "##o m", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##o m", "to": "new york", "value": 1}, {"from": "##o m", "to": "##bia university,", "value": 1}, {"from": "##o m", "to": "), shin e", "value": 1}, {"from": "##o m", "to": "##ring cancer", "value": 1}, {"from": "##o m", "to": "##rk, new", "value": 1}, {"from": "##o m", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##o m", "to": "##isied", "value": 1}, {"from": "##o m", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##o m", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##o m", "to": "ancers. sinha s", "value": 1}, {"from": "##o m", "to": "##is - filho j", "value": 1}, {"from": "##o m", "to": "##rk,", "value": 1}, {"from": "##o m", "to": "), gardner r", "value": 1}, {"from": "9", "to": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "value": 1}, {"from": "9", "to": "kette", "value": 1}, {"from": "9", "to": "yo", "value": 1}, {"from": "9", "to": "##ettering cancer", "value": 1}, {"from": "9", "to": "##rk, usa.", "value": 1}, {"from": "9", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "9", "to": "new york", "value": 1}, {"from": "9", "to": "##bia university,", "value": 1}, {"from": "9", "to": "), shin e", "value": 1}, {"from": "9", "to": "##ring cancer", "value": 1}, {"from": "9", "to": "##rk, new", "value": 1}, {"from": "9", "to": "##urent, quebec, canada.", "value": 1}, {"from": "9", "to": "##isied", "value": 1}, {"from": "9", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "9", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "9", "to": "ancers. sinha s", "value": 1}, {"from": "9", "to": "##is - filho j", "value": 1}, {"from": "9", "to": "##rk,", "value": 1}, {"from": "9", "to": "), gardner r", "value": 1}, {"from": "9", "to": "), huarte m", "value": 1}, {"from": "9", "to": "12", "value": 1}, {"from": "9", "to": "##407.", "value": 1}, {"from": "9", "to": "), par", "value": 1}, {"from": "9", "to": "ins", "value": 1}, {"from": "9", "to": "##or", "value": 1}, {"from": "9", "to": "##e", "value": 1}, {"from": "9", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "9", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "9", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "9", "to": "), aragon s", "value": 1}, {"from": "9", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "9", "to": "##ory", "value": 1}, {"from": "9", "to": "), gimenez j", "value": 1}, {"from": "9", "to": "- lopez i", "value": 1}, {"from": "9", "to": "##rine", "value": 1}, {"from": "9", "to": "er + / her2 -", "value": 1}, {"from": "9", "to": "), prat a", "value": 1}, {"from": "9", "to": "research", "value": 2}, {"from": "9", "to": "##e. lg is /", "value": 1}, {"from": "9", "to": "), buch e", "value": 1}, {"from": "9", "to": "##roga v", "value": 1}, {"from": "9", "to": "been holding research", "value": 1}, {"from": "9", "to": "11", "value": 2}, {"from": "9", "to": "101", "value": 1}, {"from": "9", "to": "##riaga k", "value": 1}, {"from": "9", "to": "), etxabe i", "value": 1}, {"from": "9", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "9", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "9", "to": "13", "value": 2}, {"from": "9", "to": "therapy", "value": 1}, {"from": "9", "to": "##ui", "value": 1}, {"from": "9", "to": "##ez", "value": 1}, {"from": "9", "to": "##vita", "value": 1}, {"from": "9", "to": "contracts", "value": 1}, {"from": "9", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "9", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "9", "to": "). author information :", "value": 1}, {"from": "9", "to": "), urruticoechea a", "value": 1}, {"from": "9", "to": ") department of", "value": 1}, {"from": "9", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "9", "to": "for cancer", "value": 1}, {"from": "9", "to": "##lia", "value": 1}, {"from": "9", "to": "##vanger,", "value": 1}, {"from": "9", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "9", "to": "##vanger university, s", "value": 1}, {"from": "9", "to": "8", "value": 1}, {"from": "9", "to": "of cancer genetics,", "value": 1}, {"from": "9", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "9", "to": "12 ) department", "value": 1}, {"from": "9", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "9", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "9", "to": "##vanger university hospital, s", "value": 1}, {"from": "9", "to": "ha", "value": 1}, {"from": "9", "to": "norway", "value": 1}, {"from": "9", "to": "institute", "value": 1}, {"from": "9", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "9", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "9", "to": "of pathology, s", "value": 1}, {"from": "9", "to": ";", "value": 1}, {"from": "9", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "9", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "9", "to": "##way", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "kette", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "yo", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##ettering cancer", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##rk, usa.", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "new york", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##bia university,", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "), shin e", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##ring cancer", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##rk, new", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##urent, quebec, canada.", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##isied", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "ancers. sinha s", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##is - filho j", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "##rk,", "value": 1}, {"from": "cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa,", "to": "), gardner r", "value": 1}, {"from": "kette", "to": "yo", "value": 1}, {"from": "kette", "to": "##ettering cancer", "value": 1}, {"from": "kette", "to": "##rk, usa.", "value": 1}, {"from": "kette", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "kette", "to": "new york", "value": 1}, {"from": "kette", "to": "##bia university,", "value": 1}, {"from": "kette", "to": "), shin e", "value": 1}, {"from": "kette", "to": "##ring cancer", "value": 1}, {"from": "kette", "to": "##rk, new", "value": 1}, {"from": "kette", "to": "##urent, quebec, canada.", "value": 1}, {"from": "kette", "to": "##isied", "value": 1}, {"from": "kette", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "kette", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "kette", "to": "ancers. sinha s", "value": 1}, {"from": "kette", "to": "##is - filho j", "value": 1}, {"from": "kette", "to": "##rk,", "value": 1}, {"from": "kette", "to": "), gardner r", "value": 1}, {"from": "yo", "to": "##ettering cancer", "value": 1}, {"from": "yo", "to": "##rk, usa.", "value": 1}, {"from": "yo", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "yo", "to": "new york", "value": 1}, {"from": "yo", "to": "##bia university,", "value": 1}, {"from": "yo", "to": "), shin e", "value": 1}, {"from": "yo", "to": "##ring cancer", "value": 1}, {"from": "yo", "to": "##rk, new", "value": 1}, {"from": "yo", "to": "##urent, quebec, canada.", "value": 1}, {"from": "yo", "to": "##isied", "value": 1}, {"from": "yo", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "yo", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "yo", "to": "ancers. sinha s", "value": 1}, {"from": "yo", "to": "##is - filho j", "value": 1}, {"from": "yo", "to": "##rk,", "value": 1}, {"from": "yo", "to": "), gardner r", "value": 1}, {"from": "##ettering cancer", "to": "##rk, usa.", "value": 1}, {"from": "##ettering cancer", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##ettering cancer", "to": "new york", "value": 1}, {"from": "##ettering cancer", "to": "##bia university,", "value": 1}, {"from": "##ettering cancer", "to": "), shin e", "value": 1}, {"from": "##ettering cancer", "to": "##ring cancer", "value": 1}, {"from": "##ettering cancer", "to": "##rk, new", "value": 1}, {"from": "##ettering cancer", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##ettering cancer", "to": "##isied", "value": 1}, {"from": "##ettering cancer", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##ettering cancer", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##ettering cancer", "to": "ancers. sinha s", "value": 1}, {"from": "##ettering cancer", "to": "##is - filho j", "value": 1}, {"from": "##ettering cancer", "to": "##rk,", "value": 1}, {"from": "##ettering cancer", "to": "), gardner r", "value": 1}, {"from": "##rk, usa.", "to": "of radiation oncology, memorial sloan ket", "value": 1}, {"from": "##rk, usa.", "to": "new york", "value": 1}, {"from": "##rk, usa.", "to": "##bia university,", "value": 1}, {"from": "##rk, usa.", "to": "), shin e", "value": 1}, {"from": "##rk, usa.", "to": "##ring cancer", "value": 1}, {"from": "##rk, usa.", "to": "##rk, new", "value": 1}, {"from": "##rk, usa.", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##rk, usa.", "to": "##isied", "value": 1}, {"from": "##rk, usa.", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##rk, usa.", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##rk, usa.", "to": "ancers. sinha s", "value": 1}, {"from": "##rk, usa.", "to": "##is - filho j", "value": 1}, {"from": "##rk, usa.", "to": "##rk,", "value": 1}, {"from": "##rk, usa.", "to": "), gardner r", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "new york", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##bia university,", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "), shin e", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##ring cancer", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##rk, new", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##urent, quebec, canada.", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##isied", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "ancers. sinha s", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##is - filho j", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "##rk,", "value": 1}, {"from": "of radiation oncology, memorial sloan ket", "to": "), gardner r", "value": 1}, {"from": "new york", "to": "##bia university,", "value": 1}, {"from": "new york", "to": "), shin e", "value": 1}, {"from": "new york", "to": "##ring cancer", "value": 1}, {"from": "new york", "to": "##rk, new", "value": 1}, {"from": "new york", "to": "##urent, quebec, canada.", "value": 1}, {"from": "new york", "to": "##isied", "value": 1}, {"from": "new york", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "new york", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "new york", "to": "ancers. sinha s", "value": 1}, {"from": "new york", "to": "##is - filho j", "value": 1}, {"from": "new york", "to": "##rk,", "value": 1}, {"from": "new york", "to": "), gardner r", "value": 1}, {"from": "##bia university,", "to": "), shin e", "value": 1}, {"from": "##bia university,", "to": "##ring cancer", "value": 1}, {"from": "##bia university,", "to": "##rk, new", "value": 1}, {"from": "##bia university,", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##bia university,", "to": "##isied", "value": 1}, {"from": "##bia university,", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##bia university,", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##bia university,", "to": "ancers. sinha s", "value": 1}, {"from": "##bia university,", "to": "##is - filho j", "value": 1}, {"from": "##bia university,", "to": "##rk,", "value": 1}, {"from": "##bia university,", "to": "), gardner r", "value": 1}, {"from": "), shin e", "to": "##ring cancer", "value": 1}, {"from": "), shin e", "to": "##rk, new", "value": 1}, {"from": "), shin e", "to": "##urent, quebec, canada.", "value": 1}, {"from": "), shin e", "to": "##isied", "value": 1}, {"from": "), shin e", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "), shin e", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "), shin e", "to": "ancers. sinha s", "value": 1}, {"from": "), shin e", "to": "##is - filho j", "value": 1}, {"from": "), shin e", "to": "##rk,", "value": 1}, {"from": "), shin e", "to": "), gardner r", "value": 1}, {"from": "##ring cancer", "to": "##rk, new", "value": 1}, {"from": "##ring cancer", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##ring cancer", "to": "##isied", "value": 1}, {"from": "##ring cancer", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##ring cancer", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##ring cancer", "to": "ancers. sinha s", "value": 1}, {"from": "##ring cancer", "to": "##is - filho j", "value": 1}, {"from": "##ring cancer", "to": "##rk,", "value": 1}, {"from": "##ring cancer", "to": "), gardner r", "value": 1}, {"from": "##rk, new", "to": "##urent, quebec, canada.", "value": 1}, {"from": "##rk, new", "to": "##isied", "value": 1}, {"from": "##rk, new", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##rk, new", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##rk, new", "to": "ancers. sinha s", "value": 1}, {"from": "##rk, new", "to": "##is - filho j", "value": 1}, {"from": "##rk, new", "to": "##rk,", "value": 1}, {"from": "##rk, new", "to": "), gardner r", "value": 1}, {"from": "##urent, quebec, canada.", "to": "##isied", "value": 1}, {"from": "##urent, quebec, canada.", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##urent, quebec, canada.", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##urent, quebec, canada.", "to": "ancers. sinha s", "value": 1}, {"from": "##urent, quebec, canada.", "to": "##is - filho j", "value": 1}, {"from": "##urent, quebec, canada.", "to": "##rk,", "value": 1}, {"from": "##urent, quebec, canada.", "to": "), gardner r", "value": 1}, {"from": "##isied", "to": "##pare therapeutics, saint -", "value": 1}, {"from": "##isied", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##isied", "to": "ancers. sinha s", "value": 1}, {"from": "##isied", "to": "##is - filho j", "value": 1}, {"from": "##isied", "to": "##rk,", "value": 1}, {"from": "##isied", "to": "), gardner r", "value": 1}, {"from": "##pare therapeutics, saint -", "to": ") department of radiation oncology, memorial sloan", "value": 1}, {"from": "##pare therapeutics, saint -", "to": "ancers. sinha s", "value": 1}, {"from": "##pare therapeutics, saint -", "to": "##is - filho j", "value": 1}, {"from": "##pare therapeutics, saint -", "to": "##rk,", "value": 1}, {"from": "##pare therapeutics, saint -", "to": "), gardner r", "value": 1}, {"from": ") department of radiation oncology, memorial sloan", "to": "ancers. sinha s", "value": 1}, {"from": ") department of radiation oncology, memorial sloan", "to": "##is - filho j", "value": 1}, {"from": ") department of radiation oncology, memorial sloan", "to": "##rk,", "value": 1}, {"from": ") department of radiation oncology, memorial sloan", "to": "), gardner r", "value": 1}, {"from": "ancers. sinha s", "to": "##is - filho j", "value": 1}, {"from": "ancers. sinha s", "to": "##rk,", "value": 1}, {"from": "ancers. sinha s", "to": "), gardner r", "value": 1}, {"from": "##is - filho j", "to": "##rk,", "value": 1}, {"from": "##is - filho j", "to": "), gardner r", "value": 1}, {"from": "##rk,", "to": "), gardner r", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##rates were assessed by flow c", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": ". org.", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "regulator", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "methods", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": ". org khana7 @ msk", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##yt", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##ase functions,", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "colorec", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "are known", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "polymer", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##r in murine triple -", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##tal", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##lt", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "mutated", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "negative", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "crisp", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##ometry and immunohis", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": ": we generated isogenic atm - null models using", "to": "##to", "value": 1}, {"from": "##rates were assessed by flow c", "to": ". org.", "value": 1}, {"from": "##rates were assessed by flow c", "to": "regulator", "value": 1}, {"from": "##rates were assessed by flow c", "to": "methods", "value": 1}, {"from": "##rates were assessed by flow c", "to": ". org khana7 @ msk", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##yt", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##ase functions,", "value": 1}, {"from": "##rates were assessed by flow c", "to": "colorec", "value": 1}, {"from": "##rates were assessed by flow c", "to": "are known", "value": 1}, {"from": "##rates were assessed by flow c", "to": "polymer", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##r in murine triple -", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##tal", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##lt", "value": 1}, {"from": "##rates were assessed by flow c", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##rates were assessed by flow c", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##rates were assessed by flow c", "to": "mutated", "value": 1}, {"from": "##rates were assessed by flow c", "to": "negative", "value": 1}, {"from": "##rates were assessed by flow c", "to": "crisp", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##ometry and immunohis", "value": 1}, {"from": "##rates were assessed by flow c", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##rates were assessed by flow c", "to": "##to", "value": 1}, {"from": ". org.", "to": "regulator", "value": 1}, {"from": ". org.", "to": "methods", "value": 1}, {"from": ". org.", "to": ". org khana7 @ msk", "value": 1}, {"from": ". org.", "to": "##yt", "value": 1}, {"from": ". org.", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": ". org.", "to": "##ase functions,", "value": 1}, {"from": ". org.", "to": "colorec", "value": 1}, {"from": ". org.", "to": "are known", "value": 1}, {"from": ". org.", "to": "polymer", "value": 1}, {"from": ". org.", "to": "##r in murine triple -", "value": 1}, {"from": ". org.", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": ". org.", "to": "##tal", "value": 1}, {"from": ". org.", "to": "##lt", "value": 1}, {"from": ". org.", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": ". org.", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": ". org.", "to": "mutated", "value": 1}, {"from": ". org.", "to": "negative", "value": 1}, {"from": ". org.", "to": "crisp", "value": 1}, {"from": ". org.", "to": "##ometry and immunohis", "value": 1}, {"from": ". org.", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": ". org.", "to": "##to", "value": 1}, {"from": "regulator", "to": "methods", "value": 1}, {"from": "regulator", "to": ". org khana7 @ msk", "value": 1}, {"from": "regulator", "to": "##yt", "value": 1}, {"from": "regulator", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "regulator", "to": "##ase functions,", "value": 1}, {"from": "regulator", "to": "colorec", "value": 1}, {"from": "regulator", "to": "are known", "value": 1}, {"from": "regulator", "to": "polymer", "value": 1}, {"from": "regulator", "to": "##r in murine triple -", "value": 1}, {"from": "regulator", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "regulator", "to": "##tal", "value": 1}, {"from": "regulator", "to": "##lt", "value": 1}, {"from": "regulator", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "regulator", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "regulator", "to": "mutated", "value": 1}, {"from": "regulator", "to": "negative", "value": 1}, {"from": "regulator", "to": "crisp", "value": 1}, {"from": "regulator", "to": "##ometry and immunohis", "value": 1}, {"from": "regulator", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "regulator", "to": "##to", "value": 1}, {"from": "methods", "to": ". org khana7 @ msk", "value": 1}, {"from": "methods", "to": "##yt", "value": 1}, {"from": "methods", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "methods", "to": "##ase functions,", "value": 1}, {"from": "methods", "to": "colorec", "value": 1}, {"from": "methods", "to": "are known", "value": 1}, {"from": "methods", "to": "polymer", "value": 1}, {"from": "methods", "to": "##r in murine triple -", "value": 1}, {"from": "methods", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "methods", "to": "##tal", "value": 1}, {"from": "methods", "to": "##lt", "value": 1}, {"from": "methods", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "methods", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "methods", "to": "mutated", "value": 1}, {"from": "methods", "to": "negative", "value": 1}, {"from": "methods", "to": "crisp", "value": 1}, {"from": "methods", "to": "##ometry and immunohis", "value": 1}, {"from": "methods", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "methods", "to": "##to", "value": 1}, {"from": "methods", "to": "the", "value": 1}, {"from": "methods", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "methods", "to": "hormone receptor positive", "value": 1}, {"from": "methods", "to": "societal perspective", "value": 1}, {"from": "methods", "to": "benefits", "value": 1}, {"from": "methods", "to": "surgery", "value": 1}, {"from": "methods", "to": "cost -", "value": 1}, {"from": "methods", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "methods", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "methods", "to": "decision", "value": 1}, {"from": "methods", "to": "to aid adjuvant treatment", "value": 1}, {"from": "methods", "to": "##al", "value": 1}, {"from": "methods", "to": "emit - 1 trial", "value": 1}, {"from": "methods", "to": "post", "value": 1}, {"from": "methods", "to": ". materials", "value": 1}, {"from": "methods", "to": "model was", "value": 1}, {"from": "methods", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "methods", "to": "used", "value": 1}, {"from": "methods", "to": "institute", "value": 1}, {"from": "methods", "to": ": the", "value": 1}, {"from": "methods", "to": "ki - 67", "value": 1}, {"from": "methods", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "methods", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "methods", "to": "prosigna was tested", "value": 1}, {"from": "methods", "to": "prospective", "value": 1}, {"from": "methods", "to": "were measured", "value": 1}, {"from": "methods", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "methods", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "methods", "to": "observation", "value": 1}, {"from": "methods", "to": "division", "value": 1}, {"from": "methods", "to": "decisions in", "value": 1}, {"from": "methods", "to": "built", "value": 1}, {"from": "methods", "to": "impact of", "value": 1}, {"from": ". org khana7 @ msk", "to": "##yt", "value": 1}, {"from": ". org khana7 @ msk", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": ". org khana7 @ msk", "to": "##ase functions,", "value": 1}, {"from": ". org khana7 @ msk", "to": "colorec", "value": 1}, {"from": ". org khana7 @ msk", "to": "are known", "value": 1}, {"from": ". org khana7 @ msk", "to": "polymer", "value": 1}, {"from": ". org khana7 @ msk", "to": "##r in murine triple -", "value": 1}, {"from": ". org khana7 @ msk", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": ". org khana7 @ msk", "to": "##tal", "value": 1}, {"from": ". org khana7 @ msk", "to": "##lt", "value": 1}, {"from": ". org khana7 @ msk", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": ". org khana7 @ msk", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": ". org khana7 @ msk", "to": "mutated", "value": 1}, {"from": ". org khana7 @ msk", "to": "negative", "value": 1}, {"from": ". org khana7 @ msk", "to": "crisp", "value": 1}, {"from": ". org khana7 @ msk", "to": "##ometry and immunohis", "value": 1}, {"from": ". org khana7 @ msk", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": ". org khana7 @ msk", "to": "##to", "value": 1}, {"from": "##yt", "to": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "value": 1}, {"from": "##yt", "to": "##ase functions,", "value": 1}, {"from": "##yt", "to": "colorec", "value": 1}, {"from": "##yt", "to": "are known", "value": 1}, {"from": "##yt", "to": "polymer", "value": 1}, {"from": "##yt", "to": "##r in murine triple -", "value": 1}, {"from": "##yt", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##yt", "to": "##tal", "value": 1}, {"from": "##yt", "to": "##lt", "value": 1}, {"from": "##yt", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##yt", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##yt", "to": "mutated", "value": 1}, {"from": "##yt", "to": "negative", "value": 1}, {"from": "##yt", "to": "crisp", "value": 1}, {"from": "##yt", "to": "##ometry and immunohis", "value": 1}, {"from": "##yt", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##yt", "to": "##to", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##ase functions,", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "colorec", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "are known", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "polymer", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##r in murine triple -", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##tal", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##lt", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "mutated", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "negative", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "crisp", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##ometry and immunohis", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi", "to": "##to", "value": 1}, {"from": "##ase functions,", "to": "colorec", "value": 1}, {"from": "##ase functions,", "to": "are known", "value": 1}, {"from": "##ase functions,", "to": "polymer", "value": 1}, {"from": "##ase functions,", "to": "##r in murine triple -", "value": 1}, {"from": "##ase functions,", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##ase functions,", "to": "##tal", "value": 1}, {"from": "##ase functions,", "to": "##lt", "value": 1}, {"from": "##ase functions,", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##ase functions,", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##ase functions,", "to": "mutated", "value": 1}, {"from": "##ase functions,", "to": "negative", "value": 1}, {"from": "##ase functions,", "to": "crisp", "value": 1}, {"from": "##ase functions,", "to": "##ometry and immunohis", "value": 1}, {"from": "##ase functions,", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##ase functions,", "to": "##to", "value": 1}, {"from": "colorec", "to": "are known", "value": 1}, {"from": "colorec", "to": "polymer", "value": 1}, {"from": "colorec", "to": "##r in murine triple -", "value": 1}, {"from": "colorec", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "colorec", "to": "##tal", "value": 1}, {"from": "colorec", "to": "##lt", "value": 1}, {"from": "colorec", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "colorec", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "colorec", "to": "mutated", "value": 1}, {"from": "colorec", "to": "negative", "value": 1}, {"from": "colorec", "to": "crisp", "value": 1}, {"from": "colorec", "to": "##ometry and immunohis", "value": 1}, {"from": "colorec", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "colorec", "to": "##to", "value": 1}, {"from": "are known", "to": "polymer", "value": 1}, {"from": "are known", "to": "##r in murine triple -", "value": 1}, {"from": "are known", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "are known", "to": "##tal", "value": 1}, {"from": "are known", "to": "##lt", "value": 1}, {"from": "are known", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "are known", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "are known", "to": "mutated", "value": 1}, {"from": "are known", "to": "negative", "value": 1}, {"from": "are known", "to": "crisp", "value": 1}, {"from": "are known", "to": "##ometry and immunohis", "value": 1}, {"from": "are known", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "are known", "to": "##to", "value": 1}, {"from": "polymer", "to": "##r in murine triple -", "value": 1}, {"from": "polymer", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "polymer", "to": "##tal", "value": 1}, {"from": "polymer", "to": "##lt", "value": 1}, {"from": "polymer", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "polymer", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "polymer", "to": "mutated", "value": 1}, {"from": "polymer", "to": "negative", "value": 1}, {"from": "polymer", "to": "crisp", "value": 1}, {"from": "polymer", "to": "##ometry and immunohis", "value": 1}, {"from": "polymer", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "polymer", "to": "##to", "value": 1}, {"from": "##r in murine triple -", "to": "##chemistry in both murine tumors and human samples from breast and lung cancers", "value": 1}, {"from": "##r in murine triple -", "to": "##tal", "value": 1}, {"from": "##r in murine triple -", "to": "##lt", "value": 1}, {"from": "##r in murine triple -", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##r in murine triple -", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##r in murine triple -", "to": "mutated", "value": 1}, {"from": "##r in murine triple -", "to": "negative", "value": 1}, {"from": "##r in murine triple -", "to": "crisp", "value": 1}, {"from": "##r in murine triple -", "to": "##ometry and immunohis", "value": 1}, {"from": "##r in murine triple -", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##r in murine triple -", "to": "##to", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "##tal", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "##lt", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "mutated", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "negative", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "crisp", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "##ometry and immunohis", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##chemistry in both murine tumors and human samples from breast and lung cancers", "to": "##to", "value": 1}, {"from": "##tal", "to": "##lt", "value": 1}, {"from": "##tal", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##tal", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##tal", "to": "mutated", "value": 1}, {"from": "##tal", "to": "negative", "value": 1}, {"from": "##tal", "to": "crisp", "value": 1}, {"from": "##tal", "to": "##ometry and immunohis", "value": 1}, {"from": "##tal", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##tal", "to": "##to", "value": 1}, {"from": "##lt", "to": "to enhance tumor immunogenicity. ataxia telangiectasia", "value": 1}, {"from": "##lt", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "##lt", "to": "mutated", "value": 1}, {"from": "##lt", "to": "negative", "value": 1}, {"from": "##lt", "to": "crisp", "value": 1}, {"from": "##lt", "to": "##ometry and immunohis", "value": 1}, {"from": "##lt", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##lt", "to": "##to", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "tering cancer center, new york, new york, usa riazn @ msk", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "mutated", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "negative", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "crisp", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "##ometry and immunohis", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "to enhance tumor immunogenicity. ataxia telangiectasia", "to": "##to", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "mutated", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "negative", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "crisp", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "##ometry and immunohis", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "tering cancer center, new york, new york, usa riazn @ msk", "to": "##to", "value": 1}, {"from": "mutated", "to": "negative", "value": 1}, {"from": "mutated", "to": "crisp", "value": 1}, {"from": "mutated", "to": "##ometry and immunohis", "value": 1}, {"from": "mutated", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "mutated", "to": "##to", "value": 1}, {"from": "negative", "to": "crisp", "value": 1}, {"from": "negative", "to": "##ometry and immunohis", "value": 1}, {"from": "negative", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "negative", "to": "##to", "value": 1}, {"from": "crisp", "to": "##ometry and immunohis", "value": 1}, {"from": "crisp", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "crisp", "to": "##to", "value": 1}, {"from": "##ometry and immunohis", "to": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "value": 1}, {"from": "##ometry and immunohis", "to": "##to", "value": 1}, {"from": "of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood.", "to": "##to", "value": 1}, {"from": "), and the top", "to": "), a parp", "value": 1}, {"from": "), and the top", "to": "##point blockade", "value": 1}, {"from": "), and the top", "to": "etop", "value": 1}, {"from": "), and the top", "to": "##ide - on", "value": 1}, {"from": "), and the top", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "), and the top", "to": "##ide, a top", "value": 1}, {"from": "), and the top", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "), and the top", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "), and the top", "to": "##ase ii", "value": 1}, {"from": "), and the top", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "), and the top", "to": "interfer", "value": 1}, {"from": "), and the top", "to": "fails", "value": 1}, {"from": "), and the top", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "), and the top", "to": "type", "value": 1}, {"from": "), and the top", "to": "if", "value": 1}, {"from": "), and the top", "to": "##fi", "value": 1}, {"from": "), and the top", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "), and the top", "to": "##oisomer", "value": 1}, {"from": "), and the top", "to": "##n ) signaling, with etop", "value": 1}, {"from": "), and the top", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "), and the top", "to": "to encourage immune effector cell in", "value": 1}, {"from": "), and the top", "to": "does", "value": 1}, {"from": "), and the top", "to": "##ltration into tumors, and", "value": 1}, {"from": "), and the top", "to": "##on - stimulated gene", "value": 1}, {"from": "), and the top", "to": "check", "value": 1}, {"from": "), and the top", "to": "##on", "value": 1}, {"from": "), and the top", "to": "inhibitor", "value": 1}, {"from": "), a parp", "to": "##point blockade", "value": 1}, {"from": "), a parp", "to": "etop", "value": 1}, {"from": "), a parp", "to": "##ide - on", "value": 1}, {"from": "), a parp", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "), a parp", "to": "##ide, a top", "value": 1}, {"from": "), a parp", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "), a parp", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "), a parp", "to": "##ase ii", "value": 1}, {"from": "), a parp", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "), a parp", "to": "interfer", "value": 1}, {"from": "), a parp", "to": "fails", "value": 1}, {"from": "), a parp", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "), a parp", "to": "type", "value": 1}, {"from": "), a parp", "to": "if", "value": 1}, {"from": "), a parp", "to": "##fi", "value": 1}, {"from": "), a parp", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "), a parp", "to": "##oisomer", "value": 1}, {"from": "), a parp", "to": "##n ) signaling, with etop", "value": 1}, {"from": "), a parp", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "), a parp", "to": "to encourage immune effector cell in", "value": 1}, {"from": "), a parp", "to": "does", "value": 1}, {"from": "), a parp", "to": "##ltration into tumors, and", "value": 1}, {"from": "), a parp", "to": "##on - stimulated gene", "value": 1}, {"from": "), a parp", "to": "check", "value": 1}, {"from": "), a parp", "to": "##on", "value": 1}, {"from": "), a parp", "to": "inhibitor", "value": 1}, {"from": "##point blockade", "to": "etop", "value": 1}, {"from": "##point blockade", "to": "##ide - on", "value": 1}, {"from": "##point blockade", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "##point blockade", "to": "##ide, a top", "value": 1}, {"from": "##point blockade", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##point blockade", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##point blockade", "to": "##ase ii", "value": 1}, {"from": "##point blockade", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##point blockade", "to": "interfer", "value": 1}, {"from": "##point blockade", "to": "fails", "value": 1}, {"from": "##point blockade", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##point blockade", "to": "type", "value": 1}, {"from": "##point blockade", "to": "if", "value": 1}, {"from": "##point blockade", "to": "##fi", "value": 1}, {"from": "##point blockade", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##point blockade", "to": "##oisomer", "value": 1}, {"from": "##point blockade", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##point blockade", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##point blockade", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##point blockade", "to": "does", "value": 1}, {"from": "##point blockade", "to": "##ltration into tumors, and", "value": 1}, {"from": "##point blockade", "to": "##on - stimulated gene", "value": 1}, {"from": "##point blockade", "to": "check", "value": 1}, {"from": "##point blockade", "to": "##on", "value": 1}, {"from": "##point blockade", "to": "inhibitor", "value": 1}, {"from": "etop", "to": "##ide - on", "value": 1}, {"from": "etop", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "etop", "to": "##ide, a top", "value": 1}, {"from": "etop", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "etop", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "etop", "to": "##ase ii", "value": 1}, {"from": "etop", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "etop", "to": "interfer", "value": 1}, {"from": "etop", "to": "fails", "value": 1}, {"from": "etop", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "etop", "to": "type", "value": 1}, {"from": "etop", "to": "if", "value": 1}, {"from": "etop", "to": "##fi", "value": 1}, {"from": "etop", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "etop", "to": "##oisomer", "value": 1}, {"from": "etop", "to": "##n ) signaling, with etop", "value": 1}, {"from": "etop", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "etop", "to": "to encourage immune effector cell in", "value": 1}, {"from": "etop", "to": "does", "value": 1}, {"from": "etop", "to": "##ltration into tumors, and", "value": 1}, {"from": "etop", "to": "##on - stimulated gene", "value": 1}, {"from": "etop", "to": "check", "value": 1}, {"from": "etop", "to": "##on", "value": 1}, {"from": "etop", "to": "inhibitor", "value": 1}, {"from": "##ide - on", "to": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "value": 1}, {"from": "##ide - on", "to": "##ide, a top", "value": 1}, {"from": "##ide - on", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##ide - on", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##ide - on", "to": "##ase ii", "value": 1}, {"from": "##ide - on", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##ide - on", "to": "interfer", "value": 1}, {"from": "##ide - on", "to": "fails", "value": 1}, {"from": "##ide - on", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##ide - on", "to": "type", "value": 1}, {"from": "##ide - on", "to": "if", "value": 1}, {"from": "##ide - on", "to": "##fi", "value": 1}, {"from": "##ide - on", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##ide - on", "to": "##oisomer", "value": 1}, {"from": "##ide - on", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##ide - on", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##ide - on", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##ide - on", "to": "does", "value": 1}, {"from": "##ide - on", "to": "##ltration into tumors, and", "value": 1}, {"from": "##ide - on", "to": "##on - stimulated gene", "value": 1}, {"from": "##ide - on", "to": "check", "value": 1}, {"from": "##ide - on", "to": "##on", "value": 1}, {"from": "##ide - on", "to": "inhibitor", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##ide, a top", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##ase ii", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "interfer", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "fails", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "type", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "if", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##fi", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##oisomer", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "does", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##ltration into tumors, and", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##on - stimulated gene", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "check", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "##on", "value": 1}, {"from": "##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency", "to": "inhibitor", "value": 1}, {"from": "##ide, a top", "to": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "value": 1}, {"from": "##ide, a top", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "##ide, a top", "to": "##ase ii", "value": 1}, {"from": "##ide, a top", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##ide, a top", "to": "interfer", "value": 1}, {"from": "##ide, a top", "to": "fails", "value": 1}, {"from": "##ide, a top", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##ide, a top", "to": "type", "value": 1}, {"from": "##ide, a top", "to": "if", "value": 1}, {"from": "##ide, a top", "to": "##fi", "value": 1}, {"from": "##ide, a top", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##ide, a top", "to": "##oisomer", "value": 1}, {"from": "##ide, a top", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##ide, a top", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##ide, a top", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##ide, a top", "to": "does", "value": 1}, {"from": "##ide, a top", "to": "##ltration into tumors, and", "value": 1}, {"from": "##ide, a top", "to": "##on - stimulated gene", "value": 1}, {"from": "##ide, a top", "to": "check", "value": 1}, {"from": "##ide, a top", "to": "##on", "value": 1}, {"from": "##ide, a top", "to": "inhibitor", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##ase ii", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "interfer", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "fails", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "type", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "if", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##fi", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##oisomer", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##n ) signaling, with etop", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "to encourage immune effector cell in", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "does", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##ltration into tumors, and", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##on - stimulated gene", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "check", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "##on", "value": 1}, {"from": "s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune", "to": "inhibitor", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##ase ii", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "interfer", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "fails", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "type", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "if", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##fi", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##oisomer", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##n ) signaling, with etop", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "to encourage immune effector cell in", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "does", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##ltration into tumors, and", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##on - stimulated gene", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "check", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "##on", "value": 1}, {"from": "not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr", "to": "inhibitor", "value": 1}, {"from": "##ase ii", "to": "##g under these conditions. yet, pd - 1 - targeted immune check", "value": 1}, {"from": "##ase ii", "to": "interfer", "value": 1}, {"from": "##ase ii", "to": "fails", "value": 1}, {"from": "##ase ii", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##ase ii", "to": "type", "value": 1}, {"from": "##ase ii", "to": "if", "value": 1}, {"from": "##ase ii", "to": "##fi", "value": 1}, {"from": "##ase ii", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##ase ii", "to": "##oisomer", "value": 1}, {"from": "##ase ii", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##ase ii", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##ase ii", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##ase ii", "to": "does", "value": 1}, {"from": "##ase ii", "to": "##ltration into tumors, and", "value": 1}, {"from": "##ase ii", "to": "##on - stimulated gene", "value": 1}, {"from": "##ase ii", "to": "check", "value": 1}, {"from": "##ase ii", "to": "##on", "value": 1}, {"from": "##ase ii", "to": "inhibitor", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "interfer", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "fails", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "type", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "if", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##fi", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##oisomer", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "does", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##ltration into tumors, and", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##on - stimulated gene", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "check", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "##on", "value": 1}, {"from": "##g under these conditions. yet, pd - 1 - targeted immune check", "to": "inhibitor", "value": 1}, {"from": "interfer", "to": "fails", "value": 1}, {"from": "interfer", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "interfer", "to": "type", "value": 1}, {"from": "interfer", "to": "if", "value": 1}, {"from": "interfer", "to": "##fi", "value": 1}, {"from": "interfer", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "interfer", "to": "##oisomer", "value": 1}, {"from": "interfer", "to": "##n ) signaling, with etop", "value": 1}, {"from": "interfer", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "interfer", "to": "to encourage immune effector cell in", "value": 1}, {"from": "interfer", "to": "does", "value": 1}, {"from": "interfer", "to": "##ltration into tumors, and", "value": 1}, {"from": "interfer", "to": "##on - stimulated gene", "value": 1}, {"from": "interfer", "to": "check", "value": 1}, {"from": "interfer", "to": "##on", "value": 1}, {"from": "interfer", "to": "inhibitor", "value": 1}, {"from": "fails", "to": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "value": 1}, {"from": "fails", "to": "type", "value": 1}, {"from": "fails", "to": "if", "value": 1}, {"from": "fails", "to": "##fi", "value": 1}, {"from": "fails", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "fails", "to": "##oisomer", "value": 1}, {"from": "fails", "to": "##n ) signaling, with etop", "value": 1}, {"from": "fails", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "fails", "to": "to encourage immune effector cell in", "value": 1}, {"from": "fails", "to": "does", "value": 1}, {"from": "fails", "to": "##ltration into tumors, and", "value": 1}, {"from": "fails", "to": "##on - stimulated gene", "value": 1}, {"from": "fails", "to": "check", "value": 1}, {"from": "fails", "to": "##on", "value": 1}, {"from": "fails", "to": "inhibitor", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "type", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "if", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##fi", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##oisomer", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "does", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##ltration into tumors, and", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##on - stimulated gene", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "check", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "##on", "value": 1}, {"from": "##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of", "to": "inhibitor", "value": 1}, {"from": "type", "to": "if", "value": 1}, {"from": "type", "to": "##fi", "value": 1}, {"from": "type", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "type", "to": "##oisomer", "value": 1}, {"from": "type", "to": "##n ) signaling, with etop", "value": 1}, {"from": "type", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "type", "to": "to encourage immune effector cell in", "value": 1}, {"from": "type", "to": "does", "value": 1}, {"from": "type", "to": "##ltration into tumors, and", "value": 1}, {"from": "type", "to": "##on - stimulated gene", "value": 1}, {"from": "type", "to": "check", "value": 1}, {"from": "type", "to": "##on", "value": 1}, {"from": "type", "to": "inhibitor", "value": 1}, {"from": "if", "to": "##fi", "value": 1}, {"from": "if", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "if", "to": "##oisomer", "value": 1}, {"from": "if", "to": "##n ) signaling, with etop", "value": 1}, {"from": "if", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "if", "to": "to encourage immune effector cell in", "value": 1}, {"from": "if", "to": "does", "value": 1}, {"from": "if", "to": "##ltration into tumors, and", "value": 1}, {"from": "if", "to": "##on - stimulated gene", "value": 1}, {"from": "if", "to": "check", "value": 1}, {"from": "if", "to": "##on", "value": 1}, {"from": "if", "to": "inhibitor", "value": 1}, {"from": "if", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "if", "to": "##ifer", "value": 1}, {"from": "if", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "if", "to": "in the", "value": 1}, {"from": "if", "to": "##ne - c", "value": 1}, {"from": "if", "to": ", tnf signaling", "value": 1}, {"from": "if", "to": ", which", "value": 1}, {"from": "if", "to": "down - regulated", "value": 1}, {"from": "if", "to": "including c", "value": 1}, {"from": "if", "to": "##ytoki", "value": 1}, {"from": "if", "to": "detected", "value": 1}, {"from": "if", "to": "cancer", "value": 1}, {"from": "if", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "if", "to": "vs", "value": 1}, {"from": "if", "to": "##cer assays. the", "value": 1}, {"from": "if", "to": "or", "value": 1}, {"from": "if", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "if", "to": "##ne receptor", "value": 1}, {"from": "if", "to": "##ap", "value": 1}, {"from": "if", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "if", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "if", "to": "via", "value": 2}, {"from": "if", "to": "anti", "value": 1}, {"from": "if", "to": "##n - \u03b3", "value": 1}, {"from": "if", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "if", "to": "f biotechnology engineering,", "value": 1}, {"from": "if", "to": "were up -", "value": 1}, {"from": "if", "to": ", nod - like receptor signaling", "value": 1}, {"from": "if", "to": "##ation, pro", "value": 1}, {"from": "if", "to": "pathways", "value": 1}, {"from": "if", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "if", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "if", "to": "pathway", "value": 1}, {"from": "if", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "if", "to": "- regulate", "value": 1}, {"from": "if", "to": "the", "value": 1}, {"from": "if", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "if", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "if", "to": "##tic", "value": 1}, {"from": "if", "to": "##6 /", "value": 1}, {"from": "if", "to": "##6", "value": 1}, {"from": "if", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "if", "to": "##xic effect of", "value": 1}, {"from": "if", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "if", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "if", "to": "##xic efficacy of the", "value": 1}, {"from": "if", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "if", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "if", "to": "up -", "value": 1}, {"from": "if", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "if", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "if", "to": "development of tumor cells, a", "value": 1}, {"from": "if", "to": "##348089 conflict o", "value": 1}, {"from": "if", "to": "regulate", "value": 1}, {"from": "if", "to": "101", "value": 1}, {"from": "if", "to": "of pro", "value": 1}, {"from": "if", "to": "##cl -", "value": 1}, {"from": "if", "to": "##biotec. 2025.", "value": 1}, {"from": "if", "to": "04", "value": 1}, {"from": "if", "to": "##apopto", "value": 1}, {"from": "if", "to": "to", "value": 1}, {"from": "if", "to": "##cer and antiviral functions of", "value": 1}, {"from": "if", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "if", "to": "and p", "value": 1}, {"from": "if", "to": "##c cell line", "value": 1}, {"from": "if", "to": "hi", "value": 1}, {"from": "if", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "if", "to": "##53", "value": 1}, {"from": "if", "to": ". 022 pmid :", "value": 1}, {"from": "if", "to": "bax", "value": 1}, {"from": "##fi", "to": ", emerging as the strongest activator of", "value": 1}, {"from": "##fi", "to": "##oisomer", "value": 1}, {"from": "##fi", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##fi", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##fi", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##fi", "to": "does", "value": 1}, {"from": "##fi", "to": "##ltration into tumors, and", "value": 1}, {"from": "##fi", "to": "##on - stimulated gene", "value": 1}, {"from": "##fi", "to": "check", "value": 1}, {"from": "##fi", "to": "##on", "value": 1}, {"from": "##fi", "to": "inhibitor", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "##oisomer", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "##n ) signaling, with etop", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "to encourage immune effector cell in", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "does", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "##ltration into tumors, and", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "##on - stimulated gene", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "check", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "##on", "value": 1}, {"from": ", emerging as the strongest activator of", "to": "inhibitor", "value": 1}, {"from": "##oisomer", "to": "##n ) signaling, with etop", "value": 1}, {"from": "##oisomer", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##oisomer", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##oisomer", "to": "does", "value": 1}, {"from": "##oisomer", "to": "##ltration into tumors, and", "value": 1}, {"from": "##oisomer", "to": "##on - stimulated gene", "value": 1}, {"from": "##oisomer", "to": "check", "value": 1}, {"from": "##oisomer", "to": "##on", "value": 1}, {"from": "##oisomer", "to": "inhibitor", "value": 1}, {"from": "##n ) signaling, with etop", "to": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "value": 1}, {"from": "##n ) signaling, with etop", "to": "to encourage immune effector cell in", "value": 1}, {"from": "##n ) signaling, with etop", "to": "does", "value": 1}, {"from": "##n ) signaling, with etop", "to": "##ltration into tumors, and", "value": 1}, {"from": "##n ) signaling, with etop", "to": "##on - stimulated gene", "value": 1}, {"from": "##n ) signaling, with etop", "to": "check", "value": 1}, {"from": "##n ) signaling, with etop", "to": "##on", "value": 1}, {"from": "##n ) signaling, with etop", "to": "inhibitor", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "to encourage immune effector cell in", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "does", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "##ltration into tumors, and", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "##on - stimulated gene", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "check", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "##on", "value": 1}, {"from": "1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr", "to": "inhibitor", "value": 1}, {"from": "to encourage immune effector cell in", "to": "does", "value": 1}, {"from": "to encourage immune effector cell in", "to": "##ltration into tumors, and", "value": 1}, {"from": "to encourage immune effector cell in", "to": "##on - stimulated gene", "value": 1}, {"from": "to encourage immune effector cell in", "to": "check", "value": 1}, {"from": "to encourage immune effector cell in", "to": "##on", "value": 1}, {"from": "to encourage immune effector cell in", "to": "inhibitor", "value": 1}, {"from": "does", "to": "##ltration into tumors, and", "value": 1}, {"from": "does", "to": "##on - stimulated gene", "value": 1}, {"from": "does", "to": "check", "value": 1}, {"from": "does", "to": "##on", "value": 1}, {"from": "does", "to": "inhibitor", "value": 1}, {"from": "does", "to": "conclusions", "value": 1}, {"from": "does", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "does", "to": "10. 113", "value": 1}, {"from": "does", "to": "interests", "value": 1}, {"from": "does", "to": ". no commercial re -", "value": 1}, {"from": "does", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "does", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "does", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "does", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "does", "to": ": nr receives research support from bm", "value": 1}, {"from": "does", "to": "use", "value": 1}, {"from": "does", "to": ": atm deficiency, while com", "value": 1}, {"from": "does", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "does", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "does", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##ltration into tumors, and", "to": "##on - stimulated gene", "value": 1}, {"from": "##ltration into tumors, and", "to": "check", "value": 1}, {"from": "##ltration into tumors, and", "to": "##on", "value": 1}, {"from": "##ltration into tumors, and", "to": "inhibitor", "value": 1}, {"from": "##on - stimulated gene", "to": "check", "value": 1}, {"from": "##on - stimulated gene", "to": "##on", "value": 1}, {"from": "##on - stimulated gene", "to": "inhibitor", "value": 1}, {"from": "check", "to": "##on", "value": 1}, {"from": "check", "to": "inhibitor", "value": 1}, {"from": "##on", "to": "inhibitor", "value": 1}, {"from": "##on", "to": "is cost - effective", "value": 1}, {"from": "##on", "to": "of agriculture and natural", "value": 1}, {"from": "##on", "to": ". ac.", "value": 1}, {"from": "##on", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "##on", "to": "resources", "value": 1}, {"from": "##on", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "##on", "to": "##za. he", "value": 1}, {"from": "##on", "to": "##6 /", "value": 1}, {"from": "##on", "to": "are", "value": 1}, {"from": "##on", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##on", "to": "##ri - japelaghi r", "value": 1}, {"from": "##on", "to": "##r.", "value": 1}, {"from": "##on", "to": "who", "value": 1}, {"from": "##on", "to": "inter", "value": 1}, {"from": "##on", "to": "##vin", "value": 1}, {"from": "##on", "to": "of tabriz,", "value": 1}, {"from": "##on", "to": "@ org.", "value": 1}, {"from": "##on", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##on", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##on", "to": "##idari", "value": 1}, {"from": "##on", "to": "s", "value": 1}, {"from": "##on", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##on", "to": "ta", "value": 1}, {"from": "##on", "to": "##ran. electronic address :", "value": 1}, {"from": "##on", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##on", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##on", "to": "101", "value": 1}, {"from": "##on", "to": "perspectives", "value": 1}, {"from": "##on", "to": "##briz,", "value": 1}, {"from": "##on", "to": "of agriculture,", "value": 1}, {"from": "##on", "to": "##fer", "value": 1}, {"from": "##on", "to": "##ki", "value": 1}, {"from": "##on", "to": "from both", "value": 1}, {"from": "##on", "to": "##ran.", "value": 1}, {"from": "conclusions", "to": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "value": 1}, {"from": "conclusions", "to": "10. 113", "value": 1}, {"from": "conclusions", "to": "interests", "value": 1}, {"from": "conclusions", "to": ". no commercial re -", "value": 1}, {"from": "conclusions", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "conclusions", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "conclusions", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "conclusions", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "conclusions", "to": ": nr receives research support from bm", "value": 1}, {"from": "conclusions", "to": "use", "value": 1}, {"from": "conclusions", "to": ": atm deficiency, while com", "value": 1}, {"from": "conclusions", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "conclusions", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "conclusions", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "10. 113", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "interests", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": ". no commercial re -", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": ": nr receives research support from bm", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "use", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": ": atm deficiency, while com", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##romising dna repair and enhancing sensitivity to radiation and atr inhibition,", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "10. 113", "to": "interests", "value": 1}, {"from": "10. 113", "to": ". no commercial re -", "value": 1}, {"from": "10. 113", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "10. 113", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "10. 113", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "10. 113", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "10. 113", "to": ": nr receives research support from bm", "value": 1}, {"from": "10. 113", "to": "use", "value": 1}, {"from": "10. 113", "to": ": atm deficiency, while com", "value": 1}, {"from": "10. 113", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "10. 113", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "10. 113", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "interests", "to": ". no commercial re -", "value": 1}, {"from": "interests", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": "interests", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "interests", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "interests", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "interests", "to": ": nr receives research support from bm", "value": 1}, {"from": "interests", "to": "use", "value": 1}, {"from": "interests", "to": ": atm deficiency, while com", "value": 1}, {"from": "interests", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "interests", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "interests", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": ". no commercial re -", "to": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "value": 1}, {"from": ". no commercial re -", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": ". no commercial re -", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": ". no commercial re -", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": ". no commercial re -", "to": ": nr receives research support from bm", "value": 1}, {"from": ". no commercial re -", "to": "use", "value": 1}, {"from": ". no commercial re -", "to": ": atm deficiency, while com", "value": 1}, {"from": ". no commercial re -", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": ". no commercial re -", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": ". no commercial re -", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "##ed for medline ] conflict of interest statement : competing", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": ": nr receives research support from bm", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "use", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": ": atm deficiency, while com", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms.", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": ": nr receives research support from bm", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": "use", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": ": atm deficiency, while com", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##ed for medline ] conflict of interest statement : competing", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": ". see rights and permissions. published by bmj group.", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": ": nr receives research support from bm", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": "use", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": ": atm deficiency, while com", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. \u00a9 author", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": ": nr receives research support from bm", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": "use", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": ": atm deficiency, while com", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": ". see rights and permissions. published by bmj group.", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": ": nr receives research support from bm", "to": "use", "value": 1}, {"from": ": nr receives research support from bm", "to": ": atm deficiency, while com", "value": 1}, {"from": ": nr receives research support from bm", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": ": nr receives research support from bm", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": ": nr receives research support from bm", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "use", "to": ": atm deficiency, while com", "value": 1}, {"from": "use", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": "use", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "use", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": ": atm deficiency, while com", "to": "##ide in atm - null syngeneic tumor models, nor", "value": 1}, {"from": ": atm deficiency, while com", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": ": atm deficiency, while com", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##ide in atm - null syngeneic tumor models, nor", "to": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "value": 1}, {"from": "##ide in atm - null syngeneic tumor models, nor", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "##6 / jitc - 2024 - 010548 pmid : 40350205 [", "to": "point blockade does not bolster the therapeutic activity of etop", "value": 1}, {"from": "), huarte m", "to": "12", "value": 1}, {"from": "), huarte m", "to": "##407.", "value": 1}, {"from": "), huarte m", "to": "), par", "value": 1}, {"from": "), huarte m", "to": "ins", "value": 1}, {"from": "), huarte m", "to": "##or", "value": 1}, {"from": "), huarte m", "to": "##e", "value": 1}, {"from": "), huarte m", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "), huarte m", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "), huarte m", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "), huarte m", "to": "), aragon s", "value": 1}, {"from": "), huarte m", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "), huarte m", "to": "##ory", "value": 1}, {"from": "), huarte m", "to": "), gimenez j", "value": 1}, {"from": "), huarte m", "to": "- lopez i", "value": 1}, {"from": "), huarte m", "to": "##rine", "value": 1}, {"from": "), huarte m", "to": "er + / her2 -", "value": 1}, {"from": "), huarte m", "to": "), prat a", "value": 1}, {"from": "), huarte m", "to": "research", "value": 1}, {"from": "), huarte m", "to": "##e. lg is /", "value": 1}, {"from": "), huarte m", "to": "), buch e", "value": 1}, {"from": "), huarte m", "to": "##roga v", "value": 1}, {"from": "), huarte m", "to": "been holding research", "value": 1}, {"from": "), huarte m", "to": "11", "value": 1}, {"from": "), huarte m", "to": "101", "value": 1}, {"from": "), huarte m", "to": "##riaga k", "value": 1}, {"from": "), huarte m", "to": "), etxabe i", "value": 1}, {"from": "), huarte m", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), huarte m", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), huarte m", "to": "13", "value": 1}, {"from": "), huarte m", "to": "therapy", "value": 1}, {"from": "), huarte m", "to": "##ui", "value": 1}, {"from": "), huarte m", "to": "##ez", "value": 1}, {"from": "), huarte m", "to": "##vita", "value": 1}, {"from": "), huarte m", "to": "contracts", "value": 1}, {"from": "), huarte m", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), huarte m", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), huarte m", "to": "). author information :", "value": 1}, {"from": "), huarte m", "to": "), urruticoechea a", "value": 1}, {"from": "12", "to": "##407.", "value": 1}, {"from": "12", "to": "), par", "value": 1}, {"from": "12", "to": "ins", "value": 1}, {"from": "12", "to": "##or", "value": 1}, {"from": "12", "to": "##e", "value": 1}, {"from": "12", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "12", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "12", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "12", "to": "), aragon s", "value": 1}, {"from": "12", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "12", "to": "##ory", "value": 1}, {"from": "12", "to": "), gimenez j", "value": 1}, {"from": "12", "to": "- lopez i", "value": 1}, {"from": "12", "to": "##rine", "value": 1}, {"from": "12", "to": "er + / her2 -", "value": 1}, {"from": "12", "to": "), prat a", "value": 1}, {"from": "12", "to": "research", "value": 1}, {"from": "12", "to": "##e. lg is /", "value": 1}, {"from": "12", "to": "), buch e", "value": 1}, {"from": "12", "to": "##roga v", "value": 1}, {"from": "12", "to": "been holding research", "value": 1}, {"from": "12", "to": "11", "value": 1}, {"from": "12", "to": "101", "value": 1}, {"from": "12", "to": "##riaga k", "value": 1}, {"from": "12", "to": "), etxabe i", "value": 1}, {"from": "12", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "12", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "12", "to": "13", "value": 2}, {"from": "12", "to": "therapy", "value": 1}, {"from": "12", "to": "##ui", "value": 1}, {"from": "12", "to": "##ez", "value": 1}, {"from": "12", "to": "##vita", "value": 1}, {"from": "12", "to": "contracts", "value": 1}, {"from": "12", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "12", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "12", "to": "). author information :", "value": 1}, {"from": "12", "to": "), urruticoechea a", "value": 1}, {"from": "12", "to": "after net", "value": 1}, {"from": "12", "to": "a significant", "value": 1}, {"from": "12", "to": "offers the opportunity of", "value": 1}, {"from": "12", "to": "##ip", "value": 1}, {"from": "12", "to": "t", "value": 1}, {"from": "12", "to": ") health", "value": 1}, {"from": "12", "to": "background", "value": 1}, {"from": "12", "to": "##re population of", "value": 1}, {"from": "12", "to": "negative breast", "value": 1}, {"from": "12", "to": "barrier", "value": 1}, {"from": "12", "to": "##gipuzkoa", "value": 1}, {"from": "12", "to": "clinical", "value": 1}, {"from": "12", "to": "##2 -", "value": 1}, {"from": "12", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "12", "to": "##zkoa", "value": 1}, {"from": "12", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "12", "to": "##gi", "value": 1}, {"from": "12", "to": "##donostia ) health", "value": 1}, {"from": "12", "to": "##tian,", "value": 1}, {"from": "12", "to": "cancer", "value": 1}, {"from": "12", "to": "spain", "value": 1}, {"from": "12", "to": "##uzkoa. eus.", "value": 1}, {"from": "12", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "12", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "12", "to": "personal", "value": 1}, {"from": "12", "to": "##ised therapy.", "value": 1}, {"from": "12", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "12", "to": "##donost", "value": 1}, {"from": "12", "to": "##cent", "value": 1}, {"from": "12", "to": "research institute", "value": 1}, {"from": "12", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "12", "to": "sa", "value": 1}, {"from": "12", "to": "sebas", "value": 1}, {"from": "12", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "12", "to": "her", "value": 1}, {"from": "12", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "12", "to": "##n sebastian,", "value": 1}, {"from": "12", "to": "##umour response", "value": 1}, {"from": "12", "to": "a,", "value": 1}, {"from": "12", "to": "##pu", "value": 1}, {"from": "12", "to": "##n", "value": 1}, {"from": "12", "to": "sebastian", "value": 1}, {"from": "12", "to": "##uc", "value": 1}, {"from": "12", "to": ", the lack of reprod", "value": 1}, {"from": "12", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "12", "to": "##c ) allows", "value": 1}, {"from": "12", "to": "##gnosis", "value": 1}, {"from": "12", "to": "- g", "value": 1}, {"from": "##407.", "to": "), par", "value": 1}, {"from": "##407.", "to": "ins", "value": 1}, {"from": "##407.", "to": "##or", "value": 1}, {"from": "##407.", "to": "##e", "value": 1}, {"from": "##407.", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "##407.", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "##407.", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "##407.", "to": "), aragon s", "value": 1}, {"from": "##407.", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "##407.", "to": "##ory", "value": 1}, {"from": "##407.", "to": "), gimenez j", "value": 1}, {"from": "##407.", "to": "- lopez i", "value": 1}, {"from": "##407.", "to": "##rine", "value": 1}, {"from": "##407.", "to": "er + / her2 -", "value": 1}, {"from": "##407.", "to": "), prat a", "value": 1}, {"from": "##407.", "to": "research", "value": 1}, {"from": "##407.", "to": "##e. lg is /", "value": 1}, {"from": "##407.", "to": "), buch e", "value": 1}, {"from": "##407.", "to": "##roga v", "value": 1}, {"from": "##407.", "to": "been holding research", "value": 1}, {"from": "##407.", "to": "11", "value": 1}, {"from": "##407.", "to": "101", "value": 1}, {"from": "##407.", "to": "##riaga k", "value": 1}, {"from": "##407.", "to": "), etxabe i", "value": 1}, {"from": "##407.", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##407.", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##407.", "to": "13", "value": 1}, {"from": "##407.", "to": "therapy", "value": 1}, {"from": "##407.", "to": "##ui", "value": 1}, {"from": "##407.", "to": "##ez", "value": 1}, {"from": "##407.", "to": "##vita", "value": 1}, {"from": "##407.", "to": "contracts", "value": 1}, {"from": "##407.", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##407.", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##407.", "to": "). author information :", "value": 1}, {"from": "##407.", "to": "), urruticoechea a", "value": 1}, {"from": "), par", "to": "ins", "value": 1}, {"from": "), par", "to": "##or", "value": 1}, {"from": "), par", "to": "##e", "value": 1}, {"from": "), par", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "), par", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "), par", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "), par", "to": "), aragon s", "value": 1}, {"from": "), par", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "), par", "to": "##ory", "value": 1}, {"from": "), par", "to": "), gimenez j", "value": 1}, {"from": "), par", "to": "- lopez i", "value": 1}, {"from": "), par", "to": "##rine", "value": 1}, {"from": "), par", "to": "er + / her2 -", "value": 1}, {"from": "), par", "to": "), prat a", "value": 1}, {"from": "), par", "to": "research", "value": 1}, {"from": "), par", "to": "##e. lg is /", "value": 1}, {"from": "), par", "to": "), buch e", "value": 1}, {"from": "), par", "to": "##roga v", "value": 1}, {"from": "), par", "to": "been holding research", "value": 1}, {"from": "), par", "to": "11", "value": 1}, {"from": "), par", "to": "101", "value": 1}, {"from": "), par", "to": "##riaga k", "value": 1}, {"from": "), par", "to": "), etxabe i", "value": 1}, {"from": "), par", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), par", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), par", "to": "13", "value": 1}, {"from": "), par", "to": "therapy", "value": 1}, {"from": "), par", "to": "##ui", "value": 1}, {"from": "), par", "to": "##ez", "value": 1}, {"from": "), par", "to": "##vita", "value": 1}, {"from": "), par", "to": "contracts", "value": 1}, {"from": "), par", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), par", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), par", "to": "). author information :", "value": 1}, {"from": "), par", "to": "), urruticoechea a", "value": 1}, {"from": "ins", "to": "##or", "value": 1}, {"from": "ins", "to": "##e", "value": 1}, {"from": "ins", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "ins", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "ins", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "ins", "to": "), aragon s", "value": 1}, {"from": "ins", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "ins", "to": "##ory", "value": 1}, {"from": "ins", "to": "), gimenez j", "value": 1}, {"from": "ins", "to": "- lopez i", "value": 1}, {"from": "ins", "to": "##rine", "value": 1}, {"from": "ins", "to": "er + / her2 -", "value": 1}, {"from": "ins", "to": "), prat a", "value": 1}, {"from": "ins", "to": "research", "value": 1}, {"from": "ins", "to": "##e. lg is /", "value": 1}, {"from": "ins", "to": "), buch e", "value": 1}, {"from": "ins", "to": "##roga v", "value": 1}, {"from": "ins", "to": "been holding research", "value": 1}, {"from": "ins", "to": "11", "value": 1}, {"from": "ins", "to": "101", "value": 1}, {"from": "ins", "to": "##riaga k", "value": 1}, {"from": "ins", "to": "), etxabe i", "value": 1}, {"from": "ins", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "ins", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "ins", "to": "13", "value": 1}, {"from": "ins", "to": "therapy", "value": 1}, {"from": "ins", "to": "##ui", "value": 1}, {"from": "ins", "to": "##ez", "value": 1}, {"from": "ins", "to": "##vita", "value": 1}, {"from": "ins", "to": "contracts", "value": 1}, {"from": "ins", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "ins", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "ins", "to": "). author information :", "value": 1}, {"from": "ins", "to": "), urruticoechea a", "value": 1}, {"from": "##or", "to": "##e", "value": 1}, {"from": "##or", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "##or", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "##or", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "##or", "to": "), aragon s", "value": 1}, {"from": "##or", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "##or", "to": "##ory", "value": 1}, {"from": "##or", "to": "), gimenez j", "value": 1}, {"from": "##or", "to": "- lopez i", "value": 1}, {"from": "##or", "to": "##rine", "value": 1}, {"from": "##or", "to": "er + / her2 -", "value": 1}, {"from": "##or", "to": "), prat a", "value": 1}, {"from": "##or", "to": "research", "value": 1}, {"from": "##or", "to": "##e. lg is /", "value": 1}, {"from": "##or", "to": "), buch e", "value": 1}, {"from": "##or", "to": "##roga v", "value": 1}, {"from": "##or", "to": "been holding research", "value": 1}, {"from": "##or", "to": "11", "value": 1}, {"from": "##or", "to": "101", "value": 1}, {"from": "##or", "to": "##riaga k", "value": 1}, {"from": "##or", "to": "), etxabe i", "value": 1}, {"from": "##or", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##or", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##or", "to": "13", "value": 1}, {"from": "##or", "to": "therapy", "value": 1}, {"from": "##or", "to": "##ui", "value": 1}, {"from": "##or", "to": "##ez", "value": 1}, {"from": "##or", "to": "##vita", "value": 1}, {"from": "##or", "to": "contracts", "value": 1}, {"from": "##or", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##or", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##or", "to": "). author information :", "value": 1}, {"from": "##or", "to": "), urruticoechea a", "value": 1}, {"from": "##e", "to": "s, pfizer, repare therapuetics, and in", "value": 1}, {"from": "##e", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "##e", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "##e", "to": "), aragon s", "value": 1}, {"from": "##e", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "##e", "to": "##ory", "value": 1}, {"from": "##e", "to": "), gimenez j", "value": 1}, {"from": "##e", "to": "- lopez i", "value": 1}, {"from": "##e", "to": "##rine", "value": 1}, {"from": "##e", "to": "er + / her2 -", "value": 1}, {"from": "##e", "to": "), prat a", "value": 1}, {"from": "##e", "to": "research", "value": 1}, {"from": "##e", "to": "##e. lg is /", "value": 1}, {"from": "##e", "to": "), buch e", "value": 1}, {"from": "##e", "to": "##roga v", "value": 1}, {"from": "##e", "to": "been holding research", "value": 1}, {"from": "##e", "to": "11", "value": 1}, {"from": "##e", "to": "101", "value": 1}, {"from": "##e", "to": "##riaga k", "value": 1}, {"from": "##e", "to": "), etxabe i", "value": 1}, {"from": "##e", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##e", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##e", "to": "13", "value": 1}, {"from": "##e", "to": "therapy", "value": 1}, {"from": "##e", "to": "##ui", "value": 1}, {"from": "##e", "to": "##ez", "value": 1}, {"from": "##e", "to": "##vita", "value": 1}, {"from": "##e", "to": "contracts", "value": 1}, {"from": "##e", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##e", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##e", "to": "). author information :", "value": 1}, {"from": "##e", "to": "), urruticoechea a", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "with lytix biopharma, promontory and onxeo,", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), aragon s", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##ory", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), gimenez j", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "- lopez i", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##rine", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "er + / her2 -", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), prat a", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "research", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##e. lg is /", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), buch e", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##roga v", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "been holding research", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "11", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "101", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##riaga k", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), etxabe i", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "13", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "therapy", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##ui", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##ez", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##vita", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "contracts", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "). author information :", "value": 1}, {"from": "s, pfizer, repare therapuetics, and in", "to": "), urruticoechea a", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), aragon s", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##ory", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), gimenez j", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "- lopez i", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##rine", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "er + / her2 -", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), prat a", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "research", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##e. lg is /", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), buch e", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##roga v", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "been holding research", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "11", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "101", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##riaga k", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), etxabe i", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "13", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "therapy", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##ui", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##ez", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##vita", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "contracts", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "). author information :", "value": 1}, {"from": "with lytix biopharma, promontory and onxeo,", "to": "), urruticoechea a", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), aragon s", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##ory", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), gimenez j", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "- lopez i", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##rine", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "er + / her2 -", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), prat a", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "research", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##e. lg is /", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), buch e", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##roga v", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "been holding research", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "11", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "101", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##riaga k", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), etxabe i", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "1 ) biogipuzkoa", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "13", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "therapy", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##ui", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##ez", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##vita", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "contracts", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "). author information :", "value": 1}, {"from": ", noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 :", "to": "), urruticoechea a", "value": 1}, {"from": "), aragon s", "to": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "value": 1}, {"from": "), aragon s", "to": "##ory", "value": 1}, {"from": "), aragon s", "to": "), gimenez j", "value": 1}, {"from": "), aragon s", "to": "- lopez i", "value": 1}, {"from": "), aragon s", "to": "##rine", "value": 1}, {"from": "), aragon s", "to": "er + / her2 -", "value": 1}, {"from": "), aragon s", "to": "), prat a", "value": 1}, {"from": "), aragon s", "to": "research", "value": 1}, {"from": "), aragon s", "to": "##e. lg is /", "value": 1}, {"from": "), aragon s", "to": "), buch e", "value": 1}, {"from": "), aragon s", "to": "##roga v", "value": 1}, {"from": "), aragon s", "to": "been holding research", "value": 1}, {"from": "), aragon s", "to": "11", "value": 1}, {"from": "), aragon s", "to": "101", "value": 1}, {"from": "), aragon s", "to": "##riaga k", "value": 1}, {"from": "), aragon s", "to": "), etxabe i", "value": 1}, {"from": "), aragon s", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), aragon s", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), aragon s", "to": "13", "value": 1}, {"from": "), aragon s", "to": "therapy", "value": 1}, {"from": "), aragon s", "to": "##ui", "value": 1}, {"from": "), aragon s", "to": "##ez", "value": 1}, {"from": "), aragon s", "to": "##vita", "value": 1}, {"from": "), aragon s", "to": "contracts", "value": 1}, {"from": "), aragon s", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), aragon s", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), aragon s", "to": "). author information :", "value": 1}, {"from": "), aragon s", "to": "), urruticoechea a", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##ory", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "), gimenez j", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "- lopez i", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##rine", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "er + / her2 -", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "), prat a", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "research", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##e. lg is /", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "), buch e", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##roga v", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "been holding research", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "11", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "101", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##riaga k", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "), etxabe i", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "13", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "therapy", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##ui", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##ez", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##vita", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "contracts", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "). author information :", "value": 1}, {"from": "cancer uncovers biomarkers of tumour response. lopez - velazco ji", "to": "), urruticoechea a", "value": 1}, {"from": "##ory", "to": "), gimenez j", "value": 1}, {"from": "##ory", "to": "- lopez i", "value": 1}, {"from": "##ory", "to": "##rine", "value": 1}, {"from": "##ory", "to": "er + / her2 -", "value": 1}, {"from": "##ory", "to": "), prat a", "value": 1}, {"from": "##ory", "to": "research", "value": 1}, {"from": "##ory", "to": "##e. lg is /", "value": 1}, {"from": "##ory", "to": "), buch e", "value": 1}, {"from": "##ory", "to": "##roga v", "value": 1}, {"from": "##ory", "to": "been holding research", "value": 1}, {"from": "##ory", "to": "11", "value": 1}, {"from": "##ory", "to": "101", "value": 1}, {"from": "##ory", "to": "##riaga k", "value": 1}, {"from": "##ory", "to": "), etxabe i", "value": 1}, {"from": "##ory", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##ory", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##ory", "to": "13", "value": 1}, {"from": "##ory", "to": "therapy", "value": 1}, {"from": "##ory", "to": "##ui", "value": 1}, {"from": "##ory", "to": "##ez", "value": 1}, {"from": "##ory", "to": "##vita", "value": 1}, {"from": "##ory", "to": "contracts", "value": 1}, {"from": "##ory", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##ory", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##ory", "to": "). author information :", "value": 1}, {"from": "##ory", "to": "), urruticoechea a", "value": 1}, {"from": "), gimenez j", "to": "- lopez i", "value": 1}, {"from": "), gimenez j", "to": "##rine", "value": 1}, {"from": "), gimenez j", "to": "er + / her2 -", "value": 1}, {"from": "), gimenez j", "to": "), prat a", "value": 1}, {"from": "), gimenez j", "to": "research", "value": 1}, {"from": "), gimenez j", "to": "##e. lg is /", "value": 1}, {"from": "), gimenez j", "to": "), buch e", "value": 1}, {"from": "), gimenez j", "to": "##roga v", "value": 1}, {"from": "), gimenez j", "to": "been holding research", "value": 1}, {"from": "), gimenez j", "to": "11", "value": 1}, {"from": "), gimenez j", "to": "101", "value": 1}, {"from": "), gimenez j", "to": "##riaga k", "value": 1}, {"from": "), gimenez j", "to": "), etxabe i", "value": 1}, {"from": "), gimenez j", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), gimenez j", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), gimenez j", "to": "13", "value": 1}, {"from": "), gimenez j", "to": "therapy", "value": 1}, {"from": "), gimenez j", "to": "##ui", "value": 1}, {"from": "), gimenez j", "to": "##ez", "value": 1}, {"from": "), gimenez j", "to": "##vita", "value": 1}, {"from": "), gimenez j", "to": "contracts", "value": 1}, {"from": "), gimenez j", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), gimenez j", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), gimenez j", "to": "). author information :", "value": 1}, {"from": "), gimenez j", "to": "), urruticoechea a", "value": 1}, {"from": "- lopez i", "to": "##rine", "value": 1}, {"from": "- lopez i", "to": "er + / her2 -", "value": 1}, {"from": "- lopez i", "to": "), prat a", "value": 1}, {"from": "- lopez i", "to": "research", "value": 1}, {"from": "- lopez i", "to": "##e. lg is /", "value": 1}, {"from": "- lopez i", "to": "), buch e", "value": 1}, {"from": "- lopez i", "to": "##roga v", "value": 1}, {"from": "- lopez i", "to": "been holding research", "value": 1}, {"from": "- lopez i", "to": "11", "value": 1}, {"from": "- lopez i", "to": "101", "value": 1}, {"from": "- lopez i", "to": "##riaga k", "value": 1}, {"from": "- lopez i", "to": "), etxabe i", "value": 1}, {"from": "- lopez i", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "- lopez i", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "- lopez i", "to": "13", "value": 1}, {"from": "- lopez i", "to": "therapy", "value": 1}, {"from": "- lopez i", "to": "##ui", "value": 1}, {"from": "- lopez i", "to": "##ez", "value": 1}, {"from": "- lopez i", "to": "##vita", "value": 1}, {"from": "- lopez i", "to": "contracts", "value": 1}, {"from": "- lopez i", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "- lopez i", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "- lopez i", "to": "). author information :", "value": 1}, {"from": "- lopez i", "to": "), urruticoechea a", "value": 1}, {"from": "##rine", "to": "er + / her2 -", "value": 1}, {"from": "##rine", "to": "), prat a", "value": 1}, {"from": "##rine", "to": "research", "value": 1}, {"from": "##rine", "to": "##e. lg is /", "value": 1}, {"from": "##rine", "to": "), buch e", "value": 1}, {"from": "##rine", "to": "##roga v", "value": 1}, {"from": "##rine", "to": "been holding research", "value": 1}, {"from": "##rine", "to": "11", "value": 1}, {"from": "##rine", "to": "101", "value": 1}, {"from": "##rine", "to": "##riaga k", "value": 1}, {"from": "##rine", "to": "), etxabe i", "value": 1}, {"from": "##rine", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##rine", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##rine", "to": "13", "value": 1}, {"from": "##rine", "to": "therapy", "value": 1}, {"from": "##rine", "to": "##ui", "value": 1}, {"from": "##rine", "to": "##ez", "value": 1}, {"from": "##rine", "to": "##vita", "value": 1}, {"from": "##rine", "to": "contracts", "value": 1}, {"from": "##rine", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##rine", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##rine", "to": "). author information :", "value": 1}, {"from": "##rine", "to": "), urruticoechea a", "value": 1}, {"from": "er + / her2 -", "to": "), prat a", "value": 1}, {"from": "er + / her2 -", "to": "research", "value": 1}, {"from": "er + / her2 -", "to": "##e. lg is /", "value": 1}, {"from": "er + / her2 -", "to": "), buch e", "value": 1}, {"from": "er + / her2 -", "to": "##roga v", "value": 1}, {"from": "er + / her2 -", "to": "been holding research", "value": 1}, {"from": "er + / her2 -", "to": "11", "value": 1}, {"from": "er + / her2 -", "to": "101", "value": 1}, {"from": "er + / her2 -", "to": "##riaga k", "value": 1}, {"from": "er + / her2 -", "to": "), etxabe i", "value": 1}, {"from": "er + / her2 -", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "er + / her2 -", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "er + / her2 -", "to": "13", "value": 1}, {"from": "er + / her2 -", "to": "therapy", "value": 1}, {"from": "er + / her2 -", "to": "##ui", "value": 1}, {"from": "er + / her2 -", "to": "##ez", "value": 1}, {"from": "er + / her2 -", "to": "##vita", "value": 1}, {"from": "er + / her2 -", "to": "contracts", "value": 1}, {"from": "er + / her2 -", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "er + / her2 -", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "er + / her2 -", "to": "). author information :", "value": 1}, {"from": "er + / her2 -", "to": "), urruticoechea a", "value": 1}, {"from": "), prat a", "to": "research", "value": 1}, {"from": "), prat a", "to": "##e. lg is /", "value": 1}, {"from": "), prat a", "to": "), buch e", "value": 1}, {"from": "), prat a", "to": "##roga v", "value": 1}, {"from": "), prat a", "to": "been holding research", "value": 1}, {"from": "), prat a", "to": "11", "value": 1}, {"from": "), prat a", "to": "101", "value": 1}, {"from": "), prat a", "to": "##riaga k", "value": 1}, {"from": "), prat a", "to": "), etxabe i", "value": 1}, {"from": "), prat a", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), prat a", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), prat a", "to": "13", "value": 1}, {"from": "), prat a", "to": "therapy", "value": 1}, {"from": "), prat a", "to": "##ui", "value": 1}, {"from": "), prat a", "to": "##ez", "value": 1}, {"from": "), prat a", "to": "##vita", "value": 1}, {"from": "), prat a", "to": "contracts", "value": 1}, {"from": "), prat a", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), prat a", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), prat a", "to": "). author information :", "value": 1}, {"from": "), prat a", "to": "), urruticoechea a", "value": 1}, {"from": "research", "to": "##e. lg is /", "value": 1}, {"from": "research", "to": "), buch e", "value": 1}, {"from": "research", "to": "##roga v", "value": 1}, {"from": "research", "to": "been holding research", "value": 1}, {"from": "research", "to": "11", "value": 2}, {"from": "research", "to": "101", "value": 1}, {"from": "research", "to": "##riaga k", "value": 1}, {"from": "research", "to": "), etxabe i", "value": 1}, {"from": "research", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "research", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "research", "to": "13", "value": 2}, {"from": "research", "to": "therapy", "value": 1}, {"from": "research", "to": "##ui", "value": 1}, {"from": "research", "to": "##ez", "value": 1}, {"from": "research", "to": "##vita", "value": 1}, {"from": "research", "to": "contracts", "value": 1}, {"from": "research", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "research", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "research", "to": "). author information :", "value": 1}, {"from": "research", "to": "), urruticoechea a", "value": 1}, {"from": "research", "to": ") department of", "value": 1}, {"from": "research", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "research", "to": "for cancer", "value": 1}, {"from": "research", "to": "##lia", "value": 1}, {"from": "research", "to": "##vanger,", "value": 1}, {"from": "research", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "research", "to": "##vanger university, s", "value": 1}, {"from": "research", "to": "8", "value": 1}, {"from": "research", "to": "of cancer genetics,", "value": 1}, {"from": "research", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "research", "to": "12 ) department", "value": 1}, {"from": "research", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "research", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "research", "to": "##vanger university hospital, s", "value": 1}, {"from": "research", "to": "ha", "value": 1}, {"from": "research", "to": "norway", "value": 1}, {"from": "research", "to": "institute", "value": 1}, {"from": "research", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "research", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "research", "to": "of pathology, s", "value": 1}, {"from": "research", "to": ";", "value": 1}, {"from": "research", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "research", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "research", "to": "##way", "value": 1}, {"from": "##e. lg is /", "to": "), buch e", "value": 1}, {"from": "##e. lg is /", "to": "##roga v", "value": 1}, {"from": "##e. lg is /", "to": "been holding research", "value": 1}, {"from": "##e. lg is /", "to": "11", "value": 1}, {"from": "##e. lg is /", "to": "101", "value": 1}, {"from": "##e. lg is /", "to": "##riaga k", "value": 1}, {"from": "##e. lg is /", "to": "), etxabe i", "value": 1}, {"from": "##e. lg is /", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##e. lg is /", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##e. lg is /", "to": "13", "value": 1}, {"from": "##e. lg is /", "to": "therapy", "value": 1}, {"from": "##e. lg is /", "to": "##ui", "value": 1}, {"from": "##e. lg is /", "to": "##ez", "value": 1}, {"from": "##e. lg is /", "to": "##vita", "value": 1}, {"from": "##e. lg is /", "to": "contracts", "value": 1}, {"from": "##e. lg is /", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##e. lg is /", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##e. lg is /", "to": "). author information :", "value": 1}, {"from": "##e. lg is /", "to": "), urruticoechea a", "value": 1}, {"from": "), buch e", "to": "##roga v", "value": 1}, {"from": "), buch e", "to": "been holding research", "value": 1}, {"from": "), buch e", "to": "11", "value": 1}, {"from": "), buch e", "to": "101", "value": 1}, {"from": "), buch e", "to": "##riaga k", "value": 1}, {"from": "), buch e", "to": "), etxabe i", "value": 1}, {"from": "), buch e", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), buch e", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), buch e", "to": "13", "value": 1}, {"from": "), buch e", "to": "therapy", "value": 1}, {"from": "), buch e", "to": "##ui", "value": 1}, {"from": "), buch e", "to": "##ez", "value": 1}, {"from": "), buch e", "to": "##vita", "value": 1}, {"from": "), buch e", "to": "contracts", "value": 1}, {"from": "), buch e", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), buch e", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), buch e", "to": "). author information :", "value": 1}, {"from": "), buch e", "to": "), urruticoechea a", "value": 1}, {"from": "##roga v", "to": "been holding research", "value": 1}, {"from": "##roga v", "to": "11", "value": 1}, {"from": "##roga v", "to": "101", "value": 1}, {"from": "##roga v", "to": "##riaga k", "value": 1}, {"from": "##roga v", "to": "), etxabe i", "value": 1}, {"from": "##roga v", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##roga v", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##roga v", "to": "13", "value": 1}, {"from": "##roga v", "to": "therapy", "value": 1}, {"from": "##roga v", "to": "##ui", "value": 1}, {"from": "##roga v", "to": "##ez", "value": 1}, {"from": "##roga v", "to": "##vita", "value": 1}, {"from": "##roga v", "to": "contracts", "value": 1}, {"from": "##roga v", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##roga v", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##roga v", "to": "). author information :", "value": 1}, {"from": "##roga v", "to": "), urruticoechea a", "value": 1}, {"from": "been holding research", "to": "11", "value": 1}, {"from": "been holding research", "to": "101", "value": 1}, {"from": "been holding research", "to": "##riaga k", "value": 1}, {"from": "been holding research", "to": "), etxabe i", "value": 1}, {"from": "been holding research", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "been holding research", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "been holding research", "to": "13", "value": 1}, {"from": "been holding research", "to": "therapy", "value": 1}, {"from": "been holding research", "to": "##ui", "value": 1}, {"from": "been holding research", "to": "##ez", "value": 1}, {"from": "been holding research", "to": "##vita", "value": 1}, {"from": "been holding research", "to": "contracts", "value": 1}, {"from": "been holding research", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "been holding research", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "been holding research", "to": "). author information :", "value": 1}, {"from": "been holding research", "to": "), urruticoechea a", "value": 1}, {"from": "11", "to": "101", "value": 1}, {"from": "11", "to": "##riaga k", "value": 1}, {"from": "11", "to": "), etxabe i", "value": 1}, {"from": "11", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "11", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "11", "to": "13", "value": 2}, {"from": "11", "to": "therapy", "value": 1}, {"from": "11", "to": "##ui", "value": 1}, {"from": "11", "to": "##ez", "value": 1}, {"from": "11", "to": "##vita", "value": 1}, {"from": "11", "to": "contracts", "value": 1}, {"from": "11", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "11", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "11", "to": "). author information :", "value": 1}, {"from": "11", "to": "), urruticoechea a", "value": 1}, {"from": "11", "to": "##rio de v", "value": 1}, {"from": "11", "to": "t", "value": 1}, {"from": "11", "to": "##kolog", "value": 1}, {"from": "11", "to": ", san", "value": 1}, {"from": "11", "to": "##it", "value": 1}, {"from": "11", "to": ") health", "value": 1}, {"from": "11", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "11", "to": "##iba", "value": 1}, {"from": "11", "to": "##ialdea", "value": 1}, {"from": "11", "to": "##gipuzkoa", "value": 1}, {"from": "11", "to": "##ko", "value": 1}, {"from": "11", "to": "##obe", "value": 1}, {"from": "11", "to": "se", "value": 1}, {"from": "11", "to": "##gi", "value": 1}, {"from": "11", "to": "##tian,", "value": 1}, {"from": "11", "to": ") hospital clinico univers", "value": 1}, {"from": "11", "to": "##r 12, madrid,", "value": 1}, {"from": "11", "to": "spain", "value": 1}, {"from": "11", "to": "##ale", "value": 1}, {"from": "11", "to": "##a", "value": 1}, {"from": "11", "to": "##ute", "value": 1}, {"from": "11", "to": "##ikoa,", "value": 1}, {"from": "11", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "11", "to": "##donost", "value": 1}, {"from": "11", "to": ") hospital oct", "value": 1}, {"from": "11", "to": "research institute", "value": 1}, {"from": "11", "to": "institute", "value": 2}, {"from": "11", "to": "sa", "value": 1}, {"from": "11", "to": "sebas", "value": 1}, {"from": "11", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "11", "to": "##ita", "value": 1}, {"from": "11", "to": ", v", "value": 1}, {"from": "11", "to": "##ps, barcelon", "value": 1}, {"from": "11", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "11", "to": "##n", "value": 1}, {"from": "11", "to": "##pu", "value": 1}, {"from": "11", "to": "sebastian", "value": 1}, {"from": "11", "to": "; gip", "value": 1}, {"from": "11", "to": "- on", "value": 1}, {"from": "11", "to": "7 ) valencia oncology", "value": 1}, {"from": "11", "to": "##ncia,", "value": 1}, {"from": "11", "to": "##uz", "value": 1}, {"from": "11", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "11", "to": "- onkologikoa, san", "value": 1}, {"from": "11", "to": "##z", "value": 1}, {"from": "11", "to": "##bastian, spa", "value": 1}, {"from": "11", "to": ") department of", "value": 1}, {"from": "11", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "11", "to": "for cancer", "value": 1}, {"from": "11", "to": "##lia", "value": 1}, {"from": "11", "to": "##vanger,", "value": 1}, {"from": "11", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "11", "to": "##vanger university, s", "value": 1}, {"from": "11", "to": "8", "value": 1}, {"from": "11", "to": "of cancer genetics,", "value": 1}, {"from": "11", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "11", "to": "12 ) department", "value": 1}, {"from": "11", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "11", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "11", "to": "##vanger university hospital, s", "value": 1}, {"from": "11", "to": "ha", "value": 1}, {"from": "11", "to": "norway", "value": 1}, {"from": "11", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "11", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "11", "to": "of pathology, s", "value": 1}, {"from": "11", "to": ";", "value": 1}, {"from": "11", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "11", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "11", "to": "##way", "value": 1}, {"from": "101", "to": "##riaga k", "value": 1}, {"from": "101", "to": "), etxabe i", "value": 1}, {"from": "101", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "101", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "101", "to": "13", "value": 1}, {"from": "101", "to": "therapy", "value": 1}, {"from": "101", "to": "##ui", "value": 1}, {"from": "101", "to": "##ez", "value": 1}, {"from": "101", "to": "##vita", "value": 1}, {"from": "101", "to": "contracts", "value": 1}, {"from": "101", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "101", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "101", "to": "). author information :", "value": 1}, {"from": "101", "to": "), urruticoechea a", "value": 1}, {"from": "101", "to": "is cost - effective", "value": 1}, {"from": "101", "to": "of agriculture and natural", "value": 1}, {"from": "101", "to": ". ac.", "value": 1}, {"from": "101", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "101", "to": "resources", "value": 1}, {"from": "101", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "101", "to": "##za. he", "value": 1}, {"from": "101", "to": "##6 /", "value": 2}, {"from": "101", "to": "are", "value": 1}, {"from": "101", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "101", "to": "##ri - japelaghi r", "value": 1}, {"from": "101", "to": "##r.", "value": 1}, {"from": "101", "to": "who", "value": 1}, {"from": "101", "to": "inter", "value": 1}, {"from": "101", "to": "##vin", "value": 1}, {"from": "101", "to": "of tabriz,", "value": 1}, {"from": "101", "to": "@ org.", "value": 1}, {"from": "101", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "101", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "101", "to": "##idari", "value": 1}, {"from": "101", "to": "s", "value": 1}, {"from": "101", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "101", "to": "ta", "value": 1}, {"from": "101", "to": "##ran. electronic address :", "value": 1}, {"from": "101", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "101", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "101", "to": "perspectives", "value": 1}, {"from": "101", "to": "##briz,", "value": 1}, {"from": "101", "to": "of agriculture,", "value": 1}, {"from": "101", "to": "##fer", "value": 1}, {"from": "101", "to": "##ki", "value": 1}, {"from": "101", "to": "from both", "value": 1}, {"from": "101", "to": "##ran.", "value": 1}, {"from": "101", "to": "- regulate", "value": 1}, {"from": "101", "to": "the", "value": 1}, {"from": "101", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "101", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "101", "to": "##tic", "value": 1}, {"from": "101", "to": "##6", "value": 1}, {"from": "101", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "101", "to": "##xic effect of", "value": 1}, {"from": "101", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "101", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "101", "to": "##xic efficacy of the", "value": 1}, {"from": "101", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "101", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "101", "to": "up -", "value": 1}, {"from": "101", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "101", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "101", "to": "development of tumor cells, a", "value": 1}, {"from": "101", "to": "##348089 conflict o", "value": 1}, {"from": "101", "to": "regulate", "value": 1}, {"from": "101", "to": "of pro", "value": 1}, {"from": "101", "to": "##cl -", "value": 1}, {"from": "101", "to": "##biotec. 2025.", "value": 1}, {"from": "101", "to": "04", "value": 1}, {"from": "101", "to": "##apopto", "value": 1}, {"from": "101", "to": "to", "value": 1}, {"from": "101", "to": "##cer and antiviral functions of", "value": 1}, {"from": "101", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "101", "to": "via", "value": 1}, {"from": "101", "to": "and p", "value": 1}, {"from": "101", "to": "##c cell line", "value": 1}, {"from": "101", "to": "hi", "value": 1}, {"from": "101", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "101", "to": "##53", "value": 1}, {"from": "101", "to": ". 022 pmid :", "value": 1}, {"from": "101", "to": "bax", "value": 1}, {"from": "##riaga k", "to": "), etxabe i", "value": 1}, {"from": "##riaga k", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "##riaga k", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##riaga k", "to": "13", "value": 1}, {"from": "##riaga k", "to": "therapy", "value": 1}, {"from": "##riaga k", "to": "##ui", "value": 1}, {"from": "##riaga k", "to": "##ez", "value": 1}, {"from": "##riaga k", "to": "##vita", "value": 1}, {"from": "##riaga k", "to": "contracts", "value": 1}, {"from": "##riaga k", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##riaga k", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##riaga k", "to": "). author information :", "value": 1}, {"from": "##riaga k", "to": "), urruticoechea a", "value": 1}, {"from": "), etxabe i", "to": "##6 / j. tranon. 2025.", "value": 1}, {"from": "), etxabe i", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "), etxabe i", "to": "13", "value": 1}, {"from": "), etxabe i", "to": "therapy", "value": 1}, {"from": "), etxabe i", "to": "##ui", "value": 1}, {"from": "), etxabe i", "to": "##ez", "value": 1}, {"from": "), etxabe i", "to": "##vita", "value": 1}, {"from": "), etxabe i", "to": "contracts", "value": 1}, {"from": "), etxabe i", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "), etxabe i", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "), etxabe i", "to": "). author information :", "value": 1}, {"from": "), etxabe i", "to": "), urruticoechea a", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "1 ) biogipuzkoa", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "13", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "therapy", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "##ui", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "##ez", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "##vita", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "contracts", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "). author information :", "value": 1}, {"from": "##6 / j. tranon. 2025.", "to": "), urruticoechea a", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "13", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "therapy", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "##ui", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "##ez", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "##vita", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "contracts", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "). author information :", "value": 1}, {"from": "1 ) biogipuzkoa", "to": "), urruticoechea a", "value": 1}, {"from": "13", "to": "therapy", "value": 1}, {"from": "13", "to": "##ui", "value": 1}, {"from": "13", "to": "##ez", "value": 1}, {"from": "13", "to": "##vita", "value": 1}, {"from": "13", "to": "contracts", "value": 1}, {"from": "13", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "13", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "13", "to": "). author information :", "value": 1}, {"from": "13", "to": "), urruticoechea a", "value": 1}, {"from": "13", "to": "after net", "value": 1}, {"from": "13", "to": "a significant", "value": 1}, {"from": "13", "to": "offers the opportunity of", "value": 1}, {"from": "13", "to": "##ip", "value": 1}, {"from": "13", "to": "t", "value": 1}, {"from": "13", "to": ") health", "value": 1}, {"from": "13", "to": "background", "value": 1}, {"from": "13", "to": "##re population of", "value": 1}, {"from": "13", "to": "negative breast", "value": 1}, {"from": "13", "to": "barrier", "value": 1}, {"from": "13", "to": "##gipuzkoa", "value": 1}, {"from": "13", "to": "clinical", "value": 1}, {"from": "13", "to": "##2 -", "value": 1}, {"from": "13", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "13", "to": "##zkoa", "value": 1}, {"from": "13", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "13", "to": "##gi", "value": 1}, {"from": "13", "to": "##donostia ) health", "value": 1}, {"from": "13", "to": "##tian,", "value": 1}, {"from": "13", "to": "cancer", "value": 1}, {"from": "13", "to": "spain", "value": 1}, {"from": "13", "to": "##uzkoa. eus.", "value": 1}, {"from": "13", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "13", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "13", "to": "personal", "value": 1}, {"from": "13", "to": "##ised therapy.", "value": 1}, {"from": "13", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "13", "to": "##donost", "value": 1}, {"from": "13", "to": "##cent", "value": 1}, {"from": "13", "to": "research institute", "value": 1}, {"from": "13", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "13", "to": "sa", "value": 1}, {"from": "13", "to": "sebas", "value": 1}, {"from": "13", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "13", "to": "her", "value": 1}, {"from": "13", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "13", "to": "##n sebastian,", "value": 1}, {"from": "13", "to": "##umour response", "value": 1}, {"from": "13", "to": "a,", "value": 1}, {"from": "13", "to": "##pu", "value": 1}, {"from": "13", "to": "##n", "value": 1}, {"from": "13", "to": "sebastian", "value": 1}, {"from": "13", "to": "##uc", "value": 1}, {"from": "13", "to": ", the lack of reprod", "value": 1}, {"from": "13", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "13", "to": "##c ) allows", "value": 1}, {"from": "13", "to": "##gnosis", "value": 1}, {"from": "13", "to": "- g", "value": 1}, {"from": "13", "to": ") department of", "value": 1}, {"from": "13", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "13", "to": "for cancer", "value": 1}, {"from": "13", "to": "##lia", "value": 1}, {"from": "13", "to": "##vanger,", "value": 1}, {"from": "13", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "13", "to": "##vanger university, s", "value": 1}, {"from": "13", "to": "8", "value": 1}, {"from": "13", "to": "of cancer genetics,", "value": 1}, {"from": "13", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "13", "to": "12 ) department", "value": 1}, {"from": "13", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "13", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "13", "to": "##vanger university hospital, s", "value": 1}, {"from": "13", "to": "ha", "value": 1}, {"from": "13", "to": "norway", "value": 1}, {"from": "13", "to": "institute", "value": 1}, {"from": "13", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "13", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "13", "to": "of pathology, s", "value": 1}, {"from": "13", "to": ";", "value": 1}, {"from": "13", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "13", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "13", "to": "##way", "value": 1}, {"from": "therapy", "to": "##ui", "value": 1}, {"from": "therapy", "to": "##ez", "value": 1}, {"from": "therapy", "to": "##vita", "value": 1}, {"from": "therapy", "to": "contracts", "value": 1}, {"from": "therapy", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "therapy", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "therapy", "to": "). author information :", "value": 1}, {"from": "therapy", "to": "), urruticoechea a", "value": 1}, {"from": "##ui", "to": "##ez", "value": 1}, {"from": "##ui", "to": "##vita", "value": 1}, {"from": "##ui", "to": "contracts", "value": 1}, {"from": "##ui", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##ui", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##ui", "to": "). author information :", "value": 1}, {"from": "##ui", "to": "), urruticoechea a", "value": 1}, {"from": "##ez", "to": "##vita", "value": 1}, {"from": "##ez", "to": "contracts", "value": 1}, {"from": "##ez", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##ez", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##ez", "to": "). author information :", "value": 1}, {"from": "##ez", "to": "), urruticoechea a", "value": 1}, {"from": "##vita", "to": "contracts", "value": 1}, {"from": "##vita", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "##vita", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##vita", "to": "). author information :", "value": 1}, {"from": "##vita", "to": "), urruticoechea a", "value": 1}, {"from": "contracts", "to": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "value": 1}, {"from": "contracts", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "contracts", "to": "). author information :", "value": 1}, {"from": "contracts", "to": "), urruticoechea a", "value": 1}, {"from": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "to": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "value": 1}, {"from": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "to": "). author information :", "value": 1}, {"from": "##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc", "to": "), urruticoechea a", "value": 1}, {"from": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "to": "). author information :", "value": 1}, {"from": "received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont", "to": "), urruticoechea a", "value": 1}, {"from": "). author information :", "to": "), urruticoechea a", "value": 1}, {"from": "##rio de v", "to": "t", "value": 1}, {"from": "##rio de v", "to": "##kolog", "value": 1}, {"from": "##rio de v", "to": ", san", "value": 1}, {"from": "##rio de v", "to": "##it", "value": 1}, {"from": "##rio de v", "to": ") health", "value": 1}, {"from": "##rio de v", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "##rio de v", "to": "##iba", "value": 1}, {"from": "##rio de v", "to": "##ialdea", "value": 1}, {"from": "##rio de v", "to": "##gipuzkoa", "value": 1}, {"from": "##rio de v", "to": "##ko", "value": 1}, {"from": "##rio de v", "to": "##obe", "value": 1}, {"from": "##rio de v", "to": "se", "value": 1}, {"from": "##rio de v", "to": "##gi", "value": 1}, {"from": "##rio de v", "to": "##tian,", "value": 1}, {"from": "##rio de v", "to": ") hospital clinico univers", "value": 1}, {"from": "##rio de v", "to": "##r 12, madrid,", "value": 1}, {"from": "##rio de v", "to": "spain", "value": 1}, {"from": "##rio de v", "to": "##ale", "value": 1}, {"from": "##rio de v", "to": "##a", "value": 1}, {"from": "##rio de v", "to": "##ute", "value": 1}, {"from": "##rio de v", "to": "##ikoa,", "value": 1}, {"from": "##rio de v", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##rio de v", "to": "##donost", "value": 1}, {"from": "##rio de v", "to": ") hospital oct", "value": 1}, {"from": "##rio de v", "to": "research institute", "value": 1}, {"from": "##rio de v", "to": "institute", "value": 1}, {"from": "##rio de v", "to": "sa", "value": 1}, {"from": "##rio de v", "to": "sebas", "value": 1}, {"from": "##rio de v", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##rio de v", "to": "##ita", "value": 1}, {"from": "##rio de v", "to": ", v", "value": 1}, {"from": "##rio de v", "to": "##ps, barcelon", "value": 1}, {"from": "##rio de v", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##rio de v", "to": "##n", "value": 1}, {"from": "##rio de v", "to": "##pu", "value": 1}, {"from": "##rio de v", "to": "sebastian", "value": 1}, {"from": "##rio de v", "to": "; gip", "value": 1}, {"from": "##rio de v", "to": "- on", "value": 1}, {"from": "##rio de v", "to": "7 ) valencia oncology", "value": 1}, {"from": "##rio de v", "to": "##ncia,", "value": 1}, {"from": "##rio de v", "to": "##uz", "value": 1}, {"from": "##rio de v", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##rio de v", "to": "- onkologikoa, san", "value": 1}, {"from": "##rio de v", "to": "##z", "value": 1}, {"from": "##rio de v", "to": "##bastian, spa", "value": 1}, {"from": "t", "to": "##kolog", "value": 1}, {"from": "t", "to": ", san", "value": 1}, {"from": "t", "to": "##it", "value": 1}, {"from": "t", "to": ") health", "value": 2}, {"from": "t", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "t", "to": "##iba", "value": 1}, {"from": "t", "to": "##ialdea", "value": 1}, {"from": "t", "to": "##gipuzkoa", "value": 2}, {"from": "t", "to": "##ko", "value": 1}, {"from": "t", "to": "##obe", "value": 1}, {"from": "t", "to": "se", "value": 1}, {"from": "t", "to": "##gi", "value": 2}, {"from": "t", "to": "##tian,", "value": 2}, {"from": "t", "to": ") hospital clinico univers", "value": 1}, {"from": "t", "to": "##r 12, madrid,", "value": 1}, {"from": "t", "to": "spain", "value": 2}, {"from": "t", "to": "##ale", "value": 1}, {"from": "t", "to": "##a", "value": 1}, {"from": "t", "to": "##ute", "value": 1}, {"from": "t", "to": "##ikoa,", "value": 1}, {"from": "t", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "t", "to": "##donost", "value": 2}, {"from": "t", "to": ") hospital oct", "value": 1}, {"from": "t", "to": "research institute", "value": 2}, {"from": "t", "to": "institute", "value": 2}, {"from": "t", "to": "sa", "value": 2}, {"from": "t", "to": "sebas", "value": 2}, {"from": "t", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "t", "to": "##ita", "value": 1}, {"from": "t", "to": ", v", "value": 1}, {"from": "t", "to": "##ps, barcelon", "value": 1}, {"from": "t", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "t", "to": "##n", "value": 2}, {"from": "t", "to": "##pu", "value": 2}, {"from": "t", "to": "sebastian", "value": 2}, {"from": "t", "to": "; gip", "value": 1}, {"from": "t", "to": "- on", "value": 1}, {"from": "t", "to": "7 ) valencia oncology", "value": 1}, {"from": "t", "to": "##ncia,", "value": 1}, {"from": "t", "to": "##uz", "value": 1}, {"from": "t", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "t", "to": "- onkologikoa, san", "value": 1}, {"from": "t", "to": "##z", "value": 1}, {"from": "t", "to": "##bastian, spa", "value": 1}, {"from": "t", "to": "after net", "value": 1}, {"from": "t", "to": "a significant", "value": 1}, {"from": "t", "to": "offers the opportunity of", "value": 1}, {"from": "t", "to": "##ip", "value": 1}, {"from": "t", "to": "background", "value": 1}, {"from": "t", "to": "##re population of", "value": 1}, {"from": "t", "to": "negative breast", "value": 1}, {"from": "t", "to": "barrier", "value": 1}, {"from": "t", "to": "clinical", "value": 1}, {"from": "t", "to": "##2 -", "value": 2}, {"from": "t", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "t", "to": "##zkoa", "value": 1}, {"from": "t", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "t", "to": "##donostia ) health", "value": 1}, {"from": "t", "to": "cancer", "value": 1}, {"from": "t", "to": "##uzkoa. eus.", "value": 1}, {"from": "t", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "t", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "t", "to": "personal", "value": 1}, {"from": "t", "to": "##ised therapy.", "value": 1}, {"from": "t", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "t", "to": "##cent", "value": 1}, {"from": "t", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "t", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "t", "to": "her", "value": 2}, {"from": "t", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "t", "to": "##n sebastian,", "value": 1}, {"from": "t", "to": "##umour response", "value": 1}, {"from": "t", "to": "a,", "value": 1}, {"from": "t", "to": "##uc", "value": 1}, {"from": "t", "to": ", the lack of reprod", "value": 1}, {"from": "t", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "t", "to": "##c ) allows", "value": 1}, {"from": "t", "to": "##gnosis", "value": 1}, {"from": "t", "to": "- g", "value": 1}, {"from": "t", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "t", "to": "in ki", "value": 1}, {"from": "t", "to": "##cu", "value": 1}, {"from": "t", "to": "positive", "value": 1}, {"from": "t", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "t", "to": "##rrence", "value": 1}, {"from": "t", "to": "percentage", "value": 1}, {"from": "t", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "t", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "t", "to": "from l", "value": 1}, {"from": "t", "to": "presented", "value": 1}, {"from": "t", "to": "results", "value": 1}, {"from": "t", "to": "pam50 - derived risk of", "value": 1}, {"from": "t", "to": "er + /", "value": 1}, {"from": "t", "to": "##nal a to normal - like", "value": 1}, {"from": "t", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "t", "to": "cells", "value": 1}, {"from": "t", "to": "change", "value": 1}, {"from": "t", "to": "after", "value": 1}, {"from": "t", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "t", "to": "of intrinsic sub", "value": 1}, {"from": "t", "to": "p53", "value": 1}, {"from": "t", "to": "##is.", "value": 1}, {"from": "t", "to": "biomark", "value": 1}, {"from": "t", "to": "subtype after", "value": 1}, {"from": "t", "to": "net", "value": 1}, {"from": "t", "to": "of", "value": 1}, {"from": "t", "to": "##c patients", "value": 1}, {"from": "t", "to": "net as a putative", "value": 1}, {"from": "t", "to": "##umour cellularity size", "value": 1}, {"from": "t", "to": "radio", "value": 1}, {"from": "t", "to": ") and lower", "value": 1}, {"from": "t", "to": "better", "value": 1}, {"from": "t", "to": "of prosigna for adjuvant treatment decisions", "value": 1}, {"from": "t", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "t", "to": "##6 /", "value": 1}, {"from": "t", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "t", "to": "be validated in independent cohorts,", "value": 1}, {"from": "t", "to": "cost - effectiveness", "value": 1}, {"from": "t", "to": "##ers of response to net and pro", "value": 1}, {"from": "t", "to": "10. 101", "value": 1}, {"from": "t", "to": "help", "value": 1}, {"from": "t", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "t", "to": "##sis, which", "value": 1}, {"from": "t", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "t", "to": "##lin", "value": 1}, {"from": "t", "to": "should", "value": 1}, {"from": "t", "to": "202", "value": 1}, {"from": "t", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "t", "to": "helping to the", "value": 1}, {"from": "t", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "t", "to": "implementation of net", "value": 1}, {"from": "t", "to": "##mark", "value": 1}, {"from": "t", "to": "##ranon.", "value": 1}, {"from": "t", "to": ". clbc. 202", "value": 1}, {"from": "t", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "t", "to": "##5.", "value": 1}, {"from": "t", "to": "##rgen, norway.", "value": 1}, {"from": "t", "to": "##rgen, nor", "value": 1}, {"from": "t", "to": "economics", "value": 1}, {"from": "t", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "t", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "t", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "t", "to": "clinical trials", "value": 1}, {"from": "t", "to": "of health management and health", "value": 1}, {"from": "t", "to": ";", "value": 1}, {"from": "t", "to": ") department of p", "value": 1}, {"from": "t", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "t", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "t", "to": "), heie a", "value": 1}, {"from": "t", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "t", "to": "be", "value": 1}, {"from": "t", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "t", "to": "ug", "value": 1}, {"from": "t", "to": "##way", "value": 1}, {"from": "##kolog", "to": ", san", "value": 1}, {"from": "##kolog", "to": "##it", "value": 1}, {"from": "##kolog", "to": ") health", "value": 1}, {"from": "##kolog", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "##kolog", "to": "##iba", "value": 1}, {"from": "##kolog", "to": "##ialdea", "value": 1}, {"from": "##kolog", "to": "##gipuzkoa", "value": 1}, {"from": "##kolog", "to": "##ko", "value": 1}, {"from": "##kolog", "to": "##obe", "value": 1}, {"from": "##kolog", "to": "se", "value": 1}, {"from": "##kolog", "to": "##gi", "value": 1}, {"from": "##kolog", "to": "##tian,", "value": 1}, {"from": "##kolog", "to": ") hospital clinico univers", "value": 1}, {"from": "##kolog", "to": "##r 12, madrid,", "value": 1}, {"from": "##kolog", "to": "spain", "value": 1}, {"from": "##kolog", "to": "##ale", "value": 1}, {"from": "##kolog", "to": "##a", "value": 1}, {"from": "##kolog", "to": "##ute", "value": 1}, {"from": "##kolog", "to": "##ikoa,", "value": 1}, {"from": "##kolog", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##kolog", "to": "##donost", "value": 1}, {"from": "##kolog", "to": ") hospital oct", "value": 1}, {"from": "##kolog", "to": "research institute", "value": 1}, {"from": "##kolog", "to": "institute", "value": 1}, {"from": "##kolog", "to": "sa", "value": 1}, {"from": "##kolog", "to": "sebas", "value": 1}, {"from": "##kolog", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##kolog", "to": "##ita", "value": 1}, {"from": "##kolog", "to": ", v", "value": 1}, {"from": "##kolog", "to": "##ps, barcelon", "value": 1}, {"from": "##kolog", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##kolog", "to": "##n", "value": 1}, {"from": "##kolog", "to": "##pu", "value": 1}, {"from": "##kolog", "to": "sebastian", "value": 1}, {"from": "##kolog", "to": "; gip", "value": 1}, {"from": "##kolog", "to": "- on", "value": 1}, {"from": "##kolog", "to": "7 ) valencia oncology", "value": 1}, {"from": "##kolog", "to": "##ncia,", "value": 1}, {"from": "##kolog", "to": "##uz", "value": 1}, {"from": "##kolog", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##kolog", "to": "- onkologikoa, san", "value": 1}, {"from": "##kolog", "to": "##z", "value": 1}, {"from": "##kolog", "to": "##bastian, spa", "value": 1}, {"from": ", san", "to": "##it", "value": 1}, {"from": ", san", "to": ") health", "value": 1}, {"from": ", san", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": ", san", "to": "##iba", "value": 1}, {"from": ", san", "to": "##ialdea", "value": 1}, {"from": ", san", "to": "##gipuzkoa", "value": 1}, {"from": ", san", "to": "##ko", "value": 1}, {"from": ", san", "to": "##obe", "value": 1}, {"from": ", san", "to": "se", "value": 1}, {"from": ", san", "to": "##gi", "value": 1}, {"from": ", san", "to": "##tian,", "value": 1}, {"from": ", san", "to": ") hospital clinico univers", "value": 1}, {"from": ", san", "to": "##r 12, madrid,", "value": 1}, {"from": ", san", "to": "spain", "value": 1}, {"from": ", san", "to": "##ale", "value": 1}, {"from": ", san", "to": "##a", "value": 1}, {"from": ", san", "to": "##ute", "value": 1}, {"from": ", san", "to": "##ikoa,", "value": 1}, {"from": ", san", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ", san", "to": "##donost", "value": 1}, {"from": ", san", "to": ") hospital oct", "value": 1}, {"from": ", san", "to": "research institute", "value": 1}, {"from": ", san", "to": "institute", "value": 1}, {"from": ", san", "to": "sa", "value": 1}, {"from": ", san", "to": "sebas", "value": 1}, {"from": ", san", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ", san", "to": "##ita", "value": 1}, {"from": ", san", "to": ", v", "value": 1}, {"from": ", san", "to": "##ps, barcelon", "value": 1}, {"from": ", san", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ", san", "to": "##n", "value": 1}, {"from": ", san", "to": "##pu", "value": 1}, {"from": ", san", "to": "sebastian", "value": 1}, {"from": ", san", "to": "; gip", "value": 1}, {"from": ", san", "to": "- on", "value": 1}, {"from": ", san", "to": "7 ) valencia oncology", "value": 1}, {"from": ", san", "to": "##ncia,", "value": 1}, {"from": ", san", "to": "##uz", "value": 1}, {"from": ", san", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ", san", "to": "- onkologikoa, san", "value": 1}, {"from": ", san", "to": "##z", "value": 1}, {"from": ", san", "to": "##bastian, spa", "value": 1}, {"from": "##it", "to": ") health", "value": 1}, {"from": "##it", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": "##it", "to": "##iba", "value": 1}, {"from": "##it", "to": "##ialdea", "value": 1}, {"from": "##it", "to": "##gipuzkoa", "value": 1}, {"from": "##it", "to": "##ko", "value": 1}, {"from": "##it", "to": "##obe", "value": 1}, {"from": "##it", "to": "se", "value": 1}, {"from": "##it", "to": "##gi", "value": 1}, {"from": "##it", "to": "##tian,", "value": 1}, {"from": "##it", "to": ") hospital clinico univers", "value": 1}, {"from": "##it", "to": "##r 12, madrid,", "value": 1}, {"from": "##it", "to": "spain", "value": 1}, {"from": "##it", "to": "##ale", "value": 1}, {"from": "##it", "to": "##a", "value": 1}, {"from": "##it", "to": "##ute", "value": 1}, {"from": "##it", "to": "##ikoa,", "value": 1}, {"from": "##it", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##it", "to": "##donost", "value": 1}, {"from": "##it", "to": ") hospital oct", "value": 1}, {"from": "##it", "to": "research institute", "value": 1}, {"from": "##it", "to": "institute", "value": 1}, {"from": "##it", "to": "sa", "value": 1}, {"from": "##it", "to": "sebas", "value": 1}, {"from": "##it", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##it", "to": "##ita", "value": 1}, {"from": "##it", "to": ", v", "value": 1}, {"from": "##it", "to": "##ps, barcelon", "value": 1}, {"from": "##it", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##it", "to": "##n", "value": 1}, {"from": "##it", "to": "##pu", "value": 1}, {"from": "##it", "to": "sebastian", "value": 1}, {"from": "##it", "to": "; gip", "value": 1}, {"from": "##it", "to": "- on", "value": 1}, {"from": "##it", "to": "7 ) valencia oncology", "value": 1}, {"from": "##it", "to": "##ncia,", "value": 1}, {"from": "##it", "to": "##uz", "value": 1}, {"from": "##it", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##it", "to": "- onkologikoa, san", "value": 1}, {"from": "##it", "to": "##z", "value": 1}, {"from": "##it", "to": "##bastian, spa", "value": 1}, {"from": ") health", "to": ") gynecology and general surgery departments - breast unit, on", "value": 1}, {"from": ") health", "to": "##iba", "value": 1}, {"from": ") health", "to": "##ialdea", "value": 1}, {"from": ") health", "to": "##gipuzkoa", "value": 2}, {"from": ") health", "to": "##ko", "value": 1}, {"from": ") health", "to": "##obe", "value": 1}, {"from": ") health", "to": "se", "value": 1}, {"from": ") health", "to": "##gi", "value": 2}, {"from": ") health", "to": "##tian,", "value": 2}, {"from": ") health", "to": ") hospital clinico univers", "value": 1}, {"from": ") health", "to": "##r 12, madrid,", "value": 1}, {"from": ") health", "to": "spain", "value": 2}, {"from": ") health", "to": "##ale", "value": 1}, {"from": ") health", "to": "##a", "value": 1}, {"from": ") health", "to": "##ute", "value": 1}, {"from": ") health", "to": "##ikoa,", "value": 1}, {"from": ") health", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ") health", "to": "##donost", "value": 2}, {"from": ") health", "to": ") hospital oct", "value": 1}, {"from": ") health", "to": "research institute", "value": 2}, {"from": ") health", "to": "institute", "value": 1}, {"from": ") health", "to": "sa", "value": 2}, {"from": ") health", "to": "sebas", "value": 2}, {"from": ") health", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ") health", "to": "##ita", "value": 1}, {"from": ") health", "to": ", v", "value": 1}, {"from": ") health", "to": "##ps, barcelon", "value": 1}, {"from": ") health", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ") health", "to": "##n", "value": 2}, {"from": ") health", "to": "##pu", "value": 2}, {"from": ") health", "to": "sebastian", "value": 2}, {"from": ") health", "to": "; gip", "value": 1}, {"from": ") health", "to": "- on", "value": 1}, {"from": ") health", "to": "7 ) valencia oncology", "value": 1}, {"from": ") health", "to": "##ncia,", "value": 1}, {"from": ") health", "to": "##uz", "value": 1}, {"from": ") health", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ") health", "to": "- onkologikoa, san", "value": 1}, {"from": ") health", "to": "##z", "value": 1}, {"from": ") health", "to": "##bastian, spa", "value": 1}, {"from": ") health", "to": "after net", "value": 1}, {"from": ") health", "to": "a significant", "value": 1}, {"from": ") health", "to": "offers the opportunity of", "value": 1}, {"from": ") health", "to": "##ip", "value": 1}, {"from": ") health", "to": "background", "value": 1}, {"from": ") health", "to": "##re population of", "value": 1}, {"from": ") health", "to": "negative breast", "value": 1}, {"from": ") health", "to": "barrier", "value": 1}, {"from": ") health", "to": "clinical", "value": 1}, {"from": ") health", "to": "##2 -", "value": 1}, {"from": ") health", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": ") health", "to": "##zkoa", "value": 1}, {"from": ") health", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": ") health", "to": "##donostia ) health", "value": 1}, {"from": ") health", "to": "cancer", "value": 1}, {"from": ") health", "to": "##uzkoa. eus.", "value": 1}, {"from": ") health", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": ") health", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": ") health", "to": "personal", "value": 1}, {"from": ") health", "to": "##ised therapy.", "value": 1}, {"from": ") health", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ") health", "to": "##cent", "value": 1}, {"from": ") health", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ") health", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ") health", "to": "her", "value": 1}, {"from": ") health", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ") health", "to": "##n sebastian,", "value": 1}, {"from": ") health", "to": "##umour response", "value": 1}, {"from": ") health", "to": "a,", "value": 1}, {"from": ") health", "to": "##uc", "value": 1}, {"from": ") health", "to": ", the lack of reprod", "value": 1}, {"from": ") health", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ") health", "to": "##c ) allows", "value": 1}, {"from": ") health", "to": "##gnosis", "value": 1}, {"from": ") health", "to": "- g", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##iba", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ialdea", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##gipuzkoa", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ko", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##obe", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "se", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##gi", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##tian,", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": ") hospital clinico univers", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##r 12, madrid,", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "spain", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ale", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##a", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ute", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ikoa,", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##donost", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": ") hospital oct", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "research institute", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "institute", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "sa", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "sebas", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ita", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": ", v", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ps, barcelon", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##n", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##pu", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "sebastian", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "; gip", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "- on", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "7 ) valencia oncology", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##ncia,", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##uz", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "- onkologikoa, san", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##z", "value": 1}, {"from": ") gynecology and general surgery departments - breast unit, on", "to": "##bastian, spa", "value": 1}, {"from": "##iba", "to": "##ialdea", "value": 1}, {"from": "##iba", "to": "##gipuzkoa", "value": 1}, {"from": "##iba", "to": "##ko", "value": 1}, {"from": "##iba", "to": "##obe", "value": 1}, {"from": "##iba", "to": "se", "value": 1}, {"from": "##iba", "to": "##gi", "value": 1}, {"from": "##iba", "to": "##tian,", "value": 1}, {"from": "##iba", "to": ") hospital clinico univers", "value": 1}, {"from": "##iba", "to": "##r 12, madrid,", "value": 1}, {"from": "##iba", "to": "spain", "value": 1}, {"from": "##iba", "to": "##ale", "value": 1}, {"from": "##iba", "to": "##a", "value": 1}, {"from": "##iba", "to": "##ute", "value": 1}, {"from": "##iba", "to": "##ikoa,", "value": 1}, {"from": "##iba", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##iba", "to": "##donost", "value": 1}, {"from": "##iba", "to": ") hospital oct", "value": 1}, {"from": "##iba", "to": "research institute", "value": 1}, {"from": "##iba", "to": "institute", "value": 1}, {"from": "##iba", "to": "sa", "value": 1}, {"from": "##iba", "to": "sebas", "value": 1}, {"from": "##iba", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##iba", "to": "##ita", "value": 1}, {"from": "##iba", "to": ", v", "value": 1}, {"from": "##iba", "to": "##ps, barcelon", "value": 1}, {"from": "##iba", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##iba", "to": "##n", "value": 1}, {"from": "##iba", "to": "##pu", "value": 1}, {"from": "##iba", "to": "sebastian", "value": 1}, {"from": "##iba", "to": "; gip", "value": 1}, {"from": "##iba", "to": "- on", "value": 1}, {"from": "##iba", "to": "7 ) valencia oncology", "value": 1}, {"from": "##iba", "to": "##ncia,", "value": 1}, {"from": "##iba", "to": "##uz", "value": 1}, {"from": "##iba", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##iba", "to": "- onkologikoa, san", "value": 1}, {"from": "##iba", "to": "##z", "value": 1}, {"from": "##iba", "to": "##bastian, spa", "value": 1}, {"from": "##ialdea", "to": "##gipuzkoa", "value": 1}, {"from": "##ialdea", "to": "##ko", "value": 1}, {"from": "##ialdea", "to": "##obe", "value": 1}, {"from": "##ialdea", "to": "se", "value": 1}, {"from": "##ialdea", "to": "##gi", "value": 1}, {"from": "##ialdea", "to": "##tian,", "value": 1}, {"from": "##ialdea", "to": ") hospital clinico univers", "value": 1}, {"from": "##ialdea", "to": "##r 12, madrid,", "value": 1}, {"from": "##ialdea", "to": "spain", "value": 1}, {"from": "##ialdea", "to": "##ale", "value": 1}, {"from": "##ialdea", "to": "##a", "value": 1}, {"from": "##ialdea", "to": "##ute", "value": 1}, {"from": "##ialdea", "to": "##ikoa,", "value": 1}, {"from": "##ialdea", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ialdea", "to": "##donost", "value": 1}, {"from": "##ialdea", "to": ") hospital oct", "value": 1}, {"from": "##ialdea", "to": "research institute", "value": 1}, {"from": "##ialdea", "to": "institute", "value": 1}, {"from": "##ialdea", "to": "sa", "value": 1}, {"from": "##ialdea", "to": "sebas", "value": 1}, {"from": "##ialdea", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ialdea", "to": "##ita", "value": 1}, {"from": "##ialdea", "to": ", v", "value": 1}, {"from": "##ialdea", "to": "##ps, barcelon", "value": 1}, {"from": "##ialdea", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ialdea", "to": "##n", "value": 1}, {"from": "##ialdea", "to": "##pu", "value": 1}, {"from": "##ialdea", "to": "sebastian", "value": 1}, {"from": "##ialdea", "to": "; gip", "value": 1}, {"from": "##ialdea", "to": "- on", "value": 1}, {"from": "##ialdea", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ialdea", "to": "##ncia,", "value": 1}, {"from": "##ialdea", "to": "##uz", "value": 1}, {"from": "##ialdea", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ialdea", "to": "- onkologikoa, san", "value": 1}, {"from": "##ialdea", "to": "##z", "value": 1}, {"from": "##ialdea", "to": "##bastian, spa", "value": 1}, {"from": "##gipuzkoa", "to": "##ko", "value": 1}, {"from": "##gipuzkoa", "to": "##obe", "value": 1}, {"from": "##gipuzkoa", "to": "se", "value": 1}, {"from": "##gipuzkoa", "to": "##gi", "value": 2}, {"from": "##gipuzkoa", "to": "##tian,", "value": 2}, {"from": "##gipuzkoa", "to": ") hospital clinico univers", "value": 1}, {"from": "##gipuzkoa", "to": "##r 12, madrid,", "value": 1}, {"from": "##gipuzkoa", "to": "spain", "value": 2}, {"from": "##gipuzkoa", "to": "##ale", "value": 1}, {"from": "##gipuzkoa", "to": "##a", "value": 1}, {"from": "##gipuzkoa", "to": "##ute", "value": 1}, {"from": "##gipuzkoa", "to": "##ikoa,", "value": 1}, {"from": "##gipuzkoa", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##gipuzkoa", "to": "##donost", "value": 2}, {"from": "##gipuzkoa", "to": ") hospital oct", "value": 1}, {"from": "##gipuzkoa", "to": "research institute", "value": 2}, {"from": "##gipuzkoa", "to": "institute", "value": 1}, {"from": "##gipuzkoa", "to": "sa", "value": 2}, {"from": "##gipuzkoa", "to": "sebas", "value": 2}, {"from": "##gipuzkoa", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##gipuzkoa", "to": "##ita", "value": 1}, {"from": "##gipuzkoa", "to": ", v", "value": 1}, {"from": "##gipuzkoa", "to": "##ps, barcelon", "value": 1}, {"from": "##gipuzkoa", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##gipuzkoa", "to": "##n", "value": 2}, {"from": "##gipuzkoa", "to": "##pu", "value": 2}, {"from": "##gipuzkoa", "to": "sebastian", "value": 2}, {"from": "##gipuzkoa", "to": "; gip", "value": 1}, {"from": "##gipuzkoa", "to": "- on", "value": 1}, {"from": "##gipuzkoa", "to": "7 ) valencia oncology", "value": 1}, {"from": "##gipuzkoa", "to": "##ncia,", "value": 1}, {"from": "##gipuzkoa", "to": "##uz", "value": 1}, {"from": "##gipuzkoa", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##gipuzkoa", "to": "- onkologikoa, san", "value": 1}, {"from": "##gipuzkoa", "to": "##z", "value": 1}, {"from": "##gipuzkoa", "to": "##bastian, spa", "value": 1}, {"from": "##gipuzkoa", "to": "after net", "value": 1}, {"from": "##gipuzkoa", "to": "a significant", "value": 1}, {"from": "##gipuzkoa", "to": "offers the opportunity of", "value": 1}, {"from": "##gipuzkoa", "to": "##ip", "value": 1}, {"from": "##gipuzkoa", "to": "background", "value": 1}, {"from": "##gipuzkoa", "to": "##re population of", "value": 1}, {"from": "##gipuzkoa", "to": "negative breast", "value": 1}, {"from": "##gipuzkoa", "to": "barrier", "value": 1}, {"from": "##gipuzkoa", "to": "clinical", "value": 1}, {"from": "##gipuzkoa", "to": "##2 -", "value": 1}, {"from": "##gipuzkoa", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##gipuzkoa", "to": "##zkoa", "value": 1}, {"from": "##gipuzkoa", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##gipuzkoa", "to": "##donostia ) health", "value": 1}, {"from": "##gipuzkoa", "to": "cancer", "value": 1}, {"from": "##gipuzkoa", "to": "##uzkoa. eus.", "value": 1}, {"from": "##gipuzkoa", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##gipuzkoa", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##gipuzkoa", "to": "personal", "value": 1}, {"from": "##gipuzkoa", "to": "##ised therapy.", "value": 1}, {"from": "##gipuzkoa", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##gipuzkoa", "to": "##cent", "value": 1}, {"from": "##gipuzkoa", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##gipuzkoa", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##gipuzkoa", "to": "her", "value": 1}, {"from": "##gipuzkoa", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##gipuzkoa", "to": "##n sebastian,", "value": 1}, {"from": "##gipuzkoa", "to": "##umour response", "value": 1}, {"from": "##gipuzkoa", "to": "a,", "value": 1}, {"from": "##gipuzkoa", "to": "##uc", "value": 1}, {"from": "##gipuzkoa", "to": ", the lack of reprod", "value": 1}, {"from": "##gipuzkoa", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##gipuzkoa", "to": "##c ) allows", "value": 1}, {"from": "##gipuzkoa", "to": "##gnosis", "value": 1}, {"from": "##gipuzkoa", "to": "- g", "value": 1}, {"from": "##ko", "to": "##obe", "value": 1}, {"from": "##ko", "to": "se", "value": 1}, {"from": "##ko", "to": "##gi", "value": 1}, {"from": "##ko", "to": "##tian,", "value": 1}, {"from": "##ko", "to": ") hospital clinico univers", "value": 1}, {"from": "##ko", "to": "##r 12, madrid,", "value": 1}, {"from": "##ko", "to": "spain", "value": 1}, {"from": "##ko", "to": "##ale", "value": 1}, {"from": "##ko", "to": "##a", "value": 1}, {"from": "##ko", "to": "##ute", "value": 1}, {"from": "##ko", "to": "##ikoa,", "value": 1}, {"from": "##ko", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ko", "to": "##donost", "value": 1}, {"from": "##ko", "to": ") hospital oct", "value": 1}, {"from": "##ko", "to": "research institute", "value": 1}, {"from": "##ko", "to": "institute", "value": 1}, {"from": "##ko", "to": "sa", "value": 1}, {"from": "##ko", "to": "sebas", "value": 1}, {"from": "##ko", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ko", "to": "##ita", "value": 1}, {"from": "##ko", "to": ", v", "value": 1}, {"from": "##ko", "to": "##ps, barcelon", "value": 1}, {"from": "##ko", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ko", "to": "##n", "value": 1}, {"from": "##ko", "to": "##pu", "value": 1}, {"from": "##ko", "to": "sebastian", "value": 1}, {"from": "##ko", "to": "; gip", "value": 1}, {"from": "##ko", "to": "- on", "value": 1}, {"from": "##ko", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ko", "to": "##ncia,", "value": 1}, {"from": "##ko", "to": "##uz", "value": 1}, {"from": "##ko", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ko", "to": "- onkologikoa, san", "value": 1}, {"from": "##ko", "to": "##z", "value": 1}, {"from": "##ko", "to": "##bastian, spa", "value": 1}, {"from": "##obe", "to": "se", "value": 1}, {"from": "##obe", "to": "##gi", "value": 1}, {"from": "##obe", "to": "##tian,", "value": 1}, {"from": "##obe", "to": ") hospital clinico univers", "value": 1}, {"from": "##obe", "to": "##r 12, madrid,", "value": 1}, {"from": "##obe", "to": "spain", "value": 1}, {"from": "##obe", "to": "##ale", "value": 1}, {"from": "##obe", "to": "##a", "value": 1}, {"from": "##obe", "to": "##ute", "value": 1}, {"from": "##obe", "to": "##ikoa,", "value": 1}, {"from": "##obe", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##obe", "to": "##donost", "value": 1}, {"from": "##obe", "to": ") hospital oct", "value": 1}, {"from": "##obe", "to": "research institute", "value": 1}, {"from": "##obe", "to": "institute", "value": 1}, {"from": "##obe", "to": "sa", "value": 1}, {"from": "##obe", "to": "sebas", "value": 1}, {"from": "##obe", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##obe", "to": "##ita", "value": 1}, {"from": "##obe", "to": ", v", "value": 1}, {"from": "##obe", "to": "##ps, barcelon", "value": 1}, {"from": "##obe", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##obe", "to": "##n", "value": 1}, {"from": "##obe", "to": "##pu", "value": 1}, {"from": "##obe", "to": "sebastian", "value": 1}, {"from": "##obe", "to": "; gip", "value": 1}, {"from": "##obe", "to": "- on", "value": 1}, {"from": "##obe", "to": "7 ) valencia oncology", "value": 1}, {"from": "##obe", "to": "##ncia,", "value": 1}, {"from": "##obe", "to": "##uz", "value": 1}, {"from": "##obe", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##obe", "to": "- onkologikoa, san", "value": 1}, {"from": "##obe", "to": "##z", "value": 1}, {"from": "##obe", "to": "##bastian, spa", "value": 1}, {"from": "se", "to": "##gi", "value": 1}, {"from": "se", "to": "##tian,", "value": 1}, {"from": "se", "to": ") hospital clinico univers", "value": 1}, {"from": "se", "to": "##r 12, madrid,", "value": 1}, {"from": "se", "to": "spain", "value": 1}, {"from": "se", "to": "##ale", "value": 1}, {"from": "se", "to": "##a", "value": 1}, {"from": "se", "to": "##ute", "value": 1}, {"from": "se", "to": "##ikoa,", "value": 1}, {"from": "se", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "se", "to": "##donost", "value": 1}, {"from": "se", "to": ") hospital oct", "value": 1}, {"from": "se", "to": "research institute", "value": 1}, {"from": "se", "to": "institute", "value": 1}, {"from": "se", "to": "sa", "value": 1}, {"from": "se", "to": "sebas", "value": 1}, {"from": "se", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "se", "to": "##ita", "value": 1}, {"from": "se", "to": ", v", "value": 1}, {"from": "se", "to": "##ps, barcelon", "value": 1}, {"from": "se", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "se", "to": "##n", "value": 1}, {"from": "se", "to": "##pu", "value": 1}, {"from": "se", "to": "sebastian", "value": 1}, {"from": "se", "to": "; gip", "value": 1}, {"from": "se", "to": "- on", "value": 1}, {"from": "se", "to": "7 ) valencia oncology", "value": 1}, {"from": "se", "to": "##ncia,", "value": 1}, {"from": "se", "to": "##uz", "value": 1}, {"from": "se", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "se", "to": "- onkologikoa, san", "value": 1}, {"from": "se", "to": "##z", "value": 1}, {"from": "se", "to": "##bastian, spa", "value": 1}, {"from": "##gi", "to": "##tian,", "value": 2}, {"from": "##gi", "to": ") hospital clinico univers", "value": 1}, {"from": "##gi", "to": "##r 12, madrid,", "value": 1}, {"from": "##gi", "to": "spain", "value": 2}, {"from": "##gi", "to": "##ale", "value": 1}, {"from": "##gi", "to": "##a", "value": 1}, {"from": "##gi", "to": "##ute", "value": 1}, {"from": "##gi", "to": "##ikoa,", "value": 1}, {"from": "##gi", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##gi", "to": "##donost", "value": 2}, {"from": "##gi", "to": ") hospital oct", "value": 1}, {"from": "##gi", "to": "research institute", "value": 2}, {"from": "##gi", "to": "institute", "value": 1}, {"from": "##gi", "to": "sa", "value": 2}, {"from": "##gi", "to": "sebas", "value": 2}, {"from": "##gi", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##gi", "to": "##ita", "value": 1}, {"from": "##gi", "to": ", v", "value": 1}, {"from": "##gi", "to": "##ps, barcelon", "value": 1}, {"from": "##gi", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##gi", "to": "##n", "value": 2}, {"from": "##gi", "to": "##pu", "value": 2}, {"from": "##gi", "to": "sebastian", "value": 2}, {"from": "##gi", "to": "; gip", "value": 1}, {"from": "##gi", "to": "- on", "value": 1}, {"from": "##gi", "to": "7 ) valencia oncology", "value": 1}, {"from": "##gi", "to": "##ncia,", "value": 1}, {"from": "##gi", "to": "##uz", "value": 1}, {"from": "##gi", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##gi", "to": "- onkologikoa, san", "value": 1}, {"from": "##gi", "to": "##z", "value": 1}, {"from": "##gi", "to": "##bastian, spa", "value": 1}, {"from": "##gi", "to": "after net", "value": 1}, {"from": "##gi", "to": "a significant", "value": 1}, {"from": "##gi", "to": "offers the opportunity of", "value": 1}, {"from": "##gi", "to": "##ip", "value": 1}, {"from": "##gi", "to": "background", "value": 1}, {"from": "##gi", "to": "##re population of", "value": 1}, {"from": "##gi", "to": "negative breast", "value": 1}, {"from": "##gi", "to": "barrier", "value": 1}, {"from": "##gi", "to": "clinical", "value": 1}, {"from": "##gi", "to": "##2 -", "value": 1}, {"from": "##gi", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##gi", "to": "##zkoa", "value": 1}, {"from": "##gi", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##gi", "to": "##donostia ) health", "value": 1}, {"from": "##gi", "to": "cancer", "value": 1}, {"from": "##gi", "to": "##uzkoa. eus.", "value": 1}, {"from": "##gi", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##gi", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##gi", "to": "personal", "value": 1}, {"from": "##gi", "to": "##ised therapy.", "value": 1}, {"from": "##gi", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##gi", "to": "##cent", "value": 1}, {"from": "##gi", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##gi", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##gi", "to": "her", "value": 1}, {"from": "##gi", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##gi", "to": "##n sebastian,", "value": 1}, {"from": "##gi", "to": "##umour response", "value": 1}, {"from": "##gi", "to": "a,", "value": 1}, {"from": "##gi", "to": "##uc", "value": 1}, {"from": "##gi", "to": ", the lack of reprod", "value": 1}, {"from": "##gi", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##gi", "to": "##c ) allows", "value": 1}, {"from": "##gi", "to": "##gnosis", "value": 1}, {"from": "##gi", "to": "- g", "value": 1}, {"from": "##tian,", "to": ") hospital clinico univers", "value": 1}, {"from": "##tian,", "to": "##r 12, madrid,", "value": 1}, {"from": "##tian,", "to": "spain", "value": 2}, {"from": "##tian,", "to": "##ale", "value": 1}, {"from": "##tian,", "to": "##a", "value": 1}, {"from": "##tian,", "to": "##ute", "value": 1}, {"from": "##tian,", "to": "##ikoa,", "value": 1}, {"from": "##tian,", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##tian,", "to": "##donost", "value": 2}, {"from": "##tian,", "to": ") hospital oct", "value": 1}, {"from": "##tian,", "to": "research institute", "value": 2}, {"from": "##tian,", "to": "institute", "value": 1}, {"from": "##tian,", "to": "sa", "value": 2}, {"from": "##tian,", "to": "sebas", "value": 2}, {"from": "##tian,", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##tian,", "to": "##ita", "value": 1}, {"from": "##tian,", "to": ", v", "value": 1}, {"from": "##tian,", "to": "##ps, barcelon", "value": 1}, {"from": "##tian,", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##tian,", "to": "##n", "value": 2}, {"from": "##tian,", "to": "##pu", "value": 2}, {"from": "##tian,", "to": "sebastian", "value": 2}, {"from": "##tian,", "to": "; gip", "value": 1}, {"from": "##tian,", "to": "- on", "value": 1}, {"from": "##tian,", "to": "7 ) valencia oncology", "value": 1}, {"from": "##tian,", "to": "##ncia,", "value": 1}, {"from": "##tian,", "to": "##uz", "value": 1}, {"from": "##tian,", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##tian,", "to": "- onkologikoa, san", "value": 1}, {"from": "##tian,", "to": "##z", "value": 1}, {"from": "##tian,", "to": "##bastian, spa", "value": 1}, {"from": "##tian,", "to": "after net", "value": 1}, {"from": "##tian,", "to": "a significant", "value": 1}, {"from": "##tian,", "to": "offers the opportunity of", "value": 1}, {"from": "##tian,", "to": "##ip", "value": 1}, {"from": "##tian,", "to": "background", "value": 1}, {"from": "##tian,", "to": "##re population of", "value": 1}, {"from": "##tian,", "to": "negative breast", "value": 1}, {"from": "##tian,", "to": "barrier", "value": 1}, {"from": "##tian,", "to": "clinical", "value": 1}, {"from": "##tian,", "to": "##2 -", "value": 1}, {"from": "##tian,", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##tian,", "to": "##zkoa", "value": 1}, {"from": "##tian,", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##tian,", "to": "##donostia ) health", "value": 1}, {"from": "##tian,", "to": "cancer", "value": 1}, {"from": "##tian,", "to": "##uzkoa. eus.", "value": 1}, {"from": "##tian,", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##tian,", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##tian,", "to": "personal", "value": 1}, {"from": "##tian,", "to": "##ised therapy.", "value": 1}, {"from": "##tian,", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##tian,", "to": "##cent", "value": 1}, {"from": "##tian,", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##tian,", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##tian,", "to": "her", "value": 1}, {"from": "##tian,", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##tian,", "to": "##n sebastian,", "value": 1}, {"from": "##tian,", "to": "##umour response", "value": 1}, {"from": "##tian,", "to": "a,", "value": 1}, {"from": "##tian,", "to": "##uc", "value": 1}, {"from": "##tian,", "to": ", the lack of reprod", "value": 1}, {"from": "##tian,", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##tian,", "to": "##c ) allows", "value": 1}, {"from": "##tian,", "to": "##gnosis", "value": 1}, {"from": "##tian,", "to": "- g", "value": 1}, {"from": ") hospital clinico univers", "to": "##r 12, madrid,", "value": 1}, {"from": ") hospital clinico univers", "to": "spain", "value": 1}, {"from": ") hospital clinico univers", "to": "##ale", "value": 1}, {"from": ") hospital clinico univers", "to": "##a", "value": 1}, {"from": ") hospital clinico univers", "to": "##ute", "value": 1}, {"from": ") hospital clinico univers", "to": "##ikoa,", "value": 1}, {"from": ") hospital clinico univers", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": ") hospital clinico univers", "to": "##donost", "value": 1}, {"from": ") hospital clinico univers", "to": ") hospital oct", "value": 1}, {"from": ") hospital clinico univers", "to": "research institute", "value": 1}, {"from": ") hospital clinico univers", "to": "institute", "value": 1}, {"from": ") hospital clinico univers", "to": "sa", "value": 1}, {"from": ") hospital clinico univers", "to": "sebas", "value": 1}, {"from": ") hospital clinico univers", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ") hospital clinico univers", "to": "##ita", "value": 1}, {"from": ") hospital clinico univers", "to": ", v", "value": 1}, {"from": ") hospital clinico univers", "to": "##ps, barcelon", "value": 1}, {"from": ") hospital clinico univers", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ") hospital clinico univers", "to": "##n", "value": 1}, {"from": ") hospital clinico univers", "to": "##pu", "value": 1}, {"from": ") hospital clinico univers", "to": "sebastian", "value": 1}, {"from": ") hospital clinico univers", "to": "; gip", "value": 1}, {"from": ") hospital clinico univers", "to": "- on", "value": 1}, {"from": ") hospital clinico univers", "to": "7 ) valencia oncology", "value": 1}, {"from": ") hospital clinico univers", "to": "##ncia,", "value": 1}, {"from": ") hospital clinico univers", "to": "##uz", "value": 1}, {"from": ") hospital clinico univers", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ") hospital clinico univers", "to": "- onkologikoa, san", "value": 1}, {"from": ") hospital clinico univers", "to": "##z", "value": 1}, {"from": ") hospital clinico univers", "to": "##bastian, spa", "value": 1}, {"from": "##r 12, madrid,", "to": "spain", "value": 1}, {"from": "##r 12, madrid,", "to": "##ale", "value": 1}, {"from": "##r 12, madrid,", "to": "##a", "value": 1}, {"from": "##r 12, madrid,", "to": "##ute", "value": 1}, {"from": "##r 12, madrid,", "to": "##ikoa,", "value": 1}, {"from": "##r 12, madrid,", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##r 12, madrid,", "to": "##donost", "value": 1}, {"from": "##r 12, madrid,", "to": ") hospital oct", "value": 1}, {"from": "##r 12, madrid,", "to": "research institute", "value": 1}, {"from": "##r 12, madrid,", "to": "institute", "value": 1}, {"from": "##r 12, madrid,", "to": "sa", "value": 1}, {"from": "##r 12, madrid,", "to": "sebas", "value": 1}, {"from": "##r 12, madrid,", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##r 12, madrid,", "to": "##ita", "value": 1}, {"from": "##r 12, madrid,", "to": ", v", "value": 1}, {"from": "##r 12, madrid,", "to": "##ps, barcelon", "value": 1}, {"from": "##r 12, madrid,", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##r 12, madrid,", "to": "##n", "value": 1}, {"from": "##r 12, madrid,", "to": "##pu", "value": 1}, {"from": "##r 12, madrid,", "to": "sebastian", "value": 1}, {"from": "##r 12, madrid,", "to": "; gip", "value": 1}, {"from": "##r 12, madrid,", "to": "- on", "value": 1}, {"from": "##r 12, madrid,", "to": "7 ) valencia oncology", "value": 1}, {"from": "##r 12, madrid,", "to": "##ncia,", "value": 1}, {"from": "##r 12, madrid,", "to": "##uz", "value": 1}, {"from": "##r 12, madrid,", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##r 12, madrid,", "to": "- onkologikoa, san", "value": 1}, {"from": "##r 12, madrid,", "to": "##z", "value": 1}, {"from": "##r 12, madrid,", "to": "##bastian, spa", "value": 1}, {"from": "spain", "to": "##ale", "value": 1}, {"from": "spain", "to": "##a", "value": 1}, {"from": "spain", "to": "##ute", "value": 1}, {"from": "spain", "to": "##ikoa,", "value": 1}, {"from": "spain", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "spain", "to": "##donost", "value": 2}, {"from": "spain", "to": ") hospital oct", "value": 1}, {"from": "spain", "to": "research institute", "value": 2}, {"from": "spain", "to": "institute", "value": 1}, {"from": "spain", "to": "sa", "value": 2}, {"from": "spain", "to": "sebas", "value": 2}, {"from": "spain", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "spain", "to": "##ita", "value": 1}, {"from": "spain", "to": ", v", "value": 1}, {"from": "spain", "to": "##ps, barcelon", "value": 1}, {"from": "spain", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "spain", "to": "##n", "value": 2}, {"from": "spain", "to": "##pu", "value": 2}, {"from": "spain", "to": "sebastian", "value": 2}, {"from": "spain", "to": "; gip", "value": 1}, {"from": "spain", "to": "- on", "value": 1}, {"from": "spain", "to": "7 ) valencia oncology", "value": 1}, {"from": "spain", "to": "##ncia,", "value": 1}, {"from": "spain", "to": "##uz", "value": 1}, {"from": "spain", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "spain", "to": "- onkologikoa, san", "value": 1}, {"from": "spain", "to": "##z", "value": 1}, {"from": "spain", "to": "##bastian, spa", "value": 1}, {"from": "spain", "to": "after net", "value": 1}, {"from": "spain", "to": "a significant", "value": 1}, {"from": "spain", "to": "offers the opportunity of", "value": 1}, {"from": "spain", "to": "##ip", "value": 1}, {"from": "spain", "to": "background", "value": 1}, {"from": "spain", "to": "##re population of", "value": 1}, {"from": "spain", "to": "negative breast", "value": 1}, {"from": "spain", "to": "barrier", "value": 1}, {"from": "spain", "to": "clinical", "value": 1}, {"from": "spain", "to": "##2 -", "value": 1}, {"from": "spain", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "spain", "to": "##zkoa", "value": 1}, {"from": "spain", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "spain", "to": "##donostia ) health", "value": 1}, {"from": "spain", "to": "cancer", "value": 1}, {"from": "spain", "to": "##uzkoa. eus.", "value": 1}, {"from": "spain", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "spain", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "spain", "to": "personal", "value": 1}, {"from": "spain", "to": "##ised therapy.", "value": 1}, {"from": "spain", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "spain", "to": "##cent", "value": 1}, {"from": "spain", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "spain", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "spain", "to": "her", "value": 1}, {"from": "spain", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "spain", "to": "##n sebastian,", "value": 1}, {"from": "spain", "to": "##umour response", "value": 1}, {"from": "spain", "to": "a,", "value": 1}, {"from": "spain", "to": "##uc", "value": 1}, {"from": "spain", "to": ", the lack of reprod", "value": 1}, {"from": "spain", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "spain", "to": "##c ) allows", "value": 1}, {"from": "spain", "to": "##gnosis", "value": 1}, {"from": "spain", "to": "- g", "value": 1}, {"from": "##ale", "to": "##a", "value": 1}, {"from": "##ale", "to": "##ute", "value": 1}, {"from": "##ale", "to": "##ikoa,", "value": 1}, {"from": "##ale", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ale", "to": "##donost", "value": 1}, {"from": "##ale", "to": ") hospital oct", "value": 1}, {"from": "##ale", "to": "research institute", "value": 1}, {"from": "##ale", "to": "institute", "value": 1}, {"from": "##ale", "to": "sa", "value": 1}, {"from": "##ale", "to": "sebas", "value": 1}, {"from": "##ale", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ale", "to": "##ita", "value": 1}, {"from": "##ale", "to": ", v", "value": 1}, {"from": "##ale", "to": "##ps, barcelon", "value": 1}, {"from": "##ale", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ale", "to": "##n", "value": 1}, {"from": "##ale", "to": "##pu", "value": 1}, {"from": "##ale", "to": "sebastian", "value": 1}, {"from": "##ale", "to": "; gip", "value": 1}, {"from": "##ale", "to": "- on", "value": 1}, {"from": "##ale", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ale", "to": "##ncia,", "value": 1}, {"from": "##ale", "to": "##uz", "value": 1}, {"from": "##ale", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ale", "to": "- onkologikoa, san", "value": 1}, {"from": "##ale", "to": "##z", "value": 1}, {"from": "##ale", "to": "##bastian, spa", "value": 1}, {"from": "##a", "to": "##ute", "value": 1}, {"from": "##a", "to": "##ikoa,", "value": 1}, {"from": "##a", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##a", "to": "##donost", "value": 1}, {"from": "##a", "to": ") hospital oct", "value": 1}, {"from": "##a", "to": "research institute", "value": 1}, {"from": "##a", "to": "institute", "value": 1}, {"from": "##a", "to": "sa", "value": 1}, {"from": "##a", "to": "sebas", "value": 1}, {"from": "##a", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##a", "to": "##ita", "value": 1}, {"from": "##a", "to": ", v", "value": 1}, {"from": "##a", "to": "##ps, barcelon", "value": 1}, {"from": "##a", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##a", "to": "##n", "value": 1}, {"from": "##a", "to": "##pu", "value": 1}, {"from": "##a", "to": "sebastian", "value": 1}, {"from": "##a", "to": "; gip", "value": 1}, {"from": "##a", "to": "- on", "value": 1}, {"from": "##a", "to": "7 ) valencia oncology", "value": 1}, {"from": "##a", "to": "##ncia,", "value": 1}, {"from": "##a", "to": "##uz", "value": 1}, {"from": "##a", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##a", "to": "- onkologikoa, san", "value": 1}, {"from": "##a", "to": "##z", "value": 1}, {"from": "##a", "to": "##bastian, spa", "value": 1}, {"from": "##ute", "to": "##ikoa,", "value": 1}, {"from": "##ute", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ute", "to": "##donost", "value": 1}, {"from": "##ute", "to": ") hospital oct", "value": 1}, {"from": "##ute", "to": "research institute", "value": 1}, {"from": "##ute", "to": "institute", "value": 1}, {"from": "##ute", "to": "sa", "value": 1}, {"from": "##ute", "to": "sebas", "value": 1}, {"from": "##ute", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ute", "to": "##ita", "value": 1}, {"from": "##ute", "to": ", v", "value": 1}, {"from": "##ute", "to": "##ps, barcelon", "value": 1}, {"from": "##ute", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ute", "to": "##n", "value": 1}, {"from": "##ute", "to": "##pu", "value": 1}, {"from": "##ute", "to": "sebastian", "value": 1}, {"from": "##ute", "to": "; gip", "value": 1}, {"from": "##ute", "to": "- on", "value": 1}, {"from": "##ute", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ute", "to": "##ncia,", "value": 1}, {"from": "##ute", "to": "##uz", "value": 1}, {"from": "##ute", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ute", "to": "- onkologikoa, san", "value": 1}, {"from": "##ute", "to": "##z", "value": 1}, {"from": "##ute", "to": "##bastian, spa", "value": 1}, {"from": "##ikoa,", "to": "##koa cancer unit / osi donost", "value": 1}, {"from": "##ikoa,", "to": "##donost", "value": 1}, {"from": "##ikoa,", "to": ") hospital oct", "value": 1}, {"from": "##ikoa,", "to": "research institute", "value": 1}, {"from": "##ikoa,", "to": "institute", "value": 1}, {"from": "##ikoa,", "to": "sa", "value": 1}, {"from": "##ikoa,", "to": "sebas", "value": 1}, {"from": "##ikoa,", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##ikoa,", "to": "##ita", "value": 1}, {"from": "##ikoa,", "to": ", v", "value": 1}, {"from": "##ikoa,", "to": "##ps, barcelon", "value": 1}, {"from": "##ikoa,", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ikoa,", "to": "##n", "value": 1}, {"from": "##ikoa,", "to": "##pu", "value": 1}, {"from": "##ikoa,", "to": "sebastian", "value": 1}, {"from": "##ikoa,", "to": "; gip", "value": 1}, {"from": "##ikoa,", "to": "- on", "value": 1}, {"from": "##ikoa,", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ikoa,", "to": "##ncia,", "value": 1}, {"from": "##ikoa,", "to": "##uz", "value": 1}, {"from": "##ikoa,", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ikoa,", "to": "- onkologikoa, san", "value": 1}, {"from": "##ikoa,", "to": "##z", "value": 1}, {"from": "##ikoa,", "to": "##bastian, spa", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##donost", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": ") hospital oct", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "research institute", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "institute", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "sa", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "sebas", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##ita", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": ", v", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##ps, barcelon", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##n", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##pu", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "sebastian", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "; gip", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "- on", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "7 ) valencia oncology", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##ncia,", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##uz", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "- onkologikoa, san", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##z", "value": 1}, {"from": "##koa cancer unit / osi donost", "to": "##bastian, spa", "value": 1}, {"from": "##donost", "to": ") hospital oct", "value": 1}, {"from": "##donost", "to": "research institute", "value": 2}, {"from": "##donost", "to": "institute", "value": 1}, {"from": "##donost", "to": "sa", "value": 2}, {"from": "##donost", "to": "sebas", "value": 2}, {"from": "##donost", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "##donost", "to": "##ita", "value": 1}, {"from": "##donost", "to": ", v", "value": 1}, {"from": "##donost", "to": "##ps, barcelon", "value": 1}, {"from": "##donost", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##donost", "to": "##n", "value": 2}, {"from": "##donost", "to": "##pu", "value": 2}, {"from": "##donost", "to": "sebastian", "value": 2}, {"from": "##donost", "to": "; gip", "value": 1}, {"from": "##donost", "to": "- on", "value": 1}, {"from": "##donost", "to": "7 ) valencia oncology", "value": 1}, {"from": "##donost", "to": "##ncia,", "value": 1}, {"from": "##donost", "to": "##uz", "value": 1}, {"from": "##donost", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##donost", "to": "- onkologikoa, san", "value": 1}, {"from": "##donost", "to": "##z", "value": 1}, {"from": "##donost", "to": "##bastian, spa", "value": 1}, {"from": "##donost", "to": "after net", "value": 1}, {"from": "##donost", "to": "a significant", "value": 1}, {"from": "##donost", "to": "offers the opportunity of", "value": 1}, {"from": "##donost", "to": "##ip", "value": 1}, {"from": "##donost", "to": "background", "value": 1}, {"from": "##donost", "to": "##re population of", "value": 1}, {"from": "##donost", "to": "negative breast", "value": 1}, {"from": "##donost", "to": "barrier", "value": 1}, {"from": "##donost", "to": "clinical", "value": 1}, {"from": "##donost", "to": "##2 -", "value": 1}, {"from": "##donost", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##donost", "to": "##zkoa", "value": 1}, {"from": "##donost", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##donost", "to": "##donostia ) health", "value": 1}, {"from": "##donost", "to": "cancer", "value": 1}, {"from": "##donost", "to": "##uzkoa. eus.", "value": 1}, {"from": "##donost", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##donost", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##donost", "to": "personal", "value": 1}, {"from": "##donost", "to": "##ised therapy.", "value": 1}, {"from": "##donost", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##donost", "to": "##cent", "value": 1}, {"from": "##donost", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##donost", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##donost", "to": "her", "value": 1}, {"from": "##donost", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##donost", "to": "##n sebastian,", "value": 1}, {"from": "##donost", "to": "##umour response", "value": 1}, {"from": "##donost", "to": "a,", "value": 1}, {"from": "##donost", "to": "##uc", "value": 1}, {"from": "##donost", "to": ", the lack of reprod", "value": 1}, {"from": "##donost", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##donost", "to": "##c ) allows", "value": 1}, {"from": "##donost", "to": "##gnosis", "value": 1}, {"from": "##donost", "to": "- g", "value": 1}, {"from": ") hospital oct", "to": "research institute", "value": 1}, {"from": ") hospital oct", "to": "institute", "value": 1}, {"from": ") hospital oct", "to": "sa", "value": 1}, {"from": ") hospital oct", "to": "sebas", "value": 1}, {"from": ") hospital oct", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": ") hospital oct", "to": "##ita", "value": 1}, {"from": ") hospital oct", "to": ", v", "value": 1}, {"from": ") hospital oct", "to": "##ps, barcelon", "value": 1}, {"from": ") hospital oct", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ") hospital oct", "to": "##n", "value": 1}, {"from": ") hospital oct", "to": "##pu", "value": 1}, {"from": ") hospital oct", "to": "sebastian", "value": 1}, {"from": ") hospital oct", "to": "; gip", "value": 1}, {"from": ") hospital oct", "to": "- on", "value": 1}, {"from": ") hospital oct", "to": "7 ) valencia oncology", "value": 1}, {"from": ") hospital oct", "to": "##ncia,", "value": 1}, {"from": ") hospital oct", "to": "##uz", "value": 1}, {"from": ") hospital oct", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ") hospital oct", "to": "- onkologikoa, san", "value": 1}, {"from": ") hospital oct", "to": "##z", "value": 1}, {"from": ") hospital oct", "to": "##bastian, spa", "value": 1}, {"from": "research institute", "to": "institute", "value": 1}, {"from": "research institute", "to": "sa", "value": 2}, {"from": "research institute", "to": "sebas", "value": 2}, {"from": "research institute", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "research institute", "to": "##ita", "value": 1}, {"from": "research institute", "to": ", v", "value": 1}, {"from": "research institute", "to": "##ps, barcelon", "value": 1}, {"from": "research institute", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "research institute", "to": "##n", "value": 2}, {"from": "research institute", "to": "##pu", "value": 2}, {"from": "research institute", "to": "sebastian", "value": 2}, {"from": "research institute", "to": "; gip", "value": 1}, {"from": "research institute", "to": "- on", "value": 1}, {"from": "research institute", "to": "7 ) valencia oncology", "value": 1}, {"from": "research institute", "to": "##ncia,", "value": 1}, {"from": "research institute", "to": "##uz", "value": 1}, {"from": "research institute", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "research institute", "to": "- onkologikoa, san", "value": 1}, {"from": "research institute", "to": "##z", "value": 1}, {"from": "research institute", "to": "##bastian, spa", "value": 1}, {"from": "research institute", "to": "after net", "value": 1}, {"from": "research institute", "to": "a significant", "value": 1}, {"from": "research institute", "to": "offers the opportunity of", "value": 1}, {"from": "research institute", "to": "##ip", "value": 1}, {"from": "research institute", "to": "background", "value": 1}, {"from": "research institute", "to": "##re population of", "value": 1}, {"from": "research institute", "to": "negative breast", "value": 1}, {"from": "research institute", "to": "barrier", "value": 1}, {"from": "research institute", "to": "clinical", "value": 1}, {"from": "research institute", "to": "##2 -", "value": 1}, {"from": "research institute", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "research institute", "to": "##zkoa", "value": 1}, {"from": "research institute", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "research institute", "to": "##donostia ) health", "value": 1}, {"from": "research institute", "to": "cancer", "value": 1}, {"from": "research institute", "to": "##uzkoa. eus.", "value": 1}, {"from": "research institute", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "research institute", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "research institute", "to": "personal", "value": 1}, {"from": "research institute", "to": "##ised therapy.", "value": 1}, {"from": "research institute", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "research institute", "to": "##cent", "value": 1}, {"from": "research institute", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "research institute", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "research institute", "to": "her", "value": 1}, {"from": "research institute", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "research institute", "to": "##n sebastian,", "value": 1}, {"from": "research institute", "to": "##umour response", "value": 1}, {"from": "research institute", "to": "a,", "value": 1}, {"from": "research institute", "to": "##uc", "value": 1}, {"from": "research institute", "to": ", the lack of reprod", "value": 1}, {"from": "research institute", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "research institute", "to": "##c ) allows", "value": 1}, {"from": "research institute", "to": "##gnosis", "value": 1}, {"from": "research institute", "to": "- g", "value": 1}, {"from": "institute", "to": "sa", "value": 1}, {"from": "institute", "to": "sebas", "value": 1}, {"from": "institute", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "institute", "to": "##ita", "value": 1}, {"from": "institute", "to": ", v", "value": 1}, {"from": "institute", "to": "##ps, barcelon", "value": 1}, {"from": "institute", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "institute", "to": "##n", "value": 1}, {"from": "institute", "to": "##pu", "value": 1}, {"from": "institute", "to": "sebastian", "value": 1}, {"from": "institute", "to": "; gip", "value": 1}, {"from": "institute", "to": "- on", "value": 1}, {"from": "institute", "to": "7 ) valencia oncology", "value": 1}, {"from": "institute", "to": "##ncia,", "value": 1}, {"from": "institute", "to": "##uz", "value": 1}, {"from": "institute", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "institute", "to": "- onkologikoa, san", "value": 1}, {"from": "institute", "to": "##z", "value": 1}, {"from": "institute", "to": "##bastian, spa", "value": 1}, {"from": "institute", "to": "##rgen, norway.", "value": 1}, {"from": "institute", "to": "##rgen, nor", "value": 1}, {"from": "institute", "to": "economics", "value": 1}, {"from": "institute", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "institute", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "institute", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "institute", "to": "clinical trials", "value": 1}, {"from": "institute", "to": "of health management and health", "value": 1}, {"from": "institute", "to": ";", "value": 3}, {"from": "institute", "to": ") department of p", "value": 1}, {"from": "institute", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "institute", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "institute", "to": "), heie a", "value": 1}, {"from": "institute", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": "be", "value": 1}, {"from": "institute", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "institute", "to": "ug", "value": 1}, {"from": "institute", "to": "##way", "value": 3}, {"from": "institute", "to": ") department of", "value": 1}, {"from": "institute", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "institute", "to": "for cancer", "value": 1}, {"from": "institute", "to": "##lia", "value": 1}, {"from": "institute", "to": "##vanger,", "value": 1}, {"from": "institute", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "institute", "to": "##vanger university, s", "value": 1}, {"from": "institute", "to": "8", "value": 1}, {"from": "institute", "to": "of cancer genetics,", "value": 2}, {"from": "institute", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "institute", "to": "12 ) department", "value": 1}, {"from": "institute", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "institute", "to": "##vanger university hospital, s", "value": 1}, {"from": "institute", "to": "ha", "value": 1}, {"from": "institute", "to": "norway", "value": 1}, {"from": "institute", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "institute", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "institute", "to": "of pathology, s", "value": 1}, {"from": "institute", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": ", drammen, norway.", "value": 1}, {"from": "institute", "to": "of clinical medicine,", "value": 1}, {"from": "institute", "to": "##dheim, norway.", "value": 1}, {"from": "institute", "to": "25", "value": 1}, {"from": "institute", "to": "trust", "value": 1}, {"from": "institute", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "institute", "to": ", hamar, norway.", "value": 1}, {"from": "institute", "to": ", kalnes, norway.", "value": 1}, {"from": "institute", "to": ", skien, norway.", "value": 1}, {"from": "institute", "to": "of oslo, oslo, nor", "value": 1}, {"from": "institute", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "institute", "to": ") department of oncolog", "value": 1}, {"from": "institute", "to": "##ron", "value": 1}, {"from": "institute", "to": "the", "value": 1}, {"from": "institute", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "institute", "to": "hormone receptor positive", "value": 1}, {"from": "institute", "to": "societal perspective", "value": 1}, {"from": "institute", "to": "benefits", "value": 1}, {"from": "institute", "to": "surgery", "value": 1}, {"from": "institute", "to": "cost -", "value": 1}, {"from": "institute", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "institute", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "institute", "to": "decision", "value": 1}, {"from": "institute", "to": "to aid adjuvant treatment", "value": 1}, {"from": "institute", "to": "##al", "value": 1}, {"from": "institute", "to": "emit - 1 trial", "value": 1}, {"from": "institute", "to": "post", "value": 1}, {"from": "institute", "to": ". materials", "value": 1}, {"from": "institute", "to": "model was", "value": 1}, {"from": "institute", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "institute", "to": "used", "value": 1}, {"from": "institute", "to": ": the", "value": 1}, {"from": "institute", "to": "ki - 67", "value": 1}, {"from": "institute", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "institute", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "institute", "to": "prosigna was tested", "value": 1}, {"from": "institute", "to": "prospective", "value": 1}, {"from": "institute", "to": "were measured", "value": 1}, {"from": "institute", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "institute", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "institute", "to": "observation", "value": 1}, {"from": "institute", "to": "division", "value": 1}, {"from": "institute", "to": "decisions in", "value": 1}, {"from": "institute", "to": "built", "value": 1}, {"from": "institute", "to": "impact of", "value": 1}, {"from": "sa", "to": "sebas", "value": 2}, {"from": "sa", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "sa", "to": "##ita", "value": 1}, {"from": "sa", "to": ", v", "value": 1}, {"from": "sa", "to": "##ps, barcelon", "value": 1}, {"from": "sa", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "sa", "to": "##n", "value": 2}, {"from": "sa", "to": "##pu", "value": 2}, {"from": "sa", "to": "sebastian", "value": 2}, {"from": "sa", "to": "; gip", "value": 1}, {"from": "sa", "to": "- on", "value": 1}, {"from": "sa", "to": "7 ) valencia oncology", "value": 1}, {"from": "sa", "to": "##ncia,", "value": 1}, {"from": "sa", "to": "##uz", "value": 1}, {"from": "sa", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "sa", "to": "- onkologikoa, san", "value": 1}, {"from": "sa", "to": "##z", "value": 1}, {"from": "sa", "to": "##bastian, spa", "value": 1}, {"from": "sa", "to": "after net", "value": 1}, {"from": "sa", "to": "a significant", "value": 1}, {"from": "sa", "to": "offers the opportunity of", "value": 1}, {"from": "sa", "to": "##ip", "value": 1}, {"from": "sa", "to": "background", "value": 1}, {"from": "sa", "to": "##re population of", "value": 1}, {"from": "sa", "to": "negative breast", "value": 1}, {"from": "sa", "to": "barrier", "value": 1}, {"from": "sa", "to": "clinical", "value": 1}, {"from": "sa", "to": "##2 -", "value": 1}, {"from": "sa", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "sa", "to": "##zkoa", "value": 1}, {"from": "sa", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "sa", "to": "##donostia ) health", "value": 1}, {"from": "sa", "to": "cancer", "value": 1}, {"from": "sa", "to": "##uzkoa. eus.", "value": 1}, {"from": "sa", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "sa", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "sa", "to": "personal", "value": 1}, {"from": "sa", "to": "##ised therapy.", "value": 1}, {"from": "sa", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "sa", "to": "##cent", "value": 1}, {"from": "sa", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "sa", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "sa", "to": "her", "value": 1}, {"from": "sa", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "sa", "to": "##n sebastian,", "value": 1}, {"from": "sa", "to": "##umour response", "value": 1}, {"from": "sa", "to": "a,", "value": 1}, {"from": "sa", "to": "##uc", "value": 1}, {"from": "sa", "to": ", the lack of reprod", "value": 1}, {"from": "sa", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "sa", "to": "##c ) allows", "value": 1}, {"from": "sa", "to": "##gnosis", "value": 1}, {"from": "sa", "to": "- g", "value": 1}, {"from": "sebas", "to": "; gynecology and general surgery departments - breast unit, onkologikoa,", "value": 1}, {"from": "sebas", "to": "##ita", "value": 1}, {"from": "sebas", "to": ", v", "value": 1}, {"from": "sebas", "to": "##ps, barcelon", "value": 1}, {"from": "sebas", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "sebas", "to": "##n", "value": 2}, {"from": "sebas", "to": "##pu", "value": 2}, {"from": "sebas", "to": "sebastian", "value": 2}, {"from": "sebas", "to": "; gip", "value": 1}, {"from": "sebas", "to": "- on", "value": 1}, {"from": "sebas", "to": "7 ) valencia oncology", "value": 1}, {"from": "sebas", "to": "##ncia,", "value": 1}, {"from": "sebas", "to": "##uz", "value": 1}, {"from": "sebas", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "sebas", "to": "- onkologikoa, san", "value": 1}, {"from": "sebas", "to": "##z", "value": 1}, {"from": "sebas", "to": "##bastian, spa", "value": 1}, {"from": "sebas", "to": "after net", "value": 1}, {"from": "sebas", "to": "a significant", "value": 1}, {"from": "sebas", "to": "offers the opportunity of", "value": 1}, {"from": "sebas", "to": "##ip", "value": 1}, {"from": "sebas", "to": "background", "value": 1}, {"from": "sebas", "to": "##re population of", "value": 1}, {"from": "sebas", "to": "negative breast", "value": 1}, {"from": "sebas", "to": "barrier", "value": 1}, {"from": "sebas", "to": "clinical", "value": 1}, {"from": "sebas", "to": "##2 -", "value": 1}, {"from": "sebas", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "sebas", "to": "##zkoa", "value": 1}, {"from": "sebas", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "sebas", "to": "##donostia ) health", "value": 1}, {"from": "sebas", "to": "cancer", "value": 1}, {"from": "sebas", "to": "##uzkoa. eus.", "value": 1}, {"from": "sebas", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "sebas", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "sebas", "to": "personal", "value": 1}, {"from": "sebas", "to": "##ised therapy.", "value": 1}, {"from": "sebas", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "sebas", "to": "##cent", "value": 1}, {"from": "sebas", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "sebas", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "sebas", "to": "her", "value": 1}, {"from": "sebas", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "sebas", "to": "##n sebastian,", "value": 1}, {"from": "sebas", "to": "##umour response", "value": 1}, {"from": "sebas", "to": "a,", "value": 1}, {"from": "sebas", "to": "##uc", "value": 1}, {"from": "sebas", "to": ", the lack of reprod", "value": 1}, {"from": "sebas", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "sebas", "to": "##c ) allows", "value": 1}, {"from": "sebas", "to": "##gnosis", "value": 1}, {"from": "sebas", "to": "- g", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##ita", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": ", v", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##ps, barcelon", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##n", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##pu", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "sebastian", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "; gip", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "- on", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "7 ) valencia oncology", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##ncia,", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##uz", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "- onkologikoa, san", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##z", "value": 1}, {"from": "; gynecology and general surgery departments - breast unit, onkologikoa,", "to": "##bastian, spa", "value": 1}, {"from": "##ita", "to": ", v", "value": 1}, {"from": "##ita", "to": "##ps, barcelon", "value": 1}, {"from": "##ita", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ita", "to": "##n", "value": 1}, {"from": "##ita", "to": "##pu", "value": 1}, {"from": "##ita", "to": "sebastian", "value": 1}, {"from": "##ita", "to": "; gip", "value": 1}, {"from": "##ita", "to": "- on", "value": 1}, {"from": "##ita", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ita", "to": "##ncia,", "value": 1}, {"from": "##ita", "to": "##uz", "value": 1}, {"from": "##ita", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ita", "to": "- onkologikoa, san", "value": 1}, {"from": "##ita", "to": "##z", "value": 1}, {"from": "##ita", "to": "##bastian, spa", "value": 1}, {"from": ", v", "to": "##ps, barcelon", "value": 1}, {"from": ", v", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": ", v", "to": "##n", "value": 1}, {"from": ", v", "to": "##pu", "value": 1}, {"from": ", v", "to": "sebastian", "value": 1}, {"from": ", v", "to": "; gip", "value": 1}, {"from": ", v", "to": "- on", "value": 1}, {"from": ", v", "to": "7 ) valencia oncology", "value": 1}, {"from": ", v", "to": "##ncia,", "value": 1}, {"from": ", v", "to": "##uz", "value": 1}, {"from": ", v", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ", v", "to": "- onkologikoa, san", "value": 1}, {"from": ", v", "to": "##z", "value": 1}, {"from": ", v", "to": "##bastian, spa", "value": 1}, {"from": "##ps, barcelon", "to": ") hospital clinic, barcelona - id", "value": 1}, {"from": "##ps, barcelon", "to": "##n", "value": 1}, {"from": "##ps, barcelon", "to": "##pu", "value": 1}, {"from": "##ps, barcelon", "to": "sebastian", "value": 1}, {"from": "##ps, barcelon", "to": "; gip", "value": 1}, {"from": "##ps, barcelon", "to": "- on", "value": 1}, {"from": "##ps, barcelon", "to": "7 ) valencia oncology", "value": 1}, {"from": "##ps, barcelon", "to": "##ncia,", "value": 1}, {"from": "##ps, barcelon", "to": "##uz", "value": 1}, {"from": "##ps, barcelon", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ps, barcelon", "to": "- onkologikoa, san", "value": 1}, {"from": "##ps, barcelon", "to": "##z", "value": 1}, {"from": "##ps, barcelon", "to": "##bastian, spa", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##n", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##pu", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "sebastian", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "; gip", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "- on", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "7 ) valencia oncology", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##ncia,", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##uz", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "- onkologikoa, san", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##z", "value": 1}, {"from": ") hospital clinic, barcelona - id", "to": "##bastian, spa", "value": 1}, {"from": "##n", "to": "##pu", "value": 2}, {"from": "##n", "to": "sebastian", "value": 2}, {"from": "##n", "to": "; gip", "value": 1}, {"from": "##n", "to": "- on", "value": 1}, {"from": "##n", "to": "7 ) valencia oncology", "value": 1}, {"from": "##n", "to": "##ncia,", "value": 1}, {"from": "##n", "to": "##uz", "value": 1}, {"from": "##n", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##n", "to": "- onkologikoa, san", "value": 1}, {"from": "##n", "to": "##z", "value": 1}, {"from": "##n", "to": "##bastian, spa", "value": 1}, {"from": "##n", "to": "after net", "value": 1}, {"from": "##n", "to": "a significant", "value": 1}, {"from": "##n", "to": "offers the opportunity of", "value": 1}, {"from": "##n", "to": "##ip", "value": 1}, {"from": "##n", "to": "background", "value": 1}, {"from": "##n", "to": "##re population of", "value": 1}, {"from": "##n", "to": "negative breast", "value": 1}, {"from": "##n", "to": "barrier", "value": 1}, {"from": "##n", "to": "clinical", "value": 1}, {"from": "##n", "to": "##2 -", "value": 1}, {"from": "##n", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##n", "to": "##zkoa", "value": 1}, {"from": "##n", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##n", "to": "##donostia ) health", "value": 1}, {"from": "##n", "to": "cancer", "value": 1}, {"from": "##n", "to": "##uzkoa. eus.", "value": 1}, {"from": "##n", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##n", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##n", "to": "personal", "value": 1}, {"from": "##n", "to": "##ised therapy.", "value": 1}, {"from": "##n", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##n", "to": "##cent", "value": 1}, {"from": "##n", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##n", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##n", "to": "her", "value": 1}, {"from": "##n", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##n", "to": "##n sebastian,", "value": 1}, {"from": "##n", "to": "##umour response", "value": 1}, {"from": "##n", "to": "a,", "value": 1}, {"from": "##n", "to": "##uc", "value": 1}, {"from": "##n", "to": ", the lack of reprod", "value": 1}, {"from": "##n", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##n", "to": "##c ) allows", "value": 1}, {"from": "##n", "to": "##gnosis", "value": 1}, {"from": "##n", "to": "- g", "value": 1}, {"from": "##pu", "to": "sebastian", "value": 2}, {"from": "##pu", "to": "; gip", "value": 1}, {"from": "##pu", "to": "- on", "value": 1}, {"from": "##pu", "to": "7 ) valencia oncology", "value": 1}, {"from": "##pu", "to": "##ncia,", "value": 1}, {"from": "##pu", "to": "##uz", "value": 1}, {"from": "##pu", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##pu", "to": "- onkologikoa, san", "value": 1}, {"from": "##pu", "to": "##z", "value": 1}, {"from": "##pu", "to": "##bastian, spa", "value": 1}, {"from": "##pu", "to": "after net", "value": 1}, {"from": "##pu", "to": "a significant", "value": 1}, {"from": "##pu", "to": "offers the opportunity of", "value": 1}, {"from": "##pu", "to": "##ip", "value": 1}, {"from": "##pu", "to": "background", "value": 1}, {"from": "##pu", "to": "##re population of", "value": 1}, {"from": "##pu", "to": "negative breast", "value": 1}, {"from": "##pu", "to": "barrier", "value": 1}, {"from": "##pu", "to": "clinical", "value": 1}, {"from": "##pu", "to": "##2 -", "value": 1}, {"from": "##pu", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##pu", "to": "##zkoa", "value": 1}, {"from": "##pu", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##pu", "to": "##donostia ) health", "value": 1}, {"from": "##pu", "to": "cancer", "value": 1}, {"from": "##pu", "to": "##uzkoa. eus.", "value": 1}, {"from": "##pu", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##pu", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##pu", "to": "personal", "value": 1}, {"from": "##pu", "to": "##ised therapy.", "value": 1}, {"from": "##pu", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##pu", "to": "##cent", "value": 1}, {"from": "##pu", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##pu", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##pu", "to": "her", "value": 1}, {"from": "##pu", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##pu", "to": "##n sebastian,", "value": 1}, {"from": "##pu", "to": "##umour response", "value": 1}, {"from": "##pu", "to": "a,", "value": 1}, {"from": "##pu", "to": "##uc", "value": 1}, {"from": "##pu", "to": ", the lack of reprod", "value": 1}, {"from": "##pu", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##pu", "to": "##c ) allows", "value": 1}, {"from": "##pu", "to": "##gnosis", "value": 1}, {"from": "##pu", "to": "- g", "value": 1}, {"from": "sebastian", "to": "; gip", "value": 1}, {"from": "sebastian", "to": "- on", "value": 1}, {"from": "sebastian", "to": "7 ) valencia oncology", "value": 1}, {"from": "sebastian", "to": "##ncia,", "value": 1}, {"from": "sebastian", "to": "##uz", "value": 1}, {"from": "sebastian", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "sebastian", "to": "- onkologikoa, san", "value": 1}, {"from": "sebastian", "to": "##z", "value": 1}, {"from": "sebastian", "to": "##bastian, spa", "value": 1}, {"from": "sebastian", "to": "after net", "value": 1}, {"from": "sebastian", "to": "a significant", "value": 1}, {"from": "sebastian", "to": "offers the opportunity of", "value": 1}, {"from": "sebastian", "to": "##ip", "value": 1}, {"from": "sebastian", "to": "background", "value": 1}, {"from": "sebastian", "to": "##re population of", "value": 1}, {"from": "sebastian", "to": "negative breast", "value": 1}, {"from": "sebastian", "to": "barrier", "value": 1}, {"from": "sebastian", "to": "clinical", "value": 1}, {"from": "sebastian", "to": "##2 -", "value": 1}, {"from": "sebastian", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "sebastian", "to": "##zkoa", "value": 1}, {"from": "sebastian", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "sebastian", "to": "##donostia ) health", "value": 1}, {"from": "sebastian", "to": "cancer", "value": 1}, {"from": "sebastian", "to": "##uzkoa. eus.", "value": 1}, {"from": "sebastian", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "sebastian", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "sebastian", "to": "personal", "value": 1}, {"from": "sebastian", "to": "##ised therapy.", "value": 1}, {"from": "sebastian", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "sebastian", "to": "##cent", "value": 1}, {"from": "sebastian", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "sebastian", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "sebastian", "to": "her", "value": 1}, {"from": "sebastian", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "sebastian", "to": "##n sebastian,", "value": 1}, {"from": "sebastian", "to": "##umour response", "value": 1}, {"from": "sebastian", "to": "a,", "value": 1}, {"from": "sebastian", "to": "##uc", "value": 1}, {"from": "sebastian", "to": ", the lack of reprod", "value": 1}, {"from": "sebastian", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "sebastian", "to": "##c ) allows", "value": 1}, {"from": "sebastian", "to": "##gnosis", "value": 1}, {"from": "sebastian", "to": "- g", "value": 1}, {"from": "; gip", "to": "- on", "value": 1}, {"from": "; gip", "to": "7 ) valencia oncology", "value": 1}, {"from": "; gip", "to": "##ncia,", "value": 1}, {"from": "; gip", "to": "##uz", "value": 1}, {"from": "; gip", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "; gip", "to": "- onkologikoa, san", "value": 1}, {"from": "; gip", "to": "##z", "value": 1}, {"from": "; gip", "to": "##bastian, spa", "value": 1}, {"from": "- on", "to": "7 ) valencia oncology", "value": 1}, {"from": "- on", "to": "##ncia,", "value": 1}, {"from": "- on", "to": "##uz", "value": 1}, {"from": "- on", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "- on", "to": "- onkologikoa, san", "value": 1}, {"from": "- on", "to": "##z", "value": 1}, {"from": "- on", "to": "##bastian, spa", "value": 1}, {"from": "7 ) valencia oncology", "to": "##ncia,", "value": 1}, {"from": "7 ) valencia oncology", "to": "##uz", "value": 1}, {"from": "7 ) valencia oncology", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "7 ) valencia oncology", "to": "- onkologikoa, san", "value": 1}, {"from": "7 ) valencia oncology", "to": "##z", "value": 1}, {"from": "7 ) valencia oncology", "to": "##bastian, spa", "value": 1}, {"from": "##ncia,", "to": "##uz", "value": 1}, {"from": "##ncia,", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##ncia,", "to": "- onkologikoa, san", "value": 1}, {"from": "##ncia,", "to": "##z", "value": 1}, {"from": "##ncia,", "to": "##bastian, spa", "value": 1}, {"from": "##uz", "to": "; gynecology department - breast unit, osi donost", "value": 1}, {"from": "##uz", "to": "- onkologikoa, san", "value": 1}, {"from": "##uz", "to": "##z", "value": 1}, {"from": "##uz", "to": "##bastian, spa", "value": 1}, {"from": "; gynecology department - breast unit, osi donost", "to": "- onkologikoa, san", "value": 1}, {"from": "; gynecology department - breast unit, osi donost", "to": "##z", "value": 1}, {"from": "; gynecology department - breast unit, osi donost", "to": "##bastian, spa", "value": 1}, {"from": "- onkologikoa, san", "to": "##z", "value": 1}, {"from": "- onkologikoa, san", "to": "##bastian, spa", "value": 1}, {"from": "##z", "to": "##bastian, spa", "value": 1}, {"from": "after net", "to": "a significant", "value": 1}, {"from": "after net", "to": "offers the opportunity of", "value": 1}, {"from": "after net", "to": "##ip", "value": 1}, {"from": "after net", "to": "background", "value": 1}, {"from": "after net", "to": "##re population of", "value": 1}, {"from": "after net", "to": "negative breast", "value": 1}, {"from": "after net", "to": "barrier", "value": 1}, {"from": "after net", "to": "clinical", "value": 1}, {"from": "after net", "to": "##2 -", "value": 1}, {"from": "after net", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "after net", "to": "##zkoa", "value": 1}, {"from": "after net", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "after net", "to": "##donostia ) health", "value": 1}, {"from": "after net", "to": "cancer", "value": 1}, {"from": "after net", "to": "##uzkoa. eus.", "value": 1}, {"from": "after net", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "after net", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "after net", "to": "personal", "value": 1}, {"from": "after net", "to": "##ised therapy.", "value": 1}, {"from": "after net", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "after net", "to": "##cent", "value": 1}, {"from": "after net", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "after net", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "after net", "to": "her", "value": 1}, {"from": "after net", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "after net", "to": "##n sebastian,", "value": 1}, {"from": "after net", "to": "##umour response", "value": 1}, {"from": "after net", "to": "a,", "value": 1}, {"from": "after net", "to": "##uc", "value": 1}, {"from": "after net", "to": ", the lack of reprod", "value": 1}, {"from": "after net", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "after net", "to": "##c ) allows", "value": 1}, {"from": "after net", "to": "##gnosis", "value": 1}, {"from": "after net", "to": "- g", "value": 1}, {"from": "a significant", "to": "offers the opportunity of", "value": 1}, {"from": "a significant", "to": "##ip", "value": 1}, {"from": "a significant", "to": "background", "value": 1}, {"from": "a significant", "to": "##re population of", "value": 1}, {"from": "a significant", "to": "negative breast", "value": 1}, {"from": "a significant", "to": "barrier", "value": 1}, {"from": "a significant", "to": "clinical", "value": 1}, {"from": "a significant", "to": "##2 -", "value": 1}, {"from": "a significant", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "a significant", "to": "##zkoa", "value": 1}, {"from": "a significant", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "a significant", "to": "##donostia ) health", "value": 1}, {"from": "a significant", "to": "cancer", "value": 1}, {"from": "a significant", "to": "##uzkoa. eus.", "value": 1}, {"from": "a significant", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "a significant", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "a significant", "to": "personal", "value": 1}, {"from": "a significant", "to": "##ised therapy.", "value": 1}, {"from": "a significant", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "a significant", "to": "##cent", "value": 1}, {"from": "a significant", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "a significant", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "a significant", "to": "her", "value": 1}, {"from": "a significant", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "a significant", "to": "##n sebastian,", "value": 1}, {"from": "a significant", "to": "##umour response", "value": 1}, {"from": "a significant", "to": "a,", "value": 1}, {"from": "a significant", "to": "##uc", "value": 1}, {"from": "a significant", "to": ", the lack of reprod", "value": 1}, {"from": "a significant", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "a significant", "to": "##c ) allows", "value": 1}, {"from": "a significant", "to": "##gnosis", "value": 1}, {"from": "a significant", "to": "- g", "value": 1}, {"from": "offers the opportunity of", "to": "##ip", "value": 1}, {"from": "offers the opportunity of", "to": "background", "value": 1}, {"from": "offers the opportunity of", "to": "##re population of", "value": 1}, {"from": "offers the opportunity of", "to": "negative breast", "value": 1}, {"from": "offers the opportunity of", "to": "barrier", "value": 1}, {"from": "offers the opportunity of", "to": "clinical", "value": 1}, {"from": "offers the opportunity of", "to": "##2 -", "value": 1}, {"from": "offers the opportunity of", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "offers the opportunity of", "to": "##zkoa", "value": 1}, {"from": "offers the opportunity of", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "offers the opportunity of", "to": "##donostia ) health", "value": 1}, {"from": "offers the opportunity of", "to": "cancer", "value": 1}, {"from": "offers the opportunity of", "to": "##uzkoa. eus.", "value": 1}, {"from": "offers the opportunity of", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "offers the opportunity of", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "offers the opportunity of", "to": "personal", "value": 1}, {"from": "offers the opportunity of", "to": "##ised therapy.", "value": 1}, {"from": "offers the opportunity of", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "offers the opportunity of", "to": "##cent", "value": 1}, {"from": "offers the opportunity of", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "offers the opportunity of", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "offers the opportunity of", "to": "her", "value": 1}, {"from": "offers the opportunity of", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "offers the opportunity of", "to": "##n sebastian,", "value": 1}, {"from": "offers the opportunity of", "to": "##umour response", "value": 1}, {"from": "offers the opportunity of", "to": "a,", "value": 1}, {"from": "offers the opportunity of", "to": "##uc", "value": 1}, {"from": "offers the opportunity of", "to": ", the lack of reprod", "value": 1}, {"from": "offers the opportunity of", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "offers the opportunity of", "to": "##c ) allows", "value": 1}, {"from": "offers the opportunity of", "to": "##gnosis", "value": 1}, {"from": "offers the opportunity of", "to": "- g", "value": 1}, {"from": "##ip", "to": "background", "value": 1}, {"from": "##ip", "to": "##re population of", "value": 1}, {"from": "##ip", "to": "negative breast", "value": 1}, {"from": "##ip", "to": "barrier", "value": 1}, {"from": "##ip", "to": "clinical", "value": 1}, {"from": "##ip", "to": "##2 -", "value": 1}, {"from": "##ip", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##ip", "to": "##zkoa", "value": 1}, {"from": "##ip", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##ip", "to": "##donostia ) health", "value": 1}, {"from": "##ip", "to": "cancer", "value": 1}, {"from": "##ip", "to": "##uzkoa. eus.", "value": 1}, {"from": "##ip", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##ip", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##ip", "to": "personal", "value": 1}, {"from": "##ip", "to": "##ised therapy.", "value": 1}, {"from": "##ip", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##ip", "to": "##cent", "value": 1}, {"from": "##ip", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##ip", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##ip", "to": "her", "value": 1}, {"from": "##ip", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##ip", "to": "##n sebastian,", "value": 1}, {"from": "##ip", "to": "##umour response", "value": 1}, {"from": "##ip", "to": "a,", "value": 1}, {"from": "##ip", "to": "##uc", "value": 1}, {"from": "##ip", "to": ", the lack of reprod", "value": 1}, {"from": "##ip", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##ip", "to": "##c ) allows", "value": 1}, {"from": "##ip", "to": "##gnosis", "value": 1}, {"from": "##ip", "to": "- g", "value": 1}, {"from": "background", "to": "##re population of", "value": 1}, {"from": "background", "to": "negative breast", "value": 1}, {"from": "background", "to": "barrier", "value": 1}, {"from": "background", "to": "clinical", "value": 1}, {"from": "background", "to": "##2 -", "value": 1}, {"from": "background", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "background", "to": "##zkoa", "value": 1}, {"from": "background", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "background", "to": "##donostia ) health", "value": 1}, {"from": "background", "to": "cancer", "value": 1}, {"from": "background", "to": "##uzkoa. eus.", "value": 1}, {"from": "background", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "background", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "background", "to": "personal", "value": 1}, {"from": "background", "to": "##ised therapy.", "value": 1}, {"from": "background", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "background", "to": "##cent", "value": 1}, {"from": "background", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "background", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "background", "to": "her", "value": 1}, {"from": "background", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "background", "to": "##n sebastian,", "value": 1}, {"from": "background", "to": "##umour response", "value": 1}, {"from": "background", "to": "a,", "value": 1}, {"from": "background", "to": "##uc", "value": 1}, {"from": "background", "to": ", the lack of reprod", "value": 1}, {"from": "background", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "background", "to": "##c ) allows", "value": 1}, {"from": "background", "to": "##gnosis", "value": 1}, {"from": "background", "to": "- g", "value": 1}, {"from": "##re population of", "to": "negative breast", "value": 1}, {"from": "##re population of", "to": "barrier", "value": 1}, {"from": "##re population of", "to": "clinical", "value": 1}, {"from": "##re population of", "to": "##2 -", "value": 1}, {"from": "##re population of", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##re population of", "to": "##zkoa", "value": 1}, {"from": "##re population of", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##re population of", "to": "##donostia ) health", "value": 1}, {"from": "##re population of", "to": "cancer", "value": 1}, {"from": "##re population of", "to": "##uzkoa. eus.", "value": 1}, {"from": "##re population of", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##re population of", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##re population of", "to": "personal", "value": 1}, {"from": "##re population of", "to": "##ised therapy.", "value": 1}, {"from": "##re population of", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##re population of", "to": "##cent", "value": 1}, {"from": "##re population of", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##re population of", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##re population of", "to": "her", "value": 1}, {"from": "##re population of", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##re population of", "to": "##n sebastian,", "value": 1}, {"from": "##re population of", "to": "##umour response", "value": 1}, {"from": "##re population of", "to": "a,", "value": 1}, {"from": "##re population of", "to": "##uc", "value": 1}, {"from": "##re population of", "to": ", the lack of reprod", "value": 1}, {"from": "##re population of", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##re population of", "to": "##c ) allows", "value": 1}, {"from": "##re population of", "to": "##gnosis", "value": 1}, {"from": "##re population of", "to": "- g", "value": 1}, {"from": "negative breast", "to": "barrier", "value": 1}, {"from": "negative breast", "to": "clinical", "value": 1}, {"from": "negative breast", "to": "##2 -", "value": 1}, {"from": "negative breast", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "negative breast", "to": "##zkoa", "value": 1}, {"from": "negative breast", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "negative breast", "to": "##donostia ) health", "value": 1}, {"from": "negative breast", "to": "cancer", "value": 1}, {"from": "negative breast", "to": "##uzkoa. eus.", "value": 1}, {"from": "negative breast", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "negative breast", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "negative breast", "to": "personal", "value": 1}, {"from": "negative breast", "to": "##ised therapy.", "value": 1}, {"from": "negative breast", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "negative breast", "to": "##cent", "value": 1}, {"from": "negative breast", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "negative breast", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "negative breast", "to": "her", "value": 1}, {"from": "negative breast", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "negative breast", "to": "##n sebastian,", "value": 1}, {"from": "negative breast", "to": "##umour response", "value": 1}, {"from": "negative breast", "to": "a,", "value": 1}, {"from": "negative breast", "to": "##uc", "value": 1}, {"from": "negative breast", "to": ", the lack of reprod", "value": 1}, {"from": "negative breast", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "negative breast", "to": "##c ) allows", "value": 1}, {"from": "negative breast", "to": "##gnosis", "value": 1}, {"from": "negative breast", "to": "- g", "value": 1}, {"from": "barrier", "to": "clinical", "value": 1}, {"from": "barrier", "to": "##2 -", "value": 1}, {"from": "barrier", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "barrier", "to": "##zkoa", "value": 1}, {"from": "barrier", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "barrier", "to": "##donostia ) health", "value": 1}, {"from": "barrier", "to": "cancer", "value": 1}, {"from": "barrier", "to": "##uzkoa. eus.", "value": 1}, {"from": "barrier", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "barrier", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "barrier", "to": "personal", "value": 1}, {"from": "barrier", "to": "##ised therapy.", "value": 1}, {"from": "barrier", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "barrier", "to": "##cent", "value": 1}, {"from": "barrier", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "barrier", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "barrier", "to": "her", "value": 1}, {"from": "barrier", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "barrier", "to": "##n sebastian,", "value": 1}, {"from": "barrier", "to": "##umour response", "value": 1}, {"from": "barrier", "to": "a,", "value": 1}, {"from": "barrier", "to": "##uc", "value": 1}, {"from": "barrier", "to": ", the lack of reprod", "value": 1}, {"from": "barrier", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "barrier", "to": "##c ) allows", "value": 1}, {"from": "barrier", "to": "##gnosis", "value": 1}, {"from": "barrier", "to": "- g", "value": 1}, {"from": "clinical", "to": "##2 -", "value": 1}, {"from": "clinical", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "clinical", "to": "##zkoa", "value": 1}, {"from": "clinical", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "clinical", "to": "##donostia ) health", "value": 1}, {"from": "clinical", "to": "cancer", "value": 1}, {"from": "clinical", "to": "##uzkoa. eus.", "value": 1}, {"from": "clinical", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "clinical", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "clinical", "to": "personal", "value": 1}, {"from": "clinical", "to": "##ised therapy.", "value": 1}, {"from": "clinical", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "clinical", "to": "##cent", "value": 1}, {"from": "clinical", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "clinical", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "clinical", "to": "her", "value": 1}, {"from": "clinical", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "clinical", "to": "##n sebastian,", "value": 1}, {"from": "clinical", "to": "##umour response", "value": 1}, {"from": "clinical", "to": "a,", "value": 1}, {"from": "clinical", "to": "##uc", "value": 1}, {"from": "clinical", "to": ", the lack of reprod", "value": 1}, {"from": "clinical", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "clinical", "to": "##c ) allows", "value": 1}, {"from": "clinical", "to": "##gnosis", "value": 1}, {"from": "clinical", "to": "- g", "value": 1}, {"from": "##2 -", "to": "##ly relevant molecular reporters of response to net in a multi", "value": 1}, {"from": "##2 -", "to": "##zkoa", "value": 1}, {"from": "##2 -", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##2 -", "to": "##donostia ) health", "value": 1}, {"from": "##2 -", "to": "cancer", "value": 1}, {"from": "##2 -", "to": "##uzkoa. eus.", "value": 1}, {"from": "##2 -", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##2 -", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##2 -", "to": "personal", "value": 1}, {"from": "##2 -", "to": "##ised therapy.", "value": 1}, {"from": "##2 -", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##2 -", "to": "##cent", "value": 1}, {"from": "##2 -", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##2 -", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##2 -", "to": "her", "value": 2}, {"from": "##2 -", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##2 -", "to": "##n sebastian,", "value": 1}, {"from": "##2 -", "to": "##umour response", "value": 1}, {"from": "##2 -", "to": "a,", "value": 1}, {"from": "##2 -", "to": "##uc", "value": 1}, {"from": "##2 -", "to": ", the lack of reprod", "value": 1}, {"from": "##2 -", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##2 -", "to": "##c ) allows", "value": 1}, {"from": "##2 -", "to": "##gnosis", "value": 1}, {"from": "##2 -", "to": "- g", "value": 1}, {"from": "##2 -", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "##2 -", "to": "in ki", "value": 1}, {"from": "##2 -", "to": "##cu", "value": 1}, {"from": "##2 -", "to": "positive", "value": 1}, {"from": "##2 -", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##2 -", "to": "##rrence", "value": 1}, {"from": "##2 -", "to": "percentage", "value": 1}, {"from": "##2 -", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##2 -", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##2 -", "to": "from l", "value": 1}, {"from": "##2 -", "to": "presented", "value": 1}, {"from": "##2 -", "to": "results", "value": 1}, {"from": "##2 -", "to": "pam50 - derived risk of", "value": 1}, {"from": "##2 -", "to": "er + /", "value": 1}, {"from": "##2 -", "to": "##nal a to normal - like", "value": 1}, {"from": "##2 -", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##2 -", "to": "cells", "value": 1}, {"from": "##2 -", "to": "change", "value": 1}, {"from": "##2 -", "to": "after", "value": 1}, {"from": "##2 -", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##2 -", "to": "of intrinsic sub", "value": 1}, {"from": "##2 -", "to": "p53", "value": 1}, {"from": "##2 -", "to": "##is.", "value": 1}, {"from": "##2 -", "to": "biomark", "value": 1}, {"from": "##2 -", "to": "subtype after", "value": 1}, {"from": "##2 -", "to": "net", "value": 1}, {"from": "##2 -", "to": "of", "value": 1}, {"from": "##2 -", "to": "##c patients", "value": 1}, {"from": "##2 -", "to": "net as a putative", "value": 1}, {"from": "##2 -", "to": "##umour cellularity size", "value": 1}, {"from": "##2 -", "to": "radio", "value": 1}, {"from": "##2 -", "to": ") and lower", "value": 1}, {"from": "##2 -", "to": "better", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##zkoa", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##donostia ) health", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "cancer", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##uzkoa. eus.", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "personal", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##ised therapy.", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##cent", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "her", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##n sebastian,", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##umour response", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "a,", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##uc", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": ", the lack of reprod", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##c ) allows", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "##gnosis", "value": 1}, {"from": "##ly relevant molecular reporters of response to net in a multi", "to": "- g", "value": 1}, {"from": "##zkoa", "to": "to increase its indications. methods : in this study we searched for", "value": 1}, {"from": "##zkoa", "to": "##donostia ) health", "value": 1}, {"from": "##zkoa", "to": "cancer", "value": 1}, {"from": "##zkoa", "to": "##uzkoa. eus.", "value": 1}, {"from": "##zkoa", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##zkoa", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##zkoa", "to": "personal", "value": 1}, {"from": "##zkoa", "to": "##ised therapy.", "value": 1}, {"from": "##zkoa", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##zkoa", "to": "##cent", "value": 1}, {"from": "##zkoa", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##zkoa", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##zkoa", "to": "her", "value": 1}, {"from": "##zkoa", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##zkoa", "to": "##n sebastian,", "value": 1}, {"from": "##zkoa", "to": "##umour response", "value": 1}, {"from": "##zkoa", "to": "a,", "value": 1}, {"from": "##zkoa", "to": "##uc", "value": 1}, {"from": "##zkoa", "to": ", the lack of reprod", "value": 1}, {"from": "##zkoa", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##zkoa", "to": "##c ) allows", "value": 1}, {"from": "##zkoa", "to": "##gnosis", "value": 1}, {"from": "##zkoa", "to": "- g", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##donostia ) health", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "cancer", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##uzkoa. eus.", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "personal", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##ised therapy.", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##cent", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "her", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##n sebastian,", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##umour response", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "a,", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##uc", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": ", the lack of reprod", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##c ) allows", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "##gnosis", "value": 1}, {"from": "to increase its indications. methods : in this study we searched for", "to": "- g", "value": 1}, {"from": "##donostia ) health", "to": "cancer", "value": 1}, {"from": "##donostia ) health", "to": "##uzkoa. eus.", "value": 1}, {"from": "##donostia ) health", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##donostia ) health", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##donostia ) health", "to": "personal", "value": 1}, {"from": "##donostia ) health", "to": "##ised therapy.", "value": 1}, {"from": "##donostia ) health", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##donostia ) health", "to": "##cent", "value": 1}, {"from": "##donostia ) health", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##donostia ) health", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##donostia ) health", "to": "her", "value": 1}, {"from": "##donostia ) health", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##donostia ) health", "to": "##n sebastian,", "value": 1}, {"from": "##donostia ) health", "to": "##umour response", "value": 1}, {"from": "##donostia ) health", "to": "a,", "value": 1}, {"from": "##donostia ) health", "to": "##uc", "value": 1}, {"from": "##donostia ) health", "to": ", the lack of reprod", "value": 1}, {"from": "##donostia ) health", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##donostia ) health", "to": "##c ) allows", "value": 1}, {"from": "##donostia ) health", "to": "##gnosis", "value": 1}, {"from": "##donostia ) health", "to": "- g", "value": 1}, {"from": "cancer", "to": "##uzkoa. eus.", "value": 1}, {"from": "cancer", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "cancer", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "cancer", "to": "personal", "value": 1}, {"from": "cancer", "to": "##ised therapy.", "value": 1}, {"from": "cancer", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "cancer", "to": "##cent", "value": 1}, {"from": "cancer", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "cancer", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "cancer", "to": "her", "value": 1}, {"from": "cancer", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "cancer", "to": "##n sebastian,", "value": 1}, {"from": "cancer", "to": "##umour response", "value": 1}, {"from": "cancer", "to": "a,", "value": 1}, {"from": "cancer", "to": "##uc", "value": 1}, {"from": "cancer", "to": ", the lack of reprod", "value": 1}, {"from": "cancer", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "cancer", "to": "##c ) allows", "value": 1}, {"from": "cancer", "to": "##gnosis", "value": 1}, {"from": "cancer", "to": "- g", "value": 1}, {"from": "cancer", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "cancer", "to": "##ifer", "value": 1}, {"from": "cancer", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "cancer", "to": "in the", "value": 1}, {"from": "cancer", "to": "##ne - c", "value": 1}, {"from": "cancer", "to": ", tnf signaling", "value": 1}, {"from": "cancer", "to": ", which", "value": 1}, {"from": "cancer", "to": "down - regulated", "value": 1}, {"from": "cancer", "to": "including c", "value": 1}, {"from": "cancer", "to": "##ytoki", "value": 1}, {"from": "cancer", "to": "detected", "value": 1}, {"from": "cancer", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "cancer", "to": "vs", "value": 1}, {"from": "cancer", "to": "##cer assays. the", "value": 1}, {"from": "cancer", "to": "or", "value": 1}, {"from": "cancer", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "cancer", "to": "##ne receptor", "value": 1}, {"from": "cancer", "to": "##ap", "value": 1}, {"from": "cancer", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "cancer", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "cancer", "to": "via", "value": 1}, {"from": "cancer", "to": "anti", "value": 1}, {"from": "cancer", "to": "##n - \u03b3", "value": 1}, {"from": "cancer", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "cancer", "to": "f biotechnology engineering,", "value": 1}, {"from": "cancer", "to": "were up -", "value": 1}, {"from": "cancer", "to": ", nod - like receptor signaling", "value": 1}, {"from": "cancer", "to": "##ation, pro", "value": 1}, {"from": "cancer", "to": "pathways", "value": 1}, {"from": "cancer", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "cancer", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "cancer", "to": "pathway", "value": 1}, {"from": "cancer", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##uzkoa. eus.", "to": ". electronic address : aurruticoechea @ onkologikoa. org.", "value": 1}, {"from": "##uzkoa. eus.", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": "##uzkoa. eus.", "to": "personal", "value": 1}, {"from": "##uzkoa. eus.", "to": "##ised therapy.", "value": 1}, {"from": "##uzkoa. eus.", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##uzkoa. eus.", "to": "##cent", "value": 1}, {"from": "##uzkoa. eus.", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##uzkoa. eus.", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##uzkoa. eus.", "to": "her", "value": 1}, {"from": "##uzkoa. eus.", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##uzkoa. eus.", "to": "##n sebastian,", "value": 1}, {"from": "##uzkoa. eus.", "to": "##umour response", "value": 1}, {"from": "##uzkoa. eus.", "to": "a,", "value": 1}, {"from": "##uzkoa. eus.", "to": "##uc", "value": 1}, {"from": "##uzkoa. eus.", "to": ", the lack of reprod", "value": 1}, {"from": "##uzkoa. eus.", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##uzkoa. eus.", "to": "##c ) allows", "value": 1}, {"from": "##uzkoa. eus.", "to": "##gnosis", "value": 1}, {"from": "##uzkoa. eus.", "to": "- g", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": ": neoadjuvant endocrine therapy", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "personal", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##ised therapy.", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##cent", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "her", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##n sebastian,", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##umour response", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "a,", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##uc", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": ", the lack of reprod", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##c ) allows", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "##gnosis", "value": 1}, {"from": ". electronic address : aurruticoechea @ onkologikoa. org.", "to": "- g", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "personal", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##ised therapy.", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##cent", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "oestrogen receptor - positive /", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "her", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##n sebastian,", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##umour response", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "a,", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##uc", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": ", the lack of reprod", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##c ) allows", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "##gnosis", "value": 1}, {"from": ": neoadjuvant endocrine therapy", "to": "- g", "value": 1}, {"from": "personal", "to": "##ised therapy.", "value": 1}, {"from": "personal", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "personal", "to": "##cent", "value": 1}, {"from": "personal", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "personal", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "personal", "to": "her", "value": 1}, {"from": "personal", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "personal", "to": "##n sebastian,", "value": 1}, {"from": "personal", "to": "##umour response", "value": 1}, {"from": "personal", "to": "a,", "value": 1}, {"from": "personal", "to": "##uc", "value": 1}, {"from": "personal", "to": ", the lack of reprod", "value": 1}, {"from": "personal", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "personal", "to": "##c ) allows", "value": 1}, {"from": "personal", "to": "##gnosis", "value": 1}, {"from": "personal", "to": "- g", "value": 1}, {"from": "##ised therapy.", "to": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "value": 1}, {"from": "##ised therapy.", "to": "##cent", "value": 1}, {"from": "##ised therapy.", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##ised therapy.", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##ised therapy.", "to": "her", "value": 1}, {"from": "##ised therapy.", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##ised therapy.", "to": "##n sebastian,", "value": 1}, {"from": "##ised therapy.", "to": "##umour response", "value": 1}, {"from": "##ised therapy.", "to": "a,", "value": 1}, {"from": "##ised therapy.", "to": "##uc", "value": 1}, {"from": "##ised therapy.", "to": ", the lack of reprod", "value": 1}, {"from": "##ised therapy.", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##ised therapy.", "to": "##c ) allows", "value": 1}, {"from": "##ised therapy.", "to": "##gnosis", "value": 1}, {"from": "##ised therapy.", "to": "- g", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##cent", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "her", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##n sebastian,", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##umour response", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "a,", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##uc", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": ", the lack of reprod", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##c ) allows", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "##gnosis", "value": 1}, {"from": "; gipuzkoa cancer unit / osi donostialdea - onkologikoa,", "to": "- g", "value": 1}, {"from": "##cent", "to": "oestrogen receptor - positive /", "value": 1}, {"from": "##cent", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "##cent", "to": "her", "value": 1}, {"from": "##cent", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "##cent", "to": "##n sebastian,", "value": 1}, {"from": "##cent", "to": "##umour response", "value": 1}, {"from": "##cent", "to": "a,", "value": 1}, {"from": "##cent", "to": "##uc", "value": 1}, {"from": "##cent", "to": ", the lack of reprod", "value": 1}, {"from": "##cent", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##cent", "to": "##c ) allows", "value": 1}, {"from": "##cent", "to": "##gnosis", "value": 1}, {"from": "##cent", "to": "- g", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "evaluation of treatment sensitivity by monitoring", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "her", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##n sebastian,", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##umour response", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "a,", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##uc", "value": 1}, {"from": "oestrogen receptor - positive /", "to": ", the lack of reprod", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##c ) allows", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "##gnosis", "value": 1}, {"from": "oestrogen receptor - positive /", "to": "- g", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "her", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##n sebastian,", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##umour response", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "a,", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##uc", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": ", the lack of reprod", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##c ) allows", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "##gnosis", "value": 1}, {"from": "evaluation of treatment sensitivity by monitoring", "to": "- g", "value": 1}, {"from": "her", "to": "##ible biomarkers to assess response and long - term pro", "value": 1}, {"from": "her", "to": "##n sebastian,", "value": 1}, {"from": "her", "to": "##umour response", "value": 1}, {"from": "her", "to": "a,", "value": 1}, {"from": "her", "to": "##uc", "value": 1}, {"from": "her", "to": ", the lack of reprod", "value": 1}, {"from": "her", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "her", "to": "##c ) allows", "value": 1}, {"from": "her", "to": "##gnosis", "value": 1}, {"from": "her", "to": "- g", "value": 1}, {"from": "her", "to": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "value": 1}, {"from": "her", "to": "in ki", "value": 1}, {"from": "her", "to": "##cu", "value": 1}, {"from": "her", "to": "positive", "value": 1}, {"from": "her", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "her", "to": "##rrence", "value": 1}, {"from": "her", "to": "percentage", "value": 1}, {"from": "her", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "her", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "her", "to": "from l", "value": 1}, {"from": "her", "to": "presented", "value": 1}, {"from": "her", "to": "results", "value": 1}, {"from": "her", "to": "pam50 - derived risk of", "value": 1}, {"from": "her", "to": "er + /", "value": 1}, {"from": "her", "to": "##nal a to normal - like", "value": 1}, {"from": "her", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "her", "to": "cells", "value": 1}, {"from": "her", "to": "change", "value": 1}, {"from": "her", "to": "after", "value": 1}, {"from": "her", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "her", "to": "of intrinsic sub", "value": 1}, {"from": "her", "to": "p53", "value": 1}, {"from": "her", "to": "##is.", "value": 1}, {"from": "her", "to": "biomark", "value": 1}, {"from": "her", "to": "subtype after", "value": 1}, {"from": "her", "to": "net", "value": 1}, {"from": "her", "to": "of", "value": 1}, {"from": "her", "to": "##c patients", "value": 1}, {"from": "her", "to": "net as a putative", "value": 1}, {"from": "her", "to": "##umour cellularity size", "value": 1}, {"from": "her", "to": "radio", "value": 1}, {"from": "her", "to": ") and lower", "value": 1}, {"from": "her", "to": "better", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "##n sebastian,", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "##umour response", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "a,", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "##uc", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": ", the lack of reprod", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "##c ) allows", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "##gnosis", "value": 1}, {"from": "##ible biomarkers to assess response and long - term pro", "to": "- g", "value": 1}, {"from": "##n sebastian,", "to": "##umour response", "value": 1}, {"from": "##n sebastian,", "to": "a,", "value": 1}, {"from": "##n sebastian,", "to": "##uc", "value": 1}, {"from": "##n sebastian,", "to": ", the lack of reprod", "value": 1}, {"from": "##n sebastian,", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##n sebastian,", "to": "##c ) allows", "value": 1}, {"from": "##n sebastian,", "to": "##gnosis", "value": 1}, {"from": "##n sebastian,", "to": "- g", "value": 1}, {"from": "##umour response", "to": "a,", "value": 1}, {"from": "##umour response", "to": "##uc", "value": 1}, {"from": "##umour response", "to": ", the lack of reprod", "value": 1}, {"from": "##umour response", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##umour response", "to": "##c ) allows", "value": 1}, {"from": "##umour response", "to": "##gnosis", "value": 1}, {"from": "##umour response", "to": "- g", "value": 1}, {"from": "a,", "to": "##uc", "value": 1}, {"from": "a,", "to": ", the lack of reprod", "value": 1}, {"from": "a,", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "a,", "to": "##c ) allows", "value": 1}, {"from": "a,", "to": "##gnosis", "value": 1}, {"from": "a,", "to": "- g", "value": 1}, {"from": "##uc", "to": ", the lack of reprod", "value": 1}, {"from": "##uc", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": "##uc", "to": "##c ) allows", "value": 1}, {"from": "##uc", "to": "##gnosis", "value": 1}, {"from": "##uc", "to": "- g", "value": 1}, {"from": ", the lack of reprod", "to": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "value": 1}, {"from": ", the lack of reprod", "to": "##c ) allows", "value": 1}, {"from": ", the lack of reprod", "to": "##gnosis", "value": 1}, {"from": ", the lack of reprod", "to": "- g", "value": 1}, {"from": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "to": "##c ) allows", "value": 1}, {"from": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "to": "##gnosis", "value": 1}, {"from": "; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @", "to": "- g", "value": 1}, {"from": "##c ) allows", "to": "##gnosis", "value": 1}, {"from": "##c ) allows", "to": "- g", "value": 1}, {"from": "##gnosis", "to": "- g", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "in ki", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##cu", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "positive", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##rrence", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "percentage", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "from l", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "presented", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "results", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "pam50 - derived risk of", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "er + /", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##nal a to normal - like", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "cells", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "change", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "after", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "of intrinsic sub", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "p53", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##is.", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "biomark", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "subtype after", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "net", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "of", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##c patients", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "net as a putative", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "##umour cellularity size", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "radio", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": ") and lower", "value": 1}, {"from": "##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p", "to": "better", "value": 1}, {"from": "in ki", "to": "##cu", "value": 1}, {"from": "in ki", "to": "positive", "value": 1}, {"from": "in ki", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "in ki", "to": "##rrence", "value": 1}, {"from": "in ki", "to": "percentage", "value": 1}, {"from": "in ki", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "in ki", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "in ki", "to": "from l", "value": 1}, {"from": "in ki", "to": "presented", "value": 1}, {"from": "in ki", "to": "results", "value": 1}, {"from": "in ki", "to": "pam50 - derived risk of", "value": 1}, {"from": "in ki", "to": "er + /", "value": 1}, {"from": "in ki", "to": "##nal a to normal - like", "value": 1}, {"from": "in ki", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "in ki", "to": "cells", "value": 1}, {"from": "in ki", "to": "change", "value": 1}, {"from": "in ki", "to": "after", "value": 1}, {"from": "in ki", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "in ki", "to": "of intrinsic sub", "value": 1}, {"from": "in ki", "to": "p53", "value": 1}, {"from": "in ki", "to": "##is.", "value": 1}, {"from": "in ki", "to": "biomark", "value": 1}, {"from": "in ki", "to": "subtype after", "value": 1}, {"from": "in ki", "to": "net", "value": 1}, {"from": "in ki", "to": "of", "value": 1}, {"from": "in ki", "to": "##c patients", "value": 1}, {"from": "in ki", "to": "net as a putative", "value": 1}, {"from": "in ki", "to": "##umour cellularity size", "value": 1}, {"from": "in ki", "to": "radio", "value": 1}, {"from": "in ki", "to": ") and lower", "value": 1}, {"from": "in ki", "to": "better", "value": 1}, {"from": "##cu", "to": "positive", "value": 1}, {"from": "##cu", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "##cu", "to": "##rrence", "value": 1}, {"from": "##cu", "to": "percentage", "value": 1}, {"from": "##cu", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##cu", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##cu", "to": "from l", "value": 1}, {"from": "##cu", "to": "presented", "value": 1}, {"from": "##cu", "to": "results", "value": 1}, {"from": "##cu", "to": "pam50 - derived risk of", "value": 1}, {"from": "##cu", "to": "er + /", "value": 1}, {"from": "##cu", "to": "##nal a to normal - like", "value": 1}, {"from": "##cu", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##cu", "to": "cells", "value": 1}, {"from": "##cu", "to": "change", "value": 1}, {"from": "##cu", "to": "after", "value": 1}, {"from": "##cu", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##cu", "to": "of intrinsic sub", "value": 1}, {"from": "##cu", "to": "p53", "value": 1}, {"from": "##cu", "to": "##is.", "value": 1}, {"from": "##cu", "to": "biomark", "value": 1}, {"from": "##cu", "to": "subtype after", "value": 1}, {"from": "##cu", "to": "net", "value": 1}, {"from": "##cu", "to": "of", "value": 1}, {"from": "##cu", "to": "##c patients", "value": 1}, {"from": "##cu", "to": "net as a putative", "value": 1}, {"from": "##cu", "to": "##umour cellularity size", "value": 1}, {"from": "##cu", "to": "radio", "value": 1}, {"from": "##cu", "to": ") and lower", "value": 1}, {"from": "##cu", "to": "better", "value": 1}, {"from": "positive", "to": "##logical and pathological tumour responses, a significant larger decrease", "value": 1}, {"from": "positive", "to": "##rrence", "value": 1}, {"from": "positive", "to": "percentage", "value": 1}, {"from": "positive", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "positive", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "positive", "to": "from l", "value": 1}, {"from": "positive", "to": "presented", "value": 1}, {"from": "positive", "to": "results", "value": 1}, {"from": "positive", "to": "pam50 - derived risk of", "value": 1}, {"from": "positive", "to": "er + /", "value": 1}, {"from": "positive", "to": "##nal a to normal - like", "value": 1}, {"from": "positive", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "positive", "to": "cells", "value": 1}, {"from": "positive", "to": "change", "value": 1}, {"from": "positive", "to": "after", "value": 1}, {"from": "positive", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "positive", "to": "of intrinsic sub", "value": 1}, {"from": "positive", "to": "p53", "value": 1}, {"from": "positive", "to": "##is.", "value": 1}, {"from": "positive", "to": "biomark", "value": 1}, {"from": "positive", "to": "subtype after", "value": 1}, {"from": "positive", "to": "net", "value": 1}, {"from": "positive", "to": "of", "value": 1}, {"from": "positive", "to": "##c patients", "value": 1}, {"from": "positive", "to": "net as a putative", "value": 1}, {"from": "positive", "to": "##umour cellularity size", "value": 1}, {"from": "positive", "to": "radio", "value": 1}, {"from": "positive", "to": ") and lower", "value": 1}, {"from": "positive", "to": "better", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##rrence", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "percentage", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "from l", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "presented", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "results", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "pam50 - derived risk of", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "er + /", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##nal a to normal - like", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "cells", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "change", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "after", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "of intrinsic sub", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "p53", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##is.", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "biomark", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "subtype after", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "net", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "of", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##c patients", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "net as a putative", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "##umour cellularity size", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "radio", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": ") and lower", "value": 1}, {"from": "##logical and pathological tumour responses, a significant larger decrease", "to": "better", "value": 1}, {"from": "##rrence", "to": "percentage", "value": 1}, {"from": "##rrence", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "##rrence", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##rrence", "to": "from l", "value": 1}, {"from": "##rrence", "to": "presented", "value": 1}, {"from": "##rrence", "to": "results", "value": 1}, {"from": "##rrence", "to": "pam50 - derived risk of", "value": 1}, {"from": "##rrence", "to": "er + /", "value": 1}, {"from": "##rrence", "to": "##nal a to normal - like", "value": 1}, {"from": "##rrence", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##rrence", "to": "cells", "value": 1}, {"from": "##rrence", "to": "change", "value": 1}, {"from": "##rrence", "to": "after", "value": 1}, {"from": "##rrence", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##rrence", "to": "of intrinsic sub", "value": 1}, {"from": "##rrence", "to": "p53", "value": 1}, {"from": "##rrence", "to": "##is.", "value": 1}, {"from": "##rrence", "to": "biomark", "value": 1}, {"from": "##rrence", "to": "subtype after", "value": 1}, {"from": "##rrence", "to": "net", "value": 1}, {"from": "##rrence", "to": "of", "value": 1}, {"from": "##rrence", "to": "##c patients", "value": 1}, {"from": "##rrence", "to": "net as a putative", "value": 1}, {"from": "##rrence", "to": "##umour cellularity size", "value": 1}, {"from": "##rrence", "to": "radio", "value": 1}, {"from": "##rrence", "to": ") and lower", "value": 1}, {"from": "##rrence", "to": "better", "value": 1}, {"from": "percentage", "to": "##67 at surgery, lower preoperative endocrine prognostic", "value": 1}, {"from": "percentage", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "percentage", "to": "from l", "value": 1}, {"from": "percentage", "to": "presented", "value": 1}, {"from": "percentage", "to": "results", "value": 1}, {"from": "percentage", "to": "pam50 - derived risk of", "value": 1}, {"from": "percentage", "to": "er + /", "value": 1}, {"from": "percentage", "to": "##nal a to normal - like", "value": 1}, {"from": "percentage", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "percentage", "to": "cells", "value": 1}, {"from": "percentage", "to": "change", "value": 1}, {"from": "percentage", "to": "after", "value": 1}, {"from": "percentage", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "percentage", "to": "of intrinsic sub", "value": 1}, {"from": "percentage", "to": "p53", "value": 1}, {"from": "percentage", "to": "##is.", "value": 1}, {"from": "percentage", "to": "biomark", "value": 1}, {"from": "percentage", "to": "subtype after", "value": 1}, {"from": "percentage", "to": "net", "value": 1}, {"from": "percentage", "to": "of", "value": 1}, {"from": "percentage", "to": "##c patients", "value": 1}, {"from": "percentage", "to": "net as a putative", "value": 1}, {"from": "percentage", "to": "##umour cellularity size", "value": 1}, {"from": "percentage", "to": "radio", "value": 1}, {"from": "percentage", "to": ") and lower", "value": 1}, {"from": "percentage", "to": "better", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "was associated with decreased response to net. conclusions : our findings highlight the", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "from l", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "presented", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "results", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "pam50 - derived risk of", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "er + /", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "##nal a to normal - like", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "cells", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "change", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "after", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "of intrinsic sub", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "p53", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "##is.", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "biomark", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "subtype after", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "net", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "of", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "##c patients", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "net as a putative", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "##umour cellularity size", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "radio", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": ") and lower", "value": 1}, {"from": "##67 at surgery, lower preoperative endocrine prognostic", "to": "better", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "from l", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "presented", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "results", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "pam50 - derived risk of", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "er + /", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "##nal a to normal - like", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "cells", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "change", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "after", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "of intrinsic sub", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "p53", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "##is.", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "biomark", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "subtype after", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "net", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "of", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "##c patients", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "net as a putative", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "##umour cellularity size", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "radio", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": ") and lower", "value": 1}, {"from": "was associated with decreased response to net. conclusions : our findings highlight the", "to": "better", "value": 1}, {"from": "from l", "to": "presented", "value": 1}, {"from": "from l", "to": "results", "value": 1}, {"from": "from l", "to": "pam50 - derived risk of", "value": 1}, {"from": "from l", "to": "er + /", "value": 1}, {"from": "from l", "to": "##nal a to normal - like", "value": 1}, {"from": "from l", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "from l", "to": "cells", "value": 1}, {"from": "from l", "to": "change", "value": 1}, {"from": "from l", "to": "after", "value": 1}, {"from": "from l", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "from l", "to": "of intrinsic sub", "value": 1}, {"from": "from l", "to": "p53", "value": 1}, {"from": "from l", "to": "##is.", "value": 1}, {"from": "from l", "to": "biomark", "value": 1}, {"from": "from l", "to": "subtype after", "value": 1}, {"from": "from l", "to": "net", "value": 1}, {"from": "from l", "to": "of", "value": 1}, {"from": "from l", "to": "##c patients", "value": 1}, {"from": "from l", "to": "net as a putative", "value": 1}, {"from": "from l", "to": "##umour cellularity size", "value": 1}, {"from": "from l", "to": "radio", "value": 1}, {"from": "from l", "to": ") and lower", "value": 1}, {"from": "from l", "to": "better", "value": 1}, {"from": "presented", "to": "results", "value": 1}, {"from": "presented", "to": "pam50 - derived risk of", "value": 1}, {"from": "presented", "to": "er + /", "value": 1}, {"from": "presented", "to": "##nal a to normal - like", "value": 1}, {"from": "presented", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "presented", "to": "cells", "value": 1}, {"from": "presented", "to": "change", "value": 1}, {"from": "presented", "to": "after", "value": 1}, {"from": "presented", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "presented", "to": "of intrinsic sub", "value": 1}, {"from": "presented", "to": "p53", "value": 1}, {"from": "presented", "to": "##is.", "value": 1}, {"from": "presented", "to": "biomark", "value": 1}, {"from": "presented", "to": "subtype after", "value": 1}, {"from": "presented", "to": "net", "value": 1}, {"from": "presented", "to": "of", "value": 1}, {"from": "presented", "to": "##c patients", "value": 1}, {"from": "presented", "to": "net as a putative", "value": 1}, {"from": "presented", "to": "##umour cellularity size", "value": 1}, {"from": "presented", "to": "radio", "value": 1}, {"from": "presented", "to": ") and lower", "value": 1}, {"from": "presented", "to": "better", "value": 1}, {"from": "results", "to": "pam50 - derived risk of", "value": 1}, {"from": "results", "to": "er + /", "value": 1}, {"from": "results", "to": "##nal a to normal - like", "value": 1}, {"from": "results", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "results", "to": "cells", "value": 1}, {"from": "results", "to": "change", "value": 1}, {"from": "results", "to": "after", "value": 1}, {"from": "results", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "results", "to": "of intrinsic sub", "value": 1}, {"from": "results", "to": "p53", "value": 1}, {"from": "results", "to": "##is.", "value": 1}, {"from": "results", "to": "biomark", "value": 1}, {"from": "results", "to": "subtype after", "value": 1}, {"from": "results", "to": "net", "value": 1}, {"from": "results", "to": "of", "value": 1}, {"from": "results", "to": "##c patients", "value": 1}, {"from": "results", "to": "net as a putative", "value": 1}, {"from": "results", "to": "##umour cellularity size", "value": 1}, {"from": "results", "to": "radio", "value": 1}, {"from": "results", "to": ") and lower", "value": 1}, {"from": "results", "to": "better", "value": 1}, {"from": "results", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "results", "to": "benefit", "value": 1}, {"from": "results", "to": "##26, 000 ;", "value": 1}, {"from": "results", "to": "effective", "value": 1}, {"from": "results", "to": "it was cost - saving", "value": 1}, {"from": "results", "to": "threshold", "value": 1}, {"from": "results", "to": "- 435, 677 )", "value": 1}, {"from": "results", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "results", "to": "##aly", "value": 1}, {"from": "results", "to": "in the", "value": 1}, {"from": "results", "to": "cost", "value": 1}, {"from": "results", "to": "\u20ac", "value": 1}, {"from": "results", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "results", "to": "- 620170,", "value": 1}, {"from": "results", "to": "##r )", "value": 1}, {"from": "results", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "results", "to": "societal perspective", "value": 1}, {"from": "results", "to": "candidates, the strategy", "value": 1}, {"from": "results", "to": "cost - effective", "value": 1}, {"from": "results", "to": "incre", "value": 1}, {"from": "results", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "results", "to": "##mental", "value": 1}, {"from": "results", "to": "the cost -", "value": 1}, {"from": "results", "to": "was cost - effective", "value": 1}, {"from": "results", "to": "above", "value": 1}, {"from": "results", "to": "was obtained from statistics norway.", "value": 1}, {"from": "results", "to": "per quality - adjusted life -", "value": 1}, {"from": "results", "to": "was cost - saving", "value": 1}, {"from": "results", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "results", "to": "chemotherapy", "value": 1}, {"from": "results", "to": "in both the healthcare", "value": 1}, {"from": "results", "to": "years", "value": 1}, {"from": "results", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "results", "to": "- per q", "value": 1}, {"from": "results", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "results", "to": ". conclusions", "value": 1}, {"from": "results", "to": ". selecting patient", "value": 1}, {"from": "results", "to": "ice", "value": 1}, {"from": "results", "to": "##8884 and", "value": 1}, {"from": "results", "to": "gained", "value": 1}, {"from": "results", "to": "the emit", "value": 1}, {"from": "results", "to": "records. including all pn0 patients", "value": 1}, {"from": "results", "to": "sector", "value": 1}, {"from": "results", "to": "not", "value": 1}, {"from": "pam50 - derived risk of", "to": "er + /", "value": 1}, {"from": "pam50 - derived risk of", "to": "##nal a to normal - like", "value": 1}, {"from": "pam50 - derived risk of", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "pam50 - derived risk of", "to": "cells", "value": 1}, {"from": "pam50 - derived risk of", "to": "change", "value": 1}, {"from": "pam50 - derived risk of", "to": "after", "value": 1}, {"from": "pam50 - derived risk of", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "pam50 - derived risk of", "to": "of intrinsic sub", "value": 1}, {"from": "pam50 - derived risk of", "to": "p53", "value": 1}, {"from": "pam50 - derived risk of", "to": "##is.", "value": 1}, {"from": "pam50 - derived risk of", "to": "biomark", "value": 1}, {"from": "pam50 - derived risk of", "to": "subtype after", "value": 1}, {"from": "pam50 - derived risk of", "to": "net", "value": 1}, {"from": "pam50 - derived risk of", "to": "of", "value": 1}, {"from": "pam50 - derived risk of", "to": "##c patients", "value": 1}, {"from": "pam50 - derived risk of", "to": "net as a putative", "value": 1}, {"from": "pam50 - derived risk of", "to": "##umour cellularity size", "value": 1}, {"from": "pam50 - derived risk of", "to": "radio", "value": 1}, {"from": "pam50 - derived risk of", "to": ") and lower", "value": 1}, {"from": "pam50 - derived risk of", "to": "better", "value": 1}, {"from": "er + /", "to": "##nal a to normal - like", "value": 1}, {"from": "er + /", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "er + /", "to": "cells", "value": 1}, {"from": "er + /", "to": "change", "value": 1}, {"from": "er + /", "to": "after", "value": 1}, {"from": "er + /", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "er + /", "to": "of intrinsic sub", "value": 1}, {"from": "er + /", "to": "p53", "value": 1}, {"from": "er + /", "to": "##is.", "value": 1}, {"from": "er + /", "to": "biomark", "value": 1}, {"from": "er + /", "to": "subtype after", "value": 1}, {"from": "er + /", "to": "net", "value": 1}, {"from": "er + /", "to": "of", "value": 1}, {"from": "er + /", "to": "##c patients", "value": 1}, {"from": "er + /", "to": "net as a putative", "value": 1}, {"from": "er + /", "to": "##umour cellularity size", "value": 1}, {"from": "er + /", "to": "radio", "value": 1}, {"from": "er + /", "to": ") and lower", "value": 1}, {"from": "er + /", "to": "better", "value": 1}, {"from": "##nal a to normal - like", "to": ": our pam50 analyses show that tumours changing from l", "value": 1}, {"from": "##nal a to normal - like", "to": "cells", "value": 1}, {"from": "##nal a to normal - like", "to": "change", "value": 1}, {"from": "##nal a to normal - like", "to": "after", "value": 1}, {"from": "##nal a to normal - like", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "##nal a to normal - like", "to": "of intrinsic sub", "value": 1}, {"from": "##nal a to normal - like", "to": "p53", "value": 1}, {"from": "##nal a to normal - like", "to": "##is.", "value": 1}, {"from": "##nal a to normal - like", "to": "biomark", "value": 1}, {"from": "##nal a to normal - like", "to": "subtype after", "value": 1}, {"from": "##nal a to normal - like", "to": "net", "value": 1}, {"from": "##nal a to normal - like", "to": "of", "value": 1}, {"from": "##nal a to normal - like", "to": "##c patients", "value": 1}, {"from": "##nal a to normal - like", "to": "net as a putative", "value": 1}, {"from": "##nal a to normal - like", "to": "##umour cellularity size", "value": 1}, {"from": "##nal a to normal - like", "to": "radio", "value": 1}, {"from": "##nal a to normal - like", "to": ") and lower", "value": 1}, {"from": "##nal a to normal - like", "to": "better", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "cells", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "change", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "after", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "##or ) following net. in addition, the", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "of intrinsic sub", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "p53", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "##is.", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "biomark", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "subtype after", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "net", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "of", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "##c patients", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "net as a putative", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "##umour cellularity size", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "radio", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": ") and lower", "value": 1}, {"from": ": our pam50 analyses show that tumours changing from l", "to": "better", "value": 1}, {"from": "cells", "to": "change", "value": 1}, {"from": "cells", "to": "after", "value": 1}, {"from": "cells", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "cells", "to": "of intrinsic sub", "value": 1}, {"from": "cells", "to": "p53", "value": 1}, {"from": "cells", "to": "##is.", "value": 1}, {"from": "cells", "to": "biomark", "value": 1}, {"from": "cells", "to": "subtype after", "value": 1}, {"from": "cells", "to": "net", "value": 1}, {"from": "cells", "to": "of", "value": 1}, {"from": "cells", "to": "##c patients", "value": 1}, {"from": "cells", "to": "net as a putative", "value": 1}, {"from": "cells", "to": "##umour cellularity size", "value": 1}, {"from": "cells", "to": "radio", "value": 1}, {"from": "cells", "to": ") and lower", "value": 1}, {"from": "cells", "to": "better", "value": 1}, {"from": "change", "to": "after", "value": 1}, {"from": "change", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "change", "to": "of intrinsic sub", "value": 1}, {"from": "change", "to": "p53", "value": 1}, {"from": "change", "to": "##is.", "value": 1}, {"from": "change", "to": "biomark", "value": 1}, {"from": "change", "to": "subtype after", "value": 1}, {"from": "change", "to": "net", "value": 1}, {"from": "change", "to": "of", "value": 1}, {"from": "change", "to": "##c patients", "value": 1}, {"from": "change", "to": "net as a putative", "value": 1}, {"from": "change", "to": "##umour cellularity size", "value": 1}, {"from": "change", "to": "radio", "value": 1}, {"from": "change", "to": ") and lower", "value": 1}, {"from": "change", "to": "better", "value": 1}, {"from": "after", "to": "##or ) following net. in addition, the", "value": 1}, {"from": "after", "to": "of intrinsic sub", "value": 1}, {"from": "after", "to": "p53", "value": 1}, {"from": "after", "to": "##is.", "value": 1}, {"from": "after", "to": "biomark", "value": 1}, {"from": "after", "to": "subtype after", "value": 1}, {"from": "after", "to": "net", "value": 1}, {"from": "after", "to": "of", "value": 1}, {"from": "after", "to": "##c patients", "value": 1}, {"from": "after", "to": "net as a putative", "value": 1}, {"from": "after", "to": "##umour cellularity size", "value": 1}, {"from": "after", "to": "radio", "value": 1}, {"from": "after", "to": ") and lower", "value": 1}, {"from": "after", "to": "better", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "of intrinsic sub", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "p53", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "##is.", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "biomark", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "subtype after", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "net", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "of", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "##c patients", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "net as a putative", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "##umour cellularity size", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "radio", "value": 1}, {"from": "##or ) following net. in addition, the", "to": ") and lower", "value": 1}, {"from": "##or ) following net. in addition, the", "to": "better", "value": 1}, {"from": "of intrinsic sub", "to": "p53", "value": 1}, {"from": "of intrinsic sub", "to": "##is.", "value": 1}, {"from": "of intrinsic sub", "to": "biomark", "value": 1}, {"from": "of intrinsic sub", "to": "subtype after", "value": 1}, {"from": "of intrinsic sub", "to": "net", "value": 1}, {"from": "of intrinsic sub", "to": "of", "value": 1}, {"from": "of intrinsic sub", "to": "##c patients", "value": 1}, {"from": "of intrinsic sub", "to": "net as a putative", "value": 1}, {"from": "of intrinsic sub", "to": "##umour cellularity size", "value": 1}, {"from": "of intrinsic sub", "to": "radio", "value": 1}, {"from": "of intrinsic sub", "to": ") and lower", "value": 1}, {"from": "of intrinsic sub", "to": "better", "value": 1}, {"from": "p53", "to": "##is.", "value": 1}, {"from": "p53", "to": "biomark", "value": 1}, {"from": "p53", "to": "subtype after", "value": 1}, {"from": "p53", "to": "net", "value": 1}, {"from": "p53", "to": "of", "value": 1}, {"from": "p53", "to": "##c patients", "value": 1}, {"from": "p53", "to": "net as a putative", "value": 1}, {"from": "p53", "to": "##umour cellularity size", "value": 1}, {"from": "p53", "to": "radio", "value": 1}, {"from": "p53", "to": ") and lower", "value": 1}, {"from": "p53", "to": "better", "value": 1}, {"from": "##is.", "to": "biomark", "value": 1}, {"from": "##is.", "to": "subtype after", "value": 1}, {"from": "##is.", "to": "net", "value": 1}, {"from": "##is.", "to": "of", "value": 1}, {"from": "##is.", "to": "##c patients", "value": 1}, {"from": "##is.", "to": "net as a putative", "value": 1}, {"from": "##is.", "to": "##umour cellularity size", "value": 1}, {"from": "##is.", "to": "radio", "value": 1}, {"from": "##is.", "to": ") and lower", "value": 1}, {"from": "##is.", "to": "better", "value": 1}, {"from": "biomark", "to": "subtype after", "value": 1}, {"from": "biomark", "to": "net", "value": 1}, {"from": "biomark", "to": "of", "value": 1}, {"from": "biomark", "to": "##c patients", "value": 1}, {"from": "biomark", "to": "net as a putative", "value": 1}, {"from": "biomark", "to": "##umour cellularity size", "value": 1}, {"from": "biomark", "to": "radio", "value": 1}, {"from": "biomark", "to": ") and lower", "value": 1}, {"from": "biomark", "to": "better", "value": 1}, {"from": "subtype after", "to": "net", "value": 1}, {"from": "subtype after", "to": "of", "value": 1}, {"from": "subtype after", "to": "##c patients", "value": 1}, {"from": "subtype after", "to": "net as a putative", "value": 1}, {"from": "subtype after", "to": "##umour cellularity size", "value": 1}, {"from": "subtype after", "to": "radio", "value": 1}, {"from": "subtype after", "to": ") and lower", "value": 1}, {"from": "subtype after", "to": "better", "value": 1}, {"from": "net", "to": "of", "value": 1}, {"from": "net", "to": "##c patients", "value": 1}, {"from": "net", "to": "net as a putative", "value": 1}, {"from": "net", "to": "##umour cellularity size", "value": 1}, {"from": "net", "to": "radio", "value": 1}, {"from": "net", "to": ") and lower", "value": 1}, {"from": "net", "to": "better", "value": 1}, {"from": "of", "to": "##c patients", "value": 1}, {"from": "of", "to": "net as a putative", "value": 1}, {"from": "of", "to": "##umour cellularity size", "value": 1}, {"from": "of", "to": "radio", "value": 1}, {"from": "of", "to": ") and lower", "value": 1}, {"from": "of", "to": "better", "value": 1}, {"from": "##c patients", "to": "net as a putative", "value": 1}, {"from": "##c patients", "to": "##umour cellularity size", "value": 1}, {"from": "##c patients", "to": "radio", "value": 1}, {"from": "##c patients", "to": ") and lower", "value": 1}, {"from": "##c patients", "to": "better", "value": 1}, {"from": "net as a putative", "to": "##umour cellularity size", "value": 1}, {"from": "net as a putative", "to": "radio", "value": 1}, {"from": "net as a putative", "to": ") and lower", "value": 1}, {"from": "net as a putative", "to": "better", "value": 1}, {"from": "##umour cellularity size", "to": "radio", "value": 1}, {"from": "##umour cellularity size", "to": ") and lower", "value": 1}, {"from": "##umour cellularity size", "to": "better", "value": 1}, {"from": "radio", "to": ") and lower", "value": 1}, {"from": "radio", "to": "better", "value": 1}, {"from": ") and lower", "to": "better", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "am50 - derived ror score and p53 evaluation could also", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##6 /", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "be validated in independent cohorts,", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "cost - effectiveness", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##ers of response to net and pro", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "10. 101", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "help", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##sis, which", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##lin", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "should", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "202", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "helping to the", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "implementation of net", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##mark", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##ranon.", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": ". clbc. 202", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "of prosigna for adjuvant treatment decisions", "to": "##5.", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##6 /", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "be validated in independent cohorts,", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "cost - effectiveness", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##ers of response to net and pro", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "10. 101", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "help", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##sis, which", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##lin", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "should", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "202", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "helping to the", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "implementation of net", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##mark", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##ranon.", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": ". clbc. 202", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "am50 - derived ror score and p53 evaluation could also", "to": "##5.", "value": 1}, {"from": "##6 /", "to": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "value": 1}, {"from": "##6 /", "to": "be validated in independent cohorts,", "value": 1}, {"from": "##6 /", "to": "cost - effectiveness", "value": 1}, {"from": "##6 /", "to": "##ers of response to net and pro", "value": 1}, {"from": "##6 /", "to": "10. 101", "value": 1}, {"from": "##6 /", "to": "help", "value": 1}, {"from": "##6 /", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "##6 /", "to": "##sis, which", "value": 1}, {"from": "##6 /", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "##6 /", "to": "##lin", "value": 1}, {"from": "##6 /", "to": "should", "value": 1}, {"from": "##6 /", "to": "202", "value": 1}, {"from": "##6 /", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##6 /", "to": "helping to the", "value": 1}, {"from": "##6 /", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##6 /", "to": "implementation of net", "value": 1}, {"from": "##6 /", "to": "##mark", "value": 1}, {"from": "##6 /", "to": "##ranon.", "value": 1}, {"from": "##6 /", "to": ". clbc. 202", "value": 1}, {"from": "##6 /", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##6 /", "to": "##5.", "value": 1}, {"from": "##6 /", "to": "is cost - effective", "value": 1}, {"from": "##6 /", "to": "of agriculture and natural", "value": 1}, {"from": "##6 /", "to": ". ac.", "value": 1}, {"from": "##6 /", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "##6 /", "to": "resources", "value": 1}, {"from": "##6 /", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "##6 /", "to": "##za. he", "value": 1}, {"from": "##6 /", "to": "are", "value": 1}, {"from": "##6 /", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##6 /", "to": "##ri - japelaghi r", "value": 1}, {"from": "##6 /", "to": "##r.", "value": 1}, {"from": "##6 /", "to": "who", "value": 1}, {"from": "##6 /", "to": "inter", "value": 1}, {"from": "##6 /", "to": "##vin", "value": 1}, {"from": "##6 /", "to": "of tabriz,", "value": 1}, {"from": "##6 /", "to": "@ org.", "value": 1}, {"from": "##6 /", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##6 /", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##6 /", "to": "##idari", "value": 1}, {"from": "##6 /", "to": "s", "value": 1}, {"from": "##6 /", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##6 /", "to": "ta", "value": 1}, {"from": "##6 /", "to": "##ran. electronic address :", "value": 1}, {"from": "##6 /", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##6 /", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##6 /", "to": "perspectives", "value": 1}, {"from": "##6 /", "to": "##briz,", "value": 1}, {"from": "##6 /", "to": "of agriculture,", "value": 1}, {"from": "##6 /", "to": "##fer", "value": 1}, {"from": "##6 /", "to": "##ki", "value": 1}, {"from": "##6 /", "to": "from both", "value": 1}, {"from": "##6 /", "to": "##ran.", "value": 1}, {"from": "##6 /", "to": "- regulate", "value": 1}, {"from": "##6 /", "to": "the", "value": 1}, {"from": "##6 /", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "##6 /", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "##6 /", "to": "##tic", "value": 1}, {"from": "##6 /", "to": "##6", "value": 1}, {"from": "##6 /", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##6 /", "to": "##xic effect of", "value": 1}, {"from": "##6 /", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##6 /", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##6 /", "to": "##xic efficacy of the", "value": 1}, {"from": "##6 /", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##6 /", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##6 /", "to": "up -", "value": 1}, {"from": "##6 /", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##6 /", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##6 /", "to": "development of tumor cells, a", "value": 1}, {"from": "##6 /", "to": "##348089 conflict o", "value": 1}, {"from": "##6 /", "to": "regulate", "value": 1}, {"from": "##6 /", "to": "of pro", "value": 1}, {"from": "##6 /", "to": "##cl -", "value": 1}, {"from": "##6 /", "to": "##biotec. 2025.", "value": 1}, {"from": "##6 /", "to": "04", "value": 1}, {"from": "##6 /", "to": "##apopto", "value": 1}, {"from": "##6 /", "to": "to", "value": 1}, {"from": "##6 /", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##6 /", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##6 /", "to": "via", "value": 1}, {"from": "##6 /", "to": "and p", "value": 1}, {"from": "##6 /", "to": "##c cell line", "value": 1}, {"from": "##6 /", "to": "hi", "value": 1}, {"from": "##6 /", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##6 /", "to": "##53", "value": 1}, {"from": "##6 /", "to": ". 022 pmid :", "value": 1}, {"from": "##6 /", "to": "bax", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "be validated in independent cohorts,", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "cost - effectiveness", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##ers of response to net and pro", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "10. 101", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "help", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##sis, which", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##lin", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "should", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "202", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "helping to the", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "implementation of net", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##mark", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##ranon.", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": ". clbc. 202", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "the clinical practice. copyright \u00a9 2025. published by elsevier inc.", "to": "##5.", "value": 1}, {"from": "be validated in independent cohorts,", "to": "cost - effectiveness", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##ers of response to net and pro", "value": 1}, {"from": "be validated in independent cohorts,", "to": "10. 101", "value": 1}, {"from": "be validated in independent cohorts,", "to": "help", "value": 1}, {"from": "be validated in independent cohorts,", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##sis, which", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##lin", "value": 1}, {"from": "be validated in independent cohorts,", "to": "should", "value": 1}, {"from": "be validated in independent cohorts,", "to": "202", "value": 1}, {"from": "be validated in independent cohorts,", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "be validated in independent cohorts,", "to": "helping to the", "value": 1}, {"from": "be validated in independent cohorts,", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "be validated in independent cohorts,", "to": "implementation of net", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##mark", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##ranon.", "value": 1}, {"from": "be validated in independent cohorts,", "to": ". clbc. 202", "value": 1}, {"from": "be validated in independent cohorts,", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "be validated in independent cohorts,", "to": "##5.", "value": 1}, {"from": "cost - effectiveness", "to": "##ers of response to net and pro", "value": 1}, {"from": "cost - effectiveness", "to": "10. 101", "value": 1}, {"from": "cost - effectiveness", "to": "help", "value": 1}, {"from": "cost - effectiveness", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "cost - effectiveness", "to": "##sis, which", "value": 1}, {"from": "cost - effectiveness", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "cost - effectiveness", "to": "##lin", "value": 1}, {"from": "cost - effectiveness", "to": "should", "value": 1}, {"from": "cost - effectiveness", "to": "202", "value": 1}, {"from": "cost - effectiveness", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "cost - effectiveness", "to": "helping to the", "value": 1}, {"from": "cost - effectiveness", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "cost - effectiveness", "to": "implementation of net", "value": 1}, {"from": "cost - effectiveness", "to": "##mark", "value": 1}, {"from": "cost - effectiveness", "to": "##ranon.", "value": 1}, {"from": "cost - effectiveness", "to": ". clbc. 202", "value": 1}, {"from": "cost - effectiveness", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "cost - effectiveness", "to": "##5.", "value": 1}, {"from": "##ers of response to net and pro", "to": "10. 101", "value": 1}, {"from": "##ers of response to net and pro", "to": "help", "value": 1}, {"from": "##ers of response to net and pro", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "##ers of response to net and pro", "to": "##sis, which", "value": 1}, {"from": "##ers of response to net and pro", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "##ers of response to net and pro", "to": "##lin", "value": 1}, {"from": "##ers of response to net and pro", "to": "should", "value": 1}, {"from": "##ers of response to net and pro", "to": "202", "value": 1}, {"from": "##ers of response to net and pro", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##ers of response to net and pro", "to": "helping to the", "value": 1}, {"from": "##ers of response to net and pro", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##ers of response to net and pro", "to": "implementation of net", "value": 1}, {"from": "##ers of response to net and pro", "to": "##mark", "value": 1}, {"from": "##ers of response to net and pro", "to": "##ranon.", "value": 1}, {"from": "##ers of response to net and pro", "to": ". clbc. 202", "value": 1}, {"from": "##ers of response to net and pro", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##ers of response to net and pro", "to": "##5.", "value": 1}, {"from": "10. 101", "to": "help", "value": 1}, {"from": "10. 101", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "10. 101", "to": "##sis, which", "value": 1}, {"from": "10. 101", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "10. 101", "to": "##lin", "value": 1}, {"from": "10. 101", "to": "should", "value": 1}, {"from": "10. 101", "to": "202", "value": 1}, {"from": "10. 101", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "10. 101", "to": "helping to the", "value": 1}, {"from": "10. 101", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "10. 101", "to": "implementation of net", "value": 1}, {"from": "10. 101", "to": "##mark", "value": 1}, {"from": "10. 101", "to": "##ranon.", "value": 1}, {"from": "10. 101", "to": ". clbc. 202", "value": 1}, {"from": "10. 101", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "10. 101", "to": "##5.", "value": 1}, {"from": "help", "to": "breast cancer. 2025 apr 15 : s1526 - 8209", "value": 1}, {"from": "help", "to": "##sis, which", "value": 1}, {"from": "help", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "help", "to": "##lin", "value": 1}, {"from": "help", "to": "should", "value": 1}, {"from": "help", "to": "202", "value": 1}, {"from": "help", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "help", "to": "helping to the", "value": 1}, {"from": "help", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "help", "to": "implementation of net", "value": 1}, {"from": "help", "to": "##mark", "value": 1}, {"from": "help", "to": "##ranon.", "value": 1}, {"from": "help", "to": ". clbc. 202", "value": 1}, {"from": "help", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "help", "to": "##5.", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##sis, which", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##lin", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "should", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "202", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "helping to the", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "implementation of net", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##mark", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##ranon.", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": ". clbc. 202", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "breast cancer. 2025 apr 15 : s1526 - 8209", "to": "##5.", "value": 1}, {"from": "##sis, which", "to": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "value": 1}, {"from": "##sis, which", "to": "##lin", "value": 1}, {"from": "##sis, which", "to": "should", "value": 1}, {"from": "##sis, which", "to": "202", "value": 1}, {"from": "##sis, which", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##sis, which", "to": "helping to the", "value": 1}, {"from": "##sis, which", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##sis, which", "to": "implementation of net", "value": 1}, {"from": "##sis, which", "to": "##mark", "value": 1}, {"from": "##sis, which", "to": "##ranon.", "value": 1}, {"from": "##sis, which", "to": ". clbc. 202", "value": 1}, {"from": "##sis, which", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##sis, which", "to": "##5.", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "##lin", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "should", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "202", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "helping to the", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "implementation of net", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "##mark", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "##ranon.", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": ". clbc. 202", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c", "to": "##5.", "value": 1}, {"from": "##lin", "to": "should", "value": 1}, {"from": "##lin", "to": "202", "value": 1}, {"from": "##lin", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "##lin", "to": "helping to the", "value": 1}, {"from": "##lin", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "##lin", "to": "implementation of net", "value": 1}, {"from": "##lin", "to": "##mark", "value": 1}, {"from": "##lin", "to": "##ranon.", "value": 1}, {"from": "##lin", "to": ". clbc. 202", "value": 1}, {"from": "##lin", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##lin", "to": "##5.", "value": 1}, {"from": "should", "to": "202", "value": 1}, {"from": "should", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "should", "to": "helping to the", "value": 1}, {"from": "should", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "should", "to": "implementation of net", "value": 1}, {"from": "should", "to": "##mark", "value": 1}, {"from": "should", "to": "##ranon.", "value": 1}, {"from": "should", "to": ". clbc. 202", "value": 1}, {"from": "should", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "should", "to": "##5.", "value": 1}, {"from": "202", "to": "to identify those patients. thus, this study uncovers potential bio", "value": 1}, {"from": "202", "to": "helping to the", "value": 1}, {"from": "202", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "202", "to": "implementation of net", "value": 1}, {"from": "202", "to": "##mark", "value": 1}, {"from": "202", "to": "##ranon.", "value": 1}, {"from": "202", "to": ". clbc. 202", "value": 1}, {"from": "202", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "202", "to": "##5.", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "helping to the", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "implementation of net", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "##mark", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "##ranon.", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": ". clbc. 202", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "to identify those patients. thus, this study uncovers potential bio", "to": "##5.", "value": 1}, {"from": "helping to the", "to": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "value": 1}, {"from": "helping to the", "to": "implementation of net", "value": 1}, {"from": "helping to the", "to": "##mark", "value": 1}, {"from": "helping to the", "to": "##ranon.", "value": 1}, {"from": "helping to the", "to": ". clbc. 202", "value": 1}, {"from": "helping to the", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "helping to the", "to": "##5.", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": "implementation of net", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": "##mark", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": "##ranon.", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": ". clbc. 202", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "early breast cancer : healthcare sector and societal perspectives. asphaug l", "to": "##5.", "value": 1}, {"from": "implementation of net", "to": "##mark", "value": 1}, {"from": "implementation of net", "to": "##ranon.", "value": 1}, {"from": "implementation of net", "to": ". clbc. 202", "value": 1}, {"from": "implementation of net", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "implementation of net", "to": "##5.", "value": 1}, {"from": "##mark", "to": "##ranon.", "value": 1}, {"from": "##mark", "to": ". clbc. 202", "value": 1}, {"from": "##mark", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##mark", "to": "##5.", "value": 1}, {"from": "##ranon.", "to": ". clbc. 202", "value": 1}, {"from": "##ranon.", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": "##ranon.", "to": "##5.", "value": 1}, {"from": ". clbc. 202", "to": ". 04. 011. online ahead of print.", "value": 1}, {"from": ". clbc. 202", "to": "##5.", "value": 1}, {"from": ". 04. 011. online ahead of print.", "to": "##5.", "value": 1}, {"from": "##rgen, norway.", "to": "##rgen, nor", "value": 1}, {"from": "##rgen, norway.", "to": "economics", "value": 1}, {"from": "##rgen, norway.", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "##rgen, norway.", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "##rgen, norway.", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "##rgen, norway.", "to": "clinical trials", "value": 1}, {"from": "##rgen, norway.", "to": "of health management and health", "value": 1}, {"from": "##rgen, norway.", "to": ";", "value": 1}, {"from": "##rgen, norway.", "to": ") department of p", "value": 1}, {"from": "##rgen, norway.", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "##rgen, norway.", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "##rgen, norway.", "to": "), heie a", "value": 1}, {"from": "##rgen, norway.", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "##rgen, norway.", "to": "be", "value": 1}, {"from": "##rgen, norway.", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "##rgen, norway.", "to": "ug", "value": 1}, {"from": "##rgen, norway.", "to": "##way", "value": 1}, {"from": "##rgen, nor", "to": "economics", "value": 1}, {"from": "##rgen, nor", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "##rgen, nor", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "##rgen, nor", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "##rgen, nor", "to": "clinical trials", "value": 1}, {"from": "##rgen, nor", "to": "of health management and health", "value": 1}, {"from": "##rgen, nor", "to": ";", "value": 1}, {"from": "##rgen, nor", "to": ") department of p", "value": 1}, {"from": "##rgen, nor", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "##rgen, nor", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "##rgen, nor", "to": "), heie a", "value": 1}, {"from": "##rgen, nor", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "##rgen, nor", "to": "be", "value": 1}, {"from": "##rgen, nor", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "##rgen, nor", "to": "ug", "value": 1}, {"from": "##rgen, nor", "to": "##way", "value": 1}, {"from": "economics", "to": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "value": 1}, {"from": "economics", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "economics", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "economics", "to": "clinical trials", "value": 1}, {"from": "economics", "to": "of health management and health", "value": 1}, {"from": "economics", "to": ";", "value": 1}, {"from": "economics", "to": ") department of p", "value": 1}, {"from": "economics", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "economics", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "economics", "to": "), heie a", "value": 1}, {"from": "economics", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "economics", "to": "be", "value": 1}, {"from": "economics", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "economics", "to": "ug", "value": 1}, {"from": "economics", "to": "##way", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "##roms\u00f8, norway ;", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "clinical trials", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "of health management and health", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": ";", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": ") department of p", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "), heie a", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "be", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "ug", "value": 1}, {"from": "of clinical medicine, uit the arctic university of norway, troms\u00f8, norway.", "to": "##way", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "of oncology, hospital of southern norway, kristiansand, norway.", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "clinical trials", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "of health management and health", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": ";", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": ") department of p", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "), heie a", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "be", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "ug", "value": 1}, {"from": "##roms\u00f8, norway ;", "to": "##way", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "clinical trials", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "of health management and health", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": ";", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": ") department of p", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "), heie a", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "be", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "ug", "value": 1}, {"from": "of oncology, hospital of southern norway, kristiansand, norway.", "to": "##way", "value": 1}, {"from": "clinical trials", "to": "of health management and health", "value": 1}, {"from": "clinical trials", "to": ";", "value": 1}, {"from": "clinical trials", "to": ") department of p", "value": 1}, {"from": "clinical trials", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "clinical trials", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "clinical trials", "to": "), heie a", "value": 1}, {"from": "clinical trials", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "clinical trials", "to": "be", "value": 1}, {"from": "clinical trials", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "clinical trials", "to": "ug", "value": 1}, {"from": "clinical trials", "to": "##way", "value": 1}, {"from": "of health management and health", "to": ";", "value": 1}, {"from": "of health management and health", "to": ") department of p", "value": 1}, {"from": "of health management and health", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": "of health management and health", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": "of health management and health", "to": "), heie a", "value": 1}, {"from": "of health management and health", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "of health management and health", "to": "be", "value": 1}, {"from": "of health management and health", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "of health management and health", "to": "ug", "value": 1}, {"from": "of health management and health", "to": "##way", "value": 1}, {"from": ";", "to": ") department of p", "value": 1}, {"from": ";", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": ";", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": ";", "to": "), heie a", "value": 1}, {"from": ";", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": "be", "value": 1}, {"from": ";", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": ";", "to": "ug", "value": 1}, {"from": ";", "to": "##way", "value": 3}, {"from": ";", "to": ") department of", "value": 1}, {"from": ";", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": ";", "to": "for cancer", "value": 1}, {"from": ";", "to": "##lia", "value": 1}, {"from": ";", "to": "##vanger,", "value": 1}, {"from": ";", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": ";", "to": "##vanger university, s", "value": 1}, {"from": ";", "to": "8", "value": 1}, {"from": ";", "to": "of cancer genetics,", "value": 2}, {"from": ";", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": ";", "to": "12 ) department", "value": 1}, {"from": ";", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ";", "to": "##vanger university hospital, s", "value": 1}, {"from": ";", "to": "ha", "value": 1}, {"from": ";", "to": "norway", "value": 1}, {"from": ";", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ";", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ";", "to": "of pathology, s", "value": 1}, {"from": ";", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": ", drammen, norway.", "value": 1}, {"from": ";", "to": "of clinical medicine,", "value": 1}, {"from": ";", "to": "##dheim, norway.", "value": 1}, {"from": ";", "to": "25", "value": 1}, {"from": ";", "to": "trust", "value": 1}, {"from": ";", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": ";", "to": ", hamar, norway.", "value": 1}, {"from": ";", "to": ", kalnes, norway.", "value": 1}, {"from": ";", "to": ", skien, norway.", "value": 1}, {"from": ";", "to": "of oslo, oslo, nor", "value": 1}, {"from": ";", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ";", "to": ") department of oncolog", "value": 1}, {"from": ";", "to": "##ron", "value": 1}, {"from": ") department of p", "to": ") department of oncology, university of north norway,", "value": 1}, {"from": ") department of p", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": ") department of p", "to": "), heie a", "value": 1}, {"from": ") department of p", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of p", "to": "be", "value": 1}, {"from": ") department of p", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": ") department of p", "to": "ug", "value": 1}, {"from": ") department of p", "to": "##way", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "), heie a", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "be", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "ug", "value": 1}, {"from": ") department of oncology, university of north norway,", "to": "##way", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "), heie a", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "be", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "ug", "value": 1}, {"from": "society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no.", "to": "##way", "value": 1}, {"from": "), heie a", "to": "unit, oslo university hospital, oslo, nor", "value": 1}, {"from": "), heie a", "to": "be", "value": 1}, {"from": "), heie a", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "), heie a", "to": "ug", "value": 1}, {"from": "), heie a", "to": "##way", "value": 1}, {"from": "unit, oslo university hospital, oslo, nor", "to": "be", "value": 1}, {"from": "unit, oslo university hospital, oslo, nor", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "unit, oslo university hospital, oslo, nor", "to": "ug", "value": 1}, {"from": "unit, oslo university hospital, oslo, nor", "to": "##way", "value": 1}, {"from": "be", "to": "; department of pathology haukeland university hospital,", "value": 1}, {"from": "be", "to": "ug", "value": 1}, {"from": "be", "to": "##way", "value": 1}, {"from": "; department of pathology haukeland university hospital,", "to": "ug", "value": 1}, {"from": "; department of pathology haukeland university hospital,", "to": "##way", "value": 1}, {"from": "ug", "to": "##way", "value": 1}, {"from": "##way", "to": ") department of", "value": 1}, {"from": "##way", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": "##way", "to": "for cancer", "value": 1}, {"from": "##way", "to": "##lia", "value": 1}, {"from": "##way", "to": "##vanger,", "value": 1}, {"from": "##way", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "##way", "to": "##vanger university, s", "value": 1}, {"from": "##way", "to": "8", "value": 1}, {"from": "##way", "to": "of cancer genetics,", "value": 2}, {"from": "##way", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "##way", "to": "12 ) department", "value": 1}, {"from": "##way", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "##way", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "##way", "to": "##vanger university hospital, s", "value": 1}, {"from": "##way", "to": "ha", "value": 1}, {"from": "##way", "to": "norway", "value": 1}, {"from": "##way", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##way", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##way", "to": "of pathology, s", "value": 1}, {"from": "##way", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##way", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##way", "to": ", drammen, norway.", "value": 1}, {"from": "##way", "to": "of clinical medicine,", "value": 1}, {"from": "##way", "to": "##dheim, norway.", "value": 1}, {"from": "##way", "to": "25", "value": 1}, {"from": "##way", "to": "trust", "value": 1}, {"from": "##way", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "##way", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "##way", "to": ", hamar, norway.", "value": 1}, {"from": "##way", "to": ", kalnes, norway.", "value": 1}, {"from": "##way", "to": ", skien, norway.", "value": 1}, {"from": "##way", "to": "of oslo, oslo, nor", "value": 1}, {"from": "##way", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##way", "to": ") department of oncolog", "value": 1}, {"from": "##way", "to": "##ron", "value": 1}, {"from": ") department of", "to": "; menzies health institute queensland and griffith university, southport, austra", "value": 1}, {"from": ") department of", "to": "for cancer", "value": 1}, {"from": ") department of", "to": "##lia", "value": 1}, {"from": ") department of", "to": "##vanger,", "value": 1}, {"from": ") department of", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": ") department of", "to": "##vanger university, s", "value": 1}, {"from": ") department of", "to": "8", "value": 1}, {"from": ") department of", "to": "of cancer genetics,", "value": 1}, {"from": ") department of", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": ") department of", "to": "12 ) department", "value": 1}, {"from": ") department of", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ") department of", "to": "##vanger university hospital, s", "value": 1}, {"from": ") department of", "to": "ha", "value": 1}, {"from": ") department of", "to": "norway", "value": 1}, {"from": ") department of", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ") department of", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ") department of", "to": "of pathology, s", "value": 1}, {"from": ") department of", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "for cancer", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "##lia", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "##vanger,", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "##vanger university, s", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "8", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "of cancer genetics,", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "12 ) department", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "##vanger university hospital, s", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "ha", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "norway", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "of pathology, s", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "; menzies health institute queensland and griffith university, southport, austra", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "for cancer", "to": "##lia", "value": 1}, {"from": "for cancer", "to": "##vanger,", "value": 1}, {"from": "for cancer", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "for cancer", "to": "##vanger university, s", "value": 1}, {"from": "for cancer", "to": "8", "value": 1}, {"from": "for cancer", "to": "of cancer genetics,", "value": 1}, {"from": "for cancer", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "for cancer", "to": "12 ) department", "value": 1}, {"from": "for cancer", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "for cancer", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "for cancer", "to": "##vanger university hospital, s", "value": 1}, {"from": "for cancer", "to": "ha", "value": 1}, {"from": "for cancer", "to": "norway", "value": 1}, {"from": "for cancer", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "for cancer", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "for cancer", "to": "of pathology, s", "value": 1}, {"from": "for cancer", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "for cancer", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##lia", "to": "##vanger,", "value": 1}, {"from": "##lia", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "##lia", "to": "##vanger university, s", "value": 1}, {"from": "##lia", "to": "8", "value": 1}, {"from": "##lia", "to": "of cancer genetics,", "value": 1}, {"from": "##lia", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "##lia", "to": "12 ) department", "value": 1}, {"from": "##lia", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "##lia", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "##lia", "to": "##vanger university hospital, s", "value": 1}, {"from": "##lia", "to": "ha", "value": 1}, {"from": "##lia", "to": "norway", "value": 1}, {"from": "##lia", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##lia", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##lia", "to": "of pathology, s", "value": 1}, {"from": "##lia", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##lia", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger,", "to": "of breast surgery, haukeland university hospital, bergen, norway.", "value": 1}, {"from": "##vanger,", "to": "##vanger university, s", "value": 1}, {"from": "##vanger,", "to": "8", "value": 1}, {"from": "##vanger,", "to": "of cancer genetics,", "value": 1}, {"from": "##vanger,", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "##vanger,", "to": "12 ) department", "value": 1}, {"from": "##vanger,", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger,", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "##vanger,", "to": "##vanger university hospital, s", "value": 1}, {"from": "##vanger,", "to": "ha", "value": 1}, {"from": "##vanger,", "to": "norway", "value": 1}, {"from": "##vanger,", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##vanger,", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##vanger,", "to": "of pathology, s", "value": 1}, {"from": "##vanger,", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger,", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "##vanger university, s", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "8", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "of cancer genetics,", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "12 ) department", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "##vanger university hospital, s", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "ha", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "norway", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "of pathology, s", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "of breast surgery, haukeland university hospital, bergen, norway.", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger university, s", "to": "8", "value": 1}, {"from": "##vanger university, s", "to": "of cancer genetics,", "value": 1}, {"from": "##vanger university, s", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "##vanger university, s", "to": "12 ) department", "value": 1}, {"from": "##vanger university, s", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger university, s", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "##vanger university, s", "to": "##vanger university hospital, s", "value": 1}, {"from": "##vanger university, s", "to": "ha", "value": 1}, {"from": "##vanger university, s", "to": "norway", "value": 1}, {"from": "##vanger university, s", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##vanger university, s", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##vanger university, s", "to": "of pathology, s", "value": 1}, {"from": "##vanger university, s", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger university, s", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "8", "to": "of cancer genetics,", "value": 1}, {"from": "8", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "8", "to": "12 ) department", "value": 1}, {"from": "8", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "8", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "8", "to": "##vanger university hospital, s", "value": 1}, {"from": "8", "to": "ha", "value": 1}, {"from": "8", "to": "norway", "value": 1}, {"from": "8", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "8", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "8", "to": "of pathology, s", "value": 1}, {"from": "8", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "8", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": ") department of pathology, st olavs hospital, trondheim, norway.", "value": 1}, {"from": "of cancer genetics,", "to": "12 ) department", "value": 1}, {"from": "of cancer genetics,", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "of cancer genetics,", "to": "##vanger university hospital, s", "value": 1}, {"from": "of cancer genetics,", "to": "ha", "value": 1}, {"from": "of cancer genetics,", "to": "norway", "value": 1}, {"from": "of cancer genetics,", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "of cancer genetics,", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "of cancer genetics,", "to": "of pathology, s", "value": 1}, {"from": "of cancer genetics,", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": ", drammen, norway.", "value": 1}, {"from": "of cancer genetics,", "to": "of clinical medicine,", "value": 1}, {"from": "of cancer genetics,", "to": "##dheim, norway.", "value": 1}, {"from": "of cancer genetics,", "to": "25", "value": 1}, {"from": "of cancer genetics,", "to": "trust", "value": 1}, {"from": "of cancer genetics,", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "of cancer genetics,", "to": ", hamar, norway.", "value": 1}, {"from": "of cancer genetics,", "to": ", kalnes, norway.", "value": 1}, {"from": "of cancer genetics,", "to": ", skien, norway.", "value": 1}, {"from": "of cancer genetics,", "to": "of oslo, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of cancer genetics,", "to": ") department of oncolog", "value": 1}, {"from": "of cancer genetics,", "to": "##ron", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "12 ) department", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "##vanger university hospital, s", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "ha", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "norway", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "of pathology, s", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of pathology, st olavs hospital, trondheim, norway.", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "12 ) department", "to": ", oslo university hospital, oslo, nor", "value": 1}, {"from": "12 ) department", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": "12 ) department", "to": "##vanger university hospital, s", "value": 1}, {"from": "12 ) department", "to": "ha", "value": 1}, {"from": "12 ) department", "to": "norway", "value": 1}, {"from": "12 ) department", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "12 ) department", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "12 ) department", "to": "of pathology, s", "value": 1}, {"from": "12 ) department", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "12 ) department", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "of chemistry, bioscience and environmental engineering, s", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "##vanger university hospital, s", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "ha", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "norway", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "of pathology, s", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ", oslo university hospital, oslo, nor", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "##vanger university hospital, s", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "ha", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "norway", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "of pathology, s", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "of chemistry, bioscience and environmental engineering, s", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger university hospital, s", "to": "ha", "value": 1}, {"from": "##vanger university hospital, s", "to": "norway", "value": 1}, {"from": "##vanger university hospital, s", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "##vanger university hospital, s", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##vanger university hospital, s", "to": "of pathology, s", "value": 1}, {"from": "##vanger university hospital, s", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##vanger university hospital, s", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "ha", "to": "norway", "value": 1}, {"from": "ha", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "ha", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "ha", "to": "of pathology, s", "value": 1}, {"from": "ha", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "ha", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "norway", "to": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "value": 1}, {"from": "norway", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "norway", "to": "of pathology, s", "value": 1}, {"from": "norway", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "norway", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "to": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "value": 1}, {"from": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "to": "of pathology, s", "value": 1}, {"from": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "##ematology and oncology, stavanger university hospital, stavanger, norway.", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "to": "of pathology, s", "value": 1}, {"from": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": ") department of breast surgery, akershus university hospital, l\u00f8renskog, norway.", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of pathology, s", "to": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "value": 1}, {"from": "of pathology, s", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ") national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor", "to": "athology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", drammen, norway.", "to": "of clinical medicine,", "value": 1}, {"from": ", drammen, norway.", "to": "##dheim, norway.", "value": 1}, {"from": ", drammen, norway.", "to": "25", "value": 1}, {"from": ", drammen, norway.", "to": "trust", "value": 1}, {"from": ", drammen, norway.", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": ", drammen, norway.", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": ", drammen, norway.", "to": ", hamar, norway.", "value": 1}, {"from": ", drammen, norway.", "to": ", kalnes, norway.", "value": 1}, {"from": ", drammen, norway.", "to": ", skien, norway.", "value": 1}, {"from": ", drammen, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": ", drammen, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", drammen, norway.", "to": ") department of oncolog", "value": 1}, {"from": ", drammen, norway.", "to": "##ron", "value": 1}, {"from": "of clinical medicine,", "to": "##dheim, norway.", "value": 1}, {"from": "of clinical medicine,", "to": "25", "value": 1}, {"from": "of clinical medicine,", "to": "trust", "value": 1}, {"from": "of clinical medicine,", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "of clinical medicine,", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "of clinical medicine,", "to": ", hamar, norway.", "value": 1}, {"from": "of clinical medicine,", "to": ", kalnes, norway.", "value": 1}, {"from": "of clinical medicine,", "to": ", skien, norway.", "value": 1}, {"from": "of clinical medicine,", "to": "of oslo, oslo, nor", "value": 1}, {"from": "of clinical medicine,", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of clinical medicine,", "to": ") department of oncolog", "value": 1}, {"from": "of clinical medicine,", "to": "##ron", "value": 1}, {"from": "##dheim, norway.", "to": "25", "value": 1}, {"from": "##dheim, norway.", "to": "trust", "value": 1}, {"from": "##dheim, norway.", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "##dheim, norway.", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "##dheim, norway.", "to": ", hamar, norway.", "value": 1}, {"from": "##dheim, norway.", "to": ", kalnes, norway.", "value": 1}, {"from": "##dheim, norway.", "to": ", skien, norway.", "value": 1}, {"from": "##dheim, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": "##dheim, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "##dheim, norway.", "to": ") department of oncolog", "value": 1}, {"from": "##dheim, norway.", "to": "##ron", "value": 1}, {"from": "25", "to": "trust", "value": 1}, {"from": "25", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "25", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "25", "to": ", hamar, norway.", "value": 1}, {"from": "25", "to": ", kalnes, norway.", "value": 1}, {"from": "25", "to": ", skien, norway.", "value": 1}, {"from": "25", "to": "of oslo, oslo, nor", "value": 1}, {"from": "25", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "25", "to": ") department of oncolog", "value": 1}, {"from": "25", "to": "##ron", "value": 1}, {"from": "trust", "to": "for cancer research, oslo university hospital, oslo, nor", "value": 1}, {"from": "trust", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "trust", "to": ", hamar, norway.", "value": 1}, {"from": "trust", "to": ", kalnes, norway.", "value": 1}, {"from": "trust", "to": ", skien, norway.", "value": 1}, {"from": "trust", "to": "of oslo, oslo, nor", "value": 1}, {"from": "trust", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "trust", "to": ") department of oncolog", "value": 1}, {"from": "trust", "to": "##ron", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": ", hamar, norway.", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": ", kalnes, norway.", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": ", skien, norway.", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": "of oslo, oslo, nor", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": ") department of oncolog", "value": 1}, {"from": "for cancer research, oslo university hospital, oslo, nor", "to": "##ron", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": ", hamar, norway.", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": ", kalnes, norway.", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": ", skien, norway.", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": ") department of oncolog", "value": 1}, {"from": "ent of oncology, m\u00f8re og romsdal hospital trust, alesund, norway.", "to": "##ron", "value": 1}, {"from": ", hamar, norway.", "to": ", kalnes, norway.", "value": 1}, {"from": ", hamar, norway.", "to": ", skien, norway.", "value": 1}, {"from": ", hamar, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": ", hamar, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", hamar, norway.", "to": ") department of oncolog", "value": 1}, {"from": ", hamar, norway.", "to": "##ron", "value": 1}, {"from": ", kalnes, norway.", "to": ", skien, norway.", "value": 1}, {"from": ", kalnes, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": ", kalnes, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", kalnes, norway.", "to": ") department of oncolog", "value": 1}, {"from": ", kalnes, norway.", "to": "##ron", "value": 1}, {"from": ", skien, norway.", "to": "of oslo, oslo, nor", "value": 1}, {"from": ", skien, norway.", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": ", skien, norway.", "to": ") department of oncolog", "value": 1}, {"from": ", skien, norway.", "to": "##ron", "value": 1}, {"from": "of oslo, oslo, nor", "to": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "value": 1}, {"from": "of oslo, oslo, nor", "to": ") department of oncolog", "value": 1}, {"from": "of oslo, oslo, nor", "to": "##ron", "value": 1}, {"from": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "to": ") department of oncolog", "value": 1}, {"from": "of pathology, division of laboratory medicine, oslo university hospital, oslo, nor", "to": "##ron", "value": 1}, {"from": ") department of oncolog", "to": "##ron", "value": 1}, {"from": "the", "to": "profiling tests such as the prosigna - assay are", "value": 1}, {"from": "the", "to": "hormone receptor positive", "value": 1}, {"from": "the", "to": "societal perspective", "value": 1}, {"from": "the", "to": "benefits", "value": 1}, {"from": "the", "to": "surgery", "value": 1}, {"from": "the", "to": "cost -", "value": 1}, {"from": "the", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "the", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "the", "to": "decision", "value": 1}, {"from": "the", "to": "to aid adjuvant treatment", "value": 1}, {"from": "the", "to": "##al", "value": 1}, {"from": "the", "to": "emit - 1 trial", "value": 1}, {"from": "the", "to": "post", "value": 1}, {"from": "the", "to": ". materials", "value": 1}, {"from": "the", "to": "model was", "value": 1}, {"from": "the", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "the", "to": "used", "value": 1}, {"from": "the", "to": ": the", "value": 1}, {"from": "the", "to": "ki - 67", "value": 1}, {"from": "the", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "the", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "the", "to": "prosigna was tested", "value": 1}, {"from": "the", "to": "prospective", "value": 1}, {"from": "the", "to": "were measured", "value": 1}, {"from": "the", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "the", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "the", "to": "observation", "value": 1}, {"from": "the", "to": "division", "value": 1}, {"from": "the", "to": "decisions in", "value": 1}, {"from": "the", "to": "built", "value": 1}, {"from": "the", "to": "impact of", "value": 1}, {"from": "the", "to": "- regulate", "value": 1}, {"from": "the", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "the", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "the", "to": "##tic", "value": 1}, {"from": "the", "to": "##6", "value": 1}, {"from": "the", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "the", "to": "##xic effect of", "value": 1}, {"from": "the", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "the", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "the", "to": "##xic efficacy of the", "value": 1}, {"from": "the", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "the", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "the", "to": "up -", "value": 1}, {"from": "the", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "the", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "the", "to": "development of tumor cells, a", "value": 1}, {"from": "the", "to": "##348089 conflict o", "value": 1}, {"from": "the", "to": "regulate", "value": 1}, {"from": "the", "to": "of pro", "value": 1}, {"from": "the", "to": "##cl -", "value": 1}, {"from": "the", "to": "##biotec. 2025.", "value": 1}, {"from": "the", "to": "04", "value": 1}, {"from": "the", "to": "##apopto", "value": 1}, {"from": "the", "to": "to", "value": 1}, {"from": "the", "to": "##cer and antiviral functions of", "value": 1}, {"from": "the", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "the", "to": "via", "value": 1}, {"from": "the", "to": "and p", "value": 1}, {"from": "the", "to": "##c cell line", "value": 1}, {"from": "the", "to": "hi", "value": 1}, {"from": "the", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "the", "to": "##53", "value": 1}, {"from": "the", "to": ". 022 pmid :", "value": 1}, {"from": "the", "to": "bax", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "hormone receptor positive", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "societal perspective", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "benefits", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "surgery", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "cost -", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "decision", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "to aid adjuvant treatment", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "##al", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "emit - 1 trial", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "post", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": ". materials", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "model was", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "used", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": ": the", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "ki - 67", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "prosigna was tested", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "prospective", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "were measured", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "observation", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "division", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "decisions in", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "built", "value": 1}, {"from": "profiling tests such as the prosigna - assay are", "to": "impact of", "value": 1}, {"from": "hormone receptor positive", "to": "societal perspective", "value": 1}, {"from": "hormone receptor positive", "to": "benefits", "value": 1}, {"from": "hormone receptor positive", "to": "surgery", "value": 1}, {"from": "hormone receptor positive", "to": "cost -", "value": 1}, {"from": "hormone receptor positive", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "hormone receptor positive", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "hormone receptor positive", "to": "decision", "value": 1}, {"from": "hormone receptor positive", "to": "to aid adjuvant treatment", "value": 1}, {"from": "hormone receptor positive", "to": "##al", "value": 1}, {"from": "hormone receptor positive", "to": "emit - 1 trial", "value": 1}, {"from": "hormone receptor positive", "to": "post", "value": 1}, {"from": "hormone receptor positive", "to": ". materials", "value": 1}, {"from": "hormone receptor positive", "to": "model was", "value": 1}, {"from": "hormone receptor positive", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "hormone receptor positive", "to": "used", "value": 1}, {"from": "hormone receptor positive", "to": ": the", "value": 1}, {"from": "hormone receptor positive", "to": "ki - 67", "value": 1}, {"from": "hormone receptor positive", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "hormone receptor positive", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "hormone receptor positive", "to": "prosigna was tested", "value": 1}, {"from": "hormone receptor positive", "to": "prospective", "value": 1}, {"from": "hormone receptor positive", "to": "were measured", "value": 1}, {"from": "hormone receptor positive", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "hormone receptor positive", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "hormone receptor positive", "to": "observation", "value": 1}, {"from": "hormone receptor positive", "to": "division", "value": 1}, {"from": "hormone receptor positive", "to": "decisions in", "value": 1}, {"from": "hormone receptor positive", "to": "built", "value": 1}, {"from": "hormone receptor positive", "to": "impact of", "value": 1}, {"from": "societal perspective", "to": "benefits", "value": 1}, {"from": "societal perspective", "to": "surgery", "value": 1}, {"from": "societal perspective", "to": "cost -", "value": 1}, {"from": "societal perspective", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "societal perspective", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "societal perspective", "to": "decision", "value": 1}, {"from": "societal perspective", "to": "to aid adjuvant treatment", "value": 1}, {"from": "societal perspective", "to": "##al", "value": 1}, {"from": "societal perspective", "to": "emit - 1 trial", "value": 1}, {"from": "societal perspective", "to": "post", "value": 1}, {"from": "societal perspective", "to": ". materials", "value": 1}, {"from": "societal perspective", "to": "model was", "value": 1}, {"from": "societal perspective", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "societal perspective", "to": "used", "value": 1}, {"from": "societal perspective", "to": ": the", "value": 1}, {"from": "societal perspective", "to": "ki - 67", "value": 1}, {"from": "societal perspective", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "societal perspective", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "societal perspective", "to": "prosigna was tested", "value": 1}, {"from": "societal perspective", "to": "prospective", "value": 1}, {"from": "societal perspective", "to": "were measured", "value": 1}, {"from": "societal perspective", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "societal perspective", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "societal perspective", "to": "observation", "value": 1}, {"from": "societal perspective", "to": "division", "value": 1}, {"from": "societal perspective", "to": "decisions in", "value": 1}, {"from": "societal perspective", "to": "built", "value": 1}, {"from": "societal perspective", "to": "impact of", "value": 1}, {"from": "societal perspective", "to": "from a healthcare perspective, but from the societal perspective", "value": 1}, {"from": "societal perspective", "to": "benefit", "value": 1}, {"from": "societal perspective", "to": "##26, 000 ;", "value": 1}, {"from": "societal perspective", "to": "effective", "value": 1}, {"from": "societal perspective", "to": "it was cost - saving", "value": 1}, {"from": "societal perspective", "to": "threshold", "value": 1}, {"from": "societal perspective", "to": "- 435, 677 )", "value": 1}, {"from": "societal perspective", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "societal perspective", "to": "##aly", "value": 1}, {"from": "societal perspective", "to": "in the", "value": 1}, {"from": "societal perspective", "to": "cost", "value": 1}, {"from": "societal perspective", "to": "\u20ac", "value": 1}, {"from": "societal perspective", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "societal perspective", "to": "- 620170,", "value": 1}, {"from": "societal perspective", "to": "##r )", "value": 1}, {"from": "societal perspective", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "societal perspective", "to": "candidates, the strategy", "value": 1}, {"from": "societal perspective", "to": "cost - effective", "value": 1}, {"from": "societal perspective", "to": "incre", "value": 1}, {"from": "societal perspective", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "societal perspective", "to": "##mental", "value": 1}, {"from": "societal perspective", "to": "the cost -", "value": 1}, {"from": "societal perspective", "to": "was cost - effective", "value": 1}, {"from": "societal perspective", "to": "above", "value": 1}, {"from": "societal perspective", "to": "was obtained from statistics norway.", "value": 1}, {"from": "societal perspective", "to": "per quality - adjusted life -", "value": 1}, {"from": "societal perspective", "to": "was cost - saving", "value": 1}, {"from": "societal perspective", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "societal perspective", "to": "chemotherapy", "value": 1}, {"from": "societal perspective", "to": "in both the healthcare", "value": 1}, {"from": "societal perspective", "to": "years", "value": 1}, {"from": "societal perspective", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "societal perspective", "to": "- per q", "value": 1}, {"from": "societal perspective", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "societal perspective", "to": ". conclusions", "value": 1}, {"from": "societal perspective", "to": ". selecting patient", "value": 1}, {"from": "societal perspective", "to": "ice", "value": 1}, {"from": "societal perspective", "to": "##8884 and", "value": 1}, {"from": "societal perspective", "to": "gained", "value": 1}, {"from": "societal perspective", "to": "the emit", "value": 1}, {"from": "societal perspective", "to": "records. including all pn0 patients", "value": 1}, {"from": "societal perspective", "to": "sector", "value": 1}, {"from": "societal perspective", "to": "not", "value": 1}, {"from": "benefits", "to": "surgery", "value": 1}, {"from": "benefits", "to": "cost -", "value": 1}, {"from": "benefits", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "benefits", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "benefits", "to": "decision", "value": 1}, {"from": "benefits", "to": "to aid adjuvant treatment", "value": 1}, {"from": "benefits", "to": "##al", "value": 1}, {"from": "benefits", "to": "emit - 1 trial", "value": 1}, {"from": "benefits", "to": "post", "value": 1}, {"from": "benefits", "to": ". materials", "value": 1}, {"from": "benefits", "to": "model was", "value": 1}, {"from": "benefits", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "benefits", "to": "used", "value": 1}, {"from": "benefits", "to": ": the", "value": 1}, {"from": "benefits", "to": "ki - 67", "value": 1}, {"from": "benefits", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "benefits", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "benefits", "to": "prosigna was tested", "value": 1}, {"from": "benefits", "to": "prospective", "value": 1}, {"from": "benefits", "to": "were measured", "value": 1}, {"from": "benefits", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "benefits", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "benefits", "to": "observation", "value": 1}, {"from": "benefits", "to": "division", "value": 1}, {"from": "benefits", "to": "decisions in", "value": 1}, {"from": "benefits", "to": "built", "value": 1}, {"from": "benefits", "to": "impact of", "value": 1}, {"from": "surgery", "to": "cost -", "value": 1}, {"from": "surgery", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "surgery", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "surgery", "to": "decision", "value": 1}, {"from": "surgery", "to": "to aid adjuvant treatment", "value": 1}, {"from": "surgery", "to": "##al", "value": 1}, {"from": "surgery", "to": "emit - 1 trial", "value": 1}, {"from": "surgery", "to": "post", "value": 1}, {"from": "surgery", "to": ". materials", "value": 1}, {"from": "surgery", "to": "model was", "value": 1}, {"from": "surgery", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "surgery", "to": "used", "value": 1}, {"from": "surgery", "to": ": the", "value": 1}, {"from": "surgery", "to": "ki - 67", "value": 1}, {"from": "surgery", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "surgery", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "surgery", "to": "prosigna was tested", "value": 1}, {"from": "surgery", "to": "prospective", "value": 1}, {"from": "surgery", "to": "were measured", "value": 1}, {"from": "surgery", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "surgery", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "surgery", "to": "observation", "value": 1}, {"from": "surgery", "to": "division", "value": 1}, {"from": "surgery", "to": "decisions in", "value": 1}, {"from": "surgery", "to": "built", "value": 1}, {"from": "surgery", "to": "impact of", "value": 1}, {"from": "cost -", "to": ". using individual data collected the first 12 months", "value": 1}, {"from": "cost -", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": "cost -", "to": "decision", "value": 1}, {"from": "cost -", "to": "to aid adjuvant treatment", "value": 1}, {"from": "cost -", "to": "##al", "value": 1}, {"from": "cost -", "to": "emit - 1 trial", "value": 1}, {"from": "cost -", "to": "post", "value": 1}, {"from": "cost -", "to": ". materials", "value": 1}, {"from": "cost -", "to": "model was", "value": 1}, {"from": "cost -", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "cost -", "to": "used", "value": 1}, {"from": "cost -", "to": ": the", "value": 1}, {"from": "cost -", "to": "ki - 67", "value": 1}, {"from": "cost -", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "cost -", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "cost -", "to": "prosigna was tested", "value": 1}, {"from": "cost -", "to": "prospective", "value": 1}, {"from": "cost -", "to": "were measured", "value": 1}, {"from": "cost -", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "cost -", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "cost -", "to": "observation", "value": 1}, {"from": "cost -", "to": "division", "value": 1}, {"from": "cost -", "to": "decisions in", "value": 1}, {"from": "cost -", "to": "built", "value": 1}, {"from": "cost -", "to": "impact of", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "effectiveness of prosigna against immunohistochemical", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "decision", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "to aid adjuvant treatment", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "##al", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "emit - 1 trial", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "post", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": ". materials", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "model was", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "used", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": ": the", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "ki - 67", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "prosigna was tested", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "prospective", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "were measured", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "observation", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "division", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "decisions in", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "built", "value": 1}, {"from": ". using individual data collected the first 12 months", "to": "impact of", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "decision", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "to aid adjuvant treatment", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "##al", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "emit - 1 trial", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "post", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": ". materials", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "model was", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "used", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": ": the", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "ki - 67", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "prosigna was tested", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "prospective", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "were measured", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "observation", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "division", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "decisions in", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "built", "value": 1}, {"from": "effectiveness of prosigna against immunohistochemical", "to": "impact of", "value": 1}, {"from": "decision", "to": "to aid adjuvant treatment", "value": 1}, {"from": "decision", "to": "##al", "value": 1}, {"from": "decision", "to": "emit - 1 trial", "value": 1}, {"from": "decision", "to": "post", "value": 1}, {"from": "decision", "to": ". materials", "value": 1}, {"from": "decision", "to": "model was", "value": 1}, {"from": "decision", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "decision", "to": "used", "value": 1}, {"from": "decision", "to": ": the", "value": 1}, {"from": "decision", "to": "ki - 67", "value": 1}, {"from": "decision", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "decision", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "decision", "to": "prosigna was tested", "value": 1}, {"from": "decision", "to": "prospective", "value": 1}, {"from": "decision", "to": "were measured", "value": 1}, {"from": "decision", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "decision", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "decision", "to": "observation", "value": 1}, {"from": "decision", "to": "division", "value": 1}, {"from": "decision", "to": "decisions in", "value": 1}, {"from": "decision", "to": "built", "value": 1}, {"from": "decision", "to": "impact of", "value": 1}, {"from": "to aid adjuvant treatment", "to": "##al", "value": 1}, {"from": "to aid adjuvant treatment", "to": "emit - 1 trial", "value": 1}, {"from": "to aid adjuvant treatment", "to": "post", "value": 1}, {"from": "to aid adjuvant treatment", "to": ". materials", "value": 1}, {"from": "to aid adjuvant treatment", "to": "model was", "value": 1}, {"from": "to aid adjuvant treatment", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "to aid adjuvant treatment", "to": "used", "value": 1}, {"from": "to aid adjuvant treatment", "to": ": the", "value": 1}, {"from": "to aid adjuvant treatment", "to": "ki - 67", "value": 1}, {"from": "to aid adjuvant treatment", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "to aid adjuvant treatment", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "to aid adjuvant treatment", "to": "prosigna was tested", "value": 1}, {"from": "to aid adjuvant treatment", "to": "prospective", "value": 1}, {"from": "to aid adjuvant treatment", "to": "were measured", "value": 1}, {"from": "to aid adjuvant treatment", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "to aid adjuvant treatment", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "to aid adjuvant treatment", "to": "observation", "value": 1}, {"from": "to aid adjuvant treatment", "to": "division", "value": 1}, {"from": "to aid adjuvant treatment", "to": "decisions in", "value": 1}, {"from": "to aid adjuvant treatment", "to": "built", "value": 1}, {"from": "to aid adjuvant treatment", "to": "impact of", "value": 1}, {"from": "##al", "to": "emit - 1 trial", "value": 1}, {"from": "##al", "to": "post", "value": 1}, {"from": "##al", "to": ". materials", "value": 1}, {"from": "##al", "to": "model was", "value": 1}, {"from": "##al", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "##al", "to": "used", "value": 1}, {"from": "##al", "to": ": the", "value": 1}, {"from": "##al", "to": "ki - 67", "value": 1}, {"from": "##al", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "##al", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "##al", "to": "prosigna was tested", "value": 1}, {"from": "##al", "to": "prospective", "value": 1}, {"from": "##al", "to": "were measured", "value": 1}, {"from": "##al", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "##al", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "##al", "to": "observation", "value": 1}, {"from": "##al", "to": "division", "value": 1}, {"from": "##al", "to": "decisions in", "value": 1}, {"from": "##al", "to": "built", "value": 1}, {"from": "##al", "to": "impact of", "value": 1}, {"from": "emit - 1 trial", "to": "post", "value": 1}, {"from": "emit - 1 trial", "to": ". materials", "value": 1}, {"from": "emit - 1 trial", "to": "model was", "value": 1}, {"from": "emit - 1 trial", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "emit - 1 trial", "to": "used", "value": 1}, {"from": "emit - 1 trial", "to": ": the", "value": 1}, {"from": "emit - 1 trial", "to": "ki - 67", "value": 1}, {"from": "emit - 1 trial", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "emit - 1 trial", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "emit - 1 trial", "to": "prosigna was tested", "value": 1}, {"from": "emit - 1 trial", "to": "prospective", "value": 1}, {"from": "emit - 1 trial", "to": "were measured", "value": 1}, {"from": "emit - 1 trial", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "emit - 1 trial", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "emit - 1 trial", "to": "observation", "value": 1}, {"from": "emit - 1 trial", "to": "division", "value": 1}, {"from": "emit - 1 trial", "to": "decisions in", "value": 1}, {"from": "emit - 1 trial", "to": "built", "value": 1}, {"from": "emit - 1 trial", "to": "impact of", "value": 1}, {"from": "post", "to": ". materials", "value": 1}, {"from": "post", "to": "model was", "value": 1}, {"from": "post", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "post", "to": "used", "value": 1}, {"from": "post", "to": ": the", "value": 1}, {"from": "post", "to": "ki - 67", "value": 1}, {"from": "post", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "post", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "post", "to": "prosigna was tested", "value": 1}, {"from": "post", "to": "prospective", "value": 1}, {"from": "post", "to": "were measured", "value": 1}, {"from": "post", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "post", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "post", "to": "observation", "value": 1}, {"from": "post", "to": "division", "value": 1}, {"from": "post", "to": "decisions in", "value": 1}, {"from": "post", "to": "built", "value": 1}, {"from": "post", "to": "impact of", "value": 1}, {"from": ". materials", "to": "model was", "value": 1}, {"from": ". materials", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": ". materials", "to": "used", "value": 1}, {"from": ". materials", "to": ": the", "value": 1}, {"from": ". materials", "to": "ki - 67", "value": 1}, {"from": ". materials", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": ". materials", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ". materials", "to": "prosigna was tested", "value": 1}, {"from": ". materials", "to": "prospective", "value": 1}, {"from": ". materials", "to": "were measured", "value": 1}, {"from": ". materials", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ". materials", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ". materials", "to": "observation", "value": 1}, {"from": ". materials", "to": "division", "value": 1}, {"from": ". materials", "to": "decisions in", "value": 1}, {"from": ". materials", "to": "built", "value": 1}, {"from": ". materials", "to": "impact of", "value": 1}, {"from": "model was", "to": "of cancer medicine, oslo university hospital, oslo, norway ;", "value": 1}, {"from": "model was", "to": "used", "value": 1}, {"from": "model was", "to": ": the", "value": 1}, {"from": "model was", "to": "ki - 67", "value": 1}, {"from": "model was", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "model was", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "model was", "to": "prosigna was tested", "value": 1}, {"from": "model was", "to": "prospective", "value": 1}, {"from": "model was", "to": "were measured", "value": 1}, {"from": "model was", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "model was", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "model was", "to": "observation", "value": 1}, {"from": "model was", "to": "division", "value": 1}, {"from": "model was", "to": "decisions in", "value": 1}, {"from": "model was", "to": "built", "value": 1}, {"from": "model was", "to": "impact of", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "used", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": ": the", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "ki - 67", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "prosigna was tested", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "prospective", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "were measured", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "observation", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "division", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "decisions in", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "built", "value": 1}, {"from": "of cancer medicine, oslo university hospital, oslo, norway ;", "to": "impact of", "value": 1}, {"from": "used", "to": ": the", "value": 1}, {"from": "used", "to": "ki - 67", "value": 1}, {"from": "used", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "used", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "used", "to": "prosigna was tested", "value": 1}, {"from": "used", "to": "prospective", "value": 1}, {"from": "used", "to": "were measured", "value": 1}, {"from": "used", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "used", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "used", "to": "observation", "value": 1}, {"from": "used", "to": "division", "value": 1}, {"from": "used", "to": "decisions in", "value": 1}, {"from": "used", "to": "built", "value": 1}, {"from": "used", "to": "impact of", "value": 1}, {"from": ": the", "to": "ki - 67", "value": 1}, {"from": ": the", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": ": the", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ": the", "to": "prosigna was tested", "value": 1}, {"from": ": the", "to": "prospective", "value": 1}, {"from": ": the", "to": "were measured", "value": 1}, {"from": ": the", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ": the", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ": the", "to": "observation", "value": 1}, {"from": ": the", "to": "division", "value": 1}, {"from": ": the", "to": "decisions in", "value": 1}, {"from": ": the", "to": "built", "value": 1}, {"from": ": the", "to": "impact of", "value": 1}, {"from": "ki - 67", "to": ", was evaluated from the norwegian healthcare -", "value": 1}, {"from": "ki - 67", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": "ki - 67", "to": "prosigna was tested", "value": 1}, {"from": "ki - 67", "to": "prospective", "value": 1}, {"from": "ki - 67", "to": "were measured", "value": 1}, {"from": "ki - 67", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "ki - 67", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "ki - 67", "to": "observation", "value": 1}, {"from": "ki - 67", "to": "division", "value": 1}, {"from": "ki - 67", "to": "decisions in", "value": 1}, {"from": "ki - 67", "to": "built", "value": 1}, {"from": "ki - 67", "to": "impact of", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "of clinical medicine, university of oslo, oslo, norway. background : gene", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "prosigna was tested", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "prospective", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "were measured", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "observation", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "division", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "decisions in", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "built", "value": 1}, {"from": ", was evaluated from the norwegian healthcare -", "to": "impact of", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "prosigna was tested", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "prospective", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "were measured", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "observation", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "division", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "decisions in", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "built", "value": 1}, {"from": "of clinical medicine, university of oslo, oslo, norway. background : gene", "to": "impact of", "value": 1}, {"from": "prosigna was tested", "to": "prospective", "value": 1}, {"from": "prosigna was tested", "to": "were measured", "value": 1}, {"from": "prosigna was tested", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "prosigna was tested", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "prosigna was tested", "to": "observation", "value": 1}, {"from": "prosigna was tested", "to": "division", "value": 1}, {"from": "prosigna was tested", "to": "decisions in", "value": 1}, {"from": "prosigna was tested", "to": "built", "value": 1}, {"from": "prosigna was tested", "to": "impact of", "value": 1}, {"from": "prospective", "to": "were measured", "value": 1}, {"from": "prospective", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "prospective", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "prospective", "to": "observation", "value": 1}, {"from": "prospective", "to": "division", "value": 1}, {"from": "prospective", "to": "decisions in", "value": 1}, {"from": "prospective", "to": "built", "value": 1}, {"from": "prospective", "to": "impact of", "value": 1}, {"from": "were measured", "to": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "value": 1}, {"from": "were measured", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "were measured", "to": "observation", "value": 1}, {"from": "were measured", "to": "division", "value": 1}, {"from": "were measured", "to": "decisions in", "value": 1}, {"from": "were measured", "to": "built", "value": 1}, {"from": "were measured", "to": "impact of", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "observation", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "division", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "decisions in", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "built", "value": 1}, {"from": "to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health", "to": "impact of", "value": 1}, {"from": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "to": "observation", "value": 1}, {"from": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "to": "division", "value": 1}, {"from": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "to": "decisions in", "value": 1}, {"from": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "to": "built", "value": 1}, {"from": "y, division of cancer medicine, oslo university hospital, oslo, norway.", "to": "impact of", "value": 1}, {"from": "observation", "to": "division", "value": 1}, {"from": "observation", "to": "decisions in", "value": 1}, {"from": "observation", "to": "built", "value": 1}, {"from": "observation", "to": "impact of", "value": 1}, {"from": "division", "to": "decisions in", "value": 1}, {"from": "division", "to": "built", "value": 1}, {"from": "division", "to": "impact of", "value": 1}, {"from": "decisions in", "to": "built", "value": 1}, {"from": "decisions in", "to": "impact of", "value": 1}, {"from": "built", "to": "impact of", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "benefit", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##26, 000 ;", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "effective", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "it was cost - saving", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "threshold", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "- 435, 677 )", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##aly", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "in the", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "cost", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "\u20ac", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "- 620170,", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##r )", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "candidates, the strategy", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "cost - effective", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "incre", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##mental", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "the cost -", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "was cost - effective", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "above", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "was obtained from statistics norway.", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "per quality - adjusted life -", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "was cost - saving", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "chemotherapy", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "in both the healthcare", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "years", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "- per q", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": ". conclusions", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": ". selecting patient", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "ice", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "##8884 and", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "gained", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "the emit", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "records. including all pn0 patients", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "sector", "value": 1}, {"from": "from a healthcare perspective, but from the societal perspective", "to": "not", "value": 1}, {"from": "benefit", "to": "##26, 000 ;", "value": 1}, {"from": "benefit", "to": "effective", "value": 1}, {"from": "benefit", "to": "it was cost - saving", "value": 1}, {"from": "benefit", "to": "threshold", "value": 1}, {"from": "benefit", "to": "- 435, 677 )", "value": 1}, {"from": "benefit", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "benefit", "to": "##aly", "value": 1}, {"from": "benefit", "to": "in the", "value": 1}, {"from": "benefit", "to": "cost", "value": 1}, {"from": "benefit", "to": "\u20ac", "value": 1}, {"from": "benefit", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "benefit", "to": "- 620170,", "value": 1}, {"from": "benefit", "to": "##r )", "value": 1}, {"from": "benefit", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "benefit", "to": "candidates, the strategy", "value": 1}, {"from": "benefit", "to": "cost - effective", "value": 1}, {"from": "benefit", "to": "incre", "value": 1}, {"from": "benefit", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "benefit", "to": "##mental", "value": 1}, {"from": "benefit", "to": "the cost -", "value": 1}, {"from": "benefit", "to": "was cost - effective", "value": 1}, {"from": "benefit", "to": "above", "value": 1}, {"from": "benefit", "to": "was obtained from statistics norway.", "value": 1}, {"from": "benefit", "to": "per quality - adjusted life -", "value": 1}, {"from": "benefit", "to": "was cost - saving", "value": 1}, {"from": "benefit", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "benefit", "to": "chemotherapy", "value": 1}, {"from": "benefit", "to": "in both the healthcare", "value": 1}, {"from": "benefit", "to": "years", "value": 1}, {"from": "benefit", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "benefit", "to": "- per q", "value": 1}, {"from": "benefit", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "benefit", "to": ". conclusions", "value": 1}, {"from": "benefit", "to": ". selecting patient", "value": 1}, {"from": "benefit", "to": "ice", "value": 1}, {"from": "benefit", "to": "##8884 and", "value": 1}, {"from": "benefit", "to": "gained", "value": 1}, {"from": "benefit", "to": "the emit", "value": 1}, {"from": "benefit", "to": "records. including all pn0 patients", "value": 1}, {"from": "benefit", "to": "sector", "value": 1}, {"from": "benefit", "to": "not", "value": 1}, {"from": "##26, 000 ;", "to": "effective", "value": 1}, {"from": "##26, 000 ;", "to": "it was cost - saving", "value": 1}, {"from": "##26, 000 ;", "to": "threshold", "value": 1}, {"from": "##26, 000 ;", "to": "- 435, 677 )", "value": 1}, {"from": "##26, 000 ;", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##26, 000 ;", "to": "##aly", "value": 1}, {"from": "##26, 000 ;", "to": "in the", "value": 1}, {"from": "##26, 000 ;", "to": "cost", "value": 1}, {"from": "##26, 000 ;", "to": "\u20ac", "value": 1}, {"from": "##26, 000 ;", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "##26, 000 ;", "to": "- 620170,", "value": 1}, {"from": "##26, 000 ;", "to": "##r )", "value": 1}, {"from": "##26, 000 ;", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "##26, 000 ;", "to": "candidates, the strategy", "value": 1}, {"from": "##26, 000 ;", "to": "cost - effective", "value": 1}, {"from": "##26, 000 ;", "to": "incre", "value": 1}, {"from": "##26, 000 ;", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "##26, 000 ;", "to": "##mental", "value": 1}, {"from": "##26, 000 ;", "to": "the cost -", "value": 1}, {"from": "##26, 000 ;", "to": "was cost - effective", "value": 1}, {"from": "##26, 000 ;", "to": "above", "value": 1}, {"from": "##26, 000 ;", "to": "was obtained from statistics norway.", "value": 1}, {"from": "##26, 000 ;", "to": "per quality - adjusted life -", "value": 1}, {"from": "##26, 000 ;", "to": "was cost - saving", "value": 1}, {"from": "##26, 000 ;", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##26, 000 ;", "to": "chemotherapy", "value": 1}, {"from": "##26, 000 ;", "to": "in both the healthcare", "value": 1}, {"from": "##26, 000 ;", "to": "years", "value": 1}, {"from": "##26, 000 ;", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "##26, 000 ;", "to": "- per q", "value": 1}, {"from": "##26, 000 ;", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "##26, 000 ;", "to": ". conclusions", "value": 1}, {"from": "##26, 000 ;", "to": ". selecting patient", "value": 1}, {"from": "##26, 000 ;", "to": "ice", "value": 1}, {"from": "##26, 000 ;", "to": "##8884 and", "value": 1}, {"from": "##26, 000 ;", "to": "gained", "value": 1}, {"from": "##26, 000 ;", "to": "the emit", "value": 1}, {"from": "##26, 000 ;", "to": "records. including all pn0 patients", "value": 1}, {"from": "##26, 000 ;", "to": "sector", "value": 1}, {"from": "##26, 000 ;", "to": "not", "value": 1}, {"from": "effective", "to": "it was cost - saving", "value": 1}, {"from": "effective", "to": "threshold", "value": 1}, {"from": "effective", "to": "- 435, 677 )", "value": 1}, {"from": "effective", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "effective", "to": "##aly", "value": 1}, {"from": "effective", "to": "in the", "value": 1}, {"from": "effective", "to": "cost", "value": 1}, {"from": "effective", "to": "\u20ac", "value": 1}, {"from": "effective", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "effective", "to": "- 620170,", "value": 1}, {"from": "effective", "to": "##r )", "value": 1}, {"from": "effective", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "effective", "to": "candidates, the strategy", "value": 1}, {"from": "effective", "to": "cost - effective", "value": 1}, {"from": "effective", "to": "incre", "value": 1}, {"from": "effective", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "effective", "to": "##mental", "value": 1}, {"from": "effective", "to": "the cost -", "value": 1}, {"from": "effective", "to": "was cost - effective", "value": 1}, {"from": "effective", "to": "above", "value": 1}, {"from": "effective", "to": "was obtained from statistics norway.", "value": 1}, {"from": "effective", "to": "per quality - adjusted life -", "value": 1}, {"from": "effective", "to": "was cost - saving", "value": 1}, {"from": "effective", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "effective", "to": "chemotherapy", "value": 1}, {"from": "effective", "to": "in both the healthcare", "value": 1}, {"from": "effective", "to": "years", "value": 1}, {"from": "effective", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "effective", "to": "- per q", "value": 1}, {"from": "effective", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "effective", "to": ". conclusions", "value": 1}, {"from": "effective", "to": ". selecting patient", "value": 1}, {"from": "effective", "to": "ice", "value": 1}, {"from": "effective", "to": "##8884 and", "value": 1}, {"from": "effective", "to": "gained", "value": 1}, {"from": "effective", "to": "the emit", "value": 1}, {"from": "effective", "to": "records. including all pn0 patients", "value": 1}, {"from": "effective", "to": "sector", "value": 1}, {"from": "effective", "to": "not", "value": 1}, {"from": "it was cost - saving", "to": "threshold", "value": 1}, {"from": "it was cost - saving", "to": "- 435, 677 )", "value": 1}, {"from": "it was cost - saving", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "it was cost - saving", "to": "##aly", "value": 1}, {"from": "it was cost - saving", "to": "in the", "value": 1}, {"from": "it was cost - saving", "to": "cost", "value": 1}, {"from": "it was cost - saving", "to": "\u20ac", "value": 1}, {"from": "it was cost - saving", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "it was cost - saving", "to": "- 620170,", "value": 1}, {"from": "it was cost - saving", "to": "##r )", "value": 1}, {"from": "it was cost - saving", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "it was cost - saving", "to": "candidates, the strategy", "value": 1}, {"from": "it was cost - saving", "to": "cost - effective", "value": 1}, {"from": "it was cost - saving", "to": "incre", "value": 1}, {"from": "it was cost - saving", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "it was cost - saving", "to": "##mental", "value": 1}, {"from": "it was cost - saving", "to": "the cost -", "value": 1}, {"from": "it was cost - saving", "to": "was cost - effective", "value": 1}, {"from": "it was cost - saving", "to": "above", "value": 1}, {"from": "it was cost - saving", "to": "was obtained from statistics norway.", "value": 1}, {"from": "it was cost - saving", "to": "per quality - adjusted life -", "value": 1}, {"from": "it was cost - saving", "to": "was cost - saving", "value": 1}, {"from": "it was cost - saving", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "it was cost - saving", "to": "chemotherapy", "value": 1}, {"from": "it was cost - saving", "to": "in both the healthcare", "value": 1}, {"from": "it was cost - saving", "to": "years", "value": 1}, {"from": "it was cost - saving", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "it was cost - saving", "to": "- per q", "value": 1}, {"from": "it was cost - saving", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "it was cost - saving", "to": ". conclusions", "value": 1}, {"from": "it was cost - saving", "to": ". selecting patient", "value": 1}, {"from": "it was cost - saving", "to": "ice", "value": 1}, {"from": "it was cost - saving", "to": "##8884 and", "value": 1}, {"from": "it was cost - saving", "to": "gained", "value": 1}, {"from": "it was cost - saving", "to": "the emit", "value": 1}, {"from": "it was cost - saving", "to": "records. including all pn0 patients", "value": 1}, {"from": "it was cost - saving", "to": "sector", "value": 1}, {"from": "it was cost - saving", "to": "not", "value": 1}, {"from": "threshold", "to": "- 435, 677 )", "value": 1}, {"from": "threshold", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "threshold", "to": "##aly", "value": 1}, {"from": "threshold", "to": "in the", "value": 1}, {"from": "threshold", "to": "cost", "value": 1}, {"from": "threshold", "to": "\u20ac", "value": 1}, {"from": "threshold", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "threshold", "to": "- 620170,", "value": 1}, {"from": "threshold", "to": "##r )", "value": 1}, {"from": "threshold", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "threshold", "to": "candidates, the strategy", "value": 1}, {"from": "threshold", "to": "cost - effective", "value": 1}, {"from": "threshold", "to": "incre", "value": 1}, {"from": "threshold", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "threshold", "to": "##mental", "value": 1}, {"from": "threshold", "to": "the cost -", "value": 1}, {"from": "threshold", "to": "was cost - effective", "value": 1}, {"from": "threshold", "to": "above", "value": 1}, {"from": "threshold", "to": "was obtained from statistics norway.", "value": 1}, {"from": "threshold", "to": "per quality - adjusted life -", "value": 1}, {"from": "threshold", "to": "was cost - saving", "value": 1}, {"from": "threshold", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "threshold", "to": "chemotherapy", "value": 1}, {"from": "threshold", "to": "in both the healthcare", "value": 1}, {"from": "threshold", "to": "years", "value": 1}, {"from": "threshold", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "threshold", "to": "- per q", "value": 1}, {"from": "threshold", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "threshold", "to": ". conclusions", "value": 1}, {"from": "threshold", "to": ". selecting patient", "value": 1}, {"from": "threshold", "to": "ice", "value": 1}, {"from": "threshold", "to": "##8884 and", "value": 1}, {"from": "threshold", "to": "gained", "value": 1}, {"from": "threshold", "to": "the emit", "value": 1}, {"from": "threshold", "to": "records. including all pn0 patients", "value": 1}, {"from": "threshold", "to": "sector", "value": 1}, {"from": "threshold", "to": "not", "value": 1}, {"from": "- 435, 677 )", "to": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "- 435, 677 )", "to": "##aly", "value": 1}, {"from": "- 435, 677 )", "to": "in the", "value": 1}, {"from": "- 435, 677 )", "to": "cost", "value": 1}, {"from": "- 435, 677 )", "to": "\u20ac", "value": 1}, {"from": "- 435, 677 )", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "- 435, 677 )", "to": "- 620170,", "value": 1}, {"from": "- 435, 677 )", "to": "##r )", "value": 1}, {"from": "- 435, 677 )", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "- 435, 677 )", "to": "candidates, the strategy", "value": 1}, {"from": "- 435, 677 )", "to": "cost - effective", "value": 1}, {"from": "- 435, 677 )", "to": "incre", "value": 1}, {"from": "- 435, 677 )", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "- 435, 677 )", "to": "##mental", "value": 1}, {"from": "- 435, 677 )", "to": "the cost -", "value": 1}, {"from": "- 435, 677 )", "to": "was cost - effective", "value": 1}, {"from": "- 435, 677 )", "to": "above", "value": 1}, {"from": "- 435, 677 )", "to": "was obtained from statistics norway.", "value": 1}, {"from": "- 435, 677 )", "to": "per quality - adjusted life -", "value": 1}, {"from": "- 435, 677 )", "to": "was cost - saving", "value": 1}, {"from": "- 435, 677 )", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "- 435, 677 )", "to": "chemotherapy", "value": 1}, {"from": "- 435, 677 )", "to": "in both the healthcare", "value": 1}, {"from": "- 435, 677 )", "to": "years", "value": 1}, {"from": "- 435, 677 )", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "- 435, 677 )", "to": "- per q", "value": 1}, {"from": "- 435, 677 )", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "- 435, 677 )", "to": ". conclusions", "value": 1}, {"from": "- 435, 677 )", "to": ". selecting patient", "value": 1}, {"from": "- 435, 677 )", "to": "ice", "value": 1}, {"from": "- 435, 677 )", "to": "##8884 and", "value": 1}, {"from": "- 435, 677 )", "to": "gained", "value": 1}, {"from": "- 435, 677 )", "to": "the emit", "value": 1}, {"from": "- 435, 677 )", "to": "records. including all pn0 patients", "value": 1}, {"from": "- 435, 677 )", "to": "sector", "value": 1}, {"from": "- 435, 677 )", "to": "not", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "##aly", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "in the", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "cost", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "\u20ac", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "- 620170,", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "##r )", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "candidates, the strategy", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "cost - effective", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "incre", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "prosigna - test strategy, the test", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "##mental", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "the cost -", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "was cost - effective", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "above", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "was obtained from statistics norway.", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "per quality - adjusted life -", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "was cost - saving", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "chemotherapy", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "in both the healthcare", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "years", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "- per q", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": ". conclusions", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": ". selecting patient", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "ice", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "##8884 and", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "gained", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "the emit", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "records. including all pn0 patients", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "sector", "value": 1}, {"from": ": using the prosigna - assay for all hr + / her2 - pn0 ebc patients", "to": "not", "value": 1}, {"from": "##aly", "to": "in the", "value": 1}, {"from": "##aly", "to": "cost", "value": 1}, {"from": "##aly", "to": "\u20ac", "value": 1}, {"from": "##aly", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "##aly", "to": "- 620170,", "value": 1}, {"from": "##aly", "to": "##r )", "value": 1}, {"from": "##aly", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "##aly", "to": "candidates, the strategy", "value": 1}, {"from": "##aly", "to": "cost - effective", "value": 1}, {"from": "##aly", "to": "incre", "value": 1}, {"from": "##aly", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "##aly", "to": "##mental", "value": 1}, {"from": "##aly", "to": "the cost -", "value": 1}, {"from": "##aly", "to": "was cost - effective", "value": 1}, {"from": "##aly", "to": "above", "value": 1}, {"from": "##aly", "to": "was obtained from statistics norway.", "value": 1}, {"from": "##aly", "to": "per quality - adjusted life -", "value": 1}, {"from": "##aly", "to": "was cost - saving", "value": 1}, {"from": "##aly", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##aly", "to": "chemotherapy", "value": 1}, {"from": "##aly", "to": "in both the healthcare", "value": 1}, {"from": "##aly", "to": "years", "value": 1}, {"from": "##aly", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "##aly", "to": "- per q", "value": 1}, {"from": "##aly", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "##aly", "to": ". conclusions", "value": 1}, {"from": "##aly", "to": ". selecting patient", "value": 1}, {"from": "##aly", "to": "ice", "value": 1}, {"from": "##aly", "to": "##8884 and", "value": 1}, {"from": "##aly", "to": "gained", "value": 1}, {"from": "##aly", "to": "the emit", "value": 1}, {"from": "##aly", "to": "records. including all pn0 patients", "value": 1}, {"from": "##aly", "to": "sector", "value": 1}, {"from": "##aly", "to": "not", "value": 1}, {"from": "in the", "to": "cost", "value": 1}, {"from": "in the", "to": "\u20ac", "value": 1}, {"from": "in the", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "in the", "to": "- 620170,", "value": 1}, {"from": "in the", "to": "##r )", "value": 1}, {"from": "in the", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "in the", "to": "candidates, the strategy", "value": 1}, {"from": "in the", "to": "cost - effective", "value": 1}, {"from": "in the", "to": "incre", "value": 1}, {"from": "in the", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "in the", "to": "##mental", "value": 1}, {"from": "in the", "to": "the cost -", "value": 1}, {"from": "in the", "to": "was cost - effective", "value": 1}, {"from": "in the", "to": "above", "value": 1}, {"from": "in the", "to": "was obtained from statistics norway.", "value": 1}, {"from": "in the", "to": "per quality - adjusted life -", "value": 1}, {"from": "in the", "to": "was cost - saving", "value": 1}, {"from": "in the", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "in the", "to": "chemotherapy", "value": 1}, {"from": "in the", "to": "in both the healthcare", "value": 1}, {"from": "in the", "to": "years", "value": 1}, {"from": "in the", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "in the", "to": "- per q", "value": 1}, {"from": "in the", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "in the", "to": ". conclusions", "value": 1}, {"from": "in the", "to": ". selecting patient", "value": 1}, {"from": "in the", "to": "ice", "value": 1}, {"from": "in the", "to": "##8884 and", "value": 1}, {"from": "in the", "to": "gained", "value": 1}, {"from": "in the", "to": "the emit", "value": 1}, {"from": "in the", "to": "records. including all pn0 patients", "value": 1}, {"from": "in the", "to": "sector", "value": 1}, {"from": "in the", "to": "not", "value": 1}, {"from": "in the", "to": "of agriculture and natural resources, imam khomeini international university, qazvin,", "value": 1}, {"from": "in the", "to": "##ifer", "value": 1}, {"from": "in the", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "in the", "to": "##ne - c", "value": 1}, {"from": "in the", "to": ", tnf signaling", "value": 1}, {"from": "in the", "to": ", which", "value": 1}, {"from": "in the", "to": "down - regulated", "value": 1}, {"from": "in the", "to": "including c", "value": 1}, {"from": "in the", "to": "##ytoki", "value": 1}, {"from": "in the", "to": "detected", "value": 1}, {"from": "in the", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "in the", "to": "vs", "value": 1}, {"from": "in the", "to": "##cer assays. the", "value": 1}, {"from": "in the", "to": "or", "value": 1}, {"from": "in the", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "in the", "to": "##ne receptor", "value": 1}, {"from": "in the", "to": "##ap", "value": 1}, {"from": "in the", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "in the", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "in the", "to": "via", "value": 1}, {"from": "in the", "to": "anti", "value": 1}, {"from": "in the", "to": "##n - \u03b3", "value": 1}, {"from": "in the", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "in the", "to": "f biotechnology engineering,", "value": 1}, {"from": "in the", "to": "were up -", "value": 1}, {"from": "in the", "to": ", nod - like receptor signaling", "value": 1}, {"from": "in the", "to": "##ation, pro", "value": 1}, {"from": "in the", "to": "pathways", "value": 1}, {"from": "in the", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "in the", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "in the", "to": "pathway", "value": 1}, {"from": "in the", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "cost", "to": "\u20ac", "value": 1}, {"from": "cost", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "cost", "to": "- 620170,", "value": 1}, {"from": "cost", "to": "##r )", "value": 1}, {"from": "cost", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "cost", "to": "candidates, the strategy", "value": 1}, {"from": "cost", "to": "cost - effective", "value": 1}, {"from": "cost", "to": "incre", "value": 1}, {"from": "cost", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "cost", "to": "##mental", "value": 1}, {"from": "cost", "to": "the cost -", "value": 1}, {"from": "cost", "to": "was cost - effective", "value": 1}, {"from": "cost", "to": "above", "value": 1}, {"from": "cost", "to": "was obtained from statistics norway.", "value": 1}, {"from": "cost", "to": "per quality - adjusted life -", "value": 1}, {"from": "cost", "to": "was cost - saving", "value": 1}, {"from": "cost", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "cost", "to": "chemotherapy", "value": 1}, {"from": "cost", "to": "in both the healthcare", "value": 1}, {"from": "cost", "to": "years", "value": 1}, {"from": "cost", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "cost", "to": "- per q", "value": 1}, {"from": "cost", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "cost", "to": ". conclusions", "value": 1}, {"from": "cost", "to": ". selecting patient", "value": 1}, {"from": "cost", "to": "ice", "value": 1}, {"from": "cost", "to": "##8884 and", "value": 1}, {"from": "cost", "to": "gained", "value": 1}, {"from": "cost", "to": "the emit", "value": 1}, {"from": "cost", "to": "records. including all pn0 patients", "value": 1}, {"from": "cost", "to": "sector", "value": 1}, {"from": "cost", "to": "not", "value": 1}, {"from": "\u20ac", "to": "perspective. incorporating also productivity costs, prosigna", "value": 1}, {"from": "\u20ac", "to": "- 620170,", "value": 1}, {"from": "\u20ac", "to": "##r )", "value": 1}, {"from": "\u20ac", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "\u20ac", "to": "candidates, the strategy", "value": 1}, {"from": "\u20ac", "to": "cost - effective", "value": 1}, {"from": "\u20ac", "to": "incre", "value": 1}, {"from": "\u20ac", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "\u20ac", "to": "##mental", "value": 1}, {"from": "\u20ac", "to": "the cost -", "value": 1}, {"from": "\u20ac", "to": "was cost - effective", "value": 1}, {"from": "\u20ac", "to": "above", "value": 1}, {"from": "\u20ac", "to": "was obtained from statistics norway.", "value": 1}, {"from": "\u20ac", "to": "per quality - adjusted life -", "value": 1}, {"from": "\u20ac", "to": "was cost - saving", "value": 1}, {"from": "\u20ac", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "\u20ac", "to": "chemotherapy", "value": 1}, {"from": "\u20ac", "to": "in both the healthcare", "value": 1}, {"from": "\u20ac", "to": "years", "value": 1}, {"from": "\u20ac", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "\u20ac", "to": "- per q", "value": 1}, {"from": "\u20ac", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "\u20ac", "to": ". conclusions", "value": 1}, {"from": "\u20ac", "to": ". selecting patient", "value": 1}, {"from": "\u20ac", "to": "ice", "value": 1}, {"from": "\u20ac", "to": "##8884 and", "value": 1}, {"from": "\u20ac", "to": "gained", "value": 1}, {"from": "\u20ac", "to": "the emit", "value": 1}, {"from": "\u20ac", "to": "records. including all pn0 patients", "value": 1}, {"from": "\u20ac", "to": "sector", "value": 1}, {"from": "\u20ac", "to": "not", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "- 620170,", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "##r )", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "candidates, the strategy", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "cost - effective", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "incre", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "##mental", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "the cost -", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "was cost - effective", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "above", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "was obtained from statistics norway.", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "per quality - adjusted life -", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "was cost - saving", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "chemotherapy", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "in both the healthcare", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "years", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "- per q", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": ". conclusions", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": ". selecting patient", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "ice", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "##8884 and", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "gained", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "the emit", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "records. including all pn0 patients", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "sector", "value": 1}, {"from": "perspective. incorporating also productivity costs, prosigna", "to": "not", "value": 1}, {"from": "- 620170,", "to": "##r )", "value": 1}, {"from": "- 620170,", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "- 620170,", "to": "candidates, the strategy", "value": 1}, {"from": "- 620170,", "to": "cost - effective", "value": 1}, {"from": "- 620170,", "to": "incre", "value": 1}, {"from": "- 620170,", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "- 620170,", "to": "##mental", "value": 1}, {"from": "- 620170,", "to": "the cost -", "value": 1}, {"from": "- 620170,", "to": "was cost - effective", "value": 1}, {"from": "- 620170,", "to": "above", "value": 1}, {"from": "- 620170,", "to": "was obtained from statistics norway.", "value": 1}, {"from": "- 620170,", "to": "per quality - adjusted life -", "value": 1}, {"from": "- 620170,", "to": "was cost - saving", "value": 1}, {"from": "- 620170,", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "- 620170,", "to": "chemotherapy", "value": 1}, {"from": "- 620170,", "to": "in both the healthcare", "value": 1}, {"from": "- 620170,", "to": "years", "value": 1}, {"from": "- 620170,", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "- 620170,", "to": "- per q", "value": 1}, {"from": "- 620170,", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "- 620170,", "to": ". conclusions", "value": 1}, {"from": "- 620170,", "to": ". selecting patient", "value": 1}, {"from": "- 620170,", "to": "ice", "value": 1}, {"from": "- 620170,", "to": "##8884 and", "value": 1}, {"from": "- 620170,", "to": "gained", "value": 1}, {"from": "- 620170,", "to": "the emit", "value": 1}, {"from": "- 620170,", "to": "records. including all pn0 patients", "value": 1}, {"from": "- 620170,", "to": "sector", "value": 1}, {"from": "- 620170,", "to": "not", "value": 1}, {"from": "##r )", "to": "restricting prosigna - testing to patients assessed as clear / uncertain", "value": 1}, {"from": "##r )", "to": "candidates, the strategy", "value": 1}, {"from": "##r )", "to": "cost - effective", "value": 1}, {"from": "##r )", "to": "incre", "value": 1}, {"from": "##r )", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "##r )", "to": "##mental", "value": 1}, {"from": "##r )", "to": "the cost -", "value": 1}, {"from": "##r )", "to": "was cost - effective", "value": 1}, {"from": "##r )", "to": "above", "value": 1}, {"from": "##r )", "to": "was obtained from statistics norway.", "value": 1}, {"from": "##r )", "to": "per quality - adjusted life -", "value": 1}, {"from": "##r )", "to": "was cost - saving", "value": 1}, {"from": "##r )", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##r )", "to": "chemotherapy", "value": 1}, {"from": "##r )", "to": "in both the healthcare", "value": 1}, {"from": "##r )", "to": "years", "value": 1}, {"from": "##r )", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "##r )", "to": "- per q", "value": 1}, {"from": "##r )", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "##r )", "to": ". conclusions", "value": 1}, {"from": "##r )", "to": ". selecting patient", "value": 1}, {"from": "##r )", "to": "ice", "value": 1}, {"from": "##r )", "to": "##8884 and", "value": 1}, {"from": "##r )", "to": "gained", "value": 1}, {"from": "##r )", "to": "the emit", "value": 1}, {"from": "##r )", "to": "records. including all pn0 patients", "value": 1}, {"from": "##r )", "to": "sector", "value": 1}, {"from": "##r )", "to": "not", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "candidates, the strategy", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "cost - effective", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "incre", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "##mental", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "the cost -", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "was cost - effective", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "above", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "was obtained from statistics norway.", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "per quality - adjusted life -", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "was cost - saving", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "chemotherapy", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "in both the healthcare", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "years", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "- per q", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": ". conclusions", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": ". selecting patient", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "ice", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "##8884 and", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "gained", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "the emit", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "records. including all pn0 patients", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "sector", "value": 1}, {"from": "restricting prosigna - testing to patients assessed as clear / uncertain", "to": "not", "value": 1}, {"from": "candidates, the strategy", "to": "cost - effective", "value": 1}, {"from": "candidates, the strategy", "to": "incre", "value": 1}, {"from": "candidates, the strategy", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "candidates, the strategy", "to": "##mental", "value": 1}, {"from": "candidates, the strategy", "to": "the cost -", "value": 1}, {"from": "candidates, the strategy", "to": "was cost - effective", "value": 1}, {"from": "candidates, the strategy", "to": "above", "value": 1}, {"from": "candidates, the strategy", "to": "was obtained from statistics norway.", "value": 1}, {"from": "candidates, the strategy", "to": "per quality - adjusted life -", "value": 1}, {"from": "candidates, the strategy", "to": "was cost - saving", "value": 1}, {"from": "candidates, the strategy", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "candidates, the strategy", "to": "chemotherapy", "value": 1}, {"from": "candidates, the strategy", "to": "in both the healthcare", "value": 1}, {"from": "candidates, the strategy", "to": "years", "value": 1}, {"from": "candidates, the strategy", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "candidates, the strategy", "to": "- per q", "value": 1}, {"from": "candidates, the strategy", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "candidates, the strategy", "to": ". conclusions", "value": 1}, {"from": "candidates, the strategy", "to": ". selecting patient", "value": 1}, {"from": "candidates, the strategy", "to": "ice", "value": 1}, {"from": "candidates, the strategy", "to": "##8884 and", "value": 1}, {"from": "candidates, the strategy", "to": "gained", "value": 1}, {"from": "candidates, the strategy", "to": "the emit", "value": 1}, {"from": "candidates, the strategy", "to": "records. including all pn0 patients", "value": 1}, {"from": "candidates, the strategy", "to": "sector", "value": 1}, {"from": "candidates, the strategy", "to": "not", "value": 1}, {"from": "cost - effective", "to": "incre", "value": 1}, {"from": "cost - effective", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "cost - effective", "to": "##mental", "value": 1}, {"from": "cost - effective", "to": "the cost -", "value": 1}, {"from": "cost - effective", "to": "was cost - effective", "value": 1}, {"from": "cost - effective", "to": "above", "value": 1}, {"from": "cost - effective", "to": "was obtained from statistics norway.", "value": 1}, {"from": "cost - effective", "to": "per quality - adjusted life -", "value": 1}, {"from": "cost - effective", "to": "was cost - saving", "value": 1}, {"from": "cost - effective", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "cost - effective", "to": "chemotherapy", "value": 1}, {"from": "cost - effective", "to": "in both the healthcare", "value": 1}, {"from": "cost - effective", "to": "years", "value": 1}, {"from": "cost - effective", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "cost - effective", "to": "- per q", "value": 1}, {"from": "cost - effective", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "cost - effective", "to": ". conclusions", "value": 1}, {"from": "cost - effective", "to": ". selecting patient", "value": 1}, {"from": "cost - effective", "to": "ice", "value": 1}, {"from": "cost - effective", "to": "##8884 and", "value": 1}, {"from": "cost - effective", "to": "gained", "value": 1}, {"from": "cost - effective", "to": "the emit", "value": 1}, {"from": "cost - effective", "to": "records. including all pn0 patients", "value": 1}, {"from": "cost - effective", "to": "sector", "value": 1}, {"from": "cost - effective", "to": "not", "value": 1}, {"from": "incre", "to": "prosigna - test strategy, the test", "value": 1}, {"from": "incre", "to": "##mental", "value": 1}, {"from": "incre", "to": "the cost -", "value": 1}, {"from": "incre", "to": "was cost - effective", "value": 1}, {"from": "incre", "to": "above", "value": 1}, {"from": "incre", "to": "was obtained from statistics norway.", "value": 1}, {"from": "incre", "to": "per quality - adjusted life -", "value": 1}, {"from": "incre", "to": "was cost - saving", "value": 1}, {"from": "incre", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "incre", "to": "chemotherapy", "value": 1}, {"from": "incre", "to": "in both the healthcare", "value": 1}, {"from": "incre", "to": "years", "value": 1}, {"from": "incre", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "incre", "to": "- per q", "value": 1}, {"from": "incre", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "incre", "to": ". conclusions", "value": 1}, {"from": "incre", "to": ". selecting patient", "value": 1}, {"from": "incre", "to": "ice", "value": 1}, {"from": "incre", "to": "##8884 and", "value": 1}, {"from": "incre", "to": "gained", "value": 1}, {"from": "incre", "to": "the emit", "value": 1}, {"from": "incre", "to": "records. including all pn0 patients", "value": 1}, {"from": "incre", "to": "sector", "value": 1}, {"from": "incre", "to": "not", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "##mental", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "the cost -", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "was cost - effective", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "above", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "was obtained from statistics norway.", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "per quality - adjusted life -", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "was cost - saving", "value": 1}, {"from": "prosigna - test strategy, the test", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "chemotherapy", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "in both the healthcare", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "years", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "- per q", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "prosigna - test strategy, the test", "to": ". conclusions", "value": 1}, {"from": "prosigna - test strategy, the test", "to": ". selecting patient", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "ice", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "##8884 and", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "gained", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "the emit", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "records. including all pn0 patients", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "sector", "value": 1}, {"from": "prosigna - test strategy, the test", "to": "not", "value": 1}, {"from": "##mental", "to": "the cost -", "value": 1}, {"from": "##mental", "to": "was cost - effective", "value": 1}, {"from": "##mental", "to": "above", "value": 1}, {"from": "##mental", "to": "was obtained from statistics norway.", "value": 1}, {"from": "##mental", "to": "per quality - adjusted life -", "value": 1}, {"from": "##mental", "to": "was cost - saving", "value": 1}, {"from": "##mental", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "##mental", "to": "chemotherapy", "value": 1}, {"from": "##mental", "to": "in both the healthcare", "value": 1}, {"from": "##mental", "to": "years", "value": 1}, {"from": "##mental", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "##mental", "to": "- per q", "value": 1}, {"from": "##mental", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "##mental", "to": ". conclusions", "value": 1}, {"from": "##mental", "to": ". selecting patient", "value": 1}, {"from": "##mental", "to": "ice", "value": 1}, {"from": "##mental", "to": "##8884 and", "value": 1}, {"from": "##mental", "to": "gained", "value": 1}, {"from": "##mental", "to": "the emit", "value": 1}, {"from": "##mental", "to": "records. including all pn0 patients", "value": 1}, {"from": "##mental", "to": "sector", "value": 1}, {"from": "##mental", "to": "not", "value": 1}, {"from": "the cost -", "to": "was cost - effective", "value": 1}, {"from": "the cost -", "to": "above", "value": 1}, {"from": "the cost -", "to": "was obtained from statistics norway.", "value": 1}, {"from": "the cost -", "to": "per quality - adjusted life -", "value": 1}, {"from": "the cost -", "to": "was cost - saving", "value": 1}, {"from": "the cost -", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "the cost -", "to": "chemotherapy", "value": 1}, {"from": "the cost -", "to": "in both the healthcare", "value": 1}, {"from": "the cost -", "to": "years", "value": 1}, {"from": "the cost -", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "the cost -", "to": "- per q", "value": 1}, {"from": "the cost -", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "the cost -", "to": ". conclusions", "value": 1}, {"from": "the cost -", "to": ". selecting patient", "value": 1}, {"from": "the cost -", "to": "ice", "value": 1}, {"from": "the cost -", "to": "##8884 and", "value": 1}, {"from": "the cost -", "to": "gained", "value": 1}, {"from": "the cost -", "to": "the emit", "value": 1}, {"from": "the cost -", "to": "records. including all pn0 patients", "value": 1}, {"from": "the cost -", "to": "sector", "value": 1}, {"from": "the cost -", "to": "not", "value": 1}, {"from": "was cost - effective", "to": "above", "value": 1}, {"from": "was cost - effective", "to": "was obtained from statistics norway.", "value": 1}, {"from": "was cost - effective", "to": "per quality - adjusted life -", "value": 1}, {"from": "was cost - effective", "to": "was cost - saving", "value": 1}, {"from": "was cost - effective", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "was cost - effective", "to": "chemotherapy", "value": 1}, {"from": "was cost - effective", "to": "in both the healthcare", "value": 1}, {"from": "was cost - effective", "to": "years", "value": 1}, {"from": "was cost - effective", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "was cost - effective", "to": "- per q", "value": 1}, {"from": "was cost - effective", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "was cost - effective", "to": ". conclusions", "value": 1}, {"from": "was cost - effective", "to": ". selecting patient", "value": 1}, {"from": "was cost - effective", "to": "ice", "value": 1}, {"from": "was cost - effective", "to": "##8884 and", "value": 1}, {"from": "was cost - effective", "to": "gained", "value": 1}, {"from": "was cost - effective", "to": "the emit", "value": 1}, {"from": "was cost - effective", "to": "records. including all pn0 patients", "value": 1}, {"from": "was cost - effective", "to": "sector", "value": 1}, {"from": "was cost - effective", "to": "not", "value": 1}, {"from": "above", "to": "was obtained from statistics norway.", "value": 1}, {"from": "above", "to": "per quality - adjusted life -", "value": 1}, {"from": "above", "to": "was cost - saving", "value": 1}, {"from": "above", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "above", "to": "chemotherapy", "value": 1}, {"from": "above", "to": "in both the healthcare", "value": 1}, {"from": "above", "to": "years", "value": 1}, {"from": "above", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "above", "to": "- per q", "value": 1}, {"from": "above", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "above", "to": ". conclusions", "value": 1}, {"from": "above", "to": ". selecting patient", "value": 1}, {"from": "above", "to": "ice", "value": 1}, {"from": "above", "to": "##8884 and", "value": 1}, {"from": "above", "to": "gained", "value": 1}, {"from": "above", "to": "the emit", "value": 1}, {"from": "above", "to": "records. including all pn0 patients", "value": 1}, {"from": "above", "to": "sector", "value": 1}, {"from": "above", "to": "not", "value": 1}, {"from": "was obtained from statistics norway.", "to": "per quality - adjusted life -", "value": 1}, {"from": "was obtained from statistics norway.", "to": "was cost - saving", "value": 1}, {"from": "was obtained from statistics norway.", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "was obtained from statistics norway.", "to": "chemotherapy", "value": 1}, {"from": "was obtained from statistics norway.", "to": "in both the healthcare", "value": 1}, {"from": "was obtained from statistics norway.", "to": "years", "value": 1}, {"from": "was obtained from statistics norway.", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "was obtained from statistics norway.", "to": "- per q", "value": 1}, {"from": "was obtained from statistics norway.", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "was obtained from statistics norway.", "to": ". conclusions", "value": 1}, {"from": "was obtained from statistics norway.", "to": ". selecting patient", "value": 1}, {"from": "was obtained from statistics norway.", "to": "ice", "value": 1}, {"from": "was obtained from statistics norway.", "to": "##8884 and", "value": 1}, {"from": "was obtained from statistics norway.", "to": "gained", "value": 1}, {"from": "was obtained from statistics norway.", "to": "the emit", "value": 1}, {"from": "was obtained from statistics norway.", "to": "records. including all pn0 patients", "value": 1}, {"from": "was obtained from statistics norway.", "to": "sector", "value": 1}, {"from": "was obtained from statistics norway.", "to": "not", "value": 1}, {"from": "per quality - adjusted life -", "to": "was cost - saving", "value": 1}, {"from": "per quality - adjusted life -", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "per quality - adjusted life -", "to": "chemotherapy", "value": 1}, {"from": "per quality - adjusted life -", "to": "in both the healthcare", "value": 1}, {"from": "per quality - adjusted life -", "to": "years", "value": 1}, {"from": "per quality - adjusted life -", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "per quality - adjusted life -", "to": "- per q", "value": 1}, {"from": "per quality - adjusted life -", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "per quality - adjusted life -", "to": ". conclusions", "value": 1}, {"from": "per quality - adjusted life -", "to": ". selecting patient", "value": 1}, {"from": "per quality - adjusted life -", "to": "ice", "value": 1}, {"from": "per quality - adjusted life -", "to": "##8884 and", "value": 1}, {"from": "per quality - adjusted life -", "to": "gained", "value": 1}, {"from": "per quality - adjusted life -", "to": "the emit", "value": 1}, {"from": "per quality - adjusted life -", "to": "records. including all pn0 patients", "value": 1}, {"from": "per quality - adjusted life -", "to": "sector", "value": 1}, {"from": "per quality - adjusted life -", "to": "not", "value": 1}, {"from": "was cost - saving", "to": ": of 2, 178 hr + / her2 - pn0 ebc patients", "value": 1}, {"from": "was cost - saving", "to": "chemotherapy", "value": 1}, {"from": "was cost - saving", "to": "in both the healthcare", "value": 1}, {"from": "was cost - saving", "to": "years", "value": 1}, {"from": "was cost - saving", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "was cost - saving", "to": "- per q", "value": 1}, {"from": "was cost - saving", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "was cost - saving", "to": ". conclusions", "value": 1}, {"from": "was cost - saving", "to": ". selecting patient", "value": 1}, {"from": "was cost - saving", "to": "ice", "value": 1}, {"from": "was cost - saving", "to": "##8884 and", "value": 1}, {"from": "was cost - saving", "to": "gained", "value": 1}, {"from": "was cost - saving", "to": "the emit", "value": 1}, {"from": "was cost - saving", "to": "records. including all pn0 patients", "value": 1}, {"from": "was cost - saving", "to": "sector", "value": 1}, {"from": "was cost - saving", "to": "not", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "chemotherapy", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "in both the healthcare", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "years", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "- per q", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": ". conclusions", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": ". selecting patient", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "ice", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "##8884 and", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "gained", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "the emit", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "records. including all pn0 patients", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "sector", "value": 1}, {"from": ": of 2, 178 hr + / her2 - pn0 ebc patients", "to": "not", "value": 1}, {"from": "chemotherapy", "to": "in both the healthcare", "value": 1}, {"from": "chemotherapy", "to": "years", "value": 1}, {"from": "chemotherapy", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "chemotherapy", "to": "- per q", "value": 1}, {"from": "chemotherapy", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "chemotherapy", "to": ". conclusions", "value": 1}, {"from": "chemotherapy", "to": ". selecting patient", "value": 1}, {"from": "chemotherapy", "to": "ice", "value": 1}, {"from": "chemotherapy", "to": "##8884 and", "value": 1}, {"from": "chemotherapy", "to": "gained", "value": 1}, {"from": "chemotherapy", "to": "the emit", "value": 1}, {"from": "chemotherapy", "to": "records. including all pn0 patients", "value": 1}, {"from": "chemotherapy", "to": "sector", "value": 1}, {"from": "chemotherapy", "to": "not", "value": 1}, {"from": "in both the healthcare", "to": "years", "value": 1}, {"from": "in both the healthcare", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "in both the healthcare", "to": "- per q", "value": 1}, {"from": "in both the healthcare", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "in both the healthcare", "to": ". conclusions", "value": 1}, {"from": "in both the healthcare", "to": ". selecting patient", "value": 1}, {"from": "in both the healthcare", "to": "ice", "value": 1}, {"from": "in both the healthcare", "to": "##8884 and", "value": 1}, {"from": "in both the healthcare", "to": "gained", "value": 1}, {"from": "in both the healthcare", "to": "the emit", "value": 1}, {"from": "in both the healthcare", "to": "records. including all pn0 patients", "value": 1}, {"from": "in both the healthcare", "to": "sector", "value": 1}, {"from": "in both the healthcare", "to": "not", "value": 1}, {"from": "years", "to": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "value": 1}, {"from": "years", "to": "- per q", "value": 1}, {"from": "years", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "years", "to": ". conclusions", "value": 1}, {"from": "years", "to": ". selecting patient", "value": 1}, {"from": "years", "to": "ice", "value": 1}, {"from": "years", "to": "##8884 and", "value": 1}, {"from": "years", "to": "gained", "value": 1}, {"from": "years", "to": "the emit", "value": 1}, {"from": "years", "to": "records. including all pn0 patients", "value": 1}, {"from": "years", "to": "sector", "value": 1}, {"from": "years", "to": "not", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "- per q", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": ". conclusions", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": ". selecting patient", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "ice", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "##8884 and", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "gained", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "the emit", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "records. including all pn0 patients", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "sector", "value": 1}, {"from": "1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare", "to": "not", "value": 1}, {"from": "- per q", "to": "##255, 622 ) in a healthcare", "value": 1}, {"from": "- per q", "to": ". conclusions", "value": 1}, {"from": "- per q", "to": ". selecting patient", "value": 1}, {"from": "- per q", "to": "ice", "value": 1}, {"from": "- per q", "to": "##8884 and", "value": 1}, {"from": "- per q", "to": "gained", "value": 1}, {"from": "- per q", "to": "the emit", "value": 1}, {"from": "- per q", "to": "records. including all pn0 patients", "value": 1}, {"from": "- per q", "to": "sector", "value": 1}, {"from": "- per q", "to": "not", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": ". conclusions", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": ". selecting patient", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "ice", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "##8884 and", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "gained", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "the emit", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "records. including all pn0 patients", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "sector", "value": 1}, {"from": "##255, 622 ) in a healthcare", "to": "not", "value": 1}, {"from": ". conclusions", "to": ". selecting patient", "value": 1}, {"from": ". conclusions", "to": "ice", "value": 1}, {"from": ". conclusions", "to": "##8884 and", "value": 1}, {"from": ". conclusions", "to": "gained", "value": 1}, {"from": ". conclusions", "to": "the emit", "value": 1}, {"from": ". conclusions", "to": "records. including all pn0 patients", "value": 1}, {"from": ". conclusions", "to": "sector", "value": 1}, {"from": ". conclusions", "to": "not", "value": 1}, {"from": ". selecting patient", "to": "ice", "value": 1}, {"from": ". selecting patient", "to": "##8884 and", "value": 1}, {"from": ". selecting patient", "to": "gained", "value": 1}, {"from": ". selecting patient", "to": "the emit", "value": 1}, {"from": ". selecting patient", "to": "records. including all pn0 patients", "value": 1}, {"from": ". selecting patient", "to": "sector", "value": 1}, {"from": ". selecting patient", "to": "not", "value": 1}, {"from": "ice", "to": "##8884 and", "value": 1}, {"from": "ice", "to": "gained", "value": 1}, {"from": "ice", "to": "the emit", "value": 1}, {"from": "ice", "to": "records. including all pn0 patients", "value": 1}, {"from": "ice", "to": "sector", "value": 1}, {"from": "ice", "to": "not", "value": 1}, {"from": "##8884 and", "to": "gained", "value": 1}, {"from": "##8884 and", "to": "the emit", "value": 1}, {"from": "##8884 and", "to": "records. including all pn0 patients", "value": 1}, {"from": "##8884 and", "to": "sector", "value": 1}, {"from": "##8884 and", "to": "not", "value": 1}, {"from": "gained", "to": "the emit", "value": 1}, {"from": "gained", "to": "records. including all pn0 patients", "value": 1}, {"from": "gained", "to": "sector", "value": 1}, {"from": "gained", "to": "not", "value": 1}, {"from": "the emit", "to": "records. including all pn0 patients", "value": 1}, {"from": "the emit", "to": "sector", "value": 1}, {"from": "the emit", "to": "not", "value": 1}, {"from": "records. including all pn0 patients", "to": "sector", "value": 1}, {"from": "records. including all pn0 patients", "to": "not", "value": 1}, {"from": "sector", "to": "not", "value": 1}, {"from": "is cost - effective", "to": "of agriculture and natural", "value": 1}, {"from": "is cost - effective", "to": ". ac.", "value": 1}, {"from": "is cost - effective", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "is cost - effective", "to": "resources", "value": 1}, {"from": "is cost - effective", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "is cost - effective", "to": "##za. he", "value": 1}, {"from": "is cost - effective", "to": "are", "value": 1}, {"from": "is cost - effective", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "is cost - effective", "to": "##ri - japelaghi r", "value": 1}, {"from": "is cost - effective", "to": "##r.", "value": 1}, {"from": "is cost - effective", "to": "who", "value": 1}, {"from": "is cost - effective", "to": "inter", "value": 1}, {"from": "is cost - effective", "to": "##vin", "value": 1}, {"from": "is cost - effective", "to": "of tabriz,", "value": 1}, {"from": "is cost - effective", "to": "@ org.", "value": 1}, {"from": "is cost - effective", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "is cost - effective", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "is cost - effective", "to": "##idari", "value": 1}, {"from": "is cost - effective", "to": "s", "value": 1}, {"from": "is cost - effective", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "is cost - effective", "to": "ta", "value": 1}, {"from": "is cost - effective", "to": "##ran. electronic address :", "value": 1}, {"from": "is cost - effective", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "is cost - effective", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "is cost - effective", "to": "perspectives", "value": 1}, {"from": "is cost - effective", "to": "##briz,", "value": 1}, {"from": "is cost - effective", "to": "of agriculture,", "value": 1}, {"from": "is cost - effective", "to": "##fer", "value": 1}, {"from": "is cost - effective", "to": "##ki", "value": 1}, {"from": "is cost - effective", "to": "from both", "value": 1}, {"from": "is cost - effective", "to": "##ran.", "value": 1}, {"from": "of agriculture and natural", "to": ". ac.", "value": 1}, {"from": "of agriculture and natural", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": "of agriculture and natural", "to": "resources", "value": 1}, {"from": "of agriculture and natural", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "of agriculture and natural", "to": "##za. he", "value": 1}, {"from": "of agriculture and natural", "to": "are", "value": 1}, {"from": "of agriculture and natural", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "of agriculture and natural", "to": "##ri - japelaghi r", "value": 1}, {"from": "of agriculture and natural", "to": "##r.", "value": 1}, {"from": "of agriculture and natural", "to": "who", "value": 1}, {"from": "of agriculture and natural", "to": "inter", "value": 1}, {"from": "of agriculture and natural", "to": "##vin", "value": 1}, {"from": "of agriculture and natural", "to": "of tabriz,", "value": 1}, {"from": "of agriculture and natural", "to": "@ org.", "value": 1}, {"from": "of agriculture and natural", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "of agriculture and natural", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "of agriculture and natural", "to": "##idari", "value": 1}, {"from": "of agriculture and natural", "to": "s", "value": 1}, {"from": "of agriculture and natural", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "of agriculture and natural", "to": "ta", "value": 1}, {"from": "of agriculture and natural", "to": "##ran. electronic address :", "value": 1}, {"from": "of agriculture and natural", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "of agriculture and natural", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "of agriculture and natural", "to": "perspectives", "value": 1}, {"from": "of agriculture and natural", "to": "##briz,", "value": 1}, {"from": "of agriculture and natural", "to": "of agriculture,", "value": 1}, {"from": "of agriculture and natural", "to": "##fer", "value": 1}, {"from": "of agriculture and natural", "to": "##ki", "value": 1}, {"from": "of agriculture and natural", "to": "from both", "value": 1}, {"from": "of agriculture and natural", "to": "##ran.", "value": 1}, {"from": ". ac.", "to": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "value": 1}, {"from": ". ac.", "to": "resources", "value": 1}, {"from": ". ac.", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": ". ac.", "to": "##za. he", "value": 1}, {"from": ". ac.", "to": "are", "value": 1}, {"from": ". ac.", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": ". ac.", "to": "##ri - japelaghi r", "value": 1}, {"from": ". ac.", "to": "##r.", "value": 1}, {"from": ". ac.", "to": "who", "value": 1}, {"from": ". ac.", "to": "inter", "value": 1}, {"from": ". ac.", "to": "##vin", "value": 1}, {"from": ". ac.", "to": "of tabriz,", "value": 1}, {"from": ". ac.", "to": "@ org.", "value": 1}, {"from": ". ac.", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": ". ac.", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": ". ac.", "to": "##idari", "value": 1}, {"from": ". ac.", "to": "s", "value": 1}, {"from": ". ac.", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": ". ac.", "to": "ta", "value": 1}, {"from": ". ac.", "to": "##ran. electronic address :", "value": 1}, {"from": ". ac.", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": ". ac.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ". ac.", "to": "perspectives", "value": 1}, {"from": ". ac.", "to": "##briz,", "value": 1}, {"from": ". ac.", "to": "of agriculture,", "value": 1}, {"from": ". ac.", "to": "##fer", "value": 1}, {"from": ". ac.", "to": "##ki", "value": 1}, {"from": ". ac.", "to": "from both", "value": 1}, {"from": ". ac.", "to": "##ran.", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "resources", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##za. he", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "are", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##ri - japelaghi r", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##r.", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "who", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "inter", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##vin", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "of tabriz,", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "@ org.", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##idari", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "s", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "ta", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##ran. electronic address :", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "perspectives", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##briz,", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "of agriculture,", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##fer", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##ki", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "from both", "value": 1}, {"from": "##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest.", "to": "##ran.", "value": 1}, {"from": "resources", "to": "biotechnol. 2025 may 8 : s0168 - 1656", "value": 1}, {"from": "resources", "to": "##za. he", "value": 1}, {"from": "resources", "to": "are", "value": 1}, {"from": "resources", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "resources", "to": "##ri - japelaghi r", "value": 1}, {"from": "resources", "to": "##r.", "value": 1}, {"from": "resources", "to": "who", "value": 1}, {"from": "resources", "to": "inter", "value": 1}, {"from": "resources", "to": "##vin", "value": 1}, {"from": "resources", "to": "of tabriz,", "value": 1}, {"from": "resources", "to": "@ org.", "value": 1}, {"from": "resources", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "resources", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "resources", "to": "##idari", "value": 1}, {"from": "resources", "to": "s", "value": 1}, {"from": "resources", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "resources", "to": "ta", "value": 1}, {"from": "resources", "to": "##ran. electronic address :", "value": 1}, {"from": "resources", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "resources", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "resources", "to": "perspectives", "value": 1}, {"from": "resources", "to": "##briz,", "value": 1}, {"from": "resources", "to": "of agriculture,", "value": 1}, {"from": "resources", "to": "##fer", "value": 1}, {"from": "resources", "to": "##ki", "value": 1}, {"from": "resources", "to": "from both", "value": 1}, {"from": "resources", "to": "##ran.", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##za. he", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "are", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##ri - japelaghi r", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##r.", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "who", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "inter", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##vin", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "of tabriz,", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "@ org.", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##idari", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "s", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "ta", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##ran. electronic address :", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "perspectives", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##briz,", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "of agriculture,", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##fer", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##ki", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "from both", "value": 1}, {"from": "biotechnol. 2025 may 8 : s0168 - 1656", "to": "##ran.", "value": 1}, {"from": "##za. he", "to": "are", "value": 1}, {"from": "##za. he", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "##za. he", "to": "##ri - japelaghi r", "value": 1}, {"from": "##za. he", "to": "##r.", "value": 1}, {"from": "##za. he", "to": "who", "value": 1}, {"from": "##za. he", "to": "inter", "value": 1}, {"from": "##za. he", "to": "##vin", "value": 1}, {"from": "##za. he", "to": "of tabriz,", "value": 1}, {"from": "##za. he", "to": "@ org.", "value": 1}, {"from": "##za. he", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##za. he", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##za. he", "to": "##idari", "value": 1}, {"from": "##za. he", "to": "s", "value": 1}, {"from": "##za. he", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##za. he", "to": "ta", "value": 1}, {"from": "##za. he", "to": "##ran. electronic address :", "value": 1}, {"from": "##za. he", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##za. he", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##za. he", "to": "perspectives", "value": 1}, {"from": "##za. he", "to": "##briz,", "value": 1}, {"from": "##za. he", "to": "of agriculture,", "value": 1}, {"from": "##za. he", "to": "##fer", "value": 1}, {"from": "##za. he", "to": "##ki", "value": 1}, {"from": "##za. he", "to": "from both", "value": 1}, {"from": "##za. he", "to": "##ran.", "value": 1}, {"from": "are", "to": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "value": 1}, {"from": "are", "to": "##ri - japelaghi r", "value": 1}, {"from": "are", "to": "##r.", "value": 1}, {"from": "are", "to": "who", "value": 1}, {"from": "are", "to": "inter", "value": 1}, {"from": "are", "to": "##vin", "value": 1}, {"from": "are", "to": "of tabriz,", "value": 1}, {"from": "are", "to": "@ org.", "value": 1}, {"from": "are", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "are", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "are", "to": "##idari", "value": 1}, {"from": "are", "to": "s", "value": 1}, {"from": "are", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "are", "to": "ta", "value": 1}, {"from": "are", "to": "##ran. electronic address :", "value": 1}, {"from": "are", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "are", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "are", "to": "perspectives", "value": 1}, {"from": "are", "to": "##briz,", "value": 1}, {"from": "are", "to": "of agriculture,", "value": 1}, {"from": "are", "to": "##fer", "value": 1}, {"from": "are", "to": "##ki", "value": 1}, {"from": "are", "to": "from both", "value": 1}, {"from": "are", "to": "##ran.", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##ri - japelaghi r", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##r.", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "who", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "inter", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##vin", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "of tabriz,", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "@ org.", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##idari", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "s", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "ta", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##ran. electronic address :", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "perspectives", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##briz,", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "of agriculture,", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##fer", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##ki", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "from both", "value": 1}, {"from": "gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he", "to": "##ran.", "value": 1}, {"from": "##ri - japelaghi r", "to": "##r.", "value": 1}, {"from": "##ri - japelaghi r", "to": "who", "value": 1}, {"from": "##ri - japelaghi r", "to": "inter", "value": 1}, {"from": "##ri - japelaghi r", "to": "##vin", "value": 1}, {"from": "##ri - japelaghi r", "to": "of tabriz,", "value": 1}, {"from": "##ri - japelaghi r", "to": "@ org.", "value": 1}, {"from": "##ri - japelaghi r", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##ri - japelaghi r", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##ri - japelaghi r", "to": "##idari", "value": 1}, {"from": "##ri - japelaghi r", "to": "s", "value": 1}, {"from": "##ri - japelaghi r", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##ri - japelaghi r", "to": "ta", "value": 1}, {"from": "##ri - japelaghi r", "to": "##ran. electronic address :", "value": 1}, {"from": "##ri - japelaghi r", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##ri - japelaghi r", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##ri - japelaghi r", "to": "perspectives", "value": 1}, {"from": "##ri - japelaghi r", "to": "##briz,", "value": 1}, {"from": "##ri - japelaghi r", "to": "of agriculture,", "value": 1}, {"from": "##ri - japelaghi r", "to": "##fer", "value": 1}, {"from": "##ri - japelaghi r", "to": "##ki", "value": 1}, {"from": "##ri - japelaghi r", "to": "from both", "value": 1}, {"from": "##ri - japelaghi r", "to": "##ran.", "value": 1}, {"from": "##r.", "to": "who", "value": 1}, {"from": "##r.", "to": "inter", "value": 1}, {"from": "##r.", "to": "##vin", "value": 1}, {"from": "##r.", "to": "of tabriz,", "value": 1}, {"from": "##r.", "to": "@ org.", "value": 1}, {"from": "##r.", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##r.", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##r.", "to": "##idari", "value": 1}, {"from": "##r.", "to": "s", "value": 1}, {"from": "##r.", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##r.", "to": "ta", "value": 1}, {"from": "##r.", "to": "##ran. electronic address :", "value": 1}, {"from": "##r.", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##r.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##r.", "to": "perspectives", "value": 1}, {"from": "##r.", "to": "##briz,", "value": 1}, {"from": "##r.", "to": "of agriculture,", "value": 1}, {"from": "##r.", "to": "##fer", "value": 1}, {"from": "##r.", "to": "##ki", "value": 1}, {"from": "##r.", "to": "from both", "value": 1}, {"from": "##r.", "to": "##ran.", "value": 1}, {"from": "who", "to": "inter", "value": 1}, {"from": "who", "to": "##vin", "value": 1}, {"from": "who", "to": "of tabriz,", "value": 1}, {"from": "who", "to": "@ org.", "value": 1}, {"from": "who", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "who", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "who", "to": "##idari", "value": 1}, {"from": "who", "to": "s", "value": 1}, {"from": "who", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "who", "to": "ta", "value": 1}, {"from": "who", "to": "##ran. electronic address :", "value": 1}, {"from": "who", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "who", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "who", "to": "perspectives", "value": 1}, {"from": "who", "to": "##briz,", "value": 1}, {"from": "who", "to": "of agriculture,", "value": 1}, {"from": "who", "to": "##fer", "value": 1}, {"from": "who", "to": "##ki", "value": 1}, {"from": "who", "to": "from both", "value": 1}, {"from": "who", "to": "##ran.", "value": 1}, {"from": "inter", "to": "##vin", "value": 1}, {"from": "inter", "to": "of tabriz,", "value": 1}, {"from": "inter", "to": "@ org.", "value": 1}, {"from": "inter", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "inter", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "inter", "to": "##idari", "value": 1}, {"from": "inter", "to": "s", "value": 1}, {"from": "inter", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "inter", "to": "ta", "value": 1}, {"from": "inter", "to": "##ran. electronic address :", "value": 1}, {"from": "inter", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "inter", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "inter", "to": "perspectives", "value": 1}, {"from": "inter", "to": "##briz,", "value": 1}, {"from": "inter", "to": "of agriculture,", "value": 1}, {"from": "inter", "to": "##fer", "value": 1}, {"from": "inter", "to": "##ki", "value": 1}, {"from": "inter", "to": "from both", "value": 1}, {"from": "inter", "to": "##ran.", "value": 1}, {"from": "##vin", "to": "of tabriz,", "value": 1}, {"from": "##vin", "to": "@ org.", "value": 1}, {"from": "##vin", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "##vin", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "##vin", "to": "##idari", "value": 1}, {"from": "##vin", "to": "s", "value": 1}, {"from": "##vin", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##vin", "to": "ta", "value": 1}, {"from": "##vin", "to": "##ran. electronic address :", "value": 1}, {"from": "##vin", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##vin", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##vin", "to": "perspectives", "value": 1}, {"from": "##vin", "to": "##briz,", "value": 1}, {"from": "##vin", "to": "of agriculture,", "value": 1}, {"from": "##vin", "to": "##fer", "value": 1}, {"from": "##vin", "to": "##ki", "value": 1}, {"from": "##vin", "to": "from both", "value": 1}, {"from": "##vin", "to": "##ran.", "value": 1}, {"from": "of tabriz,", "to": "@ org.", "value": 1}, {"from": "of tabriz,", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "of tabriz,", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "of tabriz,", "to": "##idari", "value": 1}, {"from": "of tabriz,", "to": "s", "value": 1}, {"from": "of tabriz,", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "of tabriz,", "to": "ta", "value": 1}, {"from": "of tabriz,", "to": "##ran. electronic address :", "value": 1}, {"from": "of tabriz,", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "of tabriz,", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "of tabriz,", "to": "perspectives", "value": 1}, {"from": "of tabriz,", "to": "##briz,", "value": 1}, {"from": "of tabriz,", "to": "of agriculture,", "value": 1}, {"from": "of tabriz,", "to": "##fer", "value": 1}, {"from": "of tabriz,", "to": "##ki", "value": 1}, {"from": "of tabriz,", "to": "from both", "value": 1}, {"from": "of tabriz,", "to": "##ran.", "value": 1}, {"from": "@ org.", "to": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "value": 1}, {"from": "@ org.", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "@ org.", "to": "##idari", "value": 1}, {"from": "@ org.", "to": "s", "value": 1}, {"from": "@ org.", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "@ org.", "to": "ta", "value": 1}, {"from": "@ org.", "to": "##ran. electronic address :", "value": 1}, {"from": "@ org.", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "@ org.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "@ org.", "to": "perspectives", "value": 1}, {"from": "@ org.", "to": "##briz,", "value": 1}, {"from": "@ org.", "to": "of agriculture,", "value": 1}, {"from": "@ org.", "to": "##fer", "value": 1}, {"from": "@ org.", "to": "##ki", "value": 1}, {"from": "@ org.", "to": "from both", "value": 1}, {"from": "@ org.", "to": "##ran.", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": ". clbc. 2025. 04. 011 pmid :", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##idari", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "s", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "ta", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##ran. electronic address :", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "perspectives", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##briz,", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "of agriculture,", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##fer", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##ki", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "from both", "value": 1}, {"from": "clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna", "to": "##ran.", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##idari", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "s", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "ta", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##ran. electronic address :", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "perspectives", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##briz,", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "of agriculture,", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##fer", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##ki", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "from both", "value": 1}, {"from": ". clbc. 2025. 04. 011 pmid :", "to": "##ran.", "value": 1}, {"from": "##idari", "to": "s", "value": 1}, {"from": "##idari", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "##idari", "to": "ta", "value": 1}, {"from": "##idari", "to": "##ran. electronic address :", "value": 1}, {"from": "##idari", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##idari", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##idari", "to": "perspectives", "value": 1}, {"from": "##idari", "to": "##briz,", "value": 1}, {"from": "##idari", "to": "of agriculture,", "value": 1}, {"from": "##idari", "to": "##fer", "value": 1}, {"from": "##idari", "to": "##ki", "value": 1}, {"from": "##idari", "to": "from both", "value": 1}, {"from": "##idari", "to": "##ran.", "value": 1}, {"from": "s", "to": "##biotec. 2025. 04. 022. online ahead of print.", "value": 1}, {"from": "s", "to": "ta", "value": 1}, {"from": "s", "to": "##ran. electronic address :", "value": 1}, {"from": "s", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "s", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "s", "to": "perspectives", "value": 1}, {"from": "s", "to": "##briz,", "value": 1}, {"from": "s", "to": "of agriculture,", "value": 1}, {"from": "s", "to": "##fer", "value": 1}, {"from": "s", "to": "##ki", "value": 1}, {"from": "s", "to": "from both", "value": 1}, {"from": "s", "to": "##ran.", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "ta", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "##ran. electronic address :", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "perspectives", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "##briz,", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "of agriculture,", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "##fer", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "##ki", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "from both", "value": 1}, {"from": "##biotec. 2025. 04. 022. online ahead of print.", "to": "##ran.", "value": 1}, {"from": "ta", "to": "##ran. electronic address :", "value": 1}, {"from": "ta", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "ta", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "ta", "to": "perspectives", "value": 1}, {"from": "ta", "to": "##briz,", "value": 1}, {"from": "ta", "to": "of agriculture,", "value": 1}, {"from": "ta", "to": "##fer", "value": 1}, {"from": "ta", "to": "##ki", "value": 1}, {"from": "ta", "to": "from both", "value": 1}, {"from": "ta", "to": "##ran.", "value": 1}, {"from": "##ran. electronic address :", "to": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "value": 1}, {"from": "##ran. electronic address :", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": "##ran. electronic address :", "to": "perspectives", "value": 1}, {"from": "##ran. electronic address :", "to": "##briz,", "value": 1}, {"from": "##ran. electronic address :", "to": "of agriculture,", "value": 1}, {"from": "##ran. electronic address :", "to": "##fer", "value": 1}, {"from": "##ran. electronic address :", "to": "##ki", "value": 1}, {"from": "##ran. electronic address :", "to": "from both", "value": 1}, {"from": "##ran. electronic address :", "to": "##ran.", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": ", imam khomeini international university, qaz", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "perspectives", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "##briz,", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "of agriculture,", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "##fer", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "##ki", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "from both", "value": 1}, {"from": ". copyright \u00a9 2025 the authors. published by elsevier inc. all rights reserved.", "to": "##ran.", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "perspectives", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "##briz,", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "of agriculture,", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "##fer", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "##ki", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "from both", "value": 1}, {"from": ", imam khomeini international university, qaz", "to": "##ran.", "value": 1}, {"from": "perspectives", "to": "##briz,", "value": 1}, {"from": "perspectives", "to": "of agriculture,", "value": 1}, {"from": "perspectives", "to": "##fer", "value": 1}, {"from": "perspectives", "to": "##ki", "value": 1}, {"from": "perspectives", "to": "from both", "value": 1}, {"from": "perspectives", "to": "##ran.", "value": 1}, {"from": "##briz,", "to": "of agriculture,", "value": 1}, {"from": "##briz,", "to": "##fer", "value": 1}, {"from": "##briz,", "to": "##ki", "value": 1}, {"from": "##briz,", "to": "from both", "value": 1}, {"from": "##briz,", "to": "##ran.", "value": 1}, {"from": "of agriculture,", "to": "##fer", "value": 1}, {"from": "of agriculture,", "to": "##ki", "value": 1}, {"from": "of agriculture,", "to": "from both", "value": 1}, {"from": "of agriculture,", "to": "##ran.", "value": 1}, {"from": "##fer", "to": "##ki", "value": 1}, {"from": "##fer", "to": "from both", "value": 1}, {"from": "##fer", "to": "##ran.", "value": 1}, {"from": "##ki", "to": "from both", "value": 1}, {"from": "##ki", "to": "##ran.", "value": 1}, {"from": "from both", "to": "##ran.", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ifer", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ne - c", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": ", tnf signaling", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": ", which", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "down - regulated", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "including c", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ytoki", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "detected", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "vs", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##cer assays. the", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "or", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ne receptor", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ap", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "via", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "anti", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##n - \u03b3", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "f biotechnology engineering,", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "were up -", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": ", nod - like receptor signaling", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##ation, pro", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "pathways", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "pathway", "value": 1}, {"from": "of agriculture and natural resources, imam khomeini international university, qazvin,", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ifer", "to": "that their activation leads to the antiprol", "value": 1}, {"from": "##ifer", "to": "##ne - c", "value": 1}, {"from": "##ifer", "to": ", tnf signaling", "value": 1}, {"from": "##ifer", "to": ", which", "value": 1}, {"from": "##ifer", "to": "down - regulated", "value": 1}, {"from": "##ifer", "to": "including c", "value": 1}, {"from": "##ifer", "to": "##ytoki", "value": 1}, {"from": "##ifer", "to": "detected", "value": 1}, {"from": "##ifer", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "##ifer", "to": "vs", "value": 1}, {"from": "##ifer", "to": "##cer assays. the", "value": 1}, {"from": "##ifer", "to": "or", "value": 1}, {"from": "##ifer", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##ifer", "to": "##ne receptor", "value": 1}, {"from": "##ifer", "to": "##ap", "value": 1}, {"from": "##ifer", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##ifer", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##ifer", "to": "via", "value": 1}, {"from": "##ifer", "to": "anti", "value": 1}, {"from": "##ifer", "to": "##n - \u03b3", "value": 1}, {"from": "##ifer", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##ifer", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ifer", "to": "were up -", "value": 1}, {"from": "##ifer", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ifer", "to": "##ation, pro", "value": 1}, {"from": "##ifer", "to": "pathways", "value": 1}, {"from": "##ifer", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ifer", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ifer", "to": "pathway", "value": 1}, {"from": "##ifer", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ne - c", "value": 1}, {"from": "that their activation leads to the antiprol", "to": ", tnf signaling", "value": 1}, {"from": "that their activation leads to the antiprol", "to": ", which", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "down - regulated", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "including c", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ytoki", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "detected", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "vs", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##cer assays. the", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "or", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ne receptor", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ap", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "via", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "anti", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##n - \u03b3", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "f biotechnology engineering,", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "were up -", "value": 1}, {"from": "that their activation leads to the antiprol", "to": ", nod - like receptor signaling", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##ation, pro", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "pathways", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "that their activation leads to the antiprol", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "pathway", "value": 1}, {"from": "that their activation leads to the antiprol", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ne - c", "to": ", tnf signaling", "value": 1}, {"from": "##ne - c", "to": ", which", "value": 1}, {"from": "##ne - c", "to": "down - regulated", "value": 1}, {"from": "##ne - c", "to": "including c", "value": 1}, {"from": "##ne - c", "to": "##ytoki", "value": 1}, {"from": "##ne - c", "to": "detected", "value": 1}, {"from": "##ne - c", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "##ne - c", "to": "vs", "value": 1}, {"from": "##ne - c", "to": "##cer assays. the", "value": 1}, {"from": "##ne - c", "to": "or", "value": 1}, {"from": "##ne - c", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##ne - c", "to": "##ne receptor", "value": 1}, {"from": "##ne - c", "to": "##ap", "value": 1}, {"from": "##ne - c", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##ne - c", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##ne - c", "to": "via", "value": 1}, {"from": "##ne - c", "to": "anti", "value": 1}, {"from": "##ne - c", "to": "##n - \u03b3", "value": 1}, {"from": "##ne - c", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##ne - c", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ne - c", "to": "were up -", "value": 1}, {"from": "##ne - c", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ne - c", "to": "##ation, pro", "value": 1}, {"from": "##ne - c", "to": "pathways", "value": 1}, {"from": "##ne - c", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ne - c", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ne - c", "to": "pathway", "value": 1}, {"from": "##ne - c", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": ", tnf signaling", "to": ", which", "value": 1}, {"from": ", tnf signaling", "to": "down - regulated", "value": 1}, {"from": ", tnf signaling", "to": "including c", "value": 1}, {"from": ", tnf signaling", "to": "##ytoki", "value": 1}, {"from": ", tnf signaling", "to": "detected", "value": 1}, {"from": ", tnf signaling", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": ", tnf signaling", "to": "vs", "value": 1}, {"from": ", tnf signaling", "to": "##cer assays. the", "value": 1}, {"from": ", tnf signaling", "to": "or", "value": 1}, {"from": ", tnf signaling", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": ", tnf signaling", "to": "##ne receptor", "value": 1}, {"from": ", tnf signaling", "to": "##ap", "value": 1}, {"from": ", tnf signaling", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": ", tnf signaling", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": ", tnf signaling", "to": "via", "value": 1}, {"from": ", tnf signaling", "to": "anti", "value": 1}, {"from": ", tnf signaling", "to": "##n - \u03b3", "value": 1}, {"from": ", tnf signaling", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": ", tnf signaling", "to": "f biotechnology engineering,", "value": 1}, {"from": ", tnf signaling", "to": "were up -", "value": 1}, {"from": ", tnf signaling", "to": ", nod - like receptor signaling", "value": 1}, {"from": ", tnf signaling", "to": "##ation, pro", "value": 1}, {"from": ", tnf signaling", "to": "pathways", "value": 1}, {"from": ", tnf signaling", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": ", tnf signaling", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": ", tnf signaling", "to": "pathway", "value": 1}, {"from": ", tnf signaling", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": ", which", "to": "down - regulated", "value": 1}, {"from": ", which", "to": "including c", "value": 1}, {"from": ", which", "to": "##ytoki", "value": 1}, {"from": ", which", "to": "detected", "value": 1}, {"from": ", which", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": ", which", "to": "vs", "value": 1}, {"from": ", which", "to": "##cer assays. the", "value": 1}, {"from": ", which", "to": "or", "value": 1}, {"from": ", which", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": ", which", "to": "##ne receptor", "value": 1}, {"from": ", which", "to": "##ap", "value": 1}, {"from": ", which", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": ", which", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": ", which", "to": "via", "value": 1}, {"from": ", which", "to": "anti", "value": 1}, {"from": ", which", "to": "##n - \u03b3", "value": 1}, {"from": ", which", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": ", which", "to": "f biotechnology engineering,", "value": 1}, {"from": ", which", "to": "were up -", "value": 1}, {"from": ", which", "to": ", nod - like receptor signaling", "value": 1}, {"from": ", which", "to": "##ation, pro", "value": 1}, {"from": ", which", "to": "pathways", "value": 1}, {"from": ", which", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": ", which", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": ", which", "to": "pathway", "value": 1}, {"from": ", which", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "down - regulated", "to": "including c", "value": 1}, {"from": "down - regulated", "to": "##ytoki", "value": 1}, {"from": "down - regulated", "to": "detected", "value": 1}, {"from": "down - regulated", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "down - regulated", "to": "vs", "value": 1}, {"from": "down - regulated", "to": "##cer assays. the", "value": 1}, {"from": "down - regulated", "to": "or", "value": 1}, {"from": "down - regulated", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "down - regulated", "to": "##ne receptor", "value": 1}, {"from": "down - regulated", "to": "##ap", "value": 1}, {"from": "down - regulated", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "down - regulated", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "down - regulated", "to": "via", "value": 1}, {"from": "down - regulated", "to": "anti", "value": 1}, {"from": "down - regulated", "to": "##n - \u03b3", "value": 1}, {"from": "down - regulated", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "down - regulated", "to": "f biotechnology engineering,", "value": 1}, {"from": "down - regulated", "to": "were up -", "value": 1}, {"from": "down - regulated", "to": ", nod - like receptor signaling", "value": 1}, {"from": "down - regulated", "to": "##ation, pro", "value": 1}, {"from": "down - regulated", "to": "pathways", "value": 1}, {"from": "down - regulated", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "down - regulated", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "down - regulated", "to": "pathway", "value": 1}, {"from": "down - regulated", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "including c", "to": "##ytoki", "value": 1}, {"from": "including c", "to": "detected", "value": 1}, {"from": "including c", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "including c", "to": "vs", "value": 1}, {"from": "including c", "to": "##cer assays. the", "value": 1}, {"from": "including c", "to": "or", "value": 1}, {"from": "including c", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "including c", "to": "##ne receptor", "value": 1}, {"from": "including c", "to": "##ap", "value": 1}, {"from": "including c", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "including c", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "including c", "to": "via", "value": 1}, {"from": "including c", "to": "anti", "value": 1}, {"from": "including c", "to": "##n - \u03b3", "value": 1}, {"from": "including c", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "including c", "to": "f biotechnology engineering,", "value": 1}, {"from": "including c", "to": "were up -", "value": 1}, {"from": "including c", "to": ", nod - like receptor signaling", "value": 1}, {"from": "including c", "to": "##ation, pro", "value": 1}, {"from": "including c", "to": "pathways", "value": 1}, {"from": "including c", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "including c", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "including c", "to": "pathway", "value": 1}, {"from": "including c", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ytoki", "to": "detected", "value": 1}, {"from": "##ytoki", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "##ytoki", "to": "vs", "value": 1}, {"from": "##ytoki", "to": "##cer assays. the", "value": 1}, {"from": "##ytoki", "to": "or", "value": 1}, {"from": "##ytoki", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##ytoki", "to": "##ne receptor", "value": 1}, {"from": "##ytoki", "to": "##ap", "value": 1}, {"from": "##ytoki", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##ytoki", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##ytoki", "to": "via", "value": 1}, {"from": "##ytoki", "to": "anti", "value": 1}, {"from": "##ytoki", "to": "##n - \u03b3", "value": 1}, {"from": "##ytoki", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##ytoki", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ytoki", "to": "were up -", "value": 1}, {"from": "##ytoki", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ytoki", "to": "##ation, pro", "value": 1}, {"from": "##ytoki", "to": "pathways", "value": 1}, {"from": "##ytoki", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ytoki", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ytoki", "to": "pathway", "value": 1}, {"from": "##ytoki", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "detected", "to": "##viral role of the hifn - \u03b3 preparations was evaluated by", "value": 1}, {"from": "detected", "to": "vs", "value": 1}, {"from": "detected", "to": "##cer assays. the", "value": 1}, {"from": "detected", "to": "or", "value": 1}, {"from": "detected", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "detected", "to": "##ne receptor", "value": 1}, {"from": "detected", "to": "##ap", "value": 1}, {"from": "detected", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "detected", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "detected", "to": "via", "value": 1}, {"from": "detected", "to": "anti", "value": 1}, {"from": "detected", "to": "##n - \u03b3", "value": 1}, {"from": "detected", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "detected", "to": "f biotechnology engineering,", "value": 1}, {"from": "detected", "to": "were up -", "value": 1}, {"from": "detected", "to": ", nod - like receptor signaling", "value": 1}, {"from": "detected", "to": "##ation, pro", "value": 1}, {"from": "detected", "to": "pathways", "value": 1}, {"from": "detected", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "detected", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "detected", "to": "pathway", "value": 1}, {"from": "detected", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "vs", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##cer assays. the", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "or", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##ne receptor", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##ap", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "via", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "anti", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##n - \u03b3", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "f biotechnology engineering,", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "were up -", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##ation, pro", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "pathways", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "pathway", "value": 1}, {"from": "##viral role of the hifn - \u03b3 preparations was evaluated by", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "vs", "to": "##cer assays. the", "value": 1}, {"from": "vs", "to": "or", "value": 1}, {"from": "vs", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "vs", "to": "##ne receptor", "value": 1}, {"from": "vs", "to": "##ap", "value": 1}, {"from": "vs", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "vs", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "vs", "to": "via", "value": 1}, {"from": "vs", "to": "anti", "value": 1}, {"from": "vs", "to": "##n - \u03b3", "value": 1}, {"from": "vs", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "vs", "to": "f biotechnology engineering,", "value": 1}, {"from": "vs", "to": "were up -", "value": 1}, {"from": "vs", "to": ", nod - like receptor signaling", "value": 1}, {"from": "vs", "to": "##ation, pro", "value": 1}, {"from": "vs", "to": "pathways", "value": 1}, {"from": "vs", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "vs", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "vs", "to": "pathway", "value": 1}, {"from": "vs", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##cer assays. the", "to": "or", "value": 1}, {"from": "##cer assays. the", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "##cer assays. the", "to": "##ne receptor", "value": 1}, {"from": "##cer assays. the", "to": "##ap", "value": 1}, {"from": "##cer assays. the", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##cer assays. the", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##cer assays. the", "to": "via", "value": 1}, {"from": "##cer assays. the", "to": "anti", "value": 1}, {"from": "##cer assays. the", "to": "##n - \u03b3", "value": 1}, {"from": "##cer assays. the", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##cer assays. the", "to": "f biotechnology engineering,", "value": 1}, {"from": "##cer assays. the", "to": "were up -", "value": 1}, {"from": "##cer assays. the", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##cer assays. the", "to": "##ation, pro", "value": 1}, {"from": "##cer assays. the", "to": "pathways", "value": 1}, {"from": "##cer assays. the", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##cer assays. the", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##cer assays. the", "to": "pathway", "value": 1}, {"from": "##cer assays. the", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "or", "to": "##hibition of vesicular stomatitis virus", "value": 1}, {"from": "or", "to": "##ne receptor", "value": 1}, {"from": "or", "to": "##ap", "value": 1}, {"from": "or", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "or", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "or", "to": "via", "value": 1}, {"from": "or", "to": "anti", "value": 1}, {"from": "or", "to": "##n - \u03b3", "value": 1}, {"from": "or", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "or", "to": "f biotechnology engineering,", "value": 1}, {"from": "or", "to": "were up -", "value": 1}, {"from": "or", "to": ", nod - like receptor signaling", "value": 1}, {"from": "or", "to": "##ation, pro", "value": 1}, {"from": "or", "to": "pathways", "value": 1}, {"from": "or", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "or", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "or", "to": "pathway", "value": 1}, {"from": "or", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##ne receptor", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##ap", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "via", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "anti", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##n - \u03b3", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "f biotechnology engineering,", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "were up -", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##ation, pro", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "pathways", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "pathway", "value": 1}, {"from": "##hibition of vesicular stomatitis virus", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ne receptor", "to": "##ap", "value": 1}, {"from": "##ne receptor", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##ne receptor", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##ne receptor", "to": "via", "value": 1}, {"from": "##ne receptor", "to": "anti", "value": 1}, {"from": "##ne receptor", "to": "##n - \u03b3", "value": 1}, {"from": "##ne receptor", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##ne receptor", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ne receptor", "to": "were up -", "value": 1}, {"from": "##ne receptor", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ne receptor", "to": "##ation, pro", "value": 1}, {"from": "##ne receptor", "to": "pathways", "value": 1}, {"from": "##ne receptor", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ne receptor", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ne receptor", "to": "pathway", "value": 1}, {"from": "##ne receptor", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ap", "to": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "value": 1}, {"from": "##ap", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##ap", "to": "via", "value": 1}, {"from": "##ap", "to": "anti", "value": 1}, {"from": "##ap", "to": "##n - \u03b3", "value": 1}, {"from": "##ap", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##ap", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ap", "to": "were up -", "value": 1}, {"from": "##ap", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ap", "to": "##ation, pro", "value": 1}, {"from": "##ap", "to": "pathways", "value": 1}, {"from": "##ap", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ap", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ap", "to": "pathway", "value": 1}, {"from": "##ap", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##n - \u03b3. moreover, several", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "via", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "anti", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##n - \u03b3", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "f biotechnology engineering,", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "were up -", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##ation, pro", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "pathways", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "pathway", "value": 1}, {"from": "##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "via", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "anti", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "##n - \u03b3", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "f biotechnology engineering,", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "were up -", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "##ation, pro", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "pathways", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "pathway", "value": 1}, {"from": "##n - \u03b3. moreover, several", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "via", "to": "anti", "value": 1}, {"from": "via", "to": "##n - \u03b3", "value": 1}, {"from": "via", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "via", "to": "f biotechnology engineering,", "value": 1}, {"from": "via", "to": "were up -", "value": 1}, {"from": "via", "to": ", nod - like receptor signaling", "value": 1}, {"from": "via", "to": "##ation, pro", "value": 1}, {"from": "via", "to": "pathways", "value": 1}, {"from": "via", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "via", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "via", "to": "pathway", "value": 1}, {"from": "via", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "via", "to": "- regulate", "value": 1}, {"from": "via", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "via", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "via", "to": "##tic", "value": 1}, {"from": "via", "to": "##6", "value": 1}, {"from": "via", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "via", "to": "##xic effect of", "value": 1}, {"from": "via", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "via", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "via", "to": "##xic efficacy of the", "value": 1}, {"from": "via", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "via", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "via", "to": "up -", "value": 1}, {"from": "via", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "via", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "via", "to": "development of tumor cells, a", "value": 1}, {"from": "via", "to": "##348089 conflict o", "value": 1}, {"from": "via", "to": "regulate", "value": 1}, {"from": "via", "to": "of pro", "value": 1}, {"from": "via", "to": "##cl -", "value": 1}, {"from": "via", "to": "##biotec. 2025.", "value": 1}, {"from": "via", "to": "04", "value": 1}, {"from": "via", "to": "##apopto", "value": 1}, {"from": "via", "to": "to", "value": 1}, {"from": "via", "to": "##cer and antiviral functions of", "value": 1}, {"from": "via", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "via", "to": "and p", "value": 1}, {"from": "via", "to": "##c cell line", "value": 1}, {"from": "via", "to": "hi", "value": 1}, {"from": "via", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "via", "to": "##53", "value": 1}, {"from": "via", "to": ". 022 pmid :", "value": 1}, {"from": "via", "to": "bax", "value": 1}, {"from": "anti", "to": "##n - \u03b3", "value": 1}, {"from": "anti", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "anti", "to": "f biotechnology engineering,", "value": 1}, {"from": "anti", "to": "were up -", "value": 1}, {"from": "anti", "to": ", nod - like receptor signaling", "value": 1}, {"from": "anti", "to": "##ation, pro", "value": 1}, {"from": "anti", "to": "pathways", "value": 1}, {"from": "anti", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "anti", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "anti", "to": "pathway", "value": 1}, {"from": "anti", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##n - \u03b3", "to": "##ran. by performing a biological network analysis, we identified some hub", "value": 1}, {"from": "##n - \u03b3", "to": "f biotechnology engineering,", "value": 1}, {"from": "##n - \u03b3", "to": "were up -", "value": 1}, {"from": "##n - \u03b3", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##n - \u03b3", "to": "##ation, pro", "value": 1}, {"from": "##n - \u03b3", "to": "pathways", "value": 1}, {"from": "##n - \u03b3", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##n - \u03b3", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##n - \u03b3", "to": "pathway", "value": 1}, {"from": "##n - \u03b3", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "f biotechnology engineering,", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "were up -", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": ", nod - like receptor signaling", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "##ation, pro", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "pathways", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "pathway", "value": 1}, {"from": "##ran. by performing a biological network analysis, we identified some hub", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "f biotechnology engineering,", "to": "were up -", "value": 1}, {"from": "f biotechnology engineering,", "to": ", nod - like receptor signaling", "value": 1}, {"from": "f biotechnology engineering,", "to": "##ation, pro", "value": 1}, {"from": "f biotechnology engineering,", "to": "pathways", "value": 1}, {"from": "f biotechnology engineering,", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "f biotechnology engineering,", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "f biotechnology engineering,", "to": "pathway", "value": 1}, {"from": "f biotechnology engineering,", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "were up -", "to": ", nod - like receptor signaling", "value": 1}, {"from": "were up -", "to": "##ation, pro", "value": 1}, {"from": "were up -", "to": "pathways", "value": 1}, {"from": "were up -", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "were up -", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "were up -", "to": "pathway", "value": 1}, {"from": "were up -", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": ", nod - like receptor signaling", "to": "##ation, pro", "value": 1}, {"from": ", nod - like receptor signaling", "to": "pathways", "value": 1}, {"from": ", nod - like receptor signaling", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": ", nod - like receptor signaling", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": ", nod - like receptor signaling", "to": "pathway", "value": 1}, {"from": ", nod - like receptor signaling", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##ation, pro", "to": "pathways", "value": 1}, {"from": "##ation, pro", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "##ation, pro", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##ation, pro", "to": "pathway", "value": 1}, {"from": "##ation, pro", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "pathways", "to": "##bility was observed at different concentrations of recombinant", "value": 1}, {"from": "pathways", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "pathways", "to": "pathway", "value": 1}, {"from": "pathways", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "##bility was observed at different concentrations of recombinant", "to": ", and nf - \u03bab signaling pathway were", "value": 1}, {"from": "##bility was observed at different concentrations of recombinant", "to": "pathway", "value": 1}, {"from": "##bility was observed at different concentrations of recombinant", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": ", and nf - \u03bab signaling pathway were", "to": "pathway", "value": 1}, {"from": ", and nf - \u03bab signaling pathway were", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "pathway", "to": "##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human", "value": 1}, {"from": "- regulate", "to": "##fn - \u03b3 toward mcf - 7 cells via a", "value": 1}, {"from": "- regulate", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "- regulate", "to": "##tic", "value": 1}, {"from": "- regulate", "to": "##6", "value": 1}, {"from": "- regulate", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "- regulate", "to": "##xic effect of", "value": 1}, {"from": "- regulate", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "- regulate", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "- regulate", "to": "##xic efficacy of the", "value": 1}, {"from": "- regulate", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "- regulate", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "- regulate", "to": "up -", "value": 1}, {"from": "- regulate", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "- regulate", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "- regulate", "to": "development of tumor cells, a", "value": 1}, {"from": "- regulate", "to": "##348089 conflict o", "value": 1}, {"from": "- regulate", "to": "regulate", "value": 1}, {"from": "- regulate", "to": "of pro", "value": 1}, {"from": "- regulate", "to": "##cl -", "value": 1}, {"from": "- regulate", "to": "##biotec. 2025.", "value": 1}, {"from": "- regulate", "to": "04", "value": 1}, {"from": "- regulate", "to": "##apopto", "value": 1}, {"from": "- regulate", "to": "to", "value": 1}, {"from": "- regulate", "to": "##cer and antiviral functions of", "value": 1}, {"from": "- regulate", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "- regulate", "to": "and p", "value": 1}, {"from": "- regulate", "to": "##c cell line", "value": 1}, {"from": "- regulate", "to": "hi", "value": 1}, {"from": "- regulate", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "- regulate", "to": "##53", "value": 1}, {"from": "- regulate", "to": ". 022 pmid :", "value": 1}, {"from": "- regulate", "to": "bax", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##tic", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##6", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##xic effect of", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##xic efficacy of the", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "up -", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "development of tumor cells, a", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##348089 conflict o", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "regulate", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "of pro", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##cl -", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##biotec. 2025.", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "04", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##apopto", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "to", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "and p", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##c cell line", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "hi", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "##53", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": ". 022 pmid :", "value": 1}, {"from": "##fn - \u03b3 toward mcf - 7 cells via a", "to": "bax", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##tic", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##6", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##xic effect of", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##xic efficacy of the", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "up -", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "development of tumor cells, a", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##348089 conflict o", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "regulate", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "of pro", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##cl -", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##biotec. 2025.", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "04", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##apopto", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "to", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "and p", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##c cell line", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "hi", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "##53", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": ". 022 pmid :", "value": 1}, {"from": "##n - \u03b3 were confirmed via the expression analysis of hub genes cd74, cxcl10, il", "to": "bax", "value": 1}, {"from": "##tic", "to": "##6", "value": 1}, {"from": "##tic", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##tic", "to": "##xic effect of", "value": 1}, {"from": "##tic", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##tic", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##tic", "to": "##xic efficacy of the", "value": 1}, {"from": "##tic", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##tic", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##tic", "to": "up -", "value": 1}, {"from": "##tic", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##tic", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##tic", "to": "development of tumor cells, a", "value": 1}, {"from": "##tic", "to": "##348089 conflict o", "value": 1}, {"from": "##tic", "to": "regulate", "value": 1}, {"from": "##tic", "to": "of pro", "value": 1}, {"from": "##tic", "to": "##cl -", "value": 1}, {"from": "##tic", "to": "##biotec. 2025.", "value": 1}, {"from": "##tic", "to": "04", "value": 1}, {"from": "##tic", "to": "##apopto", "value": 1}, {"from": "##tic", "to": "to", "value": 1}, {"from": "##tic", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##tic", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##tic", "to": "and p", "value": 1}, {"from": "##tic", "to": "##c cell line", "value": 1}, {"from": "##tic", "to": "hi", "value": 1}, {"from": "##tic", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##tic", "to": "##53", "value": 1}, {"from": "##tic", "to": ". 022 pmid :", "value": 1}, {"from": "##tic", "to": "bax", "value": 1}, {"from": "##6", "to": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "value": 1}, {"from": "##6", "to": "##xic effect of", "value": 1}, {"from": "##6", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##6", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##6", "to": "##xic efficacy of the", "value": 1}, {"from": "##6", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##6", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##6", "to": "up -", "value": 1}, {"from": "##6", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##6", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##6", "to": "development of tumor cells, a", "value": 1}, {"from": "##6", "to": "##348089 conflict o", "value": 1}, {"from": "##6", "to": "regulate", "value": 1}, {"from": "##6", "to": "of pro", "value": 1}, {"from": "##6", "to": "##cl -", "value": 1}, {"from": "##6", "to": "##biotec. 2025.", "value": 1}, {"from": "##6", "to": "04", "value": 1}, {"from": "##6", "to": "##apopto", "value": 1}, {"from": "##6", "to": "to", "value": 1}, {"from": "##6", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##6", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##6", "to": "and p", "value": 1}, {"from": "##6", "to": "##c cell line", "value": 1}, {"from": "##6", "to": "hi", "value": 1}, {"from": "##6", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##6", "to": "##53", "value": 1}, {"from": "##6", "to": ". 022 pmid :", "value": 1}, {"from": "##6", "to": "bax", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##xic effect of", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##xic efficacy of the", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "up -", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "development of tumor cells, a", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##348089 conflict o", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "regulate", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "of pro", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##cl -", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##biotec. 2025.", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "04", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##apopto", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "to", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##cer and antiviral functions of", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "and p", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##c cell line", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "hi", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "##53", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": ". 022 pmid :", "value": 1}, {"from": "induction. copyright \u00a9 2025 elsevier b. v. all rights reserved.", "to": "bax", "value": 1}, {"from": "##xic effect of", "to": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "value": 1}, {"from": "##xic effect of", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "##xic effect of", "to": "##xic efficacy of the", "value": 1}, {"from": "##xic effect of", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##xic effect of", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##xic effect of", "to": "up -", "value": 1}, {"from": "##xic effect of", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##xic effect of", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##xic effect of", "to": "development of tumor cells, a", "value": 1}, {"from": "##xic effect of", "to": "##348089 conflict o", "value": 1}, {"from": "##xic effect of", "to": "regulate", "value": 1}, {"from": "##xic effect of", "to": "of pro", "value": 1}, {"from": "##xic effect of", "to": "##cl -", "value": 1}, {"from": "##xic effect of", "to": "##biotec. 2025.", "value": 1}, {"from": "##xic effect of", "to": "04", "value": 1}, {"from": "##xic effect of", "to": "##apopto", "value": 1}, {"from": "##xic effect of", "to": "to", "value": 1}, {"from": "##xic effect of", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##xic effect of", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##xic effect of", "to": "and p", "value": 1}, {"from": "##xic effect of", "to": "##c cell line", "value": 1}, {"from": "##xic effect of", "to": "hi", "value": 1}, {"from": "##xic effect of", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##xic effect of", "to": "##53", "value": 1}, {"from": "##xic effect of", "to": ". 022 pmid :", "value": 1}, {"from": "##xic effect of", "to": "bax", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##fn - \u03b3 preparations on the growth", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##xic efficacy of the", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "up -", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "development of tumor cells, a", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##348089 conflict o", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "regulate", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "of pro", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##cl -", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##biotec. 2025.", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "04", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##apopto", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "to", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##cer and antiviral functions of", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "and p", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##c cell line", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "hi", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "##53", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": ". 022 pmid :", "value": 1}, {"from": "dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32.", "to": "bax", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##xic efficacy of the", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "up -", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "development of tumor cells, a", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##348089 conflict o", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "regulate", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "of pro", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##cl -", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##biotec. 2025.", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "04", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##apopto", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "to", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "and p", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##c cell line", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "hi", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "##53", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": ". 022 pmid :", "value": 1}, {"from": "##fn - \u03b3 preparations on the growth", "to": "bax", "value": 1}, {"from": "##xic efficacy of the", "to": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "value": 1}, {"from": "##xic efficacy of the", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##xic efficacy of the", "to": "up -", "value": 1}, {"from": "##xic efficacy of the", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##xic efficacy of the", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##xic efficacy of the", "to": "development of tumor cells, a", "value": 1}, {"from": "##xic efficacy of the", "to": "##348089 conflict o", "value": 1}, {"from": "##xic efficacy of the", "to": "regulate", "value": 1}, {"from": "##xic efficacy of the", "to": "of pro", "value": 1}, {"from": "##xic efficacy of the", "to": "##cl -", "value": 1}, {"from": "##xic efficacy of the", "to": "##biotec. 2025.", "value": 1}, {"from": "##xic efficacy of the", "to": "04", "value": 1}, {"from": "##xic efficacy of the", "to": "##apopto", "value": 1}, {"from": "##xic efficacy of the", "to": "to", "value": 1}, {"from": "##xic efficacy of the", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##xic efficacy of the", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##xic efficacy of the", "to": "and p", "value": 1}, {"from": "##xic efficacy of the", "to": "##c cell line", "value": 1}, {"from": "##xic efficacy of the", "to": "hi", "value": 1}, {"from": "##xic efficacy of the", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##xic efficacy of the", "to": "##53", "value": 1}, {"from": "##xic efficacy of the", "to": ". 022 pmid :", "value": 1}, {"from": "##xic efficacy of the", "to": "bax", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": ", and stat1 using rt - pcr. furthermore, the", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "up -", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "development of tumor cells, a", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##348089 conflict o", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "regulate", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "of pro", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##cl -", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##biotec. 2025.", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "04", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##apopto", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "to", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "and p", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##c cell line", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "hi", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "##53", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": ". 022 pmid :", "value": 1}, {"from": "##pg / ml hifn - \u03b3 after 72h incubation. anti", "to": "bax", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "up -", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "development of tumor cells, a", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##348089 conflict o", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "regulate", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "of pro", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##cl -", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##biotec. 2025.", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "04", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##apopto", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "to", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##cer and antiviral functions of", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "and p", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##c cell line", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "hi", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "##53", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": ". 022 pmid :", "value": 1}, {"from": ", and stat1 using rt - pcr. furthermore, the", "to": "bax", "value": 1}, {"from": "up -", "to": "proteins. the maximum amount of the cell", "value": 1}, {"from": "up -", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "up -", "to": "development of tumor cells, a", "value": 1}, {"from": "up -", "to": "##348089 conflict o", "value": 1}, {"from": "up -", "to": "regulate", "value": 1}, {"from": "up -", "to": "of pro", "value": 1}, {"from": "up -", "to": "##cl -", "value": 1}, {"from": "up -", "to": "##biotec. 2025.", "value": 1}, {"from": "up -", "to": "04", "value": 1}, {"from": "up -", "to": "##apopto", "value": 1}, {"from": "up -", "to": "to", "value": 1}, {"from": "up -", "to": "##cer and antiviral functions of", "value": 1}, {"from": "up -", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "up -", "to": "and p", "value": 1}, {"from": "up -", "to": "##c cell line", "value": 1}, {"from": "up -", "to": "hi", "value": 1}, {"from": "up -", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "up -", "to": "##53", "value": 1}, {"from": "up -", "to": ". 022 pmid :", "value": 1}, {"from": "up -", "to": "bax", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##fn - \u03b3 preparations were significantly able", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "development of tumor cells, a", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##348089 conflict o", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "regulate", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "of pro", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##cl -", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##biotec. 2025.", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "04", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##apopto", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "to", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##cer and antiviral functions of", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "and p", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##c cell line", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "hi", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "##53", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": ". 022 pmid :", "value": 1}, {"from": "proteins. the maximum amount of the cell", "to": "bax", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "development of tumor cells, a", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##348089 conflict o", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "regulate", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "of pro", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##cl -", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##biotec. 2025.", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "04", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##apopto", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "to", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "and p", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##c cell line", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "hi", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "##53", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": ". 022 pmid :", "value": 1}, {"from": "##fn - \u03b3 preparations were significantly able", "to": "bax", "value": 1}, {"from": "development of tumor cells, a", "to": "##348089 conflict o", "value": 1}, {"from": "development of tumor cells, a", "to": "regulate", "value": 1}, {"from": "development of tumor cells, a", "to": "of pro", "value": 1}, {"from": "development of tumor cells, a", "to": "##cl -", "value": 1}, {"from": "development of tumor cells, a", "to": "##biotec. 2025.", "value": 1}, {"from": "development of tumor cells, a", "to": "04", "value": 1}, {"from": "development of tumor cells, a", "to": "##apopto", "value": 1}, {"from": "development of tumor cells, a", "to": "to", "value": 1}, {"from": "development of tumor cells, a", "to": "##cer and antiviral functions of", "value": 1}, {"from": "development of tumor cells, a", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "development of tumor cells, a", "to": "and p", "value": 1}, {"from": "development of tumor cells, a", "to": "##c cell line", "value": 1}, {"from": "development of tumor cells, a", "to": "hi", "value": 1}, {"from": "development of tumor cells, a", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "development of tumor cells, a", "to": "##53", "value": 1}, {"from": "development of tumor cells, a", "to": ". 022 pmid :", "value": 1}, {"from": "development of tumor cells, a", "to": "bax", "value": 1}, {"from": "##348089 conflict o", "to": "regulate", "value": 1}, {"from": "##348089 conflict o", "to": "of pro", "value": 1}, {"from": "##348089 conflict o", "to": "##cl -", "value": 1}, {"from": "##348089 conflict o", "to": "##biotec. 2025.", "value": 1}, {"from": "##348089 conflict o", "to": "04", "value": 1}, {"from": "##348089 conflict o", "to": "##apopto", "value": 1}, {"from": "##348089 conflict o", "to": "to", "value": 1}, {"from": "##348089 conflict o", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##348089 conflict o", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##348089 conflict o", "to": "and p", "value": 1}, {"from": "##348089 conflict o", "to": "##c cell line", "value": 1}, {"from": "##348089 conflict o", "to": "hi", "value": 1}, {"from": "##348089 conflict o", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##348089 conflict o", "to": "##53", "value": 1}, {"from": "##348089 conflict o", "to": ". 022 pmid :", "value": 1}, {"from": "##348089 conflict o", "to": "bax", "value": 1}, {"from": "regulate", "to": "of pro", "value": 1}, {"from": "regulate", "to": "##cl -", "value": 1}, {"from": "regulate", "to": "##biotec. 2025.", "value": 1}, {"from": "regulate", "to": "04", "value": 1}, {"from": "regulate", "to": "##apopto", "value": 1}, {"from": "regulate", "to": "to", "value": 1}, {"from": "regulate", "to": "##cer and antiviral functions of", "value": 1}, {"from": "regulate", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "regulate", "to": "and p", "value": 1}, {"from": "regulate", "to": "##c cell line", "value": 1}, {"from": "regulate", "to": "hi", "value": 1}, {"from": "regulate", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "regulate", "to": "##53", "value": 1}, {"from": "regulate", "to": ". 022 pmid :", "value": 1}, {"from": "regulate", "to": "bax", "value": 1}, {"from": "of pro", "to": "##cl -", "value": 1}, {"from": "of pro", "to": "##biotec. 2025.", "value": 1}, {"from": "of pro", "to": "04", "value": 1}, {"from": "of pro", "to": "##apopto", "value": 1}, {"from": "of pro", "to": "to", "value": 1}, {"from": "of pro", "to": "##cer and antiviral functions of", "value": 1}, {"from": "of pro", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "of pro", "to": "and p", "value": 1}, {"from": "of pro", "to": "##c cell line", "value": 1}, {"from": "of pro", "to": "hi", "value": 1}, {"from": "of pro", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "of pro", "to": "##53", "value": 1}, {"from": "of pro", "to": ". 022 pmid :", "value": 1}, {"from": "of pro", "to": "bax", "value": 1}, {"from": "##cl -", "to": "##biotec. 2025.", "value": 1}, {"from": "##cl -", "to": "04", "value": 1}, {"from": "##cl -", "to": "##apopto", "value": 1}, {"from": "##cl -", "to": "to", "value": 1}, {"from": "##cl -", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##cl -", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##cl -", "to": "and p", "value": 1}, {"from": "##cl -", "to": "##c cell line", "value": 1}, {"from": "##cl -", "to": "hi", "value": 1}, {"from": "##cl -", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##cl -", "to": "##53", "value": 1}, {"from": "##cl -", "to": ". 022 pmid :", "value": 1}, {"from": "##cl -", "to": "bax", "value": 1}, {"from": "##biotec. 2025.", "to": "04", "value": 1}, {"from": "##biotec. 2025.", "to": "##apopto", "value": 1}, {"from": "##biotec. 2025.", "to": "to", "value": 1}, {"from": "##biotec. 2025.", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##biotec. 2025.", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##biotec. 2025.", "to": "and p", "value": 1}, {"from": "##biotec. 2025.", "to": "##c cell line", "value": 1}, {"from": "##biotec. 2025.", "to": "hi", "value": 1}, {"from": "##biotec. 2025.", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##biotec. 2025.", "to": "##53", "value": 1}, {"from": "##biotec. 2025.", "to": ". 022 pmid :", "value": 1}, {"from": "##biotec. 2025.", "to": "bax", "value": 1}, {"from": "04", "to": "##apopto", "value": 1}, {"from": "04", "to": "to", "value": 1}, {"from": "04", "to": "##cer and antiviral functions of", "value": 1}, {"from": "04", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "04", "to": "and p", "value": 1}, {"from": "04", "to": "##c cell line", "value": 1}, {"from": "04", "to": "hi", "value": 1}, {"from": "04", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "04", "to": "##53", "value": 1}, {"from": "04", "to": ". 022 pmid :", "value": 1}, {"from": "04", "to": "bax", "value": 1}, {"from": "##apopto", "to": "to", "value": 1}, {"from": "##apopto", "to": "##cer and antiviral functions of", "value": 1}, {"from": "##apopto", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##apopto", "to": "and p", "value": 1}, {"from": "##apopto", "to": "##c cell line", "value": 1}, {"from": "##apopto", "to": "hi", "value": 1}, {"from": "##apopto", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##apopto", "to": "##53", "value": 1}, {"from": "##apopto", "to": ". 022 pmid :", "value": 1}, {"from": "##apopto", "to": "bax", "value": 1}, {"from": "to", "to": "##cer and antiviral functions of", "value": 1}, {"from": "to", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "to", "to": "and p", "value": 1}, {"from": "to", "to": "##c cell line", "value": 1}, {"from": "to", "to": "hi", "value": 1}, {"from": "to", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "to", "to": "##53", "value": 1}, {"from": "to", "to": ". 022 pmid :", "value": 1}, {"from": "to", "to": "bax", "value": 1}, {"from": "##cer and antiviral functions of", "to": "2 as an antiapoptotic gene, showing the cyt", "value": 1}, {"from": "##cer and antiviral functions of", "to": "and p", "value": 1}, {"from": "##cer and antiviral functions of", "to": "##c cell line", "value": 1}, {"from": "##cer and antiviral functions of", "to": "hi", "value": 1}, {"from": "##cer and antiviral functions of", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##cer and antiviral functions of", "to": "##53", "value": 1}, {"from": "##cer and antiviral functions of", "to": ". 022 pmid :", "value": 1}, {"from": "##cer and antiviral functions of", "to": "bax", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "and p", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "##c cell line", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "hi", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "##53", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": ". 022 pmid :", "value": 1}, {"from": "2 as an antiapoptotic gene, showing the cyt", "to": "bax", "value": 1}, {"from": "and p", "to": "##c cell line", "value": 1}, {"from": "and p", "to": "hi", "value": 1}, {"from": "and p", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "and p", "to": "##53", "value": 1}, {"from": "and p", "to": ". 022 pmid :", "value": 1}, {"from": "and p", "to": "bax", "value": 1}, {"from": "##c cell line", "to": "hi", "value": 1}, {"from": "##c cell line", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "##c cell line", "to": "##53", "value": 1}, {"from": "##c cell line", "to": ". 022 pmid :", "value": 1}, {"from": "##c cell line", "to": "bax", "value": 1}, {"from": "hi", "to": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "value": 1}, {"from": "hi", "to": "##53", "value": 1}, {"from": "hi", "to": ". 022 pmid :", "value": 1}, {"from": "hi", "to": "bax", "value": 1}, {"from": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "to": "##53", "value": 1}, {"from": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "to": ". 022 pmid :", "value": 1}, {"from": "##bility detected for the hifn - \u03b3 preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt", "to": "bax", "value": 1}, {"from": "##53", "to": ". 022 pmid :", "value": 1}, {"from": "##53", "to": "bax", "value": 1}, {"from": ". 022 pmid :", "to": "bax", "value": 1}]);

                  nodeColors = {};
                  allNodes = nodes.get({ returnType: "Object" });
                  for (nodeId in allNodes) {
                    nodeColors[nodeId] = allNodes[nodeId].color;
                  }
                  allEdges = edges.get({ returnType: "Object" });
                  // adding nodes and edges to the graph
                  data = {nodes: nodes, edges: edges};

                  var options = {
    "configure": {
        "enabled": false
    },
    "edges": {
        "color": {
            "inherit": true
        },
        "smooth": {
            "enabled": true,
            "type": "dynamic"
        }
    },
    "interaction": {
        "dragNodes": true,
        "hideEdgesOnDrag": false,
        "hideNodesOnDrag": false
    },
    "physics": {
        "enabled": true,
        "stabilization": {
            "enabled": true,
            "fit": true,
            "iterations": 1000,
            "onlyDynamicEdges": false,
            "updateInterval": 50
        }
    }
};

                  


                  

                  network = new vis.Network(container, data, options);

                  

                  

                  


                  
                      network.on("stabilizationProgress", function(params) {
                          document.getElementById('loadingBar').removeAttribute("style");
                          var maxWidth = 496;
                          var minWidth = 20;
                          var widthFactor = params.iterations/params.total;
                          var width = Math.max(minWidth,maxWidth * widthFactor);
                          document.getElementById('bar').style.width = width + 'px';
                          document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
                      });
                      network.once("stabilizationIterationsDone", function() {
                          document.getElementById('text').innerHTML = '100%';
                          document.getElementById('bar').style.width = '496px';
                          document.getElementById('loadingBar').style.opacity = 0;
                          // really clean the dom element
                          setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
                      });
                  

                  return network;

              }
              drawGraph();
        </script>
    </body>
</html>